[{"drug": "carboplatin", "orig_sen": "MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Furthermore, the protein levels of FAT10 were elevated in cisplatin- and carboplatin-resistant NSCLC cells, and knockdown of FAT10 reduced the drug resistance of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The platinum compounds currently used in NSCLC are cisplatin and carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Cisplatin and carboplatin-based chemotherapy in the first-line treatment of NSCLC: Analysis from the European FRAME study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced NSCLC was evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Carboplatin and nab-paclitaxel every 21 days demonstrated promising efficacy with tolerable toxicity in NSCLC patients ineligible for bevacizumab therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced NSCLC-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "RESULTS: The combination of carboplatin with paclitaxel was most frequently used as the first-line treatment for NSCLC patients with ILD (61\u00a0%). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for NSCLC: North Central Cancer Treatment Group (NCCTG)-N0321. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The combination of bortezomib and carboplatin/paclitaxel and concurrent radiation in unresectable stage III NSCLC was evaluated in this phase I/II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Patients with untreated advanced NSCLC received oral meloxicam (150 mg daily), carboplatin (area under the curve = 5 mg/ml \u00d7 min on day 1) and docetaxel (60 mg/m(2) on day 1) every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A method for biomarker directed survival prediction in advanced NSCLC patients treated with Carboplatin-based therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Two randomized phase III trials of carboplatin-based chemotherapy in advanced NSCLC were used for learning and validating the predictive value of ERCC1 in situ protein levels, as measured by accurate quantitative analysis (AQUA). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Efficacy and feasibility of gemcitabine and carboplatin as first-line chemotherapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The purpose of this study was to evaluate the efficacy and safety of gemcitabine and carboplatin as first-line treatment in elderly patients with advanced NSCLC and to evaluate the prognostic factors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Gemcitabine and carboplatin combination chemotherapy is an effective and manageable treatment option in elderly advanced NSCLC patients with good performance status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced NSCLC: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for NSCLC after failure of platinum-doublet chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The primary objective of this study was to determine whether repeated doses of bexarotene capsules affect pharmacokinetic parameters of paclitaxel or carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Bavituximab plus paclitaxel and carboplatin for the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Bavituximab in combination with paclitaxel-carboplatin as first-line therapy demonstrated a tolerable safety profile and potential efficacy in this single-arm phase II trial in patients with advanced local or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This study evaluated the safety of CA4P when combined with carboplatin, paclitaxel, and bevacizumab in chemotherapy-na\u00efve subjects with advanced nonsquamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Adult subjects with confirmed American Joint Committee on Cancer six stage IIIB/IV NSCLC and an Eastern Cooperative Oncology Group performance score of 0 or 1 were randomized to receive six cycles (treatment phase) of paclitaxel (200 mg/m(2)), carboplatin (area under the concentration versus time curve 6), and bevacizumab (15 mg/kg) on day 1 and repeated every 21 days, or this regimen plus CA4P (60 mg/m(2)) on days 7, 14, and 21 of each cycle. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: CA4P plus carboplatin, paclitaxel, and bevacizumab appears to be a tolerable regimen with an acceptable toxicity profile in subjects with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous NSCLC (NS-NSCLC), particularly in those excluded from clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, NSCLC (NS-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " [18F]FDG PET/CT-based response assessment of stage IV NSCLC treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This phase Ia/Ib study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of pictilisib in monotherapy or in combination with carboplatin-paclitaxel and bevacizumab (CP\u00a0+\u00a0BEV) in Japanese patients with advanced solid tumors or non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We previously reported that carboplatin-paclitaxel plus bevacizumab was effective for patients with advanced non-squamous NSCLC and MPE, although we did not evaluate the relationship between treatment outcomes and plasma or pleural effusion levels of VEGF. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous NSCLC: Outcomes according to Thymidylate Synthase Expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous NSCLC through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In NSCLC, fit older patients, like their younger counterparts, benefit from platinum-based doublets, with carboplatin preferred to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous NSCLC with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous NSCLC with pre-existing interstitial lung disease (ILD). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced NSCLC who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4\u2009\u00b1\u20090.9\u00a0MBq (mean\u2009\u00b1\u2009SD) (89)Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous NSCLC were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "OBJECTIVE: To evaluate biomarkers to predict the benefit of paclitaxel and carboplatin plus bevacizumab (PCB) therapy in patients with advanced or recurrent non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced NSCLC patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Chemonaive patients (n = 939) with stage IIIB/IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomized (1:1) to pemetrexed-carboplatin-bevacizumab (pemetrexed arm) or paclitaxel-carboplatin-bevacizumab (paclitaxel arm). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We evaluated dynamic CT-based vascular parameters and plasma cytokines after bevacizumab alone and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore potential biomarkers of treatment response and resistance to this regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous NSCLC harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVES: We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous NSCLC who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by\u00a0Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This study aimed to compare overall survival for Medicare patients diagnosed with NSCLC and treated with either first-line bevacizumab-carboplatin-paclitaxel (BCP) or carboplatin-paclitaxel (CP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-na\u00efve patients with stage IIIB/IV non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Cost-Effectiveness Analysis of Bevacizumab- Paclitaxel-Carboplatin (PC) Versus PC in First-Line Therapy of Advanced NSCLC from Patients' Perspective in Vietnam. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " We report a case of an elderly patient with non-squamous NSCLC who was successfully treated with chemotherapy using carboplatin(CBDCA), pemetrexed(PEM), and bevacizumab(Bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-na\u00efve patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous NSCLC with interstitial lung disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: Optimal chemotherapy for patients with advanced NSCLC with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: We analyzed the outcomes of 21 patients with advanced nonsquamous NSCLC with ILD who received paclitaxel and carboplatin without (paclitaxel-carboplatin group; n\u00a0=\u00a011) or with bevacizumab (paclitaxel-carboplatin-bevacizumab group; n\u00a0=\u00a010) between April 2008 and October 2013. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: The addition of bevacizumab to paclitaxel and carboplatin may provide an effective and safe treatment option for patients with advanced nonsquamous NSCLC with ILD. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel-carboplatin chemotherapy in patients with advanced NSCLC resulted in a 6-month progression-free survival (PFS) rate that compares favorably with the historic rate for bevacizumab combined with paclitaxel-carboplatin in this patient population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: In this phase II, single-arm, open-label, multicenter study, 40 patients with advanced NSCLC received ramucirumab (10 mg/kg intravenous [IV]) followed by paclitaxel (200 mg/m IV) and carboplatin area under the curve = 6 on day 1 every 21 days as first-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous NSCLC with good performance status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: We hypothesized that the combination of bevacizumab, carboplatin, and pemetrexed will be an effective first-line regimen in fit, elderly patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " MO06.12 Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous NSCLC (NSCLC): analyses based on age in the phase 3 PointBreak and E4599 trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous NSCLC: results of the phase II randomized ABIGAIL study (BO21015). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: Bevacizumab plus carboplatin-paclitaxel (BCP) chemotherapy has Food and Drug Administration approval for advanced nonsquamous, NSCLC based upon improved survival in a clinical trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Using data from four health maintenance organizations (HMOs) belonging to the Cancer Research Network, 1605 HMO nonsquamous, NSCLC patients aged younger than 21 years, diagnosed 2002-2010, who received carboplatin-paclitaxel (CP), with and without bevacizumab for first-line treatment of stage IIIB/IV disease were identified. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " AIM: The aim of this retrospective study was to evaluate bevacizumab combined with weekly paclitaxel with and without carboplatin in pre-treated patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Between November 2009 and October 2011, 43 pre-treated patients with non-squamous NSCLC received bevacizumab (15 mg/kg, day 1) plus weekly paclitaxel (60-80 mg/m(2), days 1, 8, 15) with carboplatin (area under the curve=4-5, day 1) (n=36), or bevacizumab plus weekly paclitaxel (n=7) alone every four weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Even for heavily pre-treated patients, bevacizumab plus weekly paclitaxel with or without carboplatin was effective and tolerable in non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous NSCLC was evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous NSCLC: SWOG S0536. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous NSCLC) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Chemo-naive Chinese patients with locally advanced, metastatic or recurrent NSCLC were randomized to receive Bev 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous NSCLC with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase2 study of bevacizumab with carboplatin-paclitaxel for NSCLC with malignant pleural effusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "moto19781205@yahoo.co.jp  Vascular endothelial growth factor (VEGF) is involved in NSCLC with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: One standard of care for advanced NSCLC is paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In the current study, the authors evaluated the efficacy and safety of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab in chemotherapy-naive patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: The regimen of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab was active and feasible as first-line treatment for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: A patient with advanced NSCLC received four cycles of carboplatin AUC 6, paclitaxel 200\u2009mg/m(2), and bevacizumab 15\u2009mg/kg, and was continued on every-3-week maintenance bevacizumab 15\u2009mg/kg. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "philip_bonomi@rush.edu  INTRODUCTION: We conducted a phase II study of dual-agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with paclitaxel and carboplatin chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with stage IIIB/IV nonsquamous NSCLC randomly received cetuximab (400 mg/m initially, 250 mg/m weekly thereafter) plus bevacizumab (15 mg/kg) for six cycles combined with paclitaxel (200 mg/m) and carboplatin (area under the curve 6) for either six cycles (six-cycle arm) or the first three cycles (three-cycle arm) (one cycle = 3 weeks). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "jardimde@gmail.com  OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic NSCLC, in combination with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " [A case of complete resection of non-squamous NSCLC after induction chemotherapy using carboplatin, paclitaxel, and bevacizumab]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin and paclitaxel (CP) in comparison with CP chemotherapy alone in patients with previously untreated advanced, metastatic or recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This phase II study examined ixabepilone/carboplatin (cohort A) and ixabepilone/carboplatin/bevacizumab (cohort B) as first-line therapy for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Ixabepilone can be safely combined with carboplatin in newly diagnosed patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Prognostic models to predict survival in NSCLC patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "txh@medicine.wisc.edu  BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced NSCLC patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLC patients can be estimated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "bpiperdi@montefiore.org  BACKGROUND: This study aimed to establish the maximum tolerated dose (MTD) of weekly bortezomib in combination with fixed standard doses of carboplatin and bevacizumab, and to estimate the efficacy (response rate and progression free survival [PFS]) and safety of combination therapy with carboplatin, bortezomib, and bevacizumab as first-line therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " CONTEXT: A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "OBJECTIVE: To examine whether adding bevacizumab to carboplatin and paclitaxel chemotherapy is associated with improved survival in older patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Adding bevacizumab to carboplatin and paclitaxel chemotherapy was not associated with better survival among Medicare patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "riessjo@stanford.edu  We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "siniho@east.ncc.go.jp  PURPOSE: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "As an application example, we describe the analysis for the comparison of four regimens, cisplatin plus irinotecan, carboplatin plus paclitaxel, cisplatin plus gemcitabine (GP), and cisplatin plus vinorelbine, for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The results showed the concentrations of paclitaxel and carboplatin in sputum of patients treated with ambroxol hydrochloride were significantly higher than those of the control group, suggesting that ambroxol hydrochloride significantly increased the local concentrations of chemotherapeutic agents in lung tissues of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin in combination with thoracic radiotherapy for patients with locally advanced stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "[Epub ahead of print]  Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III NSCLC: A Systematic Review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB NSCLC are carboplatin-paclitaxel and cisplatin-etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Objective: To conduct a systematic review of published trials to compare outcomes and toxic effects between cisplatin-etoposide and carboplatin-paclitaxel in patients with NSCLC receiving thoracic radiation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Methods In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced NSCLC, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: This multicenter study evaluated the feasibility of novel adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent, long-term maintenance with S-1 in patients with completely resected stage II-IIIA NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: We concluded that adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 is feasible and tolerable in patients with completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "[Epub ahead of print]  Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We investigated if drug doses per kilogram of LBM were associated with severe hematologic toxicity (HT) in patients with stage IIIB/IV NSCLC enrolled onto randomized trials comparing first-line carboplatin-doublets. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "[Epub ahead of print]  Randomized, Placebo-Controlled, Phase 2 Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The primary endpoint of this phase 2 trial determined whether addition of veliparib to carboplatin and paclitaxel improved PFS in previously untreated advanced/metastatic NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "[Epub ahead of print]  Carboplatin-induced hematotoxicity among patients with NSCLC: Analysis on clinical adverse events and drug-gene interactions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " In order to clarify the risk of hematotoxicity of carboplatin, we inspected 19901 case reports of NSCLC patients that were submitted to the FDA Adverse Event Reporting System (FAERS) between January 2004 and December 2015. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Given the early awareness of the hematologic risks, great caution should be exercised in prescribing carboplatin to NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "[Epub ahead of print]  Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " To clarify the association between carboplatin and electrolyte abnormality, a pooled-analysis was performed with the adverse event reports of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous NSCLC: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: The present study was a phase I/II study to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities of the biweekly carboplatin/gemcitabine combination and evaluate its safety and efficacy in patients aged\u00a0\u2265 70 years with advanced squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients aged\u00a0\u2265 70 years with advanced or metastatic squamous NSCLC received escalated doses of carboplatin (area under the curve [AUC] 2-2.5 intravenously) and gemcitabine (800-1100 mg/m(2) intravenously) every 2 weeks (phase I). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: The biweekly regimen of gemcitabine and carboplatin showed satisfactory efficacy and a favorable toxicity profile in elderly patients with advanced or metastatic squamous cell NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous NSCLC: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In preclinical models of NSCLC with gain of NRF2 function, ML385 in combination with carboplatin showed significant antitumor activity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " CONTEXT: Paclitaxel (PTX) and carboplatin (CBP) are widely used for the combined chemotherapy of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " P1.48: nab-Paclitaxel + Carboplatin in Advanced Non-Small Cell Lung Cancer:\u00a0Outcomes in Elderly Patients\u00a0With Squamous Histology: Track: Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVE: This phase I study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase (HDAC) inhibitor, in combination with paclitaxel and carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "When administered as a single agent or in combination with the standard-of-care drug carboplatin, ND-646 markedly suppressed lung tumor growth in the Kras;Trp53(-/-) (also known as KRAS p53) and Kras;Stk11(-/-) (also known as KRAS Lkb1) mouse models of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The patient was diagnosed with NSCLC 9 months ago and received 6 cycles of chemotherapy with motesanib, paclitaxel, and carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We compared the combination of chemotherapy drug carboplatin and the radish-derived isothiocyanate compound sulforaphene, which synergistically induces higher apoptosis and growth inhibition in A549, to the drug alone in human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "To summarize, this is the first report that sulforaphene-carboplatin combination treatment synergistically promotes enhanced apoptosis and antiproliferative effect over single drug treatment against A549, human NSCLC cells through caspase activation, MMP disruption, and cell cycle arrest. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In this study, we examined the drug interaction between pemetrexed and PPIs in hOAT3-expressing cultured cells, and retrospectively analyzed the impact of PPIs on the development of hematologic toxicity in 108 patients who received pemetrexed and carboplatin treatment of nonsquamous NSCLC for the first time between January 2011 and June 2015. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: The objective of this clinical trial was to explore the efficacy and tolerability of first-line chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a novel agent that uses a drug delivery system, plus carboplatin, in elderly Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Nab-paclitaxel plus carboplatin, without dose reduction, is indicated to be toxic and intolerable as first-line chemotherapy in elderly Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Health-related quality of life in elderly patients with advanced NSCLC comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced NSCLC were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of platinum doublets, TKIs, pemetrexed and nivolumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVE: To evaluate the cytotoxic effects of ampelopsin sodium (Amp-Na) and carboplatin (CBP) used alone or in combination on human NSCLC cells SPC-A1 in vitro and its related mechanism. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in NSCLC Stage IIIB/IV. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "OBJECTIVE: Carboplatin plus etoposide chemotherapy, which was formerly used as a low-cost first-line treatment, was used as third-line therapy for advanced NSCLC in order to compare its results with those of best supportive care as a treatment for improved quality of life (QoL) and progression-free survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Carboplatin plus etoposide as third-line chemotherapy regimen demonstrated higher median progression-free survival in advanced NSCLC patients and did not adversely affect QoL. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Chemo-na\u00efve patients with advanced NSCLC who received carboplatin-based chemotherapy were treated with doublet antiemetic therapy with dexamethasone and a 5-HT3 receptor antagonist during the first cycle of chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Subsequent addition of aprepitant significantly improved the overall complete response rate in NSCLC patients receiving a second cycle of carboplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced NSCLC: Analysis of Safety and Efficacy in Patients With Diabetes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: To examine outcomes in a phase 3 trial of nab-paclitaxel plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C) in a subset of patients with advanced NSCLC and diabetes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " 216PD: nab-Paclitaxel + carboplatin (nab-P/C) in advanced NSCLC: outcomes in elderly patients (pts) with squamous (SCC) histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Carboplatin is a commonly used drug in the chemotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: We used Carboplatin to treat NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The effects of Carboplatin or miR-21-modification on NSCLC cell invasion were evaluated in either a transwell cell invasion assay, or a scratch wound healing assay. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "RESULTS: We found that Carboplatin inhibited the NSCLC cell invasion, in either a transwell cell invasion assay, or a scratch wound healing assay. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Moreover, Carboplatin increased the levels of SMAD7 protein, but not mRNA, in NSCLC cells, suggesting presence of post-transcriptional control of SMAD7 by Carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Carboplatin may upregulate SMAD7 through suppression of miR-21 to inhibit TGF\u03b2 receptor signaling mediated NSCLC cell invasion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Background The combination of cisplatin or carboplatin with vinorelbine is one of the standard regimens in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Safety and efficacy of S-1 in combination with carboplatin in NSCLC patients with interstitial lung disease: a pilot study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: This is the first prospective study to evaluate the safety and efficacy of S-1 plus carboplatin treatment for NSCLC patients with ILD. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous NSCLC: The Central Japan Lung Study Group Trial 0906. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The aim of this phase II study was to evaluate the efficacy and safety of pemetrexed-carboplatin combination as first-line chemotherapy in advanced non-squamous NSCLC limited to EGFR-wild-type cases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: The pemetrexed-carboplatin combination was effective and well-tolerated in patients with EGFR-wild-type non-squamous NSCLC (UMIN-CTR number: UMIN000003393). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Nineteen patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-l, and adequate organ function were treated with 60-66 Gy thoracic radiation therapy over 30-33 fractions concurrent with weekly 7.5 mg/m(2) endostatin for 14 days, 50 mg/m(2) paclitaxel, and 2 mg/mL/min carboplatin over 30 min. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous NSCLC: treating the right patients based on individualized treatment effect prediction. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In this study, we developed and validated a prediction model for estimating absolute treatment effect of pemetrexed plus carboplatin versus single-agent pemetrexed in the second-line treatment of non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Using data of relapsed patients with advanced non-squamous NSCLC from the NVALT-7 trial, a Weibull model for prediction of gain in median progression-free survival (PFS) by pemetrexed-carboplatin was derived based on patient and tumor characteristics. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "There is important heterogeneity in the effects on PFS of pemetrexed-carboplatin versus pemetrexed in pretreated patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: In a multicenter, open-label, phase III trial, elderly patients \u2265 70 years old with a PS of 0 to 2 and stage IV NSCLC were randomly assigned between chemotherapy allocation on the basis of PS and age (standard arm: carboplatin-based doublet if PS \u2264 1 and age \u2264 75 years; docetaxel if PS = 2 or age > 75 years) and treatment allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel for vulnerable patients, and best supportive care for frail patients). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced NSCLC regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We compared the efficacy and safety of triple antiemetic therapy using aprepitant, palonosetron, and dexamethasone with that of double antiemetic therapy using palonosetron and dexamethasone in patients with advanced NSCLC receiving carboplatin-containing chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced NSCLC and Impaired Performance Status as Selected by a Serum Proteomics Assay. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: This study evaluated Reolysin combined with paclitaxel and carboplatin in patients with metastatic/recurrent KRAS-mutated or epidermal growth factor receptor (EGFR)-mutated/amplified NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS AND MATERIALS: We included 52 patients with NSCLC treated with definitive concurrent carboplatin-paclitaxel and RT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pharmacogenetic analysis of advanced NSCLC patients treated with first-line paclitaxel and carboplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We investigated the effects of genetic polymorphisms on the clinical outcome of advanced NSCLC patients with first-line paclitaxel and carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: This study showed that the SLCO1B3 c.699 G>A polymorphism may predict anemia and ABCB1, HIF1A polymorphism are highly predictive for worse survival in advanced NSCLC with first-line paclitaxel and carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Most importantly, we have been able to extend these findings clinically, following the observation that those patients with ovarian and NSCLC carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase I study recommended carboplatin (CBDCA, area under the curve\u00a0=\u00a05) plus pemetrexed (PEM, 500\u00a0mg/m(2)) for elderly patients (\u226575-years old) with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic NSCLC: a single center 10-year experience. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: The primary objective of this retrospective analysis is to assess efficacy and toxicity of a chemotherapeutic regimen using weekly carboplatin in combination with weekly paclitaxel as first-line therapy for advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: All patients with stage IIIB/IV NSCLC treated with weekly carboplatin AUC (area under the curve) 3 days 1, 8, 15, q4w in combination with weekly paclitaxel 75 mg/m(2) days 1, 8, 15, q4w as first-line therapy at the Kantonsspital Graubuenden between August 2004 and May 2014 were retrospectively analyzed by medical record review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Weekly carboplatin in combination with weekly paclitaxel results in good response rates and acceptable toxicity in patients with advanced and metastatic NSCLC including patients with poor risk features (brain metastases, older age, and impaired PS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of NSCLC in patients who are not candidates for curative surgery and/or radiation therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In a phase\u00a03 study, chemonaive advanced NSCLC patients with PS2 receiving pemetrexed\u2011carboplatin versus pemetrexed experienced improved overall survival [hazard ratio\u00a0(HR)=0.62; P=0.001], progression-free survival (HR=0.46; P<0.001) and response (P=0.032). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-na\u00efve NSCLC in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " We investigated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) with concurrent radiotherapy for unresectable locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Preliminary efficacy suggests veliparib may enhance carboplatin and paclitaxel activity, providing benefit to patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVES: Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced NSCLC both as monotherapy in the relapsed setting or with carboplatin and paclitaxel in the first-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This signature was validated on baseline plasma samples from patients enrolled in a randomized trial of daily linifanib 7.5 mg, linifanib 12.5 mg, or placebo added to first-line carboplatin and paclitaxel chemotherapy for advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Cost-effectiveness analysis of EGFR mutation testing in patients with NSCLC with gefitinib or carboplatin-paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pemetrexed plus carboplatin therapy is widely administered to patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: The participants were patients with chemo-na\u00efve advanced NSCLC treated with PMT plus carboplatin (CBDCA) in prospective clinical phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiation for Stage III NSCLC: Is There an Impact on Radiation Pneumonitis Rates?  Palma DA(1), Senan S(2), Rodrigues G(3). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced NSCLC and performance status 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: A cost-effectiveness analysis was conducted based on a randomized phase III trial in patients with advanced NSCLC and ECOG performance status of 2 (PS2), comparing doublet regimen pemetrexed plus carboplatin with pemetrexed alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Our study suggests superiority of the combined pemetrexed plus carboplatin regimen in terms of efficacy as well as cost-effectiveness in advanced NSCLC patients with a poor performance status of 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced NSCLC in older patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Here, using Epo-Cy5.5 as theranostic near-infrared fluorescent probe we analyzed the effects of rhuEpo as co-medication to carboplatin in non-small-cell-lung-cancer (NSCLC)-xenografts with different tumor cell EpoR-expression (H838 ~8-fold higher than A549). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Nude mice bearing subcutaneous A549 and H838 NSCLC-xenografts received either only carboplatin or carboplatin and co-medication of rhuEpo in two different doses. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in NSCLC: Findings From the Florida Initiative for Quality Cancer Care. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "MSA-eCrCl was used to simulate carboplatin dosing in a retrospective series of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In calculating carboplatin doses for 89 NSCLC patients with MSA and CG-eCrCl, median error of CG-determined carboplatin dose was 5.5\u00a0% (range -19.0 to 44.2\u00a0%), assuming that MSA was better at estimating CrCl. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS AND MATERIALS: Forty-eight patients with previously untreated NSCLC received intensity modulated radiation therapy (63 Gy/35 fractions) on Monday through Friday, with chemotherapy (paclitaxel 45 mg/m\u00b2, carboplatin area under the curve [AUC] = 2) on Mondays, for 7 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "To investigate whether the abnormal expression of CNTN-1 is associated with characteristics of patients with NSCLC, immunohistochemistry was used to detect CNTN-1 expression in 143 tissue samples from NSCLC patients and the results showed that the degree of CNTN-1 expression positively correlated with lymphatic invasion in patients with lung adenocarcinoma who received adjuvant cisplatin- or carboplatin-based treatment after surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin (CBDCA) in a phased schedule improved progression-free survival in a phase II NSCLC study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Investigation of prognostic factors affecting efficacy in carboplatin- and paclitaxel-based first-line chemotherapies for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The present meta-analysis aims to investigate prognostic factors affecting overall survival (OS), progression-free survival (PFS) or time to progression (TTP), and overall response rate (ORR) in carboplatin and paclitaxel-based first-line chemotherapies for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: We performed a literature search in PubMed for randomized phase II and III clinical trials in patients with NSCLC treated with carboplatin and paclitaxel as first-line chemotherapy published from January 2000 to December 2013 to investigate prognostic factors affecting OS, PFS or TTP, and ORR by linear regression analysis and logistic regression analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " LESSONS LEARNED: The concomitant use of weekly nab-paclitaxel and carboplatin with concurrent radiotherapy was demonstrated to be a safe therapeutic approach in this phase I trial of 10 evaluable patients with stage III NSCLC.Despite the lack of systemic glucocorticoids, there were no reported infusion reactions or cases of peripheral neuropathy in this trial, both of which are known to occur with the use of paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Food and Drug Administration in October 2012 for use along with carboplatin in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This study was undertaken to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly nab-paclitaxel given in combination with carboplatin and concurrent radiotherapy in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Concurrent chemoradiotherapy with nab-paclitaxel 40 mg/m(2) and carboplatin AUC 2 is a safe and well-tolerated therapeutic regimen in patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The objectives of the present study were to define maximum tolerated dose and the recommended phase II dose (RPTD) of AXL1717 in combination with gemcitabine HCl and carboplatin in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "AXL1717 in combination with gemcitabine HCl and carboplatin is a possible treatment approach in previously untreated, locally advanced, or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Plasma samples from 40 patients with stage IV adeno-NSCLC, treated with first-line chemotherapy with carboplatin (AUC5) plus pemetrexed (500 mg/m(2)), were collected prior to chemotherapy and 48 h after treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pemetrexed and gemcitabine versus carboplatin and gemcitabine in NSCLC: a randomized noninferiority phase II study in one center. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Although carboplatin is one of the standard chemotherapeutic agents for NSCLC, it has limited therapeutic efficacy due to activation of a survival signaling pathway and the induction of multidrug resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Based on this mechanism, curcumin has potential as a chemosensitizer for carboplatin in the treatment of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The most common regimen at all stages was carboplatin and paclitaxel.BACKGROUND: Platin-based adjuvant chemotherapy has extended survival in clinical trials in patients with completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced NSCLC patients with activating epidermal growth factor receptor mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This was a multicentre, single-arm, phase II trial of carboplatin, S-1, and gefitinib in advanced NSCLC patients with activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Combination chemotherapy with carboplatin, S-1, and gefitinib is efficacious and well tolerated as a first-line treatment in advanced NSCLC patients with activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB NSCLC (RTOG 0617): a randomised, two-by-two factorial phase 3 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the NSCLC cell line H460. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " The present study investigated the ability of carboplatin and paclitaxel to sensitize human NSCLC cells to carbon-ion beam irradiation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "NSCLC H460 cells treated with carboplatin or paclitaxel were irradiated with X-rays or carbon-ion beams, and radiosensitivity was evaluated by clonogenic survival assay. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced NSCLC: analysis of safety and efficacy in patients with renal impairment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This analysis evaluated the safety and efficacy of nab-paclitaxel (nab-P) versus solvent-based paclitaxel (sb-P), both in combination with carboplatin (C), in patients with advanced NSCLC and renal impairment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "To evaluate the efficacy and tolerability of combination chemotherapy with biweekly paclitaxel and carboplatin for elderly patients with advanced NSCLC, we conducted a multicenter, non-randomized, open label, phase II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: The combination of biweekly paclitaxel and carboplatin was effective and well tolerated in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m(2)) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous NSCLC: Kumamoto thoracic oncology study group trial 1002. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVES: This study was designed to determine the recommended dose of carboplatin and pemetrexed for elderly (\u226570-year-old) chemotherapy-na\u00efve patients with advanced nonsquamous NSCLC and to investigate the pharmacokinetics of pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: For elderly chemotherapy-na\u00efve patients with advanced nonsquamous NSCLC, the combination of carboplatin AUC 5 plus pemetrexed 500 mg/m(2) is recommended as a promising regimen; however, a reduction of the pemetrexed dose may be required for patients with renal dysfunction because of the high risk of hematotoxicities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Irinotecan and Carboplatin (IC) Regimen for Small-Cell Lung Cancer and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " First-line chemotherapy treatment of advanced NSCLC: does cisplatin versus carboplatin make a difference?  Tiseo M(1), Ardizzoni A, Boni L. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "For each tumor type, Medicare patients who were 75 years or older had median survivals that were six to eight weeks shorter than those of trial patients (4.3 vs 5.8 months following treatment with single agent gemcitabine for advanced pancreatic cancer, P = .03; 7.3 vs 8.9 months following treatment with carboplatin and paclitaxel for stage IV NSCLC, P = .91; 8.2 vs 10.2 months following treatment with CDDP/ VP16 for extensive stage small cell lung cancer, P \u2264 .01), whereas younger Medicare patients had survival times that were similar to those of trial patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III NSCLC: an analysis of Veterans Health Administration data. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with poor-risk unresectable stage III NSCLC received two cycles of carboplatin at an AUC of 5 and nab-paclitaxel at 100 mg/m on days 1 and 8 every 21 days, followed by erlotinib administered concurrently with thoracic radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Patients with poor-risk stage III NSCLC had better than expected outcomes with a regimen of induction carboplatin/nab-paclitaxel followed by thoracic radiotherapy and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Cost-Utility Analysis of First-Line Regimen Between Cisplatin Plus Pemetrexed and Carboplatin Plus Paclitaxel In Advanced Non-Squamous NSCLC in Thailand. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced NSCLC treated primarily with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or meta-static nsclc. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous NSCLC, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: This phase II study evaluated the response rate (RR) and safety of combination therapy with carboplatin (CBDCA) and pemetrexed (PEM) in Japanese patients with non-squamous NSCLC (non-sq NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "MATERIAL AND METHODS: In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m(2) or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m(2) (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Recently, a subset analysis of a completed phase III trial demonstrated that use of nab-paclitaxel with carboplatin led to improved responses in patients with squamous NSCLC compared with solvent-based paclitaxel with carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In this review, the current experience and evolving role of nab-paclitaxel with carboplatin in the treatment of squamous NSCLC is discussed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Comparing docetaxel plus Cisplatin with Paclitaxel plus Carboplatin in chemotherapy-na\u00efve patients with advanced NSCLC: a single institute study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Motesanib plus carboplatin/paclitaxel in patients with advanced squamous NSCLC: results from the randomized controlled MONET1 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with stage IIIB/IV or recurrent squamous NSCLC (without prior systemic therapy for advanced disease) received up to six 3-week cycles of chemotherapy (carboplatin, area under the curve 6 mg/mL\u2022min/paclitaxel, 200 mg/m) and were randomized 1:1 to receive motesanib 125 mg (Arm A) or placebo (Arm B) once daily. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Motesanib plus carboplatin/paclitaxel had unacceptable toxicity compared with carboplatin/paclitaxel alone in patients with advanced squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "carboplatin-based chemoradiotherapy in patients >65 years of age with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Cisplatin or Carboplatin for advanced NSCLC?  Sun X(1), Zheng Y. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "S-1 and cisplatin is an active first-line chemotherapy regimen for advanced NSCLC and S-1 and carboplatin is noninferior to a carboplatin and paclitaexel regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "EXPERT OPINION: Encouraging results have been described with the administration of motesanib as first-line treatment in combination with carboplatin and paclitaxel in Asian patients with non-squamous advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVE: To compare the efficacy and safety between liposome-paclitaxel plus carboplatin (LPC) and paclitaxel plus carboplatin (PC) as first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of nimotuzumab in combination with chemotherapy (docetaxel and carboplatin) versus chemotherapy alone in patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Analysis of continuous first-line treatment with docetaxel and carboplatin for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " The present study aimed to analyze the efficacy and safety of multiple cycles of docetaxel and carboplatin (CBDCA) as a first-line treatment in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " [Clinical experience of the use of pemetrexed (PEM) combined with cisplatin (CDDP)/Carboplatin (CBDCA) followed by long-term maintenance PEM in patients with non-squamous NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous NSCLC that were treated in our hospital. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology received open-label figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (area under the concentration-time curve, 6 mg \u00b7 min/mL) or paclitaxel and carboplatin alone once every 3 weeks for up to six cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This study investigates the potential of (18)F-FLT to monitor acute effects of chemotherapy on cellular proliferation and its recovery in bone marrow, spleen, and liver during treatment with 2 different chemotherapy regimens.METHODS: Sixty patients with NSCLC underwent concurrent radical chemoradiotherapy to 60 Gy in 6 wk with either cisplatin/etoposide (C/E, n = 28) weeks 1 and 5 or weekly carboplatin/paclitaxel (C/P, n = 32) regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), NSCLC, and small cell lung cancer (SCLC) tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVE: Gemcitabine combined with carboplatin (GC) is a widely used regimen for advanced NSCLC, but clinical outcome is still hampered by its toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Forty patients with stage IIIB or IV NSCLC were randomized to receive either a biweekly regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 14) and carboplatin (area under the concentration-time curve, AUC = 3 on days 1 and 14)] every 28 days or a standard regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 8) and carboplatin (AUC = 5 on day 1)] every 21 days. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This phase 1 dose-escalation study evaluated the pharmacokinetics, safety, and efficacy of linifanib in combination with carboplatin/paclitaxel in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Linifanib added to carboplatin/paclitaxel is well tolerated in Japanese patients with advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced NSCLC: A case series of 20 patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The Japan Clinical Oncology Group 0301 trial (JCOG0301) was the first study to demonstrate that thoracic radiation therapy (TRT) with daily low-dose carboplatin may improve the outcome of elderly patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We retrospectively assessed the efficacy and toxicity of weekly paclitaxel in combination with carboplatin and concurrent TRT in patients aged \u226575 years with previously untreated locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The aim of this study was to assess the safety and efficacy of concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In conclusion, concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine is well-tolerated and effective in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Aprepitant in patients with advanced NSCLC receiving carboplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We evaluated the efficacy and safety of triple antiemetic therapy with aprepitant, a 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonist, and dexamethasone in patients with advanced NSCLC who received carboplatin-based first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVE: The primary objective of this study was to evaluate the safety and tolerability of carboplatin plus pemetrexed for elderly patients (\u226575 years) with chemotherapy-na\u00efve advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: The combination of carboplatin at an area under the concentration-time curve of 5 plus pemetrexed at 500 mg/m(2) was determined as the recommended dose in chemotherapy-na\u00efve elderly patients (\u226575 years) with advanced non-squamous NSCLC, in view of overall safety and tolerability. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Synergistic antitumor effect of a combination of paclitaxel and carboplatin with nobiletin from Citrus depressa on NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced NSCLC: north japan lung cancer group trial 0801. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: While platinum-based doublet chemotherapy is standard of care for patients presenting with metastatic NSCLC, the optimal platinum agent (cisplatin versus carboplatin) is unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Acute cerebral arterial embolism following pemetrexed and carboplatin treatment in NSCLC: A case report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The combination of pemetrexed and carboplatin has exhibited significant antitumor activity, with mild manageable toxicity in patients with advanced non-small-cell lung cancer (NSCLC), whereas cerebral arterial embolism has not been recognized as a side effect associated with this regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Pemetrexed plus carboplatin is routinely used for the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "(18)F-ICMT-11 uptake was compared to molecular biochemical measures of cell death in PC9 and A549 NSCLC cells following treatment with carboplatin in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This study aimed to evaluate the efficacy and safety of weekly docetaxel with carboplatin as first-line chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 NSCLC harbouring EGFR mutations: a randomized, phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II trial of paclitaxel-carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: This study was conducted to evaluate the efficacy and safety of paclitaxel-carboplatin combined with intercalated gefitinib in patients with advanced, untreated, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "MATERIALS AND METHODS: TS immunohistochem\u00edstry was performed on biopsies and available resection specimens from 65 NSCLC patients stage T1-3N0-2 treated with preoperative carboplatin and paclitaxel [neoadjuvant chemotherapy (NAC)-group] and from 53 NSCLC patients stage T1-4N0-1 treated with surgery without preceding chemotherapy [operation (OP)-group] that served as controls. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "MATERIALS AND METHODS: Patients \u2265 70 years with untreated, metastatic NSCLC were randomized to Erlotinib (E), 150 mg/day or Carboplatin (AUC5) plus Vinorelbine (25mg/m(2) on days 1 and 8) every three weeks (CV). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB or stage IV advanced primary NSCLC were randomly assigned (1:1:1) to receive up to 6 courses of standard-dose paclitaxel and carboplatin or a combination of paclitaxel, carboplatin, and mapatumumab (10 mg/kg or 30 mg/kg). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: This study showed no clinical benefit from adding mapatumumab to carboplatin and paclitaxel in unselected patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A retrospective comparison of adjuvant chemotherapeutic regimens for NSCLC: paclitaxel plus carboplatin versus vinorelbine plus cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Although paclitaxel plus carboplatin (PC) failed to demonstrate efficacy in patients with stage IB NSCLC, an exploratory analysis suggested that patients with large tumors can benefit from adjuvant PC therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The aim of the study was to evaluate the efficacy and safety of first-line chemotherapy based on platinums (carboplatin or cisplatin) plus a third generation compound (vinorelbine or gemcitabine) in elderly patients with advanced NSCLC in daily clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " The 130 nm albumin-bound form of paclitaxel, nab-paclitaxel (Abraxane(\u00ae)), was recently approved by the US FDA for the first-line treatment of locally advanced or metastatic NSCLC in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In a Phase III registrational trial, nab-paclitaxel plus carboplatin demonstrated a significantly improved overall response rate, the primary endpoint, and a trend toward improved survival compared with solvent-based paclitaxel plus carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Associations between TS, TTF-1, FR-\u03b1, FPGS, and overall survival in patients with advanced NSCLC receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The aim was to investigate associations between these biomarkers and survival in patients who participated in a phase III trial comparing pemetrexed plus carboplatin with gemcitabine plus carboplatin as first-line chemotherapy in advanced NSCLC (n = 436). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Phase II clinical trials in advanced NSCLC found efficacy and safety of DCP-plus-paclitaxel comparable to carboplatin-plus-paclitaxel but better tolerability. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "A recent Phase III trial compared the effects of weekly nab-paclitaxel in combination with carboplatin versus sb-paclitaxel in combination with carboplatin given every 3 weeks for first line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: This two-part phase 2 study evaluated the efficacy and safety of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, combined with carboplatin/paclitaxel in patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Although toxicity was predictable and manageable, the addition of panitumumab to paclitaxel/carboplatin did not improve TTP in patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Pemetrexed plus carboplatin (PC) had better chemotherapy compliance and efficiency in advanced non-squamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced NSCLC: NCIC Clinical Trials Group study BR29. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: This randomised double-blind placebo-controlled study evaluated the addition of cediranib, an inhibitor of vascular endothelial growth factor receptors 1-3, to standard carboplatin/paclitaxel chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: nab-Paclitaxel (nab-P) is approved, in the United States, in combination with carboplatin for the first-line treatment of advanced NSCLC, based on a randomized phase 3 trial of nab-P plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II trial of pemetrexed continuation--maintenance after carboplatin-based induction in untreated non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " AIM: We conducted a phase II study to evaluate the efficacy and safety of pemetrexed continuation-maintenance after carboplatin-based induction for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Thirty-four patients with advanced or recurrent non-squamous NSCLC received carboplatin (area under the concentration-time curve 6 mg/ml\u00d7min) plus pemetrexed (500 mg/m(2)) on day 1 tri-weekly. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The favorable risk-benefit profile of pemetrexed + carboplatin makes it an appropriate first-line treatment option for elderly patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Author information: (1)Beijing Lung Cancer Center, Capital Medical University, Beijing, China;  BACKGROUND: To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: In this rapidly accrued study, docetaxel and carboplatin were well-tolerated in the adjuvant treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "MATERIALS AND METHODS: TUBB3 expression was investigated by immunohistochemistry performed on diagnostic biopsies and on available subsequent resection specimens in 65 NSCLC patients stage T1-3N0-2 who received neoadjuvant carboplatin and paclitaxel (NAC-group). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced NSCLC: LOGIK0401. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Concurrent chemoradiation with weekly carboplatin and paclitaxel followed by vinorelbine consolidation is effective for stage III NSCLC and shows a generally mild toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-na\u00efve metastatic/unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-na\u00efve patients with metastatic/unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Tigatuzumab was well tolerated but did not improve efficacy of carboplatin/paclitaxel in systemic therapy-na\u00efve, unselected advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "paclitaxel plus carboplatin in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Carboplatin-containing regimens as front-line treatment for advanced NSCLC in two groups of elderly. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVES: We evaluated the impact of a carboplatin-based doublet in two groups of elderly patients with advanced NSCLCs (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "MATERIALS AND METHODS: A retrospective analysis of all consecutive elderly patients (\u226770 year old) with advanced NSCLC who received a carboplatin-based doublet as front-line therapy at our medical oncology unit was performed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: This evaluation shows the safety and efficacy of a carboplatin-based doublet given as first-line chemotherapy in elderly advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Tissue samples were collected from NSCLC mice treated with gemcitabine plus carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " This study sought to investigate the efficacy and tolerability of the regimen of low-dose gemcitabine combined with carboplatin in chemo-na\u00efve patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III NSCLC: a phase I trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The purpose of this phase I trial was to explore the maximum tolerated dose (MTD) of accelerated hypofractionated three-dimensional conformal radiotherapy (3-DCRT) (at 3 Gy/fraction) administered in combination with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Cisplatin versus carboplatin in combination with third-generation drugs for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "OBJECTIVES: To assess the efficacy and safety of carboplatin-based chemotherapy when compared with cisplatin-based chemotherapy, both in combination with a third-generation drug, in people with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third-generation drug. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "SELECTION CRITERIA: Randomised clinical trials comparing regimens with carboplatin or cisplatin combined with a third-generation drug in people with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "AUTHORS' CONCLUSIONS: The initial treatment of people with advanced NSCLC is palliative, and carboplatin can be a treatment option. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced NSCLC: a feasibility study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The purpose of this study was to evaluate the feasibility of utilizing high-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for the treatment of local advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We performed a retrospective analysis of 722 stage IIIB/IV NSCLC patients from a double-blind placebo-controlled trial of thalidomide or placebo 100-200 mg/day, combined with gemcitabine/carboplatin (for up to four cycles), then given as single agent maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "hzsx888@163.com  OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "mnishio@jfcr.or.jp  BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-na\u00efve NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "socinskima@upmc.edu  BACKGROUND: This analysis compared the efficacy and safety outcomes by histology of nab-paclitaxel (nab-P) plus carboplatin (C) versus solvent-based paclitaxel (sb-P) plus C in patients with advanced NSCLC based on preplanned stratification factors specified in the phase III trial protocol. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Feasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: The purpose of this study was to evaluate the feasibility and compliance of adjuvant chemotherapy of S-1 plus carboplatin for patients with completely resected NSCLC of pathological stage IB-IIIB. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC: a randomized, phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Continuation maintenance with pemetrexed may be a feasible treatment option for patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin and pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: In this phase 3 trial, patients with untreated stage IIIB/IV NSCLC were randomly assigned in a 1:1 ratio by use of an interactive internet response system with minimisation algorithm (stratified by disease stage, tumour histology, smoking status, and chemotherapy regimen) to receive six cycles of gemcitabine (1250 mg/m(2) on days 1 and 8, intravenously) plus platinum (carboplatin 5\u2008\u00d7\u2008area under the curve or cisplatin 75 mg/m(2) on day 1, intravenously) with intercalated erlotinib (150 mg/day on days 15-28, orally; chemotherapy plus erlotinib) or placebo orally (chemotherapy plus placebo) every 4 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Carboplatin-paclitaxel chemotherapy combination is the standard first-line treatment of advanced ovarian cancer and is the most commonly used treatment combination shown to be effective in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The study was prospectively performed from February 2009 to July 2011 and involved 103 patients with stages Ic-IV ovarian (n = 51) and advanced NSCLC (n = 52) who were administered a maximum of 6 cycles of carboplatin-paclitaxel as a first-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced NSCLC and Eastern Cooperative Oncology Group performance status of 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced NSCLC with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The treatment approach for early-stage disease does not differ from that of other histologic subtypes of NSCLC; in locally advanced unresectable or metastatic disease, doublet chemotherapy regimens (including cisplatin or carboplatin and a third-generation agent such as gemcitabine, taxanes, or vinorelbine) remain the cornerstone of front-line systemic treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Author information: (1)Department of Medical Oncology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA  INTRODUCTION: After early reports of vandetanib's efficacy in the induction setting, we evaluated the effect of combination docetaxel, carboplatin, and vandetanib, followed by maintenance therapy with either vandetanib, or placebo on progression-free survival (PFS) in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with advanced NSCLC were randomized to induction docetaxel (75 mg/m) + carboplatin (area under the curve of 6) on day 1 of a 21-day cycle, and daily vandetanib (100 mg/day orally) for four cycles, followed by daily vandetanib (300 35 mg/day orally) or placebo until progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with NSCLC prospectively stratified by beta-3 tubulin status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Hypersensitivity reactions to carboplatin and cisplatin in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "A 74-year-old male developed relapsed NSCLC two years after a lobectomy and adjuvant chemotherapy including carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Irinotecan and carboplatin are effective against NSCLC and demonstrated synergism with non-cross-resistance in preclinical studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We conducted a phase II study of weekly combination of carboplatin and irinotecan as first-line chemotherapy for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: The weekly combination of carboplatin and irinotecan showed favorable activity and manageable toxicity profiles in chemo-na\u00efve patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "gbanna@yahoo.com  The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "yokomise@kms.ac.jp  BACKGROUND: We have reported promising results of surgery after induction chemoradiotherapy (carboplatin-taxane, 50 Gy radiation) for cN2,3 non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced NSCLC: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with stages II and IIIA/B NSCLC received induction paclitaxel 225 mg/m2 intravenously (IV) and carboplatin area under the curve (AUC) 6 both days 1 and 22, followed by concurrent weekly paclitaxel (50 mg/m2) and carboplatin (AUC 2), with hyperfractionated radiation therapy (69.6 Gy at 1.2 Gy BID). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-na\u00efve patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: This study prospectively evaluated the efficacy and safety of pemetrexed and carboplatin followed by maintenance pemetrexed in chemo-na\u00efve patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Pemetrexed/carboplatin followed by pemetrexed was well tolerated and active for front-line treatment of advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Carboplatin-paclitaxel is a reference regimen in the treatment of locally advanced or disseminated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In order to understand and overcome the drug resistance pattern of NSCLC after carboplatin plus paclitaxel exposure, levels of mRNA expression of multidrug resistance 1 (MDR1) and multidrug resistance-associated protein 3 (MRP3) were investigated in primary NSCLC cell lines (A-549 and A-427) and a metastasis-derived NSCLC cell line (NODO). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced NSCLC: a phase II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " The synergistic activity of pemetrexed with platinum agents in NSCLC and the renal safety of carboplatin suggest a balanced benefit/risk profile for this combination in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This multicenter, single-arm, phase II study included 62 patients (\u226570 years) with chemona\u00efve advanced NSCLC, Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and assigned to receive 6 cycles of 3-weekly pemetrexed 500 mg/m(2) and carboplatin AUC 5. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The ORR is within the range of data reported for pemetrexed-carboplatin in the general NSCLC population (24-31%). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " The combination of carboplatin and paclitaxel is one of the most commonly used regimens for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We retrospectively analyzed the weekly [paclitaxel, 70 mg/m(2)/week on days 1, 8 and 15, and carboplatin, area under the curve (AUC)=6, every 4 weeks] and standard tri-weekly (paclitaxel, 200 mg/m(2), and carboplatin, AUC=6, on day 1 every 3 weeks] schedules in patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "lpazares@hotmail.com  INTRODUCTION: This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced NSCLC: A Randomized Clinical Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of nedaplatin/gemcitabine (NG) and carboplatin/gemcitabine (CG) in the management of untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Carboplatin is a platinum agent that is used for treatment of NSCLC and ovarian cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "\u201cPhase II study of the anti\u2013insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic NSCLC\u201d. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced NSCLC: updated results of the West Japan Oncology Group LETS study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: A phase III study (Lung Cancer Evaluation of TS-1) previously demonstrated noninferiority in terms of overall survival (OS) at interim analysis for carboplatin-S-1 compared with carboplatin-paclitaxel for first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: These results establish the efficacy and safety of carboplatin-S-1 in patients with advanced NSCLC regardless of tumor histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Images were acquired in 22 consecutive patients with advanced NSCLC randomized to receive carboplatin/paclitaxel/sorafenib or placebo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase I clinical and pharmacokinetic study of bi-weekly carboplatin/paclitaxel chemotherapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " AIM: We evaluated the pharmacokinetics and quality of life of elderly patients with advanced NSCLC treated with bi-weekly carboplatin and paclitaxel chemotherapy, and determined the maximum tolerated dose (MTD) of this treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced NSCLC: North Central Cancer Treatment Group Study N0528. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " INTRODUCTION: The purpose of this study was to assess the safety and efficacy of gemcitabine and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Mistletoe as complementary treatment in patients with advanced NSCLC treated with carboplatin-based combinations: a randomised phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This randomised phase II study of iscador combined with carboplatin-containing regimens was conducted in chemotherapy-na\u00efve advanced NSCLC patients to assess its influence on chemotherapy-related side-effects and QoL. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We evaluated the effectiveness of PCRT for inducing downstaging using mainly three chemoradiotherapy regimens; cisplatin plus Tegafur-Gimeracil-Oteracil Potassium (S-1), cisplatin plus Tegafur-Uracil (UFT), or 1,1'cyclobutanedicarboxylate (Carboplatin, CBDCA) plus paclitaxel, with concurrent radiation therapy in 19 patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced NSCLC receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with advanced, previously untreated NSCLC were randomly assigned to an endostatin treatment group (paclitaxel + carboplatin + endostatin) and a control group (paclitaxel + carboplatin + placebo). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: CECs and CKs could be biomarkers for selecting patients with NSCLC who will benefit from treatment with endostatin in combination with paclitaxel plus carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Carboplatin has efficacy in treating advanced NSCLC in combination with other drugs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Combining ABT-751 with carboplatin suppressed growth of lung cancer cell lines and had modest clinical antitumor activity in advanced NSCLC previously treated predominantly with carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Safety and efficacy of weekly nab\u00ae-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The present study was conducted to evaluate the efficacy and safety of the combination of gemcitabine at a low-dose prolonged infusion in comparison with standard dose gemcitabine with carboplatin in chemonaive patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: In NSCLC, gemcitabine low-dose prolonged infusion with carboplatin has low toxicity, especially thrombocytopenia, and has an activity comparable with gemcitabine given in higher dose in standard infusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Tissue and peripheral blood samples were collected from 49 advanced NSCLC patients treated with gemcitabine plus carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: The expression of RRMI and ERCC1 genes in tumor tissues and RRM1 in peripheral blood lymphocytes is closely correlated with the response to chemotherapy and prognosis of patients with advanced NSCLC treated with gemcitabine plus carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " RE: A phase I trial of radiation dose escalation using accelerated concomitant boost radiotherapy concurrently with weekly carboplatin/paclitaxel in patients with good performance status and Stage IIB-IIIA/B NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with NSCLC stage IIIB or IV received as first-line treatment four cycles of carboplatin (AUC 5) (day 1) plus gemcitabine 1000\u00a0mg/m(2) (days 1 and 8) every 3\u00a0weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Our results support both the feasibility of incorporating 3D-CRT with concurrent vinorelbine and carboplatin and a dose escalation to 70 Gy for Chinese patients with NSCLC, based on the acceptable toxicity and encouraging overall response and survival rates. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na\u00efve NSCLC with sensitive EGFR gene mutations (NEJ002). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "akinoue@idac.tohoku.ac.jp  BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced NSCLC harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Between January 2007 and January 2012, 141 patients with advanced NSCLC were treated with curative intent according to the CRT protocol (50-70 Gy at 2 Gy/day with paclitaxel 135-175 mg/m(2) and carboplatin 100 mg/m(2) on days 1, 22, and 43). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "For example, in patients with NSCLC treated with paclitaxel and carboplatin, the phased administration of ipilimumab (an antibody against CTLA-4) resulted in substantial improvements in immune-related progression-free survival compared with chemotherapy alone (5.7 versus 4.6 months; P\u00a0=\u00a00.05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase Ib safety and pharmacokinetic study of volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin and paclitaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: This phase Ib study evaluated volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin (Eli Lilly and Co., Indianapolis, IN) and paclitaxel (Taxol) in advanced, untreated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Volociximab combined with carboplatin and paclitaxel was generally well-tolerated and showed preliminary evidence of efficacy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced NSCLC: evaluation of patients recruited from mainland China. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Pharmacogenetic study of patients with advanced NSCLC treated with second-line pemetrexed or pemetrexed-carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "mtiseo@ao.pr.it  PURPOSE: To correlate candidate polymorphisms affecting pemetrexed and carboplatin activity with clinical outcome of patients with advanced NSCLC treated in second-line with pemetrexed or pemetrexed plus carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Because of safety findings from the Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy in NSCLC (ESCAPE) trial, patients with squamous cell histology were withdrawn from the trial in February 2008 and excluded from analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We propose to define the recommended dose (RD) of VFL in combination with carboplatin in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Twenty-one chemonaive patients with advanced NSCLC were treated with a first-line chemotherapy of VFL and carboplatin both given on day 1 every 3 weeks with 3 dose levels. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: The combination of VFL (320 mg/m(2)) and carboplatin AUC 5 given once every 3 weeks is established as the RD of the combination, which was shown to be active in these chemonaive NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " [Efficacy and adverse effets of nimotuzumab plus palitaxel liposome and carboplatin in the treatment for advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " OBJECTIVE: To evaluate the efficacy of nimotuzumab combined with palitaxel liposome and carboplatin (LP) regimen for treatment of advanced NSCLC, and to observe the changes of tumor markers and toxicities in the treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS Forty-one patients with advanced NSCLC were randomly divided into 2 groups: 21 patients in the observation group were treated with nimotuzumab (200 mg per week for 6 weeks), palitaxel liposome 160 mg/m2 and carboplatin (AUC = 6). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous NSCLC: MONET1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous NSCLC and in the subset of patients with adenocarcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under the curve, 6 mg/ml \u00b7 min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase II study of carboplatin and pemetrexed in advanced non-squamous, NSCLC: Kyoto Thoracic Oncology Research Group Trial 0902. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: This was a single-arm phase II study of carboplatin and pemetrexed in Japanese patients with chemo-naive advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: The combination of carboplatin and pemetrexed was safe and effective in advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced NSCLC: a randomized, phase-II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We wanted to evaluate the efficacy and safety of biweekly gemcitabine and low-dose carboplatin combination therapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: In this phase-II trial, chemotherapy-naive elderly patients (aged \u226576 years) with NSCLC were randomly treated with biweekly combination therapy with gemcitabine and carboplatin (1000 mg/m(2) gemcitabine and carboplatin at an area under the curve (AUC) of 3 on days 1 and 15, every 4 weeks) or gemcitabine monotherapy (1000 mg/m(2) on days 1, 8 and 15, every 4 weeks). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Biweekly gemcitabine and low-dose carboplatin combination chemotherapy showed acceptable efficacy, toxicity, and tolerability in those aged \u226576 years with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients with stage III locally advanced NSCLC received paclitaxel, 50\u2009mg/m(2)/week, with carboplatin area under the curve (AUC)\u2009=\u20092, weekly for 7\u2009weeks, and concurrent radiotherapy, 64.8\u2009Gy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with NSCLC: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The aim of this study was to assess whether radiotherapy plus carboplatin results in longer survival than radiotherapy alone in elderly patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Patients older than 70 years with unresectable stage III NSCLC were randomly assigned to chemoradiotherapy (60 Gy plus concurrent low-dose carboplatin [30 mg/m(2) per day, 5 days a week for 20 days]) or radiotherapy alone, using a minimisation method with biased-coin assignment balancing on Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1 vs 2), stage (IIIA vs IIIB), and institution. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " BACKGROUND: For NSCLC patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV NSCLC: results from a randomized, double-blind, multicenter phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: Patients (N = 204) with chemotherapy-naive NSCLC were randomly assigned 1:1:1 to receive paclitaxel (175 mg/m(2)) and carboplatin (area under the curve, 6) with either placebo (control) or ipilimumab in one of the following two regimens: concurrent ipilimumab (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or phased ipilimumab (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimumab plus paclitaxel and carboplatin).Treatment was administered intravenously every 3 weeks for \u2264 18 weeks (induction). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipilimumab in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced NSCLC: final results of a phase III trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus carboplatin in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "PATIENTS AND METHODS: In all, 1,052 untreated patients with stage IIIB to IV NSCLC were randomly assigned 1:1 to receive 100 mg/m(2) nab-paclitaxel weekly and carboplatin at area under the concentration-time curve (AUC) 6 once every 3 weeks (nab-PC) or 200 mg/m(2) sb-paclitaxel plus carboplatin AUC 6 once every 3 weeks (sb-PC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS AND MATERIALS: Nine of 44 patients with stage III NSCLC in a prospective phase II trial of concurrent paclitaxel/carboplatin with proton radiation [74 Gy(RBE) in 37 fractions] had modifications to their original treatment plans after re-evaluation revealed changes that would compromise coverage of the target volume or violate dose constraints; plans for the other 35 patients were not changed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "RESULTS: The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with a mean IC(50) of 2.5 \u03bcmol/l in a variety of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "In particular, ipilimumab showed promising results in a first-line NSCLC phase II study combining carboplatin/paclitaxel chemotherapy with concurrent or phased ipilimumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "wlhwq@yahoo.com  OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "kmori@tcc.pref.tochigi.lg.jp  BACKGROUND: The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We report our experience with an upfront association of carboplatin and pemetrexed (areas under the curve, 5 and 500 mg/m(2), respectively), every 3 weeks, in 30 patients presenting with newly diagnosed brain metastases and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "The upfront association of carboplatin plus pemetrexed allows simultaneous treatment of cerebral and systemic disease in patients with NSCLC with newly diagnosed brain metastases and appears to be particularly interesting in terms of radiologic response and overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "This phase I, open-label dose-escalation study investigated BIBF 1120 combined with paclitaxel (Taxol) and carboplatin in first-line patients with advanced (IIIB/IV) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced NSCLC: West Japan Thoracic Oncology Group Trial (WJTOG) 2905. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: A combination phase I/II study was conducted in chemo-naive elderly patients with NSCLC to establish the toxicity and maximum tolerated dose (MTD) and to investigate the antitumor activity of carboplatin (CBDCA) plus gemcitabine (GEM). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: A total of 49 patients with advanced NSCLC receiving gemcitabine plus carboplatin chemotherapy were studied. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III NSCLC: the ECOG 3598 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients \u226575 years of age and with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSION: Use of 20 mg/m(2) vinorelbine on days 1 and 8, followed by carboplatin area under the curve of 4 mg/mL/min on day 1 every 4 weeks warrants a phase III study for elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "MATERIALS AND METHODS: Nineteen patients with regionally advanced NSCLC were treated with concurrent chemotherapy (carboplatin and paclitaxel [n = 18]) and proton therapy from August 2008 to April 2010 either with (n = 7) or without (n = 12) induction chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS AND MATERIALS: Patients with unresectable Stage III NSCLC were treated intravenously with carboplatin (area under the concentration curve 2) and paclitaxel (40 mg/m(2)) on Days 1, 8, 15, and 22 with concurrent twice-daily thoracic radiotherapy (1.5 Gy per fraction) beginning on Day 1 followed by two cycles of consolidation chemotherapy using carboplatin (area under the concentration curve 5) and paclitaxel (200 mg/m(2)). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: Patients (n\u00a0=\u00a048) with advanced NSCLC were treated with repetitive cycles of either paclitaxel/carboplatin or cisplatin/vinorelbine chemotherapy, bexarotene (400\u00a0mg/m(2)/day) administered continuously starting on day 4 of chemotherapy, and a lipid-lowering drug, either atorvastatin or fenofibrate, starting at least 5\u00a0days before chemotherapy due to hypertriglyceridemia induced by bexarotene. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic NSCLC--results of the nonrandomised phase II study TaxErb. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "jr.fischer@klinik-loewenstein.de  This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Figitumumab combined with carboplatin and paclitaxel in treatment-na\u00efve Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "METHODS: This phase I, open-label, dose-escalation study (ClinicalTrials.gov: NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg\u00b7min/mL) and paclitaxel (200 mg/m(2)) in Japanese patients (N = 19) with chemotherapy-na\u00efve, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel was well tolerated in chemotherapy-na\u00efve Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, NSCLC: clinical application of a protocol used in a previous phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "junsaito@sannet.ne.jp  PURPOSE: To assess the clinical applicability of a protocol evaluated in a previously reported phase II study of concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin in patients with stage III, unresectable, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": " Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-na\u00efve patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "We have evaluated the safety, tolerability, pharmacokinetics, and tumor response profile of weekly nab-paclitaxel (100 mg/m(2)) infusion together with administration of carboplatin at an area under the curve (AUC) of 6 every 3 weeks in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "carboplatin", "orig_sen": "CONCLUSIONS: The combination of nab-paclitaxel (100 mg/m(2)) administered weekly and carboplatin at an AUC of 6 every 3 weeks was well tolerated in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic NSCLC: An Indian study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Survival analysis in advanced NSCLC treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "For this reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II trial, who received fractioned cisplatin (30\u2009mg/sqm days 1-3q21) and oral etoposide (50\u2009mg, days 1-15q21) (mPE doublet) \u00b1bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III NSCLC: SWOG S0533. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "[Epub ahead of print]  Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III NSCLC: A Systematic Review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB NSCLC are carboplatin-paclitaxel and cisplatin-etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Objective: To conduct a systematic review of published trials to compare outcomes and toxic effects between cisplatin-etoposide and carboplatin-paclitaxel in patients with NSCLC receiving thoracic radiation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in NSCLC Stage IIIB/IV. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "OBJECTIVE: Carboplatin plus etoposide chemotherapy, which was formerly used as a low-cost first-line treatment, was used as third-line therapy for advanced NSCLC in order to compare its results with those of best supportive care as a treatment for improved quality of life (QoL) and progression-free survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "CONCLUSION: Carboplatin plus etoposide as third-line chemotherapy regimen demonstrated higher median progression-free survival in advanced NSCLC patients and did not adversely affect QoL. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiation for Stage III NSCLC: Is There an Impact on Radiation Pneumonitis Rates?  Palma DA(1), Senan S(2), Rodrigues G(3). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III NSCLC: an analysis of Veterans Health Administration data. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "This study investigates the potential of (18)F-FLT to monitor acute effects of chemotherapy on cellular proliferation and its recovery in bone marrow, spleen, and liver during treatment with 2 different chemotherapy regimens.METHODS: Sixty patients with NSCLC underwent concurrent radical chemoradiotherapy to 60 Gy in 6 wk with either cisplatin/etoposide (C/E, n = 28) weeks 1 and 5 or weekly carboplatin/paclitaxel (C/P, n = 32) regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), NSCLC, and small cell lung cancer (SCLC) tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "wlhwq@yahoo.com  OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "In the present study, NSCLC cell lines (H520 and SK-MES-1) were transfected with ARRB1 plasmids or small interfering ribonucleic acid (siRNA) and received treatment with DNA-damaging agents (cisplatin and etoposide). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "[Epub ahead of print]  Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced NSCLC (RTOG 3505). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m(2) intravenously (I.V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m(2) I.V. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "A phase 3 trial of lipegfilgrastim was conducted in patients with advanced NSCLC receiving cisplatin/etoposide (which produces mild-to-moderate myelosuppression). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced NSCLC treated with chemoradiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "The phase III PROCLAIM trial, recently published in the Journal of Clinical Oncology entitled \"PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous NSCLC\", compared two different chemotherapy regimens given concurrently with radiotherapy in patients with stage III non-squamous lung cancer: pemetrexed plus cisplatin versus cisplatin plus etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " AIM: PROCLAIM, a phase III trial of patients with nonsquamous NSCLC comparing concurrent pemetrexed-cisplatin and thoracic radiation therapy followed by consolidation pemetrexed, did not meet its primary endpoint of superior overall survival versus etoposide-cisplatin and thoracic radiation therapy followed by a consolidation platinum doublet of choice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIA/B unresectable nonsquamous NSCLC randomly received (1:1) pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) intravenously every 3 weeks for three cycles plus concurrent TRT (60 to 66 Gy) followed by pemetrexed consolidation every 3 weeks for four cycles (arm A), or standard therapy with etoposide 50 mg/m(2) and cisplatin 50 mg/m(2) intravenously, every 4 weeks for two cycles plus concurrent TRT (60 to 66 Gy) followed by two cycles of consolidation platinum-based doublet chemotherapy (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " BACKGROUND: Etoposide and other type-II human topoisomerase (TOPOII) poisons are widely used for the treatment of many different cancer types, including NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "CONCLUSIONS: Cisplatin and etoposide in these doses with conventionally fractionated TRT is a well-tolerated, effective treatment schedule in the definitive treatment of unresectable or inoperable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "METHODS: Patients with histologically proven and radiologically defined T3 to 4, N0 to 1, M0 superior sulcus NSCLC underwent induction therapy with\u00a0cisplatin-etoposide, concurrently with thoracic radiotherapy at 45 Gy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " OBJECTIVE: To test the effectiveness of combining conventional antineoplastic drugs (cisplatin and etoposide) with metformin in the treatment of NSCLC in the NCI-H460 cell line, in order to develop new therapeutic options with high efficacy and low toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Group I (12 patients) diagnosed with NSCLC treated with PE schema (cisplatin, etoposide), Group II (12 patients) with breast cancer treated with FAC schema (fluorouracil, doxorubicin, cyclophosphamide), Group III (12 patients) with bowel cancer treated with FU/LV schema (fluorouracil, leucovorin). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced NSCLC-a multicenter phase-II trial (CISTAXOL). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Updated survival and outcomes for older adults with inoperable stage III NSCLC treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "sjalal@iupui.edu  BACKGROUND: Concurrent chemoradiation with etoposide and cisplatin (EP/XRT) is standard treatment for inoperable stage III locally advanced non-small-cell lung cancer (LA-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " The objective of present investigation was to develop and assess comparative enhancement in cytotoxicity of liposomal Etoposide and Docetaxel in NSCLC cell lines after pre-treatment and co-administration of p53 tumor suppressor gene and to assess direct lung targeting of optimized formulations by dry powder inhaler technology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Anti-Metastatic and Anti-Angiogenic Activities of Core-Shell SiO2@LDH Loaded with Etoposide in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "The fine properties synthetic SiO2@LDH-VP16 (VP16: etoposide) are practiced to exhibit the nanoparticle's suppression on migration and invasion of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "These results suggested that LDH-VP16 diminishes hematotoxicity, targets NSCLC tumor, performs more effectively than VP16, and different signaling pathway is involved compared to VP16.STATEMENT OF SIGNIFICANCE: This paper explored that nano-sized layered double hydroxide (LDH) could be used as a pH sensitive delivery system to overcome hematotoxicity and enhance the bioavailability and anticancer efficacy of etoposide (VP16) against NSCLC, which was not reported before, as the best of our knowledge. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "This work provides a novel system for the safe and efficient use of etoposide on NSCLC and explores the mechanism of the function of nano carrier in cancer therapy both in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human NSCLC Cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Etoposide (VP-16), a topoisomerase II inhibitor, is an effective anti-cancer drug used for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "However, the role of ERK1/2 and AKT-mediated XRCC1 expression in etoposide treatment alone or combined with resveratrol-induced cytotoxicity in NSCLC cells has not been identified. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "In this study, etoposide treatment increased XRCC1 mRNA and protein expression through AKT and ERK1/2 activation in two NSCLC cells, H1703 and H1975. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Knockdown of XRCC1 in NSCLC cells by transfection of XRCC1 siRNA or inactivation of ERK1/2 and AKT resulted in enhancing cytotoxicity and cell growth inhibition induced by etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Resveratrol inhibited the expression of XRCC1 and enhanced the etoposide-induced cell death and anti-proliferation effect in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "These findings suggested that down-regulation of XRCC1 expression by resveratrol can enhance the chemosensitivity of etoposide in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": " Prolonged response of meningeal carcinomatosis from NSCLC to salvage intrathecal etoposide subsequent to failure of first-line methotrexate: a case report and literature review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Here, we report the case of an NSCLC patient with MC who showed durable response to salvage intrathecal etoposide subsequent to failure of first-line methotrexate. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "CONCLUSIONS: To our knowledge, this is the first case report in which intrathecal etoposide was successfully used to treat MC from NSCLC after failure of MTx. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Interestingly, both compounds sensitized NSCLC cell lines toward the induction of apoptosis by the DNA-damaging agent etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "In this study, the effects of p38 mitogen-activated protein kinase (MAPK) signal on the ERCC1 expression induced by etoposide in NSCLC cell lines was investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Moreover, SB202190, a p38 inhibitor, or knockdown of p38 expression by specific short interfering RNA (siRNA) significantly decreased the etoposide-induced ERCC1 protein levels and DNA repair capacity in etoposide-exposed NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "etoposide", "orig_sen": "Our results suggest that in human NSCLC cells, ERCC1 is induced by etoposide through the p38 MAPK pathway, and this phenomenon is required for NSCLC survival and resistant DNA damage. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "haemorrhage", "orig_sen": " Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "haemorrhage", "orig_sen": "Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "CONCLUSION: The addition of bevacizumab to therapy in advanced NSCLC did significantly increase the risk of proteinuria, hypertension, and hemorrhagic events but not arterial/venous thromboembolic events, gastrointestinal perforation, or fatal adverse events. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "We aimed to evaluate the effect of bevacizumab-induced hypertension in terms of prognosis in patients with colorectal cancer and NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "In the patient group with NSCLC, treated with bevacizumab, Grade 2-3 hypertension was present in 20.5%. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "Patients who developed hypertension during treatment with bevacizumab for colorectal cancer and NSCLC had significantly prolonged overall survival when compared with normotensive patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": " Incidence and risk of hypertension with bevacizumab in NSCLC patients: a meta-analysis of randomized controlled trials. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": " AIM: A study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%-34.3%) and 6.95% (95% CI 5.81%-8.30%). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": " A 60-year-old woman with hypertension, dyslipidemia, and 35-pack-year smoking history is referred for treatment of advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": " Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "This review provides a summary of currently available, clinically relevant data on the incidence of hypertension with VEGF-targeted antibodies and multitargeted antiangiogenic TKIs in advanced NSCLC and discusses the potential predictive role of hypertension on antiangiogenic therapy in such patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "Accumulated safety data with bevacizumab in NSCLC shows that patients are at risk for hemorrhage, venous thromboembolism, hypertension, and proteinuria. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "baumanje@upmc.edu  BACKGROUND: In NSCLC, interstitial hypertension is a barrier to chemotherapy delivery, and is mediated by platelet derived growth factor receptor (PDGFR). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": " Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced NSCLC who were receiving vandetanib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": " BACKGROUND: A meta-analysis of published data was conducted to investigate the overall risks of hypertension and QTc prolongation in patients with advanced NSCLC who were receiving vandetanib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "METHODS: A computerized search through electronic databases, including PubMed and Embase (until Dec 2014), was performed to obtain eligible randomized controlled trials (RCTs) that compared hypertension and/or QTc prolongation profile of vandetanib alone or plus chemotherapy with control groups (placebo, single targeted therapy, chemotherapy, or a combination of them) in patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "A significant increase in risk was observed for all-grade hypertension (RR 5.58; 95% CI 4.16 to 7.48; P\u2009<\u20090.00001) and grade \u22653 hypertension (RR 4.79; 95% CI 2.31 to 9.93; P\u2009<\u20090.0001) in advanced NSCLC patients who were receiving vandetanib compared with the controls. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "CONCLUSIONS: Current evidence showed that significant risks in developing hypertension and QTc prolongation exist in advanced NSCLC patients who were receiving vandetanib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "hypertension", "orig_sen": "Adverse events were generally consistent with previous NSCLC studies of vandetanib 300 mg; common events occurring with a greater frequency in the vandetanib arm versus placebo included diarrhea (46% v 11%), rash (42% v 11%), and hypertension (26% v 3%). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "A total of 108 NSCLC patients (stages I-IIIA) were treated with a standard chemotherapy regimen of cisplatin plus vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "SNPs were determined by SNaPshot PCR\u00ae in DNA isolated from peripheral blood of 55 NSCLC patients treated with platinum compound and vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: Selected SNPs of genes encoding DNA repair enzymes and cell division regulation proteins could be useful biomarkers for prediction of platinum and vinorelbine-based chemotherapy toxicity in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced NSCLC patients treated with vinorelbine combined cisplatin regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We aimed to investigate whether polymorphisms in BAG-1 and XPD have effects on chemotherapy sensitivity and survival in patients with advanced NSCLC treated with vinorelbine combined cisplatin (NP) regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous NSCLC: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: Patients with stage III NSCLC received 2 induction cycles of intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: In non-operable IIIA-IIIB NSCLC, the combination oral vinorelbine (fractionated fixed dose) plus cisplatin, during concomitant CT-RT, could offer a well-tolerated option, with comparable activity to I.V. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced NSCLC (Italian GEMVIN3/NCIC CTG BR14 trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Dynamic contrast-enhanced MRI to predict response to vinorelbine-cisplatin alone or with rh-endostatin in patients with NSCLC and bone metastases: a randomised, double-blind, placebo-controlled trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine-cisplatin plus rh-endostatinfor previously untreated NSCLC with bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "INTERPRETATION: Addition of rh-endostatin to treatment with vinorelbine-cisplatin increased the treatment response in patients with NSCLC and bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous NSCLC: a phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous NSCLC chemo-na\u00efve patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "luis.leon.mateos@sergas.es  OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "As an application example, we describe the analysis for the comparison of four regimens, cisplatin plus irinotecan, carboplatin plus paclitaxel, cisplatin plus gemcitabine (GP), and cisplatin plus vinorelbine, for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced NSCLC were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Background The combination of cisplatin or carboplatin with vinorelbine is one of the standard regimens in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " BACKGROUND/AIM: A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in NSCLC has been previously reported. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The aim of this study was to assess the safety and efficacy of concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "In conclusion, concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine is well-tolerated and effective in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Author information: (1)Miyagi Cancer Center, Natori, Japan;  BACKGROUND: Standard first-line chemotherapy for elderly NSCLC patients has been monotherapy with vinorelbine or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "MATERIALS AND METHODS: Patients \u2265 70 years with untreated, metastatic NSCLC were randomized to Erlotinib (E), 150 mg/day or Carboplatin (AUC5) plus Vinorelbine (25mg/m(2) on days 1 and 8) every three weeks (CV). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " A retrospective comparison of adjuvant chemotherapeutic regimens for NSCLC: paclitaxel plus carboplatin versus vinorelbine plus cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " BACKGROUND: Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The aim of the study was to evaluate the efficacy and safety of first-line chemotherapy based on platinums (carboplatin or cisplatin) plus a third generation compound (vinorelbine or gemcitabine) in elderly patients with advanced NSCLC in daily clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: Concurrent chemoradiation with weekly carboplatin and paclitaxel followed by vinorelbine consolidation is effective for stage III NSCLC and shows a generally mild toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III NSCLC: a phase I trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The purpose of this phase I trial was to explore the maximum tolerated dose (MTD) of accelerated hypofractionated three-dimensional conformal radiotherapy (3-DCRT) (at 3 Gy/fraction) administered in combination with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced NSCLC: a feasibility study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The purpose of this study was to evaluate the feasibility of utilizing high-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for the treatment of local advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The treatment approach for early-stage disease does not differ from that of other histologic subtypes of NSCLC; in locally advanced unresectable or metastatic disease, doublet chemotherapy regimens (including cisplatin or carboplatin and a third-generation agent such as gemcitabine, taxanes, or vinorelbine) remain the cornerstone of front-line systemic treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with NSCLC with interstitial lung disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The aim of this study was to assess the safety and efficacy profiles of the combination chemotherapy of vinorelbine and a platinum agent in patients with advanced NSCLC with ILD. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: The combination chemotherapy with vinorelbine and a platinum agent can be considered as a treatment option for patients with advanced NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Vinorelbine-based chemo-radiotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Our results support both the feasibility of incorporating 3D-CRT with concurrent vinorelbine and carboplatin and a dose escalation to 70 Gy for Chinese patients with NSCLC, based on the acceptable toxicity and encouraging overall response and survival rates. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The first trial devoted to older patients with advanced NSCLC was a comparison between vinorelbine and best supportive care. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients \u226575 years of age and with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: Use of 20 mg/m(2) vinorelbine on days 1 and 8, followed by carboplatin area under the curve of 4 mg/mL/min on day 1 every 4 weeks warrants a phase III study for elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: Patients (n\u00a0=\u00a048) with advanced NSCLC were treated with repetitive cycles of either paclitaxel/carboplatin or cisplatin/vinorelbine chemotherapy, bexarotene (400\u00a0mg/m(2)/day) administered continuously starting on day 4 of chemotherapy, and a lipid-lowering drug, either atorvastatin or fenofibrate, starting at least 5\u00a0days before chemotherapy due to hypertriglyceridemia induced by bexarotene. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "A recent phase IIb study demonstrated that disulfiram (DSF) in combination with cisplatin and vinorelbine was well tolerated and prolonged the survival of patients with newly diagnosed NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The methodology is applied on the retrospective data of thirteen patients with NSCLC who received cisplatin in combination with gemcitabine, vinorelbine or docetaxel in the neoadjuvant context. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable NSCLC: A retrospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: We retrospectively analyzed the efficacy and toxicity of cisplatin and either S-1 or vinorelbine for treating stage III unresectable NSCLC patients who were treated with CCRT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "RESULTS: Between September 2006 and May 2014, 56 patients with unresectable stage III NSCLC were treated with CCRT with S-1 and cisplatin (median age: 63 years) and 58 patients were treated with CCRT with vinorelbine and cisplatin (median age: 61 years). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "[Epub ahead of print]  Efficacy of Aidi Injection () on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " OBJECTIVE: To investigate the efficacy of Aidi Injection () on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with NSCLC, and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: Patients with potentially operable stage IIIA(N2) or selected stage IIIB NSCLC received three cycles of cisplatin/paclitaxel (induction chemotherapy) followed by neoadjuvant radiochemotherapy (RCT) to 45 Gy (1.5 Gy twice per day concurrent cisplatin/vinorelbine) within the ESPATUE (Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA[N2] and Selected IIIB NSCLC After Induction Chemotherapy and Concurrent Chemoradiotherapy) trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous NSCLC: cost minimization analysis in 12 European countries. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " OBJECTIVE: A combination of vinorelbine and cisplatin is a standard treatment in NSCLC; oral vinorelbine is registered in 45 countries. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: Given the reported efficacy with both regimens, this pan-European economic analysis provides compelling evidence supporting oral vinorelbine use over pemetrexed for the treatment of NS-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: A comprehensive review of the literature data regarding use of oral vinorelbine concurrently with radiotherapy in NSCLC was done. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Concurrent RT with oral vinorelbine and cisplatin demonstrated a favourable safety profile and represents a suitable treatment regimen for inoperable stage\u00a0III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (TREAT study) was designed to test the hypothesis that a protocol with reduced toxicity might improve feasibility of postoperative delivery of adjuvant chemotherapy drugs to patients with NSCLC, thereby improving compliance and, potentially, survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Serial dilutions of gemcitabine, cisplatin, 5-fluorouracil, vinorelbine, and paclitaxel were administered to the A549 NSCLC cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III NSCLC: an open-label phase II multicentre trial (COVeRT study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "This South Australian multicentre prospective phase II study evaluated the safety, activity and outcomes of combination oral vinorelbine and cisplatin administered concurrently with radiotherapy for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Two cycles of chemotherapy with oral vinorelbine and cisplatin administered concurrently with radical radiation had an acceptable toxicity profile and was active in inoperable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " INTRODUCTION: To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with stage IB-III MAGE-A3-positive NSCLC who were or were not undergoing standard cisplatin/vinorelbine chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " PURPOSE: Vinorelbine plus cisplatin is a commonly used doublet for the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "This study aimed to investigate the efficacy of oral vinorelbine as maintenance therapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: This multicenter phase II open-label, non-comparative study was designed to evaluate the three-weekly combination of cisplatin 80 mg/m(2) on day 1 in combination with oral vinorelbine on day 1 and 8 in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: The addition of disulfiram to a combination regimen of cisplatin and vinorelbine was well tolerated and appeared to prolong survival in patients with newly diagnosed NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " OBJECTIVES: Cisplatin and vinorelbine given intravenously is a well-established adjuvant chemotherapy regimen after surgery for early-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "However, the efficacy of orally administrated vinorelbine in adjuvant treatment of NSCLC is unknown. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "In conclusion we observed that intravenous or oral administration of vinorelbine in combination with cisplatin after surgery for NSCLC appear equally effective in terms of overall and disease-free survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected NSCLC, but has negative impact on quality of life (QoL). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Ninety-one patients who had NSCLC with soft carotid plaques were selected for treatment either with the NP regimen (vinorelbine + cisplatin) (43 patients) or with the ENP regimen (Endostar + NP) (48 patients). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Vinorelbine and cisplatin in patients with advanced NSCLC with interstitial pneumonia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " AIM: The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) NSCLC with interstitial pneumonia (IP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III NSCLC: a single-center experience. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) in patients with inoperable stage III NSCLC followed in our oncology clinic. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "MATERIAL AND METHODS: Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with cisplatin-vinorelbine were retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced NSCLC: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " PURPOSE: To evaluate the safety and efficacy of metronomic vinorelbine in combination with cisplatin as first-line treatment in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: A total of 41 patients with inoperable stage IIIb or stage IV NSCLC (14 with adenocarcinomas, 19 with squamous cell carcinoma and eight with other types), PS = 0-2, were treated with cisplatin (80 mg/m(2)) in combination with oral metronomic vinorelbine (60 mg total dose, every other day) in cycles of 21 days. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: Cisplatin in combination with metronomic vinorelbine is an active, although myelotoxic, therapeutic option in the first-line setting for the treatment of patients with locally advanced and metastatic NSCLC, which merits further evaluation in randomized trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: Patients with pathologically proven untreated NSCLC, receiving 1st line cisplatin-vinorelbine and with an assessable lesion were eligible. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: In this prospective study with advanced NSCLC treated with cisplatin-vinorelbine, we were able to derive with high throughput techniques predictive and prognostic signatures based on transcriptomic analyses. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " AIM: To enhance the anticancer activity of vinorelbine, cisplatin and ionizing radiation (IR) combination against NSCLC cells by co-administration of sodium valproate (VPA), a histone deacetylase inhibitor, and to elucidate molecular events underpinning treatment efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "MATERIALS AND METHODS: The NSCLC A549 cell line was treated with cisplatin (0.2 \u03bcg/ml), vinorelbine (2 nM), VPA (1 mM) and IR (2.5 Gy) alone, or in combination. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " PURPOSE: Adjuvant vinorelbine and cisplatin chemotherapy is recognized as a standard regimen for patients with completely resected stage II and III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "However, efficacy of adjuvant chemotherapy in Japanese phase III trials with cisplatin-containing regimen has been controversial, and data are limited on the long-term outcome of adjuvant vinorelbine and cisplatin chemotherapy for NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We observed the cavitation of lesions in patients with stage IIIB/IV NSCLC treated with Endostar and vinorelbine-cisplatin (NP) chemotherapy, and evaluated the imaging characteristics and clinical outcome of patients who developed tumor cavitation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Fractionated scheme of oral vinorelbine as single-agent therapy or in combination with cisplatin concomitantly with thoracic radiotherapy in stage III NSCLC: dose-escalation phase I trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " INTRODUCTION: A dose-determination study was conducted in untreated stage III NSCLC to assess continuous exposure to fractionated oral vinorelbine (NVBo), a radiosensitizer, during the radiotherapy period, either alone (first cohort) or in combination with cisplatin (second cohort). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous NSCLC: final results of an International randomized phase II study (NAVotrial 01). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " BACKGROUND: The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with NSCLC regardless of histologic subtype. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: This is a phase II trial of locally advanced NSCLC patients treated with cisplatin and vinorelbine plus concurrent nitroglycerin with radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III NSCLC: a multi-center phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " AIM: To evaluate the efficacy and toxicities of combination of cisplatin and oral vinorelbine given at full doses concomitantly with radiotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: Full doses of cisplatin and oral vinorelbine can be administered with concomitant radiotherapy, with good efficacy and an acceptable safety profile for patients with stage IIIA/IIIB NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " INTRODUCTION: The phase III FLEX study (NCT00148798) in advanced NSCLC indicated that the survival benefit associated with the addition of cetuximab to cisplatin and vinorelbine was limited to patients whose tumors expressed high levels of epidermal growth factor receptor (EGFR) (immunohistochemistry score of \u2265200; scale 0-300). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Novel chemoradiotherapy with concomitant boost thoracic radiation and concurrent cisplatin and vinorelbine for stage IIIA and IIIB NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced NSCLC: A meta-analysis of randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "China ;  Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced NSCLC remains controversial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " AIM: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with NSCLC after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " OBJECTIVES: Adding nitroglycerin to the combination of vinorelbine plus cisplatin has been reported to improve the overall survival (OS) of Asian patients with stage IIIB/IV NSCLC probably due to better drug delivery based on changed vascular tonus. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: 66 chemona\u00efve patients with stage IIIB/IV NSCLC received oral vinorelbine (first cycle 60 mg/m(2), subsequent cycles: 80 mg/m(2) in the absence of any hematological toxicity \u2265 grade 3 in cycle 1) once daily on days 1 and 8 of each cycle and cisplatin (80 mg/m(2) i.v.) on day 1 of each cycle (q3w). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: Overall, oral vinorelbine plus cisplatin showed a high level of efficacy and adequate tolerability in first line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " OBJECTIVE: To compare the efficacy and toxicity of chemotherapy under the guidance of molecular markers and with vinorelbine in elderly patients with epidermal growth factor receptor (EGFR) wild-type advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "However, the administration of docetaxel to patients with metastatic prostate or breast cancer, as well as that of cisplatin plus vinorelbine to NSCLC patients, appears to significantly increase the ratio between effector T cells and Tregs and to reduce the immunosuppressive activity of the latter in the majority of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy na\u00efve NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " AIMS AND BACKGROUND: To investigate the efficacy and tolerability of biweekly scheduled triplet chemotherapy consisting of gemcitabine, cisplatin and vinorelbine for chemotherapy-na\u00efve advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: The biweekly schedule of the triplet chemotherapy combination including gemcitabine, cisplatin and vinorelbine was effective in advanced, mostly metastatic NSCLC with acceptable and manageable side effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Identification of microRNA-based signatures for response and survival for NSCLC treated with cisplatin-vinorelbine A ELCWP prospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "In a prospective study, we assessed the predictive value for response and survival of tumour miRNA in NSCLC patients treated by 1st line cisplatin and vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The signature distinguished patients with good (n = 18) and poor (n = 20) prognosis with respective median survival times of 47.3 months (95% CI 29.8-52.4) and 15.5 months (95% CI 9.1-22.8) (p < 0.001; hazard ratio 21.1, 95% CI 4.7-94.9).CONCLUSIONS: miRNA signature allows predicting response and is of prognostic value for survival in patients with NSCLC treated with first line cisplatin and vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " BACKGROUND: The combination of cisplatin and vinorelbine is an evidence-supported regimen for adjuvant chemotherapy for treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "AREAS COVERED: This paper reviews the role of vinorelbine , both alone and in combination with platinum-derivates, in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "EXPERT OPINION: In the first-line treatment of advanced NSCLC, the use of vinorelbine-based regimens may be less efficacious in controlling disease than other combinations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "However, since their activity is not related to histology, vinorelbine still has potential as a first-line treatment for NSCLC patients in whom histology has failed to distinguish non-squamous from squamous histotypes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III NSCLC: NJLCG 0601. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "This randomized phase II study of concurrent chemoradiotherapy was conducted to compare uracil/tegafur (UFT) and cisplatin with vinorelbine and cisplatin for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage III NSCLC were randomized to receive UP (400 mg/m(2) UFT on days 1-14 and 29-42 and 80 mg/m(2) cisplatin on days 8 and 36) or NP (20 mg/m(2) vinorelbine on days 1, 8, 29, and 36 and 80 mg/m(2) cisplatin on days 1 and 29). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Cisplatin plus oral vinorelbine as first-line treatment for advanced NSCLC: a prospective study confirming that the day-8 hemogram is unnecessary. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " INTRODUCTION: Cisplatin plus oral vinorelbine, one of the standard treatments for metastatic NSCLC, is associated with a high rate of neutropenia, and a hemogram is performed on day 8. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Long-term survival rates of patients with stage IIIB and IV NSCLC treated with cisplatin plus vinorelbine or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected NSCLC: a retrospective study in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "h.kenmotsu@scchr.jp  BACKGROUND: The efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy, such as the combination of CDDP and vinorelbine (VNR), has been established for surgically resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "In addition, it showed that adjuvant cisplatin-based CT is detrimental in cases of stage Ia resected NSCLC; it also suggested that the combination of vinorelbine and cisplatin was of more benefit than older two and three drug combinations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The prognosis signature was found to especially accurate at identifying early stage patients at risk of disease specific death within 24\u2009months of diagnosis when compared to traditional methods of outcome prediction.Separately, NSCLC patients with the 37-gene ACT-response signature (n\u2009=\u200970, 64\u2009%), benefited significantly from cisplatin/vinorelbine (adjusted HR: 0.23, P\u2009=\u20090.0032). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " OBJECTIVE: A previous large, randomized, control trial(JBR.10)revealed that adjuvant chemotherapy with cisplatin(CDDP) and vinorelbine(VNR)was effective for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Chemotherapy with platinum doublets, including cisplatin plus vinorelbine, is standard of care for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "tshukuya@juntendo.ac.jp  BACKGROUND: Based on the results of phase I/II studies, S-1 plus cisplatin (CDDP) and vinorelbine (VNR) plus CDDP are commonly used chemoradiotherapeutic regimens for the treatment of NSCLC(NSCCLC) in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: A total of 433 stage IIIB-IV NSCLC patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: Chemoradiotherapy with cisplatin and vinorelbine followed by S-1 consolidation demonstrated a reasonable overall survival in patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: Patients (n = 26) with advanced-stage NSCLC received intravenous cisplatin 100 mg/m(2) on day 1 and at 4-week intervals plus intravenous vinorelbine 25 mg/m(2) weekly. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced NSCLC: effects on quality of life and survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We designed this trial to determine whether APS injection integrated with vinorelbine and cisplatin (VC) offered an improved QOL over VC for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "PATIENTS AND METHODS: Eligible patients with unresectable Stage III NSCLC, age \u2265 20 years, performance status 0-1, percent of volume of normal lung receiving 20 GY or more (V(20)) \u2264 30% received three to four cycles of cisplatin (80 mg/m(2) Day 1) and vinorelbine (20 mg/m(2) Days 1 and 8) repeated every 4 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Involved agents included paclitaxel, docetaxel and vinorelbine; Malignancies included NSCLC, gastric cancer, esophageal carcinoma, ovarian carcinoma, malignant pleural mesothelioma, breast cancer, and small cell lung cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Case 1: An 86-year-old man was diagnosed with large cell or squamous cell lung cancer of clinical Stage II A.He was administered nanoparticle albumin-bound paclitaxel(nab-PTX)as fourth-line chemotherapy after monochemotherapy with docetaxel, vinorelbine, and S-1.The patient continues to show complete remission at the 15 courses of nab-PTX.Case 2: A 79-year-old man underwent partial resection of the right lower lung, and the pathological diagnosis was large cell lung cancer of pStage I A.However, recurrence in the right lung and multiple lymph node metastases were identified 3 years after the surgery.He was administered nab-PTX as second-line chemotherapy after vinorelbine monotherapy, and he has shown complete remission for a year.Weekly intravenous nab-PTX may be useful in elderly patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " BACKGROUND: The efficacy of docetaxel, vinorelbine, or gemcitabine monotherapy in previously untreated elderly patients with NSCLC has been reported.Pemetrexed monotherapy has shown clinically equivalent efficacy to docetaxel, a standard therapeutic option, in patients with previously treated NSCLC and in those with a lower incidence of toxicity such as febrile neutropenia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " [A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The aim of this study is to evaluate the efficacy and safety of docetaxel plus platinum (DP) compared with vinorelbine plus platinum (VP) regimens in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u4ee5\u94c2\u7c7b\u4e3a\u57fa\u7840\u8054\u5408\u7b2c\u4e09\u4ee3\u836f\u7269\u7684\u53cc\u836f\u5316\u7597\u65b9\u6848\u662f\u6cbb\u7597\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC, NSCLC\uff09\u7684\u6807\u51c6\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u3002\u672c\u7814\u7a76\u91c7\u7528meta\u5206\u6790\u7684\u65b9\u6cd5\u8bc4\u4ef7\u591a\u897f\u4ed6\u8d5b\u8054\u5408\u94c2\u7c7b\uff08docetaxel plus platinum, DP\uff09\u65b9\u6848\u5bf9\u6bd4\u957f\u6625\u745e\u6ee8\u8054\u5408\u94c2\u7c7b\uff08vinorelbine plus platinum, VP\uff09\u65b9\u6848\u6cbb\u7597\u665a\u671fNSCLC\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u65b9\u6cd5 \u8ba1\u7b97\u673a\u68c0\u7d22Pubmed\u3001EMBASE\u3001Cochrane Library\u3001\u4e2d\u56fd\u671f\u520a\u5168\u6587\u6570\u636e\u5e93\uff08CNKI\uff09\u3001\u4e2d\u56fd\u751f\u7269\u533b\u5b66\u6587\u732e\u6570\u636e\u5e93\uff08CBM\uff09\u3001\u4e2d\u6587\u79d1\u6280\u671f\u520a\u5168\u6587\u6570\u636e\uff08VIP\uff09\u5e93\u53ca\u4e07\u65b9\u6570\u636e\u5e93\u5173\u4e8eDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u6cbb\u7597\u665a\u671fNSC LC\u7684\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\uff08randomized controlled trial, RCT\uff09\u3002\u6839\u636eCochrane Handbook 5.1.0\u7684\u8d28\u91cf\u8bc4\u4ef7\u6807\u51c6\uff0c\u7528Stata 12.0\u8f6f\u4ef6\u8fdb\u884c\u7edf\u8ba1\u5b66\u5206\u6790\u3002\u7ed3\u679c \u7814\u7a76\u5171\u7eb3\u51657\u9879RCTs\uff0c\u5305\u62ec\u665a\u671fNSCLC\u60a3\u80052,381\u4f8b\u3002DP\u65b9\u6848\u76842\u5e74\u751f\u5b58\u7387\uff08HR=0.887, 95%CI: 0.810-0.972, P=0.010\uff09\u3001\u6709\u6548\u7387\uff08RR=1.276, 95%CI: 1.107-1.450, P=0.001\uff09\u548c\u8179\u6cfb\u53d1\u751f\u7387\uff08RR=3.134, 95%CI: 1.918-5.121, P<0.001\uff09\u8f83VP\u65b9\u6848\u9ad8\uff1bDP\u65b9\u6848\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff08RR=0.386, 95%CI: 0.311-0.478, P<0.001\uff09\uff1bDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u57281\u5e74\u751f\u5b58\u7387\u3001\u767d\u7ec6\u80de\u51cf\u5c11\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u3001\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u538c\u98df\u3001\u6076\u5fc3\u3001\u5455\u5410\u65b9\u9762\u7684\u5dee\u5f02\u65e0\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u7ed3\u8bba DP\u65b9\u6848\u867d\u7136\u589e\u52a0\u4e86\u8179\u6cfb\u53d1\u751f\u7387\uff0c\u4f46\u5374\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff0c\u540c\u65f6\u63d0\u9ad8\u4e862\u5e74\u751f\u5b58\u7387\u548c\u6709\u6548\u7387\u3002\u76f8\u6bd4VP\u65b9\u6848\uff0cDP\u65b9\u6848\u53ef\u80fd\u66f4\u9002\u5408\u4e00\u7ebf\u6cbb\u7597\u665a\u671fNSCLC\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.07 PMID: 24758908 [PubMed - indexed for MEDLINE]   299. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: The established method should be helpful for the pharmacokinetic monitoring of paclitaxel, docetaxel, vinblastine, and vinorelbine in the human plasma of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "ekim@kuhp.kyoto-u.ac.jp  BACKGROUND: Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "SETTING: Five randomised controlled trials comparing docetaxel-based chemotherapy with vinorelbine-based chemotherapy for the first-line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "vinorelbine in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced NSCLC Using Two Different Schedules. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " PURPOSE: This study aimed to evaluate the safety, tolerability and pharmacokinetics of the combination of oral vinorelbine with erlotinib using the conventional (CSV) and metronomic (MSV) dosing schedules in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Thirty patients with Stage IIIB/IV NSCLC were treated with escalating doses of oral vinorelbine starting at 40 mg/m2 on day 1 and 8 in the CSV group (N = 16) and at 100 mg/week in the MSV group (N = 14). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, NSCLC patients aged 70 years or older. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "ymchen@vghtpe.gov.tw  INTRODUCTION: The primary objective of this study was to compare the response rates of elderly, chemonaive patients with advanced NSCLC treated with daily oral erlotinib versus oral vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: Chemonaive Taiwanese patients aged 70 years or older who had advanced NSCLC were randomized to receive either oral erlotinib 150 mg (E) daily or oral vinorelbine 60 mg/m (V) on days 1 and 8 every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Gemcitabine plus vinorelbine as the second-line treatment and beyond in elderly patients with platinum-pretreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " BACKGROUND: The efficacy and tolerance of a gemcitabine and vinorelbine (GV) combination as salvage therapy have not been reported in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Phase II study of triplet chemotherapy using Tegafur-Uracil, Vinorelbine, Gemcitabine for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "s-atagi@kch.hosp.go.jp  AIM: To evaluate the efficacy and toxicity of triplet chemotherapy using tegafur-uracil (UFT), vinorelbine, and gemcitabine for patients with stage IIIB or IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " [Gemcitabine combined with vinorelbine in the treatment of refractory patients with advanced NSCLC: a multi-center retrospective study]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "lushun1964@hotmail.com  BACKGROUND: The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN as second-line or further-line treatment) in refractory advanced NSCLC patients in China. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " [Efficacy of gemcitabine and vinorelbine in first-line treatment with advanced NSCLC: a multicentre retrospective study]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN) in advanced NSCLC first-line treatment in China. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Vinorelbine and paclitaxel are effective as single agents in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "MATERIALS AND METHODS: Patients with treatment na\u00efve metastatic NSCLC received two cycles comprising 6 weekly doses of vinorelbine and paclitaxel, with restaging scans at week 8. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "In our analysis, NSCLC patients treated with paclitaxel had more favorable clinical outcomes than those treated with vinorelbine (Chi(2)=3.69, P=0.05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Pemetrexed versus vinorelbine treatment of advanced non-squamous NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "vinorelbine in NSCLC elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " [Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "In our study, the efficacy and safety of combined chemotherapy of vinorelbine and ifosfamide as third-line therapy or beyond for advanced NSCLC was evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: Vinorelbine and ifosfamide as third-line treatment and beyond of NSCLC were well tolerated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "MATERIALS AND METHODS: We selected patients with advanced NSCLC who received treatment with platinum/vinorelbine at Chungnam National University Hospital from August 2001 to December 2013. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic NSCLC and malignant pleural mesothelioma: rationale and study protocol. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " BACKGROUND: Metronomic oral vinorelbine is effective in metastatic NSCLC and malignant pleural mesothelioma, but all the studies published thus far were based upon a variety of empirical and possibly suboptimal schedules, with inconsistent results. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Metronomic oral vinorelbine in advanced breast cancer and NSCLC: current status and future development. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Oral vinorelbine has emerged as a promising metronomic treatment in patients with metastatic breast cancer and NSCLC and is the only orally available microtubule-targeting agent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Health Related Quality Of Life Of Caregivers And Patients Treated For Metastatic NSCLC (Nsclc) With Oral Vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " PURPOSE: The combination of platinum compounds and vinorelbine is often used as a first-line treatment in patients with locally advanced or metastatic NSCLC, without activating EGFR mutations and ALK rearrangement. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The aim of the study was to determine the relationship between a single nucleotide polymorphism (SNP) of the promoter of STMN1 gene -2166T>C) and the effectiveness of chemotherapy based on platinum compounds and vinorelbine in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: The investigated population consisted of 110 locally advanced or metastatic NSCLC patients treated with first-line chemotherapy, based on platinum compounds and vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: Rare TT genotype of STMN1 gene may be an unfavorable predictive factor of chemotherapy based on platinum compounds and vinorelbine, in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Vinorelbine is often used as concurrent chemoradiotherapy for NSCLC in Japan and has antitumor activity in breast cancer as well. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The antitumor efficacy of different treatment sequences using vinorelbine (VNB) and gefitinib (GEF) was investigated both in vitro and in vivo in NSCLC cell lines with the rationale of potentially translating these findings into the clinical setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced NSCLC: results of a phase II trial (MOVE trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " BACKGROUND: Metronomic oral vinorelbine could be a safe option for elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: Metronomic oral vinorelbine is safe in elderly patients with advanced NSCLC with an interesting activity mainly consisting in long-term disease stabilization coupled with an optimal patient compliance (Eudra-CT 2010-018762-23, AIFA OSS on 26 February 2010). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Metronomic vinorelbine (oral) in combination with sorafenib in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSIONS: Sorafenib and metronomic oral vinorelbine is active in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "[Epub ahead of print]  Acute ischaemic stroke and myocardial infarction after chemotherapy with vinorelbine for NSCLC: a case report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Vinorelbine is an important chemotherapeutic agent which is used in metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We report about a 70-year-old male with metastatic NSCLC who received vinorelbine as an outpatient. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "130 patients with inoperable stage III NSCLC and PS 0-1 were randomised to receive cisplatinum and vinorelbine with either sequential or concurrent chemo-radiation using 55Gy in 20 fractions over four weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Vinorelbine is a vinca-alcalo\u00efd that remains the backbone of several regimens to treat patients with metastatic breast cancer or NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Oral vinorelbine in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Oral vinorelbine has demonstrated significant activity in different settings for NSCLC, including adjuvant treatment for resected disease, concurrent chemoradiation for locally advanced NSCLC and palliative chemotherapy for recurrent/metastatic NSCLC, as part of combination schedules or as a single-agent treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "AREAS COVERED: The authors explored the available data describing the use of oral vinorelbine in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Vinorelbine (VLB) is a semi-synthetic Vinca alkaloid which is currently used in treatment of different cancer types mainly advanced breast cancer (ABC) and advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u4ee5\u94c2\u7c7b\u4e3a\u57fa\u7840\u8054\u5408\u7b2c\u4e09\u4ee3\u836f\u7269\u7684\u53cc\u836f\u5316\u7597\u65b9\u6848\u662f\u6cbb\u7597\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC, NSCLC\uff09\u7684\u6807\u51c6\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u3002\u672c\u7814\u7a76\u91c7\u7528meta\u5206\u6790\u7684\u65b9\u6cd5\u8bc4\u4ef7\u591a\u897f\u4ed6\u8d5b\u8054\u5408\u94c2\u7c7b\uff08docetaxel plus platinum, DP\uff09\u65b9\u6848\u5bf9\u6bd4\u957f\u6625\u745e\u6ee8\u8054\u5408\u94c2\u7c7b\uff08vinorelbine plus platinum, VP\uff09\u65b9\u6848\u6cbb\u7597\u665a\u671fNSCLC\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u65b9\u6cd5 \u8ba1\u7b97\u673a\u68c0\u7d22Pubmed\u3001EMBASE\u3001Cochrane Library\u3001\u4e2d\u56fd\u671f\u520a\u5168\u6587\u6570\u636e\u5e93\uff08CNKI\uff09\u3001\u4e2d\u56fd\u751f\u7269\u533b\u5b66\u6587\u732e\u6570\u636e\u5e93\uff08CBM\uff09\u3001\u4e2d\u6587\u79d1\u6280\u671f\u520a\u5168\u6587\u6570\u636e\uff08VIP\uff09\u5e93\u53ca\u4e07\u65b9\u6570\u636e\u5e93\u5173\u4e8eDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u6cbb\u7597\u665a\u671fNSC LC\u7684\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\uff08randomized controlled trial, RCT\uff09\u3002\u6839\u636eCochrane Handbook 5.1.0\u7684\u8d28\u91cf\u8bc4\u4ef7\u6807\u51c6\uff0c\u7528Stata 12.0\u8f6f\u4ef6\u8fdb\u884c\u7edf\u8ba1\u5b66\u5206\u6790\u3002\u7ed3\u679c \u7814\u7a76\u5171\u7eb3\u51657\u9879RCTs\uff0c\u5305\u62ec\u665a\u671fNSCLC\u60a3\u80052,381\u4f8b\u3002DP\u65b9\u6848\u76842\u5e74\u751f\u5b58\u7387\uff08HR=0.887, 95%CI: 0.810-0.972, P=0.010\uff09\u3001\u6709\u6548\u7387\uff08RR=1.276, 95%CI: 1.107-1.450, P=0.001\uff09\u548c\u8179\u6cfb\u53d1\u751f\u7387\uff08RR=3.134, 95%CI: 1.918-5.121, P<0.001\uff09\u8f83VP\u65b9\u6848\u9ad8\uff1bDP\u65b9\u6848\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff08RR=0.386, 95%CI: 0.311-0.478, P<0.001\uff09\uff1bDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u57281\u5e74\u751f\u5b58\u7387\u3001\u767d\u7ec6\u80de\u51cf\u5c11\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u3001\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u538c\u98df\u3001\u6076\u5fc3\u3001\u5455\u5410\u65b9\u9762\u7684\u5dee\u5f02\u65e0\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u7ed3\u8bba DP\u65b9\u6848\u867d\u7136\u589e\u52a0\u4e86\u8179\u6cfb\u53d1\u751f\u7387\uff0c\u4f46\u5374\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff0c\u540c\u65f6\u63d0\u9ad8\u4e862\u5e74\u751f\u5b58\u7387\u548c\u6709\u6548\u7387\u3002\u76f8\u6bd4VP\u65b9\u6848\uff0cDP\u65b9\u6848\u53ef\u80fd\u66f4\u9002\u5408\u4e00\u7ebf\u6cbb\u7597\u665a\u671fNSCLC\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.07 PMID: 24758908 [PubMed - indexed for MEDLINE]   116. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Activation of AKT/ERK confers NSCLC cells resistance to vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Vinorelbine is a semi-synthetic vinca-alkaloid approved for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "However, the lower objective response rate and higher adverse effects of vinorelbine hinder its wide use in treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "Therefore, it is of great interest to uncover the biomarkers for sensitivity of NSCLC cells to vinorelbine to allow the identification of patients most likely to benefit from vinorelbine-based chemotherapy and to improve the therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "In present work, four NSCLC cell lines were divided into vinorelbine-sensitive (VS) group and vinorelbine-resistant (VR) group according to their sensitivities to vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "The higher expression of RAF1 mRNA and the activation of AKT/ERK proteins in VR NSCLC cell lines may confer resistance to vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " High expression levels of class III \u03b2-tubulin in resected NSCLC patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Author information: (1)Southern Medical University, Guangzhou, Guandong 510515; ; Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guandong 510120;  The aim of the present study was to determine the frequency and predictive value of the expression of tumor microtubule components in patients with resected NSCLC (R-NSCLC) subsequently treated with vinorelbine-based adjuvant chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "These findings suggest that high class III \u03b2-tubulin expression levels in resected tumors are predictive of improved DFS in R-NSCLC patients receiving vinorelbine-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: Patients with recurrent metastatic breast (BC), prostate (PC) or NSCLC and adequate organ functions were randomly assigned to 30, 40 or 50 mg vinorelbine, taken orally three times a week. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Histology as a potential clinical predictor of outcome in advanced NSCLC treated with vinorelbine and mitomycin combination chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "This retrospective study analyzed the combined patient-level data from two phase II trials that investigated the efficacy and safety of combination chemotherapy with vinorelbine and mitomycin in patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " A phase II study of metronomic oral vinorelbine administered in the second line and beyond in NSCLC: a phase II study of the Hellenic Oncology Research Group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "We evaluated a metronomic regimen of oral vinorelbine in pre-treated patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "METHODS: Forty-six pre-treated NSCLC patients received oral vinorelbine at a fixed dose of 50 mg three times a week. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "CONCLUSION: The administration of metronomic oral vinorelbine is feasible and results in acceptable clinical efficacy associated with manageable toxicity in a population consisting mostly of heavily pre-treated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " A series of 3-demethoxycarbonyl-3-acylamide methyl vinorelbine derivatives (compounds 7a-7z) were designed, synthesized, and evaluated for their inhibition activities against human NSCLC cell line (A549). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " BACKGROUND AND OBJECTIVE: Multidrug resistance (MDR) is the main cause of chemotherapeutic failure in lung cancer, and vinorelbine (NVB) is one of the most efficient drugs that threaten NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": " Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced NSCLC: West Japan Thoracic Oncology Group (WJTOG3005-DI). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "vinorelbine", "orig_sen": "h.harada@scchr.jp  PURPOSE: To investigate the safety and efficacy of concurrent vinorelbine and thoracic radiotherapy in elderly patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Maintenance erlotinib versus erlotinib at disease progression in patients with advanced NSCLC who have not progressed following platinum-based chemotherapy (IUNO study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVE: The phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at progression in advanced/metastatic NSCLC that had not progressed following four cycles of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Thus, maintenance treatment with erlotinib in patients with advanced/metastatic NSCLC without EGFR-activating mutations is considered unfavorable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV NSCLC: METLung. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Purpose The phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic NSCLC selected by MET immunohistochemistry whose disease had progressed after treatment with a platinum-based chemotherapy regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Conclusion Onartuzumab plus erlotinib did not improve clinical outcomes, with shorter OS in the onartuzumab arm, compared with erlotinib in patients with MET-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Gefitinib, erlotinib and afatinib provide remarkable response rates and progression-free survival compared to platinum-based chemotherapy in patients with NSCLC harboring epidermal growth factor receptor-activating mutations, and are therefore standard first-line treatment in these patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "FINDINGS: Of the 1006 patients diagnosed with stage IIIb and IV NSCLC in the study period, 448 (44.5%) had EGFR-activating mutations and received first-line therapy with gefitinib (n = 304, 67.6%), erlotinib (n = 63, 14.3%), or afatinib (n = 81, 18.1%). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "INTERPRETATION: Afatinib and erlotinib provide significant benefits in progression-free survival compared to gefitinib in first-line treatment of patients with NSCLCs harboring EGFR-activating mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In the second-line treatment of advanced squamous NSCLC, afatinib significantly prolonged PFS and OS, compared with erlotinib, regardless of EGFR mutation status (LUX-Lung 8 trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced NSCLC (CurrentS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: Active smokers with NSCLC have increased erlotinib metabolism versus non-smoking patients, which reduces exposure. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The CurrentS study (NCT01183858) assessed efficacy and safety of 300mg erlotinib (E300) as second-line therapy in current smokers with locally advanced or metastatic NSCLC versus the standard 150mg dose (E150). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib has been approved as second-line treatment in patients with NSCLC experiencing relapse after first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Herein, we report two occurrences of erlotinib-associated gastrointestinal perforation (GIP) in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Two patients aged 60 and 79 years received erlotinib as third- and second-line NSCLC treatment, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Chemotherapy (platinum and pemetrexed) in combination with erlotinib in NSCLC induces major gastrointestinal toxicity: two case reports from the FLARE/GFPC 03-2013 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: A randomized phase III study was designed to assess the efficacy and safety of second-line platinum-based chemotherapy with or without erlotinib in NSCLC with EGFR-activating mutation after secondary resistance to EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "JUNIPER is a randomized study of abemaciclib (200 mg orally every 12 hours) with best supportive care (BSC) versus erlotinib (150 mg orally every 24 hours) with BSC in patients with stage IV NSCLC whose tumors have detectable Kirsten rat sarcoma (KRAS) mutations and whose disease has progressed after platinum-based chemotherapy and 1 other previous therapy, or who are not eligible for further chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib was chosen as the control arm, because it is the only agent indicated for second- and third-line therapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of NSCLC: a systematic review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Experience with erlotinib in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In the present review we analysed the available data on erlotinib in the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib is a standard second-line therapy for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " We performed a systematic review and meta-analysis to assess the potential of erlotinib plus platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Search of PubMed, EMBASE, Web of Science, CBM, CNKI, China Wan Fang databases and the Cochrane library was performed for studies regarding erlotinib plus platinum-based chemotherapy for advanced NSCLC published between 1 January 2000 and 28 August 2014. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We concluded that the erlotinib plus chemotherapy for advanced NSCLC could increase PFS and objective response rate, but not benefit OS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients in our single arm phase II study had stage IV NSCLC with no more than six sites of extracranial disease who failed early systemic chemotherapy and were able to receive SBRT and concurrent erlotinib until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Use of SBRT with erlotinib for unselected patients with stage IV NSCLC as a second- or subsequent line therapy resulted in dramatic changes in patterns of failure, was well tolerated, and resulted in high PFS and OS, substantially greater than historical values for patients who only received systemic agents. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Maintenance therapy is a new treatment strategy for advanced non-small-cell lung cancer(NSCLC), and it consists of switch maintenance and continuation maintenance.Switch maintenance is the introduction of a different drug, not included as part of the induction therapy, immediately after completion of 4 cycles of first-line platinum-based chemotherapy.Continuation maintenance is a continuation of at least one of the drugs used in the induction therapy in the absence of disease progression.Several phase III trials have reported survival benefits with continuation maintenance of pemetrexed and switch maintenance of pemetrexed or erlotinib.Therefore, maintenance therapy has become a part of the standard first-line treatment for advanced NSCLC.However, further research is needed to elucidate the selection criteria of patients who may benefit the most from maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study assessed the prognostic and predictive value of circulating micro-RNA (miRNA) in patients with non-squamous NSCLC enrolled in the phase II SAKK (Swiss Group for Clinical Cancer Research) trial 19/05, receiving uniform treatment with first-line bevacizumab and erlotinib followed by platinum-based chemotherapy at progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Patients with stage IIIB/IV NSCLC previously treated with platinum-based chemotherapy were randomized (2:1) to 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E) or placebo plus erlotinib (P/E) in 21-day cycles until disease progression or unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed+erlotinib in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Pemetrexed+erlotinib treatment significantly improved PFS, OS and TTTF in 2nd line non-squamous NSCLC and was associated with an increase in grade 3/4 toxicities compared with pemetrexed alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib versus docetaxel as second-line treatment of patients with advanced NSCLC and wild-type EGFR tumours (TAILOR): a randomised controlled trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib is registered for treatment of all patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "INTERPRETATION: Our results show that chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib in the first-line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this article, the authors analyzed data of erlotinib in NSCLC, focusing on its role in front-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "SATURN (Sequential Tarceva in Unresectable NSCLC) was a randomised, double-blind, placebo-controlled, multicentre study investigating the impact of erlotinib maintenance therapy on HRQoL in patients with locally advanced or recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Moving towards molecular-guided treatments: erlotinib and clinical outcomes in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "c.santarpia@hotmail.com  Erlotinib is an orally administered small-molecule inhibitor of EGF receptor (EGFR) tyrosine kinase that is approved for the treatment of non-small-cell lung cancer (NSCLC) and pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib was first approved for the treatment of unselected NSCLC patients with advanced disease after failure of at least one prior chemotherapy regimen, and it was subsequently demonstrated to also confer a significant clinical benefit as maintenance therapy after first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Results from recently published, randomized Phase III trials showed that first-line erlotinib significantly prolongs progression-free survival in patients with advanced EGFR mutation-positive NSCLC with favorable tolerability, compared with standard chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous NSCLC (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "francesco.zappa@clinicaluganese.ch  PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-based CT at disease progression (PD). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Currently, only erlotinib is offered as a third-line option in unselected nsclc patients after failure of first- and second-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Patients with advanced NSCLC and somatic activating mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene represent a biologically distinct disease entity that shows exquisite sensitivity to the reversible EGFR-TK inhibitors (-TKIs) gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib in salvage treatment of patients with advanced NSCLC: results of an expanded access programme in Poland. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Results of the phase III study JBR.21 proved the clinical efficacy of erlotinib-based regimens as second- or third-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We analyze efficacy of treatment with erlotinib in patients suffering from advanced stage NSCLC who participated in the multicentre, international phase IV study - MO 18109 TRUST (expanded access clinical program of Tarceva\u2122 in patients with advanced stage IIIB/IV NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Results of the TRUST study in the Polish population confirmed the efficacy of erlotinib in advanced NSCLC after failure of prior platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Herein, we report on a case treated with erlotinib plus bevacizumab for leptomeningeal metastases from EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: TGI metrics were estimated using longitudinal tumor size data from two Phase III first-line NSCLC studies evaluating bevacizumab and erlotinib as MTx in 1632 patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of NSCLC: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: Bevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Therefore, we conducted a meta-analysis to compare combination treatment with bevacizumab and erlotinib to bevacizumab or erlotinib monotherapy in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The combination of bevacizumab and erlotinib significantly improved PFS (HR=0.63, 95% CI 0.53 to 0.75; p=0.000) and the ORR (RR=1.91, 95% CI 1.19 to 3.06; p=0.007) in the second-line treatment of NSCLC compared with bevacizumab or erlotinib alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The addition of bevacizumab to erlotinib can significantly improve PFS and the ORR in the second-line treatment of NSCLC with an acceptable and manageable risk of rash and diarrhoea. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: The bevacizumab plus erlotinib study (BEVERLY) is a randomized, open-label, phase III trial investigating first-line erlotinib plus bevacizumab versus erlotinib in patients with advanced NSCLC harboring activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: If the primary endpoint of PFS is met, the erlotinib plus bevacizumab combination will be confirmed as the best first-line treatment for patients with advanced NSCLC harboring activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with NSCLC treated with bevacizumab and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Therefore we have evaluated the inter-reader reproducibility of response classification by DCE-MRI in patients with NSCLC treated with bevacizumab and erlotinib enrolled in a multicenter trial.MATERIALS AND METHODS: Twenty-one patients were scanned before and 3 weeks after start of treatment with DCE-MRI in a multicenter trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected NSCLC Patient-Derived Xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Using this methodology, we investigated the genome-wide alteration of alternative splicing in patients with NSCLC treated by bevacizumab/erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Impact of bevacizumab in combination with erlotinib on EGFR-mutated NSCLC xenograft models with T790M mutation or MET amplification. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib (ERL), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, shows notable efficacy against NSCLC harboring EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib, bevacizumab, and pemetrexed improved survival of metastatic non-small cell lung cancer (mNSCLC) in clinical trials, but their benefits are restricted to non-squamous histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In patients with NSCLC treated with bevacizumab and erlotinib, Franzini and colleagues find that angiogenesis- and hypoxia-associated gene expression signatures predict tumor response and/or clinical outcome, and may define distinct angiogenic patterns. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous NSCLC harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous NSCLC Patients (SAKK 19/05 trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: We aimed to identify gene expression signatures associated with angiogenesis and hypoxia pathways with predictive value for treatment response to bevacizumab/erlotinib (BE) of nonsquamous advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced NSCLC Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Additional data on the efficacy of first-line therapy with afatinib and the combination of erlotinib and bevacizumab for patients with EGFR mutant NSCLC were presented. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Addition of bevacizumab enhances antitumor activity of erlotinib against NSCLC xenografts depending on VEGF expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, are promising therapies for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our study was aimed to determine whether there were conditions under which the addition of bevacizumab would enhance the antitumor activity of erlotinib against NSCLC tumors in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In primarily erlotinib-resistant NSCLC cells, the levels of VEGF protein were highest in H157 cell followed in order by H460 and A549 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The availability of antineoplastic monoclonal antibodies, small molecules and newer cytotoxics such as pemetrexed, the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as the anti-angiogenic bevacizumab and the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous NSCLC harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We aimed to compare the efficacy and safety of the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non-squamous NSCLC with activating EGFR mutation-positive disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: In this open-label, randomised, multicentre, phase 2 study, patients from 30 centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating EGFR mutations, Eastern Cooperative Oncology Group performance status 0 or 1, and no previous chemotherapy for advanced disease received erlotinib 150 mg/day plus bevacizumab 15 mg/kg every 3 weeks or erlotinib 150 mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "INTERPRETATION: Erlotinib plus bevacizumab combination could be a new first-line regimen in EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced NSCLC (ATLAS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: ATLAS compared bevacizumab plus erlotinib (B+E) with bevacizumab plus placebo (B+P) as maintenance therapy after first-line bevacizumab plus chemotherapy (B+C) for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic NSCLC: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic NSCLC patients who have progressed following chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The objective of this phase Ib dose-escalation trial (3 + 3 design) was to determine the recommended phase II dose (RP2D) of IMO-2055 when combined with erlotinib and bevacizumab in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with stage 3/4 NSCLC and progressive disease (PD) following chemotherapy received IMO-2055 0.08, 0.16, 0.32, or 0.48 mg/kg once weekly plus erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: IMO-2055 demonstrated good tolerability and possible antitumor activity in combination with erlotinib and bevacizumab in heavily pretreated patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced NSCLC, and are currently approved for use in clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: This phase III trial was performed to assess the potential benefit of adding maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We identified the expression of EGFR exon 18 as a new predictive marker for patients with untreated metastatic NSCLC treated with bevacizumab and erlotinib in the first line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The TASK study evaluated the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab as first-line therapy in unselected, advanced non-squamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The TASK study did not show a benefit in terms of PFS for the combination of erlotinib with bevacizumab in unselected first-line advanced non-squamous NSCLC compared with chemotherapy plus bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD \u22656 months/PR (PR=3; SD \u22656 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Administration of bevacizumab and erlotinib in combination with first-line chemotherapy, followed by bevacizumab and erlotinib monotherapy as maintenance, showed promising results in patients with NSCLC, with reduced toxicity as compared with chemotherapy alone, but did not translate into longer overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, NSCLC with serum proteomic evaluation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "wallace.akerley@hci.utah.edu  BACKGROUND: Erlotinib alone or bevacizumab in combination with chemotherapy improve survival in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Survival in an unselected population of patients with NSNSCLC treated with bevacizumab and erlotinib approximated that expected with conventional chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Despite the fact that these improvements have been largely data-driven, the following questions arise: what is the role of adjuvant chemotherapy in elderly patients with NSCLC? What is the role of targeted agents, such as erlotinib and bevacizumab, in older NSCLC patients? These questions are relevant because the current median age of lung cancer patients at diagnosis in the USA is 69 years, and the number of older patients developing this malignancy is increasing. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "oliver.gautschi@luks.ch  BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced NSCLC who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous NSCLC, a phase II study of the Hoosier Oncology Group: LUN04-77. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "A phase II study combining erlotinib and bevacizumab for treatment of recurrent NSCLC showed encouraging efficacy and acceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: This single-arm phase II study evaluated erlotinib and bevacizumab as first-line therapy for newly diagnosed nonsquamous advanced NSCLC patients with Eastern Cooperative Oncology Group PS \u2265 2 or age 70 or older. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The combination of erlotinib and bevacizumab had insufficient activity in the absence of known activating epidermal growth factor receptor gene mutations to warrant study in newly diagnosed elderly or poor PS patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III NSCLC: results of a phase I/II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Bevacizumab and erlotinib have been shown to improve survival in stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, little is known about variation in first-line NSCLC chemotherapy use in younger patients, health maintenance organization (HMO)-based settings, and for high-cost, novel agents, such as bevacizumab and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "For both squamous and non-squamous NSCLC, switch maintenance with erlotinib has been shown to improve both PFS and OS, although the improvement is modest. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "For this reason, switch maintenance with erlotinib can be considered in patients with squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "First, the effects of tyrosine kinase inhibitors (erlotinib hydrochloride, sorafenib tosilate and sunitinib malate) against human NSCLC, breast cancer and colorectal cancer were evaluated in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "S-1 and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, showed a significant inhibition of growth in human NSCLC (Lu-99 and PC-9 cell lines). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced NSCLC: a phase III trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "giorgio.scagliotti@unito.it  PURPOSE: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in NSCLC, based on the importance of the signaling pathways involved in tumor growth, angiogenesis, and metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This phase III trial investigated overall survival (OS) for sunitinib plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients previously treated with one to two chemotherapy regimens (including one platinum-based regimen) for recurrent NSCLC, and for whom erlotinib was indicated, were randomly assigned (1:1) to sunitinib 37.5 mg/d plus erlotinib 150 mg/d or to placebo plus erlotinib 150 mg/d, stratified by prior bevacizumab use, smoking history, and epidermal growth factor receptor expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: In patients with refractory NSCLC, sunitinib plus erlotinib did not improve OS compared with erlotinib alone, but the combination was associated with a statistically significantly longer PFS and greater ORR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for NSCLC, a phase II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Variables with the greatest influence in the model were erlotinib-associated progression-free survival (EGFRm AC), toxicity (EGFRm AC), cost of SBRT (NSCLC SCC), and patient utilities (all histologies). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced NSCLC and Impaired Performance Status as Selected by a Serum Proteomics Assay. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In light of the potential role for serum proteomics in predicting the benefit of erlotinib beyond that of epidermal growth factor receptor gene (EGFR) mutational status, we conducted a trial in which the Veristrat proteomics assay was used for data enrichment when selecting a cohort of patients with NSCLC and PS2 to receive erlotinib with and without chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: In a proteomics-enriched cohort of patients with NSCLC and PS2, pharmacodynamically separated erlotinib plus chemotherapy had better efficacy than did erlotinib alone and surpassed the protocol-specified benchmark of PFS of at least 3 months required for further study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced NSCLC (OPTIMAL, CTONG-0802). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: The OPTIMAL study was the first study to compare efficacy and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutant NSCLC patients, suggesting that erlotinib should be considered standard first-line treatment of EGFR mutant patients and EGFR-TKI treatment following first-line therapy also brings significant benefits to those patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: To test, in a single-arm, prospective, phase 2 trial, whether adding the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to concurrent chemoradiotherapy for previously untreated, locally advanced, inoperable NSCLC would improve survival and disease control without increasing toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III NSCLC: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with poor-risk unresectable stage III NSCLC received two cycles of carboplatin at an AUC of 5 and nab-paclitaxel at 100 mg/m on days 1 and 8 every 21 days, followed by erlotinib administered concurrently with thoracic radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Patients with poor-risk stage III NSCLC had better than expected outcomes with a regimen of induction carboplatin/nab-paclitaxel followed by thoracic radiotherapy and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: Patients \u2265 70 years with untreated, metastatic NSCLC were randomized to Erlotinib (E), 150 mg/day or Carboplatin (AUC5) plus Vinorelbine (25mg/m(2) on days 1 and 8) every three weeks (CV). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Intercalated combination of chemotherapy and erlotinib for patients with advanced stage NSCLC (FASTACT-2): a randomised, double-blind trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: In this phase 3 trial, patients with untreated stage IIIB/IV NSCLC were randomly assigned in a 1:1 ratio by use of an interactive internet response system with minimisation algorithm (stratified by disease stage, tumour histology, smoking status, and chemotherapy regimen) to receive six cycles of gemcitabine (1250 mg/m(2) on days 1 and 8, intravenously) plus platinum (carboplatin 5\u2008\u00d7\u2008area under the curve or cisplatin 75 mg/m(2) on day 1, intravenously) with intercalated erlotinib (150 mg/day on days 15-28, orally; chemotherapy plus erlotinib) or placebo orally (chemotherapy plus placebo) every 4 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "INTERPRETATION: Intercalated chemotherapy and erlotinib is a viable first-line option for patients with NSCLC with EGFR mutation-positive disease or selected patients with unknown EGFR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Recently, a large number of studies have shown that an epidermoid growth factor receptor-tyrosine kinase inhibitor (EGFR TKI), Erlotinib, has significantly better efficacy and is better tolerated in advanced NSCLC patients with a positive EGFR gene mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib monotherapy is more cost-effective compared with platinum-based doublets chemotherapy as a first-line therapy for advanced EGFR mutation- positive NSCLC patients from within the Chinese health care system. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: The OPTIMAL study found that erlotinib improved progression-free survival (PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Erlotinib improves QoL compared with standard chemotherapy in the first-line treatment of patients with EGFR mutation-positive advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Thus, low-dose erlotinib may be effective and well tolerated by patients with NSCLC harboring EGFR mutations who are intolerant to gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Erlotinib is clinically effective in patients with NSCLC who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive NSCLC (EURTAC): a multicentre, open-label, randomised phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with NSCLC with activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib (Tarceva) is a selective epidermal growth factor receptor tyrosine kinase inhibitor for treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Intercalated chemotherapy and erlotinib for NSCLC with activating epidermal growth factor receptor (EGFR) mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib maintenance treatment improves progression-free survival compared with observation after first-line chemotherapy in unselected advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "A pharmacological inhibitor of YAP1 signaling, verteporfin also synergized with cisplatin, radiation and erlotinib in NSCLC cells by potentiating cisplatin and radiation-related double-stranded breaks and decreasing expression of YAP1 and EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC in the United States. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: To determine the cost-effectiveness of tyrosine kinase inhibitors erlotinib or afatinib, or chemotherapy cisplatin-pemetrexed, for first-line treatment of advanced epithelial growth factor receptor mutation-positive NSCLC in the United States. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Model transition and adverse-effect probabilities were from two published phase III trials: EURTAC (Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive NSCLC) and LUX-Lung (Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma) 3. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Our analysis suggests that erlotinib is the preferred first-line treatment for advanced epithelial growth factor receptor mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive NSCLC: analyses from the phase III, randomized, open-label, ENSURE study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients \u226518 years old with histologically/cytologically confirmed stage IIIB/IV EGFR mutation-positive NSCLC and Eastern Cooperative Oncology Group performance status 0-2 were randomized 1:1 to receive erlotinib (oral; 150 mg once daily until progression/unacceptable toxicity) or GP [G 1250 mg/m(2) i.v. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: These analyses demonstrate that first-line erlotinib provides a statistically significant improvement in PFS versus GP in Asian patients with EGFR mutation-positive NSCLC (NCT01342965). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The first phase II study of biomarker-guided neoadjuvant therapy for stage IIIA-N2 NSCLC patients stratified by EGFR mutation status, sponsored by CSLC0702, showed erlotinib tended to improve response rate, but failed to show benefits of disease-free survival (DFS) or OS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we evaluate the anticancer and anti-angiogenic effects of low dose erlotinib-cisplatin combination in NSCLC in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination erlotinib-cisplatin treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "These results suggest that low dose erlotinib-cisplatin combination exhibits its anti-tumor activity by targeting angiogenesis through the modulation of the c-MYC/HIF-1\u03b1/VEGF pathway in NSCLC with EGFR exon 19 deletions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with NSCLC after failure of first-line chemotherapy: GFPC 10.02 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Concomitant administration of erlotinib with standard chemotherapy does not appear to improve survival among patients with NSCLC, but preliminary studies suggest that sequential administration might be effective. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "OBJECTIVE: To assess the efficacy and tolerability of second-line sequential administration of erlotinib and docetaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Sequential erlotinib and docetaxel was not more effective than docetaxel alone as second-line treatment for advanced NSCLC with wild-type or unknown EGFR status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib and pemetrexed have been approved for the second-line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " NSCLC patients with activating mutations in the epidermal growth factor receptor (EGFR) are responsive to erlotinib, an EGFR-tyrosine kinase inhibitor (EGFR-TKI). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we investigated the effect of curcumin on the tumor growth of erlotinib-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Furthermore, curcumin significantly increased the cytotoxicity of erlotinib to erlotinib-resistant NSCLC cells, enhanced erlotinib-induced apoptosis, downregulated the expressions of EGFR, p-EGFR, and survivin, and inhibited the NF-\u03baB activation in erlotinib-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The combination of curcumin and erlotinib exhibited the same effects on apoptosis as the combination of curcumin and cisplatin in erlotinib-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Moreover, the combined treatment of curcumin and erlotinib significantly inhibited tumor growth of erlotinib-resistant NSCLC cells in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our results indicate that curcumin is a potential adjuvant for NSCLC patients during erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) benefit NSCLC patients, and an EGFR-TKIi erlotinib, is approved for patients with recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here, we investigated the role of Hh signaling in erlotinib resistance of TGF-\u03b21-induced NSCLC cells that are reminiscent of EMT cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "RESULTS: siRNA-mediated inhibition as well as pharmacological inhibition of Hh signaling abrogated resistance of NSCLC cells to erlotinib and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " This phase II study investigated dose-intense erlotinib maintenance after dose-dense chemotherapy for patients with metastatic NSCLC and examined two cell cycle biomarkers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: A phase II clinical trial previously evaluated the sequential administration of erlotinib after chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Treatment of stage IIIb/IV NSCLC with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The switch maintenance strategy with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor erlotinib (in all the histologies) or with pemetrexed (in non-squamous histologies) have been demonstrated to be two possible effective options versus the classic break from cytotoxic chemotherapy after a fixed course in the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced NSCLC to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, erlotinib resistance (ER) in NSCLC is being recognized as a major problem. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced NSCLC whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced NSCLC: the TORCH randomized trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Erlotinib prolonged survival of unselected patients with advanced NSCLC who were not eligible for further chemotherapy, and two phase II studies suggested it might be an alternative to first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell NSCLC failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: EMPHASIS-lung is a randomized phase III multicenter trial exploring the differential activity of second-line erlotinib versus docetaxel on progression-free survival (PFS) in Veristrat good versus poor patients with squamous cell NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND/AIM: The TArceva and docetaxeL In former-Smokers MAle patients with recurrent NSCLC (TALISMAN) phase II, open-label randomized trial evaluates the combination of erlotinib with docetaxel in the second-line therapy of ex-smoker males with advanced squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We have reported the analysis performed on the role of the polymorphism located in the KRAS-LCS (rs61764370) which is involved in the disruption of the let-7 complementary site in NSCLC patients enrolled within the TAILOR trial, a randomised trial comparing erlotinib versus docetaxel in second line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Clinical and biological significance of erlotinib therapy after pemetrexed in NSCLC with wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The cell growth assay confirmed that treatment with pemetrexed followed by erlotinib significantly inhibited proliferation of NSCLC cells regardless of EGFR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In conclusion, use of erlotinib at the time of progression after pemetrexed therapy confers a\u00a0survival benefit in NSCLC patients with wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib appears to be a useful second-line option in PS0/1 patients with EGFR mutation-negative advanced non-squamous NSCLC given its mild adverse effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib and gefitinib for treating NSCLC that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Randomized phase II study of gefitinib versus erlotinib in patients with advanced NSCLC who failed previous chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In EGFR unknown patients, nine trials (INTEREST, IRESSA as Second-line Therapy in Advanced NSCLC - KoreA, Li, Second-line Indication of Gefitinib in NSCLC, V-15-32, ISEL, DELTA, TITAN and BR.21) reported overall survival data and only one (BR.21) reported a statistically significant result favouring the use of erlotinib over BSC (HR 0.7, 95% CI 0.58 to 0.85). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Recently, erlotinib, a tyrosine kinase inhibitor (tki) targeting EGFR mutation, was approved as second-line treatment in EGFR wild-type nsclc. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib versus docetaxel as second- or third-line therapy in patients with advanced NSCLC in the era of personalized medicine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: The purpose of this study was to assess whether an intercalated dosing schedule of erlotinib and docetaxel could avoid possible negative interactions and optimize the benefit obtained as second-line therapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: In patients with advanced NSCLC of adenocarcinoma histology, results suggest that nintedanib plus docetaxel offers clinical benefit compared with docetaxel alone, when used as second-line treatment, and suggests that this combination may also add clinical benefit compared with erlotinib in this patient group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " AIM: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Over the past decade, well tolerated second-line therapies for advanced NSCLC have been approved including erlotinib and pemetrexed in addition to docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The discovery of a number of lung cancer-molecular alterations contributes to uniquely targeted therapies with specific inhibitors for NSCLC such as erlotinib, gefitinib and crizotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced NSCLC: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: To investigate the efficacy of erlotinib versus docetaxel in previously treated patients with advanced NSCLC in an epidermal growth factor receptor (EGFR) -unselected patient population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EGFR wild-type NSCLC was present in 109 and 90 patients in the erlotinib and docetaxel groups, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Predictive value of a proteomic signature in patients with NSCLC treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We assessed the predictive power of this test in the comparison of erlotinib and chemotherapy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed NSCLC patients: the NVALT-10 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "mmajem@santpau.cat  Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced NSCLC patients with disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "faupe@libero.it  The only approved agents for second-line therapy in unselected NSCLC are docetaxel and pemetrexed (chemotherapies) and erlotinib (targeted therapies). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Currently only three second-line NSCLC pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIAL AND METHODS: Italy was selected for base case analysis to compare the total therapy costs, estimated by combining country-specific drug costs, administration costs, and adverse event costs of erlotinib and generic docetaxel in second-line NSCLC therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The cost comparison findings for Italy show that erlotinib is still the less costly therapy alternative in second-line NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Treatment options for patients whose tumors have failed to respond to two or more conventional chemotherapy regimens are limited, with erlotinib, which targets the epidermal growth factor receptor, and crizotinib, which targets EML4/ALK, the only agents currently approved in the United States as third-line therapy for patients with advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "krapa@poczta.onet.pl  BACKGROUND: We evaluated the effectiveness of docetaxel or erlotinib in second-line treatment of NSCLC and focused on the impact of predictive factors on the outcome of therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib and docetaxel show similar efficacy in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, NSCLC with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of NSCLC, but no head-to-head data from large clinical trials are available. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as Gefitinib and Erlotinib, are effective clinical medicines for advanced NSCLC patients harboring EGFR-activating mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib seemed more effective than gefitinib in prolonging survival in leptomeningeal carcinomatosis from EGFR mutation-positive NSCLC and may be particularly beneficial in patients with EGFR exon 19 mutations, warranting further studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced NSCLC harboring EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Maintenance therapy with full-dose erlotinib for patients with advanced NSCLC has demonstrated a significant overall survival (OS) benefit. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study aimed to evaluate the efficacy and safety of low-dose erlotinib (25 mg/day) as maintenance treatment after platinum doublet chemotherapy in NSCLC harboring epidermal growth factor receptor (EGFR) mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, our study suggests that maintenance therapy with low-dose erlotinib might be useful and tolerable in selected NSCLC patients harboring EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is initially effective in NSCLC patients with tumors harboring activating mutations of EGFR, most subsequently develop acquired resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We sought to demonstrate the activity of INC-280 on select NSCLC cell lines both as a single agent and in combination with erlotinib using exogenous HGF to simulate MET up-regulation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Four NSCLC cell lines (HCC827, PC9, H1666, and H358) were treated with either single-agent INC-280 or in combination with erlotinib with or without HGF. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Although the MET inhibitor INC-280 alone had no discernible effect on cell growth, it was able to restore sensitivity to erlotinib and promote apoptosis in NSCLC models rendered erlotinib resistant by HGF. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "These data provide a preclinical rationale for an ongoing phase 1 clinical trial of erlotinib plus INC-280 in EGFR-mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "erlotinib in the second- and third-line NSCLC did not meet its primary endpoint of overall survival (OS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib and afatinib in advanced EGFR-mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced epidermal growth factor receptor (EGFR) mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We retrospectively reviewed 922 consecutive patients with EGFR-mutant NSCLC patients administered with gefitinib/erlotinib at Guangdong General Hospital. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in NSCLC harboring EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We studied 89 NSCLC Hispanic patients with EGFR mutation who were treated with erlotinib between January 2009 and November 2014. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This alteration is associated with a poor clinical response to erlotinib and represents an independent prognostic factor for patients who had NSCLC with an EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in NSCLC patients with tumors showing high EGFR gene copy number. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: A multicenter, open-label, single-arm phase II clinical trial was performed to test the efficacy of erlotinib in the first-line treatment of NSCLC patients harboring high EGFR gene copy number defined as \u22654 copies in \u226540% of cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Pharmacodynamic separation of pemetrexed and erlotinib avoids negative cellular interactions and results in antitumor synergy in erlotinib-resistant NSCLC cells, independent of EGFR (epidermal growth factor receptor) genotype. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients with platinum-treated metastatic nonsquamous NSCLC were randomly assigned 1:2 to pemetrexed alone (500 mg/m(2) provided intravenously on day 1) or pemetrexed followed by erlotinib (150 mg provided orally once daily on days 2-17) every 21 days. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: In patients with unselected or EGFR wild-type advanced nonsquamous NSCLC, pharmacodynamic separation of pemetrexed and intercalated erlotinib had promising antitumor activity without new safety concerns. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first-line treatments for advanced EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in NSCLC patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: A retrospective database analysis of 157 patients given erlotinib or gefitinib for EGFR-mutant advanced NSCLC from two institutions was conducted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The epidermal growth factor receptor (EGFR) mutant NSCLCs frequently respond to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) treatment, such as Gefitinib and Erlotinib, but the development of acquired resistance limits the utility. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This phase Ib/III study will assess safety, tolerability, and efficacy of the combination of ramucirumab with erlotinib in previously untreated stage IV NSCLC patients with an activating epidermal growth factor receptor (EGFR) mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype NSCLC Targeted by the Repurposed Drug Auranofin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Addition of the thioredoxin reductase 1 inhibitor (TXNRD1) auranofin (AF) to NSCLC cells treated with combination of TUSC2 forced expression with erlotinib increased tumor cell apoptosis and inhibited colony formation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In NSCLC tumor xenografts, tumor growth was markedly inhibited and animal survival was prolonged over controls by AF-TUSC2-erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive NSCLC just after progression on EGFR-TKI, gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study evaluated the efficacy and safety of a c-Met selective inhibitor, tivantinib (ARQ 197), in combination with erlotinib, in Japanese EGFR mutation-positive patients with NSCLC who progressed while on EGFR-TKIs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: This study enrolled 45 patients with NSCLC with acquired resistance to EGFR-TKIs, who were orally administered a daily combination of tivantinib/erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " In this study, a core-shell type polypeptide-based lipid nanocapsule was developed to enhance anticancer efficacy of erlotinib in NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced NSCLC (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib is approved for the treatment of all patients with advanced NSCLC, but is most active in the treatment of EGFR mutant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We compared the efficacy of cabozantinib alone or in combination with erlotinib versus erlotinib alone in patients with EGFR wild-type NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "INTERPRETATION: Despite its small sample size, this trial showed that, in patients with EGFR wild-type NSCLC, cabozantinib alone or combined with erlotinib has clinically meaningful, superior efficacy to that of erlotinib alone, with additional toxicity that was generally manageable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This review discusses the latest updates in molecular testing at progression and outlines treatment options for this difficult-to-treat population.IMPLICATIONS FOR PRACTICE: Although the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-gefitinib, erlotinib, and afatinib-have changed the treatment paradigm for NSCLC among those with EGFR mutation-positive disease, most patients experience progression after approximately 12 months of treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced NSCLC patients with secondary drug resistance: A single center, single arm, phase II clinical trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced NSCLC with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who had experienced drug resistance after one year of conventional treatment with gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Tyrosine kinase inhibitors, such as erlotinib, display reliable responses and survival benefits for the treatment of human NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To identify secreted proteins that are differentially regulated in erlotinib-sensitive (PC-9) and -resistant (PC-9ER) NSCLC cell lines, SILAC experiments were performed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Fourteen proteins were found to be differently regulated among erlotinib-sensitive and -resistant NSCLC cell lines, with five proteins (tissue-type plasminogen activator, epidermal growth factor receptor, urokinase-type plasminogen activator, platelet-derived growth factor D, and myeloid-derived growth factor) showing the most prominent regulation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Tissue-type plasminogen activator (t-PA) was up to 10-times upregulated in erlotinib-resistant NSCLC cells compared with erlotinib-sensitive cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "T-PA is an established tumor marker for various cancer types and seems to be a promising prognostic marker to differentiate erlotinib-sensitive from erlotinib-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Fourteen proteins were identified as potential t-PA interaction partners, deserving a closer inspection to unravel the mechanisms underlying erlotinib resistance in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Background Older NSCLC patients under erlotinib are reported to experience more acute toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "A drug that is currently in the market for the treatment of NSCLC and targets EGFR is erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Patients with advanced epidermal growth factor receptor (EGFR) mutant NSCLC are particularly sensitive to treatment with first- or second-generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell-signaling pathways that drive the growth of tumor cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Tyrosine kinase inhibitors, such as crizotinib and erlotinib, are widely used to treat NSCLC, but after initial response, relapse is common because of the emergence of resistance through multiple mechanisms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib Induced Fatal Interstitial Lung Disease in a Patient with Metastatic NSCLC: Case Report and Review of Literature. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib induces the human NSCLC cells apoptosis via activating ROS-dependent JNK pathways. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of the present study was to test whether early changes of (18)F-fluorodeoxyglucose ((18)F-FDG) uptake in animal models bearing erlotinib-resistant NSCLC may have different imaging patterns of response to erlotinib depending on the molecular mechanisms underlying resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Successful treatment of NSCLC with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: This phase I trial was conducted to determine the safety, maximum tolerated dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The MTD of the combination of crizotinib and erlotinib in patients with advanced NSCLC was crizotinib, 150 mg twice daily, with erlotinib, 100 mg once daily, which is less than the approved dose of either agent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Based on these findings, the patient was treated with erlotinib combined with cabozantinib, a type II MET inhibitor, and exhibited a response.SIGNIFICANCE: With several structurally distinct MET inhibitors undergoing development for treatment of NSCLC, it is critical to identify mechanism-based therapies for drug resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Phase 2 Study of Erlotinib in Combination With\u00a0Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With NSCLC and Activating Epidermal Growth Factor Receptor Mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: We performed a randomized, double-blind, placebo-controlled phase II study of linsitinib, a dual IGF-1R and insulin receptor tyrosine kinase inhibitor, plus erlotinib versus placebo plus erlotinib in chemotherapy-naive patients with EGFR-mutation positive, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "OBJECTIVES: To (a) describe utilization patterns and costs associated with biopsy procedures and biomarker testing in patients with NSCLC who received erlotinib or crizotinib between 2009 and 2012 and (b) investigate the timing of these procedures relative to the erlotinib or crizotinib index date. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Because there is no specific ICD-9-CM diagnostic code for NSCLC, patients with metastatic lung cancer who received erlotinib or crizotinib were considered to have metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MEDLINE, PubMed, Cochrane, and Google Scholar databases were searched until October 21, 2015 using the following search terms: lung neoplasms/lung cancer/NSCLC/NSCLC, EGFR, gene amplification, copy number, erlotinib, gefitinib, tyrosine-kinase inhibitor/TKI, predictor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: The emergence of EGFR-inhibitors such as gefitinib, erlotinib and osimertinib has provided novel treatment opportunities in EGFR-driven NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Currently, the first-generation EGFR/HER-TKIs gefitinib and erlotinib and second-generation EGFR/HER-TKI afatinib have been approved for use as the first-line treatment of metastatic NSCLC with actEGFRm. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: In Japan, the clinical efficacy of erlotinib monotherapy in epidermal growth factor receptor (EGFR) mutation-positive NSCLC was demonstrated in the phase II JO22903 trial, which reported a median progression-free survival of 11.8\u00a0months. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: JO22903 (JapicCTI-101085) was a single-arm, multicenter, phase II, open-label, non-randomized study of first-line erlotinib monotherapy in EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Eligible patients (\u226520\u00a0years) with stage IIIB/IV or recurrent NSCLC and confirmed activating mutations of EGFR (exon 19 deletion or L858R point mutation in exon 21) received oral erlotinib 150\u00a0mg/day until disease progression or unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: In this survival update, single-agent erlotinib achieved a median overall survival of more than 3\u00a0years in patients with EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  miR-17-5p down-regulation contributes to erlotinib resistance in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib is an effective drug for NSCLC patients, but its effect in advanced NSCLC is compromised because of the drug resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The mechanism of erlotinib resistance in NSCLC is largely unknown. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Consistently, miR-17-5p was down-regulated in the tumor tissues and the plasma of erlotinib-resistant NSCLC patients in comparison to those who are sensitive to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our results indicate that miR-17-5p down-regulation contributes to erlotinib resistance of NSCLC by modulating its target genes such as EZH1 and plasma miR-17-5p might be a potential biomarker of erlotinib response in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: This study was a pre-planned exploratory analysis of a randomized phase III trial conducted from 2009 to 2014 comparing erlotinib with gefitinib in advanced NSCLC harboring EGFR mutations in tumor (CTONG0901). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Leptomeningeal carcinomatosis in NSCLC: initial response to erlotinib followed by relapse despite continuing radiological resolution of disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To explore this, we have utilized an EGFR-null CHO overexpression system as well as NSCLC cell lines expressing various EGFR mutants and determined the effects of erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The present study compares the concentration of sPD-1 in the serum of advanced NSCLC patients with Epidermal Growth Factor Receptor (EGFR) mutation prior to erlotinib treatment and at the time of progression and correlates these results to patient outcome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: Blood samples from 38 patients with EGFR-mutated advanced NSCLC treated with erlotinib were analyzed for sPD-1 by sandwich ELISA. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced NSCLC: A propensity-adjusted, outcomes research-based study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: Controversy exists about the integration of erlotinib in patients with EGFR wildtype, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The present study suggests erlotinib to have similar clinical efficacy compared to chemotherapy in patients with pretreated advanced NSCLC and no known molecular targetable alterations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: The analysis included fifty two NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs): erlotinib or gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib is among the oral EGFR-tyrosine kinase inhibitors used to treat NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We develop this framework in the specific context of EGFR-driven NSCLC, which is commonly treated with the tyrosine kinase inhibitor erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, are one of the representatives of targeted therapy which have been widely used in first line, maintenance and 2nd/3rd line therapy among advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we utilized Dichloroacetate (DCA), a widely regarded PDK inhibitor, together with Erlotinib and Gefitinib, two well-known EGFR inhibitors, and demonstrated that the applications of DCA in combination with either Erlotinib or Gefitinib significantly attenuated the viability of EGFR mutant NSCLC cells (NCI-H1975 and NCI-H1650) in a synergistic manner. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we evaluate the anticancer and anti-angiogenic effects of low dose celecoxib-erlotinib combination in NSCLC in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination celecoxib-erlotinib treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The tyrosine kinase inhibitor erlotinib poorly penetrates the blood-brain barrier (BBB) because of efflux transport by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), thereby limiting its utility in the treatment of NSCLC metastases in the brain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib (Tarceva\u00ae) is a chemotherapeutic drug approved for the treatment of pancreatic cancer and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (excluding sensitizing EGFR mutations and ALK gene fusions) refractory to more than one prior therapy were randomly assigned, stratified by KRAS status, to four arms: (1) erlotinib, (2) erlotinib plus MK-2206, (3) MK-2206 plus AZD6244, or (4) sorafenib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced NSCLC: a meta-analysis of 13 randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: To compare the effects of an erlotinib-based targeted dual agent with erlotinib alone in previously treated patients with advanced non-small lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The role of erlotinib-based combinations in previously treated patients with NSCLC seemed insignificant. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We evaluated the efficacy of first-generation EGFR-tyrosine kinase inhibitors (TKIs; erlotinib, gefitinib, and icotinib) in patients with NSCLC carrying insertions and T790M and S768I mutations in EGFR exon 20. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Evaluation of erlotinib treatment response in NSCLC using metabolic and anatomic criteria. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: In this paper the clinical value of PET for early prediction of tumor response to erlotinib in patients with advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen is evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To increase in vivo efficacy and STAT3 inhibition, Debio 0617B was tested in combination with the EGFR inhibitor erlotinib in a NSCLC xenograft model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Afatinib, together with gefitinib and erlotinib, is approved for first-line treatment of advanced NSCLC with activating mutations of the epidermal growth factor receptor (EGFR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Methods The study comprised a 3\u00a0+\u00a03 dose-escalation part for LY2875358 monotherapy in patients with advanced malignancies (Part A) followed by an assessment of LY2875358 in combination with erlotinib or gefitinib in patients with NSCLC (Part B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " YAP promotes erlotinib resistance in human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here we show that YAP promotes resistance to erlotinib in human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our results indicate that YAP promotes erlotinib resistance in the erlotinib-sensitive NSCLC cell line HCC827. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Inhibition of YAP by siRNA increases sensitivity of erlotinib-resistant NSCLC cell line H1975 to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Tyrosine kinase inhibitors (TKIs), such as erlotinib, approved by the FDA as first/second line therapy for NSCLC patients have limited clinical efficacy due to acquired resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " EGFR-targeted inhibitors (gefitinib and erlotinib) provided an effective strategy for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous NSCLC: Results of the PEPiTA observational study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: Erlotinib, an inhibitor of tyrosine kinase activity of the epidermal growth factor receptor, is effective in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Data on erlotinib use in squamous NSCLC are limited. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This observational study aimed at evaluating the efficacy and safety of second-line erlotinib in patients with stage IIIB/IV squamous NSCLC in a real-life setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The results of this real-life cohort study like those of previous phase III/IV subgroups study analyses indicate that erlotinib is a valuable option for second-line treatment of stage IIIB/IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: This multicenter, randomized, placebo-controlled, double-blind, phase III study investigated intercalated first-line erlotinib or placebo with gemcitabine/platinum, followed by maintenance erlotinib or placebo, for patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Activating EGFR mutations were predictive for improved treatment outcomes with a first-line intercalated regimen of chemotherapy and erlotinib in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To determine the extent to which PLK1 inhibition overcomes EGFR TKI resistance we measured the effects of the PLK1 inhibitor volasertib alone and in combination with the EGFR inhibitor erlotinib in vitro and in vivo in EGFR mutant NSCLC cell lines with acquired resistance to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In all NSCLC cell lines with T790M mutations, volasertib markedly reduced erlotinib resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "All erlotinib-resistant NSCLC cell lines with T790M mutations had higher sensitivity to erlotinib plus volasertib than to erlotinib alone, and the combination treatment caused G2/M arrest and apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib is a tyrosine kinase inhibitor (TKI), approved for the treatment of patients with NSCLC and pancreatic cancer in combination with gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Predictive significance of thyroid transcription factor-1 expression in patients with non-squamous NSCLC with wild-type epidermal growth factor receptor treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study is a retrospective review of patients with non-squamous, NSCLC (NS-NSCLC) and wild-type EGFR who were treated with erlotinib alone as second- or later-line chemotherapy at the Tokyo Metropolitan Cancer and Infectious Diseases Center of Komagome Hospital (Tokyo, Japan) between December, 2008 and December, 2013. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Therefore, the expression of TTF-1 may serve as a useful tool for predicting the efficacy of erlotinib in patients with NS-NSCLC expressing wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Acute myocardial infarction following erlotinib treatment for NSCLC: A case report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is an oral targeted anticancer drug that is used to treat NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In the current study, the first case of acute myocardial infarction following one month of treatment with erlotinib in a 63-year-old male NSCLC patient is presented. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In elderly NSCLC patients and those with a history of coronary heart disease, cardiac function must be carefully monitored following erlotinib treatment so that serious adverse reactions, such as myocardial infarction, may be identified early and treated quickly. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Less than a quarter of NSCLC patients diagnosed in 2010 received EGFR testing and less than half of the patients with EGFR-mutant stage IV tumors received erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have greatly improved treatment efficacy in NSCLC patients with drug-sensitive EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant NSCLC Patients Treated with Erlotinib on a Phase II Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This prospective trial evaluated CTCs and cfDNA in EGFR-mutant NSCLC patients treated with erlotinib until progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EXPERIMENTAL DESIGN: EGFR-mutant NSCLC patients were enrolled in a phase II trial of erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Recently, AMPK activation was proposed to sensitize NSCLC cells against erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Although erlotinib has shown proven effectiveness against NSCLC, few studies have prospectively investigated its application to elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Although the percentage of patients requiring dose reduction seemed relatively higher than that in previous studies, erlotinib is a potentially useful therapeutic option for unselected elderly patients with previously treated advanced or recurrent NSCLC, as has been also shown for younger patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib for Japanese patients with activating EGFR mutation-positive NSCLC: combined analyses from two Phase II studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " AIMS: We evaluated the efficacy and safety of erlotinib, and patient characteristics affecting progression-free survival (PFS), by analyzing data from two Phase II studies of first-line erlotinib in activating EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " [Can positron emission tomography assessment of response to treatment help to individualize use of erlotinib in NSCLC?]  [Article in French]  Hureaux J(1), Couturier O(2), Lac\u0153uille F(2), Bouchet F(2), Choua\u00efd C(3), Saulnier P(4), Urban T(5); les investigateurs du projet. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib can be prescribed in the treatment of locally advanced or metastatic non-small lung cancer cell (NSCLC) after failure of at least one prior chemotherapy regimen on the basis of the BR-21 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The primary objective of this study is to determine if metabolic progression observed between the 7th and 14th day after initiation of treatment with erlotinib by 3'-Deoxy-3'-[18F]-Fluorothymidine PET in patients with EGFR naive NSCLC is predictive for morphological progression after 6 to 8 weeks of treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib is a BCS (biopharmaceutical classification system) class II drug used for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We have further shown that knock-out of YAP sensitizes NSCLC to EGFR inhibitor Erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " 169P: Chemotherapy is not superior to erlotinib in pretreated patients with advanced NSCLC: A retrospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Low activity of poziotinib was detected in patients with EGFR-mutant NSCLC who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib plus concurrent whole-brain radiation therapy for NSCLCs patients with multiple brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, a previous study shows that a combination of EGFR TKI erlotinib (ER) with VEGFR TKI sunitinib (SU) did not improve the overall survival in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The combination effect of pacritinib, a novel JAK2/FLT3 inhibitor, with erlotinib, the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), on NSCLC cells with EGFR activating mutations was investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " miR-223 enhances the sensitivity of NSCLC cells to erlotinib by targeting the insulin-like growth factor-1 receptor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In the present study, to characterize the biological behavior of miR\u2011223 in NSCLC, we established an miR\u2011223 overexpression model in erlotinib-resistant PC\u20119\u00a0(PC\u20119/ER) cells by infection with lentivirus to induce the overexpression of miR\u2011223. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic NSCLC (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Gefitinib and erlotinib target the ATP cleft in the tyrosine kinase EGFR, which is overexpressed in 40-80 percent of NSCLC and many other epithelial cancers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced NSCLC Using Two Different Schedules. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: This study aimed to evaluate the safety, tolerability and pharmacokinetics of the combination of oral vinorelbine with erlotinib using the conventional (CSV) and metronomic (MSV) dosing schedules in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our study indicates that AS treatment may not compromise TKI efficacy (gefitinib or erlotinib) in NSCLC patients with mutated EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive NSCLC, receiving treatment with gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The present study reports a case of a 62-year-old, non-smoking female patient with advanced NSCLC, presenting with concurrent EGFR 19+21 sensitizing mutations, who had a poor response to the first-line EGFR-TKI erlotinib and succumbed 5 months subsequent to diagnosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Affinity purification coupled with high resolution mass spectrometry was applied to isolate and characterise the EGFR interactome from HCC4006 NSCLC cells and their variant HCC4006(r)ERLO(0.5) adapted to grow in the presence of therapeutically relevant concentrations of erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Response monitoring using fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography (FDG-PET/CT) textural features has potential in targeted treatment with erlotinib in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: GSE38310, the gene expression profiles of NSCLC cell lines treated with dimethylsulfoxide or erlotinib, including HCC827, ER3, and T15-2, were downloaded from Gene Expression Omnibus database and preprocessed by normalization. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "STAT3, SOX9, STAT5B, EGR1, and STAT6 might affect the resistance of NSCLC to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "OS adjusted for mean Charlson Comorbidity Index (CCI) was not different between erlotinib- and chemotherapy-treated groups in patients with non-squamous NSCLC (adjusted HR=0.91, 95% CI= 0.37-2.23; p=0.84), but was inferior in patients with squamous NSCLC treated with erlotinib (adjusted HR=10.6, 95% CI=1.28-87.8; p=0.029). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable NSCLC: a Phase II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Although many studies have confirmed the synergic effects of combining chemotherapy (CT) and radiotherapy (RT), clinical data evaluating safety and efficacy of erlotinib in combination with RT in locally advanced NSCLC are limited. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of this study was to determine the feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to the standard three-dimensional conformal thoracic RT in patients with unresectable or locally advanced NSCLC who are not candidates for receiving standard CT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The combination of erlotinib with RT produced, in our study, a scarce clinical benefit in the treatment of unresectable or locally advanced NSCLC, limited to complete responses and longer CSS rate compared with RT alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Safe and successful treatment with afatinib in three postoperative NSCLC patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Gefitinib and/or erlotinib-induced hepatotoxicity sometimes lead to treatment failure in EGFR mutation-positive patients with NSCLC, even though the therapeutic effect is evident. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CASES: Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib is highly active in EGFR mutant NSCLC, but may benefit some with wild-type tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We examined pre-operative erlotinib in early stage NSCLC to assess response and correlation with potential biomarkers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Clinical stage IA-IIB NSCLC patients received erlotinib 150 mg daily for 4 weeks followed by resection. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from NSCLC: A Meta-Analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy of first-line erlotinib in NSCLC patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The association between dose reduction, low BSA and efficacy, including response rate, disease control rate, time to treatment failure and overall survival, were evaluated in patients prescribed first-line erlotinib for EGFR mutated NSCLC patients between April 2012 and March 2015. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of NSCLC led to tremendous development of novel EGFR inhibitors in the last decade. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We recruited 226 Chinese advanced NSCLC patients who received TKIs erlotinib, gefitinib and icotinib hydrochloride and systematically studied the genetic factors associated with therapeutic responses and ADRs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: High MTV and TLG are independently correlated with shorter PFS and OS in advanced EGFR wild-type NSCLC patients treated with second or third-line erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib for the treatment of brain metastases in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EXPERT OPINION: Preclinical and retrospective data for erlotinib provide evidence of CNS penetration, and objective responses in the setting of BM from EGFR mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Phase I and II data have demonstrated the feasibility of concomitant delivery of erlotinib and WBRT in the treatment of BM from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "As such, EGFR TKI-resistant NSCLC cells (A549, H1299, H1975) were treated with the EGFR TKI erlotinib and FAK inhibitors (PF-573,228 or PF-562,271) both as single agents and in combination. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Treatment of EGFR TKI-resistant NSCLC cells with FAK inhibitor alone effectively inhibited cell viability in all cell lines tested; however, its use in combination with the EGFR TKI erlotinib was more effective at reducing cell viability than either treatment alone when tested in both 2- and 3-dimensional assays in vitro, with enhanced benefit seen in A549 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In the randomized phase III LUX-Lung 8 trial afatinib showed a statistical significant efficacy advantage compared to erlotinib as second-line treatment of advanced/metastatic squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Serum albumin is a strong predictor of survival in patients with advanced-stage NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of our retrospective study was to evaluate the association of baseline serum albumin with outcomes in a\u00a0large cohort of patients with advanced-stage NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Clinical data of 457 patients with locally-advanced (III B) or metastatic stage (IV) NSCLC treated with erlotinib were analysed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In conclusion, the results of present retrospective study indicate that pretreatment hypoalbuminemia is associated with poor outcome of NSCLC patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Doxycycline for prevention of erlotinib-induced rash in patients with NSCLC after failure of first-line chemotherapy: A randomized, open-label trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "OBJECTIVE: We sought to evaluate the efficacy of doxycycline in preventing erlotinib-induced rash (folliculitis) in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: This open-label, randomized, prospective, phase II trial was conducted in 147 patients with locally advanced or metastatic NSCLC progressing after first-line chemotherapy, randomized for 4\u00a0months with erlotinib alone 150\u00a0mg/d per os (control arm) or combined with doxycycline 100\u00a0mg/d (doxycycline arm). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and\u00a0Gefitinib in Patients With Advanced NSCLC Harboring EGFR\u00a0Mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: From 2008 to 2011, 130 consecutive patients with advanced NSCLC harboring EGFR mutations were treated with either erlotinib or gefitinib at our institution. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Concurrent use of AS did not affect the efficacy or toxicity of erlotinib and gefitinib in patients with advanced NSCLC harboring EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "NSC305787 showed synergism with erlotinib in wild-type EGFR-expressing NSCLC cells, whereas no synergy was observed in EGFR-null cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "These findings suggest that ezrin-EGFR interaction augments oncogenic functions of EGFR and that targeting ezrin may provide a potential novel approach to overcome erlotinib resistance in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Afatinib is a second-generation epidermal growth factor receptor (EGFR) inhibitor that has been shown to be effective against EGFR-mutated NSCLC resistant to conventional EGFR inhibitors such as gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIAL AND METHODS: We retrospectively analyzed all NSCLC patients with EGFR-TKI (gefitinib or erlotinib) treatment at our institution between 2011 and 2013 who progressed after at least stable disease on erlotinib or gefitinib for more than 6 months. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic NSCLC previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We therefore conducted a cost-effectiveness analysis of first-line treatment with erlotinib versus standard chemotherapy in European\u00a0patients with advanced-stage EGFR-mutated NSCLC who were enrolled in the European Erlotinib versus Chemotherapy trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: This economic analysis shows that first-line treatment with erlotinib, versus standard chemotherapy, is a dominant strategy for EGFR-mutated advanced-stage NSCLC in three European countries. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced NSCLC (KCSG-0806). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Given their synergistic activity in combination, we conducted a phase II study to determine the clinical activity of sorafenib in combination with erlotinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Sorafenib combined with erlotinib is well-tolerated with manageable toxicity and appears to be effective against advanced NSCLC with one or two prior line of systemic treatment (NCT00801385). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: In this randomized, cross-over, pharmacokinetic study in patients with NSCLC, we studied intrapatient differences in absorption (area under the plasma concentration time curve [AUC0-12h]) after a 7-day period of concomitant treatment with erlotinib, with or without esomeprazole, with either cola or water. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: In NSCLC patients off erlotinib therapy, positron emission tomography (PET) using [(11)C]erlotinib distinguished epidermal growth factor receptor (EGFR) mutations from wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Therefore, the aims of this study were to evaluate tumor [(11)C]erlotinib uptake in NSCLC patients both on and off erlotinib therapy, to evaluate the effect of erlotinib therapy on tumor perfusion and its correlation to tumor [(11)C]erlotinib uptake, and also, to investigate simplified uptake parameters using arterial and venous blood samples. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " NSCLC patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Quantitative assessment of (11)C-erlotinib uptake may be useful in selecting NSCLC patients for erlotinib therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The purpose of this study was to find the optimal pharmacokinetic model for quantification of uptake and to evaluate various simplified methods for routine analysis of (11)C-erlotinib uptake in NSCLC patients.METHODS: Dynamic (15)O-H2O and (11)C-erlotinib scans were obtained in 17 NSCLC patients, 8 with and 9 without an activating epidermal growth factor receptor mutation (exon 19 deletion or exon 21-point mutation). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The optimal model for quantitative assessment of (11)C-erlotinib uptake in NSCLC was the 2T4k-WB model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "A 76-year-old man with NSCLC was treated with polychemotherapy, palliative thoracic irradiation (30 Gy in 12 fractions) and erlotinib thereafter. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EXPERIMENTAL DESIGN: This open-label, dose-escalation study investigated linsitinib schedules S1: once daily intermittent (days 1-3 weekly); S2, once daily continuous; S3, twice-daily continuous; each with erlotinib 100-150 mg once daily; and a NSCLC expansion cohort. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: From 2008 to 2014, 96 patients, n = 63 suffering from histologically confirmed NSCLC and n = 33 from pancreatic adenocarcinoma were observed for the occurrence and severity of skin rash after the onset of treatment with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u8111\u662f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC, NSCLC\uff09\u5e38\u89c1\u7684\u8f6c\u79fb\u90e8\u4f4d\u3002\u6709\u7814\u7a76\u663e\u793a\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKI\uff09\u53ef\u900f\u8fc7\u8840\u8111\u5c4f\u969c\uff0c\u53d1\u6325\u6297\u80bf\u7624\u4f5c\u7528\u3002\u672c\u4f8b\u62a5\u9053\u91c7\u7528\u7a81\u53d8\u6269\u589e\u963b\u6ede\u7cfb\u7edf\uff08amplification refractory mutation system, ARMS\uff09\u68c0\u6d4b\u8111\u810a\u6db2EGFR\u7a81\u53d8\u6307\u5bfc\u4e34\u5e8a\u6cbb\u7597\u7684\u53ef\u884c\u6027\uff0c\u5e76\u5206\u6790TKI\u6cbb\u7597\u80ba\u764c\u8111\u8f6c\u79fb\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u65b9\u6cd5 \u8170\u7a7f\u53d6\u5f97\u8111\u810a\u6db2\u6807\u672c\uff0c\u68c0\u6d4b\u9885\u5185\u538b\u529b\uff0c\u68c0\u9a8c\u5e38\u89c4\u3001\u751f\u5316\u53ca\u80bf\u7624\u6807\u5fd7\u7269\uff0c\u67e5\u627e\u8131\u843d\u7ec6\u80de\uff0c\u91c7\u7528ARMS\u6cd5\u68c0\u6d4bEGFR\u57fa\u56e0\u7a81\u53d8\uff0c\u5f97\u5230\u9633\u6027\u7ed3\u679c\u540e\u7ed9\u4e88\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\uff08erlotinib \uff0ctarceva\uff0c\u7279\u7f57\u51ef\uff09\u6cbb\u7597\uff0c150 mg\uff0c\u6bcf\u59291\u6b21\u3002\u6309\u7167\u5b9e\u4f53\u7624\u7597\u6548\u8bc4\u4ef7\u6807\u51c61.1\u7248\uff08Response Evaluation Criteriation in Solid Tumours, RECIST v1.1\uff09\u8bc4\u4ef7\u5ba2\u89c2\u7597\u6548\uff0c\u6309\u7167\u4e0d\u826f\u53cd\u5e94\u901a\u7528\u672f\u8bed\u6807\u51c64.0\u7248\uff08Common Terminology Criteria for Adverse Events v4.0, CTC AE v4.0\uff09\u8bc4\u4f30\u7528\u836f\u671f\u95f4\u53d1\u751f\u7684\u4e0d\u826f\u4e8b\u4ef6\u3002\u7ed3\u679c \u8be5\u60a3\u8005\u591a\u7ebf\u6cbb\u7597\u540e\uff0c\u9885\u5185\u75c5\u7076\u63a7\u5236\u6b20\u4f73\uff0c\u8111\u810a\u6db2\u4e2d\u53d1\u73b0\u5f02\u578b\u7ec6\u80de\uff0cEGFR\u57fa\u56e019\u5916\u663e\u5b50\u7f3a\u5931\u7a81\u53d8\uff0c\u670d\u7528\u5384\u6d1b\u66ff\u5c3c4\u5468\u540e\uff0c\u9885\u5185\u5ba2\u89c2\u7597\u6548\u4e3a\u90e8\u5206\u7f13\u89e3\uff08partial response, PR\uff09\uff0c\u9885\u5916\u5ba2\u89c2\u7597\u6548\u4e3a\u75be\u75c5\u7a33\u5b9a\uff08stable disease, SD\uff09\uff0c\u9885\u5185\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08progression-free survival, PFS\uff0910.5\u4e2a\u6708\uff0c\u603b\u751f\u5b58\u671f\uff08overall survival, OS\uff0911\u4e2a\u6708\u3002\u4e3b\u8981\u4e0d\u826f\u53cd\u5e94\u4e3a\u76ae\u75b9\uff081\u7ea7\uff09\u3002\u7ed3\u8bba \u8111\u810a\u6db2\u68c0\u6d4bEGFR\u7a81\u53d8\u53ef\u4e3a\u5236\u5b9a\u6cbb\u7597\u7b56\u7565\u63d0\u4f9b\u7406\u8bba\u652f\u6301\uff0c\u6839\u636e\u4e0d\u540c\u7684\u7a81\u53d8\u72b6\u6001\u7ed9\u4e88\u5c0f\u5206\u5b50\u9776\u5411\u836f\u7269\u8054\u5408\u5316\u7597\uff0c\u53ef\u5206\u522b\u63a7\u5236\u9885\u5185\u53ca\u9885\u5916\u75c5\u7076\u3002. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " TGF-\u03b21 induces erlotinib resistance in NSCLC by down-regulating PTEN. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " NSCLC with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, but responds to the ALK-TKI crizotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " RATIONALE AND OBJECTIVES: The aims of this study were to investigate the association between 8-week tumor volume decrease and survival in an independent cohort of epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, and to assess the rate of their volumetric tumor growth after the volume nadir. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, computed tomography (CT) tumor volumes of dominant lung lesions were analyzed for (1) the association with survival, and (2) the volumetric tumor growth rate after the volume nadir. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In sqNSCLC patients who respond to induction chemotherapy, maintenance therapy with erlotinib delays disease progression and may improve the survival of patients with stable disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib is the first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the National Comprehensive Cancer Network (NCCN) guidelines recommend it as a first-line agent in patients with sensitizing EGFR mutations.We conducted a meta-analysis to compare the efficacy of erlotinib and chemotherapy for advanced NSCLC, and evaluated the efficacy of them to provide references for further clinical practice and research.PubMed, EMBASE, CBM, CNKI, WanFang database, The Cochrane library, and Web of Science, as well as abstracts presented at ASCO conferences and ClinicalTrials.gov were searched to identify relevant studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Pemetrexed and erlotinib represent different agents commonly used for the second-line treatment of patients with advanced-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: We analyzed data of 137 patients with advanced-stage non-squamous NSCLC treated with pemetrexed or erlotinib in the second line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive NSCLC: The ASPIRATION Study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "OBJECTIVE: To study the efficacy of first-line erlotinib therapy in patients with NSCLC with activating EGFR mutations and postprogression erlotinib therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS AND RELEVANCE: ASPIRATION supports the efficacy of first-line erlotinib therapy in patients with EGFR mutation-positive NSCLC and that treatment beyond progression is feasible and may delay salvage therapy in selected patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed 151 patients who had NSCLC harboring EGFR mutations and had received either gefitinib or erlotinib as first-line treatment between 2005 and 2014. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced NSCLC in Caucasian patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Erlotinib is active in advanced NSCLC (aNSCLC) particularly in patients with EGFR-sensitizing mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: This phase Ib trial used a 3\u00a0+\u00a03 escalation design with a combination of erlotinib (100\u00a0mg daily) with increasing doses of capecitabine (500, 750 and 1000\u00a0mg/m(2) BD, 14/21\u00a0days), in first- and second-line aNSCLC of adenocarcinoma histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Capecitabine did not improve the efficacy of erlotinib in aNSCLC unselected for EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PC9 cells, NSCLC cells with EGFR-activating mutations, became resistant to the EGFR TKI erlotinib when cocultured in vitro with CAFs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus nimotuzumab (N) in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Combination treatment of afatinib and nimotuzumab demonstrated an acceptable safety profile and encouraging antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Afatinib beyond progression in patients with NSCLC following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Afatinib has demonstrated clinical benefit in patients with NSCLC progressing after treatment with erlotinib/gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) mutations in NSCLC patients are associated with sensitivity to small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The present study reported a case of erlotinib-induced eyelash trichomegaly in a 65-year-old Chinese female patient suffering from NSCLC with an EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced NSCLC patients by DMET microarray analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Erlotinib is a targeted agent commonly used in advanced NSCLC (aNSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: In a retrospective study, 34 erlotinib-treated aNSCLC patients were genotyped by DMET Plus chip: 23 patients experienced SR (cases), while 11 patients did not (controls). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Although exploratory, this study indicates rs8176345 in CYP27B1 gene as significantly correlated with erlotinib-induced SR in aNSCLC patients probably through a mechanism mediated by vitamin D3 and inflammation at skin level. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: From 2008 to 2012, 160 consecutive patients with advanced NSCLC harboring an EGFR mutation were treated with EGFR-TKIs (erlotinib or gefitinib). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib has been approved based on the clinical benefit in non-small cell lung cancer (NSCLC) patients over the past decade. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here, we propose a novel strategy to overcome acquired erlotinib resistance in NSCLC by inhibiting glutaminase activity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Compound 968, an inhibitor of the glutaminase C (GAC), when combined with erlotinib potently inhibited the cell proliferation of erlotinib-resistant NSCLC cells HCC827ER and NCI-H1975. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Taken together, our study provides a valuable approach to overcome acquired erlotinib resistance by blocking glutamine metabolism and suggests that combination of EGFR-TKI and GAC inhibitor maybe a potential treatment strategy for acquired erlotinib-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Afatinib-refractory brain metastases from EGFR-mutant NSCLC successfully controlled with erlotinib: a case report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Both afatinib and erlotinib are tyrosine kinase inhibitors that inhibit aberrant epidermal growth factor receptor (EGFR) signals in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Although afatinib has been shown to be effective in the treatment for erlotinib-refractory and/or gefitinib-refractory central nervous system metastases from NSCLC, little is known about the efficacy of erlotinib for afatinib-refractory central nervous system metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our report highlights the potential benefit of erlotinib for the management of brain metastases refractory over afatinib in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Effect of smoking status on progression-free and overall survival in NSCLC patients receiving erlotinib or gefitinib: a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "WHAT IS NEW AND CONCLUSION: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Erlotinib is an epidermal growth factor receptor inhibitor approved for patients with advanced NSCLC whose epidermal growth factor receptor expression status is positive or unknown. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients receiving erlotinib in the second- or third-line setting for advanced NSCLC were randomly assigned to prophylactic minocycline (100 mg twice per day for 4 weeks), reactive treatment (after rash developed, per grade of rash), or no treatment unless severe (grade 3). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Prophylactic minocycline and reactive treatment are both acceptable options for the necessary treatment of erlotinib-induced rash in the second- or third-line setting of metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced NSCLC: Possible Benefits of Iodine Quantification in Response Assessment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Dual-phase DE-CT was performed in 31 patients with NSCLC before the onset of anti-EGFR (erlotinib) therapy and as follow-up (mean 8 weeks). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Risk of elevated transaminases in NSCLC patients treated with erlotinib, gefitinib and afatinib: a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " This meta-analysis has been conducted to determine the risk of elevated transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Clinical efficacy of erlotinib, a salvage treatment for NSCLC patients following gefitinib failure. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in NSCLC patients following gefitinib failure. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National University Hospital between August 2005 and November 2011 were enrolled. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant NSCLC Patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Agents such as erlotinib used for EGFR-mutant NSCLC or imatinib for chronic myeloid leukemia, for instance, lead to rapid tumor responses. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Adverse Events Costs Associated With Erlotinib Or Afatinib In Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Mutation-Positive Tumours. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The present trial was designed to examine the efficacy and toxicity of combined erlotinib and palliative chest thoracic RT in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: Patients with newly diagnosed stage III-IV (American Joint Committee on Cancer, version 6) or recurrent NSCLC received 3 weeks of erlotinib at a dose of 150 mg daily, starting 1 week before palliative thoracic RT to 30 Gy in 10 fractions within 2 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The present single-arm, phase II trial did not demonstrate additional symptomatic benefit from concurrent erlotinib therapy with standard palliative thoracic RT for patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We report the development of CSLPHNPs composed of the lipid monolayer shell and the biodegradable polymeric core for the delivery of erlotinib, an anticancer drug, clinically used to treat NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Therefore, CSLPHNPs could be a potential delivery system for erlotinib in the therapy of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Given the rapid development of third-generation EGFR TKIs and the approval of gefitinib, erlotinib, and afatinib as first-line treatment of EGFR-mutant NSCLC patients, the future role of dacomitinib in the treatment of NSCLC seems to be limited. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "gefitinib, erlotinib, afatinib) in patients with NSCLC harboring EGFR mutations reach 60-80%, with a complete response rate as high as 40%. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this surveillance study of Japanese NSCLC patients treated with erlotinib, rash management using topical steroids was analyzed in routine clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: From December 2007 to October 2009, all recurrent/advanced NSCLC patients in Japan treated with erlotinib were enrolled into this study (POst-Launch All-patient Registration Surveillance in TARceva). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Applying a focused shRNA screening approach to identify genes whose knockdown can prevent and/or overcome acquired resistance to erlotinib in several EGFR-mutant NSCLC cell lines, we identified casein kinase 1 \u03b1 (CSNK1A1, CK1\u03b1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase 1 study of romidepsin plus erlotinib in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Preclinical studies demonstrated anti-tumor efficacy of the combination of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in NSCLC models that were insensitive to erlotinib monotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Romidepsin 8 mg/m(2) plus erlotinib appears well tolerated, has evidence of disease control, and exhibits effects on relevant molecular targets in an unselected advanced NSCLC population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Successful treatment of NSCLC with gefitinib after erlotinib-induced severe eyelid erosion: Two case reports. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " NSCLC patients whose tumors have an EGFR-activating mutation develop acquired resistance after a median of 9-11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The Risk of Neutropenia and Leukopenia in Advanced NSCLC Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, the safety of erlotinib plus chemotherapy (CT) or erlotinib alone for advanced NSCLC remains controversial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib plus CT or alone relative to CT is associated with significantly decreased risks of neutropenia and leukopenia in patients with advanced NSCLC (RR, 0.38; 95% CI, 0.21-0.71; P = 0.00; incidence: 9.9 vs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The present meta-analysis suggested that erlotinib could decrease the incidence of neutropenia and leukopenia in patients with advanced NSCLC undergoing erlotinib regardless of whether combined with CT or not. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Afatinib remains effective for a subpopulation of patients with NSCLC with acquired resistance to first generation EGFF-TKIs such as erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Heregulin activates HER3 in an autocrine fashion and causes erlotinib resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Afatinib but not erlotinib decreased EGFR mutant NSCLC PC9HRG cell proliferation in vitro and in mouse xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Clinically, a subpopulation of 33 patients with EGFR mutations and NSCLC who had received first generation EGFR-TKIs exhibited elevated plasma heregulin levels compared to healthy volunteers; one of these achieved a response with afatinib therapy despite having previously developed erlotinib resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Afatinib can overcome heregulin-mediated resistance to erlotinib in EGFR mutant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " In NSCLC patients, the activation of alternative pathways contributes to the limited efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The present study examines a panel of EGFR wild-type, K-Ras mutated, NSCLC lines, which were all intrinsically resistant to EGFR-TKIs, and demonstrates that the histone deacetylase inhibitor vorinostat can improve the therapeutic efficacy of gefitinib or erlotinib, inducing strong synergistic antiproliferative and pro-apoptotic effects that are paralleled by reactive oxygen species accumulation and by increased DNA damage. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Following resection and completion of standard adjuvant therapy, patients with EGFR-mutant NSCLC will be randomized to erlotinib versus placebo (1:1), those with ALK-rearranged NSCLC will be randomized to crizotinib versus placebo (1:1), while those not enrolled onto the adjuvant trials will continue to be followed on the screening trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced NSCLC patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The 181946C>T polymorphisms in the EGFR gene seems to be a potential predictor of higher DCR, longer PFS and OS in advanced NSCLC patients treated with erlotinib, especially in EGFR mutation-positive patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type NSCLC: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: The clinical benefit of erlotinib in treating epidermal growth factor receptor (EGFR) wildtype NSCLC has been questioned. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We examined the impact of erlotinib in confirmed EGFR wildtype patients in two placebo-controlled phase III trials: the National Cancer Institute of Canada Clinical Trials Group BR.21 (BR.21) and Sequential Tarceva in Unresectable NSCLC (SATURN) trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib provided a consistent and significant improvement in survival for patients with EGFR wildtype NSCLC in both studies, individually and in combination. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib had undergone turbulent clinical development until it was discovered that these agents have preferential activity in patients with NSCLC harboring activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of this paper is to provide a comprehensive review of the major progresses reported so far in the EGFR inhibition in this molecularly-selected subgroup of NSCLC patients, from the early successes with first generation EGFR TKIs, Erlotinib and Gefitinib, to the novel irreversible and mutant-selective inhibitors and ultimately the emerging challenges that we, in the next future, are called to deal with. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: This hypothesis-generating retrospective analysis examined data from two studies of erlotinib in NSCLC, Marker Identification Trial (MERIT; n = 102) and Sequential Tarceva in Unresectable NSCLC (SATURN; n = 262), to determine whether PTPRF expression was prognostic and/or predictive of patient outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated NSCLC Patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor used for treating NSCLC and other cancers, is frequently associated with adverse events (AE). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We used the framework to investigate the safety of high-dose erlotinib pulses proposed to limit acquired resistance while treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Continuous-time Markov models were developed using rash and diarrhea AE data from 39 NSCLC patients treated with erlotinib (150\u00a0mg/day). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib is a validated drug \"for the treatment of patients affected by advanced unresectable NSCLC with EGFR mutations\". ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: we analyzed the records of patients affected by NSCLC treated undergoing \"first line therapy with Erlotinib\" and smoking cessation (with varenicicline). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The combination of anti-EGFR treatment and concurrent therapy for smoking cessation seems to be more effective than erlotinib alone in improving lung function and clinical response in advanced NSCLC patients with EGFR-mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This model was parameterized using a novel experimental dataset derived from the HCC827 erlotinib-sensitive and -resistant NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In addition, subgroup analyses indicated that improved OS was only observed in nonsquamous NSCLC patients who received the combination of pemetrexed and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Combined erlotinib plus amrubicin therapy seems to be highly effective, with acceptable toxicity, against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: To report rapid onset of retinal toxicity in a series of patients followed on high-dose (1000 mg daily) hydroxychloroquine during an oncologic clinical trial studying hydroxychloroquine with erlotinib for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Successful Treatment of NSCLC With Erlotinib Throughout Pregnancy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " IMPORTANCE: The EURTAC trial demonstrated the greater efficacy of erlotinib compared with chemotherapy for the first-line treatment of European patients with advanced NSCLC harboring oncogenic epidermal growth factor receptor (EGFR) mutations (exon 19 deletion or L858R mutation in exon 21) in tumor tissue. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Patients had advanced NSCLC, oncogenic EGFR mutations in the tumor, and no prior chemotherapy for metastatic disease and were treated with erlotinib or chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, combination of ZSTK474 and an EGFR inhibitor (erlotinib) in NSCLC resistant to each single agent reduced cellular proliferation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A prospective, multicentre phase II trial of low-dose erlotinib in NSCLC patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in NSCLC patients with activating mutations of the epidermal growth factor receptor (EGFR) gene. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with chemotherapy pretreated NSCLC harbouring EGFR mutations received erlotinib at 50 mg/d until disease progression or unacceptable toxicities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The primary end-point was not met; low-dose erlotinib is not recommended for fit patients with NSCLC harbouring EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC previously treated with one to two systemic regimens, including a platinum doublet, were randomly assigned at a 1:1 ratio to receive erlotinib 150 mg daily plus oral tivantinib 360 mg twice daily (E + T) or erlotinib plus placebo (E + P) until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVE: To evaluate the efficacy of whole brain radiotherapy (WBRT) or/and stereotactic radiotherapy (SRT) concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (TKI), like erlotinib and gefitinib, in the treatment of brain metastases from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The impact of erlotinib use in NSCLC patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVE: To report the demographic data and clinical outcomes of NSCLC patients exposed to erlotinib in any line of treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib, an epidermal growth factor receptor and tyrosine kinase inhibitor, is a targeted drug that was approved for the treatment of NSCLCs and pancreatic cancers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this paper, we present two NSCLC cases that developed ACE under erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Dovitinib and erlotinib in patients with metastatic NSCLC: A drug-drug interaction. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This phase 1 trial was conducted to characterize the safety and determine the maximum tolerated dose of erlotinib plus dovitinib in patients with previously treated metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced NSCLC: A Meta-Analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Whether a combination of chemotherapy and erlotinib is beneficial for advanced NSCLC remains controversial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study aimed to summarize the currently available evidence and compare the efficacy and safety of chemotherapy plus erlotinib versus chemotherapy alone for treating advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Combination of chemotherapy and erlotinib is a viable treatment option for patients with NSCLC, especially for patients who never smoked and patients with EGFR mutation-positive disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Cost-effectiveness of first-line erlotinib in patients with advanced NSCLC unsuitable for chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVE: To assess the cost-effectiveness of erlotinib versus supportive care (placebo) overall and within a predefined rash subgroup in elderly patients with advanced NSCLC who are unfit for chemotherapy and receive only active supportive care due to their poor performance status or presence of comorbidities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib has about 80% chance of being cost-effective at thresholds between \u00a350,000-\u00a360,000 in a subset of elderly poor performance patients with NSCLC unfit for chemotherapy who develop first cycle (28\u2005days) rash. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: HERALD (NCT02134015) was a double-blind, phase 2 study in patients with NSCLC randomized to erlotinib with placebo or with high or low doses of patritumab, a monoclonal antibody targeted against human epidermal growth factor receptor 3 (HER3). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant NSCLC: Can High-Affinity TKI Substitute for High-Dose TKI?  Hata A(1), Katakami N. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Re: Ling Y-H, Lin R, and Perez-Soler R (2008) Erlotinib Induces Mitochondrial-Mediated Apoptosis in Human H3255 NSCLC Cells with Epidermal Growth Factor ReceptorL858R Mutation through Mitochondrial Oxidative Phosphorylation-Dependent Activation of BAX and BAK Mol Pharmacol 74:793-806; doi:10.1124/mol.107.044396. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Treatment with first-generation EGFR-TKIs, in particular erlotinib, may be considered a first- or second-line option for patients with NSCLC with minor EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for NSCLC patients with activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We tested the hypothesis that loss of LKB1 sensitizes NSCLC cells to energetic stress induced by treatment with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced NSCLC Who Previously Progressed on Erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Preclinical modeling in NSCLC showed that stimulation with hepatocyte growth factor (HGF), the ligand for MET, could reverse the cytostatic and cytotoxic effects of the EGFR inhibitor erlotinib in erlotinib-sensitive cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We conducted a phase II trial of erlotinib plus MK-2206, a highly selective inhibitor of AKT, in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Combination MK-2206 and erlotinib met its primary endpoint in erlotinib-pretreated patients with EGFR wild-type NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " RATIONALE, AIMS AND OBJECTIVES: Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefits to advanced stage NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib is a low molecular weight tyrosine kinase inhibitor (TKI) directed at epidermal growth factor receptor (EGFR), widely used in the treatment of locally advanced or metastatic-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in patients with advanced-stage NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We retrospectively analyzed clinical data of 595 patients with advanced-stage NSCLC (IIIB or IV) treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In conclusion, the results of the conducted retrospective study suggest that high baseline level of CRP was independently associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we restored TUSC2 gene expression in several wild type EGFR NSCLC cell lines resistant to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and analyzed their sensitivity to erlotinib in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "These results suggest that TUSC2 restoration in wild type EGFR NSCLC may overcome erlotinib resistance, and identify FGFR2 and mTOR as critical regulators of this activity in varying cellular contexts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " NSCLC patients with an epidermal growth factor receptor (EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Biomarkers of erlotinib response in NSCLC tumors that do not harbor the more common epidermal growth factor receptor mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The erlotinib sensitivity of cells isolated from 41 untreated NSCLC patients was determined and compared with the presence of the more frequent EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The possible correlation between erlotinib sensitivity and the expression of these genes was further analyzed using the data for the NSCLC, breast cancer and colon cancer cell lines of the NCI60 collection. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A pilot study of conformal radiotherapy combined with erlotinib-based multimodality therapy in newly diagnosed metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We aimed to determine the benefit of survival and toxicity of Conformal Radiotherapy (CRT) combined with erlotinib-based multimodality therapy in newly diagnosed metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Newly diagnosed metastatic NSCLC patients were treated with CRT and erlotinib, with or without chemotherapy matched protocol. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: In this study, patients with newly diagnosed metastatic NSCLC had survival benefits when erlotinib was used combined with CRT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which is an effective treatment for patients with NSCLC, especially those harboring activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "A previous phase III trial suggested that patients with EGFR wild-type (EGFR-wt) NSCLC or elderly patients with disease progression after cytotoxic chemotherapy might benefit from erlotinib monotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, few studies have prospectively evaluated the efficacy and safety of second- or third-line erlotinib monotherapy for elderly patients with EGFR-wt advanced or recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Pretreated patients aged \u226570 years with EGFR-wt stage IIIB/IV NSCLC or those with postoperative recurrence were enrolled and received oral erlotinib at a dose of 150 mg/day until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: In pretreated elderly patients with advanced or recurrent EGFR-wt NSCLC, daily oral erlotinib was well tolerated; however, administration of the drug should not be considered as a second line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: The efficacy of erlotinib, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer (PC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The patients included those diagnosed with NSCLC or PC who were treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Renin-Angiotensin system blockers may prolong survival of metastatic NSCLC patients receiving erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, the benefit of ARBs on OS disappeared in the multivariate analysis.The use of ARBs during erlotinib treatment may prolong OS of patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here, we find that mTOR-AKT-FOXO1 signaling cascade is deregulated in TKI-resistant NSCLC cells and that FOXO1 was highly phosphorylated and lowly acetylated upon erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Combination of mTOR or PI3K inhibitor and erlotinib overcomes TKI resistance to inhibit cell growth and induce apoptosis in TKI-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with stage IIIB/IV (AJCC 6th edition) NSCLC who progressed after at least 1 line of therapy or refused standard chemotherapy were randomized to receive erlotinib and celecoxib versus erlotinib and placebo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Multiple mutations in the EGFR gene are a major cause for the failure of Erlotinib and Gefitinib in the treatment of patients harboring NSCLC who initially responded to this therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II study of erlotinib in elderly patients with NSCLC harboring epidermal growth factor receptor mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We assessed the efficacy and safety of one EGFR tyrosine kinase inhibitor, erlotinib, in elderly Japanese patients with EGFR-mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib is effective and tolerated in elderly patients with EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced NSCLC treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We initially observed PIK3C\u03b2(D1067V) by exome sequencing analysis of an EGFR-mutant NSCLC tumor biopsy from a patient with acquired erlotinib resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Anti-HER3 monoclonal antibody patritumab sensitizes refractory NSCLC to the epidermal growth factor receptor inhibitor erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Furthermore, heregulin overexpression induced EGFR TKI resistance in NSCLC cells harbouring an activating EGFR mutation, while HER3 and AKT activation was maintained in the presence of erlotinib in heregulin-overexpressing, EGFR-mutant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This report suggests that some NSCLC patients experiencing a spectrum of cutaneous toxicities might have a good tumor response using erlotinib monotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our findings may provide a method for clinicians to predict erlotinib efficacy in NSCLC therapy without knowledge of the EGFR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Activating mutations in exons 19 or 21 of EGFR in NSCLC are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We retrospectively evaluated the efficacy and safety of high-dose erlotinib in EGFR-mutant NSCLC patients with refractory LM after failure of standard-dose EGFR-TKIs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "RESULTS: Between January 2007 and April 2013, we identified 35 patients with EGFR-mutant NSCLC, complicated with LM, and 12 underwent high-dose erlotinib, while the other 23 received only standard-dose EGFR-TKIs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The aim of this study has been to investigate the potential of serum biomarkers used in clinical practice (CEA, CYFRA 21-1, SCC) together with the serum epidermal growth factor receptor (EGFR) and its associated ligands (EGF, TGF-\u03b1, HB-EGF) as outcome predictors of NSCLC patients treated with the TKI erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our results suggest that the pre-treatment CEA and sEGFR serum levels may provide a comparable source of information to that supplied by the EGFR gene mutational status with respect to the prognosis of erlotinib treated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erratum to: prognostic factors for brain metastases from NSCLC with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " NSCLC Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: To determine if first-order and high-order textural features on fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) images of NSCLC (a) at baseline, (b) at 6 weeks, or (c) the percentage change between baseline and 6 weeks can predict response or survival in patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The study included 47 patients with NSCLC who underwent (18)F-FDG PET/computed tomography (CT) at baseline (n = 47) and 6 weeks (n = 40) after commencing treatment with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human NSCLC Cells by Down-Regulating Survivin and Up-Regulating PUMA. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here we found that resveratrol (RV) enhanced the anti-tumor effects of epidermal growth factor receptor (EGFR) inhibitor erlotinib in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Our findings suggested that RV synergistically enhanced the anti-tumor effects of erlotinib in NSCLC cells were involved in decrease of survivin expression and induction of PUMA expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287), a fully human anti-HER3 monoclonal antibody, in combination with erlotinib, an epidermal growth factor receptor-tyrosine kinase inhibitor in patients with previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: This study enrolled patients with stage IIIB/IV NSCLC with Eastern Cooperative Oncology Group performance status 0-1, life expectancy >3 months and who had progressed after at least one prior course of chemotherapy (excluding erlotinib). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we investigated the effect of TG101348 (a JAK2 inhibitor) on the tumor growth of erlotinib-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "TG101348 significantly enhanced the cytotoxicity of erlotinib to erlotinib-resistant NSCLC cells, stimulated erlotinib-induced apoptosis and downregulated the expressions of EGFR, p-EGFR, p-STAT3, Bcl-xL and survivin in erlotinib-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Moreover, the combined treatment of TG101348 and erlotinib induced apoptosis, inhibited the activation of p-EGFR and p-STAT3, and inhibited tumor growth of erlotinib-resistant NSCLC cells in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our results indicate that TG101348 is a potential adjuvant for NSCLC patients during erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy of erlotinib in previously treated patients with advanced NSCLC: analysis of the Chinese subpopulation in the TRUST study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVE: This study is to analyze the data of Chinese subpopulation in the Tarceva Lung Cancer Survival Treatment Study (TRUST-China) which was a global Phase IV study designed to provide erlotinib to previously treated patients with Stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with pathologically confirmed, unresectable Stage IIIB/IV NSCLC who were previously failed on or unsuitable for chemotherapy or radiotherapy were given erlotinib (150 mg/day, oral) until disease progression, intolerable toxicity or death. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The presence of activating gene mutations in the epidermal growth factor receptor of NSCLC patients is predictive (improved progression-free survival and improved response rate) when treated with small molecule tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Therapeutic approach by treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib or erlotinib to NSCLC patients has been limited due to emergence of acquired drug resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The clinical effectiveness of EGFR targeted therapies, including small molecules directed against the kinase domain such as gefitinib, erlotinib and afatinib, have been proven successful in treating NSCLC patients with tumors harboring EGFR kinase domain mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " [Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVE: To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "A recent example of a failed trial is the Phase III MetLung trial that compared the effects of the c-MET monovalent antibody onartuzumab with erlotinib versus erlotinib alone in late-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced NSCLC?  Charakidis M(1), Boyer M(1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Activation of bypass signaling pathways, impairment of apoptosis and mutation of epidermal growth factor receptor (EGFR) to a drug-resistant state are well known mechanisms of resistance to single-agent erlotinib therapy in NSCLC driven by EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: ROR1 expression has a differential effect on outcome to erlotinib and chemotherapy in EGFR-mutant NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The role of chemotherapy and erlotinib in EGFR-mutant NSCLC patients with high ROR1 expression warrants further investigation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " We performed a meta-analysis of fatal pulmonary events associated with erlotinib, gefitinib or afatinib in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our meta-analysis has demonstrated that erlotinib, gefitinib and afatinib are associated with an increased risk of high-grade interstitial lung disease in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We analyzed data from 21 NSCLC patients aged \u2265 80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Gefitinib and erlotinib in metastatic NSCLC: a meta-analysis of toxicity and efficacy of randomized clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib and afatinib are similar compounds approved for the treatment of metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The objective of this study was to compare the efficacy and toxicity of erlotinib, gefitinib, and afatinib in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Gefitinib has similar activity and toxicity compared with erlotinib and offers a valuable alternative to patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Onartuzumab is a monovalent, humanized, monoclonal antibody that showed significant survival benefits in combination with erlotinib in MET-positive NSCLC in pre-specified subgroup analyses of a randomized phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Stage 1 investigated the safety, tolerability, pharmacokinetics (PK), and recommended dose of onartuzumab in patients with solid tumors, and Stage 2 determined the safety, tolerability, and PK of onartuzumab plus erlotinib in patients with MET-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In a small correlative pilot human study, patients with EGFR-mutant metastatic NSCLC underwent FMISO-PET scans before and 10 to 12 days after erlotinib initiation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Adherence, exposure and patients' experiences with the use of erlotinib in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Hsp27 Inhibition with OGX-427 Sensitizes NSCLC Cells to Erlotinib and Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The role of Hsp27 in both erlotinib and cytotoxic treatment resistance was evaluated in HCC-827 and A549 NSCLC cells using the Hsp27 antisense drug OGX-427. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Hsp27 is induced by erlotinib and protects NSCLC cells from treatment-induced apoptosis, whereas OGX-427 sensitizes NSCLC cells to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To address a potential role of protein kinase C (PKC) isozymes in the resistance to TKIs, we used the isogenic NSCLC H1650 cell line and its erlotinib-resistant derivative H1650-M3, a cell line that displays a mesenchymal-like morphology driven by transforming growth factor-\u03b2 signaling. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "One of the best known examples of personalized therapy is the use of tyrosine kinase inhibitors, such as gefitinib and erlotinib, for the successful treatment of NSCLC patients selected based on the specific EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress NSCLC Cell Proliferation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Targeted therapeutics, including the epidermal growth factor receptor (EGFR) inhibitor erlotinib, have recently emerged as clinical alternatives for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we examine the ability of 2 tumor suppressor miRNAs, let-7b and miR-34a to sensitize KRAS;TP53 mutant NSCLC cells to the action of erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Together, our findings indicate that NSCLC cells can be effectively sensitized to erlotinib by supplementation with tumor suppressor miRNAs, and suggest that the use of combinations of miRNAs as adjuvant therapeutics for the treatment of lung cancer is a viable clinical strategy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) - afatinib, erlotinib, and gefitinib - are available for the treatment of patients with EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: We performed a pooled analysis of severe AEs according to the type of EGFR-TKI administered with the use of data extracted from prospective clinical trials that evaluated the clinical efficacy of gefitinib, erlotinib, or afatinib in NSCLC patients with EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We report the case of an NSCLC patient with unknown EGFR mutation status who developed resistance to erlotinib and was treated with afatinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The purpose of this exploratory study was to investigate lung tumor tissue erlotinib concentrations after neoadjuvant therapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS & METHODS: Patients with EGFR mutation-positive NSCLC were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous NSCLC: Exploratory Subgroup Analysis of a Phase II Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: Never-smoker patients (n=240) with locally advanced or metastatic nonsquamous NSCLC included 133 EA patients randomized to pemetrexed supplemented with dexamethasone, folic acid, and vitamin B12 plus erlotinib (pemetrexed-erlotinib) (n=41), erlotinib (n=49), or pemetrexed (n=43), and 107 non-EA patients randomized to pemetrexed-erlotinib (n=37), erlotinib (n=33), or pemetrexed (n=37). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Eight patients diagnosed with NSCLC (three men and five women with an average age of 69.3 years) who were initiated on treatment with EGFR inhibitors (either gefitinib [Iressa(\u00ae)] or erlotinib [Tarceva(\u00ae)]) were enrolled. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Nicotine induces resistance to erlotinib via cross-talk between \u03b1 1 nAChR and EGFR in the NSCLC xenograft model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of this study was to investigate the potential mechanism between nAChR and EGFR for nicotine-induced resistance to EGFR-TKI erlotinib in the NSCLC xenograft model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: We identified the role of nicotine to EGFR/AKT/ERK pathways and to erlotinib-resistance in NSCLC PC9 and HCC827 cells by MTS assay and western blot. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "RESULTS: We confirmed the effects of nicotine on EGFR/AKT/ERK pathways and determined nicotine's potential in preventing from the effect of erlotinib on NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: These results suggest that nicotine contributes to the progression and erlotinib-resistance of the NSCLC xenograft model via the cooperation between nAChR and EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EGFR mutation frequency was 22.1% in NSCLC, and erlotinib achieved a response rate of 60% (95% CI, 32.3% to 83.7%). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " We performed a meta-analysis of diarrhea and stomatitis associated with erlotinib use in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Eligible studies included randomized trials of patients with NSCLC on erlotinib describing events of diarrhea and stomatitis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our meta-analysis has demonstrated that regimens containing erlotinib for the treatment of advanced NSCLC are associated with a significantly increased risk of all-grade diarrhea, stomatitis and high-grade diarrhea. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Mutations in the epidermal growth factor receptor (EGFR) gene are associated with a favorable clinical response to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The FDA-approved small-molecule inhibitors of EGFR, gefitinib (Iressa) and erlotinib (Tarceva), are clinically effective in a subset of patients with NSCLC whose tumors harbor activating mutations within the kinase domain of EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?  Ulivi P(1), Delmonte A(2), Chiadini E(3), Calistri D(4), Papi M(5), Mariotti M(6), Verlicchi A(7), Ragazzini A(8), Capelli L(9), Gamboni A(10), Puccetti M(11), Dubini A(12), Burgio MA(13), Casanova C(14), Crin\u00f2 L(15), Amadori D(16), Dazzi C(17). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We considered a case series of 34 EGFR wt NSCLC patients responsive to erlotinib after at least one line of therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Combining onartuzumab with erlotinib inhibits growth of NSCLC with activating EGFR mutations and HGF overexpression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI), benefits survival of patients with NSCLC who harbor activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EGFR) to overexpress hHGF and evaluated the effects of an onartuzumab and erlotinib combination in vitro and in vivo in xenograft models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our findings raised the possibility that patients with NSCLC with EGFR mutations who express high levels of HGF may benefit from onartuzumab and erlotinib combination therapy, and that HGF can be a novel biomarker for selecting such patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced NSCLC refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "FINDINGS: New targeted therapies for molecularly selected NSCLC are changing the natural history of the disease, with results superior to standard chemotherapy as demonstrated in large phase III studies with first generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: EGFR mutation might be a predictive factor for applying EGFR-tyrosine kinase inhibitors (EGFR-TKIs, including gefitinib, erlotinib and afatinib) in NSCLC (NSCLS) patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METODS: We analyzed data of 544 patients with advanced-stage NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONSLUSION: We reported hyponatremia not only as a prognostic marker in NSCLC patients but also as predictive marker of erlotinib treatment efficacy, being an independent factor at the present large retrospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib usage after prior treatment with gefitinib in advanced NSCLC: A clinical perspective and review of published literature. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib and gefitinib are among the most widely researched, used and available molecularly targeted therapies for treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In the past decade, there have been reports on clinical benefit from use of erlotinib after gefitinib failure in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The expression profiles of the candidate genes were associated with 8-week disease control in patients with wild-type EGFR who had unresectable NSCLC treated with erlotinib, but not in patients treated with sorafenib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "P7170 at a well-tolerated daily dose of 20 mg/kg significantly inhibited the growth of NSCLC xenografts independent of different mutations (EGFR, KRAS, or PIK3CA) or sensitivity to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Our results provide evidence of antitumor activity of P7170 in the erlotinib -sensitive and -insensitive models of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Patients with EGFR-mutant NSCLC generally have a progression-free survival of 9-13 months while being treated with the EGFR tyrosine-kinase inhibitors gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: To evaluate the efficacy and safety of alternating gefitinib and erlotinib, tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), with chemotherapy in NSCLC patients with acquired TKI resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Dacomitinib versus erlotinib in patients with advanced-stage, previously treated NSCLC (ARCHER 1009): a randomised, double-blind, phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Findings from a phase 2 study in NSCLC showed favourable efficacy for dacomitinib compared with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "INTERPRETATION: Irreversible EGFR inhibition with dacomitinib was not superior to erlotinib in an unselected patient population with advanced NSCLC or in patients with KRAS wild-type tumours. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with NSCLC: a phase I/II randomized trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced NSCLC.The phase I trial determined the recommended dose and safety of erlotinib plus dalotuzumab at 5\u00a0mg/kg or 10\u00a0mg/kg weekly in 20 patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The addition of dalotuzumab to erlotinib did not improve efficacy outcome in patients with refractory advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND AND OBJECTIVE: Erlotinib is a drug used to treat NSCLC, pancreatic cancer and several other types of cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Population pharmacokinetics of erlotinib in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: This study aimed to elucidate the pharmacokinetics of erlotinib in Japanese patients with advanced NSCLC and to investigate the relationship between erlotinib exposure and the occurrence of interstitial lung disease (ILD)-like events. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced NSCLC, but the median survival of patients is short. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Predictive factors in patients with EGFR mutation-negative NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Factors predicting the efficacy of erlotinib treatment in patients with EGFR mutation-negative NSCLC have not been well studied. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This retrospective study investigates whether patient characteristics, such as site of metastasis, can predict the efficacy of erlotinib treatment in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In total, 53 EGFR mutation-negative NSCLC patients treated with erlotinib were enrolled, and the associations between clinicopathological characteristics and patient survival were analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Among the NSCLC patients treated with erlotinib, 27 patients with pulmonary metastasis exhibited significantly longer progression-free survival (PFS) and overall survival (OS) times than those without pulmonary metastasis (median PFS time, 2.9 versus 1.2 months; P=0.0010 and median OS time, 12.4 versus 4.1 months; P=0.0007). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The presence of pulmonary metastasis may be a predictive factor in patients with EGFR mutation-negative NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced NSCLC receiving first-line gefitinib or erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Other studies indicated that afatinib may offer advantages over standard chemotherapy for NSCLC in terms of enhanced symptom control and quality of life and is modestly effective in cases involving EGFRT790M-related acquired resistance to the TKIs erlotinib and gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced NSCLC in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858R. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10\u00a0708 Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "All patients with unresectable, recurrent/advanced NSCLC who were treated with erlotinib in Japan between December 2007 and October 2009 were enrolled. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "An analysis of the phase IV POLARSTAR surveillance study examined the safety and efficacy of erlotinib in elderly Japanese patients with previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: From December 2007 to October 2009, all erlotinib-treated patients with unresectable, recurrent/advanced NSCLC in Japan were enrolled. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib could be considered for elderly patients with recurrent/advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "TKIs are used first line in EGFR mutation-positive NSCLC; erlotinib is the only TKI approved for subsequent lines of treatment in EGFR wild-type NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II study of erlotinib for previously treated patients with EGFR wild-type NSCLC, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " While assessing the efficacy of erlotinib in patients with epidermal growth factor receptor (EGFR) wild-type (WT) NSCLC, the sensitivity of the method used for the EGFR mutation analysis may affect the evaluation of the efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We conducted a phase II study of erlotinib for previously treated patients with EGFR WT NSCLC screened by the peptide nucleic acid-locked nucleic acid (PNA-LNA) polymerase chain reaction (PCR) clamp method, which is known to be highly sensitive. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study did not meet the primary endpoint, although erlotinib was found to be moderately effective in pretreated patients with EGFR WT NSCLC, even when the EGFR mutational status was confirmed by the highly sensitive PNA-LNA clamp PCR method. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "NSCLC patients at advanced stage (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase II study of erlotinib monotherapy in pre-treated NSCLC without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, some studies have reported survival benefits in NSCLC patients with wild-type EGFR upon erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Targeted drugs aimed at driver gene, such as Gefitinib, Erlotinib and Crizotinib, have an irreplaceable position in the therapy of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Gastric Acid suppression is associated with decreased erlotinib efficacy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib is a key therapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Because of gastroesophageal reflux disease prevalence, this retrospective analysis was undertaken to determine if coadministering erlotinib with AS therapy affected NSCLC outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Records of advanced NSCLC patients who received erlotinib from 2007 to 2012 at a large, centralized, cancer institution were retrospectively reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV NSCLC patients: treatment rationale and protocol dynamics of the METAL trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " We present the rationale and study design of the METAL (METformin in Advanced Lung cancer) trial (EudraCT number: 2014-000349-59), a multicenter, open label phase II study, designed to evaluate the safety and activity of metformin combined with erlotinib as second-line therapy in patients with stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: Erlotinib-response associated proteins were investigated in patient-derived NSCLC mouse xenografts by reverse-phase protein array technology (RPPA) and Western blotting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clinical benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Experience with afatinib in patients with NSCLC progressing after clinical benefit from gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Modeling tumor dynamics and overall survival in advanced NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our objectives were to develop models describing NSCLC dynamics during first-line treatment with erlotinib, and survival of the cohort. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Data from patients with advanced NSCLC (n = 39) treated first-line with erlotinib (150 mg/day) were analyzed using nonlinear mixed effects modeling. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Models describing tumor dynamics and survival of advanced NSCLC patients first-treated with erlotinib were developed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The association of CFE, smoking history, occupational hazard exposure, tumor pathological type, EGFR mutation status, environmental exposure, living environment, and performance status with EGFR-TKI efficacy was determined in metastatic NSCLC patients who were treated with EGFR-TKIs (gefitinib or erlotinib). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In addition, compound 1 potentiated the activity of erlotinib and gefitinib in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Ibrutinib, which irreversibly inhibits Bruton tyrosine kinase, was evaluated for antitumor activity in a panel of NSCLC cell lines and found to selectively inhibit growth of NSCLC cells carrying mutations in the epidermal growth factor receptor (EGFR) gene, including T790M mutant and erlotinib-resistant H1975 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our results indicate that ibrutinib could be a candidate drug for treatment of EGFR-mutant NSCLC, including erlotinib-resistant tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Prognostic factors for brain metastases from NSCLC with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In addition, erlotinib therapy would be preferable in NSCLC patients with BM and EGFR mutation, especially those with exon 19 deletion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Gefitinib and erlotinib, two reversible EGFR receptor tyrosine kinases inhibitors (TKIs), have been approved for the treatment of patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib is a well-tolerated alternate treatment for NSCLC in cases of gefitinib-induced hepatotoxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " AIM: To evaluate the tolerability and efficacy of erlotinib treatment in advanced NSCLC patients who had previously experienced severe hepatotoxicity after gefitinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Erlotinib treatment was efficient and well-tolerated in NSCLC patients with EGFR mutation, despite their severe hepatotoxicity with prior gefitinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " With the successful use of gefitinib and erlotinib in clinic, some potent EGFR tyrosine kinase receptor inhibitors have gained widespread concern in the treatment of ovarian or NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase I/II study combining erlotinib and dasatinib for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We conducted a phase I/II trial of the combination of Src inhibitor dasatinib with EGFR inhibitor erlotinib to determine the maximum tolerated dose (MTD), pharmacokinetic drug interactions, biomarkers, and efficacy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The combination of erlotinib and dasatinib is safe and feasible in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EXPERIMENTAL DESIGN: Blood samples were collected from 37 patients enrolled in the TRIGGER study, a prospective phase II multi-center trial of erlotinib treatment in advanced NSCLC patients with activating EGFR mutations in tumor tissue. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Successful treatment of systemic metastasis from NSCLC using erlotinib has been documented. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We document a case and study the effect of oral erlotinib on choroidal metastasis from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib is an alternative therapy for choroidal metastasis from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), used for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our results suggest that erlotinib represents a valid treatment option for patients with KRAS WT lung adenocarcinoma and, moreover, that KRAS mutation analysis could help to identify clinically relevant subgroups of NSCLC patients that may benefit from EGFR-TKI therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are known to play a significant role in EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "When an EGFR mutation is found, gefitinib and erlotinib have been shown to have significant roles in the treatment of untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Clinical utility of erlotinib for the treatment of NSCLC in Japanese patients: current evidence. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In contrast, erlotinib is potentially effective for the treatment of EGFR wild-type NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Similar to gefitinib, erlotinib is also effective for EGFR-mutated NSCLC and has been used as an initial treatment for patients with advanced EGFR-mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced NSCLC during treatment with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: The feasibility of monitoring epidermal growth factor receptor (EGFR) mutations in plasma DNA from patients with advanced NSCLC during treatment with erlotinib and its relation to disease progression was investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Blood samples from 23 patients with adenocarcinoma of NSCLC that carried tyrosine kinase inhibitor-sensitizing EGFR mutations were taken immediately before treatment with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The results of this updated pooled analysis suggest a substantial clear PFS benefit of treating patients with EGFR mutation-positive NSCLC with erlotinib or gefitinib compared with chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for NSCLC patients whose tumors harbor activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Nude mice bearing NSCLCs with and without MET amplification were subjected to [(18)F]FLT PET/CT before and after treatment with crizotinib or erlotinib (50 mg/kg and 100 mg/kg p.o. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Association between baseline pulmonary status and interstitial lung disease in patients with NSCLC treated with erlotinib--a cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To determine the risk factors for the development of drug-induced ILD and poor-prognosis (fatal) drug-induced ILD after erlotinib treatment, we assessed the baseline pulmonary status in patients with NSCLC enrolled in a postmarketing clinical study of erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, NSCLC patients without an EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: This was a phase II study of pemetrexed and erlotinib in patients with pretreated advanced non-squamous NSCLC with wild-type epidermal growth factor receptor (EGFR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Eighty NSCLC patients with KPS of 70 and greater and multiple brain metastases were randomly assigned to placebo (n = 40) or erlotinib (100mg, n = 40) given concurrently with WBRT (20 Gy in 5 fractions). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Our study showed no advantage in nPFS or OS for concurrent erlotinib and WBRT followed by maintenance erlotinib in patients with predominantly EGFR wild-type NSCLC and multiple brain metastases compared to placebo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Second- and further-line therapy with erlotinib in patients with advanced NSCLC in daily clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: The aim of this retrospective study was to examine effect of erlotinib in patients with advanced NSCLC in second-line and further therapy in daily clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with histologically or cytologically proven NSCLC (n = 84) treated with erlotinib in second-line (n = 34), third-line (n = 36), and more-line therapy (n = 14) were examined for progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of therapy, and adverse effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-\u03baB, and cell-cycle progression in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib is a tyrosine kinase inhibitor approved for the treatment of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This preclinical study shows that quinacrine overcomes erlotinib resistance by inhibiting FACT and cell-cycle progression, and supports a clinical trial testing erlotinib alone versus this combination in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: Somatic mutations in the epidermal growth factor receptor (EGFR) are predictors of efficacy for treatment with the EGFR tyrosine kinase inhibitor erlotinib in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study evaluates the association between the CA repeat polymorphism and outcome in NSCLC patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: Number of CA repeats in the EGFR gene was evaluated with PCR-fragment length analysis by capillary electrophoresis in 432 advanced NSCLC patients treated with erlotinib irrespective of EGFR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Our study demonstrate that in EGFR mutation positive NSCLC patients treated with erlotinib a low number of CA repeats in intron 1 of the EGFR gene is a predictor for both longer progression free survival and overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The results suggest that erlotinib has a significant antitumor effect on xenografts of NSCLC in mice, and its efficacy and toxicity is dependent on the time of day of administration. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " CIP2A mediates erlotinib-induced apoptosis in NSCLC cells without EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of this study was to determine if erlotinib can also inhibit the growth of NSCLC cells by inactivating the CIP2A-dependent signaling pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Four NSCLC cell lines (H358 H441 H460 and A549) were treated with erlotinib to determine their sensitivity to erlotinib-induced cell death and apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The CIP2A-dependent pathway mediates the tumoricidal effects of erlotinib on NSCLC cells without EGFR mutations in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: For the 2010-2013 period, the authors evaluated 158 patients diagnosed with advanced or metastatic NSCLC treated in first-, second-, or third-line with the EGFR-TKIs afatinib, erlotinib, or gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Two reversible EGFR TKIs (gefitinib, erlotinib) and the irreversible ErbB family blocker afatinib are currently approved for treatment of EGFR mutation-positive NSCLC, but no head-to-head trials have been reported to date. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Identification of metabolic signatures associated with erlotinib resistance of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: Capillary electrophoresis time-of-flight mass spectrometry analysis was performed to identify the metabolic signatures associated with erlotinib resistance in erlotinib-resistant PC-9ER NSCLC cells established from the EGFR-mutant NSCLC cell line PC-9. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Preliminary analysis of the risk factors for radiation pneumonitis in patients with NSCLC treated with concurrent erlotinib and thoracic radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: The aim of this study was to investigate radiation pneumonitis and its associated risk factors in patients with NSCLC treated with concurrent erlotinib and thoracic radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: We conducted an analysis of patients with nonoperable stage IIIA-IV NSCLC who were treated with concurrent thoracic radiotherapy and erlotinib (ClinicalTrials.gov identifier: NCT00973310). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Gefitinib and erlotinib are first-generation EGFR-tyrosine kinase inhibitors(EGFR-TKIs)that play a key role in activating EGFR-mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The majority of NSCLC patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here, we have demonstrated that overexpression of CRIPTO1, an EGF-CFC protein family member, renders EGFR-TKI-sensitive and EGFR-mutated NSCLC cells resistant to erlotinib in culture and in murine xenograft models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Primary NSCLC cells derived from a patient with EGFR-mutated NSCLC that was intrinsically erlotinib resistant were CRIPTO1 positive, but gained erlotinib sensitivity upon loss of CRIPTO1 expression during culture. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CRIPTO1-induced erlotinib resistance was directly mediated through SRC but not ZEB1; therefore, cotargeting EGFR and SRC synergistically attenuated growth of erlotinib-resistant, CRIPTO1-positive, EGFR-mutated NSCLC cells in vitro and in vivo, suggesting that this combination may overcome intrinsic EGFR-inhibitor resistance in patients with CRIPTO1-positive, EGFR-mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic NSCLC with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Food and Drug Administration approved erlotinib (Tarceva, Astellas Pharma Inc., Northbrook, IL, http://www.us.astellas.com/) for the first-line treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: Twenty-three patients with stage IIIB/IV NSCLC with a total of 53 measurable lung lesions, treated in a phase II trial of erlotinib, were studied with institutional review board approval. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " [Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study investigated the relationship among pulmonary surfactant-associated protein D (SP-D), transforming growth factor \u03b1 (TGF-\u03b1), matrix metalloproteinase 9 (MMP-9), tissue polypeptide specific antigen (TPS), and Krebs von den Lungen-6 (KL-6) and response as well as survival in the patients with recurrent NSCLC, which Erlotinib was as second line treatment after failure to chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The prognostic model based on clinical parameters with TPS will be useful in identifying patients who might be most likely to benefit from Erlotinib therapy in the patients with recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic NSCLC has not been widely investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III NSCLC: a prospective phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: To prospectively evaluate diagnostic computed tomography (CT) and (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for identification of histopathologic response to neoadjuvant erlotinib, an epidermal growth factor receptor-tyrosine kinase inhibitor in patients with resectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant NSCLC xenograft models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We investigated whether E7820 in combination with erlotinib, an EGFR-TKI, could overcome EGFR-TKI-resistance in the NSCLC cell lines A549 (KRAS; G12S), H1975 (EGFR; L858R/T790M), and H1650 (PTEN; loss, EGFR; exon 19 deletion), which are resistant to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The combination of E7820 with erlotinib is an alternative strategy to overcome erlotinib resistance in NSCLC by enhancement of the anti-angiogenic activity of E7820. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: The aim of this study was to investigate the incidence of radiation pneumonitis in patients with NSCLC treated with concurrent thoracic radiotherapy and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with inoperable stages IIIA to IV NSCLC who were treated with concurrent thoracic radiotherapy and erlotinib were analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: This phase II, open-label study investigated intercalated combinations of eribulin and erlotinib in unselected patients with advanced NSCLC previously treated with platinum-based chemotherapies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Timing of metabolic response monitoring during erlotinib treatment in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The purpose of this study was to prospectively evaluate the timing of metabolic response monitoring with (18)F-FDG PET of (neoadjuvant) erlotinib treatment in patients with early-stage NSCLC.METHODS: This study was designed as an open-label phase II trial performed in 4 hospitals in The Netherlands. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  Evaluation of erlotinib treatment response in NSCLC using metabolic and anatomic criteria. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " AIM: In this paper the clinical value of PET for early prediction of tumor response to Erlotinib in patients with advanced or metastatic nonsmall cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but what it is still unclear is the efficacy of (EFGR-TKIs: gefitinib or erlotinib) monotherapy in previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In December 2013, we performed a search in the PubMed, EMBASE, Cochrane library databases and Web of Science for randomized trials exploring the role of gefitinib or erlotinib in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The first targeted agents approved for NSCLC treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "It is increasingly clear that there are molecularly distinct subtypes of various common cancers, with different therapeutic approaches required for each subtype, for example, the use of the monoclonal antibodies (trastuzumab and cetuximab) in HER2-positive breast cancer and wild-type KRAS colorectal cancer; tyrosine kinase inhibitors (imatinib, gefitinib, erlotinib and crizotinib) in chronic myeloid leukaemia, gastrointestinal stromal tumours and NSCLC and intracellular agents (vemurafenib and olaparib) in metastatic malignant melanoma and ovarian, breast and prostate cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared with chemotherapy as first-line therapies for patients with advanced NSCLC harboring epidermal growth factor receptor-activating mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "RESULTS: Literature search yielded eight randomized phase 3 clinical trials comparing gefitinib, erlotinib, or afatinib with chemotherapy as first-line therapy in patients with advanced NSCLC during the last 5 years. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib in African Americans with advanced NSCLC: a prospective randomized study with genetic and pharmacokinetic analyses. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this phase II randomized study, 55 African Americans with NSCLC received 150\u2009mg/day erlotinib or a body weight-adjusted dose with subsequent escalations to the maximum-allowable dose, 200\u2009mg/day, to achieve rash. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Pairs of the diagnostic biopsy and plasma obtained just prior to start of erlotinib treatment were collected from 199 patients with adenocarcinoma of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To clarify the role of EMT phenotype as a predictive marker for EGFR-TKI, we performed a retrospective study in 202 stage IV or recurrent NSCLC patients receiving gefitinib or erlotinib therapy from June 2008 to September 2012 in our institute. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib, a popular drug for treating NSCLC, causes diarrhea in approximately 55% of patients receiving this drug. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably NSCLC and pancreatic cancer with emphasis to the approved small molecule erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Gefitinib anderlotinib, which are epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs), have been usedfor the treatment of inoperable andrecurrent NSCLCpatients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Comparison of clinical outcomes following gefitinib and erlotinib treatment in NSCLC patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring EGFR mutations who had recurrent or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: A total of 375 patients with recurrent or metastatic stage IIIB/IV NSCLC, who had either exon 19 deletion or the L858R mutation in exon 21, and had received either gefitinib (n = 228) or erlotinib (n = 147), were included in the study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: In NSCLC patients harboring EGFR mutation, treatment with gefitinib and erlotinib resulted in similar effectiveness. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with NSCLC who were previously sensitive to erlotinib or gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Orally active microtubule-targeting agent, MPT0B271, for the treatment of human NSCLC, alone and in combination with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Finally, this study demonstrated that MPT0B271 in combination with erlotinib significantly inhibits the growth of the human NSCLC A549 cells as compared with erlotinib treatment alone, both in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Targeted erlotinib for first-line treatment of advanced NSCLC: a budget impact analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: A recent phase III trial showed that patients with advanced NSCLC whose tumors harbor specific EGFR mutations significantly benefit from first-line treatment with erlotinib compared to chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Coverage for targeted first-line erlotinib therapy in NSCLC likely results in a small budget impact for US health plans. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The aim of this study was to evaluate the safety and effectiveness of erlotinib plus DC/CIK in maintenance therapy of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Gefitinib and erlotinib are used to treat advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib\u00b1onartuzumab in advanced NSCLC: MET expression levels are predictive of patient benefit. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: In a recent phase II study of onartuzumab (MetMAb), patients whose NSCLC tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The identification of activating EGFR gene mutations and the availability of effective target therapies such as gefitinib and erlotinib have radically changed the therapeutic approach and prognosis for patients with advanced EGFR-mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: A total of 148 patients who had metastatic or recurrent NSCLC with activating EGFR mutation treated with either erlotinib or gefitinib as a first-line (n = 10) and a second-line or more treatment (n = 138) were retrospectively reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: The efficacy of erlotinib in advanced NSCLC has been demonstrated in several trials, but only two cases of complete and prolonged response in wild-type epidermal growth factor receptor locally advanced lung cancer have been published. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: This case is interesting for the choice of second-line treatment in NSCLC and, moreover, for the possibility of a complete and prolonged response to erlotinib even in patients without the activating mutation of epidermal growth factor receptor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " It has been demonstrated that erlotinib is effective in treating patients with brain metastasis from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In conclusion, a relatively high concentration of erlotinib was detected in the cerebrospinal fluid of patients with brain metastases from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of NSCLCs (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small-molecule EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib for elderly patients with NSCLC: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "It has not yet been determined whether erlotinib therapy exhibits the same efficacy and safety in elderly and younger patients with non-small-cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of this retrospective subgroup analysis of data from a population-based observational study was to assess the efficacy and safety of erlotinib in an elderly (\u226575 years, n=74) and a younger group of patients (<75 years, n=233) who received treatment for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Among the NSCLC patients receiving erlotinib treatment, the outcomes of the elderly (\u226575 years) and younger (<75 years) groups of patients were similar in our population-based observational study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "By screening 40 NSCLC cell (NSCLC) lines, we established a surprising positive correlation between the presence of a KRAS mutation and radiosensitization by the EGFR inhibitors erlotinib and cetuximab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase I/II trial of vorinostat (SAHA) and erlotinib for NSCLC patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We prospectively studied the activity of vorinostat plus erlotinib in EGFR-mutated NSCLC patients with progression to tyrosine kinase inhibitors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Patients with advanced NSCLC harboring EGFR mutations and progressive disease after a minimum of 12 weeks on erlotinib were included. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced NSCLC patient with EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Although NSCLC tumors with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib, development of acquired resistance is almost inevitable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Role of erlotinib in the targeted treatment of NSCLC in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this review, we summarize current data of clinical trials with erlotinib and discuss its role in the targeted treatment of NSCLC in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced NSCLCs (NSCLC) that harbor EGFR activating mutations in a predominantly Caucasian population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EGFR-tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib are widely used in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated NSCLC-patients with acquired extracranial progressive disease on standard dose erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Tyrosine kinase inhibitors directed against epidermal growth factor receptor (EGFR-TKI), such as erlotinib, are effective in a limited fraction of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here, we investigated the relationship of miR-34a and erlotinib and determined the therapeutic activity of the combination in NSCLC cells with primary and acquired erlotinib resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The data suggest that a majority of NSCLC and other cancers previously not suited for erlotinib may prove sensitive to the drug when used in combination with a miR-34a-based therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced NSCLC harboring EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced NSCLC who harbor EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The outcomes of first-generation EGFR-TKIs (Gefitnib and Erlotinib) have shown great advantages over traditional treatment strategies in patients with NSCLC, but unfortunately we have to face the situation that most patients still fail to respond in the long term despite initially good control. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " [\u00b9\u2078F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: The aim of this prospective study was to evaluate whether [\u00b9\u2078F]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor response defined by RECIST 1.1 criteria after 8 weeks of treatment in patients with inoperable (stage IIIA to IV) NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Morphologic response, PFS and OS survival in NSCLC patients can be predicted by [\u00b9\u2078F]FDG-PET/CT scan within 2 weeks after starting erlotinib therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced NSCLC after failure of prior chemotherapy and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with advanced NSCLC, progression on 1 or 2 regimens of chemotherapy and erlotinib, KRAS wild-type or known EGFR-sensitizing mutant tumor, and Eastern Cooperative Oncology Group performance status of 0 to 2 received 45 mg of dacomitinib once daily continuously in 21-day cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of NSCLC and when combined with gemcitabine for pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Erlotinib, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy) quinazolin-4-amine is approved for the treatment for NSCLC and pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Luteolin is effective in the NSCLC model with L858R/T790M EGF receptor mutation and erlotinib resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Small-molecule inhibitors of the EGF receptor's tyrosine kinase domain (TKIs), including gefitinib and erlotinib, have been widely used for treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "KEY RESULTS: Luteolin exerted significant anti-tumourigenic effects on the EGF receptor L858R/T790M mutation and erlotinib-resistant NSCLC both at the cellular and animal levels. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION AND IMPLICATIONS: Luteolin may be a potential candidate for NSCLC therapy, especially for treatment of patients with acquired erlotinib-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Pertuzumab and erlotinib in patients with relapsed NSCLC: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We performed a single-arm study of pertuzumab, a monoclonal antibody that inhibits HER2 dimerization, and erlotinib in relapsed NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Currently 3 targeted therapies (erlotinib, afatinib, and crizotinib) are approved by the FDA to treat patients with specific genetic abnormalities in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib (Tarceva, OSI-774), an orally available small molecular inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, is approved for clinical treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Compared to a single agent alone, tamoxifen combined with erlotinib resulted in cytotoxicity and cell growth inhibition synergistically in NSCLC cells, accompanied with reduced activation of phospho-AKT and phospho-ERK1/2, and reduced TP protein levels. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "These findings may have implications for the rational design of future drug regimens incorporating tamoxifen and erlotinib for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances antiproliferative activity in NSCLC cell lines when combined with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The presence of EGFR mutations predicts the response in Chinese NSCLC patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we evaluated the correlation between EGFR mutations and response to erlotinib in Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We recruited 36 patients with stage IIIB/IV NSCLC who had failed first-line chemotherapy, and treated them with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In conclusion, the presence of EGFR mutations could be a marker to predict the therapeutic efficacy of erlotinib and the prognosis in Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive NSCLC treated with gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we investigated [(11)C]-erlotinib positron emission tomography (PET) imaging as a tool to identify activating mutations of EGFR in both glioma and NSCLC xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: An association between skin toxicity and outcome has been reported for NSCLC patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The purposes of this study were to characterize erlotinib pharmacokinetic and to correlate drug serum and urine levels to toxicity and outcomes in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with stage IV NSCLC consecutively treated with erlotinib in second- or third-line were enrolled. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: In 2008, we initiated a prospective study to explore the frequency and predictive value of epidermal growth factor receptor (EGFR) mutations in an unselected population of Danish patients with NSCLC offered treatment with erlotinib, mainly in second-line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib, an epidermal growth factor receptor inhibitor, is approved for the treatment of advanced NSCLC as second- or third-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This phase 2, randomized, multicenter, open-label study compared dinaciclib with erlotinib in patients with previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This manuscript describes a dramatic and durable response to high-dose icotinib in a NSCLC patient who did not respond to a previous standard dose of erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II study of everolimus-erlotinib in previously treated patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Preclinical data suggest combining a mammalian target of rapamycin inhibitor with erlotinib could provide synergistic antitumor effects in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: In this multicenter, open-label, phase II study, patients with advanced NSCLC that progressed after one to two previous chemotherapy regimens were randomized 1:1 to erlotinib 150 mg/day\u00b1everolimus 5 mg/day. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Unexpectedly, we find that EGFR-A763_Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III NSCLC: a Galician Lung Cancer Group (GGCP) study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: This single arm, phase II study aims to evaluate the role of epidermal growth factor receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent chemoradiotherapy (cCRT) in unresectable locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib as maintenance therapy is an active treatment after cCRT in unselected patients with stage III NSCLC, reaching a 6-month PFR of 63.5 % and a median OS of 24 months. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Conversely, knockdown of K-RAS in K-RASmut NSCLC cells and in HNSCC cells presenting overexpression of K-RASwt resulted in sensitization to the anti-clonogenic activity of erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: In the study, there were 123 patients who were diagnosed with advanced NSCLC in Zhejiang Province Cancer Hospital between January 2009 to October 2012, all of who were received gefitinib and erlotinib therapy after failure to chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Risk of interstitial lung disease with gefitinib and erlotinib in advanced NSCLC: a systematic review and meta-analysis of clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVES: Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) widely used in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Eligible studies included randomized controlled trials with gefitinib and erlotinib in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Treatment with EGFR TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Genomic aberrations associated with erlotinib resistance in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study we aimed to elucidate remaining unknown mechanisms using erlotinib-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive NSCLC patients in Hong Kong. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVE: To compare the effectiveness and cost-effectiveness of erlotinib versus gefitinib as first-line treatment of epidermal growth factor receptor-activating mutation-positive NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In conclusion, erlotinib is cost-effective compared to gefitinib for first-line epidermal growth factor receptor-activating mutation-positive NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Patients with NSCLC who have activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), namely, gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Predictive and prognostic value of early response assessment using 18FDG-PET in advanced NSCLC patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of this study was to evaluate the predictive value of PET response after 2 days of erlotinib in unselected pretreated patients with stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib effects on glucose uptake were also studied in a panel of NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: FDG-PET assessment after 2 days of erlotinib could be useful to identify early resistant patients and to predict survival in unselected NSCLC pretreated population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Gefitinib and erlotinib for NSCLC patients who fail to respond to radiotherapy for brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We evaluated erlotinib and gefitinib as salvage treatments for NSCLC patients with brain metastases that failed to respond to radiotherapy in a retrospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The 103 NSCLC patients who were treated with gefitinib or erlotinib for salvage treatment for brain metastases between January 2005 and December 2011 had overall objective response rates (ORR) of 11.7%, disease control rates (DCR) of 53.4%, 3.6 months of median progression-free survival (PFS), and 7.5 months of median survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our retrospective data suggest a potential role for gefitinib and erlotinib in advanced NSCLC patients with brain metastases which have failed to respond to radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib in wild type epidermal growth factor receptor NSCLC: A systematic review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: This systematic review included Phase III randomized clinical trials that compared single agent erlotinib to other management options in the setting of NSCLC with reported outcome data on patients with EGFR wild type (EGFRWT) tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced NSCLC an Eastern Cooperative Oncology Group Study (E3503). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The objective of this trial was to evaluate the association of the activity of erlotinib in the first-line setting in patients with advanced NSCLC with the development of a tolerable rash via dose escalation of erlotinib or tumour characteristics. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients, with advanced NSCLC without prior systemic therapy, were treated with erlotinib 150 mg orally per day. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with NSCLC because it is commonly employed after failure of another EGFR-TKI, gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Medical records from 104 patients with NSCLC treated with erlotinib were retrospectively reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "RESULTS: There were no significant differences in erlotinib efficacy between EGFR-mutated NSCLC with gefitinib resistance and NSCLC with wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Erlotinib may be a therapeutic option for EGFR-mutated NSCLC with gefitinib resistance, as well as for NSCLC with wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib, the epidermal growth factor receptor tyrosine kinase inhibitor, and the intra-venous vinflunine vinca alkaloid microtubule inhibitor have been shown to be effective in the setting of NSCLC palliative patients with acceptable toxicities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage IIIB or stage IV NSCLC who failed one or two previous chemotherapy regimens were treated with flat doses of oral vinflunine from day 1 to day 5 and from day 8 to day 12 every 3\u00a0weeks and erlotinib daily on a continuous basis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we established novel erlotinib resistant NSCLC cells and examined their resistant mechanisms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "[Epub ahead of print]  The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Objective: This study investigates the effect of exemestane, an aromatase inhibitor, and erlotinib, an EGFR inhibitor, on human NSCLC cell lines; H23, H358 and A549. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our two patients were treated with erlotinib after a prior line of systemic platinum-doublet therapy for metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: A previous clinical study in NSCLC patients in Western countries suggested the potential for combination of a first-in-class non-ATP-competitive c-Met inhibitor tivantinib with an epidermal growth factor receptor-tyrosine kinase inhibitor erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Japanese patients with advanced/metastatic NSCLC received tivantinib in combination with erlotinib to evaluate safety and pharmacokinetics. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Serum cytokine levels in patients with advanced NSCLC: correlation with clinical outcome of erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study aimed to investigate the relationship between serum cytokine levels and the clinical outcome of erlotinib treatment in a second or third line setting in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: A total of 162 patients with advanced NSCLC who received erlotinib as either second or third line therapy were enrolled in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Survival outcomes in patients with advanced NSCLC treated with erlotinib: expanded access programme data from Belgium (the TRUST study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib has been shown to prolong progression-free (PFS) and overall survival (OS) in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "NSCLCs with EGFR mutations, are characterized by excellent responses when treated with the EGFR-TKIs gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: We conducted a phase II trial of erlotinib in patients with advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutations and evaluated the relationship between plasma concentration and efficacy of erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Erlotinib showed an ORR comparable to that seen in previous studies for patients with NSCLC harboring EGFR mutations, although response, the primary end point, did not reach the predetermined threshold level. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND AND PURPOSE: The purpose of the current study was to assess a novel anti-cancer drug, MPT0B014, which is not a substrate for the P-glycoprotein (P-gp) transporter, alone and in combination with erlotinib, against human NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib; crossover was allowed at progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human NSCLC xenograft mouse model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " AIM: Erlotinib is used to treat NSCLC, which targets epidermal growth factor receptor (EGFR) tyrosine kinase. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The aim of this study was to investigate the relationship between erlotinib plasma concentrations and phosphorylated EGFR (pEGFR) levels, as well as the relationship between pEGFR levels and tumor growth inhibition in a human NSCLC xenograft mouse model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Chemotherapy with Erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Stem cell-like ALDH(bright) cellular states in EGFR-mutant NSCLC: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The enrichment of cancer stem cell (CSC)-like cellular states has not previously been considered to be a causative mechanism in the generalized progression of EGFR-mutant non-small cell lung carcinomas (NSCLC) after an initial response to the EGFR tyrosine kinase inhibitor erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To explore this possibility, we utilized a pre-clinical model of acquired erlotinib resistance established by growing NSCLC cells containing a TKI-sensitizing EGFR exon 19 deletion (\u0394E746-A750) in the continuous presence of high doses of erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This report is the first to show that: (1) loss of responsiveness to erlotinib in EGFR-mutant NSCLC can be explained in terms of erlotinib-refractory ALDH(bright) cells, which have been shown to exhibit stem cell-like properties; and (2) erlotinib-refractory ALDH(bright) cells are sensitive to the natural agent silibinin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Are erlotinib and gefitinib interchangeable, opposite or complementary for NSCLC treatment? Biological, pharmacological and clinical aspects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous NSCLC with documentation of epidermal growth factor receptor mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: We could not demonstrate the add-on effect of intermittent erlotinib on pemetrexed in a second-line setting for patients with non-squamous NSCLC without EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Re-administration after the failure of gefitinib or erlotinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVE: Few treatment options are available for advanced NSCLC patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Re-administration of TKI seems to be a potential therapeutic option for treatment of selected advanced NSCLC patients after failure of ge\ufb01tinib or erlotinib, especially for the patients with NSCLC who once responded from the prior TKI treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We also revealed a MEK2 signal that may be associated with NSCLC cell sensitivity to the EGF receptor inhibitor erlotinib, and distinguished erlotinib-sensitive cells from intrinsic as well as acquired resistant cells to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "With 8 \u03bcg of tumor aspirates, we precisely quantified the response of 18 signaling molecules to erlotinib and MEK1 inhibitor treatments in an NSCLC patient. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In the current study we investigated a novel mechanism of NSCLC resistance to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EXPERIMENTAL DESIGN: The mechanisms of acquired erlotinib resistance were evaluated by microarray analysis in thirteen NSCLC cell lines and in vivo in mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Correlations between plasma neutrophil gelatinase associated lipocalin (NGAL) levels, erlotinib response and the EGFR mutational status were assessed in advanced stage NSCLC patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Evaluation of the plasma NGAL levels in NSCLC patients that received erlotinib revealed that patients with lower baseline NGAL demonstrated a better erlotinib response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: The phase III SATURN study demonstrated that first-line maintenance erlotinib extended progression-free survival (PFS) and overall survival (OS) versus placebo in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: These data suggest that EGFR IHC does not have value as a marker to predict erlotinib benefit in the first-line maintenance setting for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Combining erlotinib and cetuximab is associated with activity in patients with NSCLC (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Therefore, as part of a phase I study, we analyzed the outcome of 20 patients with NSCLC treated with the combination of erlotinib and cetuximab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In summary, erlotinib and cetuximab treatment was associated with SD \u2265 six months/PR in five of 20 patients with NSCLC (25%), including individuals with squamous histology, TKI-resistant EGFR mutations, and wild-type EGFR, and those who had progressed on prior erlotinib after an initial response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We performed this study to investigate whether erlotinib, an epidermal growth factor receptor inhibitor, or rapamycin, an mammalian target of rapamycin (mTOR) inhibitor, is effective in combination therapy with monensin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The fact that advanced NSCLC patients with wild type (wt) EGFR can benefit from erlotinib therapy makes it critical to find out biomarkers for effective selection of patients and improving the therapy effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In present study, 3 NSCLC cell lines (U1752, Calu-6 and NCI-H292) with wt EGFR and different sensitivities to erlotinib were used for microarray analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Collectively, activation of RAF1-MEK1-ERK/AKT axis may determine the resistance of NSCLC cell lines bearing wt EGFR to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: The study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow-up CT scans during TKI therapy, and had experienced volumetric tumor growth. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We analyzed 1,431 NSCLC patients who were treated with either gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in NSCLCs (NSCLC) are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib is associated with survival benefits in patients with EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This phase II, single-arm study examined the efficacy and safety of first-line erlotinib in Japanese patients with EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Phase II trials and retrospective reviews for gefitinib and erlotinib demonstrate these agents may have a role in both the chemoprevention of brain metastases and, in combination with WBRT, treatment for NSCLC brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib in the treatment of advanced squamous cell NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We conducted a large retrospective study based on clinical experience aiming to prove erlotinib's efficacy and safety in patients with advanced-stage squamous cell NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Totally 375 patients with advanced-stage (IIIB, IV) squamous cell NSCLC were treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "fiala.o@centrum.cz  BACKGROUND: Pemetrexed and erlotinib represent novel agents for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and NSCLC?  Chamberlain MC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Personalized therapy of advanced NSCLC has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: This randomised controlled phase 2 study compared pemetrexed and erlotinib in combination with either agent alone in terms of efficacy and safety as second-line treatment in a clinically selected population of never-smokers with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: NSCLC cells that are wild type for EGFR were assayed for sensitivity to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: The results of these studies support further clinical development of translation inhibitors for treatment of NSCLC in combination with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Advanced NSCLC patients who benefited from prior Gefitinib therapy can benefit again either with the original drug Gefitinib or the alternative drug Erlotinib when a second TKI therapy is resumed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The NSCLC cell lines and xenograft models were treated with CH5164840 and erlotinib to examine their mechanisms of action and cell growth inhibition. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Taken together, these data indicate that CH5164840 has potent antitumor activity and is highly effective in combination with erlotinib against NSCLC tumors with EGFR overexpression and mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT & SRS with temozolomide or erlotinib for NSCLC and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320: in regard to Sperduto et al. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Malignant thrombosis of the superior vena cava caused by NSCLC treated with radiation and erlotinib: a case with complete and prolonged response over 3 years. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here, for the first time as far as we are aware, we report the case of a NSCLC patient with a massive SVC malignant thrombosis who was treated with thoracic irradiation and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " LUX-Lung 4: a phase II trial of afatinib in patients with advanced NSCLC who progressed during prior treatment with erlotinib, gefitinib, or both. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: New molecular targeted agents are needed for patients with NSCLC who progress while receiving erlotinib, gefitinib, or both. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In particular, gefitinib and erlotinib have become the standard of care in patients harboring epidermal growth factor receptor mutations, while crizotinib showed an impressive efficacy in patients with ALK-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Recently, efficacy erlotinib plus concurrent WBRT for patients with brain metastases from NSCLC was reported. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: This study suggested that erlotinib had better control rate for LMC in NSCLC than gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Clinical outcomes and prognostic factors associated with the response to erlotinib in NSCLC patients with unknown EGFR mutational status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: A retrospective analysis of 109 patients with advanced NSCLC who had previously failed at least one line of chemotherapy and received subsequent treatment with erlotinib (150 mg/day orally) was performed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The Cox model indicated that an Eastern Cooperative Oncology Group performance status (ECOG PS) \u2265 2 (HR 3.82; p<0.001), presence of intra-abdominal metastasis (HR 3.42; p=0.002), 2 or more prior chemotherapy regimens (HR 2.29; p=0.021), and weight loss >5% (HR 2.05; p=0.034) were independent adverse prognostic factors for OS in NSCLC patients treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: This study suggests that NSCLC patients should be enrolled in erlotinib treatment after a first round of unsuccessful chemotherapy to improve treatment success, during which they should be monitored for intra-abdominal metastasis and weight loss. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "cbelani@psu.edu  This phase 2 study assessed PF-3512676 plus erlotinib in patients with epidermal growth factor receptor-positive advanced NSCLC after prior chemotherapy failure. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Adding PF-3512676 to erlotinib did not show potential for increased progression-free survival over erlotinib alone in patients with advanced recurrent epidermal growth factor receptor-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The addition of sunitinib to erlotinib did not significantly improve PFS in patients with advanced, platinum-pretreated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The effectiveness of erlotinib in second- or third-line treatment of NSCLC patients without EGFR activating mutation gene remains debatable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The present study was conducted in a group of 71 patients with inoperable, locally advanced or metastatic NSCLC treated with erlotinib as the second- or third-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib-induced autophagy in epidermal growth factor receptor mutated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Erlotinib is a commonly used tyrosine kinase inhibitor (TKI) in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study aims to investigate whether autophagy confers acquired resistance to erlotinib treatment in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib can induce both apoptosis and autophagy in sensitive NSCLC cell lines with activating EGFR mutation (exon 19 del). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Inhibition of autophagy can further enhance sensitivity to erlotinib in EGFR-mutated NSCLC, suggesting that autophagy may serve as a protective mechanism. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Common treatment modalities for NSCLC involve the EGF receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib and gefitinib, have been approved for the treatment of NSCLC, demonstrating an improvement in progression-free and overall survival, particularly in patients harboring activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Plasma DNA samples were obtained after discontinuation of gefitinib or erlotinib in 75 patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "erlotinib in EGFR mutant NSCLC) and a compound ready for clinical development to gain expedited FDA approval. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "These trials showed promising efficacy in patients with EGFR-mutant NSCLC or enriched for clinical benefit from EGFR tyrosine kinase inhibitors gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Pemetrexed versus erlotinib in pretreated patients with advanced NSCLC: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line treatment were randomized to receive either pemetrexed or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Both pemetrexed and erlotinib had comparable efficacy in pre-treated patients with metastatic NSCLC, and the current results indicated that genotyping of tumor cells may have an important effect on treatment efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced NSCLC for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Long-Term Treatment with Erlotinib for EGFR Wild-Type NSCLC: A Case Report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive NSCLC, although erlotinib also has activity in wild-type disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We describe the patient's disease course and treatment in the context of EGFR TKI therapy and the prognostic factors for long-term clinical outcomes of NSCLC, including the development of erlotinib-induced rash. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "alexgrigorescu2004@yahoo.com  PURPOSE: The purpose of the present trial was to investigate whether clinical benefit can be obtained by concurrent administration of erlotinib with gemcitabine as first-line treatment in patients with advanced NSCLC and ECOG performance status (PS) 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected NSCLCs?  Marquez-Medina D(1), Chachoua A, Martin-Marco A, Desai AM, Garcia-Reglero V, Salud-Salvia A, Muggia F. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib is highly effective in NSCLC patients selected by clinical characteristics and/or the presence of epidermal growth factor receptor-sensitizing mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Different erlotinib-failure modes have been reported in NSCLC, and strategies to prolong erlotinib efficacy are perhaps adaptable to them. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We report the feasibility and efficacy of continued erlotinib maintenance and local salvage radiation to overcome erlotinib resistances in selected NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Thirty of 52 consecutive erlotinib-treated advanced NSCLC from the NYU Langone Medical Center and the Arnau de Vilanova Hospital of Lleida responded initially to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Continued erlotinib maintenance and local salvage radiation is feasible and could contribute to a better outcome in selected NSCLC patients with solitary-progression to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Vemurafenib and erlotinib are two oral kinase inhibitors approved for the treatment of metastatic melanoma and advanced NSCLC, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib-related skin toxicities: treatment strategies in patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Clinical trials evaluating erlotinib for the treatment of NSCLC have reported a range of skin disorders, the most common being acneiform rash, xeroderma (dry skin), pruritus, and paronychia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This coupled with recent evidence to suggest a positive correlation between the incidence and severity of rash and clinical outcome among erlotinib-treated patients with advanced or metastatic NSCLC highlights the importance of adequately managing epidermal growth factor receptor inhibitor--related skin disorders. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this review we present a practical approach for the treatment of erlotinib-related cutaneous side effects in Japanese patients with advanced NSCLC providing details of specific treatment interventions, according to symptom severity, for each of the common skin disorders. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " [The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant NSCLC patients]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II trial of erlotinib for Japanese patients with previously treated NSCLC harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "kayamada@med.kurume-u.ac.jp  OBJECTIVE: Erlotinib has been reported to be useful for treatment of NSCLC harboring mutation of the epidermal growth factor receptor gene EGFR-mt. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: This prospective study is the first to have investigated the usefulness of erlotinib in Japanese patients with previously treated EGFR-mt NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "astsao@mdanderson.org  BACKGROUND: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial prospectively obtained serum and tumor core biopsies and randomized 255 chemorefractory NSCLC patients into four phase II trials: erlotinib, erlotinib-bexarotene, vandetanib, or sorafenib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "astsao@mdanderson.org  In recent years, the epidermal growth factor receptor (EGFR) family has become a key focus of NSCLC biology and targeted therapies, such as the reversible EGFR tyrosine kinase inhibitors erlotinib and gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR NSCLC cells to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: The epidermal growth factor receptor (EGFR) inhibitor erlotinib is much less effective in NSCLC tumors with wild-type EGFR, than in tumors with activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We used wild-type EGFR erlotinib-sensitive and erlotinib-resistant NSCLC cell lines to determine whether inhibiting autophagy by a therapeutic agent potentiated the antitumor activity of erlotinib in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "RESULTS: Erlotinib at a clinically relevant concentration (2 \u03bcM) induced autophagy in NSCLC cells with wild-type EGFR, and the degree of induction was greater in cells that were resistant than sensitive, suggesting that autophagy is cytoprotective. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The ability of CQ to potentiate the antitumor activity of erlotinib was also seen in mice bearing NSCLC tumor xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The ability to adapt to anti-EGFR therapy by triggering autophagy may be a key determinant for resistance to erlotinib in wild-type EGFR NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Inhibition of autophagy by CQ represents a novel strategy to broaden the spectrum of erlotinib efficacy in wild-type EGFR NSCLC tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "These successes include imatinib for the treatment of chronic myeloid leukemia, anti-HER2 therapies (trastuzumab, pertuzumab, and lapatinib) to treat breast cancer, anti-EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) to treat NSCLC, and anti-BRAF agents (vemurafenib and dabrafenib) to treat melanoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Gefitinib or erlotinib as maintenance therapy in patients with advanced stage NSCLC: a systematic review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: In September 2012 we performed a search in the pubmed, EMBASE and Cochrane library databases for randomized phase III trials exploring the role of gefitinib or erlotinib in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib or gefitinib, have demonstrated promising results in patients with advanced NSCLC that harbor EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The phase II study was a randomized two-arm trial in which onartuzumab or placebo was administered in combination with erlotinib in 137 patients with second and third line (2/3L) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Skin rash during erlotinib for advanced NSCLC: is age a clinical predictor?  Giuliani J(1), Marzola M. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We retrospectively analyzed all consecutive patients with advanced NSCLC who developed acneiform skin rash during erlotinib treatment at our Clinical Oncology Unit from June 2006 to May 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Among 25 patients affected by advanced NSCLC treated with erlotinib during the reference period, 19 patients (76.0 %) developed acneiform skin rash. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In conclusion, we can affirm that age is an insufficient predictor of acneiform skin rash during erlotinib treatment in advanced NSCLC and does not seem to statistically influence the appearance, duration and grade of skin rash. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The primary objective of this study was to clarify the population pharmacokinetics/pharmacodynamics of erlotinib in Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: ABCG2 can influence the apparent clearance of erlotinib and OSI-420, and their CSF permeabilities in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Synergistic effect of afatinib with su11274 in NSCLC cells resistant to gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced NSCLC: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study aims to evaluate the efficacy and safety of erlotinib versus doublets (erlotinib plus another targeted agent) in advanced NSCLC and, if adequate data are available, to investigate whether or not predefined patient groups benefit more or less from doublet-targeted therapy based on erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Randomized controlled clinical trials were conducted in which any erlotinib was compared with doublets based on erlotinib in patients with NSCLC who had failed to respond to any previous chemotherapy regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "A systematic review and meta-analysis based on aggregate data extracted from trial publications were carried out to assess the effectiveness of doublets (erlotinib plus another targeted drug) in NSCLC treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The results of this systematic review suggest that patients with advanced NSCLC might benefit from doublet-targeted therapy based on erlotinib compared to erlotinib alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Treatment for NSCLC with gefitinib and erlotinib is efficacious. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The first two reversible EGFR-TKIs, erlotinib and gefitinib, are approved for use in the first-line setting in patients with known EGFR-activating mutations and in the second- and third-line settings for all NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In phase IIa, erlotinib-na\u00efve (cohort A) or erlotinib-resistant (cohort B) patients with advanced NSCLC received BMS-690514 once-daily at the MTD. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: This phase I-IIa study suggests that BMS-690514 has manageable safety profile and antitumour activity in patients with NSCLC at 200mg/d, including those with EGFR mutations conferring resistance to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with NSCLC treated with erlotinib: a multicenter phase IV study (JO21661). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We sought to identify proteomic biomarkers associated with ILD development in erlotinib-treated Japanese patients with NSCLC to build predictive models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The participants were patients with NSCLC enrolled in a phase IV study of erlotinib in whom ILD developed within 120 days after erlotinib administration. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib in the treatment of patients with multiple metastases from NSCLC: clinical case selection for optimal response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Clinicians should be aware that gefitinib-induced neutropenia in patients with NSCLC can be treated successful by switching to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced NSCLC: a case-control study of overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "m.faehling@klinikum-es.de  INTRODUCTION: Some patients with advanced NSCLC show prolonged disease stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: We retrospectively analyzed all NSCLC patients treated with erlotinib at our institutions since 2004who progressed after at least stable disease on erlotinib for at least 6 months. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "a-hata@fbri.org  Erlotinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor that is widely used in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib versus pemetrexed for pretreated non-squamous NSCLC patients in clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "jonzuga@gmail.com  BACKGROUND/AIM: Erlotinib and chemotherapy have shown similar efficacy for pretreated NSCLC patients, but none of the large studies have selected patients based on histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We present a retrospective single-center series of advanced non-squamous NSCLC patients treated with erlotinib or pemetrexed as second-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Observational study on the efficacy and safety of erlotinib in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Author information: (1)Division of Respiratory Medicine, Ibaraki Prefectural Central Hospital and Regional Cancer Center, Kasama 309-1793;  To evaluate the efficacy and safety of erlotinib for NSCLC, we performed a population-based observational study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We deduce that erlotinib is effective against NSCLC and is tolerated in clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced NSCLC, but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targeted therapy versus erlotinib alone as second-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: With the available evidence, combining targeted therapy seems superior over erlotinib monotherapy as second-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib, the epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor, has been approved for localized as well as metastatic NSCLC where it seems to be more effective in patients with EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated NSCLC patients with EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, and Mec-3 domain only 4 (LMO4) in pretreatment tumor samples from 91 erlotinib-treated advanced NSCLC patients with EGFR mutations in whom breast cancer gene 1 (BRCA1) expression and the concomitant presence of the EGFR T790M mutation had previously been assessed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "marga.eshuis@ghz.nl  BACKGROUND: Erlotinib is used to treat patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CASE DESCRIPTION: A 68-year-old man with NSCLC, who had been undergoing treatment with erlotinib (150 mg daily) for the previous two weeks, presented with dyspnoea. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In lung cancer, 10-15% of NSCLC contain activating mutations in the EGFR kinase conferring hypersensitivity to the oral TKIs gefitinib and erlotinib, have been demonstrated to be important predictive factors when selecting patients to be treated with these two agents. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib plus parenteral nutrition: an opportunity to get through the hardest days of advanced NSCLC with cancer anorexia-cachexia syndrome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Because temozolomide (TMZ) and erlotinib (ETN) cross the blood-brain barrier and have documented activity in NSCLC, a phase 3 study was designed to test whether these drugs would improve the OS associated with WBRT + SRS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The presence of epidermal growth factor receptor (EGFR) somatic mutations in NSCLC patients is associated with response to treatment with EGFR-tyrosine kinase inhibitors, such as gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "giuliani.jacopo@alice.it  INTRODUCTION: The aim of this study is to estimate the costs for the foreseeable management of skin toxicity (papulo-pustular reactions) in patients treated with erlotinib for NSCLC in order to value the direct medical economical impact. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed all consecutive patients with NSCLC treated with erlotinib at Clinical Oncology Unit of University Hospital of Ferrara, Italy from June 2007 to May 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: To investigate the pharmacological effects of different erlotinib (ER) and gemcitabine (GM) combination schedules by in vitro and in vivo experiments and PK/PD models in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Reasoning that activation of the epidermal growth factor receptor (EGFR) contributes to radiation resistance, we undertook a phase II trial of the EGFR inhibitor erlotinib with whole-brain radiation therapy (WBRT) in an attempt to extend survival time for patients with BM from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib : a guide to its use in first-line treatment of NSCLC with epidermal growth factor-activating mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MDT@adis.com  In the EU, the approved use of erlotinib (Tarceva(\u00ae)), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has recently been expanded to include first-line treatment of locally advanced or metastatic NSCLC in patients with EGFR-activating mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In randomized, open-label, phase III clinical trials, oral erlotinib reduced the risk of progression, improved response rates, and was well tolerated relative to standard platinum-based doublet chemotherapy in Caucasian and Asian populations with advanced NSCLC with EGFR-activating mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Combined treatment with erlotinib and a transforming growth factor-\u03b2 type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: : Despite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, the majority of NSCLC patients with EGFR-activating mutations develop acquired resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: : Erlotinib-resistant PC-9ER cells were generated from PC-9 NSCLC cells, which harbor an EGFR-activating mutation, and used in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Symptom and quality of life benefit of afatinib in advanced NSCLC patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Adherence to erlotinib could be a determinant for clinical outcome and treatment toxicity in patients with advanced NSCLC (A-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study we aimed at evaluating the prognostic value of FLT and FDG uptake measured by positron emission tomography (PET) in patients with metastatic NSCLC prior to systemic therapy with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "FLT and FDG maximum standardized uptake (SUVmax) values per patient were analyzed in 40 chemotherapy naive patients with advanced NSCLC (stage IV) before treatment with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " [Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of NSCLC with unknown EGFR mutation status]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " OBJECTIVE: To evaluate the efficacy of erlotinib in patients with metastasis of NSCLC who had benefits from initial gefitinib treatment but finally demonstrated resistance, especially in those of unknown EGFR mutation status, and to compare the efficacy of erlotinib between patients who received erlotinib immediately after gefitinib failure and those who received chemotherapy before erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib can be considered either immediately after gefitinib failure or following the insertion of chemotherapy after gefitinib failure in progressive NSCLC patients who initially benefited from gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " [Therapeutic effect of erlotinib in elderly patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "835052071@qq.com  OBJECTIVE: To observe the curative and adverse side effects of erlotinib in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Seven-two elderly patients with pathologically confirmed NSCLC in advanced stage (III or IV) received treatment with oral erlotinib at the daily dose of 150 mg, and the treatment was discontinued until intolerance of the side effects or the occurrence of disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Erlotinib is safe and effective in the treatment of elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with NSCLC: a retrospective analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective for the treatment of NSCLC with somatic activating mutations of the epidermal growth factor receptor gene (EGFR-mt). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here, we conducted a retrospective analysis of AEs and drug efficacy in patients with NSCLC whose EGFR mutation status had been confirmed and who all received 250 mg gefitinib or 150 mg erlotinib once daily. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, this study has several limitations as of the nature of retrospective design; our data suggest that gefitinib and erlotinib might have almost equal efficacy for patients with EGFR-wt NSCLC, as is the case for patients with EGFR-mt tumors, although erlotinib appears to have higher toxicity than gefitinib at each approved dose. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Second line treatment in advanced NSCLC: comparison of efficacy of erlotinib and chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib is EGFR tyrosine kinase inhibitor used for treatment of the advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This presented study is focused on comparison of erlotinib and chemotherapy efficacy in the second line treatment of the advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant NSCLC cell line H1650]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Using real-time RT-PCR to analyze the EGFR mRNA expression level in EGFR wild-type NSCLC cells; MTT analysis detected the cytotoxicity for NSCLC cells to Erlotinib; Western blot analysis examined the mutant situations and the downstream signaling protein phosphorylation level in EGFR-mutant NSCLC cells with the treatment of Erlotinib or/and PI3K inhibitor, LY294002. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "RESULTS: In the EGFR wild-type NSCLC cells, the expression level of EGFR mRNA varied dramatically and all the cells showed resistant to Erlotinib; In the EGFR-mutant cells, HCC827 and H1650 (the same activating-mutation type), HCC827 cells were Erlotinib-sensitive as well as H1650 demonstrated primary relative resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: EGFR wild-type NSCLC cells were resistant to Erlotinib no matter of how EGFR mRNA expression level. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The PTEN loss and activation of AKT signaling pathway contributed to Erlotinib resistance in EGFR-mutant NSCLC cell line H1650. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " TORCH study: how much longer should we continue to use erlotinib in unselected patients with NSCLC?  Lorusso V, Silvestris N, Marech I. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "OBJECTIVE: To assess the prevalence of inappropriate medication in patients taking erlotinib for the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Patients taking erlotinib for the treatment of advanced NSCLC take many inappropriate medications for the treatment or prevention of long-term conditions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Maintenance erlotinib improves clinical outcomes of unresectable advanced NSCLC: A meta-analysis of randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable NSCLC by evidence-based methodology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib produced significant clinical benefits with acceptable toxicity as a maintenance strategy in patients with unresectable NSCLC, particularly when sequentially administered with chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Retraction: Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Effectiveness and response predictive factors of erlotinib in a NSCLC unselected European population previously treated: a retrospective, observational, multicentric study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: In this retrospective, observational, multicentric study, we assessed effectiveness and potentially response predictive factors in 222 unselected Italian patients, with stage IIIB/IV NSCLC, with performance status from 0 to 3, who had received at least one line of chemotherapy, treated with the standard dose of erlotinib (150\u2009mg once daily) until disease progression or unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "y-naruo@sc4.so-net.ne.jp  INTRODUCTION: Patients with epidermal growth factor receptor (EGFR) mutation positive NSCLC exhibited marked response to gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with EGFR-mutant stage IIIB or IV NSCLC that progressed during gefitinib or erlotinib therapy were administered pemetrexed with the continuation of EGFR-TKI treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Prognosis in patients with NSCLC who received erlotinib treatment and subsequent dose reduction due to skin rash. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We retrospectively evaluated the clinical course of NSCLC patients receiving erlotinib at a reduced dose because of skin rash. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Treatment of NSCLC with drugs targeting the epidermal growth factor receptor (EGFR), e.g., gefitinib and erlotinib, will eventually fail because of the development of secondary mutations such as T790M in EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Growing clinical evidence supports a personalized approach to NSCLC treatment, and clinical trials in advanced disease have shown the value of testing for epidermal growth factor receptor gene (EGFR) mutations prior to first-line therapy with erlotinib or gefitinib and testing for anaplastic lymphoma kinase gene (ALK) rearrangements prior to therapy with crizotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "effectiveness: erlotinib in previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "in patients with advanced or metastatic NSCLC showed statistically significant benefit of erlotinib over placebo in prolonging overall survival and progression-free survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "OBJECTIVES: The primary outcome was to compare overall survival of patients treated with erlotinib for NSCLC at Alberta Health Services - Cancer Care to the overall survival seen in the pivotal trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: A retrospective review of charts was conducted for patients with locally advanced or metastatic NSCLC who received erlotinib therapy after failure of at least one prior chemotherapy regimen between 1 August 2006 and 31 July 2009. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: This method has been successfully validated and applied to determine plasma and lung tumor tissue concentrations of erlotinib and O-desmethyl erlotinib in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Data from 88 NSCLC patients receiving gefitinib (250 mg, daily [qd]), erlotinib (150 mg, qd), and ZD6474 (100 mg, qd) in three clinical trials (IRESSA registration clinical trial, TRUST study, ZD6474 study) during November 2003 to June 2005 were retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study investigated retrospectively the benefits of local ablative therapy (LAT) to central nervous system (CNS) and/or limited systemic disease progression and continuation of crizotinib or erlotinib in patients with metastatic ALK gene rearrangement (ALK+) or EGFR-mutant (EGFR-MT) NSCLC, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with metastatic ALK+ NSCLC treated with crizotinib (n = 38) and EGFR-MT NSCLC treated with erlotinib (n = 27) were identified at a single institution. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " NSCLCpatients with activating mutations of the epidermal growth factor receptor(EGFR)gene have shown a dramatic response to EGFR tyrosine kinase inhibitors(EGFR-TKI)such as gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib and gefitinib for elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib and gefitinib are tyrosine kinase inhibitors (TKI) associated with the EGFR, which is involved in cell proliferation, growth, migration, invasion and survival, and has been found to be overexpressed in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "syylwu@live.cn  BACKGROUND: This phase II, open-label study evaluated the efficacy and safety of erlotinib as second-line therapy in NSCLC patients with brain metastases (BM). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Single-agent erlotinib was active and well tolerated in NSCLC patients with BM. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Comparison of adverse events of erlotinib with those of gefitinib in patients with NSCLC: a case-control study in a Japanese population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " VeriStrat(\u00ae) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, VeriStrat was evaluated as a pre-treatment stratification tool in patients with advanced stage NSCLC for treatment with the combination of erlotinib and sorafenib, considering both OS and progression-free survival (PFS) as end points. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: VeriStrat has shown its potential for stratification of unselected, advanced stage NSCLC patients treated in first line with a combination of erlotinib and sorafenib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " First-line erlotinib in patients with advanced NSCLC unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "INTERPRETATION: Patients with NSCLC who are deemed unsuitable for chemotherapy could be given erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced NSCLC who are Met-positive by immunohistochemistry. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Prognostic and predictive role of the VeriStrat plasma test in patients with advanced NSCLC treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "carbone@osumc.edu  INTRODUCTION: We investigated the predictive and prognostic effects of VeriStrat, a serum or plasma-based assay, on response and survival in a subset of patients enrolled on the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Two hundred and fifty-five chemorefractory NSCLC patients received tumor molecular analysis, and were randomized to erlotinib, erlotinib-bexarotene, vandetanib, or sorafenib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " First-line treatment of EGFR-mutant NSCLC: the role of erlotinib and other tyrosine kinase inhibitors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: Erlotinib had proved efficacy in patients with advanced NSCLC, especially adenocarcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MK-0646 treatment caused increased erlotinib sensitivity in NSCLC cells poorly responsive to it. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "deniz.kahraman@uk-koeln.de  PURPOSE: The aim was to assess the value of tumor lesion glycolysis (TLG) and tumor lesion proliferation (TLP) determined by FDG and 3'-deoxy-3'-F-fluorothymidine (FLT) PET for response prediction and prognostic differentiation in patients with advanced NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: FDG-PET and FLT-PET were performed in 30 patients with untreated Stage IV NSCLC before start of therapy, 1 (early) and 6 (late) weeks after erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC, percentage changes of TLG and TLP and absolute residual TLG and TLP levels under erlotinib treatment emerged as strong predictive factors for PFS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We subsequently examined the effect of combining 1,25(OH)2D3 with erlotinib, which is used clinically in the treatment of EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib and afatinib, have been investigated in the treatment of NSCLC, and to date a large amount of clinical data are available. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: Erlotinib (Tarceva) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which effectively targets EGFR-mutant driven NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced NSCLC treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Therefore, we evaluated mechanisms underlying sorafenib-erlotinib interaction in seven NSCLC cell lines selected for their heterogeneous pattern of EGFR and Raf-kinase-inhibitor protein (RKIP) expression, and EGFR/K-Ras mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "No direct drug interaction was detected by LC-MS/MS measurement, while lysates from A549 and H1975 cells exposed to erlotinib+sorafenib showed a significant inhibition in the phosphorylation of 16 overlapping peptides, including sites from RAF, VEGFR2, PDGFR, CDK2 and SRC, suggesting new markers to identify NSCLC patients who are likely to respond to this treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In conclusion, several mechanisms, including apoptosis-induction, modulation of expression/phosphorylation of RKIP and crucial kinases contribute to erlotinib-sorafenib synergistic interaction and should be evaluated in future trials for the rational development of this combination in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In particular, the tyrosine- kinase inhibitors (TKIs) gefitinib and erlotinib targeting the epidermal growth factor receptor (EGFR) have been approved for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Clinical and economic review of erlotinib in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This is an up-to-date review of the clinical and economic impact of erlotinib for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Everolimus and erlotinib as second- or third-line therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "vpapadim@ mdanderson.org  INTRODUCTION: The epidermal growth factor receptor inhibitor erlotinib is an approved treatment for chemotherapy-refractory advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We conducted a phase I study to determine feasible dosages of combination therapy with erlotinib and everolimus for previously treated metastatic or unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Both erlotinib and crizotinib have been shown to be effective and safe for subgroup populations, and now personalized treatment for nonsquamous NSCLC has progressed even further. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib is an agent of oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors which are used for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy of erlotinib in patients with advanced NSCLC: analysis of the Australian subpopulation of the TRUST study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Michael.Boyer@sswahs.nsw.gov.au  AIMS: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been demonstrated in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Tarceva lung cancer survival treatment (TRUST) is an open-label, single-arm, phase IV global trial which investigated erlotinib in advanced NSCLC patients who had failed prior therapy or were unsuitable for chemo/radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Outcomes for Australian patients confirmed the efficacy and tolerability of erlotinib for the treatment of advanced NSCLC in routine clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: The Taiwan Cancer Registry and the National Health Insurance claim databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who received gefitinib or erlotinib as third-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Gefitinib and erlotinib had similar efficacies as salvage therapy for advanced NSCLC in Taiwan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In particular, the tyrosine kinase inhibitors gefitinib and erlotinib have been approved for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Germline polymorphisms can be easily assessed in blood samples, and candidate polymorphisms in EGFR and ABCG2 have been correlated with outcome and toxicity in NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase I study of erlotinib and hydroxychloroquine in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "MATERIALS AND METHODS: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "yasukok@shinkohp.or.jp  Gefitinib and erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), are widely used anticancer drugs for patients with NSCLC, especially for those with EGFR-activating mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in NSCLC; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RAR\u03b1 for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " CT findings in NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "hmona@kcch.re.kr  PURPOSE: We performed this study to explore the association of computed tomography (CT) findings with outcomes of patients with NSCLC treated with tyrosin kinase inhibitor (TKI) such as gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " EURTAC first-line phase III randomized study in advanced NSCLC: Erlotinib works also in European population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "ongchookhoon@yahoo.com  Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitors (TKI) like erlotinib and gefitinib have been approved as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we investigated the effects of the combination of Erlotinib and Cetuximab on T790M and L858R mutation lung cancer cells lines (H1975), in the primary NSCLC cells with the T790M mutation and TKI-resistant EGFR mutations human tumor xenograft model (H1975). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "RESULTS: Compared with single-agent treatment, the combination of Cetuximab and Erlotinib increased apoptosis of EGFR TKI-resistant NSCLC cells (H1975), resulting in more pronounced growth inhibition on cell proliferation and significant inhibition of EGFR-dependent signaling. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of NSCLC in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The objective of this study was to assess the cost-effectiveness of erlotinib followed by chemotherapy after progression, compared to the reverse strategy, in fit elderly patients with advanced NSCLC participating in a prospective randomized phase 2 trial (GFPC0504). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: In terms of cost effectiveness, in fit elderly patients with NSCLC, erlotinib followed by chemotherapy compares well with the reverse strategy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: Regardless of epidermal growth factor receptor (EGFR) mutation status, erlotinib improves survival for patients with advanced NSCLC after one or more chemotherapy regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This phase II study was designed to evaluate the efficacy and safety of erlotinib and enzastaurin in NSCLC, a combination with promise to overcome EGFR resistance based on preclinical models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Eligible patients with advanced NSCLC (IIIB or IV) who had failed one or two prior systemic treatment regimen(s) were enrolled and received erlotinib 150 mg/day and enzastaurin 500 mg/day (after a 1125-mg loading dose on day 1, cycle 1), both orally in 28-day cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: In previously treated, unselected, advanced NSCLC patients, the addition of enzastaurin to erlotinib did not improve PFS, response, or OS compared with historical data of single-agent erlotinib, but was well tolerated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced NSCLC: a phase I dose-finding study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: Erlotinib and pemetrexed have been approved for the second-line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Combination chemotherapy of intermittent erlotinib with pemetrexed was well-tolerated, with promising efficacy against pretreated advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "ytogashi@kuhp.kyoto-u.ac.jp  PURPOSE: Several cases have been reported in which central nervous system (CNS) metastases of NSCLC resistant to gefitinib were improved by erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The objective of this review was to assess the predictive value of skin rash for outcome in patients with NSCLC treated with erlotinib and gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this study, we report a patient with NSCLC who remains responsive to erlotinib treatment following successful rechallenge with a reduced dose of erlonitib after presenting with severe degree of leukoclastic vasculitis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "giulio.metro@yahoo.com  INTRODUCTION: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Surrogate end points for survival in the target treatment of advanced NSCLC with gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Our aim was to determine the correlations of these surrogates with survival in the treatment of advanced NSCLC (ANSCLC) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation of progression-free survival (PFS) in NSCLC patients with EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Patients with NSCLC, Eastern Cooperative Oncology Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The objective of this prospective study was to investigate the safety of preoperative erlotinib treatment and the (in vivo) response in patients with early-stage resectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: A dosage of sunitinib 37.5 mg/d concurrently with erlotinib 150 mg/d was tolerable and established the recommended combinatorial dose in subjects with platinum-refractory NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "A 65-year-old woman with a background of NSCLC presented to the emergency department with nausea and vomiting after starting erlotinib; she was pyrexial and had raised C-reactive protein. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced NSCLC with EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced NSCLC with EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV or relapsed NSCLC with a sensitizing EGFR mutation initially treated with gefitinib, erlotinib, or chemotherapy were identified. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention of CNS metastases from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated NSCLC using sequential [18F]fluorothymidine (FLT-)PET. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " INTRODUCTION: Most NSCLC tumors with epidermal growth factor receptor mutations are responsive to EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib, but almost all such tumors ultimately acquire resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Role of erlotinib in the treatment of NSCLC: clinical outcomes in wild-type epidermal growth factor receptor patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib at the standard oral daily dose of 150 mg is approved for the treatment of unselected chemorefractory advanced NSCLC patients as well as maintenance therapy after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Management of NSCLC: focus on erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for NSCLC with activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib, a small-molecule EGFR tyrosine kinase inhibitor, has been approved by the FDA for patients with pancreatic cancer and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "michael.michael@petermac.org  Erlotinib and gemcitabine are active in NSCLC and have synergy in other cancers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Chemotherapy-na\u00efve patients with NSCLC, either stage IIIB (with plural effusion) or stage IV, with measurable disease and ECOG PS 2, and adequate organ function were randomized to receive either erlotinib (150\u00a0mg/day p.o.) plus gemcitabine (1000\u00a0mg/m2, days 1, 8, 15, every 4 weeks) in Arm A or gemcitabine monotherapy (Arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib plus gemcitabine for the treatment of ECOG 2 NSCLC patients warrants further investigation including intermittent erlotinib regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Cost analysis of erlotinib versus chemotherapy for first-line treatment of NSCLC in frail elderly patients participating in a prospective phase 2 study (GFPC 0505). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The objective of this study was to assess the cost-effectiveness of erlotinib followed by chemotherapy after progression, compared with the reverse strategy, in frail elderly patients with advanced NSCLC participating in a prospective randomized phase II trial (GFPC 0505). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: No difference in cost-effectiveness was found between an erlotinib-first strategy and a chemotherapy-first strategy in frail elderly patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However, two recent clinical case reports showed that erlotinib caused complete remission of acute myeloid leukaemia (AML)-M1 in patients who had both AML-M1 and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " While most patients with metastatic NSCLC containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib in patients with advanced NSCLC: A meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs published between January 2011 and May 2012 into a pooled analysis which had been published in 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Human papillomavirus in NSCLC: the impact of EGFR mutations and the response to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy and safety of first-line erlotinib in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib was effective and well-tolerated and may be considered for elderly patients with advanced NSCLC who are unsuitable for standard first-line chemotherapy or radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Postmarketing surveillance study of erlotinib in Japanese patients with NSCLC: an interim analysis of 3488 patients (POLARSTAR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "nakagawa@med.kindai.ac.jp  INTRODUCTION: Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in Japanese patients with NSCLC receiving erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: All patients with recurrent/advanced NSCLC receiving erlotinib in Japan were enrolled (December 2007-October 2009). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: These interim data support the clinical benefits of erlotinib in Japanese NSCLC patients with no new safety signals. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The risk/benefit balance for erlotinib in recurrent/advanced NSCLC remains favorable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "At equivalent doses, erlotinib achieved lower kinase-site occupancy in glioma-derived EGFRvIII compared with NSCLC-derived EGFR mutants. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "EGFRvIII released erlotinib rapidly compared with wild-type EGFR, whereas NSCLC-derived mutants released erlotinib slowly.SIGNIFICANCE: These data suggest that kinase-site occupancy is a biomarker for efficacy of EGFR inhibitors, that rapid binding and release of erlotinib in glioma-derived EGFRvIII opposes the blockade of downstream signaling, and that slower cycling of erlotinib within the active site of NSCLC-derived mutants underlies their improved clinical response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib and gefitinib inhibit the growth of NSCLC tumors that harbor activating epidermal growth factor receptor (EGFR) mutations but are ineffective against EGFR variants found in glioblastoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV NSCLC after failure of prior platinum-based therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This randomized phase 2b trial was designed to further evaluate pralatrexate activity in NSCLC by estimating overall survival (OS) relative to erlotinib in patients with relapsed/refractory disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Pralatrexate demonstrated a trend toward improved survival relative to erlotinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " PURPOSE: To evaluate the predictive value of early and late residual (18)F-fluorodeoxyglucose (FDG) and (18)F-fluorothymidine (FLT) uptake using different SUV measurements in PET in patients with advanced NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We retrospectively reviewed data from 30 patients with untreated stage IV NSCLC who had undergone a combined FDG PET and FLT PET scan at 1 week (early) and 6 weeks (late) after the start of erlotinib treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Early and late residual FDG uptake, measured using different quantitative SUV parameters, are predictive factors for short-term outcome in patients with advanced NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " BACKGROUND: NSCLC (nsclc) tumours with activating mutations of the epidermal growth factor receptor (efgr) tyrosine kinase are highly sensitized to the effects of oral tyrosine kinase inhibitors such as gefitinib and erlotinib, suggesting the possibility of targeted treatment of nsclc based on EFGR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Randomized phase II trial of erlotinib with and without entinostat in patients with advanced NSCLC who progressed on prior chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENTS AND METHODS: Previously treated patients with stage IIIB/IV NSCLC, no prior EGFR-TKIs, and performance status \u2264 2 were randomly administered erlotinib 150 mg on days 1 through 28 plus entinostat 10 mg orally on days 1 and 15 every 28 days (EE) or erlotinib plus placebo (EP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To date, erlotinib and gefitinib have established themselves as first-line therapy for NSCLC patients whose tumors harbor an EGF receptor gene mutation, and hence, it is crucial that we identify mechanisms of resistance that could be targeted by novel agents, while keeping an acceptable toxicity profile at the same time; something very important when we develop these new drugs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Efficacy and safety of maintenance erlotinib in Asian patients with advanced NSCLC: a subanalysis of the phase III, randomized SATURN study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The global phase III SequentiAl Tarceva in UnResectable NSCLC (SATURN) study evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib as maintenance treatment in NSCLC patients without progression after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Patients with advanced NSCLC with no evidence of progression after four cycles of chemotherapy were randomized to receive erlotinib 150 mg/day or placebo, until progressive disease or limiting toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Evaluation of circulating tumor cells and circulating tumor DNA in NSCLC: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "PATIENT AND METHODS: A 58-year-old male patient with NSCLC (adenocarcinoma) was treated with polychemotherapy, palliative RT (30 Gy in 10 fractions), and erlotinib thereafter. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To identify genes that are specifically methylated during the evolution of resistance to anti-EGFR therapeutic agents, we performed a methylation-specific array containing a panel of 56 genes that are commonly known to be regulated through promoter methylation in two parental NSCLC and head and neck squamous cell carcinoma (HNSCC) cell lines and their resistant derivatives to either erlotinib or cetuximab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Restoration of DAPK into the resistant NSCLC cells by stable transfection re-sensitized the cells to both erlotinib and cetuximab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Second-line erlotinib for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " AIMS: We analyzed the association of ABCB1 polymorphisms with erlotinib-induced toxicity and the pharmacokinetics in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "chi-okamoto@dotd.med.kindai.ac.jp  OBJECTIVE: Somatic mutations in the epidermal growth factor receptor gene are associated with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors such as gefitinib and erlotinib in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: We performed a retrospective analysis of EGFR mutation-positive NSCLC patients who received both gefitinib and erlotinib at our institution. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Afatinib versus placebo for patients with advanced, metastatic NSCLC after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "giorgio.scagliotti@unito.it  We present the rationale and design for MARQUEE, a phase III, randomized, double-blind, placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib in previously treated subjects with locally advanced or metastatic, nonsquamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: An erlotinib resistant subline (H1650-ER1) was generated upon continuous exposure of NSCLC cell line NCI-H1650 to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " 18F-FDG PET as a surrogate biomarker in NSCLC treated with erlotinib: newly identified lesions are more informative than standardized uptake value. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "thomasgb@gene.com  This study assesses the predictive value of (18)F-FDG PET for overall survival in lung cancer patients treated with a targeted drug.METHODS: (18)F-FDG PET was performed in 125 second- or third-line NSCLC patients with a baseline Eastern Cooperative Oncology Group performance status less than 3 before treatment with erlotinib (150 mg daily) and 2 wk into treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: (18)F-FDG PET in second- or third-line NSCLC patients at 2 wk after starting treatment with erlotinib carries information about overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This paper aims to systematically review the evidence from all available clinical trials of erlotinib and pemetrexed as maintenance therapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: There is evidence to suggest that maintenance treatment with erlotinib or pemetrexed has clinically relevant and statistically significant advantages over treatment with placebo or observation in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced NSCLC selected with a comprehensive geriatric assessment (the GFPC 0505 study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "herve.lecaer@ch-draguignan.fr  BACKGROUND: The aim of this randomized phase II trial was to evaluate the feasibility and activity of weekly gemcitabine (G) followed by erlotinib at disease progression (arm A) versus erlotinib followed by G at progression (arm B) in vulnerable elderly patients with advanced NSCLC, selected on the basis of a comprehensive geriatric assessment (CGA). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The effectiveness of erlotinib against brain metastases in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Erlotinib, a specific inhibitor of epidermal growth factor receptor-associated tyrosine kinase, has shown antitumor activity in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "This study evaluates erlotinib in the treatment for brain metastases from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib is modestly active and well-tolerated by NSCLC patients with brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In the last decade, the tyrosine kinase (TK) domain of the EGFR was identified in NSCLC patients, and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The administration of gefitinib in patients with advanced NSCLC after the failure of erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "francesco.grossi@istge.it  PURPOSE: Recent studies have demonstrated that erlotinib therapy may be considered an option for patients with advanced NSCLC who experienced disease progression after treatment with gefitinib, particularly in patients in whom the disease had been stabilized for a long time prior to gefitinib therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We aimed to estimate the incremental cost-effectiveness of erlotinib 150 mg/day versus best supportive care when used as first-line maintenance therapy for patients with locally advanced or metastatic NSCLC and stable disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Erlotinib is a cost-effective treatment option when used as first-line maintenance therapy for locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " [Prognostic relevance of body mass index and rash for patients with metastatic NSCLC under therapy with erlotinib]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Tyrosine kinase inhibition (TKI) such as erlotinib is a well established treatment option in the palliative care of patients with non small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer in some populations of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Successful treatment of NSCLC with gefitinib after severe erlotinib-related hepatotoxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "To the best of our knowledge, to date, two reports have stated that patients with NSCLC who develop severe hepatotoxicity secondary to gefitinib treatment can be safely switched to erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here, we present the first case with NSCLC harboring EGFR mutation who developed grade 3/4 hepatotoxicity after initiation of erlotinib, which resolved when therapy was changed to gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "As far as we know, this is the first report showing the efficacy of gefitinib for a NSCLC patient who developed severe hepatotoxicity while under erlotinib therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Resistant NSCLC cells bearing a T790M mutation (H1975) showed mean increases in (18)F-FLT uptake of 27% and 33% with high and low doses of erlotinib, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "NSCLC cells that were resistant because of dysregulation of Bcl-2 family members (H1650) showed mean reductions in (18)F-FLT uptake of 49% and 23% with high and low doses of erlotinib, respectively, whereas the addition of ABT-263 did not affect tracer uptake but significantly increased the percentage of apoptotic cells in tumor sections. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: PET/CT with (18)F-FLT may contribute to the selection of patients who may benefit from treatment with reversible and irreversible EGFR TKIs and may provide clues about which patients with NSCLC may be candidates for combination treatment with erlotinib and Bcl-x(L) inhibitors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Response to second-line erlotinib in an EGFR mutation-negative patient with NSCLC: make no assumptions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib-an oral tyrosine kinase inhibitor (tki) of the epidermal growth factor receptor (egfr)-has commonly been used as a therapeutic option in metastatic NSCLC (nsclc) patients in the second- or third-line treatment setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Second-line erlotinib in an EGFR mutation-negative patient with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib after failure of gefitinib treatment of more than 6 months in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "At the moment, established personalized treatment approaches include treatment of patients with NSCLC and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK inhibitor crizotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Impacts of treatment lines and initiation timing of erlotinib for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "aokitaku@is.icc.u-tokai.ac.jp  AIM: This study aimed to analyze whether or not the efficacy and safety of erlotinib are influenced by differences among treatment lines and initiation timing in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with NSCLC treated with erlotinib as second- or third-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "frichar214@msn.com  E-Cadherin and vimentin protein expression was assessed in late stage NSCLC tumors from the placebo controlled clinical trial, NCIC-CTG BR.21, to determine if these markers had the potential to predict outcome of erlotinib therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase II trial of erlotinib in patients with EGFR wild-type advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Erlotinib might be an alternative option for patients resistant to cytotoxic chemotherapy even in those with EGFR wild-type NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "andrew.weickhardt@ucdenver.edu  INTRODUCTION: This phase I/II study evaluated the safety and antitumor effect of the combination of erlotinib with cixutumumab, a recombinant fully humanized anti-insulin-like growth factor-1 receptor IgG1 monoclonal antibody, in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with advanced NSCLC were treated in an initial safety-lead and drop-down cohorts using erlotinib 150 mg/d with cixutumumab 6 or 5 mg/kg on days 1, 8, 15, and 22 in 28-day cycles (cohorts 1 and 2). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: The combinations of cixutumumab at 6 mg/kg every 7 days and 15 mg/kg every 21 days and full-dose erlotinib are not tolerable in unselected patients with NSCLC, as measured by DLT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Geoffrey.Liu@uhn.on.ca  BACKGROUND: BR.21 is a double-blind, placebo-controlled trial of second-/third-line erlotinib in stage IIIB/IV NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Taken together, we suggest that elevated eIF4E in NSCLC cells is associated with proliferation, invasion and acquired erlotinib resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib or best supportive care for third-line treatment of advanced NSCLC: a real-world cost-effectiveness analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib has been approved as a third-line treatment for advanced NSCLC in British Columbia (BC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "A cost-effectiveness analysis was conducted to compare costs and effectiveness in patients who received third-line erlotinib to those in a historical patient cohort that would have been eligible had erlotinib been available.METHODS: In a population of patients who have been treated with drugs for advanced NSCLC, overall survival (OS), progression-to-death survival (PTD) and probability of survival one year after end of second-line (1YS) were determined using a Kaplan-Meier survival analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSION: Our analysis suggests that erlotinib may be an effective and cost-effective third-line treatment for advanced NSCLC compared to best supportive care. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Currently, erlotinib and pemetrexed are registered as maintenance treatment in patients with NSCLC not progressing after four cycles of standard platinum-based doublet chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been shown to have benefits for NSCLC and pancreatic cancer patients; however, almost all patients develop progressive disease during the therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "For this purpose, we examined the antitumor effect of a combination therapy of a chemotherapeutic agent with erlotinib using two types of erlotinib-resistant tumor xenograft models: a NSCLC model, in which EBC-1, H1975 and HCC827TR3 tumors were implanted, and an HPAC pancreatic cancer cell xenograft which generates erlotinib-resistant tumors in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Furthermore, erlotinib alone suppressed the phosphorylation of epidermal growth factor receptor in HPAC tumors and the two NSCLC cell lines other than H1975. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Treatment of NSCLC with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib have shown efficacy in patients with NSCLC and brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which have been approved for second-line or third-line indication in previously treated advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, NSCLC patients aged 70 years or older. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "ymchen@vghtpe.gov.tw  INTRODUCTION: The primary objective of this study was to compare the response rates of elderly, chemonaive patients with advanced NSCLC treated with daily oral erlotinib versus oral vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Chemonaive Taiwanese patients aged 70 years or older who had advanced NSCLC were randomized to receive either oral erlotinib 150 mg (E) daily or oral vinorelbine 60 mg/m (V) on days 1 and 8 every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "bar.jair@gmail.com  The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have provided substantial benefits to patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "marknuijten@planet.nl  Erlotinib and pemetrexed were approved by the European Medicines Agency for first-line maintenance treatment of patients with locally advanced or metastatic NSCLC to prolong overall survival after first-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We conducted a cost-comparison analysis of erlotinib versus pemetrexed in first-line maintenance treatment of locally advanced or metastatic, non-squamous NSCLC in France, Germany, Italy and Spain, performed from the perspective of national health-care decision-makers or purchasers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Phase I study of continuous afatinib (BIBW 2992) in patients with advanced NSCLC after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "METHODS: Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "faupe@libero.it  Advanced NSCLC harboring activating mutations of epidermal growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs), namely erlotinib and gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Eligible studies included published randomized controlled trials in which erlotinib or gefitinib (alone or with chemotherapy) were compared with standard therapy in 1260 patients with EGFR-mutated NSCLCs who were included in 13 trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or gefitinib than from chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Inhibition of EGFR signaling has thus been identified as an attractive strategy in control of tumor proliferation, and over a decade of intense activity in the field has culminated in the discoveries and subsequent approvals of gefitinib and erlotinib for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " A phase II trial of erlotinib as front-line treatment in clinically selected patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "agpallis@gmail.com  BACKGROUND: The purpose of this study was to evaluate the efficacy of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "However use of clinical (smoking status) and pathologic (adenocarcinoma) criteria may identify a subgroup of patients with advanced/metastatic NSCLC who can benefit from front-line treatment with erlotinib when mutation testing is not feasible. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " [Efficacy and toxicity of erlotinib in NSCLC treatment]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "elena.yaiza.romero.ventosa2@sergas.es  OBJECTIVE: To evaluate the efficacy and toxicity of erlotinib in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous NSCLC receiving gefitinib or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "HM781-36B treatment of EGFR DelE746_A750-harboring erlotinib-sensitive HCC827 and EGFR L858R/T790M-harboring erlotinib-resistant NCI-H1975 NSCLC cells results in the inhibition of EGFR phosphorylation and the subsequent deactivation of downstream signaling proteins. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "Additionally, HM781-36B shows an excellent efficacy in a variety of EGFR- and HER-2-dependent tumor xenograft models, including erlotinib-sensitive HCC827 NSCLC cells, erlotinib-resistant NCI-H1975 NSCLC cells, HER-2 overexpressing Calu-3 NSCLC cells, NCI-N87 gastric cancer cells, SK-Ov3 ovarian cancer cells and EGFR-overexpressing A431 epidermoid carcinoma cancer cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Survival benefit with erlotinib maintenance therapy in patients with advanced NSCLC according to response to first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "BCoudert@cgfl.fr  BACKGROUND: In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS) in the overall study population of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "CONCLUSIONS: Patients with advanced NSCLC and SD following first-line platinum-based doublet chemotherapy derive a significant OS benefit from maintenance erlotinib therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": " Erlotinib in patients with advanced NSCLC: impact of dose reductions and a novel surrogate marker. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "daniel.binder@charite.de  Erlotinib is a relatively well-tolerated treatment option for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "We retrospectively reviewed the files of all patients with advanced NSCLC treated with erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "erlotinib", "orig_sen": "A 59-year-old man with advanced NSCLC developed acute respiratory failure with bilateral interstitial lung disease 4 weeks after the onset of second-line combination therapy that included gemcitabine and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "GDC-0941", "orig_sen": "[Epub ahead of print]  Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "GDC-0941", "orig_sen": "The effects of GDC-0941 (a pan PI3K inhibitor), GDC-0980 (a dual PI3K/mTOR inhibitor) and GDC-0973 (a MEK inhibitor) alone and in combination were assessed in 3 NSCLC cell lines.PIK3CA was mutated in 5.17% of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "GDC-0941", "orig_sen": "GDC-0941 and GDC-0980 treatment induced anti-proliferative and pro-apoptotic responses across all NSCLC cell lines, while GDC-0973 treatment induced only anti-proliferative responses. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "GDC-0941", "orig_sen": " The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "GDC-0941", "orig_sen": "We found that a high efficacy of antitumor activity was shown with GDC-0941 treatment in two gefitinib-resistant NSCLC cell lines, A549 and H460. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "GDC-0941", "orig_sen": "Additionally, the blockade of PI3K, mTOR and Erk with GDC-0941 and MEK inhibitors shows promise for treating gefitinib-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "[Epub ahead of print]  ERCC1 Expression-based Randomized Phase II Study of Gemcitabine/cisplatin Versus Irinotecan/cisplatin in Patients With Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "NSCLC patients with the WEE1 rs3910384 G/G homozygote genotype showed 13.5 months extended OS, 3.2 months extended PFS, and a 274% relative increase in their 3-year survival rate (from 7.4% to 27.7%) compared to the A/A+A/G genotype after treatment with platinum-gemcitabine regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In conclusion, the WEE1 rs3910384 G/G homozygote genotype can be used as a selective biomarker for NSCLC patients to indicate treatment with platinum and gemcitabine regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous NSCLC: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVE: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced NSCLC, who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Efficacy and feasibility of gemcitabine and carboplatin as first-line chemotherapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The purpose of this study was to evaluate the efficacy and safety of gemcitabine and carboplatin as first-line treatment in elderly patients with advanced NSCLC and to evaluate the prognostic factors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: Gemcitabine and carboplatin combination chemotherapy is an effective and manageable treatment option in elderly advanced NSCLC patients with good performance status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Survival analysis in advanced NSCLC treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Platinum-based chemotherapy with third generation drugs (such as gemcitabine) is an efficacious regimen of first-line treatment of patients with advanced, unresectable NSCLC, without activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We investigated whether ERCC1 (19007C>T) and RRM1 (-37C>A) polymorphisms impact response to chemotherapy and survival in 62 patients with NSCLC treated with platinum and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The analysis of RRM1 (-37C>A) more than ERCC1 (19007C>T) polymorphism may be a promising tool in the qualification of NSCLC patients for chemotherapy containing platinum compounds and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced NSCLC (Italian GEMVIN3/NCIC CTG BR14 trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In addition, low levels of expression of RRM1, a target for gemcitabine, have been associated with improved OS in advanced NSCLC patients treated with cisplatin and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "gemcitabine alone in patients with advanced NSCLC and a performance status of 2: the CAPPA-2 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The addition of cisplatin to single-agent gemcitabine improves survival as first-line treatment of PS2 patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous NSCLC: a phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A 61-year-old woman with recurrent NSCLC presented with thrombocytopenia, microangiopathic hemolytic anemia, neurological abnormalities, renal failure and a fever that appeared during chemotherapy with gemcitabine and bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "riessjo@stanford.edu  We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "As an application example, we describe the analysis for the comparison of four regimens, cisplatin plus irinotecan, carboplatin plus paclitaxel, cisplatin plus gemcitabine (GP), and cisplatin plus vinorelbine, for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous NSCLC: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: The present study was a phase I/II study to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities of the biweekly carboplatin/gemcitabine combination and evaluate its safety and efficacy in patients aged\u00a0\u2265 70 years with advanced squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "PATIENTS AND METHODS: Patients aged\u00a0\u2265 70 years with advanced or metastatic squamous NSCLC received escalated doses of carboplatin (area under the curve [AUC] 2-2.5 intravenously) and gemcitabine (800-1100 mg/m(2) intravenously) every 2 weeks (phase I). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: The biweekly regimen of gemcitabine and carboplatin showed satisfactory efficacy and a favorable toxicity profile in elderly patients with advanced or metastatic squamous cell NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced NSCLC were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) NSCLCs (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Our results suggest that, Paclitaxel or combination of Paclitaxel+Gemcitabine could serve as a suitable therapy against MDR1 in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The objectives of the present study were to define maximum tolerated dose and the recommended phase II dose (RPTD) of AXL1717 in combination with gemcitabine HCl and carboplatin in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "AXL1717 in combination with gemcitabine HCl and carboplatin is a possible treatment approach in previously untreated, locally advanced, or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Pemetrexed and gemcitabine versus carboplatin and gemcitabine in NSCLC: a randomized noninferiority phase II study in one center. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "For each tumor type, Medicare patients who were 75 years or older had median survivals that were six to eight weeks shorter than those of trial patients (4.3 vs 5.8 months following treatment with single agent gemcitabine for advanced pancreatic cancer, P = .03; 7.3 vs 8.9 months following treatment with carboplatin and paclitaxel for stage IV NSCLC, P = .91; 8.2 vs 10.2 months following treatment with CDDP/ VP16 for extensive stage small cell lung cancer, P \u2264 .01), whereas younger Medicare patients had survival times that were similar to those of trial patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVE: Gemcitabine combined with carboplatin (GC) is a widely used regimen for advanced NSCLC, but clinical outcome is still hampered by its toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Forty patients with stage IIIB or IV NSCLC were randomized to receive either a biweekly regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 14) and carboplatin (area under the concentration-time curve, AUC = 3 on days 1 and 14)] every 28 days or a standard regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 8) and carboplatin (AUC = 5 on day 1)] every 21 days. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Author information: (1)Miyagi Cancer Center, Natori, Japan;  BACKGROUND: Standard first-line chemotherapy for elderly NSCLC patients has been monotherapy with vinorelbine or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The aim of the study was to evaluate the efficacy and safety of first-line chemotherapy based on platinums (carboplatin or cisplatin) plus a third generation compound (vinorelbine or gemcitabine) in elderly patients with advanced NSCLC in daily clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Associations between TS, TTF-1, FR-\u03b1, FPGS, and overall survival in patients with advanced NSCLC receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The aim was to investigate associations between these biomarkers and survival in patients who participated in a phase III trial comparing pemetrexed plus carboplatin with gemcitabine plus carboplatin as first-line chemotherapy in advanced NSCLC (n = 436). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Tissue samples were collected from NSCLC mice treated with gemcitabine plus carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " This study sought to investigate the efficacy and tolerability of the regimen of low-dose gemcitabine combined with carboplatin in chemo-na\u00efve patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We performed a retrospective analysis of 722 stage IIIB/IV NSCLC patients from a double-blind placebo-controlled trial of thalidomide or placebo 100-200 mg/day, combined with gemcitabine/carboplatin (for up to four cycles), then given as single agent maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: The activity and synergy for the combination treatment of cisplatin and gemcitabine has been identified in a variety of human tumor cells, including ovarian cancer cells, and has been widely approved for the treatment of NSCLC, pancreatic cancer and biliary tract cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "hzsx888@163.com  OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: In this phase 3 trial, patients with untreated stage IIIB/IV NSCLC were randomly assigned in a 1:1 ratio by use of an interactive internet response system with minimisation algorithm (stratified by disease stage, tumour histology, smoking status, and chemotherapy regimen) to receive six cycles of gemcitabine (1250 mg/m(2) on days 1 and 8, intravenously) plus platinum (carboplatin 5\u2008\u00d7\u2008area under the curve or cisplatin 75 mg/m(2) on day 1, intravenously) with intercalated erlotinib (150 mg/day on days 15-28, orally; chemotherapy plus erlotinib) or placebo orally (chemotherapy plus placebo) every 4 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The treatment approach for early-stage disease does not differ from that of other histologic subtypes of NSCLC; in locally advanced unresectable or metastatic disease, doublet chemotherapy regimens (including cisplatin or carboplatin and a third-generation agent such as gemcitabine, taxanes, or vinorelbine) remain the cornerstone of front-line systemic treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "txh@medicine.wisc.edu  INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "gbanna@yahoo.com  The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced NSCLC: A Randomized Clinical Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of nedaplatin/gemcitabine (NG) and carboplatin/gemcitabine (CG) in the management of untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced NSCLC: North Central Cancer Treatment Group Study N0528. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " INTRODUCTION: The purpose of this study was to assess the safety and efficacy of gemcitabine and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The present study was conducted to evaluate the efficacy and safety of the combination of gemcitabine at a low-dose prolonged infusion in comparison with standard dose gemcitabine with carboplatin in chemonaive patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: In NSCLC, gemcitabine low-dose prolonged infusion with carboplatin has low toxicity, especially thrombocytopenia, and has an activity comparable with gemcitabine given in higher dose in standard infusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Tissue and peripheral blood samples were collected from 49 advanced NSCLC patients treated with gemcitabine plus carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: The expression of RRMI and ERCC1 genes in tumor tissues and RRM1 in peripheral blood lymphocytes is closely correlated with the response to chemotherapy and prognosis of patients with advanced NSCLC treated with gemcitabine plus carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Patients with NSCLC stage IIIB or IV received as first-line treatment four cycles of carboplatin (AUC 5) (day 1) plus gemcitabine 1000\u00a0mg/m(2) (days 1 and 8) every 3\u00a0weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "lpazares@hotmail.com  PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced NSCLC: a randomized, phase-II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We wanted to evaluate the efficacy and safety of biweekly gemcitabine and low-dose carboplatin combination therapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: In this phase-II trial, chemotherapy-naive elderly patients (aged \u226576 years) with NSCLC were randomly treated with biweekly combination therapy with gemcitabine and carboplatin (1000 mg/m(2) gemcitabine and carboplatin at an area under the curve (AUC) of 3 on days 1 and 15, every 4 weeks) or gemcitabine monotherapy (1000 mg/m(2) on days 1, 8 and 15, every 4 weeks). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Biweekly gemcitabine and low-dose carboplatin combination chemotherapy showed acceptable efficacy, toxicity, and tolerability in those aged \u226576 years with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "kmori@tcc.pref.tochigi.lg.jp  BACKGROUND: The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced NSCLC: West Japan Thoracic Oncology Group Trial (WJTOG) 2905. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: A combination phase I/II study was conducted in chemo-naive elderly patients with NSCLC to establish the toxicity and maximum tolerated dose (MTD) and to investigate the antitumor activity of carboplatin (CBDCA) plus gemcitabine (GEM). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " PURPOSE: To comparatively evaluate the prognostic or predictive value of ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) gene expression in peripheral blood versus tumor tissue from patients with advanced NSCLC treated by gemcitabine/platinum chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: A total of 49 patients with advanced NSCLC receiving gemcitabine plus carboplatin chemotherapy were studied. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This trial tested custirsen (OGX-011), an inhibitor of CLU protein production, combined with gemcitabine/platinum in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Our results suggested that metuzumab could significantly enhance chemosensitivity of human NSCLC cells to gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Metuzumab/gemcitabine combination treatment may be a potentially useful therapeutic regimen for NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " We report the case of a 58-year-old woman treated with nivolumab for an unresectable squamous NSCLC, after first-line cisplatin and gemcitabine combination chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Necitumumab (Portrazza\u2122, Eli Lilly and Company) is an anti-epidermal growth factor receptor monoclonal antibody approved for the first-line treatment of squamous cell NSCLC in combination with cisplatin and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Although considered a safe and effective treatment option for squamous cell NSCLC, the clinical utility of necitumumab may be limited due to the high cost of the drug as well as added toxicity when combined with cisplatin and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B NSCLC treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "[Epub ahead of print]  Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in NSCLC? A meta-analysis of 36 randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " PURPOSE: The purpose of this study was to observe the clinical efficacy and toxicity of cisplatin in combination with gemcitabine or Abraxane as first-line chemotherapy for stage III/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: The efficacy of cisplatin in combination with Abraxane is better than that with gemcitabine in the treatment of NSCLC, and the treatment has less risk of hematologic toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The methodology is applied on the retrospective data of thirteen patients with NSCLC who received cisplatin in combination with gemcitabine, vinorelbine or docetaxel in the neoadjuvant context. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "On the basis of the SQUIRE results, necitumumab was approved in combination with cisplatin and gemcitabine as a first-line treatment for advanced squamous NSCLC, both in the US and Europe, where its availability is limited to patients with EGFR-expressing tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "[Epub ahead of print]  Clinical Observation of Docetaxel or Gemcitabine Combined with Cisplatin in the Chemotherapy after Surgery for Stage II-III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous NSCLC: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous NSCLC (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "PATIENTS AND METHODS: Patients with pathologically confirmed stage IV sq-NSCLC were randomized 1:1 to receive a maximum of six 3-week cycles of gemcitabine (1250 mg/m(2) i.v., days 1 and 8) and cisplatin (75 mg/m(2) i.v., day 1) chemotherapy with or without necitumumab (800 mg i.v., days 1 and 8). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: In line with SQUIRE ITT, addition of necitumumab to gemcitabine-cisplatin significantly prolonged OS and was generally well tolerated in the subpopulation of patients with EGFR-expressing advanced sq-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " 162P: Molecular markers in advanced NSCLC patients receiving gemcitabine & cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A phase II, open-label trial of bortezomib (VELCADE(\u00ae)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Preclinical and phase I clinical data suggest activity of bortezomib in NSCLC, either as monotherapy or in combination with chemotherapeutic agents including gemcitabine and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: A total of 1093 patients with stage IV squamous NSCLC were randomized 1:1 to receive necitumumab (800 mg absolute dose intravenously [IV]) plus gemcitabine-cisplatin (gemcitabine\u00a0= 1250 mg/m(2) IV on days 1 and 8; cisplatin\u00a0= 75 mg/m(2) IV on day 1) or gemcitabine-cisplatin alone (every 21 days) for up to six cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Necitumumab is approved as a part of combination therapy (with gemcitabine and cisplatin) in the USA for the first-line treatment of metastatic squamous NSCLC, and regulatory submissions have been made in the EU for this same indication. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This article summarizes the milestones in the development of necitumumab leading to this first approval for the first-line treatment of metastatic squamous NSCLC, in combination with gemcitabine and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "AZD6738 potentiates the cytotoxicity of cisplatin and gemcitabine in NSCLC cell lines with intact ATM kinase signaling, and potently synergizes with cisplatin in ATM-deficient NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Serial dilutions of gemcitabine, cisplatin, 5-fluorouracil, vinorelbine, and paclitaxel were administered to the A549 NSCLC cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Take-home message in times of crisis: Is it really better to treat with cisplatin & pemetrexed than cisplatin & gemcitabine in first line NSCLC? The power of statistical considerations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: A total of 60 patients with advanced NSCLC were divided into two groups using a random number table, i.e., the gemcitabine plus cisplatin (GP) chemotherapy alone group (26 patients) and the FRG + GP chemotherapy group (34 patients), for 60-day treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " The cisplatin and gemcitabine regimen is one of the most effective regimens against advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " The aim of the present study was to investigate the efficacy and safety of combined therapy with iodine-125 seed implantation and the gemcitabine plus cisplatin chemotherapeutic regimen, as well as treatment with the radiosensitizer sodium glycididazole (CMNa), in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous NSCLC: A Biomarker-Stratified Randomized Phase II Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive NSCLC: analyses from the phase III, randomized, open-label, ENSURE study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous NSCLC (SQUIRE): an open-label, randomised, controlled phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "INTERPRETATION: Our findings show that the addition of necitumumab to gemcitabine and cisplatin chemotherapy improves overall survival in patients with advanced squamous NSCLC and represents a new first-line treatment option for this disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Here we explored the effects of these polymorphisms on the chemosensitivity and clinical outcome in Chinese NSCLC patients treated with gemcitabine-cisplatin regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: DNA sequencing was used to evaluate genetic polymorphisms of GSTP1 Ile105Val and RRM1 C37A-T524C in 47 NSCLC patients treated with gemcitabine-cisplatin regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Compared with single detection of genetic polymorphisms of GSTP1 Ile105Val or RRM1 C37A-T524C, joint detection of both may be more helpful for patients with NSCLC to receive gemcitabine-cisplatin regimens as the first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Especially, genetic polymorphism of RRM1 is more likely to be used as an important biomarker to predict the response and toxicity of gemcitabine-cisplatin combination chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Knockdown of NIPBL in NSCLC cell lines significantly reduced cellular proliferation, migration, and invasion, and enhanced cellular apoptosis and sensitivity to cisplatin, paclitaxel, and gemcitabine hydrochloride. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " INTRODUCTION: In the phase III, LUX-Lung 6 trial, afatinib prolonged progression-free survival (PFS) versus cisplatin/gemcitabine in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-na\u00efve patients with advanced/metastatic (stage IIIB/IV) squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "All NSCLC patients received gemcitabine plus cisplatin (GP regimen) for a total of two courses. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "combination of gemcitabine/cisplatin (GC) as neoadjuvant treatment in stage IIIA-N2 NSCLC with sensitizing EGFR mutation in exon 19 or 21. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected NSCLC with quality of life as the primary objective. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced NSCLC patients using microarray data. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVE: This study was performed to evaluate the therapeutic effect of cisplatin-gemcitabine combination chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " AIM: We used a panel of 17 NSCLC cell lines to investigate whether the presence of polymorphisms in the RRM1, ERCC1, ABCB1 and MTHFR genes and alterations in their mRNA expression can affect the in vitro chemosensitivity to cisplatin and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "observation after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Among the two cisplatin-based doublets of induction chemotherapy for inoperable NSCLC, both schedules of gemcitabine have a comparable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " [Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVE: The purpose of this study was to investigate the relationship between the expression of ribonucleotide reductase subunit M1 (RRM1) protein and the efficacy of gemcitabine/cisplatin (GP) adjuvant chemotherapy in postoperative NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: RRM1 protein may be a valuable predictive factor for gemcitabine/cisplatin adjuvant chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Expression of ERCC1, RRM1 and LRP in NSCLCs and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVE: To explore the clinical efficacy of gemcitabine concomitant with nedaplatin and drug resistance in the treatment of NSCLC and associated molecular predicators. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: A total of 68 patients diagnosed with NSCLC by histology served as the study objects and were randomly divided into an observation group treated with gemcitabine concomitant with nedaplatin and a control group with cisplatin concomitant with gemcitabine, 34 cases for each group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Gemcitabine concomitant with nedaplatin has significant effects in the treatment of NSCLC, with an adverse response rate obviously lower than for cisplatin concomitant with gemcitabine, suggesting that wider use in the clinic is warranted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Eli Lilly and Company is conducting a phase III, randomized, multicenter, open-label study of gemcitabine plus cisplatin plus necitumumab (GC\u2009+\u2009N) versus gemcitabine plus cisplatin (GC) for the first-line treatment of patients with stage IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: Stage III unresectable NSCLC is preferably treated with concurrent schedules of chemoradiotherapy, but none is clearly superior Gemcitabine is a radiosensitizing cytotoxic drug that has been studied in phase 1 and 2 studies in this setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This randomized phase II study investigated the addition of iniparib to gemcitabine-cisplatin in metastatic NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "PATIENTS AND METHODS: Patients with histologically confirmed stage IV NSCLC were randomized 2 : 1 to receive gemcitabine (1250 mg/m(2), days 1/8) and cisplatin (75 mg/m(2), day 1) with [gemcitabine/cisplatin/iniparib (GCI)] or without [gemcitabine/cisplatin (GC)] iniparib (5.6 mg/kg, days 1/4/8/11) every 3 weeks for six cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese NSCLC patients treated with cisplatin-gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We used polymerase chain reaction-restriction fragment length polymorphism to evaluate genetic polymorphisms of XPD (Asp312Asn and Lys751Gln) and CDA (Lys27Gln and Ala70Thr) in 93 NSCLC patients treated with a cisplatin-gemcitabine regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "H1975 NSCLC cells were treated with curcumin (0-50 \u03bcM) alone, or combined with gemcitabine or cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Clinical trials of two multitargeted tyrosine kinase inhibitors are restricting enrollment to patients with squamous NSCLC: a phase I/II trial of nintedanib added to first-line gemcitabine/cisplatin and a phase II trial of ponatinib for previously treated advanced disease, with the latter requiring not only squamous disease but also a confirmed FGFR kinase amplification or mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced NSCLC harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-positive advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "LY293111 combined with gemcitabine-cisplatin did not increase median PFS compared with placebo plus gemcitabine-cisplatin in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy na\u00efve NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " AIMS AND BACKGROUND: To investigate the efficacy and tolerability of biweekly scheduled triplet chemotherapy consisting of gemcitabine, cisplatin and vinorelbine for chemotherapy-na\u00efve advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: The biweekly schedule of the triplet chemotherapy combination including gemcitabine, cisplatin and vinorelbine was effective in advanced, mostly metastatic NSCLC with acceptable and manageable side effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: In advanced NSCLC, cisplatin-based CT is not superior to a platinum-free regimen (ifosfamide-gemcitabine) with a favourable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable NSCLC: KASLC 0401. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: In a retrospective study, 40 patients with stage III NSCLC received intra-arterial infusion chemotherapy with gemcitabine and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Tolerability and toxicity of adjuvant cisplatin and gemcitabine for treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The cisplatin and gemcitabine regimen is one of the most active and well-tolerated regimens against advanced NSCLC, but its toxicity and tolerability has not been adequately evaluated in the adjuvant setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m(2)) and gemcitabine (1250 mg/m(2)) between January 2005 and December 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVES: The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin-gemcitabine with concurrent thoracic radiotherapy for locally advanced NSCLC (LA-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " [A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "zhaowy98@yahoo.com.cn  OBJECTIVE: To prospectively evaluate the efficacy and toxicity of irinotecan plus cisplatin (IP regimen) compared with gemcitabine plus cisplatin (GP regimen) as a first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Long-term survival rates of patients with stage IIIB and IV NSCLC treated with cisplatin plus vinorelbine or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " INTRODUCTION: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced NSCLC to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " High COL4A3 expression correlates with poor prognosis after cisplatin plus gemcitabine chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " In this study, we investigated whether COL4A3 mRNA expression levels were associated with clinical outcomes after treatment with a combination of gemcitabine (Gem)/cis-diamminedichloroplatinum(II) (CDDP) regimen for patients with advanced stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "adamvilmar@hotmail.com  BACKGROUND: Platinum-based doublets (PBDs) remain the cornerstone of treatment in NSCLC and may include gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "sgray@stjames.ie  Gemcitabine is indicated in combination with cisplatin as first-line therapy for solid tumours including NSCLC, bladder cancer and mesothelioma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "NSCLC, mesothelioma and prostate cancer cell lines were treated with decitabine and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced NSCLC whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Pemetrexed plus platinum or gemcitabine plus platinum for advanced NSCLC: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced NSCLC: the TORCH randomized trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced NSCLC: a multicenter phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: These results offer a preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for patients with NSCLC, and provide potential molecular biomarkers for tailoring therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including NSCLC, colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Tetrandrine combined with gemcitabine and Cisplatin for patients with advanced NSCLC improve efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: A total of 433 stage IIIB-IV NSCLC patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "treatjo@lilly.com  INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "vkovac@onko-i.si  After a favorable experience with gemcitabine at a low dose in a prolonged infusion in combination with cisplatin for advanced NSCLC, here, we present the results from a phase II trial for patients with malignant pleural mesothelioma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This study assessed the efficacy of the combination of standard gemcitabine plus cisplatin chemotherapy with rh-endostatin in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB to IV NSCLC were randomly (1:1) assigned to receive gemcitabine/cisplatin chemotherapy alone or with 7.5 mg/ m(2) of intravenously rh-endostatin on days 1 to 14 of each 3-week cycle. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: The addition of rh-endostatin to gemcitabine plus cisplatin chemotherapy for first-line treatment of NSCLC improves objective response and may improve survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "[Epub ahead of print]  Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced NSCLC and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVES: To compare first-line treatment with docetaxel plus gemcitabine (DG) versus gemcitabine (G) in elderly patients with advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage NSCLC in a University Hospital in Turkey. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " PURPOSE: To compare the efficacy and toxicity of gemcitabine versus docetaxel in a second-line setting of nonsmall cell lung cancer (NSCLC) patients previously treated with platin-based combination chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: We retrospectively evaluated the medical records of 57 patients treated with single agent gemcitabine or docetaxel in second-line setting of advanced NSCLC who received one prior platinum-based therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Treatment with gemcitabine demonstrated clinically equivalent efficacy with a significantly improved safety profile compared with those receiving docetaxel in the second-line setting for advanced NSCLC in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Based on these results, treatment with gemcitabine should be considered a standard treatment option for second-line NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced NSCLC and a poor performance status (IFCT-0301). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: The efficacy of docetaxel, vinorelbine, or gemcitabine monotherapy in previously untreated elderly patients with NSCLC has been reported.Pemetrexed monotherapy has shown clinically equivalent efficacy to docetaxel, a standard therapeutic option, in patients with previously treated NSCLC and in those with a lower incidence of toxicity such as febrile neutropenia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Prognostic significance of circulating tumor cells in advanced NSCLC patients treated with docetaxel and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " PURPOSE: To evaluate the association in the change of circulating tumor cell (CTC) levels and clinical outcomes (PFS and OS) in patients with advanced NSCLC treated homogenously with docetaxel and gemcitabine administered every 2 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced NSCLC: a meta-analysis on 9 randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " PURPOSE: The aim was to compare the efficacy and toxicity of gemcitabine plus docetaxel (GD) with platinum-based regimens in patients with untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MATERIALS AND METHODS: This multicenter, randomized, placebo-controlled, double-blind, phase III study investigated intercalated first-line erlotinib or placebo with gemcitabine/platinum, followed by maintenance erlotinib or placebo, for patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Erlotinib is a tyrosine kinase inhibitor (TKI), approved for the treatment of patients with NSCLC and pancreatic cancer in combination with gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Patients receiving gemcitabine\u00a0+\u00a0platinum as first-line anti-cancer treatment for advanced NSCLC experienced relatively poor QoL scores throughout treatment course. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of NSCLC and when combined with gemcitabine for pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "alexgrigorescu2004@yahoo.com  PURPOSE: The purpose of the present trial was to investigate whether clinical benefit can be obtained by concurrent administration of erlotinib with gemcitabine as first-line treatment in patients with advanced NSCLC and ECOG performance status (PS) 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " PURPOSE: To investigate the pharmacological effects of different erlotinib (ER) and gemcitabine (GM) combination schedules by in vitro and in vivo experiments and PK/PD models in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "michael.michael@petermac.org  Erlotinib and gemcitabine are active in NSCLC and have synergy in other cancers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Chemotherapy-na\u00efve patients with NSCLC, either stage IIIB (with plural effusion) or stage IV, with measurable disease and ECOG PS 2, and adequate organ function were randomized to receive either erlotinib (150\u00a0mg/day p.o.) plus gemcitabine (1000\u00a0mg/m2, days 1, 8, 15, every 4 weeks) in Arm A or gemcitabine monotherapy (Arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Erlotinib plus gemcitabine for the treatment of ECOG 2 NSCLC patients warrants further investigation including intermittent erlotinib regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced NSCLC selected with a comprehensive geriatric assessment (the GFPC 0505 study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "herve.lecaer@ch-draguignan.fr  BACKGROUND: The aim of this randomized phase II trial was to evaluate the feasibility and activity of weekly gemcitabine (G) followed by erlotinib at disease progression (arm A) versus erlotinib followed by G at progression (arm B) in vulnerable elderly patients with advanced NSCLC, selected on the basis of a comprehensive geriatric assessment (CGA). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "A 59-year-old man with advanced NSCLC developed acute respiratory failure with bilateral interstitial lung disease 4 weeks after the onset of second-line combination therapy that included gemcitabine and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "[Epub ahead of print]  Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We investigated the activity and tolerability of the novel combination of dose-dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: This multicenter phase II trial evaluated the safety and efficacy of the combination of pemetrexed (400 mg/m(2)), gemcitabine (1200 mg/m(2)), and bevacizumab (10\u00a0mg/kg), given every 14 days in patients with untreated, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Treatment with dose-dense pemetrexed, gemcitabine, and bevacizumab met the primary endpoint with promising efficacy and a manageable safety profile in patients with untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: We retrospectively evaluated all patients with NSCLC treated with first-line gemcitabine-based chemotherapy in two Italian hospitals. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Thrombocytosis is neither a prognostic nor a predictive factor for PFS or OS in patients with advanced NSCLC treated with first-line gemcitabine-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: Trials investigating the efficacy and safety of combining molecular targeted agent (MTA) with platinum-gemcitabine (PG) in first-line treatment of advanced NSCLC have shown inconsistent findings. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "As anticipated, after 4-h incubation of NSCLC (A549) cells with gemcitabine at 0.5 and 2\u2009\u03bcM, there were consistent reductions in levels of deoxyribonucleoside diphosphates (dNDP) and their corresponding deoxyribonucleoside triphosphates (dNTP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In the present study, the in vitro antitumor effects and correlated molecular mechanisms of sorafenib combined with gemcitabine or pemetrexed were explored in the K-ras mutation-positive NSCLC A549 cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " AS1411 Aptamer-Decorated Biodegradable Polyethylene Glycol-Poly(lactic-co-glycolic acid) Nanopolymersomes for the Targeted Delivery of Gemcitabine to NSCLC In\u00a0Vitro. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In the present study, we have developed gemcitabine (GEM)-loaded AS1411 aptamer surface-decorated polyethylene glycol-poly(lactic-co-glycolic acid) nanopolymersome (Apt-GEM-NP) to target nucleolin-overexpressing NSCLC (NSCLC; A549). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " PURPOSE: Chemotherapy with platinum compounds and gemcitabine is frequently used in first-line treatment of advanced NSCLC patients in which tyrosine kinase inhibitors (EGFR or ALK) cannot be administered. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The aim of this study was to determine the association between single nucleotide polymorphisms (SNPs) of the RRM1 promoter (-37C>A, -524C>T) and the effectiveness of first-line chemotherapy based on platinum compounds and gemcitabine in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Presence of rare AA (-37C>A) and CC (-524C>T) genotypes of the RRM1 may be favorable predictive factors for chemotherapy with platinum compounds and gemcitabine in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in NSCLC Cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: This study examines the effect of the cytotoxic drug Gemcitabine and the EGFR tyrosine kinase inhibitor Gefitinib on the expression of NK group 2 member D (NKG2D) ligands as well as the sensitivity of NSCLC cells to the NK-mediated lysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: In keeping with the effect on NKG2D expression, Gemcitabine enhanced NK cell-mediated cytotoxicity while Gefitinib attenuated NK cell killing in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Piceatannol Enhances the Antitumor Efficacy of Gemcitabine in Human A549 NSCLC Cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " To enhance the anticancer efficacy of gemcitabine in the treatment of NSCLC, the potential synergistic effect of piceatannol on gemcitabine cytotoxicity was investigated in the human NSCLC A459 cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The findings from this study show that piceatannol can enhance the cytotoxic effects of gemcitabine by enhancing expression of the proapoptotic protein Bak, thereby providing the rational basis for a novel combination strategy for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: This analysis was conducted to evaluate the efficacy and safety of a combination of gemcitabine and nedaplatin in treating patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Clinical studies evaluating the efficacy and safety of a combination of gemcitabine and nedaplatin with attention to response and safety for patients with NSCLC were identified using a predefined search strategy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "RESULTS: In gemcitabine and nedaplatin based regimens, 4 clinical studies including 112 patients with NSCLC were considered eligible for inclusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: This evidence based analysis suggests that the combination of gemcitabine and nedaplatin is associated with good response rate and accepted toxicity for treating patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Treatment of NSCLC cells with the 4EASO resulted in decreased cap-dependent complex formation, decreased cell proliferation and increased sensitivity to gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " The anti-tumor activity of gemcitabine (GEM) has been clinically proven in several solid tumors, including pancreatic cancer, biliary tract cancer, urinary bladder cancer, and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " RRM1 expression is associated with the outcome of gemcitabine-based treatment of NSCLC patients--a short report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Through a meta-analysis of observational studies, we evaluated whether RRM1 expression levels are associated with the clinical outcome of gemcitabine-containing treatment regimens in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: The meta-analysis reported here indicates that RRM1 expression is associated with the response rate and overall survival rate of advanced NSCLC patients treated with gemcitabine-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Gemcitabine is an approved chemotherapy drug for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The objective of this study was to develop a novel strategy to improve the therapeutic efficacy of Gemcitabine for NSCLC by the co-administered iRGD peptide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The combined application of Gemcitabine with iRGD may be a novel strategy to enhance the clinical therapeutic efficacy of Gemcitabine in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In this regard, we have synthesized Pem-PEG-Gem, wherein pemetrexed (Pem) and gemcitabine (Gem) are conjugated to a heterobifunctional polyethylene glycol (PEG) polymer for the effective treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Gemcitabine plus vinorelbine as the second-line treatment and beyond in elderly patients with platinum-pretreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: The efficacy and tolerance of a gemcitabine and vinorelbine (GV) combination as salvage therapy have not been reported in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In contrast, the gemcitabine-5'-O-lipoate hybrid was found to be superior to the parent compounds against both NSCLC and bladder cancer cells as also was found to preserve the redox activity of the parent compound LA. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " The purpose of this study is the assessment of gel technology based on a lauroyl derivative of gemcitabine encapsulated in lipid nanocapsules delivered subcutaneously or intravenously after dilution to (i) target lymph nodes, (ii) induce less systemic toxicity and (iii) combat mediastinal metastases from an orthotopic model of human, squamous, NSCLC Ma44-3 cells implanted in severe combined immunodeficiency mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In the present study, we have developed gemcitabine (GEM)-loaded cetuximab (CET) surface modified poly(lactic) acid (PLA) nanoparticles (NP) (CET-GEM/PLA NP) to target to epidermal growth factor receptor (EGFR) overexpressing NSCLC (A549) cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " 2',2'-Difluoro-2'-deoxycytidine (dFdC, gemcitabine) is a cytidine analogue active against several solid tumor types, such as ovarian, pancreatic and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Here, we studied the genetic variations underlying NSCLC pathogenesis based on their association to patient outcome after gemcitabine therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: ERCC1 negativity with platinum therapy, gemcitabine therapy, good PS, and female gender all correlated with improved overall survival in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with NSCLC after first line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: This phase I/II study determined the maximal tolerable dose, dose limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of ruthenium compound NAMI-A in combination with gemcitabine in NSCLC patients after first line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: NAMI-A administered in combination with gemcitabine is only moderately tolerated and less active in NSCLC patients after first line treatment than gemcitabine alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " AIM: To identify the single-nucleotide polymorphism (SNP) of hENT1 G-706C that is associated with response to gemcitabine-containing chemotherapy, and to determine the prognosis in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: The hENT1 genetic polymorphism of hENT1 G-706C was associated with response to the gemcitabine-containing chemotherapy and prognosis of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "MV combined with gemcitabine could be explored further as chemovirotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Prognostic factors for patients with advanced NSCLC treated with gemcitabine-platinum as first-line therapy in an observational setting in China. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND: This study examined the prognostic factors associated with survival in advanced NSCLC patients receiving gemcitabine-platinum regimens as first-line therapy in real-world clinical settings in China. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Data was analyzed from a multinational, prospective, non-interventional, observational study of individuals receiving gemcitabine-platinum regimens as first-line therapy for NSCLC, focusing on 300 patients from mainland China. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Gender, T staging, M staging, liver metastases, superior vena cava obstruction, and serum albumin are prognostic factors affecting overall survival in mainland Chinese patients receiving first-line gemcitabine-platinum regimens for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " The aim of the present study was to investigate the effects of a gemcitabine plus platinum (GP) regimen combined with dendritic cell-cytokine induced killer (DC-CIK) immunotherapy on the recurrence and survival rate in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This study was designed to evaluate the efficacy and safety of Genexol-PM and gemcitabine combination in advanced NSCLC patients as a first-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Patients with advanced NSCLC received Genexol-PM at 230 mg/m(2) on day 1 and gemcitabine 1,000 mg/m(2) on day 1 and day 8 of a 3-week cycle. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: CrEL-free paclitaxel in combination with gemcitabine demonstrated favorable antitumor activity with little emetogenicities in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Gemcitabine inhibits the micrometastasis of NSCLC by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This pilot study evaluated the sensitivity of gemcitabine in micrometastasis and CTCs from NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Additionally, the survival rate in the gemcitabine group (24 months) was better than in non-gemcitabine group (21 months), suggesting a therapeutic benefit for NSCLC patient survival with the common therapy plus gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Gemcitabine treatment decreased EpCAM-positive CTCs in NSCLC patients and inhibited EMT by the HGF/cMET pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " INTRODUCTION: The aim of the present study was to evaluate the efficacy and tolerability of vandetanib plus gemcitabine (V/G) compared with gemcitabine alone in elderly patients with untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: V/G combination was associated with a statistically significant prolongation of PFS compared with gemcitabine alone in untreated elderly patients with advanced NSCLC, with an acceptable safety profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with NSCLC and prior interstitial lung disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This study was conducted to elucidate the safety and efficacy of palliative chemotherapy with gemcitabine or pemetrexed, both in combination with a platinum agent in NSCLC patients with ILD. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "PATIENTS AND METHODS: Patients with advanced or recurrent NSCLC and ILD who received gemcitabine or pemetrexed in combination with a platinum agent as first-line chemotherapy were retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: Our results suggest that gemcitabine or pemetrexed in combination with platinum agents could be a feasible option for advanced NSCLC with ILD with some risk of AE-ILD or early death. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " PURPOSE: To investigate the impact of the cytidine deaminase (CDA) A79C polymorphism on both the response to gemcitabine in NSCLC patients and the risk of hematologic toxicities in patients bearing any kind of cancer taking gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Eligible studies included clinical trials that contained the keywords \"gemcitabine\" or \"cytidine deaminase\" and information about response rate of NSCLC patients or hematologic toxicities in patients with any kind of cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: The A79C CDA polymorphism did not show a significant impact on the response rate to gemcitabine in NSCLC patients, while the wild type CDA genotype was indeed correlated to a lower rate of incidence of severe anemia in patients taking gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Genomic polymorphisms of SLC29A3 associated with overall survival in advanced NSCLC treated with gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Genes involved in the drug metabolism or elimination (SLC29A3) may be new prognostic biomarkers for patients with advanced NSCLC who receive gemcitabine as the first-line chemotherapy and may unveil an unexplored molecular pathway correlated with the drug response and further may be predictive biomarkers for these patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Two NSCLC patients achieved partial tumor responses (AZD7762 6 mg/gemcitabine 750 mg/m(2) and AZD7762 9 mg cohort). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " This report is designed to study the ability of the combined treatment with gemcitabine (Gem) and dihydroartemisinin (DHA) to induce apoptosis in a NSCLC cell line (A549 cells). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Even if most meta-analyses in NSCLC yielded contradictory results, a number of candidate biomarkers for response/resistance to conventional chemotherapeutic agents such as gemcitabine, platinum-compounds, pemetrexed and taxanes have been proposed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Gemcitabine is a chemotherapy agent commonly used in the treatment of NSCLC that has been demonstrated to induce apoptosis in NSCLC cells by increasing functionally active Fas expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "NSCLC H292 cells were cultured in the presence or absence of gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Exploratory subgroup analysis revealed the highest RR of hemorrhage in NSCLC patients (RR: 3.234; 95%CI, 1.678-6.233; p<0.001), phase II trials (RR 7.053, 95%CI: 1.591-31.27; p = 0.01), trials reported during 2006-2012 (RR: 3.750; 95%CI: 1.735-8.108, p<0.001) and gemcitabine used as single agent (RR 7.48; 95%CI: 0.78-71.92, p = 0.081). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Array analysis for potential biomarker of gemcitabine identification in NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Gemcitabine is one of the most widely used drugs for the treatment of advanced NSCLC, but modest objective response rate of patients to gemcitabine makes it necessary to identify novel biomarkers for patients who can benefit from gemcitabine-based therapy and to improve the effect of clinical therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In this work, 3 NSCLC cell lines displaying different sensitivities to gemcitabine were applied for mRNA and microRNA (miR) expression chips to figure out the biomarkers for gemcitabine sensitivity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The most intriguing is the activation of Wnt/\u03b2-catenin signaling in gemcitabine resistant NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Our results might provide potential biomarkers for gemcitabine sensitivity prediction and putative targets to overcome gemcitabine resistance in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "By encapsulating a chemodrug, gemcitabine monophosphate (GMP), and siRNA specific to the undruggable cMyc oncogene (cMyc siRNA) into a single nano-sized vesicle and systemically administering them to nude mice, we achieved potent anti-tumor activity in both subcutaneous and orthotopic models of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a NSCLC cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In addition, Gemcitabine treatment, a chemotherapy drug used in the treatment of NSCLC, resulted in the up-regulation of the IL-23R. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Our results may have implications for treating NSCLC patients with Gemcitabine or epigenetic targeted therapies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Gemcitabine plus oxaliplatin for the treatment of leptomeningeal metastases of NSCLC: A case report and review of the literature. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This may suggest that first-line therapies, including the use of gemcitabine and oxalipaltin, may be appropriate for the treatment of non-small cell lung carcinoma (NSCLC) with LM involvement. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In particular, tissue testing for epidermal growth factor receptor and anaplastic lymphoma kinase alterations is currently recommended for certain patients with advanced NSCLC, whereas excision repair cross-complementation group 1 and ribonucleotide reductase 1 as markers for outcome after platinum and gemcitabine therapy are promising but are currently not recommended outside a clinical trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Phase II study of triplet chemotherapy using Tegafur-Uracil, Vinorelbine, Gemcitabine for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "s-atagi@kch.hosp.go.jp  AIM: To evaluate the efficacy and toxicity of triplet chemotherapy using tegafur-uracil (UFT), vinorelbine, and gemcitabine for patients with stage IIIB or IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced NSCLC in a Chinese Han population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " OBJECTIVE: The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We also investigated the efficacy of concurrent and sequential administration of sorafenib and gemcitabine in epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-sensitive and EGFR-TKI-resistant NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The PC-9 (EGFR-TKI-sensitive, EGFR-mutated) and A549 (EGFR-TKI-resistant, K-Ras-mutated) NSCLC cell lines were treated with sorafenib and gemcitabine, alone, in combination or with different schedules. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We found that sorafenib exhibited dose-dependent growth inhibition in the EGFR-TKI-sensitive and EGFR-TKI-resistant NSCLC cell lines, and the sequence gemcitabine\u2192sorafenib exhibited the strongest synergism. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The results suggest that sorafenib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR and K-Ras mutations and that the sequential administration of gemcitabine followed by sorafenib is superior to sorafenib followed by gemcitabine and concurrent administration. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Gemcitabine given at a lower dose intensity than standard should be considered as valuable therapeutic option in elderly or poor PS patients with advanced NSCLC unfit for platinum. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The NSCLC cell lines A549 (mutant KRAS), H1666 (mutant BRAF) and H1975 (mutant EGFR-T790M) were treated with sorafenib and gemcitabine alone and in combination. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In conclusion, we found that sorafenib exhibits antiproliferative effects in EGFR-TKI-resistant NSCLC cell lines and when combined with gemcitabine demonstrates synergistic activity in A549 and H1666 cells but antagonistic activity in H1975 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced NSCLC: results from 6 randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " AIM: The aim was to compare the efficacy and toxicity of paclitaxel plus platinum (TP) with gemcitabine plus platinum (GP) in untreated advanced NSCLC by a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Our meta-analysis showed that paclitaxel plus platinum had similar efficacy and less toxicity compared with gemcitabine plus platinum in first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic NSCLC: a retrospective analysis in gemcitabine-plus-platinum-treated patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Patients with stage IV NSCLC receiving at least two cycles of first-line doublet chemotherapy (gemcitabine plus platinum) were reviewed retrospectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Timing of CIN is predictive of prognosis in patients with metastatic NSCLC receiving gemcitabine/platinum doublet chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: RT-PCR and chromatin immunopreciptiation (ChIP) were used to examine the levels, epigenetic regulation and effects of various drugs (DNA methyltransferase inhibitors, Histone Deacetylase inhibitors and Gemcitabine) on IL-23 expression in NSCLC cells and macrophages. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Gemcitabine, a chemotherapy drug indicated for first-line treatment of NSCLC also induced IL-23A expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: These results may therefore have important implications for treating NSCLC patients with either epigenetic targeted therapies or Gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Modelling non-homogeneous stochastic reaction-diffusion systems: the case study of gemcitabine-treated NSCLC growth. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The application of this approach to he scase of NSCLC treated with gemcitabine is also novel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced NSCLC: a meta-analysis of six trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " PURPOSE: To compare the response, survival, hematological and non-hematological toxicities of gemcitabine administrated at fixed-dose rate infusion (10 mg/m(2)/min, FDR) and standard 30 min infusion in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Electronic databases of MEDLINE, EMBASE and Cochrane Library were searched using key words of \"gemcitabine,\" \"fixed-dose rate,\" \"NSCLC\" and their alternative spellings. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: This meta-analysis found that FDR infusion of gemcitabine had equal ORR and 1-year SR with standard infusion in patients with advanced NSCLC, while FDR infusion was associated with more grade 3/4 hematological and non-hematological toxicities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "neerajombiotech@gmail.com  Gemcitabine (2', 2'-difluorodeoxycytidine) is a deoxycytidine analog with significant antitumor activity against variety of cancers including NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In addition, gemcitabine is also commonly used for the management of breast, ovarian, and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " [Gemcitabine combined with vinorelbine in the treatment of refractory patients with advanced NSCLC: a multi-center retrospective study]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "lushun1964@hotmail.com  BACKGROUND: The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN as second-line or further-line treatment) in refractory advanced NSCLC patients in China. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Even if most studies in NSCLC yielded contradictory results, several potential biomarkers for sensitivity/resistance to platinum compounds, gemcitabine, taxanes and pemetrexed have been proposed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Ectopic expression of DSP in the NSCLC cell line H157 significantly inhibited cell proliferation, anchorage-independent growth, migration and invasion and also increased the sensitivity of NSCLC cells to apoptosis induced by an anticancer drug, gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The level of ribonucleotide reductase subunit M1 (RRM1) expression is closely related to the efficacy of gemcitabine on NSCLC and pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "skatsenos@yahoo.gr  Gemcitabine, alone or in combination with a platinum-based agent, is indicated for the first-line treatment of patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Herein, we report a patient with advanced NSCLC who experienced severe peripheral edema after gemcitabine administration. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This multicentre study addressed whether the addition of low dose gemcitabine to radical radiotherapy improved 2 year event-free survival in patients with medically inoperable stages I-II NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "AIM: To determine whether low dose gemcitabine increased event-free survival in patients with T1-2 N0-1 M0 NSCLC deemed unfit for surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Patients with T1-2 N0-1 M0 NSCLC deemed unfit for surgery were randomised to 3D conformal radiotherapy delivering 55 Gy in 20 fractions over 4 weeks to known sites of cancer with (Arm B) or without (Arm A) 100mg/m(2) weekly gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: No evidence of an improvement in event-free survival was seen with the addition of weekly gemcitabine at this dose for patients with early stage NSCLC unfit for surgery, although the power of the study was low. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " [Efficacy of gemcitabine and vinorelbine in first-line treatment with advanced NSCLC: a multicentre retrospective study]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN) in advanced NSCLC first-line treatment in China. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in NSCLC patients treated with gemcitabine/platinum. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "We evaluated whether single nucleotide polymorphisms of DN- repair genes excision repair cross-complementing group 1 (ERCC1), ERCC2, x-ray repair cross-complementing group 1 (XRCC1), XRCC3, and RRM1 associate with treatment outcome in NSCLC patients receiving gemcitabine plus platinum as their first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "METHODS: Genotyping for eight polymorphisms in five DNA-repair genes was performed with the GenomeLab nucleotide polymorphismstream Genotyping System in 62 advanced NSCLC patients in a training set and 45 patients in a validation set treated with gemcitabine/platinum. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "In the validation set, only XRCC1 399 CONCLUSIONS: Genetic polymorphism of XRCC1 Arg399Gln may be a candidate for contributing interindividual difference in the OS of gemcitabine/platinum-treated advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " We assessed the prognostic and predictive value of \u03b2-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 NSCLC specimens from early-stage patients who received neoadjuvant chemotherapy (paclitaxel- or gemcitabine-based) in a phase III trial (IFCT-0002). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced NSCLC patients treated with gemcitabine plus platinum. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The aim of this study was to evaluate whether the T393C polymorphism of the GNAS1 gene could be used as a chemotherapy sensitivity and prognosis predictive marker of advanced NSCLC treated with gemcitabine plus platinum (GP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CASE REPORT: A 78 year old man with NSCLC developed uremic syndrome following treatment with multiple chemotherapy agents including gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Gemcitabine is one of the most widely used drugs for the treatment of NSCLC, and several phase II trials specifically designed for elderly patients with advanced NSCLC have confirmed the role of gemcitabine in this setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Therefore, we performed a phase II study using the combination of gemcitabine and UFT as first-line therapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: The combination of gemcitabine and UFT was effective in disease control and well tolerated first-line regimen in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Gemcitabine metabolic pathway genetic polymorphisms and response in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " BACKGROUND AND OBJECTIVE: Gemcitabine is widely used to treat NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "The aim of this study was to assess the pharmacogenomic effects of the entire gemcitabine metabolic pathway, we genotyped single nucleotide polymorphisms (SNPs) within the 17 pathway genes using DNA samples from patients with NSCLC treated with gemcitabine to determine the effect of genetic variants within gemcitabine pathway genes on overall survival (OS) of patients with NSCLC after treatment of gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Functional studies demonstrated that downregulation of SLC29A1, NT5C2, and RRM1 in NSCLC cell lines altered cell susceptibility to gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSION: These studies help in identifying biomarkers to predict gemcitabine response in NSCLC, a step toward the individualized chemotherapy of lung cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced NSCLC: a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "This meta-analysis is performed to systematically evaluate whether RRM1 expression is associated with the clinical outcome of gemcitabine-containing regimen in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "A systemic review of the studies on the association between RRM1 expression in advanced NSCLC and clinical outcome of gemcitabine-containing regimen was performed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "CONCLUSIONS: Low/negative RRM1 expression in advanced NSCLC was associated with higher response rate to gemcitabine-containing regimen and better prognosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "Large phase III randomized trials are required to identify whether RRM1 detection is clinically valuable for predicting the prognosis and sensitivity to gemcitabine-containing regimen in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": " Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gemcitabine", "orig_sen": "tiby@katamail.com  BACKGROUND: The aim of this study was to evaluate whether cytidine deaminase (CDA) polymorphisms 79A>C and 435C>T and/or CDA enzymatic activity influenced clinical outcome in 126 advanced NSCLC patients treated with gemcitabine-platinum-regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "bavituximab", "orig_sen": " Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "bavituximab", "orig_sen": "In this phase II trial the efficacy and safety of bavituximab combined with docetaxel for previously treated, advanced nonsquamous NSCLC were evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "bavituximab", "orig_sen": " Bavituximab is a chimeric monoclonal antibody with immune modulating and tumor-associated vascular disrupting properties demonstrated in models of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "bavituximab", "orig_sen": "We evaluated the tumor-targeting properties of Bavituximab for imaging of NSCLC xenografts when radiolabeled with (111)In through conjugation with a bifunctional chelating agent, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "bavituximab", "orig_sen": " Bavituximab plus paclitaxel and carboplatin for the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "bavituximab", "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "bavituximab", "orig_sen": "CONCLUSION: Bavituximab in combination with paclitaxel-carboplatin as first-line therapy demonstrated a tolerable safety profile and potential efficacy in this single-arm phase II trial in patients with advanced local or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Gefitinib, erlotinib and afatinib provide remarkable response rates and progression-free survival compared to platinum-based chemotherapy in patients with NSCLC harboring epidermal growth factor receptor-activating mutations, and are therefore standard first-line treatment in these patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "FINDINGS: Of the 1006 patients diagnosed with stage IIIb and IV NSCLC in the study period, 448 (44.5%) had EGFR-activating mutations and received first-line therapy with gefitinib (n = 304, 67.6%), erlotinib (n = 63, 14.3%), or afatinib (n = 81, 18.1%). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "INTERPRETATION: Afatinib and erlotinib provide significant benefits in progression-free survival compared to gefitinib in first-line treatment of patients with NSCLCs harboring EGFR-activating mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "[Epub ahead of print]  A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced NSCLC (KCSG LU12-01). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced NSCLC after platinum-based chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than gefitinib alone as a second-line treatment of advanced NSCLC (NCT01498562). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " EGFR and K-RAS mutations and ERCC1, TUBB3, TYMS, RRM1 and EGFR mRNA expression in NSCLC: Correlation with clinical response to gefitinib or chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Among these 52 NSCLC patients, there were 14 patients treated with gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "This is the first randomized clinical trial that showed a significant and clinical meaningful OS benefit in EGFR mutation-positive NSCLC patients following maintenance therapy with gefitinib as compared to placebo. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of NSCLC: a systematic review. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced NSCLC-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We evaluated the efficacy of second-line platinum-based chemotherapy after gefitinib for advanced NSCLCs harboring epidermal growth factor receptor mutations (the NEJ002 study). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: Seventy-one NSCLCs, treated with gefitinib as first-line therapy and then receiving platinum-based chemotherapy as second-line therapy were evaluated in NEJ002. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Gefitinib has been investigated in combination with radiotherapy for unresectable stage III NSCLC, but results in maintenance treatment after chemoradiotherapy were not encouraging. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVE: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced NSCLC, who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The aim of this study was to determine the response of advanced-stage NSCLC patients with or without EGFR mutations to platinum-based chemotherapy with or without gefitinib maintenance. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The results indicate that patients with advanced-stage NSCLC with EGFR mutations have a\u00a0better response to chemotherapy followed by gefitinib than chemotherapy alone and a\u00a0better response to chemotherapy than wild-type patients.KEYWORDS: chemotherapy, gefitinib, NSCLC, tyrosine kinase inhibitors. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "However, first-line gefitinib should not be recommended for advanced NSCLC patients only based on clinical factors, due to a very small sample-size in our study. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring wild-type epidermal growth factor receptor (EGFR). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Clinical trials have demonstrated that the response to icotinib among advanced NSCLC patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Economic outcomes of maintenance gefitinib for locally advanced/metastatic NSCLC with unknown EGFR mutations: a semi-Markov model analysis. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Maintenance gefitinib significantly prolonged progression-free survival (PFS) compared with placebo in patients from eastern Asian with locally advanced/metastatic NSCLC after four chemotherapeutic cycles (21 days per cycle) of first-line platinum-based combination chemotherapy without disease progression. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The objective of the current study was to evaluate the cost-effectiveness of maintenance gefitinib therapy after four chemotherapeutic cycle's stand first-line platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC with unknown EGFR mutations, from a Chinese health care system perspective. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Maintenance gefitinib following first-line platinum-based chemotherapy for patients with locally advanced/metastatic NSCLC with unknown EGFR mutations is not cost-effective. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Post-progression survival in patients with NSCLC with clinically acquired resistance to gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We retrospectively reviewed 81 advanced NSCLC patients with disease progression following tumor response and durable (\u2265 6 months) disease stabilization with first-line or second-line gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Icotinib versus gefitinib in previously treated advanced NSCLC (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We aimed to investigate whether icotinib is non-inferior to gefitinib in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Chemotherapy with platinum agents is the standard of care for NSCLC; however, novel molecular-targeted agents like gefitinib have been approved for advanced NSCLCs, including recurrent cases previously treated with platinum-based chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Disease progression remains the major challenge in the management of advanced (stage IIIb or IV) NSCLC after the failure of first-line or second-line chemotherapy, or even of targeted therapies such as gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The current study evaluated the tolerability and efficacy of stereotactic body radiation therapy (SBRT) in combined with gefitinib as a second-line or third-line treatment in patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: The SBRT combined with gefitinib is a promising treatment strategy for advanced (stage IIIb or IV) NSCLC after the failure of previously chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Patients with advanced NSCLC and somatic activating mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene represent a biologically distinct disease entity that shows exquisite sensitivity to the reversible EGFR-TK inhibitors (-TKIs) gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Phase II trial of gefitinib in pretreated Chinese women with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " A phase II clinical trial was performed to evaluate the efficacy and safety of gefitinib on pretreated Chinese female NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Gefitinib is a highly effective and well-tolerated agent for Chinese women with pretreated advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: Gefitinib is an effective first-line chemotherapy for advanced NSCLC patients harboring sensitive EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Therefore, we here aimed to investigate the efficacy of platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS/PATIENTS: We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations was effective and showed equivalent outcomes to first-line platinum combination chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced NSCLC with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant NSCLCs (NSCLCs) remains unknown. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations, especially those with EGFR exon 19 deletion mutations, although the primary end point was not met because the lower limit of the CI was less than 40%. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The availability of antineoplastic monoclonal antibodies, small molecules and newer cytotoxics such as pemetrexed, the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as the anti-angiogenic bevacizumab and the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced NSCLC, and are currently approved for use in clinical practice. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "oliver.gautschi@luks.ch  BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced NSCLC who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-na\u00efve NSCLC in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Cost-effectiveness analysis of EGFR mutation testing in patients with NSCLC with gefitinib or carboplatin-paclitaxel. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVES: The combination use of gefitinib and epidermal growth factor receptor (EGFR) testing is a standard first-line therapy for patients with non-small cell lung cancer (NSCLC). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: NSCLC patients with a smoking history or the EGFR L858R mutation may demonstrate a poorer response to gefitinib treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated NSCLC with sensitive EGFR mutations: NEJ005/TCOG0902. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced NSCLC patients with activating epidermal growth factor receptor mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for advanced NSCLC in patients with activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "This was a multicentre, single-arm, phase II trial of carboplatin, S-1, and gefitinib in advanced NSCLC patients with activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Combination chemotherapy with carboplatin, S-1, and gefitinib is efficacious and well tolerated as a first-line treatment in advanced NSCLC patients with activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous NSCLC: a randomised, phase 3 trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 NSCLC harbouring EGFR mutations: a randomized, phase II study. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: The administration of gefitinib following PC adjuvant therapy shows significant improvement in DFS in patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Phase II trial of paclitaxel-carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: This study was conducted to evaluate the efficacy and safety of paclitaxel-carboplatin combined with intercalated gefitinib in patients with advanced, untreated, nonsquamous NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Effectiveness of gefitinib against NSCLC with the uncommon EGFR mutations G719X and L861Q. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: The post-hoc analyses clearly demonstrated shorter survival for gefitinib-treated patients with uncommon EGFR mutations compared with the survival of those with common mutations and suggest that the first-line chemotherapy may be relatively effective for NSCLC with uncommon EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: The Iressa Alliance program provided standardized EGFR mutation testing and appropriate access to gefitinib to all patients in British Columbia with advanced, non squamous NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Tumor response and health-related quality of life in clinically selected patients from Asia with advanced NSCLC treated with first-line gefitinib: post hoc analyses from the IPASS study. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Thus, low-dose erlotinib may be effective and well tolerated by patients with NSCLC harboring EGFR mutations who are intolerant to gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na\u00efve NSCLC with sensitive EGFR gene mutations (NEJ002). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "akinoue@idac.tohoku.ac.jp  BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced NSCLC harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced NSCLC patients with an activating mutation in the epidermal growth factor receptor (EGFR). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: In the Dutch health care setting, the previously established progression free survival benefit of first-line gefitinib in advanced NSCLC EGFR M+ patients in comparison to standard doublet chemotherapy is further supported by the Quality Adjusted PFS, which takes into account the additional health-related quality of life benefits of gefitinib over doublet chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced NSCLC: evaluation of patients recruited from mainland China. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: For NSCLC patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: QoL was maintained much longer in patients treated with gefitinib than in patients treated with standard chemotherapy, indicating that gefitinib should be considered as the standard first-line therapy for advanced EGFR-mutated NSCLC in spite of no survival advantage. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "[Epub ahead of print]  Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced NSCLC in China. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "[Epub ahead of print]  A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous NSCLC: Quality of Life Results From a Randomized Phase III Trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous NSCLC (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "These LCSS outcomes provide further evidence that patients with wild-type EGFR might not benefit from first-line treatment of advanced NSCLC with gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous NSCLC: Final Overall Survival Results from a Randomized Phase 3 Study. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous NSCLC and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Curative effect analysis of different treatments for gefitinib-resistance advanced NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVE: Gefitinib is effective epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) for advanced NSCLC patients, but with the drug use, inevitable gefitinib-resistance and severe complications were observed and resulted in failure treatments. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: Total Of 120 patients acquired gefitinib-resistance NSCLC patients treated in Taian City Central Hospital of Shandong province from May, 2010 to June, 2014 were incorporated in our study according to the inclusion and exclusion criteria. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous NSCLC: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Patients, who were \u2265 18 years, chemona\u00efve, Korean, light ex-smokers/never-smokers with advanced NSCLC, were randomly assigned (1:1) to PC/G or gefitinib monotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Our results confirm that both PC/G and gefitinib were well tolerated in Korean patients, regardless of EGFR status; however, patients with EGFR wild-type NSCLC may not benefit from gefitinib monotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced NSCLC: The LOGIK0902/OLCSG0905 Intergroup Study Protocol. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive NSCLC after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Eligible patients were aged at least 18 years with histologically confirmed, chemotherapy-naive, stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has already been recommended as a first-line treatment in EGFR-mutant metastatic NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We report rare presentation of TEN involving adverse effects of AP and gefitinib combination treatment in a 42-year-old woman diagnosed with metastatic NSCLC harboring an EGFR mutation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The purpose of this study is to compare the efficacy and safety of Gefitinib versus VMP in combination with three-dimensional conformal radiotherapy (3D-CRT) for multiple brain metastases from NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "A total of 73 NSCLC patients with brain metastases from January 2010 to August 2013 were randomly divided into Gefitinib group (37 patients) and VMP chemotherapy group (36 patients). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Both oral Gefitinib and systemic VMP chemotherapy in combination with three-dimensional conformal radiotherapy (3D-CRT) could be used to treat brain metastases from NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "All together, our finding implicated that Gefitinib is an effective method for patients with brain metastases from NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "For exploring the mechanism of the failed combination therapy in lung cancer, in the present study, four therapy assessment groups, including a control group, a chemotherapy group [paclitaxel+cisplatin (TP)], a gefitinib monotherapy group (G) and a combination group[paclitaxel+cisplatin+gefitinib (TP+G)], were established in an A549 cell line and mouse xenotransplanted tumor models.By HPLC, we found that the gefitinib concentration was significantly higher in the combination group when compared to that in the G group in the NSCLC cell line, A549 (p<0.05). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in NSCLC: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Gefitinib-treated EGFR-TKI-sensitive NSCLC cells showed a wide spectrum of chemo-refractoriness, suggesting that concomitantly combined EGFR-TKI-chemotherapy might not be a good treatment strategy for NSCLC harboring SEM. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human NSCLC cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "However, whether Ori can be used in gefitinib-resistant NSCLC cells remains unclear. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Results demonstrated that this compound dose-dependently inhibited the proliferation, invasion, and migration of the gefitinib-resistant NSCLC cells in\u00a0vitro. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In addition, Ori upregulated protein phosphatase 2A (PP2A) activity of gefitinib-resistant NSCLC cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "These findings indicated that Ori can inhibit the proliferation, invasion, and migration of gefitinib-resistant NSCLC cells by suppressing EGFR/ERK/MMP-12 and CIP2A/PP2A/Akt signaling pathways. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Thus, Ori may be a novel effective candidate to treat gefitinib-resistant NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic NSCLC: evaluation of drug-drug interaction. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: Docetaxel and gefitinib play key roles in the treatment of NSCLC, and their combination could be of interest. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Erlotinib and gefitinib for treating NSCLC that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Randomized phase II study of gefitinib versus erlotinib in patients with advanced NSCLC who failed previous chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In EGFR unknown patients, nine trials (INTEREST, IRESSA as Second-line Therapy in Advanced NSCLC - KoreA, Li, Second-line Indication of Gefitinib in NSCLC, V-15-32, ISEL, DELTA, TITAN and BR.21) reported overall survival data and only one (BR.21) reported a statistically significant result favouring the use of erlotinib over BSC (HR 0.7, 95% CI 0.58 to 0.85). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced NSCLC and a poor performance status (IFCT-0301). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Sequence-dependent antiproliferative effects of gefitinib and docetaxel on NSCLC cells and the possible mechanism. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The discovery of a number of lung cancer-molecular alterations contributes to uniquely targeted therapies with specific inhibitors for NSCLC such as erlotinib, gefitinib and crizotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "V1801, an analog of gefitinib may overcome gefitinib resistance in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Our research aimed at exploring the cytotoxic interactions between gefitinib and docetaxel with different concentrations for NSCLC cell lines, and furthermore, the mechanisms underlying the cytotoxic synergism. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human NSCLC cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR-TKI-sensitive cells and antagonistic effects in EGFR-TKI-primary and acquired resistant cells, suggesting that EGFR-TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "mmajem@santpau.cat  Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced NSCLC patients with disease progression. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib enhances cytotoxicities of antimicrotubule agents in NSCLC cells exhibiting no sensitizing epidermal growth factor receptor mutation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced NSCLC from Thai payer perspective. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " AIM: To evaluate the cost utility and budget impact of second-line gefitinib for NSCLC from a Thai payer perspective. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: \u2003 Gefitinib is a dominant cost saving strategy compared with docetaxel for the second-line treatment of advanced NSCLC from the Thai payer perspective. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as Gefitinib and Erlotinib, are effective clinical medicines for advanced NSCLC patients harboring EGFR-activating mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "SKLB-178 potently inhibited cancer cell growth in both Gefitinib-sensitive and resistant NSCLC cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Erlotinib seemed more effective than gefitinib in prolonging survival in leptomeningeal carcinomatosis from EGFR mutation-positive NSCLC and may be particularly beneficial in patients with EGFR exon 19 mutations, warranting further studies. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "[Epub ahead of print]  Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib and afatinib in advanced EGFR-mutated NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced epidermal growth factor receptor (EGFR) mutated NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We retrospectively reviewed 922 consecutive patients with EGFR-mutant NSCLC patients administered with gefitinib/erlotinib at Guangdong General Hospital. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in NSCLC harboring EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first-line treatments for advanced EGFR mutation-positive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in NSCLC patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: A retrospective database analysis of 157 patients given erlotinib or gefitinib for EGFR-mutant advanced NSCLC from two institutions was conducted. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The epidermal growth factor receptor (EGFR) mutant NSCLCs frequently respond to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) treatment, such as Gefitinib and Erlotinib, but the development of acquired resistance limits the utility. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In this work, an in vitro study was designed using EGFR inhibitor (Gefitinib), IGF-1R inhibitor (NVP-AEW541), and miRNA mimics in two Gefitinib-resistant NSCLC cell lines, H460 and H1975. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive NSCLC just after progression on EGFR-TKI, gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "This review discusses the latest updates in molecular testing at progression and outlines treatment options for this difficult-to-treat population.IMPLICATIONS FOR PRACTICE: Although the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-gefitinib, erlotinib, and afatinib-have changed the treatment paradigm for NSCLC among those with EGFR mutation-positive disease, most patients experience progression after approximately 12 months of treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced NSCLC patients with secondary drug resistance: A single center, single arm, phase II clinical trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced NSCLC with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who had experienced drug resistance after one year of conventional treatment with gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Patients with advanced epidermal growth factor receptor (EGFR) mutant NSCLC are particularly sensitive to treatment with first- or second-generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell-signaling pathways that drive the growth of tumor cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Successful treatment of NSCLC with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MEDLINE, PubMed, Cochrane, and Google Scholar databases were searched until October 21, 2015 using the following search terms: lung neoplasms/lung cancer/NSCLC/NSCLC, EGFR, gene amplification, copy number, erlotinib, gefitinib, tyrosine-kinase inhibitor/TKI, predictor. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: The emergence of EGFR-inhibitors such as gefitinib, erlotinib and osimertinib has provided novel treatment opportunities in EGFR-driven NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Currently, the first-generation EGFR/HER-TKIs gefitinib and erlotinib and second-generation EGFR/HER-TKI afatinib have been approved for use as the first-line treatment of metastatic NSCLC with actEGFRm. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: This study was a pre-planned exploratory analysis of a randomized phase III trial conducted from 2009 to 2014 comparing erlotinib with gefitinib in advanced NSCLC harboring EGFR mutations in tumor (CTONG0901). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: The analysis included fifty two NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs): erlotinib or gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, are one of the representatives of targeted therapy which have been widely used in first line, maintenance and 2nd/3rd line therapy among advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In this study, we utilized Dichloroacetate (DCA), a widely regarded PDK inhibitor, together with Erlotinib and Gefitinib, two well-known EGFR inhibitors, and demonstrated that the applications of DCA in combination with either Erlotinib or Gefitinib significantly attenuated the viability of EGFR mutant NSCLC cells (NCI-H1975 and NCI-H1650) in a synergistic manner. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We evaluated the efficacy of first-generation EGFR-tyrosine kinase inhibitors (TKIs; erlotinib, gefitinib, and icotinib) in patients with NSCLC carrying insertions and T790M and S768I mutations in EGFR exon 20. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Afatinib, together with gefitinib and erlotinib, is approved for first-line treatment of advanced NSCLC with activating mutations of the epidermal growth factor receptor (EGFR). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Methods The study comprised a 3\u00a0+\u00a03 dose-escalation part for LY2875358 monotherapy in patients with advanced malignancies (Part A) followed by an assessment of LY2875358 in combination with erlotinib or gefitinib in patients with NSCLC (Part B). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " EGFR-targeted inhibitors (gefitinib and erlotinib) provided an effective strategy for the treatment of NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have greatly improved treatment efficacy in NSCLC patients with drug-sensitive EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Importantly, we show here that the Src family inhibitor, dasatinib, dramatically inhibits cell adhesion-related response and greatly enhances the cell-killing effects of EGFR TKI (gefitinib for the PC9 cells; afatinib for the H1975 cells) in NSCLC cells, which would otherwise escape the TKI-induced apoptosis. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Safety of gefitinib in NSCLC treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "EXPERT OPINION: Gefitinib is a well-tolerated treatment for advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Hence, despite being the earliest EGFR TKI developed, gefitinib continues to be one of the first-line treatments for advanced EGFR-mutated NSCLC, especially when skin and gastrointestinal toxicity is a concern. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Low activity of poziotinib was detected in patients with EGFR-mutant NSCLC who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib and erlotinib target the ATP cleft in the tyrosine kinase EGFR, which is overexpressed in 40-80 percent of NSCLC and many other epithelial cancers. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We previously established a new gefitinib-resistant NSCLC cell line, HCC827GR, which harbors the T790M mutation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "These findings suggest that multilayered crosstalk between G-protein coupled receptors (GPCRs) and EGFR may play an important role in regulating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Our study indicates that AS treatment may not compromise TKI efficacy (gefitinib or erlotinib) in NSCLC patients with mutated EGFR. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive NSCLC, receiving treatment with gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Safe and successful treatment with afatinib in three postoperative NSCLC patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Gefitinib and/or erlotinib-induced hepatotoxicity sometimes lead to treatment failure in EGFR mutation-positive patients with NSCLC, even though the therapeutic effect is evident. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CASES: Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from NSCLC: A Meta-Analysis. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of NSCLC led to tremendous development of novel EGFR inhibitors in the last decade. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We recruited 226 Chinese advanced NSCLC patients who received TKIs erlotinib, gefitinib and icotinib hydrochloride and systematically studied the genetic factors associated with therapeutic responses and ADRs. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and\u00a0Gefitinib in Patients With Advanced NSCLC Harboring EGFR\u00a0Mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: From 2008 to 2011, 130 consecutive patients with advanced NSCLC harboring EGFR mutations were treated with either erlotinib or gefitinib at our institution. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Concurrent use of AS did not affect the efficacy or toxicity of erlotinib and gefitinib in patients with advanced NSCLC harboring EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Afatinib is a second-generation epidermal growth factor receptor (EGFR) inhibitor that has been shown to be effective against EGFR-mutated NSCLC resistant to conventional EGFR inhibitors such as gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIAL AND METHODS: We retrospectively analyzed all NSCLC patients with EGFR-TKI (gefitinib or erlotinib) treatment at our institution between 2011 and 2013 who progressed after at least stable disease on erlotinib or gefitinib for more than 6 months. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " NSCLC patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " NSCLC with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, but responds to the ALK-TKI crizotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " RATIONALE AND OBJECTIVES: The aims of this study were to investigate the association between 8-week tumor volume decrease and survival in an independent cohort of epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, and to assess the rate of their volumetric tumor growth after the volume nadir. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, computed tomography (CT) tumor volumes of dominant lung lesions were analyzed for (1) the association with survival, and (2) the volumetric tumor growth rate after the volume nadir. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed 151 patients who had NSCLC harboring EGFR mutations and had received either gefitinib or erlotinib as first-line treatment between 2005 and 2014. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in NSCLC patients harboring an active EGFR mutation following gefitinib therapy failure. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Seven NSCLC patients harboring activating EGFR mutations who had developed LM during or after therapy with gefitinib, an EGFR TKI, were retrospectively analyzed. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus nimotuzumab (N) in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Combination treatment of afatinib and nimotuzumab demonstrated an acceptable safety profile and encouraging antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Afatinib beyond progression in patients with NSCLC following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Afatinib has demonstrated clinical benefit in patients with NSCLC progressing after treatment with erlotinib/gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) mutations in NSCLC patients are associated with sensitivity to small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: From 2008 to 2012, 160 consecutive patients with advanced NSCLC harboring an EGFR mutation were treated with EGFR-TKIs (erlotinib or gefitinib). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Although afatinib has been shown to be effective in the treatment for erlotinib-refractory and/or gefitinib-refractory central nervous system metastases from NSCLC, little is known about the efficacy of erlotinib for afatinib-refractory central nervous system metastases. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Effect of smoking status on progression-free and overall survival in NSCLC patients receiving erlotinib or gefitinib: a meta-analysis. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "WHAT IS NEW AND CONCLUSION: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " [Gefitinib therapy in advanced NSCLC in patients with EGFR mutations: cost-effectiveness analysis]. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Risk of elevated transaminases in NSCLC patients treated with erlotinib, gefitinib and afatinib: a meta-analysis. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " This meta-analysis has been conducted to determine the risk of elevated transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Clinical efficacy of erlotinib, a salvage treatment for NSCLC patients following gefitinib failure. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in NSCLC patients following gefitinib failure. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National University Hospital between August 2005 and November 2011 were enrolled. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Results from another large-scale randomized trial (ARCHER 1050) comparing dacomitinib to gefitinib as first-line treatment of advanced treatment-na\u00efve EGFR-mutant NSCLC patients will soon be available and will serve as the lynchpin trial for the potential approval of dacomitinib in NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Given the rapid development of third-generation EGFR TKIs and the approval of gefitinib, erlotinib, and afatinib as first-line treatment of EGFR-mutant NSCLC patients, the future role of dacomitinib in the treatment of NSCLC seems to be limited. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "gefitinib, erlotinib, afatinib) in patients with NSCLC harboring EGFR mutations reach 60-80%, with a complete response rate as high as 40%. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " [An Elderly Patient with NSCLC Who Responded to Salvage S-1 Monotherapy after Gefitinib Therapy]. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We report of an elderly patient with NSCLC who responded to S-1 monotherapy following gefitinib therapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Gefitinib following S-1 monotherapy resulted in long-term tumor size control for a total of 27 months in an elderly patient with advanced NSCLC.S -1 monotherapy might be one of the options for salvage therapy after gefitinib treatment becomes ineffective. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Successful treatment of NSCLC with gefitinib after erlotinib-induced severe eyelid erosion: Two case reports. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " NSCLC patients whose tumors have an EGFR-activating mutation develop acquired resistance after a median of 9-11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " In NSCLC patients, the activation of alternative pathways contributes to the limited efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The present study examines a panel of EGFR wild-type, K-Ras mutated, NSCLC lines, which were all intrinsically resistant to EGFR-TKIs, and demonstrates that the histone deacetylase inhibitor vorinostat can improve the therapeutic efficacy of gefitinib or erlotinib, inducing strong synergistic antiproliferative and pro-apoptotic effects that are paralleled by reactive oxygen species accumulation and by increased DNA damage. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Multi-SNP analyses were performed in 60 patients with EGFR-mutated NSCLC using blood samples obtained prior to starting treatment with gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib had undergone turbulent clinical development until it was discovered that these agents have preferential activity in patients with NSCLC harboring activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "After ten years from the individuation of activating mutations in the tyrosine kinase domain of the EGFR in NSCLC patients responding to the EGFR tyrosine kinase inhibitor (TKI) Gefitinib, several progresses have been done and first line treatment with EGFR TKIs is a firmly established option in advanced EGFR-mutated NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The aim of this paper is to provide a comprehensive review of the major progresses reported so far in the EGFR inhibition in this molecularly-selected subgroup of NSCLC patients, from the early successes with first generation EGFR TKIs, Erlotinib and Gefitinib, to the novel irreversible and mutant-selective inhibitors and ultimately the emerging challenges that we, in the next future, are called to deal with. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in NSCLC patients with activating mutations of the epidermal growth factor receptor (EGFR) gene. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVE: To evaluate the efficacy of whole brain radiotherapy (WBRT) or/and stereotactic radiotherapy (SRT) concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (TKI), like erlotinib and gefitinib, in the treatment of brain metastases from NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for NSCLC patients with activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " RATIONALE, AIMS AND OBJECTIVES: Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefits to advanced stage NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " NSCLC patients with an epidermal growth factor receptor (EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Multiple mutations in the EGFR gene are a major cause for the failure of Erlotinib and Gefitinib in the treatment of patients harboring NSCLC who initially responded to this therapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced NSCLC treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Notably, heregulin was upregulated in tissue samples from an NSCLC patient who had an activating EGFR mutation but was resistant to the TKI gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Activating mutations in exons 19 or 21 of EGFR in NSCLC are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Gefitinib was stopped and the patient died 1 month later of progressive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The presence of activating gene mutations in the epidermal growth factor receptor of NSCLC patients is predictive (improved progression-free survival and improved response rate) when treated with small molecule tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant NSCLC Cells by Inducing Apoptosis. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Therapeutic approach by treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib or erlotinib to NSCLC patients has been limited due to emergence of acquired drug resistance. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: The anticancer effect of USP8 inhibitor was determined by testing anchorage-dependent or independent growth of gefitinib-sensitive or resistant NSCLCs. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "RESULTS: Inhibition of USP8 induced overall degradation of oncogenic receptor tyrosine kinases including EGFR and Met, leading to a suppression of anchorage-dependent or independent cell growth of gefitinib-sensitive or resistant NSCLCs. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Inhibition of USP8 could be an effective strategy for overcoming gefitinib resistance in NSCLCs. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The clinical effectiveness of EGFR targeted therapies, including small molecules directed against the kinase domain such as gefitinib, erlotinib and afatinib, have been proven successful in treating NSCLC patients with tumors harboring EGFR kinase domain mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " [Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive NSCLC]. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVE: To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " We performed a meta-analysis of fatal pulmonary events associated with erlotinib, gefitinib or afatinib in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Our meta-analysis has demonstrated that erlotinib, gefitinib and afatinib are associated with an increased risk of high-grade interstitial lung disease in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We analyzed data from 21 NSCLC patients aged \u2265 80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib and erlotinib in metastatic NSCLC: a meta-analysis of toxicity and efficacy of randomized clinical trials. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The objective of this study was to compare the efficacy and toxicity of erlotinib, gefitinib, and afatinib in NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Gefitinib has similar activity and toxicity compared with erlotinib and offers a valuable alternative to patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "One of the best known examples of personalized therapy is the use of tyrosine kinase inhibitors, such as gefitinib and erlotinib, for the successful treatment of NSCLC patients selected based on the specific EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVES: Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) - afatinib, erlotinib, and gefitinib - are available for the treatment of patients with EGFR mutation-positive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: We performed a pooled analysis of severe AEs according to the type of EGFR-TKI administered with the use of data extracted from prospective clinical trials that evaluated the clinical efficacy of gefitinib, erlotinib, or afatinib in NSCLC patients with EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: Eight patients diagnosed with NSCLC (three men and five women with an average age of 69.3 years) who were initiated on treatment with EGFR inhibitors (either gefitinib [Iressa(\u00ae)] or erlotinib [Tarceva(\u00ae)]) were enrolled. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Mutations in the epidermal growth factor receptor (EGFR) gene are associated with a favorable clinical response to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib in NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The FDA-approved small-molecule inhibitors of EGFR, gefitinib (Iressa) and erlotinib (Tarceva), are clinically effective in a subset of patients with NSCLC whose tumors harbor activating mutations within the kinase domain of EGFR. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced NSCLC refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "FINDINGS: New targeted therapies for molecularly selected NSCLC are changing the natural history of the disease, with results superior to standard chemotherapy as demonstrated in large phase III studies with first generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: EGFR mutation might be a predictive factor for applying EGFR-tyrosine kinase inhibitors (EGFR-TKIs, including gefitinib, erlotinib and afatinib) in NSCLC (NSCLS) patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Erlotinib usage after prior treatment with gefitinib in advanced NSCLC: A clinical perspective and review of published literature. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Erlotinib and gefitinib are among the most widely researched, used and available molecularly targeted therapies for treatment of advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In the past decade, there have been reports on clinical benefit from use of erlotinib after gefitinib failure in NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Patients with EGFR-mutant NSCLC generally have a progression-free survival of 9-13 months while being treated with the EGFR tyrosine-kinase inhibitors gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: To evaluate the efficacy and safety of alternating gefitinib and erlotinib, tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), with chemotherapy in NSCLC patients with acquired TKI resistance. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced NSCLC, but the median survival of patients is short. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "[Epub ahead of print]  Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced NSCLC receiving first-line gefitinib or erlotinib treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Other studies indicated that afatinib may offer advantages over standard chemotherapy for NSCLC in terms of enhanced symptom control and quality of life and is modestly effective in cases involving EGFRT790M-related acquired resistance to the TKIs erlotinib and gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced NSCLC in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858R. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Here we show miR-200c overexpression was correlated with the epithelial phenotype and sensitivity to gefitinib in EGFR wild-type NSCLC cell lines. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "NSCLC patients at advanced stage (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Targeted drugs aimed at driver gene, such as Gefitinib, Erlotinib and Crizotinib, have an irreplaceable position in the therapy of advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clinical benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Experience with afatinib in patients with NSCLC progressing after clinical benefit from gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Lifestyle risks exposure and response predictor of gefitinib in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The association of CFE, smoking history, occupational hazard exposure, tumor pathological type, EGFR mutation status, environmental exposure, living environment, and performance status with EGFR-TKI efficacy was determined in metastatic NSCLC patients who were treated with EGFR-TKIs (gefitinib or erlotinib). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In addition, compound 1 potentiated the activity of erlotinib and gefitinib in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)-resistant NSCLC cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Gefitinib and erlotinib, two reversible EGFR receptor tyrosine kinases inhibitors (TKIs), have been approved for the treatment of patients with metastatic NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Erlotinib is a well-tolerated alternate treatment for NSCLC in cases of gefitinib-induced hepatotoxicity. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " AIM: To evaluate the tolerability and efficacy of erlotinib treatment in advanced NSCLC patients who had previously experienced severe hepatotoxicity after gefitinib treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Twenty-five NSCLC patients with epidermal growth factor receptor (EGFR) mutation were initially treated with gefitinib (250 mg/day). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Erlotinib treatment was efficient and well-tolerated in NSCLC patients with EGFR mutation, despite their severe hepatotoxicity with prior gefitinib treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " With the successful use of gefitinib and erlotinib in clinic, some potent EGFR tyrosine kinase receptor inhibitors have gained widespread concern in the treatment of ovarian or NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are known to play a significant role in EGFR mutation-positive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "When an EGFR mutation is found, gefitinib and erlotinib have been shown to have significant roles in the treatment of untreated advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "This study reports an EGFR mutation in NSCLC treated with gefitinib and is notable due to the patient's marked improvement following a shorter than average duration of treatment with gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), has been approved in Japan for the treatment of patients with advanced NSCLC based on Phase II clinical trials since 2002. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In 2004, activating mutations in the EGFR gene were discovered to be a predictive biomarker for EGFR-TKI treatment, and gefitinib, which is not effective for patients with EGFR wild-type NSCLC, has since been used only in patients with EGFR-mutated NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Similar to gefitinib, erlotinib is also effective for EGFR-mutated NSCLC and has been used as an initial treatment for patients with advanced EGFR-mutated NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The results of this updated pooled analysis suggest a substantial clear PFS benefit of treating patients with EGFR mutation-positive NSCLC with erlotinib or gefitinib compared with chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for NSCLC patients whose tumors harbor activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: For the 2010-2013 period, the authors evaluated 158 patients diagnosed with advanced or metastatic NSCLC treated in first-, second-, or third-line with the EGFR-TKIs afatinib, erlotinib, or gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Two reversible EGFR TKIs (gefitinib, erlotinib) and the irreversible ErbB family blocker afatinib are currently approved for treatment of EGFR mutation-positive NSCLC, but no head-to-head trials have been reported to date. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Gefitinib and erlotinib are first-generation EGFR-tyrosine kinase inhibitors(EGFR-TKIs)that play a key role in activating EGFR-mutated NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The majority of NSCLC patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic NSCLC has not been widely investigated. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but what it is still unclear is the efficacy of (EFGR-TKIs: gefitinib or erlotinib) monotherapy in previously treated NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In December 2013, we performed a search in the PubMed, EMBASE, Cochrane library databases and Web of Science for randomized trials exploring the role of gefitinib or erlotinib in advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The first targeted agents approved for NSCLC treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "It is increasingly clear that there are molecularly distinct subtypes of various common cancers, with different therapeutic approaches required for each subtype, for example, the use of the monoclonal antibodies (trastuzumab and cetuximab) in HER2-positive breast cancer and wild-type KRAS colorectal cancer; tyrosine kinase inhibitors (imatinib, gefitinib, erlotinib and crizotinib) in chronic myeloid leukaemia, gastrointestinal stromal tumours and NSCLC and intracellular agents (vemurafenib and olaparib) in metastatic malignant melanoma and ovarian, breast and prostate cancer. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " INTRODUCTION: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared with chemotherapy as first-line therapies for patients with advanced NSCLC harboring epidermal growth factor receptor-activating mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "RESULTS: Literature search yielded eight randomized phase 3 clinical trials comparing gefitinib, erlotinib, or afatinib with chemotherapy as first-line therapy in patients with advanced NSCLC during the last 5 years. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "To clarify the role of EMT phenotype as a predictive marker for EGFR-TKI, we performed a retrospective study in 202 stage IV or recurrent NSCLC patients receiving gefitinib or erlotinib therapy from June 2008 to September 2012 in our institute. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib anderlotinib, which are epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs), have been usedfor the treatment of inoperable andrecurrent NSCLCpatients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Comparison of clinical outcomes following gefitinib and erlotinib treatment in NSCLC patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring EGFR mutations who had recurrent or metastatic NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: A total of 375 patients with recurrent or metastatic stage IIIB/IV NSCLC, who had either exon 19 deletion or the L858R mutation in exon 21, and had received either gefitinib (n = 228) or erlotinib (n = 147), were included in the study. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: In NSCLC patients harboring EGFR mutation, treatment with gefitinib and erlotinib resulted in similar effectiveness. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with NSCLC who were previously sensitive to erlotinib or gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Gefitinib and erlotinib are used to treat advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Between January 2008 and September 2009, we enrolled 50 patients with advanced NSCLC who had received one or more chemotherapy regimens, including gefitinib monotherapy to which they had partial responses (PR) or stable disease (SD). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The identification of activating EGFR gene mutations and the availability of effective target therapies such as gefitinib and erlotinib have radically changed the therapeutic approach and prognosis for patients with advanced EGFR-mutated NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: A total of 148 patients who had metastatic or recurrent NSCLC with activating EGFR mutation treated with either erlotinib or gefitinib as a first-line (n = 10) and a second-line or more treatment (n = 138) were retrospectively reviewed. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of NSCLCs (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small-molecule EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced NSCLC patient with EGFR mutation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Although NSCLC tumors with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib, development of acquired resistance is almost inevitable. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We demonstrated that addition of simvastatin to gefitinib enhanced caspase-dependent apoptosis in T790M mutant NSCLC cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "To determine the role of survivin in simvastatin-induced apoptosis of gefitinib-resistant NSCLC, we showed that the proportion of apoptotic cells following treatment with survivin siRNA and the gefitinib-simvastatin combination was greater than the theoretical additive effects, whereas survivin up-regulation could confer protection against gefitinib and simvastatin-induced apoptosis. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "EGFR-tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib are widely used in the treatment of NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced NSCLC harboring EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced NSCLC who harbor EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Small-molecule inhibitors of the EGF receptor's tyrosine kinase domain (TKIs), including gefitinib and erlotinib, have been widely used for treating NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive NSCLC treated with gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: In the study, there were 123 patients who were diagnosed with advanced NSCLC in Zhejiang Province Cancer Hospital between January 2009 to October 2012, all of who were received gefitinib and erlotinib therapy after failure to chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Risk of interstitial lung disease with gefitinib and erlotinib in advanced NSCLC: a systematic review and meta-analysis of clinical trials. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVES: Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) widely used in advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Eligible studies included randomized controlled trials with gefitinib and erlotinib in advanced NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Treatment with EGFR TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib in NSCLC-an old lesson new re-visited. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In addition, several large phase III clinical trials (e.g., INFORM trial) provided evidence that maintenance therapy with gefitinib also significantly improved PFS in NSCLC patients, with greatest PFS benefit in patients harboring EGF-R mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive NSCLC patients in Hong Kong. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVE: To compare the effectiveness and cost-effectiveness of erlotinib versus gefitinib as first-line treatment of epidermal growth factor receptor-activating mutation-positive NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In conclusion, erlotinib is cost-effective compared to gefitinib for first-line epidermal growth factor receptor-activating mutation-positive NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Fulvestrant increases gefitinib sensitivity in NSCLC cells by upregulating let-7c expression. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Patients with NSCLC who have activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), namely, gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In our previous study, we found that combined treatment with fulvestrant and gefitinib decreases the proliferation of H1975 NSCLC cells, compared to treatment with either fulvestrant or gefitinib alone; however, the molecular mechanism for the improved effects of the combination treatment are still unknown. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib and erlotinib for NSCLC patients who fail to respond to radiotherapy for brain metastases. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We evaluated erlotinib and gefitinib as salvage treatments for NSCLC patients with brain metastases that failed to respond to radiotherapy in a retrospective study. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The 103 NSCLC patients who were treated with gefitinib or erlotinib for salvage treatment for brain metastases between January 2005 and December 2011 had overall objective response rates (ORR) of 11.7%, disease control rates (DCR) of 53.4%, 3.6 months of median progression-free survival (PFS), and 7.5 months of median survival. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Our retrospective data suggest a potential role for gefitinib and erlotinib in advanced NSCLC patients with brain metastases which have failed to respond to radiotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with NSCLC because it is commonly employed after failure of another EGFR-TKI, gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "RESULTS: There were no significant differences in erlotinib efficacy between EGFR-mutated NSCLC with gefitinib resistance and NSCLC with wild-type EGFR. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Erlotinib may be a therapeutic option for EGFR-mutated NSCLC with gefitinib resistance, as well as for NSCLC with wild-type EGFR. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "NSCLCs with EGFR mutations, are characterized by excellent responses when treated with the EGFR-TKIs gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Are erlotinib and gefitinib interchangeable, opposite or complementary for NSCLC treatment? Biological, pharmacological and clinical aspects. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Re-administration after the failure of gefitinib or erlotinib in patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVE: Few treatment options are available for advanced NSCLC patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: The study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow-up CT scans during TKI therapy, and had experienced volumetric tumor growth. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: We analyzed 1,431 NSCLC patients who were treated with either gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in NSCLCs (NSCLC) are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Phase II trials and retrospective reviews for gefitinib and erlotinib demonstrate these agents may have a role in both the chemoprevention of brain metastases and, in combination with WBRT, treatment for NSCLC brain metastases. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Personalized therapy of advanced NSCLC has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " [How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?]. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: In retrospect, patients with advanced NSCLC or with postoperative relapse of advanced NSCLC achieved complete response (CR), partial response (PR) or stable disease (SD) in prior Gefitinib therapy, progression free survival (PFS) \u22653 months. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Advanced NSCLC patients who benefited from prior Gefitinib therapy can benefit again either with the original drug Gefitinib or the alternative drug Erlotinib when a second TKI therapy is resumed. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " LUX-Lung 4: a phase II trial of afatinib in patients with advanced NSCLC who progressed during prior treatment with erlotinib, gefitinib, or both. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: New molecular targeted agents are needed for patients with NSCLC who progress while receiving erlotinib, gefitinib, or both. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In particular, gefitinib and erlotinib have become the standard of care in patients harboring epidermal growth factor receptor mutations, while crizotinib showed an impressive efficacy in patients with ALK-positive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: This study suggested that erlotinib had better control rate for LMC in NSCLC than gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: Common treatment modalities for NSCLC involve the EGF receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Our purpose was to test ubiquitin-specific peptidase 8 (USP8) as a potential therapeutic target for gefitinib-resistant and -sensitive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "EXPERIMENTAL DESIGN: Testing the effect of knockdown of USP8 and use of a synthetic USP8 inhibitor to selectively kill gefitinib-resistant (or -sensitive) NSCLCs with little effect on normal cells in cell culture and a xenograft mouse model. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "RESULTS: Knockdown of ubiquitin-specific peptidase 8 (USP8) selectively kills gefitinib-resistant NSCLCs while having little toxicity toward normal cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We also determined that a synthetic USP8 inhibitor markedly decreased the viability of gefitinib-resistant and -sensitive NSCLC cells by decreasing RTK expression while having no effect on normal cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Moreover, treatment with a USP8 inhibitor led to significant reductions in tumor size in a mouse xenograft model using gefitinib-resistant and -sensitive NSCLC cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We propose USP8 as a potential therapeutic target for gefitinib-resistant and -sensitive NSCLC cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib and gefitinib, have been approved for the treatment of NSCLC, demonstrating an improvement in progression-free and overall survival, particularly in patients harboring activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Plasma DNA samples were obtained after discontinuation of gefitinib or erlotinib in 75 patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "tkijima@imed3.med.osaka-u.ac.jp  INTRODUCTION: Gefitinib induces severe hepatotoxicity in approximately a quarter of Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Polymorphisms of the CYP2D6 gene were analyzed in 55 patients with NSCLC who experienced grade \u2265 2 transaminase elevation from gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "These trials showed promising efficacy in patients with EGFR-mutant NSCLC or enriched for clinical benefit from EGFR tyrosine kinase inhibitors gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced NSCLC for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive NSCLC, although erlotinib also has activity in wild-type disease. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " [The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant NSCLC patients]. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: We retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "astsao@mdanderson.org  In recent years, the epidermal growth factor receptor (EGFR) family has become a key focus of NSCLC biology and targeted therapies, such as the reversible EGFR tyrosine kinase inhibitors erlotinib and gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "These successes include imatinib for the treatment of chronic myeloid leukemia, anti-HER2 therapies (trastuzumab, pertuzumab, and lapatinib) to treat breast cancer, anti-EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) to treat NSCLC, and anti-BRAF agents (vemurafenib and dabrafenib) to treat melanoma. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib or erlotinib as maintenance therapy in patients with advanced stage NSCLC: a systematic review. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: In September 2012 we performed a search in the pubmed, EMBASE and Cochrane library databases for randomized phase III trials exploring the role of gefitinib or erlotinib in advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib or gefitinib, have demonstrated promising results in patients with advanced NSCLC that harbor EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Synergistic effect of afatinib with su11274 in NSCLC cells resistant to gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Treatment for NSCLC with gefitinib and erlotinib is efficacious. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The first two reversible EGFR-TKIs, erlotinib and gefitinib, are approved for use in the first-line setting in patients with known EGFR-activating mutations and in the second- and third-line settings for all NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Clinicians should be aware that gefitinib-induced neutropenia in patients with NSCLC can be treated successful by switching to erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In lung cancer, 10-15% of NSCLC contain activating mutations in the EGFR kinase conferring hypersensitivity to the oral TKIs gefitinib and erlotinib, have been demonstrated to be important predictive factors when selecting patients to be treated with these two agents. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The presence of epidermal growth factor receptor (EGFR) somatic mutations in NSCLC patients is associated with response to treatment with EGFR-tyrosine kinase inhibitors, such as gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " INTRODUCTION: : Despite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, the majority of NSCLC patients with EGFR-activating mutations develop acquired resistance. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Symptom and quality of life benefit of afatinib in advanced NSCLC patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " [Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of NSCLC with unknown EGFR mutation status]. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " OBJECTIVE: To evaluate the efficacy of erlotinib in patients with metastasis of NSCLC who had benefits from initial gefitinib treatment but finally demonstrated resistance, especially in those of unknown EGFR mutation status, and to compare the efficacy of erlotinib between patients who received erlotinib immediately after gefitinib failure and those who received chemotherapy before erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Erlotinib can be considered either immediately after gefitinib failure or following the insertion of chemotherapy after gefitinib failure in progressive NSCLC patients who initially benefited from gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with NSCLC: a retrospective analysis. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective for the treatment of NSCLC with somatic activating mutations of the epidermal growth factor receptor gene (EGFR-mt). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Here, we conducted a retrospective analysis of AEs and drug efficacy in patients with NSCLC whose EGFR mutation status had been confirmed and who all received 250 mg gefitinib or 150 mg erlotinib once daily. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "However, this study has several limitations as of the nature of retrospective design; our data suggest that gefitinib and erlotinib might have almost equal efficacy for patients with EGFR-wt NSCLC, as is the case for patients with EGFR-mt tumors, although erlotinib appears to have higher toxicity than gefitinib at each approved dose. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Retraction: Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "y-naruo@sc4.so-net.ne.jp  INTRODUCTION: Patients with epidermal growth factor receptor (EGFR) mutation positive NSCLC exhibited marked response to gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: Patients with EGFR-mutant stage IIIB or IV NSCLC that progressed during gefitinib or erlotinib therapy were administered pemetrexed with the continuation of EGFR-TKI treatment. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Treatment of NSCLC with drugs targeting the epidermal growth factor receptor (EGFR), e.g., gefitinib and erlotinib, will eventually fail because of the development of secondary mutations such as T790M in EGFR. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In this study, we synthesized a dozen of novel gefitinib analogues and evaluated their effects on L858R/T790M-EGFR harboring NSCLC cells, and reported that one of these gefitinib mimetics, N-(2-bromo-5-(trifluoromethyl) phenyl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine (hereafter, V1801), triggered apoptosis of the NSCLC cells and overcame gefitinib-resistance in mice inoculated with NCI-H1975 cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Growing clinical evidence supports a personalized approach to NSCLC treatment, and clinical trials in advanced disease have shown the value of testing for epidermal growth factor receptor gene (EGFR) mutations prior to first-line therapy with erlotinib or gefitinib and testing for anaplastic lymphoma kinase gene (ALK) rearrangements prior to therapy with crizotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Data from 88 NSCLC patients receiving gefitinib (250 mg, daily [qd]), erlotinib (150 mg, qd), and ZD6474 (100 mg, qd) in three clinical trials (IRESSA registration clinical trial, TRUST study, ZD6474 study) during November 2003 to June 2005 were retrospectively analyzed. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " NSCLCpatients with activating mutations of the epidermal growth factor receptor(EGFR)gene have shown a dramatic response to EGFR tyrosine kinase inhibitors(EGFR-TKI)such as gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Erlotinib and gefitinib for elderly patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Erlotinib and gefitinib are tyrosine kinase inhibitors (TKI) associated with the EGFR, which is involved in cell proliferation, growth, migration, invasion and survival, and has been found to be overexpressed in NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Comparison of adverse events of erlotinib with those of gefitinib in patients with NSCLC: a case-control study in a Japanese population. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Similarly to MET overexpression, the tumor microenvironment-derived ligand hepatocyte growth factor (HGF) was shown to activate Met and thereby induce short-term resistance to EGFR TKI treatment in gefitinib-sensitive NSCLC cell lines in vitro. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib and afatinib, have been investigated in the treatment of NSCLC, and to date a large amount of clinical data are available. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In particular, the tyrosine- kinase inhibitors (TKIs) gefitinib and erlotinib targeting the epidermal growth factor receptor (EGFR) have been approved for the treatment of NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: The Taiwan Cancer Registry and the National Health Insurance claim databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who received gefitinib or erlotinib as third-line therapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSIONS: Gefitinib and erlotinib had similar efficacies as salvage therapy for advanced NSCLC in Taiwan. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In particular, the tyrosine kinase inhibitors gefitinib and erlotinib have been approved for the treatment of NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Germline polymorphisms can be easily assessed in blood samples, and candidate polymorphisms in EGFR and ABCG2 have been correlated with outcome and toxicity in NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "yasukok@shinkohp.or.jp  Gefitinib and erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), are widely used anticancer drugs for patients with NSCLC, especially for those with EGFR-activating mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in NSCLC; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RAR\u03b1 for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " CT findings in NSCLC patients treated with gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "hmona@kcch.re.kr  PURPOSE: We performed this study to explore the association of computed tomography (CT) findings with outcomes of patients with NSCLC treated with tyrosin kinase inhibitor (TKI) such as gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "ongchookhoon@yahoo.com  Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitors (TKI) like erlotinib and gefitinib have been approved as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "ytogashi@kuhp.kyoto-u.ac.jp  PURPOSE: Several cases have been reported in which central nervous system (CNS) metastases of NSCLC resistant to gefitinib were improved by erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The objective of this review was to assess the predictive value of skin rash for outcome in patients with NSCLC treated with erlotinib and gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "giulio.metro@yahoo.com  INTRODUCTION: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Surrogate end points for survival in the target treatment of advanced NSCLC with gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Our aim was to determine the correlations of these surrogates with survival in the treatment of advanced NSCLC (ANSCLC) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation of progression-free survival (PFS) in NSCLC patients with EGFR mutation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced NSCLC with EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced NSCLC with EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV or relapsed NSCLC with a sensitizing EGFR mutation initially treated with gefitinib, erlotinib, or chemotherapy were identified. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention of CNS metastases from NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " INTRODUCTION: Most NSCLC tumors with epidermal growth factor receptor mutations are responsive to EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib, but almost all such tumors ultimately acquire resistance. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for NSCLC with activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " While most patients with metastatic NSCLC containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Erlotinib and gefitinib inhibit the growth of NSCLC tumors that harbor activating epidermal growth factor receptor (EGFR) mutations but are ineffective against EGFR variants found in glioblastoma. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: NSCLC (nsclc) tumours with activating mutations of the epidermal growth factor receptor (efgr) tyrosine kinase are highly sensitized to the effects of oral tyrosine kinase inhibitors such as gefitinib and erlotinib, suggesting the possibility of targeted treatment of nsclc based on EFGR mutation status. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "To date, erlotinib and gefitinib have established themselves as first-line therapy for NSCLC patients whose tumors harbor an EGF receptor gene mutation, and hence, it is crucial that we identify mechanisms of resistance that could be targeted by novel agents, while keeping an acceptable toxicity profile at the same time; something very important when we develop these new drugs. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "chi-okamoto@dotd.med.kindai.ac.jp  OBJECTIVE: Somatic mutations in the epidermal growth factor receptor gene are associated with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors such as gefitinib and erlotinib in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: We performed a retrospective analysis of EGFR mutation-positive NSCLC patients who received both gefitinib and erlotinib at our institution. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Afatinib versus placebo for patients with advanced, metastatic NSCLC after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In the last decade, the tyrosine kinase (TK) domain of the EGFR was identified in NSCLC patients, and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " The administration of gefitinib in patients with advanced NSCLC after the failure of erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "francesco.grossi@istge.it  PURPOSE: Recent studies have demonstrated that erlotinib therapy may be considered an option for patients with advanced NSCLC who experienced disease progression after treatment with gefitinib, particularly in patients in whom the disease had been stabilized for a long time prior to gefitinib therapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer in some populations of NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Successful treatment of NSCLC with gefitinib after severe erlotinib-related hepatotoxicity. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "To the best of our knowledge, to date, two reports have stated that patients with NSCLC who develop severe hepatotoxicity secondary to gefitinib treatment can be safely switched to erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Here, we present the first case with NSCLC harboring EGFR mutation who developed grade 3/4 hepatotoxicity after initiation of erlotinib, which resolved when therapy was changed to gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "As far as we know, this is the first report showing the efficacy of gefitinib for a NSCLC patient who developed severe hepatotoxicity while under erlotinib therapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Erlotinib after failure of gefitinib treatment of more than 6 months in advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "At the moment, established personalized treatment approaches include treatment of patients with NSCLC and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK inhibitor crizotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Treatment of NSCLC with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib have shown efficacy in patients with NSCLC and brain metastases. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "bar.jair@gmail.com  The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have provided substantial benefits to patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Phase I study of continuous afatinib (BIBW 2992) in patients with advanced NSCLC after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "faupe@libero.it  Advanced NSCLC harboring activating mutations of epidermal growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs), namely erlotinib and gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Eligible studies included published randomized controlled trials in which erlotinib or gefitinib (alone or with chemotherapy) were compared with standard therapy in 1260 patients with EGFR-mutated NSCLCs who were included in 13 trials. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or gefitinib than from chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Inhibition of EGFR signaling has thus been identified as an attractive strategy in control of tumor proliferation, and over a decade of intense activity in the field has culminated in the discoveries and subsequent approvals of gefitinib and erlotinib for the treatment of NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous NSCLC receiving gefitinib or erlotinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "masago@kuhp.kyoto-u.ac.jp  A study of patients with advanced non-squamous NSCLC evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We found that a high efficacy of antitumor activity was shown with GDC-0941 treatment in two gefitinib-resistant NSCLC cell lines, A549 and H460. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Additionally, the blockade of PI3K, mTOR and Erk with GDC-0941 and MEK inhibitors shows promise for treating gefitinib-resistant NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in NSCLC Cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: This study examines the effect of the cytotoxic drug Gemcitabine and the EGFR tyrosine kinase inhibitor Gefitinib on the expression of NK group 2 member D (NKG2D) ligands as well as the sensitivity of NSCLC cells to the NK-mediated lysis. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: In keeping with the effect on NKG2D expression, Gemcitabine enhanced NK cell-mediated cytotoxicity while Gefitinib attenuated NK cell killing in NSCLC cells. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "[Epub ahead of print]  Unconvincing Benefit of Combination Therapy With Gefitinib and Pemetrexed in Advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "[Epub ahead of print]  Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous NSCLC With Activating Epidermal Growth Factor Receptor Mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Noninvasive monitoring of the genetic evolution of EGFR-mutant NSCLC by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous NSCLC With Activating Epidermal Growth Factor Receptor Mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: To determine whether the addition of pemetrexed to gefitinib (P+G) provides clinical benefit, compared with gefitinib monotherapy, in patients with advanced nonsquamous (NS) NSCLC and activating epidermal growth factor receptor (EGFR) mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve for advanced NSCLC patients from China, Japan, Korea, and Taiwan (35 sites) with advanced, EGFR-mutant, NS NSCLC were randomly assigned (2:1; computer-generated, interactive voice response) to open-label pemetrexed (500 mg/m(2) on day 1 of every 21-day cycle) plus gefitinib (250 mg/d [n = 129]) or gefitinib alone (n = 66). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: P+G improved PFS compared with gefitinib alone in East Asian patients with advanced NS NSCLC and activating EGFR mutations. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced NSCLC Harboring EGFR Mutation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " To evaluate the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in advanced EGFR-mutated NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: The effect of different combinatorial schedules of gefitinib and pemetrexed on cell proliferation, cell cycle, apoptosis, and acquisition of gefitinib resistance in PC9 and HCC827 NSCLC cell lines and in PC9 xenograft models was investigated. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced NSCLC harboring a sensitive EGFR mutation. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "We evaluated the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in EGFR-mutated NSCLC patients. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib was compared with pemetrexed as maintenance therapy in Patients with Advanced Glandular NSCLC, mainly regarding clinical effect and side effect. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced NSCLC previously treated with chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m\u00b2 of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The purpose of the present study was to investigate the combined effects of gefitinib and pemetrexed on EGFR-TKI-sensitive and EGFR\u2011TKI\u2011resistant human non-small cell lung cancer (NSCLC) cell lines. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The antiproliferative effects of gefitinib and pemetrexed, alone and in combination, on the growth of NSCLC cell lines, were assessed using an MTT assay. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The combination of pemetrexed and gefitinib generated synergistic effects in gefitinib-acquired resistant cells and antagonistic effects in gefitinib-sensitive cells, suggesting that EGFR-TKIs combined with pemetrexed may be a beneficial treatment strategy for NSCLC patients with acquired resistance to EGFR-TKIs. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " [A randomized clinical study of Gefitinib and pemetrexed as second line therapy for advanced non-squamous NSCLC]. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND AND OBJECTIVE: Gefitinib and Pemetrexed are drugs used as second-line therapy for advanced NSCLC, although studies comparing the two drugs are limited. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The aim of this study is to explore the effects, safety, and quality of life (QoL) of Gefitinib and Pemetrexed on patients with advanced non-squamous NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "METHODS: Forty-six advanced non-squamous NSCLC patients who failed to first-line therapy were randomly divided into two groups with 23 patients each, one using oral Gefitinib (Gefitinib group) and the other using intravenous injection Pemetrexed (Pemetrexed group). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "[Epub ahead of print]  A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " We present the rationale and study design of the CGMT (combined gefitinib and metformin therapy) trial (www.ClinicalTrials.gov Identifier: NCT01864681), which is aimed at treating locally advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The CGMT trial is a multicenter, phase II randomized, double-blinded, and placebo-controlled study, which is designed to evaluate the safety and efficacy of metformin in combination with gefitinib as first-line therapy in patients presenting with stage IIIb-IV NSCLC expressing the epidermal growth factor receptor mutant. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Fuzheng Kang'ai decoction combined with gefitinib in advanced NSCLC patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: Patients with advanced NSCLC harboring mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "A total of 70 NSCLC patients with EGFR mutations will be randomly assigned to treatment group (gefitinib plus FZKA granules) or control group (gefitinib plus placebo). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "This study will provide objective evidence to evaluate the efficiency of CHM combined with gefitinib in NSCLC patients with EGFR mutations, and may provide a novel regimen for patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic NSCLC (INFORM; C-TONG 0804). ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " BACKGROUND: The results of the Iressa in NSCLC for maintenance study (NCT00770588; C-TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with advanced NSCLC without disease progression after first-line chemotherapy, were published previously. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib versus placebo in completely resected NSCLC: results of the NCIC CTG BR19 study. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "PATIENTS AND METHODS: Patients with completely resected (stage IB, II, or IIIA) NSCLC stratified by stage, histology, sex, postoperative radiotherapy, and chemotherapy were randomly assigned (1:1) to receive gefitinib 250 mg per day or placebo for 2 years. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " INFORM; C-TONG 0805: A multicenter, double blind randomized phase III trial of maintenance gefitinib compared to placebo in advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic NSCLC (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "INTERPRETATION: Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "MATERIALS AND METHODS: A phase II trial was conducted in patients with stage III/IV NSCLC, to assess the efficacy, safety and impact on quality of life (QoL) and disease-related symptoms of gefitinib rechallenge. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " A phase II trial of gefitinib monotherapy in pretreated patients with advanced NSCLC not harboring activating EGFR mutations: implications of sensitive EGFR mutation test. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " PURPOSE: Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor (EGFR) mutation status in patients with NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The aim of this trial was to evaluate the efficacy and toxicity of gefitinib in NSCLC patients with WT EGFR who failed previous chemotherapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "CONCLUSION: Small proportion of NSCLC patients with the WT EGFR benefits with gefitinib. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": " Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "gefitinib", "orig_sen": "The antitumor efficacy of different treatment sequences using vinorelbine (VNB) and gefitinib (GEF) was investigated both in vitro and in vivo in NSCLC cell lines with the rationale of potentially translating these findings into the clinical setting. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  ERCC1 Expression-based Randomized Phase II Study of Gemcitabine/cisplatin Versus Irinotecan/cisplatin in Patients With Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage NSCLC demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, the protein levels of FAT10 were elevated in cisplatin- and carboplatin-resistant NSCLC cells, and knockdown of FAT10 reduced the drug resistance of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with NSCLC pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic NSCLC: An Indian study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The platinum compounds currently used in NSCLC are cisplatin and carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " NSCLCs (NSCLC) are commonly treated with a platinum-based chemotherapy such as cisplatin (CDDP) in combination with ionizing radiation (IR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We identified and interrogated the unique time and agent-dependent activation of the DDR in NSCLC cells treated with cisplatin-IR combination therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A total of 108 NSCLC patients (stages I-IIIA) were treated with a standard chemotherapy regimen of cisplatin plus vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The results indicate that BAG1 is important in cisplatin-induced cell death in lung adenocarcinoma, suggesting that endoplasmic reticulum stress may promote the sensitivity of NSCLC patients to chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: In the present single-arm phase II trial, patients with previously untreated, unresectable stage IIIA-IIIB NSCLC (all histologic types) were treated with pemetrexed-cisplatin (500 mg/m(2) intravenously on days 1 and 22, 20 mg/m(2) intravenously on days 1-5 and days 22-26) concurrent with radiotherapy (61-66 Gy in 31-35 fractions), followed by 2 cycles of consolidation pemetrexed-cisplatin (75 mg(2)) therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with NSCLC who received cisplatin-based adjuvant chemotherapy: A prospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The expression of ERCC1 and BRCA1 was significantly associated with the DFS time in patients with NSCLC treated with adjuvant cisplatin-based chemotherapy, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin and carboplatin-based chemotherapy in the first-line treatment of NSCLC: Analysis from the European FRAME study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: This post-hoc analysis illustrated real-life differences in patients with NSCLC prescribed platinum-based first-line treatment, and suggested that baseline patient and disease characteristics were associated with physician's choice of platinum agent, with cisplatin being more frequently prescribed to younger and fitter patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In\u00a0vitro treatment studies with cisplatin or vismodegib (Shh pathway inhibitor), or both, were performed on NSCLC cell lines (H322 and A549) and primary cultures from patients with sarcomatoid carcinoma (n\u00a0=\u00a04). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, abnormal expressions of miR-17 and miR-92 families are observed in cisplatin-resistant cells, suggesting that miR-17 and miR-92 families are involved in the regulation of cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of this study is to investigate the regulatory functions of miR-17 and miR-92 families on the formation of cisplatin resistance and the predictive functions of them as biomarkers of platinum-based chemotherapy resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PAPSS1 knockdown in combination with low-dose (IC10) cisplatin reduces clonogenicity of NSCLC cells by 98.7% (p < 0.001), increases DNA damage, and induces G1/S phase cell cycle arrest and apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study compared the survival benefits of NDP and cisplatin (DDP) in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced NSCLC patients treated with vinorelbine combined cisplatin regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We aimed to investigate whether polymorphisms in BAG-1 and XPD have effects on chemotherapy sensitivity and survival in patients with advanced NSCLC treated with vinorelbine combined cisplatin (NP) regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Modulation of NF-\u03baB/miR-21/PTEN pathway sensitizes NSCLC to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our present study was aimed to determine whether inhibition of the NF-\u03baB/miR-21/PTEN pathway could increase the sensitivity of NSCLC to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Modulation of the NF-\u03baB/miR-21/PTEN pathway in NSCLC showed that inhibition of this pathway may increase cisplatin sensitivity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous NSCLC: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced NSCLC, who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "IGF2R silencing significantly enhanced the chemo-resistance of NSCLC cell lines to cisplatin treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced NSCLC: Japan Clinical Oncology Group (JCOG) 0207\u2020. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Elderly patients (age \u226570 years, ECOG performance Status 0-1) with advanced NSCLC were randomized to receive docetaxel 20 mg/m(2) plus cisplatin 25 mg/m(2) on Day 1, 8 and 15 (docetaxel plus cisplatin) or docetaxel 25 mg/m(2) on the same schedule (docetaxel). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Our results indicate that advanced NSCLC patients with positive expression of EZH2 exhibited resistance to cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "EZH2 may be a predictive and prognostic factor for cisplatin-based therapy response and disease survival in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " ERCC1 and the efficacy of cisplatin in patients with resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Excision repair cross-complementing gene 1 (ERCC1) protein is proposed as a predictor for cisplatin efficacy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The purpose of this study is to assess whether ERCC1 expression level is linked to cisplatin sensitivity and clinical outcomes in resected NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Aurora-A contributes to cisplatin resistance and lymphatic metastasis in NSCLC and predicts poor prognosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we aimed to identify the expression of Aurora-A and its correlation with cisplatin resistance and prognosis in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We used immunohistochemical analysis to determine the expression of Aurora-A protein in 102 NSCLC patients treated by surgery and adjuvant cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The potential role of Aurora-A in the regulation of cisplatin resistance in NSCLC cells was examined by transfections using expression vector and small interfering RNA or using small-molecule inhibitors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: The current findings suggest that high Aurora-A expression is correlated with cisplatin-based chemotherapeutic resistance and predicts poor patient survival in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Patients with stage III NSCLC received 2 induction cycles of intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: In non-operable IIIA-IIIB NSCLC, the combination oral vinorelbine (fractionated fixed dose) plus cisplatin, during concomitant CT-RT, could offer a well-tolerated option, with comparable activity to I.V. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Growth inhibition by DCA was also evaluated in a panel of 54 NSCLC cell lines with and without cytotoxic chemotherapeutics (cisplatin and docetaxel) in normoxic and hypoxic conditions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the cornerstone of treatment of advanced NSCLC patients, but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: MILES-3 and MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the first-line therapy of elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced NSCLC (Italian GEMVIN3/NCIC CTG BR14 trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here we studied Pt-(GpG) DNA adducts in circulating tumour cells (CTC) treated with cisplatin in medium upfront to systemic therapy from patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "faupe@libero.it  INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for NSCLC after failure with cisplatin-based doublets. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous NSCLC: AVAPERL (MO22089). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Among them, high levels of expression of ERCC1, both at protein and mRNA levels, have been associated with resistance to cisplatin in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, low levels of expression of RRM1, a target for gemcitabine, have been associated with improved OS in advanced NSCLC patients treated with cisplatin and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "No prospective randomized trial has tested the addition of cisplatin to single-agent chemotherapy in patients with advanced NSCLC and PS2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The addition of cisplatin to single-agent gemcitabine improves survival as first-line treatment of PS2 patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Using in vitro drug-resistant NSCLC cell models, we provide evidence that acquired cisplatin resistance may reduce the sensitivity of cancer cells to subsequent treatment with a molecular-targeted agent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced NSCLC treated with cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Silencing XPA gene can partly reverse the cisplatin resistance in human cisplatin-resistant NSCLC cell line A549/DDP. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: eIF3\u03b1 Arg803Lys C > T polymorphism was associated with cisplatin-induced toxicity in NSCLC patients (P = 0.02, OR = 0.54, 95% CI 0.32, 93). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In a series of in vitro and cell culture assays in a NSCLC model, we investigated both the downstream and direct treatment and damage effects of cisplatin on NHEJ catalyzed repair of a DNA DSB. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "ATP7A expression was evaluated by immunohistochemistry in tumor tissues of unresectable NSCLC patients who received cisplatin-basing chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous NSCLC in Spain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Dynamic contrast-enhanced MRI to predict response to vinorelbine-cisplatin alone or with rh-endostatin in patients with NSCLC and bone metastases: a randomised, double-blind, placebo-controlled trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine-cisplatin plus rh-endostatinfor previously untreated NSCLC with bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "INTERPRETATION: Addition of rh-endostatin to treatment with vinorelbine-cisplatin increased the treatment response in patients with NSCLC and bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous NSCLC who are eligible for bevacizumab and maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "For this reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II trial, who received fractioned cisplatin (30\u2009mg/sqm days 1-3q21) and oral etoposide (50\u2009mg, days 1-15q21) (mPE doublet) \u00b1bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, few studies have focused on cisplatin/pemetrexed with bevacizumab as the first-line therapy to treat advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: We speculate that bevacizumab in combination with cisplatin/pemetrexed as the first-line therapy is well tolerated and results in a clinically meaningful treatment benefit, irrespective of the gene drive type in advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In NSCLC, fit older patients, like their younger counterparts, benefit from platinum-based doublets, with carboplatin preferred to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The aim of the present study was to retrospectively evaluate the feasibility of cisplatin/pemetrexed/bevacizumab (CPB) therapy at a bevacizumab (BEV) dose of 15 mg/kg as a first-line chemotherapeutic strategy for patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced NSCLC Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous NSCLC: a phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III NSCLC: SWOG S0533. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Clinical data concerning 80 patients with histopathologically confirmed NSCLC who are planned to receive cisplatin-based adjuvant chemotherapy were collected. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "It was found that ERCC1 protein expression might play an important role in the prognosis of locally advanced NSCLC patients treated with cisplatin-based adjuvant chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic NSCLC: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: S-1 plus cisplatin with bevacizumab is an active and well-tolerated regimen in patients with chemotherapy-na\u00efve non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Intrapleural combination therapy with bevacizumab and cisplatin for NSCLC\u2011mediated malignant pleural effusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous NSCLC: a multicenter phase II study of the Hellenic Oncology Research Group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "kentenik@hotmail.com  BACKGROUND: The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic NSCLC, and bevacizumab (B) improves the efficacy of frontline chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous NSCLC chemo-na\u00efve patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "luis.leon.mateos@sergas.es  OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "As an application example, we describe the analysis for the comparison of four regimens, cisplatin plus irinotecan, carboplatin plus paclitaxel, cisplatin plus gemcitabine (GP), and cisplatin plus vinorelbine, for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III NSCLC: A Systematic Review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB NSCLC are carboplatin-paclitaxel and cisplatin-etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Objective: To conduct a systematic review of published trials to compare outcomes and toxic effects between cisplatin-etoposide and carboplatin-paclitaxel in patients with NSCLC receiving thoracic radiation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Methods In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced NSCLC, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Background The combination of cisplatin or carboplatin with vinorelbine is one of the standard regimens in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Most importantly, we have been able to extend these findings clinically, following the observation that those patients with ovarian and NSCLC carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4\u00a0cycles is recommended. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiation for Stage III NSCLC: Is There an Impact on Radiation Pneumonitis Rates?  Palma DA(1), Senan S(2), Rodrigues G(3). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in NSCLC: Findings From the Florida Initiative for Quality Cancer Care. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: For patients with resected NSCLC, national guidelines recommend cisplatin-based doublet chemotherapy as the preferred treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "To investigate whether the abnormal expression of CNTN-1 is associated with characteristics of patients with NSCLC, immunohistochemistry was used to detect CNTN-1 expression in 143 tissue samples from NSCLC patients and the results showed that the degree of CNTN-1 expression positively correlated with lymphatic invasion in patients with lung adenocarcinoma who received adjuvant cisplatin- or carboplatin-based treatment after surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "While results from the ongoing phase III PROCLAIM trial are needed to address definitively the efficacy of pemetrexed-cisplatin plus RT in stage III NSCLC, available results from phase II trials suggest that this regimen has promising activity with an acceptable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " First-line chemotherapy treatment of advanced NSCLC: does cisplatin versus carboplatin make a difference?  Tiseo M(1), Ardizzoni A, Boni L. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III NSCLC: an analysis of Veterans Health Administration data. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cost-Utility Analysis of First-Line Regimen Between Cisplatin Plus Pemetrexed and Carboplatin Plus Paclitaxel In Advanced Non-Squamous NSCLC in Thailand. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Comparing docetaxel plus Cisplatin with Paclitaxel plus Carboplatin in chemotherapy-na\u00efve patients with advanced NSCLC: a single institute study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin or Carboplatin for advanced NSCLC?  Sun X(1), Zheng Y. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "S-1 and cisplatin is an active first-line chemotherapy regimen for advanced NSCLC and S-1 and carboplatin is noninferior to a carboplatin and paclitaexel regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous NSCLC: a randomised, phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [Clinical experience of the use of pemetrexed (PEM) combined with cisplatin (CDDP)/Carboplatin (CBDCA) followed by long-term maintenance PEM in patients with non-squamous NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous NSCLC that were treated in our hospital. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction is recommended as a first-line treatment for patients who have advanced non-squamous NSCLC and as a maintenance strategy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This study investigates the potential of (18)F-FLT to monitor acute effects of chemotherapy on cellular proliferation and its recovery in bone marrow, spleen, and liver during treatment with 2 different chemotherapy regimens.METHODS: Sixty patients with NSCLC underwent concurrent radical chemoradiotherapy to 60 Gy in 6 wk with either cisplatin/etoposide (C/E, n = 28) weeks 1 and 5 or weekly carboplatin/paclitaxel (C/P, n = 32) regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: While platinum-based doublet chemotherapy is standard of care for patients presenting with metastatic NSCLC, the optimal platinum agent (cisplatin versus carboplatin) is unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A retrospective comparison of adjuvant chemotherapeutic regimens for NSCLC: paclitaxel plus carboplatin versus vinorelbine plus cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of the study was to evaluate the efficacy and safety of first-line chemotherapy based on platinums (carboplatin or cisplatin) plus a third generation compound (vinorelbine or gemcitabine) in elderly patients with advanced NSCLC in daily clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Cisplatin-based adjuvant chemotherapy provided a significant advantage in the overall survival (OS) of patients with stage II and III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin versus carboplatin in combination with third-generation drugs for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "OBJECTIVES: To assess the efficacy and safety of carboplatin-based chemotherapy when compared with cisplatin-based chemotherapy, both in combination with a third-generation drug, in people with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third-generation drug. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "SELECTION CRITERIA: Randomised clinical trials comparing regimens with carboplatin or cisplatin combined with a third-generation drug in people with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Supported by evidence from the LACE (Lung Adjuvant Cisplatin Evaluation) metaanalysis, cisplatin-based adjuvant chemotherapy is now recommended as the standard of care for patients with surgically resected early-stage NSCLC per American Society of Clinical Oncology and European Society for Medical Oncology clinical practice guidelines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: The activity and synergy for the combination treatment of cisplatin and gemcitabine has been identified in a variety of human tumor cells, including ovarian cancer cells, and has been widely approved for the treatment of NSCLC, pancreatic cancer and biliary tract cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: In this phase 3 trial, patients with untreated stage IIIB/IV NSCLC were randomly assigned in a 1:1 ratio by use of an interactive internet response system with minimisation algorithm (stratified by disease stage, tumour histology, smoking status, and chemotherapy regimen) to receive six cycles of gemcitabine (1250 mg/m(2) on days 1 and 8, intravenously) plus platinum (carboplatin 5\u2008\u00d7\u2008area under the curve or cisplatin 75 mg/m(2) on day 1, intravenously) with intercalated erlotinib (150 mg/day on days 15-28, orally; chemotherapy plus erlotinib) or placebo orally (chemotherapy plus placebo) every 4 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The treatment approach for early-stage disease does not differ from that of other histologic subtypes of NSCLC; in locally advanced unresectable or metastatic disease, doublet chemotherapy regimens (including cisplatin or carboplatin and a third-generation agent such as gemcitabine, taxanes, or vinorelbine) remain the cornerstone of front-line systemic treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Hypersensitivity reactions to carboplatin and cisplatin in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The weekly fractionated administration of cisplatin for patients with NSCLC has been shown to be active. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "wolfgang.schuette@martha-maria.de  BACKGROUND: Pemetrexed plus cisplatin was approved for first-line treatment of NSCLC in patients with nonsquamous histology after initiation of this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Preoperative chemoradiotherapy using cisplatin plus S-1 can induce downstaging in patients with locally advanced (stage III) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We evaluated the effectiveness of PCRT for inducing downstaging using mainly three chemoradiotherapy regimens; cisplatin plus Tegafur-Gimeracil-Oteracil Potassium (S-1), cisplatin plus Tegafur-Uracil (UFT), or 1,1'cyclobutanedicarboxylate (Carboplatin, CBDCA) plus paclitaxel, with concurrent radiation therapy in 19 patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: PCRT using cisplatin plus S-1 with concurrent radiation therapy is useful for inducing downstaging in patients with locally advanced stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "lpazares@hotmail.com  PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with a mean IC(50) of 2.5 \u03bcmol/l in a variety of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "wlhwq@yahoo.com  OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Patients (n\u00a0=\u00a048) with advanced NSCLC were treated with repetitive cycles of either paclitaxel/carboplatin or cisplatin/vinorelbine chemotherapy, bexarotene (400\u00a0mg/m(2)/day) administered continuously starting on day 4 of chemotherapy, and a lipid-lowering drug, either atorvastatin or fenofibrate, starting at least 5\u00a0days before chemotherapy due to hypertriglyceridemia induced by bexarotene. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Role of XRCC1 gene polymorphisms in NSCLC cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We investigated the association between clinical outcome and XRCC1 Arg399Gln, Arg280His, and Arg194Trp polymorphisms in advanced NSCLC patients treated with cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, there was no association between Arg399Gln and Arg280His polymorphisms and response to cisplatin-based chemotherapy and overall survival in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " We herein report that sulforaphane (SFN), a potent anti-cancer and well-tolerated dietary compound, inhibits cancer stem-like cell (CSC) properties and enhances therapeutic efficacy of cisplatin in human NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Experiments with nude mice carrying xenograft tumors showed that SFN sensitized NSCLC cells to cisplatin's efficacy, which is accompanied by inhibition of cisplatin-induced c-MYC accumulation in tumor tissues. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our results provided strong evidence and mechanisms to support consideration of SFN or synthetic derivatives as a therapeutic agent in combination with cisplatin for the treatment of patients with NSCLC and, potentially, other types of c-MYC-addicted tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, whether co-inhibition of REV3 and ATR can further increase sensitivity of NSCLC cells to cisplatin is not clear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we show that REV3 knockdown combined with ATR inhibition further enhance cytotoxicity of cisplatin in NSCLC cells, including cisplatin-sensitive and -resistant cell lines, compared to individual knockdown of REV3 or ATR, which are accompanied by markedly caspase-dependent apoptosis response, pronounced DNA damage accumulation and severe impediment of interstrand crosslink (ICL) and double strand break (DSB) repair. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our results suggest that REV3 knockdown synergize strongly with ATR inhibition to significantly increase sensitivity of cisplatin in NSCLC cells by inhibiting ICL and DSB repair. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Thus simultaneously targeting REV3 and ATR may represent one approach to overcome cisplatin resistance and improve chemotherapeutic efficacy in NSCLC treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MiR-488 inhibits proliferation and cisplatin sensibility in NSCLC cells by activating the eIF3a-mediated NER signaling pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, we found that miRNA-488 was associated with cisplatin resistance in three NSCLC cells (A549, H1299 and SK-MES-1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, miRNA-488 also participates in eIF3a mediated cisplatin resistance in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Elevated HOTAIR expression associated with cisplatin resistance in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In the present study, NSCLC cell lines (H520 and SK-MES-1) were transfected with ARRB1 plasmids or small interfering ribonucleic acid (siRNA) and received treatment with DNA-damaging agents (cisplatin and etoposide). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: Combination of cisplatin and belinostat was investigated in two pairs of parental and cisplatin-resistant NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  Valproic acid (VPA) enhances cisplatin sensitivity of NSCLC cells via HDAC2 mediated down regulation of ABCA1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our present study revealed that VPA at 1 mM, which had no effect on cell proliferation, can significantly increase the sensitivity of non-small cell lung cancer (NSCLC) cells to cisplatin (DDP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " We report the case of a 58-year-old woman treated with nivolumab for an unresectable squamous NSCLC, after first-line cisplatin and gemcitabine combination chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In the present study, we investigated the role of astragaloside IV in the chemoresistance to cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We established astragaloside IV-suppressed NSCLC cell lines including A549, HCC827, and NCI-H1299 and evaluated their sensitivity to cisplatin in vitro. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, combined treatment with astragaloside IV significantly increased chemosensitivity to cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, ectopic expression of B7-H3 diminished the sensitization role of astragaloside IV in cellular responses to cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced NSCLC (RTOG 3505). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m(2) intravenously (I.V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m(2) I.V. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  CXCR4 promotes cisplatin-resistance of NSCLC in a CYP1B1-dependent manner. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we therefore investigated whether CXCR4 plays a role in the cisplatin associated resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cisplatin-resistant NSCLC cells A549/DDP and its parental A549 cells were employed in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Finally, we found CXCR4 was significantly highly expressed in cisplatin-resistant NSCLC patients and the A549/DDP cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Immunohistochemistry also verified that CYP1B1 was upregulated in NSCLC tissues of cisplatin-resistant patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, our results indicate that overexpression of CXCR4 in NSCLC promotes cisplatin resistance via CXCR4-mediated CYP1B1 upregulation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Thus, it can be used as a potential therapeutic target in NSCLC chemoresistance patients and be used as a clinical predictor of cisplatin response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A recent phase IIb study demonstrated that disulfiram (DSF) in combination with cisplatin and vinorelbine was well tolerated and prolonged the survival of patients with newly diagnosed NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Necitumumab (Portrazza\u2122, Eli Lilly and Company) is an anti-epidermal growth factor receptor monoclonal antibody approved for the first-line treatment of squamous cell NSCLC in combination with cisplatin and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Although considered a safe and effective treatment option for squamous cell NSCLC, the clinical utility of necitumumab may be limited due to the high cost of the drug as well as added toxicity when combined with cisplatin and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The acquired drug resistance would influence the efficacy of cisplatin-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B NSCLC treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MicroRNA-185-5p modulates chemosensitivity of human NSCLC to cisplatin via targeting ABCC1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our purpose is to investigate the association of miR-185-5p expression with the sensitivity of NSCLC to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: The results of the present study demonstrated that inhibition of miR-185-5p was involved in chemo-resistance of NSCLC cells to cisplatin via down-regulating ABCC1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in NSCLC? A meta-analysis of 36 randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Clinically, combined therapy of cisplatin (CDDP) and metformin is an effective treatment for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  Knockdown of OCT4 may sensitize NSCLC cells to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: Cisplatin is commonly used in NSCLC chemotherapy; however, chemoresistance to cisplatin remains a great clinical challenge. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we aimed to investigate the potential role of OCT4 in NSCLC with chemoresistance to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Knockdown of OCT4 in NSCLC cells could decrease cell proliferation, and potentiate apoptosis induced by cisplatin, suggesting OCT4 may contribute to cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Our findings indicate that targeting OCT4 could improve cisplatin effect in NSCLC, confirming their role in modulating cisplatin sensitivity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (stage IIIB or IV) were randomized to Cisplatin-Paclitaxel (Chemotherapy group, N=112) or Cisplatin-Paclitaxel plus CADI-05 (Chemoimmunotherapy group, N=109). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: There was no survival benefit with the addition of CADI-05 to the combination of Cisplatin-Paclitaxel in patients with advanced NSCLC; however, the squamous cell subset did demonstrate a survival advantage. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Cisplatin is the standard first-line chemotherapeutic agent for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: Cisplatin, is recognized as a first line therapeutic for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We then confirmed the association between MMS19 expression and the response to Cisplatin treatment in a panel of NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: GSKJ4, alone and in combination with an anti-diabetic drug metformin, induced cell death and inhibited the growth of NSCLC cell lines efficiently at concentrations non-toxic to normal cells, irrespective of their genetic backgrounds (mutations in the KRAS, TP53 and EGFR genes) and also of their resistance to cisplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A phase 3 trial of lipegfilgrastim was conducted in patients with advanced NSCLC receiving cisplatin/etoposide (which produces mild-to-moderate myelosuppression). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here, we found that miR-101 expression was downregulated in cisplatin-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Restoration of miR-101 expression inhibited EMT and increased the sensitivity of cisplatin-resistant NSCLC cells to cisplatin in vitro by targeting ROCK2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In summary, our results provide novel mechanistic insights into the role of miR-101/ROCK2 signaling in the cisplatin resistance of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A FASN-TGF-\u03b21-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Overcoming cisplatin resistance in NSCLC with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Platinum agents, including cisplatin, are the first line treatment in lung cancer, including NSCLC, which is the predominant form of lung cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We enrolled 87 NSCLC patients who had received cisplatin-based chemotherapy to confirm the association between PAK1 expression and response to chemotherapy and outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, PAK1 confers cisplatin resistance in NSCLC via \u03b2-catenin-mediated stemness. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Therefore, we suggest that clinical use of a combination of the MEK/ERK inhibitor AZD6244 and cisplatin might improve sensitivity to cisplatin-based chemotherapy and outcomes in NSCLC patients who harbor high-PAK1-expressing tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Together, our results suggest that the combination of low dose cisplatin and scriptaid is cytotoxic to NSCLC lines, can overcome hypoxia induced resistance and mutant p53- induced instability often associated with this cancer, and has the potential to be an effective therapeutic modality. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Reversal of cisplatin resistance in NSCLC stem cells by Taxus chinensis var. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The expression of various angiogenic factors was assessed in tumour samples of patients with stage III NSCLC and further evaluated in terms of response to induction paclitaxel-ifosfamide-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: The purpose of this study was to observe the clinical efficacy and toxicity of cisplatin in combination with gemcitabine or Abraxane as first-line chemotherapy for stage III/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: The efficacy of cisplatin in combination with Abraxane is better than that with gemcitabine in the treatment of NSCLC, and the treatment has less risk of hematologic toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cisplatin has been proved as chemotherapy drug for advanced human NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A combination of cisplatin and salinomycin resulted in synergistic enhancement of cytotoxicity and cell growth inhibition in NSCLC cells, accompanied with reduced activation of phospho-AKT, and TS expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our findings suggested that the down-regulation of AKT-mediated TS expression by salinomycin enhanced the cisplatin-induced cytotoxicity in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in NSCLC through a Multiscale Mechanistic Model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The methodology is applied on the retrospective data of thirteen patients with NSCLC who received cisplatin in combination with gemcitabine, vinorelbine or docetaxel in the neoadjuvant context. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Resistance to cisplatin is a major obstacle for the success of NSCLC therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These results highlight the involvement of autophagy in cisplatin-resistance development and suggest that inhibition of autophagy via tuning the Akt/mTOR signaling could be a promising strategy in the therapy for cisplatin-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "On the basis of the SQUIRE results, necitumumab was approved in combination with cisplatin and gemcitabine as a first-line treatment for advanced squamous NSCLC, both in the US and Europe, where its availability is limited to patients with EGFR-expressing tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  Clinical Observation of Docetaxel or Gemcitabine Combined with Cisplatin in the Chemotherapy after Surgery for Stage II-III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous NSCLC: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous NSCLC (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable NSCLC: A retrospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We retrospectively analyzed the efficacy and toxicity of cisplatin and either S-1 or vinorelbine for treating stage III unresectable NSCLC patients who were treated with CCRT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: Between September 2006 and May 2014, 56 patients with unresectable stage III NSCLC were treated with CCRT with S-1 and cisplatin (median age: 63 years) and 58 patients were treated with CCRT with vinorelbine and cisplatin (median age: 61 years). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study aims to demonstrate the anti-drug resistance of YPFS in cisplatin (DDP)-resistant NSCLC cells (A549/DDP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We recruited 284 NSCLC patients at advanced stage from Department of Radiotherapy in Peace Hospital Attached to Changzhi Medical College between May 2009 and May 2011, who had received cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Pemetrexed/cisplatin is the preferred chemotherapy in nonsquamous NSCLC, but the efficacy of this treatment for nonsquamous NSCLC with BM is uncertain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: The findings of clinical trials and theoretical studies about the current pemetrexed/cisplatin in the treatment of nonsquamous NSCLC with BM are also summarized to provide a reference for the application of pemetrexed/cisplatin in nonsquamous NSCLC with BM. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Whether or not pemetrexed/cisplatin is definitely effective in nonsquamous NSCLC with BM must be proven by subsequent phase III clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Calotropin (M11), an active compound isolated from Asclepias curasavica L., was found to exert strong inhibitory and pro-apoptotic activity specifically against cisplatin-induced resistant NSCLC cells (A549/CDDP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Results of this study supported the potential application of M11 on the non-small lung cancer (NSCLC) with cisplatin resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  Efficacy of Aidi Injection () on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: To investigate the efficacy of Aidi Injection () on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with NSCLC, and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The functional status of DNA repair pathways determines the sensitization effect to cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here, we aimed to assess the contribution of the Fanconi anemia (FA), homologous recombination (HR) and nucleotide excision repair (NER) pathways to cisplatin resistance in NSCLC-derived cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: We found that acquired cisplatin-resistant NSCLC-derived A549/DR cells exhibited markedly enhanced FA and HR repair pathway capacities compared to its parental A549 cells and another independent NSCLC-derived cell line, Calu-1, which possesses a moderate innate resistance to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Although we found that expression knockdown of the NER-associated genes XPA and ERCC1 sensitized the three NSCLC-derived cell lines to cisplatin, the sensitization effect was more significant in Calu-1 cells than in A549 and A549/DR cells, implying that the innate cisplatin resistance in Calu-1 cells may result from an increased NER activity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Our results indicate that the functional status of DNA repair pathways determine the sensitivity of NSCLC cells to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Direct targeting of the pathway that is involved in cisplatin resistance may be an effective strategy to surmount cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced NSCLC treated with chemoradiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " EZH2-mediated Puma gene repression regulates NSCLC cell proliferation and cisplatin-induced apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, cisplatin-induced apoptosis of EZH2-knocking down NSCLC cells was elevated as a consequence of increased PUMA expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, Rad51c knockdown increased the killing effect of ionizing radiation (IR) and enhanced cisplatin-induced apoptotic cells in NSCLC cells by disrupting the repair of cisplatin- and IR-induced DNA damage. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, ectopic expression of Rad51c dramatically enhanced NSCLC cell resistance to cisplatin and radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "[Epub ahead of print]  An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: In this open-label, phase II study, patients with stage IV nonsquamous NSCLC and a performance status of 0 to 1 were randomized (1:1) to receive 20 mg/kg cixutumumab, 500 mg/m(2) pemetrexed, and 75 mg/m(2) cisplatin (cixutumumab [n\u00a0= 87]) or pemetrexed and cisplatin (control [n\u00a0= 85]). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Efficacy was not improved in patients with nonsquamous NSCLC when cixutumumab was added to pemetrexed/cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " EHD1 confers resistance to cisplatin in NSCLC by regulating intracellular cisplatin concentrations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, resistance to cisplatin (CDDP) remains a major challenge in NSCLC treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Using DNA microarrays, we performed a genome-wide analysis of cisplatin-resistant NSCLC cells to identify the involvement of the EHD1 gene in this resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Inhibition of miR-141 reverses cisplatin resistance in NSCLC cells via upregulation of programmed cell death protein 4. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We aimed to investigate the role of miR-141 in cisplatin resistance in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PG also significantly enhanced the sensitivity of NSCLC cells to cisplatin-induced apoptosis, and this effect was attenuated by overexpression of HO-1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Therapeutic approaches targeting COL11A1 may facilitate the optimization of cisplatin treatment of NSCLC by overcoming chemoresistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB NSCLC: 10-year follow-up of the SAKK 16/01 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The phase III PROCLAIM trial, recently published in the Journal of Clinical Oncology entitled \"PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous NSCLC\", compared two different chemotherapy regimens given concurrently with radiotherapy in patients with stage III non-squamous lung cancer: pemetrexed plus cisplatin versus cisplatin plus etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We investi-gated the possible roles of GSTP1 Ile105Val and XRCC1 Arg194Trp, and Arg399Gln gene polymorphisms in the prognosis of advanced non-small cell lung carcinoma (NSCLC) patients with cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: From January 2007 to March 2010, 58 patients with NSCLC were included who were received 18F-fluorodeoxyglucose (18F-FDG) PET/CT before and following 40 Gy radiotherapy with the concurrent cisplatin-based chemotherapy (CCRT). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIM: PROCLAIM, a phase III trial of patients with nonsquamous NSCLC comparing concurrent pemetrexed-cisplatin and thoracic radiation therapy followed by consolidation pemetrexed, did not meet its primary endpoint of superior overall survival versus etoposide-cisplatin and thoracic radiation therapy followed by a consolidation platinum doublet of choice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: For East Asian patients, pemetrexed-cisplatin combined with thoracic radiation therapy, followed by consolidation pemetrexed, did not improve overall survival but did have a good safety profile with a trend for improved progression-free survival and objective response rate compared to standard chemoradiotherapy for stage III unresectable nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with potentially operable stage IIIA(N2) or selected stage IIIB NSCLC received three cycles of cisplatin/paclitaxel (induction chemotherapy) followed by neoadjuvant radiochemotherapy (RCT) to 45 Gy (1.5 Gy twice per day concurrent cisplatin/vinorelbine) within the ESPATUE (Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA[N2] and Selected IIIB NSCLC After Induction Chemotherapy and Concurrent Chemoradiotherapy) trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous NSCLC: cost minimization analysis in 12 European countries. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: A combination of vinorelbine and cisplatin is a standard treatment in NSCLC; oral vinorelbine is registered in 45 countries. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Pemetrexed and cisplatin are recommended in front-line chemotherapy of non-squamous NSCLC (NS-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Silence of fibronectin 1 increases cisplatin sensitivity of NSCLC cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, the regulation of FN1 on cisplatin resistance in NSCLC has not been investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study aims to illustrate the effect of FN1 on cisplatin resistance in NSCLC and explore potential mechanisms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Taken together, our findings first suggest that FN1 plays a role in the development of cisplatin resistance in NSCLC, possibly by modulation of \u03b2-catenin signaling through interaction with integrin-\u03b21 in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with pathologically confirmed stage IV sq-NSCLC were randomized 1:1 to receive a maximum of six 3-week cycles of gemcitabine (1250 mg/m(2) i.v., days 1 and 8) and cisplatin (75 mg/m(2) i.v., day 1) chemotherapy with or without necitumumab (800 mg i.v., days 1 and 8). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: In line with SQUIRE ITT, addition of necitumumab to gemcitabine-cisplatin significantly prolonged OS and was generally well tolerated in the subpopulation of patients with EGFR-expressing advanced sq-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " 68P Inflammatory meditated mechanisms of cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " 24P CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " 162P: Molecular markers in advanced NSCLC patients receiving gemcitabine & cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " 155P: PD-L1 polymorphism can predict clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PD-L1 polymorphism can predict clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " This study was conducted to investigate whether polymorphisms of genes involved in immune checkpoints can predict the clinical outcomes of patients with advanced stage NSCLC after 1st line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PD-L1 rs2297136T\u2009>\u2009C and rs4143815C\u2009>\u2009G polymorphisms may be useful for the prediction of clinical outcome of 1(st) line paclitaxel-cisplatin chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Association of glutathione S-transferase (GST) genetic polymorphisms with treatment outcome of cisplatin-based chemotherapy for advanced NSCLC in a Chinese population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Potential Combinational Anti-Cancer Therapy in NSCLC with Traditional Chinese Medicine Sun-Bai-Pi Extract and Cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced NSCLC, having shown good efficacy and activity in clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of the present study is to investigate the value of Pan-Bcl-2 inhibitor as sensitizer for the chemotherapy of cisplatin-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We found the obatoclax but not the ABT-737 significantly decreased the IC50 (half maximal inhibitory concentration) of cisplatin in cisplatin-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, inhibition of MCL-1 recovered the function of NOXA and BAK in cisplatin-resistant NSCLC cells, leading to the promotion of mitochondrial apoptosis induced by cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Interestingly, our date indicated the obatoclax also reversed the cross-resistance in cisplatin-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: NSCLC cell lines A549 and H2228 were exposed to cisplatin in a variety of cell density conditions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: CDR to cisplatin was induced in NSCLC cells, whereas CDR to crizotinib, an inhibitor of activin receptor-like kinase, was not observed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: CDR to cisplatin can occur in NSCLC cells, and the TGF-\u03b2 pathway is associated with the regulation of CDR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We here hypothesized that miR-184 could be down-regulated by E6 oncoprotein to confer cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, a decrease in miR-184 level by E6 oncoprotein may predict unfavorable response to cisplatin-based chemotherapy in HPV-infected NSCLC patients via increasing Bcl-2 expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Nedaplatin sensitization of cisplatin-resistant human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin (DDP) has been one of the most widely used chemotherapy drugs for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MiR-1244 sensitizes the resistance of NSCLC A549 cell to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of this study was to find and investigate the function of miRNAs in cisplatin (DDP)-resistant NSCLC A549 cell. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Several landmark study elucidated that adjuvant cisplatin-based chemotherapy for stage II-IIIA NSCLCpatients after appropriate surgical resection can significantly improve 5-year survival rate. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "According to these evidence, cisplatin-based adjuvant chemotherapy for stage II-III A NSCLC and UFT for stage I NSCLC patients with a tumor lager than 2 cm are used standard postoperative adjuvant chemotherapy in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: This trial assessed the efficacy and safety of high-dose pemetrexed plus cisplatin in NSCLC with brain metastases after WBRT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of this study was to confirm adjuvant chemotherapy of HSS with docetaxel plus cisplatin (DP) against NSCLC by evaluating antitumor activity and attenuated effect. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin is a well-studied and widely used chemotherapeutic agent and is effective in the treatment of the advanced human NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we characterize the role of curcumin in the cytotoxicity, p38 MAPK activation, and XRCC1 expression affected by cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We show that curcumin enhanced the cytotoxicity induced by cisplatin in two NSCLC cells, A549 and H1703. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Knockdown of XRCC1 in NSCLC cells by transfection of XRCC1 siRNA or inactivation of p38 MAPK resulted in enhancing the cytotoxicity and cell growth inhibition induced by cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Curcumin inhibited the expression of XRCC1 in cisplatin-exposed NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These findings suggested that the downregulation of XRCC1 expression by curcumin can enhance the chemosensitivity of cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: The NSCLC CDX expressed lung lineage markers TTF1 and CK7 and was unresponsive to cisplatin and pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin-resistant A549 and H157 (A549CisR and H157CisR) NSCLC cells show increased stemness of cancer stem cells (CSCs) compared to their parental cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin-induced apoptosis in NSCLC cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin is a highly effective anticancer drug for treatment of various tumors including NSCLC, and is especially useful in cases nonresponsive to molecular-targeted drugs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here we demonstrated that DNA-damage inducible proapoptotic BH3 (Bcl-2 homology region 3)-only Bcl-2 family members, Noxa, Puma, Bim and Bid, are not involved in cisplatin-induced apoptosis in human NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "From this result, we tested the effect of ABT-263 (Navitoclax), the specific inhibitor of Bcl-2 and Bcl-XL, but not Mcl-1, and found that ABT-263 synergistically enhanced cisplatin-induced apoptosis in NSCLC cells in the presence or absence of p53. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These results indicate a novel regulatory system in cisplatin-induced NSCLC cell apoptosis, and a candidate efficient combination chemotherapy method against lung cancers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase II, open-label trial of bortezomib (VELCADE(\u00ae)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Preclinical and phase I clinical data suggest activity of bortezomib in NSCLC, either as monotherapy or in combination with chemotherapeutic agents including gemcitabine and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " SKA1 regulates the metastasis and cisplatin resistance of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Currently, chemotherapy with platinum-based drugs including cisplatin is the most effective therapy for the treatment of non-small cell lung carcinoma (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, we determined that SKA1 contributed to cisplatin resistance in NSCLC cells by protecting these cells from cisplatin-induced cell apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "SKA1 is required for metastasis and cisplatin resistance of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Periostin Contributes to Cisplatin Resistance in Human NSCLC A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This study was done to explore the function of periostin in the development of cisplatin (CDDP) resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: A total of 1093 patients with stage IV squamous NSCLC were randomized 1:1 to receive necitumumab (800 mg absolute dose intravenously [IV]) plus gemcitabine-cisplatin (gemcitabine\u00a0= 1250 mg/m(2) IV on days 1 and 8; cisplatin\u00a0= 75 mg/m(2) IV on day 1) or gemcitabine-cisplatin alone (every 21 days) for up to six cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " We evaluated the effects of cisplatin and paclitaxel on taste acuity and their associations with nutritional and health-related quality of life (HRQL) in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Sensitivity to taste increased with paclitaxel and cisplatin CT, making foods more unpleasant, and it was associated with neuropathy, worse HRQL, and reduced nutrient intake in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, expression of MICA/B was assessed in NSCLC cell lines treated with cisplatin in order to evaluate the regulatory mechanisms of MICA/B expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to NSCLC Cells In Vitro. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Downregulation of microRNA-196a enhances the sensitivity of NSCLC cells to cisplatin treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Although miRNA-196a has been implicated in the progression of human lung cancer, its role in enhancing the sensitivity of non\u2011small cell lung cancer (NSCLC) cells to cisplatin has not yet been confirmed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of this study was to evaluate the effects of miRNA\u2011196a on the sensitivity of NSCLC cells to cisplatin in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, the downregulation of miRNA-196a sensitized the SPC\u2011A\u20111 and A549 NSCLC cells to cisplatin in vitro and in vivo, by inducing apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The findings of this study demonstrate that the administration of cisplatin in combination with miRNA-196a-targeted therapy may be a potential therapeutic strategy for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: The effects of pirfenidone alone and in combination with cisplatin on human patient-derived CAF cell lines and NSCLC cell lines were examined. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, the combination of cisplatin and pirfenidone in NSCLC cells (A549 and H157 cells) leads to increased apoptosis and synergistic cell death. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Our studies reveal for the first time that the combination of cisplatin and pirfenidone is active in preclinical models of NSCLC and therefore may be a new therapeutic approach in this disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, miR-194 was downregulated in in cisplatin-resisted human NSCLC cell line-A549/DDP and overexpression of miR-194 increases cisplatin sensitivity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These findings suggested that miR-194 inhibits proliferation and metastasis and reverses cisplatin-resistance of NSCLC cells and may be useful as a new potential therapeutic target for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIM: It is important to know the tumor resistance against cisplatin before the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The purpose of this study was to evaluate the response to treatment and survival in patients with NSCLC treated with cisplatin-based chemotherapy according to excision repair cross-complementation 1 (ERCC1) expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [SIRT1 Influences the Sensitivity of A549 NSCLC Cell Line to \u2029Cisplatin via Modulating the Noxa Expression]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study describes the case of a 65-year-old female patient with stage IIA NSCLC who received cisplatin/pemetrexed treatment at the Leo W. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " miR-96 induces cisplatin chemoresistance in NSCLC cells by downregulating SAMD9. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin is effective as a single agent or in combination with other drugs for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A concerning clinical challenge with cisplatin-based NSCLC chemotherapy is the intrinsic and acquired chemoresistance to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "To the best of our knowledge the present study explored the role of miRNA/SAMD9 signaling in regulating cisplatin chemoresistance in NSCLC for the first time. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "miR-96 and SAMD9 were overexpressed and knocked down in the human NSCLC H358 and H23 cell lines and the half maximal inhibitory concentration (IC50) of cisplatin and cell apoptosis rate under cisplatin treatment were used as measures of cisplatin chemoresistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present results identified that overexpression of miR-96 in NSCLC cells markedly decreased SAMD9 expression and cisplatin-induced apoptosis, and increased the cisplatin IC50, which could be eliminated by overexpression of SAMD9. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "By contrast, knocking down miR-96 in NSCLC cells using antagomir-96 significantly increased SAMD9 expression and the cisplatin-induced apoptosis and decreased cisplatin IC50, which could be completely reversed by a knockdown of SAMD9. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, the current study demonstrates that miR-96 targets and downregulates SAMD9 in NSCLC, which decreases cisplatin-induced apoptosis and induces cisplatin chemoresistance in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The present study was performed to investigate the association of single nucleotide polymorphisms (SNPs) located in the miRNA target sites with the clinical outcomes of first line paclitaxel-cisplatin chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These findings suggest that the four SNPs, especially ETS2 rs461155A>G, could be used as biomarkers predicting the clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Between October 2009 and October 2011, a total of 308 patients of NSCLC on stage IIIA, IIIB or IV, treated with cisplatin-based chemotherapy were included. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Treatment failure followed by relapse and metastasis in patients with NSCLC is often the result of acquired resistance to cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin in the modern era: The backbone of first-line chemotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The treatment of advanced NSCLC may be changing, but the cisplatin-based doublet remains the foundation of treatment for the majority of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we examined the effects of suberoylanilide hydroxamic acid (SAHA) and cisplatin on DNA damage repairs, and determined the combination effects of SAHA and cisplatin on human NSCLC cells in response to treatment of ionizing radiation (IR), and on tumor growth of lung cancer H460 xenografts receiving radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our results showed that SAHA and cisplatin compromise distinct DNA damage repair pathways, and treatment with SAHA enhanced synergistic radiosensitization effects of cisplatin in established NSCLC cell lines in a p53-independent manner, and decreased the DNA damage repair capability in cisplatin-treated primary NSCLC tumor tissues in response to IR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: A discovery set (one trial, n = 824) and a validation set (three trials, n = 984) that evaluated the benefit of platinum-based adjuvant chemotherapy in NSCLC were used as part of the LACE-Bio (Lung Adjuvant Cisplatin Evaluation Biomarker) study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin (cis-diaminedichloroplatin (II), CDDP) is part of the standard therapy for a number of solid tumors including NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " We conducted a study to investigate the association between the clinical outcome and GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in advanced NSCLC patients with cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We further found that TFAM downregulation in NSCLC cells led to increased apoptotic cell death and enhanced the sensitivity of NSCLC cells to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIA/B unresectable nonsquamous NSCLC randomly received (1:1) pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) intravenously every 3 weeks for three cycles plus concurrent TRT (60 to 66 Gy) followed by pemetrexed consolidation every 3 weeks for four cycles (arm A), or standard therapy with etoposide 50 mg/m(2) and cisplatin 50 mg/m(2) intravenously, every 4 weeks for two cycles plus concurrent TRT (60 to 66 Gy) followed by two cycles of consolidation platinum-based doublet chemotherapy (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Pemetrexed-cisplatin combined with TRT followed by consolidation pemetrexed was not superior to standard chemoradiotherapy for stage III unresectable nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous NSCLC: Quality of Life Results From a Randomized Phase III Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous NSCLC (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Concurrent RT with oral vinorelbine and cisplatin demonstrated a favourable safety profile and represents a suitable treatment regimen for inoperable stage\u00a0III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (TREAT study) was designed to test the hypothesis that a protocol with reduced toxicity might improve feasibility of postoperative delivery of adjuvant chemotherapy drugs to patients with NSCLC, thereby improving compliance and, potentially, survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Necitumumab is approved as a part of combination therapy (with gemcitabine and cisplatin) in the USA for the first-line treatment of metastatic squamous NSCLC, and regulatory submissions have been made in the EU for this same indication. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This article summarizes the milestones in the development of necitumumab leading to this first approval for the first-line treatment of metastatic squamous NSCLC, in combination with gemcitabine and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous NSCLC: Final Overall Survival Results from a Randomized Phase 3 Study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous NSCLC and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Association of GSTs gene polymorphisms with treatment outcome of advanced NSCLC patients with cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "YAP1 ablation significantly improved sensitivities not only to cisplatin but also to ionizing radiation, both of which are DNA-damaging interventions, in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A pharmacological inhibitor of YAP1 signaling, verteporfin also synergized with cisplatin, radiation and erlotinib in NSCLC cells by potentiating cisplatin and radiation-related double-stranded breaks and decreasing expression of YAP1 and EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin has been a key chemotherapy drug for treatment of NSCLC for decades. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we aimed to investigate whether Fisetin was capable of enhancing cytotoxicity of Cisplatin in Cisplatin-resistant NSCLC cells, and explore the possible signaling pathways involved. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cisplatin-resistant NSCLC cells, A549-CR, was established by repeated subculturing of A549 cells with increasing Cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phloretin exhibits an anticancer effect and enhances the anticancer ability of cisplatin on NSCLC cell lines by regulating expression of apoptotic pathways and matrix metalloproteinases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Besides, evaluations revealed that phloretin enhanced the anticancer effects of cisplatin on inhibition of proliferation and induction of apoptosis in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, the present study demonstrated that phloretin possessed anticancer effects and enhanced the anticancer effects of cisplatin on NSCLC cell lines by suppressing proliferation, inducing apoptosis and inhibiting invasion and migration of the cells through regulating apoptotic pathways and MMPs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here we study the molecular basis of E1a mediated sensitivity to cisplatin in an experimental model of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Utilization of arsenic trioxide as a treatment of cisplatin-resistant NSCLC PC-9/CDDP and PC-14/CDDP cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Thus, it was hypothesized that ATO may also be active against cisplatin-resistant NSCLC PC-9/CDDP and PC-14/CDDP cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study also evaluated the effects of ATO on the cisplatin-sensitive NSCLC PC-9 and PC-14 cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Although it is likely that cisplatin resistance in PC-9 cells does not depend on the GS-X pump systems, ATO was effective against cisplatin-resistant NSCLC PC-9/CDDP and PC-14/CDDP cells in combination chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We sought to explore the potential synergistic antitumor activity and underlying mechanisms of the pro-apoptotic agent PAC-1 plus cisplatinum (Cis) in NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: PAC-1 showed anti-tumor activity in NSCLCs\u2005in vitro and a synergistic effect with cisplatin in EGFR(wt)KRAS(wt) H1299 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cost Distribution Analysis Related to the Use of Tyrisine-Kinase Inhibitors (Tki) and the Combination of Pemetrexed/Cisplatin in the Treatment of Non-Small Cell Lung Cancer (Nsclc) Locally Advanced or Metastatic in Presence of Epidermal Growth Factor Receptor (Egfr) Mutations in a Mexican Institutional Context. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In the present study, we showed that curcumin enhanced the sensitivity of the double-positive (CD166+/EpCAM+) CSC subpopulation in NSCLC cell lines (A549 and H2170) to cisplatin-induced apoptosis and inhibition of metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our results revealed that initial exposure of NSCLC cell lines to curcumin (10-40 \u00b5M) markedly reduced the percentage of viability to an average of ~51 and ~54% compared to treatment with low dose cisplatin (3 \u00b5M) with only 94 and 86% in both the A549 and H2170 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, sensitisation of NSCLC cell lines to curcumin through combined treatment enhanced the single effect induced by low dose cisplatin on the apoptosis of the double-positive CSC subpopulation by 18 and 20% in the A549 and H2170 cells, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, we provided novel evidence of the previously unknown therapeutic effects of curcumin, either alone or in combination with cisplatin on the inhibition of the CD166+/EpCAM+ subpopulation of NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This finding demonstrated the potential therapeutic approach of using curcumin that may enhance the effects of cisplatin by targeting the CSC subpopulation in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient NSCLC in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "AZD6738 potentiates the cytotoxicity of cisplatin and gemcitabine in NSCLC cell lines with intact ATM kinase signaling, and potently synergizes with cisplatin in ATM-deficient NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here, our findings testified that CD166(+) cells which were derived from fresh primary NSCLC samples displayed stem cell-like features and were resistant to chemotherapy drug cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Thus, this study widens the window for identification and targeting of a cisplatin-resistant population and contributes to the development of potential therapeutics to improve the current treatment modalities in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous NSCLC: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Serial dilutions of gemcitabine, cisplatin, 5-fluorouracil, vinorelbine, and paclitaxel were administered to the A549 NSCLC cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here, we hypothesized that mutant p53 could upregulate Nrf2 expression at the transcriptional level, thereby conferring cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Collectively, mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression, and Nrf2 mRNA level may predict chemotherapeutic response and outcomes in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We made use of three different sets of cell lines, A549 and H2030 NSCLC and A2780 ovarian cancer cells and their cisplatin-resistant variants. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Therefore, we suggest that cytoplasmic p27 (N-/C+) via ERK-activated Bcl-2 expression may predict an unfavorable response to cisplatin-based chemotherapy and poor outcomes in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Take-home message in times of crisis: Is it really better to treat with cisplatin & pemetrexed than cisplatin & gemcitabine in first line NSCLC? The power of statistical considerations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Since the data of pemetrexed in combination with cisplatin were published, several oncologists chose this schedule as first choice in non squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: We firstly investigated the expression of Pokemon in patients with NSCLC, then characterized the role of Pokemon in evaluating the response to combined cisplatin and paclitaxel chemotherapy and prognosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: In this study, 61 patients with previously untreated locally advanced or metastatic NSCLC were treated with a combination chemotherapy comprising cisplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: The serum level of Pokemon correlated with efficacy of cisplatin and paclitaxel combination chemotherapy and survival time, which indicated that Pokemon may be a potentially useful biomarker for predicting treatment effectiveness of first-line chemotherapy and prognosis in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the treatment of locally recurrent stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIMS: To study the effectiveness of human recombinant endostatin injection (Endostar\u00ae) combined with cisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CT perfusion imaging. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC in the United States. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVES: To determine the cost-effectiveness of tyrosine kinase inhibitors erlotinib or afatinib, or chemotherapy cisplatin-pemetrexed, for first-line treatment of advanced epithelial growth factor receptor mutation-positive NSCLC in the United States. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Model transition and adverse-effect probabilities were from two published phase III trials: EURTAC (Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive NSCLC) and LUX-Lung (Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma) 3. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Nitric oxide- and cisplatin-releasing silica nanoparticles for use against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Nitric oxide (NO) and cisplatin releasing wrinkle-structured amine-modified mesoporous silica (AMS) nanoparticles have been developed for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The results show that for NSCLC cell lines (i.e., H596 and A549), the toxicity of NO- and cisplatin-loaded silica nanoparticles (NO-Si-DETA-cisplatin-AMS) is significantly higher than that of silica nanoparticles loaded with only cisplatin (Si-DETA-cisplatin-AMS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Cisplatin-resistant NSCLC cells are often characterized by alterations in vitamin B-related metabolic processes, including the overexpression and hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1) and the downregulation of pyridoxal kinase (PDXK), correlating with elevated apoptosis resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP NSCLC cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " We aimed to explore the possible mechanism of microRNA-196a (miR-196a) inhibition and reversion of drug resistance to cisplatin (DDP) of the A549/DDP NSCLC cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cytotoxic properties were studied in three human cancer cell lines derived from cisplatin sensitive ovarian teratocarcinoma (CH1/PA-1), cisplatin insensitive colon carcinoma (SW480) and NSCLC (A549). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We analyzed global gene expression profiles of NSCLC clones surviving a pulse treatment with cisplatin and mapped deregulated signaling networks in silico by Ingenuity Pathway Analysis (IPA). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: The pooled cisplatin-surviving NSCLC clones from each of the biological replicates demonstrated heterogeneous gene expression patterns both in terms of the number and the identity of the altered genes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Knockdown of DKK1 by siRNA sensitized for cisplatin in two different NSCLC cell lines and in ovarian A2780 cells, but not in the A2780 cis subline made resistant to cisplatin by chronic exposure, suggesting a role of DKK1 in intrinsic but not acquired platinum refractoriness. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: We identified DKK1 as a possible marker of a cisplatin-refractory phenotype and as a potential novel therapeutic target to improve platinum response of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " We investigated the association between the polymorphisms GSTP1 rs1695 and XRCC1 rs1799782 and rs25487 and the clinical outcome of patients with NSCLC receiving cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The results of our study suggest that the GSTP1 rs1695 and XRCC1 rs25487 polymorphisms might affect the clinical outcome of patients with advanced NSCLC receiving cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III NSCLC: an open-label phase II multicentre trial (COVeRT study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This South Australian multicentre prospective phase II study evaluated the safety, activity and outcomes of combination oral vinorelbine and cisplatin administered concurrently with radiotherapy for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Two cycles of chemotherapy with oral vinorelbine and cisplatin administered concurrently with radical radiation had an acceptable toxicity profile and was active in inoperable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " miR-15a enhances the anticancer effects of cisplatin in the resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Resveratrol enhanced anticancer effects of cisplatin on NSCLC cell lines by inducing mitochondrial dysfunction and cell apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, there are scarce reports on its anticancer effects in NSCLC and its auxiliary function on the anticancer effects of cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " IL-6 signaling contributes to cisplatin resistance in NSCLC via the up-regulation of anti-apoptotic and DNA repair associated molecules. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin-based chemotherapy is currently the most effective treatment regimen for NSCLC, but eventually tumor resistance develops which limits its success. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The potential implication of IL-6 signaling in the cisplatin resistance of NSCLC was explored by testing whether NSCLC cells with different levels of intracellular IL-6 show different responses to the cytotoxic treatment of cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "When the cisplatin cytotoxicity of the IL-6 knocked down human NSCLC cells (A549IL-6si and H157IL-6si) were compared with their corresponding scramble control cells (A549sc and H157sc), higher cisplatin cytotoxicity was found in IL-6 si cells than sc cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These results provide potential for combining cisplatin and inhibitors of IL-6 signaling or its downstream signaling pathway as a future therapeutic approach in preventing development of cisplatin resistant NSCLC tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with stage IB-III MAGE-A3-positive NSCLC who were or were not undergoing standard cisplatin/vinorelbine chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND AND OBJECTIVE: Cisplatin is a standard first-line chemotherapeutic agents for treating advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in NSCLC by targeting RUNX2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our present study demonstrated for the first time that downregulation of miR-218 may contribute to the chemoresistance of NSCLC cells to cisplatin, which leads to upregulation of RUNX2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "For patients with non-squamous NSCLC, Pemetrexed plus Cisplatin is recommended in first-line systemic therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cisplatin-based doublet chemotherapy is commonly used in NSCLC patients after surgery as adjuvant therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, high ABCG4 expression was associated with a poor prognosis in patients with NSCLC treated with cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: The aims of this study were to evaluate the efficacy and safety of S-1 versus cisplatin (CDDP)+S-1 in patients with completely resected stage II and IIIA NSCLC, and to identify predictive biomarkers whose expression in the tumors was significantly associated with patient outcome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In the present study we first found that HVJ-E exhibited cytotoxic effects in the NSCLC cell (NSCLC) line A549 and cisplatin-resistant A549\u00a0cells (A549/DDP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A total of 82 NSCLC patients undergoing Docetaxel combined with Cisplatin were randomly divided into group A and group B. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Previously known effects of miR-138 upregulation on NSCLC, proliferation, cell cycle division, and cisplatin sensitivity were examined in H460 and SPC-A1 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The effects of forced overexpression of CCND3 on miR-138-induced NSCLC regulations were further examined by proliferation, cell cycle, cisplatin sensitivity, and migration assays, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Our previous study demonstrated that promoter methylation of human mutL homolog 1 (hMLH1) is involved in determining sensitivity to cisplatin in NSCLC A549/DDP cell line, The present study was designed to determine whether DNA methylation of hMLH1 affects the prognosis of NSCLC patients who received cisplatin-based adjuvant chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Methylation status of hMLH1 was examined by nested methylation-specific PCR (nested MSP) in 84 archived NSCLC surgically resected tissue specimens from patients receiving cisplatin-based adjuvant chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Multivariate logistic regression analysis showed that hMLH1 methylation may function as a significant independent prognostic factor for tumor recurrence in NSCLC patients treated with adjuvant cisplatin (HR 3.114, 95% CI 1.032-9.399; P=0.044). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "To conclude, the cisplatin-based adjuvant chemotherapy is more beneficial for NSCLC patients without hMLH1 methylation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Cisplatin and etoposide in these doses with conventionally fractionated TRT is a well-tolerated, effective treatment schedule in the definitive treatment of unresectable or inoperable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " REV3L modulates cisplatin sensitivity of NSCLC H1299 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Due to its critical role in translesion DNA synthesis, whether REV3L modulates cisplatin response in NSCLC cells remains unknown. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III NSCLC: KCSG-LU05-04. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally advanced NSCLC (LA-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: A total of 60 patients with advanced NSCLC were divided into two groups using a random number table, i.e., the gemcitabine plus cisplatin (GP) chemotherapy alone group (26 patients) and the FRG + GP chemotherapy group (34 patients), for 60-day treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The cisplatin and gemcitabine regimen is one of the most effective regimens against advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The aim of the present study was to investigate the efficacy and safety of combined therapy with iodine-125 seed implantation and the gemcitabine plus cisplatin chemotherapeutic regimen, as well as treatment with the radiosensitizer sodium glycididazole (CMNa), in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our objectives were to combine Nutlin-3 with cisplatin (CDDP), a well-known activator of the p53 pathway, in a series of NSCLC cell lines in order to increase the cytotoxic response to CDDP. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous NSCLC: A Biomarker-Stratified Randomized Phase II Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: We investigated whether thymidylate synthase (TS) expression is a predictive marker for the clinical outcome of pemetrexed/cisplatin in patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive NSCLC: analyses from the phase III, randomized, open-label, ENSURE study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced NSCLC patients with cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " We investigated the association between the clinical outcome and GSTP1 and XRCC1 gene polymorphisms in advanced NSCLC patients with cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "GSTP1 A313G and XRCC1 Arg399Gln gene polymorphisms might influence the response to cisplatin-based chemotherapy and affect the clinical outcome of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced NSCLC harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous NSCLC With Particular Regard to the KRAS Status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous NSCLC and wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin-based chronotherapy for advanced NSCLC patients: a randomized controlled study and its pharmacokinetics analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: We intended to evaluate the superiority of cisplatin-based chronotherapy in the treatment of patients with advanced NSCLC and investigate the relationship between the circadian rhythm and the variability of pharmacokinetics for cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our recent study has demonstrated that AT-101 enhanced the antitumor effect of cisplatin (CDDP) in a murine model of NSCLC via inhibition of the interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Finally, when PTEN was up-regulated in NSCLC cells, it reversed the effects of miR-2b over-expression on NSCLC migration and cisplatin chemosensitivity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, these results suggested that Meg3 may have a crucial role in the development of cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, our study found that ERCC1 rs11615 polymorphism can influence the chemotherapy response and overall survival of NSCLC patients receiving cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous NSCLC (SQUIRE): an open-label, randomised, controlled phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "INTERPRETATION: Our findings show that the addition of necitumumab to gemcitabine and cisplatin chemotherapy improves overall survival in patients with advanced squamous NSCLC and represents a new first-line treatment option for this disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: This study is to evaluate the association of polymorphisms of glutathione S-transferase P1 (GSTP1), copper-transporting P-type adenosine triphosphatase A (ATP7A) and X-ray repair cross-complementing group 1 (XRCC1) with the efficacy and toxicity of cisplatin-based treatment in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: The outcomes of 97 advanced NSCLC patients treated with cisplatin-based chemotherapy were estimated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Advanced NSCLC patients with AA genotype of GSTP1 would obtain better curative effect followed with more risk of anemia when treated by cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here we explored the effects of these polymorphisms on the chemosensitivity and clinical outcome in Chinese NSCLC patients treated with gemcitabine-cisplatin regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: DNA sequencing was used to evaluate genetic polymorphisms of GSTP1 Ile105Val and RRM1 C37A-T524C in 47 NSCLC patients treated with gemcitabine-cisplatin regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Compared with single detection of genetic polymorphisms of GSTP1 Ile105Val or RRM1 C37A-T524C, joint detection of both may be more helpful for patients with NSCLC to receive gemcitabine-cisplatin regimens as the first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Especially, genetic polymorphism of RRM1 is more likely to be used as an important biomarker to predict the response and toxicity of gemcitabine-cisplatin combination chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: Vinorelbine plus cisplatin is a commonly used doublet for the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: This multicenter phase II open-label, non-comparative study was designed to evaluate the three-weekly combination of cisplatin 80 mg/m(2) on day 1 in combination with oral vinorelbine on day 1 and 8 in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We and others have previously described in NSCLC the presence of cisplatin-resistant CD133\u207a cells with tumor-initiating potential and co-expression of CXCR4 as possible indicator of TICs with disseminating potential. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Acquired resistance to cisplatin treatment is a caveat when treating patients with NSCLC and malignant pleural mesothelioma (MPM). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We investigated the expression of Gb3, MDR1 and MRP1 in NSCLC and MPM cells with acquired cisplatin resistance, and if GCS activity or MDR1 pump inhibitors would reduce their expression and reverse cisplatin-resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Cell surface expression of Gb3, MDR1 and MRP1 and intracellular expression of MDR1 and MRP1 was analyzed by flow cytometry and confocal microscopy on P31 MPM and H1299 NSCLC cells and subline cells with acquired cisplatin resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Cell surface Gb3 expression is a likely tumour biomarker for acquired cisplatin resistance of NSCLC and MPM cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Therapy with GCS activity inhibitors or toxin targeting of the Gb3 receptor may substantially reduce acquired cisplatin drug resistance of NSCLC and MPM cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced NSCLC among East Asian populations: A meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Whether nedaplatin and cisplatin are equally effective for advanced NSCLC remains uncertain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We conducted a literature search to identify trials that had investigated the substitution of nedaplatin for cisplatin in the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Pemetrexed in combination with cisplatin is approved in the first line setting and as monotherapy in the switch or continuous maintenance of Non Squamous A-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: The aim of this study was to investigate the predictive value of Nin one binding (NOB1) expression for response to cisplatin-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Logistic regression analysis showed TMN stage, histopathological grade and NOB1 expression were independent prognosis factors for early response to cisplatin-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Our results suggest that enhanced expression of NOB1 related with poor early response to cisplatin-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Knockdown of NIPBL in NSCLC cell lines significantly reduced cellular proliferation, migration, and invasion, and enhanced cellular apoptosis and sensitivity to cisplatin, paclitaxel, and gemcitabine hydrochloride. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The results showed that in patients with an EGFR mutation, adjuvant EGFR-tyrosine kinase inhibitor monotherapy after complete resection significantly prolongs disease-free survival compared with adjuvant chemotherapy and/or radiotherapy.BACKGROUND: Adjuvant cisplatin-based chemotherapy improves NSCLC 5-year survival rates after resection. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "First, we detected miR-638 expression levels in vitro in the culture supernatants of the NSCLC cell line SPC-A1 treated with cisplatin, as well as the apoptosis rates of SPC-A1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In vivo data further revealed that cisplatin induced miR-638 upregulation in the serum derived from mice xenograft models, and in NSCLC patient sera, miR-638 expression patterns after chemotherapy significantly correlated with lymph node metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin is one of the most common chemotherapeutic drugs for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our study found that panobinostat, an HDAC inhibitor, increased the cisplatin sensitivity of several NSCLC cell lines with low ERCC1 expression but not those with high ERCC1 expression or gain-of-function (GOF) p53 mutation despite of ERCC1 expression level. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "ERCC1 knockdown increased the cisplatin sensitivity of NSCLC cell lines with high ERCC1 expression without GOF p53 mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, in low ERCC1 expression NSCLC cell lines, knockdown of GOF mutant p53 enhanced cisplatin sensitivity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Therefore, this study demonstrated that ERCC1 expression combined with p53 mutation status may determine the efficacy of cisplatin and HDACi combined therapy and guide the development of future NSCLC therapies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Downregulation of TSN by RNAi in NSCLC cells led to strong potentiation of cell death in response to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Downregulation of S100A11 by RNAi resulted in enhanced sensitivity of NSCLC cells to cisplatin, oxaliplatin and 5-fluouracil. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: In the phase III, LUX-Lung 6 trial, afatinib prolonged progression-free survival (PFS) versus cisplatin/gemcitabine in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-na\u00efve patients with advanced/metastatic (stage IIIB/IV) squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: The data showed a down-regulated of miR-148b expression and evaluated methyltransferases (DNMTs) expression in cisplatin-resisted human non-small cell lung cancer (NSCLC) cell line-A549/DDP and SPC-A1/DDP compared with their parental A549 and SPC-A1 cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Adjuvant cisplatin-based chemotherapy (ACT) after resection of stages II-IIIA NSCLC modestly increased survival in several clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced NSCLC: TCOG0701 CATS trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV NSCLC, an Eastern Cooperative Oncology Group performance status of 0-1 and adequate organ function were randomized to receive either oral S-1 80 mg/m(2)/day on days 1-21 plus cisplatin 60 mg/m(2) on day 8 every 4-5 weeks, or docetaxel 60 mg/m(2) on day 1 plus cisplatin 80 mg/m(2) on day 1 every 3-4 weeks, both up to six cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Oral S-1 plus cisplatin is not inferior to docetaxel plus cisplatin and is better tolerated in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Adjuvant cisplatin-based chemotherapy significantly improves outcomes of completely resected early-stage NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "All NSCLC patients received gemcitabine plus cisplatin (GP regimen) for a total of two courses. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis and the meta-analysis of individual participant data reported by NSCLC Meta-analysis Collaborative Group in neo-adjuvant setting validated respectively that adjuvant and neoadjuvant chemotherapy would significantly improve overall survival (OS) and recurrence-free survival for resectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "combination of gemcitabine/cisplatin (GC) as neoadjuvant treatment in stage IIIA-N2 NSCLC with sensitizing EGFR mutation in exon 19 or 21. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Potential crosstalk between cofilin-1 and EGFR pathways in cisplatin resistance of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this context, cofilin-1 (a cytosolic protein involved with actin dynamics) has been widely studied as a biomarker of an aggressive phenotype in tumors, and overexpression of cofilin-1 is associated with cisplatin resistance and poor prognosis in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We aimed to highlight new perspectives of how these interactions might affect cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: The addition of disulfiram to a combination regimen of cisplatin and vinorelbine was well tolerated and appeared to prolong survival in patients with newly diagnosed NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVES: Cisplatin and vinorelbine given intravenously is a well-established adjuvant chemotherapy regimen after surgery for early-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion we observed that intravenous or oral administration of vinorelbine in combination with cisplatin after surgery for NSCLC appear equally effective in terms of overall and disease-free survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected NSCLC with quality of life as the primary objective. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected NSCLC, but has negative impact on quality of life (QoL). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Matrine induces mitochondrial apoptosis in cisplatin-resistant NSCLC cells via suppression of \u03b2-catenin/survivin signaling. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study was carried out to determine the cytotoxic effects of matrine on cisplatin-resistant NSCLC cells and the associated molecular mechanisms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Parental and cisplatin-resistant A549 and H460 NSCLC cells were treated with 1 or 2 g/l of matrine for 48 h, and cell viability and apoptosis were assessed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Compared to the parental cells, cisplatin-resistant NSCLC cells showed increased \u03b2-catenin transcriptional activity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Matrine caused apoptotic death in the cisplatin-resistant NSCLC cells, coupled with loss of \u0394\u03a8m and activation of caspase-9 and -3. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Matrine-induced apoptosis of the cisplatin-resistant NSCLC cells was significantly reversed by overexpression of survivin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, matrine exposure induces mitochondrial apoptosis in cisplatin-resistant NSCLC cells, which is largely mediated through inactivation of \u03b2-catenin/survivin signaling. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Further investigation of the therapeutic benefit of matrine in overcoming cisplatin resistance in NSCLC is warranted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVES: This single-arm multicenter Phase II study investigated the efficacy and safety of pemetrexed (Pem) and cisplatin (Cis) induction chemotherapy (CT) followed by full-dose Pem-Cis plus concurrent radiotherapy (RT) in patients with locally advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced NSCLC patients using microarray data. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: This study was performed to evaluate the therapeutic effect of cisplatin-gemcitabine combination chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Ninety-one patients who had NSCLC with soft carotid plaques were selected for treatment either with the NP regimen (vinorelbine + cisplatin) (43 patients) or with the ENP regimen (Endostar + NP) (48 patients). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Vinorelbine and cisplatin in patients with advanced NSCLC with interstitial pneumonia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIM: The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) NSCLC with interstitial pneumonia (IP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we evaluate the anticancer and anti-angiogenic effects of low dose erlotinib-cisplatin combination in NSCLC in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination erlotinib-cisplatin treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These results suggest that low dose erlotinib-cisplatin combination exhibits its anti-tumor activity by targeting angiogenesis through the modulation of the c-MYC/HIF-1\u03b1/VEGF pathway in NSCLC with EGFR exon 19 deletions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for Japanese patients with advanced non-squamous NSCLC -- a retrospective analysis]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m/(2)) and pemetrexed (500 mg/m(2)) as a first-line treatment for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Knockdown of Med19 suppresses proliferation and enhances chemo-sensitivity to cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present findings suggest that Med19 facilitates tumorigenic properties of NSCLC cells and knockdown of Med19 may be a rational therapeutic tool for lung cancer cisplatin sensitization. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III NSCLC: a single-center experience. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) in patients with inoperable stage III NSCLC followed in our oncology clinic. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIAL AND METHODS: Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with cisplatin-vinorelbine were retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: The results of this study suggest that split-dose cisplatin may offer fewer grade III-IV toxicities without sacrificing efficacy and could be an option in patients with inoperable stage III NSCLC during CCRT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Surgery plus radiotherapy versus surgery plus radiotherapy plus adjuvant chemotherapyin patients with histologically diagnosed early stage NSCLC.(2)To investigate whether or not predefined patient subgroups benefit more or less from cisplatin-based chemotherapy in terms of survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cell cycle inhibition, currently being tested in clinical trials, might be antagonistic to cisplatin and other cytotoxic drugs.BACKGROUND: NSCLC is the leading cause of cancer-related death. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "An inhibitor of CDK4/6 (PD0332991) protected parental NSCLC cells from cisplatin cytotoxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Inhibition of CDK6 antagonizes cisplatin-induced NSCLC cell cytotoxicity, suggesting that agents that inhibit CDK6 should be avoided during cisplatin therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced NSCLC: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: To evaluate the safety and efficacy of metronomic vinorelbine in combination with cisplatin as first-line treatment in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: A total of 41 patients with inoperable stage IIIb or stage IV NSCLC (14 with adenocarcinomas, 19 with squamous cell carcinoma and eight with other types), PS = 0-2, were treated with cisplatin (80 mg/m(2)) in combination with oral metronomic vinorelbine (60 mg total dose, every other day) in cycles of 21 days. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Cisplatin in combination with metronomic vinorelbine is an active, although myelotoxic, therapeutic option in the first-line setting for the treatment of patients with locally advanced and metastatic NSCLC, which merits further evaluation in randomized trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous NSCLC (INSPIRE): an open-label, randomised, controlled phase 3 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previously untreated, stage IV, non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "INTERPRETATION: Our findings show no evidence to suggest that the addition of necitumumab to pemetrexed and cisplatin increases survival of previously untreated patients with stage IV non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " CD133-Positive Cells from NSCLC Show Distinct Sensitivity to Cisplatin and Afatinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The standard of care for advanced NSCLC consists in cisplatin-combination chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIM: Cisplatin doublets are standard 1st line treatment for advanced NSCLC, without accurate predictor for response and survival, but important toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Patients with pathologically proven untreated NSCLC, receiving 1st line cisplatin-vinorelbine and with an assessable lesion were eligible. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: In this prospective study with advanced NSCLC treated with cisplatin-vinorelbine, we were able to derive with high throughput techniques predictive and prognostic signatures based on transcriptomic analyses. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our hypothesis is that EGCG could resensitize NSCLC cells to cisplatin (DDP) through candidate genes demethylation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Even though cisplatin treatment after surgical resection of the primary tumor has been established as a standard chemotherapy for residual disease including metastatic spread, NSCLC often acquires a resistance against chemotherapy, and metastatic disease is often observed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "From January 2009 to July 2012, 41 patients with stage IIIB or IV nonsquamous NSCLC were treated with full-dose pemetrexed plus cisplatin as the first-line chemotherapy combined with concurrent thoracic radiotherapy, with or without radiotherapy for metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "As the first-line treatment for selected patients with advanced nonsquamous NSCLC, thoracic radiotherapy combined with concurrent full-dose pemetrexed plus cisplatin was safe and highly tolerable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "It is increasingly used as first-line treatment in combination with cisplatin, and as second-line treatment or maintenance monotherapy mainly in metastatic NSCLC and in malignant mesothelioma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Mitochondrial ER\u03b2 can suppress apoptosis of NSCLC cells induced by cisplatin or STS through interaction with Bad, suggesting the value of mitochondrial ER\u03b2 as a new therapeutic target for treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Targeting the invasive phenotype of cisplatin-resistant NSCLC cells by a novel histone deacetylase inhibitor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We used two NSCLC cell lines (H460 and A549) and the cisplatin-resistant variants (H460/Pt and A549/Pt), to mimic a frequent clinical condition. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Strikingly, RPN2 silencing repressed tumorigenicity and sensitized the tumors to cisplatin treatment, which led to the longer survival of NSCLC-bearing mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced NSCLC: the intergroup trial JCOG0803/WJOG4307L. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with stage III, stage IV, or recurrent NSCLC age \u2265 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel 60 mg/m(2) on day 1, every 3 weeks, or docetaxel 20 mg/m(2) plus cisplatin 25 mg/m(2) on days 1, 8, and 15, every 4 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: This study failed to demonstrate any survival advantage of weekly docetaxel plus cisplatin over docetaxel monotherapy as first-line chemotherapy for advanced NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III NSCLC: a pilot randomized controlled trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: We investigated the efficacy and safety of S-1 and cisplatin with concurrent thoracic radiation (SCCR) over cisplatin alone plus concurrent thoracic radiation (CCR) for unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: In summary, we demonstrated that S-1 and cisplatin with concurrent thoracic radiation was more effective than cisplatin plus radiotherapy in NSCLC patients with acceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " FOXM1 overexpression is associated with cisplatin resistance in NSCLC and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "To assess the role of FoxM1 in chemoresistance, we investigated FoxM1 protein expression and the correlation between FoxM1 expression, sensitivity to cisplatin-based therapy, and the survival of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our results revealed that the positive expression rate of FoxM1 in NSCLC was associated with chemosensitivity to cisplatin and a\u00a0poor prognosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These results suggest that FoxM1 plays a\u00a0critical role in chemoresistance to cisplatin and that FoxM1 depletion may be a\u00a0promising approach to lung cancer therapy.KEYWORDS: FoxM1, cisplatin, drug resistance, NSCLC, A549, JNK/mitochondrial pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIM: We used a panel of 17 NSCLC cell lines to investigate whether the presence of polymorphisms in the RRM1, ERCC1, ABCB1 and MTHFR genes and alterations in their mRNA expression can affect the in vitro chemosensitivity to cisplatin and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human NSCLC cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study aimed to examine whether AT-101 could increase the sensitivity of NSCLC A549 cells to cisplatin (CDDP) and the underlying mechanisms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced NSCLC: the Okayama Lung Cancer Study Group Trial 0501. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Although cisplatin-based chemotherapy combined with thoracic irradiation (TRT) is a standard treatment for unresectable, locally advanced NSCLC, this treatment outcome has remained unsatisfactory. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: In this phase II trial, 48 patients with stage III NSCLC received cisplatin (40mg/m(2) on days 1, 8, 29 and 36) and S-1 (80mg/m(2) on days 1-14 and 29-42) and TRT (60Gy). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "observation after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Patients with unresectable stage III NSCLC were treated with Endostar (7.5mg/m(2)/d) for 7days at weeks 1, 3, 5, and 7, while two cycles of docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) were administered on days 8 and 36, with concurrent thoracic radiation to a dose of 60-66Gy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The methylation status of the IGFBP-3 gene is strongly associated with cisplatin sensitivity in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Pharmacogenomics of cisplatin sensitivity in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In particular, cisplatin has been used to treat late stage NSCLC as the standard of care. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Considerable efforts have been invested to identify biomarkers that can be used to predict cisplatin sensitivity in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here we reviewed current evidence for cisplatin sensitivity biomarkers in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here, we found that WT1 expression is significantly higher in NSCLCs than in benign controls, and that Cisplatin-resistant patients display a notable increase in WT1 expression following relapse. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In vitro, WT1 levels were associated with the IC50 of NSCLC cells and increased along with treatment time and dose of Cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Among the two cisplatin-based doublets of induction chemotherapy for inoperable NSCLC, both schedules of gemcitabine have a comparable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " This study aimed to evaluate the biological functions of excision repair cross complementation goup 1 (ERCC1) in cell proliferation, cell cycle, invasion and cisplatin response of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Response of NSCLC cells to cisplatin was detected utilizing MTT assays, and the intracellular drug concentrations were determined by the high performance liquid chromatography (HPLC) analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In the present study, the results demonstrated that ERCC1 had no effect on cell proliferation, cell cycle and the ability of invasion, but showed significant impact on cisplatin response of the NSCLC H1299 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, siRNA-induced suppression of ERCC1 evidently enhanced sensitivity to cisplatin of NSCLC A549 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [Adjuvant chemotherapy of NSCLC: Tolerance of combined cisplatin-pemetrexed therapy]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The study analyzed a cohort of non-squamous NSCLC patients treated in an adjuvant setting by combined cisplatin (75 mg/m(2)) and pemetrexed (500 mg/m(2)), under vitamin B12 and folic acid cover, 4 cycles at 21-day intervals. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " miR-107 regulates cisplatin chemosensitivity of A549 NSCLC cell line by targeting cyclin dependent kinase 8. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, the effects of miR-107 and the mechanism through which miR-107 affects the cisplatin chemoresistance in NSCLC have not been reported. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, the present study provides the first evidence that miR-107 plays a key role in cisplatin resistance by targeting the CDK8 protein in NSCLC cell lines, suggesting that miR-107 can be used to predict a patient's response to chemotherapy as well as serve as a novel potential maker for NSCLC therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin sensitivity is enhanced in NSCLC cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: We found low concentrations of GC7 have little effect on NSCLC viability, but could enhance cisplatin cytotoxicity in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Our data indicated GC7 enhances cisplatin cytotoxicity and prevents the EMT in NSCLC cells by inhibiting eIF5A-2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: The study included 84 patients with Stage IIIA-B NSCLC, undergoing simultaneous chemoradiotherapy including radiotherapy at a dose of 66 Gy and weekly docataxel (20 mg/m2) and cisplatin (20 mg/m2). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim is to investigate the effect of daily low dose cisplatin concurrently with radiation therapy in advanced NSCLC patients with poor performance status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIM: To enhance the anticancer activity of vinorelbine, cisplatin and ionizing radiation (IR) combination against NSCLC cells by co-administration of sodium valproate (VPA), a histone deacetylase inhibitor, and to elucidate molecular events underpinning treatment efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: The NSCLC A549 cell line was treated with cisplatin (0.2 \u03bcg/ml), vinorelbine (2 nM), VPA (1 mM) and IR (2.5 Gy) alone, or in combination. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Genistein enhances the effect of cisplatin on the inhibition of NSCLC A549 cell growth in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Although cisplatin (DDP) has been reported to be a promising antitumor therapy for NSCLC, the effectiveness of the treatment remains limited due to an inherent tumor resistance to DDP. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " ATF2 contributes to cisplatin resistance in NSCLC and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The purpose of the present study was to investigate whether ATF2 may have a role in acquired resistance to cisplatin in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In the present study, two human NSCLC cell lines, H1299 and H460, were used to investigate whether Merm1/Wbscr22 affects chemosensitivity to antitumor agents, including cisplatin (CDDP), doxorubicin (ADM), paclitaxel (PTX), mitomycin (MMC), 7-Ethyl-10-hydroxycamptothecin (SN-38; the active metabolite of camptothecin) and 5-fluorouracil (5-FU). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we observed that NSCLC cells with high Id1 protein expression were vulnerable to the treatment of paclitaxel and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, immunohistochemical staining for Id1 followed by Kaplan-Meier survival analysis showed that surgically treated NSCLC patients with high Id1 expression in primary tumor tissues had better disease-free and overall survivals after adjuvant paclitaxel and cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The distinct role of Id1 reported in this study may arise from the phenomenon of Id1 dependence of NSCLC cells for survival, which renders the cancer cells additionally susceptive to the adjuvant chemotherapy with paclitaxel and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MicroRNA-106a confers cisplatin resistance in NSCLC A549 cells by targeting adenosine triphosphatase-binding cassette A1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MicroRNAs (miRNAs) have been discovered to have pivotal roles in regulating the drug resistance of various types of human cancer, including cisplatin (DDP) resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: The purpose of this study was to investigate the relationship between the expression of ribonucleotide reductase subunit M1 (RRM1) protein and the efficacy of gemcitabine/cisplatin (GP) adjuvant chemotherapy in postoperative NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: RRM1 protein may be a valuable predictive factor for gemcitabine/cisplatin adjuvant chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in NSCLC overexpressed with CD44. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we demonstrate that hyaluronan (HA)-conjugated cisplatin has highly selective and sensitive anticancer effects in NSCLC cells that overexpress the trans-membrane receptor, CD44, as HA is a specific ligand for CD44. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Based on our experimental results, we strongly believe that HA-cisplatin conjugate is a potential anticancer chemo-agent, which target CD44 overexpression in NSCLC, with minimal side effects and high therapeutic properties. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Overcoming 5-Fu resistance in human NSCLC cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we investigate the glucose metabolic profiles of NSCLC cells in response to 5-Fu and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: Adjuvant vinorelbine and cisplatin chemotherapy is recognized as a standard regimen for patients with completely resected stage II and III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, efficacy of adjuvant chemotherapy in Japanese phase III trials with cisplatin-containing regimen has been controversial, and data are limited on the long-term outcome of adjuvant vinorelbine and cisplatin chemotherapy for NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: We report exploratory gene-expression profiling data from a single-arm Phase-II-study in patients with non-squamous (ns)NSCLC treated with pemetrexed and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Treatment-na\u00efve nsNSCLC patients (IIIB/IV) received 4 cycles of pemetrexed/cisplatin; non-progressing patients continued on pemetrexed-maintenance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: A total of 68 patients diagnosed with NSCLC by histology served as the study objects and were randomly divided into an observation group treated with gemcitabine concomitant with nedaplatin and a control group with cisplatin concomitant with gemcitabine, 34 cases for each group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Gemcitabine concomitant with nedaplatin has significant effects in the treatment of NSCLC, with an adverse response rate obviously lower than for cisplatin concomitant with gemcitabine, suggesting that wider use in the clinic is warranted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Eli Lilly and Company is conducting a phase III, randomized, multicenter, open-label study of gemcitabine plus cisplatin plus necitumumab (GC\u2009+\u2009N) versus gemcitabine plus cisplatin (GC) for the first-line treatment of patients with stage IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we hypothesized that the dual inhibitor of phosphatidylinositol-3 kinase/mammalian target of rapamycin, NVP-BEZ-235, could potentially enhance radiosensitization in cisplatin-resistance (CDDP-R) NSCLC cells by disabling autophagy as a mechanism of self-preservation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Combinational treatment with zerumbone and cisplatin significantly accelerated apoptosis and promoted p53 expression and ROS production in NSCLC cells, compared with each alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These findings demonstrate that zerumbone induces mitochondrial apoptosis and enhances the susceptibility to cisplatin in NSCLC cells, which are, at least partially, mediated through activation of p53 signaling and promotion of ROS generation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in NSCLC NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " This study was aimed to elucidate the roles of inhibition of related JAK/STAT pathways in regulating cytotoxicity induced by cisplatin in NSCLC cell. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We treated five NSCLC cell lines with cisplatin alone or with cisplatin and Jak2 inhibitor (ruxolitinib) and assessed cell viability, expression of Jak2 and STAT3 and cell apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We also investigated the effect of combination treatment inhibited tumor xenograft growth in two human NSCLC xenograft models bearing the cisplatin resistant (H1299) and sensitive (A549) cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study indicates that further study is warranted to determine the effectiveness of combination treatment with cisplatin and Jak2/stat3 pathway inhibitor for platinum-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "For exploring the mechanism of the failed combination therapy in lung cancer, in the present study, four therapy assessment groups, including a control group, a chemotherapy group [paclitaxel+cisplatin (TP)], a gefitinib monotherapy group (G) and a combination group[paclitaxel+cisplatin+gefitinib (TP+G)], were established in an A549 cell line and mouse xenotransplanted tumor models.By HPLC, we found that the gefitinib concentration was significantly higher in the combination group when compared to that in the G group in the NSCLC cell line, A549 (p<0.05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We observed the cavitation of lesions in patients with stage IIIB/IV NSCLC treated with Endostar and vinorelbine-cisplatin (NP) chemotherapy, and evaluated the imaging characteristics and clinical outcome of patients who developed tumor cavitation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: The expression changes of lung CSCs cell marker in A549-Luc-C8 human NSCLC cell line with or without cisplatin treatment were detected by flow cytometry. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This randomized phase II study investigated the addition of iniparib to gemcitabine-cisplatin in metastatic NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with histologically confirmed stage IV NSCLC were randomized 2 : 1 to receive gemcitabine (1250 mg/m(2), days 1/8) and cisplatin (75 mg/m(2), day 1) with [gemcitabine/cisplatin/iniparib (GCI)] or without [gemcitabine/cisplatin (GC)] iniparib (5.6 mg/kg, days 1/4/8/11) every 3 weeks for six cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [Effect of PI3K/AKT pathway on cisplatin resistance in NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cisplatin as first-line chemotherapy are in widespread clinical use in patients with NSCLC, however, the development of cisplatin resistance significantly impedes its clinic efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Best Supportive Care Immediately Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-Squamous NSCLC\") trial, patients with advanced nonsquamous NSCLC (NS-NSCLC) benefited from pemetrexed maintenance therapy after induction therapy with pemetrexed and cisplatin by extending survival, delaying disease progression, and maintaining quality of life (QoL). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The present updated guidelines on the management of resectable NSCLC formulated by the ELCWP are designed to answer the following questions: 1) Is conventional surgery the best treatment for potentially resectable cancer? 2) What is the definition of a complete resection? 3) Should we make a systematic lymphadenectomy in case of surgery for a N0 or N1 tumor? 4) What is the role of radiation therapy after complete resection? 5) In case of clinical stage I or II, should administer adjuvant or neoadjuvant chemotherapy? 6) In case of pathological stage I or II, should administer adjuvant chemotherapy? 7) In case of complete resection for stage IIIA N2 disease, should be offered adjuvant therapy and if so which one: chemotherapy, radiotherapy, chemoradiotherapy? 8) In case of clinical stage IIIA or B, what are the indications for surgery after induction therapy? 9) In case of clinical stage IIIA or B, if surgical indication is retained, should we do an induction treatment, and if so, which one? 10) In case of incomplete resection after primary surgery, what should be the postoperative therapy? 11) In case of (neo)adjuvant chemotherapy, which association should be offered and what dosage of cisplatin to be prescribed? 12) Can stereotactic radiotherapy replace surgery in operable patients? 13) What is proposed for the patient unfit for conventional surgery treatment? 14) Have targeted therapies a place in the treatment ?   PMID: 25102579 [PubMed - indexed for MEDLINE]   558. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous NSCLC following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The PARAMOUNT phase III trial compared maintenance pemetrexed versus placebo after patients with nonsquamous NSCLC completed 4 cycles of first-line pemetrexed-cisplatin without disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Altogether, these results suggest that the combined regimen of cisplatin plus pyridoxine mediates immune-dependent antineoplastic effects against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: In this phase II trial, 78 patients with locally advanced NSCLC, of whom 56 were considered not resectable at initial diagnosis, were treated with three neoadjuvant cycles of docetaxel and cisplatin and subjected to radical surgery if resectable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here, we report the development of an NP comprised of polysilsesquioxane (PSQ) polymer crosslinked by a cisplatin prodrug (Cisplatin-PSQ) and its utilization in chemoradiotherapy using NSCLC as a disease model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Strategic targeting of the PI3K-NF\u03baB axis in cisplatin-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, targeted inhibition of three strategic points of the PI3K-NF\u03baB axis was performed with the aim of exploiting vulnerabilities in cisplatin-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MicroRNA-182 modulates chemosensitivity of human NSCLC to cisplatin by targeting PDCD4. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our aim is to investigate the association of miR-182 expression with the sensitivity of NSCLC to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: The results of the present study demonstrated that overexpression of miR-182 may involve in chemoresistance of NSCLC cells to cisplatin by down-regulating PDCD4. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Fragile histidine triad (FHIT) loss by the two-hit mechanism of loss of heterozygosity and promoter hypermethylation commonly occurrs in NSCLC and may confer cisplatin resistance in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, the underlying mechanisms of FHIT loss in cisplatin resistance and the response to cisplatin-based chemotherapy in NSCLC patients have not yet been reported. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Among NSCLC patients, low FHIT, high p-AKT, high Slug and low PUMA were correlated with shorter overall survival, relapse-free survival and poorer response to cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Pemetrexed, a folate antimetabolite, combined with cisplatin is used as a first-line therapy for malignant pleural mesothelioma (MPM) and locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Patients with histologically proven and radiologically defined T3 to 4, N0 to 1, M0 superior sulcus NSCLC underwent induction therapy with\u00a0cisplatin-etoposide, concurrently with thoracic radiotherapy at 45 Gy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non-squamous cell NSCLC in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here, we present our phase II study that assessed the efficacy and safety of cisplatin plus pemetrexed as induction chemotherapy, followed by maintenance therapy with pemetrexed in advanced NSCLC patients in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this article, we describe a comparison between cancer cells resistant to cisplatin and CSCs, both derived from the NSCLC cell lines H460 and A549. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Between April 2009 and June 2011, 39 patients with advanced non-squamous NSCLC who had received second-line chemotherapy following first-line chemotherapy treatment with cisplatin and pemetrexed were analysed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our data also show that overexpression of miR216a suppresses NSCLC cell growth and metastasis, and enhances cisplatin-induced cell growth inhibition and apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In contrast, inhibition of miR216a stimulates NSCLC cell growth and metastasis, and suppresses cisplatin-induced cell growth inhibition and apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In the A549 NSCLC cell line, ME2 depletion inhibits cell proliferation and induces cell death and differentiation, accompanied by increased reactive oxygen species (ROS) and NADP(+)/NADPH ratio, a drop in ATP, and increased sensitivity to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Fractionated scheme of oral vinorelbine as single-agent therapy or in combination with cisplatin concomitantly with thoracic radiotherapy in stage III NSCLC: dose-escalation phase I trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: A dose-determination study was conducted in untreated stage III NSCLC to assess continuous exposure to fractionated oral vinorelbine (NVBo), a radiosensitizer, during the radiotherapy period, either alone (first cohort) or in combination with cisplatin (second cohort). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous NSCLC: final results of an International randomized phase II study (NAVotrial 01). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with NSCLC regardless of histologic subtype. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "EXPERIMENTAL DESIGN: NSCLC patient-derived xenograft models (n=45) were implanted subcutaneously into panels of nude mice and randomization cohorts were treated with either cetuximab, cisplatin, cisplatin plus cetuximab, vehicle control, or else were left untreated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Three of six trials involving 300 or more patients with early-stage NSCLC demonstrated that adjuvant cisplatin-based chemotherapy can significantly improve 5-year survival in carefully selected patients with resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, the combination of KPT-330 with cisplatin synergistically enhanced the cell kill of the NSCLC cells in vitro. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human NSCLC xenografts in immunodeficient mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "AIM: The aim of the work was to compare values of Glasgow Prognostic Score (GPS) before application of the chemotherapy medication with response to chemotherapy and toxic side effects associated with chemotherapy in patients treated with cisplatin-etopozid (PE) and cisplatin-gemcitabin (PG) in stages IIIb and IV of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Twenty one NSCLC patients receiving cisplatin- based first-line treatment were analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: The PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus cisplatin induction was well tolerated and effective for patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The significant SNP on NQO1 (rs1800566) has been linked with poor survival rates in patients with NSCLC treated with cisplatin (which belongs to the same class of drugs as oxaliplatin). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Downregulation of miR-21 increases cisplatin sensitivity of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Recent studies have shown that plasma miR-21 is a biomarker of chemotherapeutic response in lung cancer, but the influence of miR-21 on the sensitivity of NSCLC to cisplatin (DDP) has not been confirmed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The data demonstrated that CIP2A silencing led to decreased proliferation, impaired clonogenicity and enhanced chemosensitivity and apoptosis to cisplatin in human NSCLC cells, as well as reduced Akt phosphorylation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, overexpression of CIP2A diminished NSCLC cell chemosensitivity to cisplatin by inducing activation of Akt pathway, suggesting critical roles of CIP2A in NSCLC cell chemoresistance to cisplatin and rasing the possibility of CIP2A inhibition as a promising approach for lung cancer therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin-mediated radiosensitization of NSCLC cells is stimulated by ATM inhibition. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND AND OBJECTIVE: Cisplatin is the first-line drug for the chemotherapy of NSCLC, but the acquired chemoresistance restricted the effect of its treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese NSCLC patients treated with cisplatin-gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We used polymerase chain reaction-restriction fragment length polymorphism to evaluate genetic polymorphisms of XPD (Asp312Asn and Lys751Gln) and CDA (Lys27Gln and Ala70Thr) in 93 NSCLC patients treated with a cisplatin-gemcitabine regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: This is a phase II trial of locally advanced NSCLC patients treated with cisplatin and vinorelbine plus concurrent nitroglycerin with radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Enhanced toxicity of cisplatin with chemosensitizer phenethyl isothiocyanate toward NSCLC cells when delivered in liposomal nanoparticles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Naturally occurring phenethyl isothiocyanate (PEITC) was previously shown to sensitize human NSCLC cells to the platinum anticancer drug cisplatin (CDDP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "H1975 NSCLC cells were treated with curcumin (0-50 \u03bcM) alone, or combined with gemcitabine or cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin (CDDP) is one of the standard first-line chemotherapeutic agents for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Over-expressed eukaryotic initiation factor 3a (eIF3a) in NSCLC contributed to cisplatin sensitivity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, interaction research between biomarkers and chemotherapy status disclosed cisplatin-based regimen trend to prolong DSS of stage II NSCLC patients with high eIF3a-C (P=0.036)and low p27-N (P=0.031). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Azithromycin enhances the favorable results of paclitaxel and cisplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Azithromycin is commonly used for the treatment of Cpn infections; however, there are only few reports regarding the application of azithromycin (A) combined with paclitaxel and cisplatin (TP) for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our study of azithromycin+paclitaxe l+cisplatin on stage III-IV NSCLC patients achieved favorable results in terms of side effects and overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Frequency and functional activity of Treg was analyzed in 31 NSCLC stage IB-IIIA patients treated by neoadjuvant Cetuximab/Docetaxel/Cisplatin prior to surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We sought to assess the preclinical efficacy of MK-5108 in a panel of NSCLC cell lines as a single agent and in combination with cisplatin and docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, oral administration of luteolin, either alone or combined with intraperitoneal injection of the cytotoxic drug cisplatin, greatly inhibited the growth of xenograft tumors from NSCLC cell line A549 cells grown subcutaneously in athymic nude mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "ESMO guidelines recommend cisplatin-based adjuvant chemotherapy (CT) for completely resected stage II-III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This study investigated efficacy of computed tomography-guided percutaneous fine-needle 5% ethanol-cisplatin intratumoral injection (CT-PFNECII) combined with second-line chemotherapy in patients with platinum-pretreated stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Consequently, our study suggests that miRNA 17 family (including miR-17, 20a, 20b) can act as TGF\u03b2R2 suppressor for reversing cisplatin-resistant and suppressing metastasis in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The Glasgow prognostic score as a prognostic factor in patients with advanced NSCLC treated with cisplatin-based first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVES: The aim of this study was to assess the predictive value of survival in patients with advanced NSCLC treated with cisplatin-based first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Clinical trials of two multitargeted tyrosine kinase inhibitors are restricting enrollment to patients with squamous NSCLC: a phase I/II trial of nintedanib added to first-line gemcitabine/cisplatin and a phase II trial of ponatinib for previously treated advanced disease, with the latter requiring not only squamous disease but also a confirmed FGFR kinase amplification or mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of this study was to identify candidate DNA methylation drivers of cisplatin (DDP) resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III NSCLC: a multi-center phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIM: To evaluate the efficacy and toxicities of combination of cisplatin and oral vinorelbine given at full doses concomitantly with radiotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Full doses of cisplatin and oral vinorelbine can be administered with concomitant radiotherapy, with good efficacy and an acceptable safety profile for patients with stage IIIA/IIIB NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: The phase III FLEX study (NCT00148798) in advanced NSCLC indicated that the survival benefit associated with the addition of cetuximab to cisplatin and vinorelbine was limited to patients whose tumors expressed high levels of epidermal growth factor receptor (EGFR) (immunohistochemistry score of \u2265200; scale 0-300). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Suppression of STAT3 by chemically modified siRNAs increases the chemotherapeutic sensitivity of parental and cisplatin-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, the effects of chemically modified anti-STAT3 small interfering (si)RNAs on cell viability, proliferation and apoptosis of parental and cisplatin resistant NSCLC cells were investigated with the aim to provide a new therapeutic strategy for overcoming cisplatin resistance in lung cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: The parental NSCLC cell line Calu1 and its cisplatin- resistant subline CR-Calu1 were used to study the effects of STAT3 suppression with chemically modified anti-STAT3 siRNAs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: NSCLC cells could be sensitized to cisplatin by targeting STAT3 with chemically modified siRNAs together, a fact which was accompanied with increased apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, Disulfiram/copper significantly increased the sensitivity of cisplatin in NSCLC cells tested by MTT assay. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Novel chemoradiotherapy with concomitant boost thoracic radiation and concurrent cisplatin and vinorelbine for stage IIIA and IIIB NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced NSCLC: A meta-analysis of randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "China ;  Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced NSCLC remains controversial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Surgery remains the corner stone of treatment in early-stage NSCLC when feasible, and the addition of adjuvant cisplatin-based chemotherapy has improved these results in resected NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: To observe the short-term efficacy, long-term survival time and adverse responses with nedaplatin (NDP) or cisplatin (DDP) concomitant with other chemotherapy in treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Adjuvant cisplatin-based chemotherapy is the standard of care for completely resected high-risk stage IB and stage II NSCLC based on a ~5% improvement in 5-year overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, ML323 potentiates cisplatin cytotoxicity in NSCLC and osteosarcoma cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The combination of curcumin and erlotinib exhibited the same effects on apoptosis as the combination of curcumin and cisplatin in erlotinib-resistant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIM: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Adjuvant cisplatin-based chemotherapy only marginally improves survival in patients with completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " It is reported that MicroRNA-503 (miR-503) regulates cell apoptosis, and thus modulates the resistance of NSCLC cells (NSCLC) to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with NSCLC after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Re-challenge with platinum combination chemotherapy was effective and safe; therefore, this therapy should be considered as a treatment option for relapsed patients after postoperative cisplatin-based adjuvant chemotherapy for resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: To test the effectiveness of combining conventional antineoplastic drugs (cisplatin and etoposide) with metformin in the treatment of NSCLC in the NCI-H460 cell line, in order to develop new therapeutic options with high efficacy and low toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Depletion of Mcl-1 via siRNA or pharmacologic inhibition of Mcl-1, using EU-5148, sensitized TWEAK-treated NSCLC cells to cisplatin- or radiation-mediated inhibition of cell survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVES: Adding nitroglycerin to the combination of vinorelbine plus cisplatin has been reported to improve the overall survival (OS) of Asian patients with stage IIIB/IV NSCLC probably due to better drug delivery based on changed vascular tonus. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: 66 chemona\u00efve patients with stage IIIB/IV NSCLC received oral vinorelbine (first cycle 60 mg/m(2), subsequent cycles: 80 mg/m(2) in the absence of any hematological toxicity \u2265 grade 3 in cycle 1) once daily on days 1 and 8 of each cycle and cisplatin (80 mg/m(2) i.v.) on day 1 of each cycle (q3w). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Overall, oral vinorelbine plus cisplatin showed a high level of efficacy and adequate tolerability in first line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: To test the hypothesis that daily intravenous pre-hydration decreases renal toxicity and improves chemotherapy adherence in patients receiving daily cisplatin to concurrent radiotherapy for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced NSCLC were treated between 2008 and August 2012 with daily 6 mg/m(2) cisplatin as a bolus injection in 10 ml; of saline and 66 Gy/24 fr radiotherapy in 32 days. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Daily pre-hydration was associated with a reduced rate of both renal and acute esophageal toxicity and an increased chemotherapy adherence in patients receiving daily dose of cisplatin and concurrent radiotherapy for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVES: We performed a post hoc analysis of progression-free survival (PFS), overall survival (OS), and recurrent sites in patients with locally advanced nonsquamous NSCLC who were enrolled in a phase I trial of combination chemotherapy consisting of pemetrexed plus cisplatin with concurrent thoracic radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced NSCLC harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-positive advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Docetaxel and Cisplatin regimen for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We evaluated pCR rate of cisplatin with pemetrexed in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cancer cells that develop resistance to cisplatin (DDP) are a major clinical obstacle to the successful treatment of cancer, including NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here, we sought to investigate the effects of arctigenin on cisplatin-treated NSCLC H460 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We used cell viability assays, Western blotting, and immunofluorescence combined with siRNA interference or plasmid transfection to investigate the underlying mechanism of cisplatin resistance in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: Three large randomized clinical trials and two meta-analyses have demonstrated a survival benefit for adjuvant cisplatin-based chemotherapy compared with surgery alone in patients with early-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against NSCLC in preclinical studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, the administration of docetaxel to patients with metastatic prostate or breast cancer, as well as that of cisplatin plus vinorelbine to NSCLC patients, appears to significantly increase the ratio between effector T cells and Tregs and to reduce the immunosuppressive activity of the latter in the majority of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "LY293111 combined with gemcitabine-cisplatin did not increase median PFS compared with placebo plus gemcitabine-cisplatin in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Since response to platinum-based therapy in NSCLC is poor, the present study was designed to rationally identify novel drug combinations in cell models including the A549 cell line and the cisplatin-resistant subline A549/Pt, characterized by reduced sensitivity to cisplatin-induced apoptosis and by upregulation of efflux transporters of the ATP binding cassette (ABC) superfamily. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin is a first-line chemotherapeutic agent in the treatment of NSCLC, but the therapeutic effect is disappointing, partly due to drug resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy na\u00efve NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " AIMS AND BACKGROUND: To investigate the efficacy and tolerability of biweekly scheduled triplet chemotherapy consisting of gemcitabine, cisplatin and vinorelbine for chemotherapy-na\u00efve advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: The biweekly schedule of the triplet chemotherapy combination including gemcitabine, cisplatin and vinorelbine was effective in advanced, mostly metastatic NSCLC with acceptable and manageable side effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: In advanced NSCLC, cisplatin-based CT is not superior to a platinum-free regimen (ifosfamide-gemcitabine) with a favourable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Cisplatin-based therapy is a pivotal type of chemotherapy for NSCLC and chemoresistance to cisplatin represents one of the most significant barriers to improving long-term clinical outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: The present study aimed at examining metallothionein (MT) expression in six NSCLC cell lines as well as examining effects of exposure to cisplatin on MT expression in the most cisplatin-resistant (97/97) and the cisplatin-sensitive (DV90) cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: The most cisplatin-resistant NSCLC cell line [97/97; (IC50)=4.659 \u03bcM] exposed to the highest concentration of cisplatin (10 \u03bcM) exhibited decreased nuclear MT expression (MTn=6) compared to cells cultured in medium with a lower concentration of cisplatin (0, 1 and 5 \u03bcM) (MTn=12). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The most cisplatin-sensitive NSCLC cell line (DV90; IC50=0.184 \u03bcM) was characterized by a significant decrease of both nuclear and cytoplasmic MT expression with increasing cisplatin concentrations (5 vs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study suggests that cisplatin resistance in NSCLC is metallothionein-independent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, HDAC inhibitors synergized with TRAIL and cisplatin in NSCLC cells in a FLIP- and caspase-8-dependent manner. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Gambogic acid synergistically potentiates cisplatin-induced apoptosis in NSCLC through suppressing NF-\u03baB and MAPK/HO-1 signalling. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The present study aims to investigate whether GA would be synergistic with cisplatin (CDDP) against the NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Between April 2009 and June 2011, 50 patients with advanced non-squamous NSCLC treated with cisplatin and pemetrexed as first-line chemotherapy were analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In vitro, HGF reduced expression of apoptosis-inducing factor (AIF) and cisplatin sensitivity in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In an autochthonous model of NSCLC, we demonstrate that MK2 is responsible for resistance of p53-deficient tumors to cisplatin, indicating synthetic lethality between p53 and MK2 can successfully be exploited for enhanced sensitization of tumors to DNA-damaging chemotherapeutics in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Not all NSCLC patients are likely to benefit from EGFR-TKIs and, therefore, cisplatin was used to further demonstrate a role of inhibition of Hh signaling in sensitization of resistant EMT cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: siRNA-mediated inhibition as well as pharmacological inhibition of Hh signaling abrogated resistance of NSCLC cells to erlotinib and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Tomotherapy (HT) is a novel radiotherapeutic technique, which allows the delivery of Image Guided-IMRT (IG-IMRT), with a highly conformal radiation dose distribution.The goal of the study was to estimate tolerability of Docetaxel concurrent with IMRT and to find the maximum tolerated dose of weekly Docetaxel concurrent with IMRT delivered with HT Tomotherapy after induction chemotherapy with Cisplatin and Docetaxel in patients affected with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A 72-yr-old male patient with stage IV NSCLC developed diarrhea repeatedly after docetaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: We investigated the efficacy and toxicity of a biweekly schedule of docetaxel and cisplatin in high-risk patients with unresectable (stages IIIB-IV) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: In this study, 48 high-risk patients with previously untreated locally advanced or metastatic NSCLC were treated with combination chemotherapy consisting of docetaxel 40 mg/m(2) and cisplatin 40 mg/m(2); both drugs were given biweekly, on days 1 and 15, every 4 weeks in an outpatient setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: As a front-line chemotherapy for high-risk patients with unresectable NSCLC in an outpatient setting, the biweekly schedule of docetaxel and cisplatin showed feasible efficacy with acceptable hematologic toxicities, comparable to the results of previous studies of triweekly or weekly schedules. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Additional large randomized studies are needed to optimize the schedule and dosage of combination therapy with docetaxel and cisplatin in high-risk patients with unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3(rd) generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Patients with newly diagnosed metastatic NSCLC received docetaxel 75 mg/m\u00b2 and cisplatin 75 mg/m\u00b2 on day 1 and pegfilgrastim on day 2 every 14 days for four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " MicroRNA-31 inhibits cisplatin-induced apoptosis in NSCLC cells by regulating the drug transporter ABCB9. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, the possible role of miR-31 in cisplatin (DDP) resistance in NSCLC remains unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These data indicate that the miR-92b play an oncogene roles by regulates cell growth, cisplatin chemosensitivity phenotype, and could serve as a novel potential maker for NSCLC therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: To determine the efficacy and safety of oral S-1 in combination with cisplatin and thoracic radiotherapy in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: The combination of oral S-1 plus cisplatin with concurrent radiotherapy is a promising treatment with a high efficacy and lower toxicity in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phosphorylation of paxillin confers cisplatin resistance in NSCLC via activating ERK-mediated Bcl-2 expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Therefore, we suggest that Src or ERK inhibitor might be helpful to improve the sensitivity for cisplatin-based chemotherapy in NSCLC patients with PXN-positive tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable NSCLC: KASLC 0401. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Modulation of peripheral immune responses by paclitaxel-ifosfamide-cisplatin chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: The aim of this study was to assess systemic immunological responses in NSCLC patients with stage III/IV disease during treatment with paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Group I (12 patients) diagnosed with NSCLC treated with PE schema (cisplatin, etoposide), Group II (12 patients) with breast cancer treated with FAC schema (fluorouracil, doxorubicin, cyclophosphamide), Group III (12 patients) with bowel cancer treated with FU/LV schema (fluorouracil, leucovorin). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The drug sensitivity assay indicated that miR-495 enhanced the cell response to cisplatin (CDDP) in NSCLC cells, while inhibition of miR-495 led to the opposite effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, immunohistochemical expression of Prx1 was evaluated in paraffin-embedded tissues from 24 NSCLC patients who had received docetaxel-cisplatin regimens as a first-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In vitro evidences suggest that cofilin-1 is a biological predictor of cisplatin resistance, supporting new treatment initiatives based on cofilin-1 levels to guide chemotherapeutic interventions in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: In this study, we examined RASSF1A's methylation status and its mRNA expression level between NSCLC cell line A549 and anti-Cisplatin cell strain A549DDP, Furthermore, methylation of A549DDP was reversed by treatment of 5-Aza-2' - deoxycytidine (5-Aza-cdR),a DNA methyltransferase inhibitor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Identification of microRNA-based signatures for response and survival for NSCLC treated with cisplatin-vinorelbine A ELCWP prospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In a prospective study, we assessed the predictive value for response and survival of tumour miRNA in NSCLC patients treated by 1st line cisplatin and vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The signature distinguished patients with good (n = 18) and poor (n = 20) prognosis with respective median survival times of 47.3 months (95% CI 29.8-52.4) and 15.5 months (95% CI 9.1-22.8) (p < 0.001; hazard ratio 21.1, 95% CI 4.7-94.9).CONCLUSIONS: miRNA signature allows predicting response and is of prognostic value for survival in patients with NSCLC treated with first line cisplatin and vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Concurrent chemoradiotherapy using S-1 containing tegafur, an oral 5-FU prodrug, plus cisplatin has been reported to show promising efficacy against locally advanced NSCLC with acceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Concurrent chemoradiotherapy using S-1 plus cisplatin followed by surgery may provide a better prognosis for locally advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in NSCLC cell. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our aim was to test the hypothesis that cisplatin resistance is associated with alteration of SOX1 expression in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We also found that SOX1 silencing enhanced the cisplatin-mediated autophagy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This study shows that inactivation of SOX1 by promoter hypermethylation, at least in part, is responsible for cisplatin resistance in human NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, acetylcholinesterase levels were increased, and miR-212 levels decreased, in NSCLC cells during cisplatin-induced apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with NSCLC treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " This study was conducted to analyze a comprehensive panel of single nucleotide polymorphisms (SNPs) in genes in DNA repair and apoptosis pathways and determine the relationship between polymorphisms and treatment outcomes of patients with NSCLC treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, these findings suggest that the six SNPs identified, particularly their combined genotypes, could be used as biomarkers predicting chemotherapy response and survival of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced NSCLC-a multicenter phase-II trial (CISTAXOL). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Mediastinoscopically proven IIIA(N2)/selected IIIB NSCLC received three cycles cisplatin (50 mg/m(2) day 1+8) and paclitaxel (175 mg/m(2)d1) qd 22. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [Meta-analysis on elemene injection combined with cisplatin chemotherapeutics in treatment of NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The findings were included into randomized controlled trials (RCTs) of elemene injection combined with cisplatin chemotherapeuties in treating small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "2 software, in order to assess the efficacy and safety of elemene injection combined with cisplatin chemotherapeutics in treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This view has gained recent support with the finding that USP1 inhibition may contribute to revert cisplatin resistance in an in vitro model of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Finally, we discuss the emerging potential of USP1 as a target, integrating published data with our novel findings on the effects of the USP1 inhibitor pimozide in combination with cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Adjuvant chemotherapy using a cisplatin-based regimen is currently recommended for patients with stage II and III NSCLC after complete tumor resection and may be considered for patients with stage IB NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In human NSCLC-cell-A549-xenograft models, Mst1 gene or cisplatin alone suppressed the growth of tumors and increased the cytoplasm-positive expression levels of YAP and Phospho-YAP (Ser127) proteins; however, their combination had the strongest anticancer effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Moreover, up-regulation of SIRT2 in NSCLC cells increased the sensitivity to Cisplatin treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: In a retrospective study, 40 patients with stage III NSCLC received intra-arterial infusion chemotherapy with gemcitabine and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These encouraging results (even in very sick ECOG 2 patients with central obstructive NSCLC having a worse prognosis and quality of life than a NSCLC in ECOG 0 of the same tumor node metastasis [TNM]-stage without central obstruction) for a chemotherapy-only protocol that differs from conventional cisplatin-based doublet chemotherapy by the route, target site, and dose paves the way for broader applications of this technique. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Pemetrexed and cisplatin for advanced non-squamous NSCLC in Japanese patients: phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Although pemetrexed/cisplatin (P-C) is a standard treatment for advanced non-squamous NSCLC (Nsq-NSCLC), neither its efficacy nor the effects of potential differences between driver mutations, such as the anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) mutations, have been thoroughly examined. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: The combination of pemetrexed and cisplatin was effective and safe in Japanese patients with Nsq-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected NSCLC: Thoracic Oncology Research Group Study 0809. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "siniho@east.ncc.go.jp  BACKGROUND: We conducted a multicentre feasibility study for single agent long-term S-1 chemotherapy following docetaxel plus cisplatin in patients with curatively resected stage II-IIIA NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " miR-503 regulates the resistance of NSCLC cells to cisplatin by targeting Bcl-2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we report that miR-503 regulates the resistance of NSCLC cells to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The expression of miR-503 was decreased in the cisplatin-resistant NSCLC cells, A549/CDDP, compared with the parental A549 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Taken together, our results suggest that miR-503 regulates cell apoptosis, at least in part by targeting Bcl-2, and thus modulates the resistance of NSCLC cells to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [Series: Clinical study from Japan and its reflections; randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin for advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous NSCLC received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexed-cisplatin induction therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Prediction of acute toxicity grade\u00a0\u2265 3 in patients with locally advanced NSCLC receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We correlated clinical and dosimetric parameters with acute toxicity grade \u2265 3 in patients with locally advanced NSCLC treated with IMRT and concurrent low-dose cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Concurrent low-dose cisplatin using IMRT is effective in a large cohort of consecutive patients with NSCLC and life threatening toxicity is rare (1%). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We assessed the efficacy of synchrotron radiation in triggering the Auger effect in human A549 NSCLC and IGROV-1 ovarian cancer cells pre-treated with cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The purpose of this study was to determine whether subtoxic-dose cisplatin and TRAIL could synergistically enhance apoptosis on NSCLC cells and investigate its underlying mechanisms.MATERIALS AND METHODS: NCI-H460 and A549 cells were treated with TRAIL alone, cisplatin alone or combination treatment in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Subtoxic-dose cisplatin could enhance both TRAIL- sensitive and TRAIL- resistant NSCLC cells to TRAIL-mediated apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for NSCLC: a study-level meta-analysis of 16 randomized trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We conducted a systematic review and a study-level meta-analysis of published randomized controlled trials (RCTs) in order to determine the overall risk of non-lung cancer-related mortality associated with adjuvant cisplatin-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Eligible publications included prospective RCTs in which cisplatin-based adjuvant chemotherapy plus local therapy was compared with local therapy alone in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this meta-analysis of RCTs in NSCLC, cisplatin-based adjuvant chemotherapy was associated with a 30\u00a0% increase in non-lung cancer-related mortality compared with local therapy alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "gerald.schmid-bindert@medma.uni-heidelberg.de  OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Pemetrexed, cisplatin, and cetuximab appeared efficacious and tolerable in advanced nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Tolerability and toxicity of adjuvant cisplatin and gemcitabine for treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: The combination of cisplatin and vinorelbine is an evidence-supported regimen for adjuvant chemotherapy for treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The cisplatin and gemcitabine regimen is one of the most active and well-tolerated regimens against advanced NSCLC, but its toxicity and tolerability has not been adequately evaluated in the adjuvant setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m(2)) and gemcitabine (1250 mg/m(2)) between January 2005 and December 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The synergistic effects of new generation chemotherapeutics when combined with cisplatin have encouraged the development of new triplet combination regimens in the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementing group-1 (ERCC1) in resected p-stage III/N2 NSCLC patients that received cisplatin-based adjuvant chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, it was found that ERCC1 protein expression might play an important role in the prognosis of p-stage III/N2 NSCLC patients treated with cisplatin-based adjuvant chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in NSCLC cell. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: The efficacy of cisplatin-based chemotherapy in NSCLC is limited by the acquired drug resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Cisplatin resistance in NSCLC cells may relate to the changes in noncoding RNAs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVES: To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy (CRT) followed by consolidation with docetaxel and cisplatin in locally advanced unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "China ;  The aim of this study was to explore the correlation between mRNA expression of \u03b2-tubulin-III and stathmin in patients with stage II NSCLC and the chemosensitivity to Navelbine plus cisplatin (NP), as well as to provide a basis for personalized treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Treatment-naive patients with nonsquamous NSCLC (stage IIIB/IV) had four cycles of first-line chemotherapy with pemetrexed/cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We are currently performing a prospective, randomized phase III trial comparing non-customized cisplatin/docetaxel with customized therapy in metastatic NSCLC patients (NCT00617656/GECP-BREC) and a parallel phase II study (ChiCTR-TRC-12001860) is being carried out in China (BREC-China) under the auspices of the SLCG. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The apoptosis of NSCLC induced by cisplatin through modulation of STIM1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cis-diamminedichloroplatinum (II) (cisplatin) is one of the most active antitumor agents used in human chemotherapy of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Its role in STIM1 cisplatin-induced apoptosis of NSCLC was the focus of study with focus on SOCE inhibitors 2-APB- and SKF96365-cisplatin-induced apoptosis in the NSCLC cell lines A549 and H460. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "It is currently in use in combination with cisplatin against malignant pleural mesothelioma and non-squamous NSCLC with favourable results. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin-based chemotherapy is recommended as the first-line therapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "However, acquired cisplatin resistance is ubiquitous in patients with NSCLC, but the molecular mechanism of such resistance remains ambiguous. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, activation of the Wnt/\u03b2-catenin signaling pathway and upregulated survivin expression due to cytoplasmic GSK-3\u03b2 inhibition might lead to cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIAL AND METHODS: 153 patients with locally advanced NSCLC treated with 66 Gy/2.75 Gy/24 fractions of radiotherapy and concurrent daily low dose cisplatin were selected. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: For NSCLC patients treated with concurrent chemotherapy and IMRT A higher number of cisplatin administrations, non-Caucasian background and higher V50oes were associated with grade 3 AET. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III NSCLC: NJLCG 0601. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This randomized phase II study of concurrent chemoradiotherapy was conducted to compare uracil/tegafur (UFT) and cisplatin with vinorelbine and cisplatin for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage III NSCLC were randomized to receive UP (400 mg/m(2) UFT on days 1-14 and 29-42 and 80 mg/m(2) cisplatin on days 8 and 36) or NP (20 mg/m(2) vinorelbine on days 1, 8, 29, and 36 and 80 mg/m(2) cisplatin on days 1 and 29). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVES: The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin-gemcitabine with concurrent thoracic radiotherapy for locally advanced NSCLC (LA-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Pemetrexed is approved as a first-line treatment for advanced non-squamous NSCLC with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The cytotoxicities of the complexes to human NSCLC cell lines sensitive and resistant to cisplatin were assayed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Complex 1 was more cytotoxic than cisplatin in both PC-9 and PC-14 NSCLC cell lines, and cross-resistance to 1 in the cisplatin-resistant cells was largely circumvented. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Advanced NSCLC patients received pemetrexed and cisplatin every three weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin-based chemotherapy is considered a golden standard for treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Therefore, the regulation of eIF2\u03b1 may improve treatment outcomes of cisplatin-based chemotherapy for patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These observations indicate that CAERS induced apoptosis and sensitized NSCLC to cisplatin via a mitochondria-mediated apoptotic pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "mtiseo@ao.pr.it  BACKGROUND: The FAST was a factorial trial in first-line treatment of advanced NSCLC, addressing the role of replacing cisplatin with a non-platinum agent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cardiotoxicity of cisplatin-based chemotherapy in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cisplatin-based combinations are standard regimens in the therapy of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "h.harada@scchr.jp  PURPOSE: To determine the recommended dose (RD) in concurrent conformal radiotherapy with S-1 and cisplatin chemotherapy for inoperable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cisplatin remains the main drug for treating advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: The excision repair cross-complementation group 1 (ERCC1) protein is a potential prognostic biomarker of the efficacy of cisplatin-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: In this cohort of patients treated for stage IV NSCLC, renal function falls below commonly used thresholds for cisplatin and for pemetrexed in fewer than a quarter of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Both estrogen and progesterone pre-treatment led to chemoresistance of A549 NSCLC cells in vitro by attenuating cisplatin-induced apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "A direct comparison of the cytotoxic effect between compound Pt-4a and cisplatin on 12 different cancer cell lines demonstrated that compound Pt-4a was in general less potent than cisplatin, but it had a comparable cytotoxic effect on NSCLC NCI-H460 cells, and the colorectal cancer cells HCT-15 and HCT-116. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIAL AND METHODS: Sixty patients with NSCLC receiving a chemotherapy regimen consisting of Cisplatin and Docetaxel were evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The goals of this phase I/II study were to determine the recommended phase II dose (RP2D) of 1,25-D3 with cisplatin and docetaxel and its efficacy in metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Synergistic interaction between cisplatin and PARP inhibitors in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The antineoplastic agent cis-diammineplatinum(II) dichloride (cisplatin, CDDP) is part of the poorly effective standard treatment of non-small cell lung carcinoma (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The combined treatment with pemetrexed-cisplatin and concurrent WBRT are effective in patients with NSCLC with newly diagnosed BM. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cisplatin-based doublet chemotherapy is recommended as the first-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Chemosensitivity of cisplatin in NSCLC cell lines was correlated with the accumulation of cisplatin DNA adducts (P=0.0004). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We assessed clonogenic survival of 16 NSCLC cell lines in response to cisplatin, mitomycin C (MMC), and the PARP inhibitor olaparib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Thirteen tumor explants from patients with NSCLC were subjected to cisplatin ex vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Substantial risk affects the stage-dependent outcomes of cisplatin-based adjuvant chemotherapy for completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here, we investigated whether \u03b2-elemene acts synergistically with cisplatin to inhibit NSCLC cell proliferation by blocking cell cycle progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "\u03b2-Elemene substantially increased the suppressive effect of cisplatin on cell growth and proliferation in the NSCLC cell lines H460 and A549. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, \u03b2-elemene augmented cisplatin in the cell cycle arrest of NSCLC cells at G(2)/M. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here we addressed if such a phenotype may contribute to radio- and cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin plus oral vinorelbine as first-line treatment for advanced NSCLC: a prospective study confirming that the day-8 hemogram is unnecessary. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: Cisplatin plus oral vinorelbine, one of the standard treatments for metastatic NSCLC, is associated with a high rate of neutropenia, and a hemogram is performed on day 8. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Generation and characterisation of cisplatin-resistant NSCLC cell lines displaying a stem-like signature. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "mbarr@stjames.ie  INTRODUCTION: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: An isogenic model of cisplatin resistance was generated in a panel of NSCLC cell lines (A549, SKMES-1, MOR, H460). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Our results identified cisplatin resistant subpopulations of NSCLC cells with a putative stem-like signature, providing a further understanding of the cellular events associated with the cisplatin resistance phenotype in lung cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Role of 14-3-3\u03c3 in resistance to cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We have investigated whether the differential expression pattern of 14-3-3\u03c3 affects cisplatin response in NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We therefore propose that increased 14-3-3\u03c3 expression is correlated with cisplatin response in NSCLC cells; monitoring its expression might become useful in the future in predicting poor outcome to cisplatin treatment and/or the verification of acquired cisplatin resistance in lung cancer patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "francoise.mornex@chu-lyon.fr  PURPOSE: This is a phase I, escalating-dose trial targeting exclusively patients with NSCLC, investigating pemetrexed and fixed-dose cisplatin concurrently administered with high-dose radiotherapy (RT) after induction chemotherapy (CT). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND MATERIALS: Patients with unresected stage III NSCLC, planned V20 \u2264 35%, and FEV \u2265 1.3 L, were treated every 21 days for 2 cycles (pemetrexed 500 mg/m2; cisplatin 75 mg/m2), followed by 2 cycles of concurrent CT-RT: pemetrexed starting dose was 400 mg/m2, escalated up to 800 mg/m2 per 100mg/m2 dose level (DL), cisplatin at 75 mg/m2 and RT at fixed dose of 66 Gy/33 fractions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous NSCLC: estimates from the perspective of the Chinese health care system. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Continuation maintenance treatment with pemetrexed is approved by current clinical guidelines as a category 2A recommendation after induction therapy with cisplatin and pemetrexed chemotherapy (CP strategy) for patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Protective effects of ADAM8 against cisplatin-mediated apoptosis in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We have investigated the effect of ADAM8 on the cisplatin resistance in NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Thus, ADAM8 is implicated in cisplatin resistance of NSCLC cells through activation of the STAT3 signalling pathway, and thus represents a potential therapeutic target in this malignancy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULTS: Compared to NLT-MSC, NSCLC-MSC showed accelerated growth kinetics and reduced sensitivity to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: To assess the efficacy and potential prognostic factors of patients with stage III N2 NSCLC treated with neoadjuvant docetaxel-cisplatin (DP) chemotherapy followed by surgical resection. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "zhaowy98@yahoo.com.cn  OBJECTIVE: To prospectively evaluate the efficacy and toxicity of irinotecan plus cisplatin (IP regimen) compared with gemcitabine plus cisplatin (GP regimen) as a first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced NSCLC: a multicenter randomized phase IIB trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The effect of small interfering RNA-induced BIRC6 knockdown on the growth of human NSCLC cell cultures and apoptosis (in combination with cisplatin) was investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Small interfering RNA-induced BIRC6 down-regulation inhibited growth of the NSCLC cells and sensitized the cells to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Dexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We examined in different human NSCLC cell lines and detected cellular senescence after cisplatin (DDP) treatment in the presence or absence of DEX. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Acquired differential regulation of caspase-8 in cisplatin-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Failure to efficiently induce apoptosis contributes to cisplatin resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In H460 NSCLC cells, caspase-8 cleavage was shown to be induced by cisplatin and is dependent on death receptor 4, death receptor 5, Fas-associated protein with death domain, acid sphingomyelinase and ceramide synthesis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "To investigate the effect of olaparib and cisplatin on PTEN-deficient lung tumors, two EGFR-mutant (deletion in exon19) NSCLC cell lines, PC-9 (PTEN wild-type) and H1650 (PTEN loss), were used. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Long-term survival rates of patients with stage IIIB and IV NSCLC treated with cisplatin plus vinorelbine or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In conclusion, cisplatin-based new-generation cytotoxic agents for combined modality therapy offer an increased hope of long-term survival for patients with locally advanced and advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Toxic epidermal necrolysis after pemetrexed and cisplatin for NSCLC in a patient with sharp syndrome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "cornelia.then@med.uni-muenchen.de  BACKGROUND: Pemetrexed is an antifolate drug approved for maintenance and second-line therapy, and, in combination with cisplatin, for first-line treatment of advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: The aim of this study was to examine the effect of hydration with magnesium and mannitol without furosemide on the nephrotoxocity accompanying combination chemotherapy using cisplatin and pemetrexed in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Fifty patients with NSCLC who received cisplatin plus pemetrexed, using either old hydration protocol including normal saline with mannitol and furosemide, or a new one including normal saline with magnesium and mannitol without furosemide were retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Univariate and multivariate analyses were performed to identify the independent factors associated with protection against nephrotoxicity in patients with NSCLC who received cisplatin plus pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The new hydration protocol with supplemented magnesium with mannitol without furosemide was an independent factor for the protection against nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced NSCLC [HR 0.232 (95% CI: 0.055-0.986), P=0.039]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected NSCLC: a retrospective study in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "h.kenmotsu@scchr.jp  BACKGROUND: The efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy, such as the combination of CDDP and vinorelbine (VNR), has been established for surgically resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Two consecutive days of treatment with liposomal cisplatin in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Liposomal cisplatin is an agent with negligible toxicity and reasonably high effectiveness even when administered to pretreated patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " INTRODUCTION: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced NSCLC to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A combination of docetaxel (D) and cisplatin (P) is one of the standard regimens for the initial treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of this study was to assess the efficacy of a lower combination dose, 60 mg/m(2) of D and 60 mg/m(2) of cisplatin (P), as a treatment for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in NSCLC xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Targeted silencing of both VEGFR2 and EGFR expression by siRNA, combined with low-dose cisplatin, was found to effectively inhibit tumor growth and extend the survival time of mice bearing the NSCLC xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " High COL4A3 expression correlates with poor prognosis after cisplatin plus gemcitabine chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in NSCLC and mesothelioma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: The both regimens have similar efficacy as the treatment for advanced nonsquamous NSCLC, but pemetrexed plus cisplatin regimen has better safety profile and seems to have longer PFS, which makes it a new option as the first line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: Sera were collected from 37 NSCLC patients before they were treated with concurrent cisplatin-based CRT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: After four 21-day cycles of pemetrexed-cisplatin (N = 939), patients with advanced nonsquamous NSCLC, whose disease had not progressed and who had a performance status of 0/1, were randomized 2:1 (N = 539) to maintenance pemetrexed 500 mg/m plus best supportive care or placebo plus best supportive care every 21 days until disease progression or unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Prognostic factors in elderly patients with advanced NSCLC treated with first-line cisplatin-based chemotherapy: a retrospective analysis of single institution. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The aim of this retrospective single-center study was to evaluate prognostic factors for overall survival (OS) in elderly (\u226565 years) patients with advanced NSCLC who received first-line cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We retrospectively reviewed 110 elderly patients with locally advanced or metastatic NSCLC who had been administered cisplatin-based first-line chemotherapy between December 2004 and November 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "sgray@stjames.ie  Gemcitabine is indicated in combination with cisplatin as first-line therapy for solid tumours including NSCLC, bladder cancer and mesothelioma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: This multicenter, randomized, phase 2 study compared continuation maintenance therapy with pemetrexed (500\u2009mg/m2 every 21\u2009days) and best supportive care (BSC) versus BSC alone in patients with advanced, non-squamous NSCLC who had not progressed after 4\u2009cycles of induction chemotherapy with pemetrexed (500\u2009mg/m2) and cisplatin (75\u2009mg/m2). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Following the results of the 1995 meta-analysis on the role of chemotherapy (CT) in NSCLC, many randomized, controlled trials were launched to evaluate the effect of adjuvant cisplatin-based CT after the complete resection of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In addition, it showed that adjuvant cisplatin-based CT is detrimental in cases of stage Ia resected NSCLC; it also suggested that the combination of vinorelbine and cisplatin was of more benefit than older two and three drug combinations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced NSCLC with bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "kyoh@east.ncc.go.jp  BACKGROUND: This study evaluated the safety and efficacy of combined zoledronic acid, cisplatin and docetaxel in patients with NSCLC with bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: The combination of zoledronic acid, cisplatin and docetaxel is well-tolerated with acceptable renal toxicity, and has modest activity as a first-line treatment of NSCLC patients with bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human NSCLC xenograft models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: These data demonstrate that motesanib had antitumor activity against five different human NSCLC xenograft models containing diverse genetic mutations, and that it had enhanced activity when combined with cisplatin or docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced NSCLC patients: a phase II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Here, we showed that depletion of HDAC6 in two NSCLC cell lines, H292 and A549, sensitized cells to cisplatin, one of the first-line chemotherapeutic agents used to treat NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, we showed that HDAC6 protein levels were positively correlated with cisplatin IC(50) in 15 NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In summary, our findings suggest that HDAC6 is positively associated with cisplatin resistance in NSCLC and reveal HDAC6 as a potential novel therapeutic target for platinum refractory NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced NSCLC whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Finally, we examined, in vitro, the potential antiproliferative effect of BKT140 combined with cisplatin or paclitaxel and after irradiation of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "teramoto@belle.shiga-med.ac.jp  PURPOSE: Nedaplatin is a cisplatin derivative, which has similar activity to cisplatin in NSCLC when combined with vindesine, and causes less nausea/vomiting and nephrotoxicity compared with cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Patients with NSCLC are routinely treated with cytotoxic agents such as cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: We investigated the efficacy of irinotecan/cisplatin (IP) versus irinotecan/capecitabine (IX) with or without isosorbide-5-mononitrate (ISMN) in chemo-na\u00efve advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced NSCLC: the TORCH randomized trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced NSCLC: a multicenter phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "tiby@katamail.com  PURPOSE: The role of cisplatin in the first-line treatment for elderly advanced NSCLC is not completely defined. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Delta-tocotrienol augments cisplatin-induced suppression of NSCLC cells via inhibition of the Notch-1 pathway. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Treatment with a combination of delta-tocotrienol and cisplatin resulted in a dose-dependent, significant inhibition of cell growth, migration, invasiveness, and induction of apoptosis in NSCLC cells, as compared to the single agents. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "These results suggest that down-regulation of Notch-1, via inhibition of NF-\u03baB signaling pathways by delta-tocotrienol and cisplatin, in combination, could provide a potential novel approach for tumor arrest in NSCLC, while lowering the effective dose of cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin is a classic chemotherapy agent used for treating human non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The prognosis signature was found to especially accurate at identifying early stage patients at risk of disease specific death within 24\u2009months of diagnosis when compared to traditional methods of outcome prediction.Separately, NSCLC patients with the 37-gene ACT-response signature (n\u2009=\u200970, 64\u2009%), benefited significantly from cisplatin/vinorelbine (adjusted HR: 0.23, P\u2009=\u20090.0032). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cyclic GMP/protein kinase G type-I\u03b1 (PKG-I\u03b1) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-I\u03b1 kinase activity synergizes with cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The data suggest that the PKG-I\u03b1 kinase activity is necessary for maintaining higher levels of CREB phosphorylation at ser133 and protein expression of c-IAP1, livin, survivin, and Mcl-1, preventing spontaneous apoptosis and promoting colony formation in NSCLC cells, which may limit the effectiveness of chemotherapeutic agents like cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The intrinsic characteristics of NSCLC (which near-to-always is chemoresistant and associated with poor prognosis) and/or the type of therapy that is employed to treat this malignancy (which near-to-always is based on cisplatin) may explain why two genes that affect the immune response to dying cells fail to influence the clinical progression of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "thierry.berghmans@bordet.be  Induction cisplatin-based CT improves survival in resectable non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In the current study, we investigated the underlying mechanism initiated by silencing of Twist1 that sensitizes NSCLC cells to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, the NSCLC cell line A549 and the cervical cancer cell line HeLa were treated with wogonin or cisplatin individually or in combination. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Between 2003 and 2010, 87 patients with stage III NSCLC underwent cisplatin-based CCRT and all subsequent follow-up at the VU University Medical Center. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Randomised trials of cisplatin-based adjuvant chemotherapy for resected NSCLC were identified. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We determined the recommended dose (RD) of thoracic radiotherapy (TRT) with a concurrent chemotherapy combination of pemetrexed and cisplatin in Japanese patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human NSCLC cells to cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we investigated the role of RBM5 in the cisplatin resistance observed in human lung NSCLC cells and evaluated the effect of RBM5 modulation on cell growth inhibition and apoptosis induced by cisplatin in the parental NSCLC cells A549 and their cisplatin resistant counterparts, A549/DDP cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Sub-toxic cisplatin mediates anoikis resistance through hydrogen peroxide-induced caveolin-1 up-regulation in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III NSCLC (JCOG9901DI). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Prospective study of transarterial infusion of docetaxel and cisplatin to treat NSCLC in patients contraindicated for standard chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "RESULT: CTR1 rs10981694 A>C polymorphism is associated with cisplatin induced severe toxicity in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: NSCLC patients carrying C allele of CTR1 rs10981694 presented more sensitivity to ototoxicity after cisplatin treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " [A randomized trial of liposomal paclitaxel plus cisplatin as first-line therapy for advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND AND OBJECTIVE: Paclitaxel plus cisplatin (TP) is used as the standard regimen for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we compared the response rate (RR), overall survival (OS), and toxicity of the combined chemotherapy regimen of liposomal paclitaxel plus cisplatin (LP) with those of TP as first-line treatments for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Three of 6 trials with 300 or more patients with early-stage NSCLC have demonstrated that adjuvant cisplatin-based chemotherapy can significantly improve 5-year survival in carefully selected patients with resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Taken together, our results suggest that the down-modulation of TP protein induced by 17-AAG represents a key factor in enhancing the cytotoxic effects of cisplatin in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cytotoxicity assays of azolato-bridged dinuclear Pt(II) complexes, [{cis-Pt(NH(3))(2)}(2)(\u03bc-OH)(\u03bc-azolato)](2+), where the azolato was pyrazolato (1), 1,2,3-triazolato-N1,N2 (2), tetrazolato-N1,N2 (3), or tetrazolato-N2,N3 (4), were performed in cisplatin-sensitive and -resistant human NSCLC cell lines (PC-9 and PC-14). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " OBJECTIVE: A previous large, randomized, control trial(JBR.10)revealed that adjuvant chemotherapy with cisplatin(CDDP) and vinorelbine(VNR)was effective for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: These results offer a preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for patients with NSCLC, and provide potential molecular biomarkers for tailoring therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin resistance induced by decreased apoptotic activity in NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "For this purpose, A549 and Calu1 NSCLC cell lines were treated with cisplatin to obtain resistant sub-lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Fifty patients with clinically diagnosed N2 or N3 NSCLC who underwent induction CRT with docetaxel and cisplatin concurrently with thoracic radiation followed by surgery were examined in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including NSCLC, colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Tetrandrine combined with gemcitabine and Cisplatin for patients with advanced NSCLC improve efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "skatsenos@yahoo.gr  Pemetrexed is indicated for locally advanced or metastatic non-squamous NSCLC as an initial treatment in combination with cisplatin or after prior chemotherapy as a single agent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for NSCLC with mediastinal lymph node metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "toyooka@md.okayama-u.ac.jp  The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for NSCLC with mediastinal nodal metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous NSCLC (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "INTERPRETATION: Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Chemotherapy with platinum doublets, including cisplatin plus vinorelbine, is standard of care for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "tshukuya@juntendo.ac.jp  BACKGROUND: Based on the results of phase I/II studies, S-1 plus cisplatin (CDDP) and vinorelbine (VNR) plus CDDP are commonly used chemoradiotherapeutic regimens for the treatment of NSCLC(NSCCLC) in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin is an effective anticancer drug used to treat many types of cancer, including non-small cell lung carcinoma (NSCLCs), but development of resistance is the primary impediment in cancer treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The transcriptional level of IGFBP7 was decreased in cisplatin-resistant human cancer cell lines and NSCLC xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "The expression of MKP3 increased in a cisplatin-resistant NSCLC cell line and lung xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Dose escalation and feasibility study of amrubicin combined with cisplatin in previously untreated patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "y-naruo@sc4.so-net.ne.jp  OBJECTIVES: Cisplatin is a key drug used in the treatment of non-small cell lung cancer (NSCLC), and amrubicin is one of the new active agents for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: We conducted a dose escalation study of amrubicin and cisplatin in previously untreated patients with stage IIIB or IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: This amrubicin and cisplatin regimen may be feasible and promising against advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This trial was designed to evaluate the safety and efficacy of first-line enzastaurin plus cisplatin-pemetrexed in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Enzastaurin and cisplatin-pemetrexed is tolerable with preliminary activity in patients with advanced NSCLC, but because of a lack of efficacy improvement in other phase II NSCLC studies, the study was terminated early. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Most NSCLC patients receive cisplatin-based chemotherapy though clinical response is restricted to a subset of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: For elderly patients with nonsquamous advanced NSCLC and PS 0-1, pemetrexed therapy, with its favorable toxicity profile, is a viable option, either in combination with cisplatin in the first-line setting or as maintenance therapy after initial chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV NSCLC patients: a multicenter randomised factorial trial (FAST). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: A total of 433 stage IIIB-IV NSCLC patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: The development of drug-resistant phenotypes has been a major obstacle to cisplatin use in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Chemoradiotherapy with cisplatin and vinorelbine followed by S-1 consolidation demonstrated a reasonable overall survival in patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Updated survival and outcomes for older adults with inoperable stage III NSCLC treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "sjalal@iupui.edu  BACKGROUND: Concurrent chemoradiation with etoposide and cisplatin (EP/XRT) is standard treatment for inoperable stage III locally advanced non-small-cell lung cancer (LA-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " BACKGROUND: Although the survival benefit of cisplatin-based adjuvant chemotherapy has been proven for patients with NSCLC, the resistance to cisplatin and its dose-dependent side effects remain a challenge. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Improvement in survival and reduction of side effects require a biomarker capable of defining the response to cisplatin treatments in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "In this study, we investigated whether the quantified mRNA expression of FATS can predict cisplatin sensitivity in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Cisplatin-induced apoptosis in NSCLC cells was evaluated by flow cytometry after Annexin V staining. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "For those NSCLC patients receiving cisplatin-based chemotherapy, the overall survival was significantly longer in FATS-high subgroup than that in FATS-low subgroup (P=0.038). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Multivariate analysis revealed the independent value of FATS mRNA in predicting the overall survival for NSCLC patients receiving cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, enhanced expression of FATS significantly sensitized NSCLC cells to cisplatin-induced apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced NSCLC: a combined analysis of three phase 3 trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "treatjo@lilly.com  INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " PURPOSE: To investigate the association between a single-nucleotide polymorphism (SNP) of ERCC1, Asn118Asn (C\u00a0\u2192\u00a0T), and the response of patients with late-stage NSCLC (n\u00a0=\u00a0142) to cisplatin-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Our results suggest that this polymorphism of ERCC1 at codon 118 is associated with patient response to cisplatin-based chemotherapy in treatments of late-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Patients (n = 26) with advanced-stage NSCLC received intravenous cisplatin 100 mg/m(2) on day 1 and at 4-week intervals plus intravenous vinorelbine 25 mg/m(2) weekly. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "vkovac@onko-i.si  After a favorable experience with gemcitabine at a low dose in a prolonged infusion in combination with cisplatin for advanced NSCLC, here, we present the results from a phase II trial for patients with malignant pleural mesothelioma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced NSCLC: effects on quality of life and survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "We designed this trial to determine whether APS injection integrated with vinorelbine and cisplatin (VC) offered an improved QOL over VC for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "excision repair cross-complementation group 1 (ERCC1) - cisplatin] may well also complement NSCLC diagnosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Our objectives were to determine the maximum tolerated dose and recommended dose of pemetrexed in combination with cisplatin, with concurrent late course accelerated hyperfractionated (LCAF) intensity modulated radiotherapy (IMRT) in patients with LANSCLC and to investigate the safety and efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSIONS: The combination of pemetrexed and cisplatin with concurrent LCAF IMRT optimized based on single photon emission photography lung perfusion imaging is well tolerated in patients with LANSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "Furthermore, two stably transfected cell lines (A549/shSTAT3 and SPC-A1/shSTAT3) were successfully established, and RNAi-mediated STAT3 inhibition could significantly increase the sensitivity of NSCLC cells to cisplatin by enhancing caspase-3-dependent apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Eligible patients with unresectable Stage III NSCLC, age \u2265 20 years, performance status 0-1, percent of volume of normal lung receiving 20 GY or more (V(20)) \u2264 30% received three to four cycles of cisplatin (80 mg/m(2) Day 1) and vinorelbine (20 mg/m(2) Days 1 and 8) repeated every 4 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " The influence of intraoperative pleural perfusion with matrine-cisplatin or cisplatin on stromal cell-derived factor-1 in NSCLC patients with subclinical pleural metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": " A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "This study assessed the efficacy of the combination of standard gemcitabine plus cisplatin chemotherapy with rh-endostatin in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB to IV NSCLC were randomly (1:1) assigned to receive gemcitabine/cisplatin chemotherapy alone or with 7.5 mg/ m(2) of intravenously rh-endostatin on days 1 to 14 of each 3-week cycle. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "CONCLUSION: The addition of rh-endostatin to gemcitabine plus cisplatin chemotherapy for first-line treatment of NSCLC improves objective response and may improve survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "cisplatin", "orig_sen": "130 patients with inoperable stage III NSCLC and PS 0-1 were randomised to receive cisplatinum and vinorelbine with either sequential or concurrent chemo-radiation using 55Gy in 20 fractions over four weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Current choices of second-line chemotherapy regimens for patients with advanced NSCLC are extremely limited. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " PURPOSE: The role of second-line chemotherapy in patients with NSCLC and preexisting interstitial pneumonia (IP) previously treated with platinum-based chemotherapy remains uncertain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "There was no significant difference between first- and second-line chemotherapy in objective response and disease control rates for advanced NSCLC harboring activating epidermal growth factor receptor mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " BACKGROUND: Disease progression remains the major challenge in the management of advanced (stage IIIb or IV) NSCLC after the failure of first-line or second-line chemotherapy, or even of targeted therapies such as gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced NSCLC: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "Currently, only erlotinib is offered as a third-line option in unselected nsclc patients after failure of first- and second-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "In this retrospective study, the charts of patients who underwent second-line chemotherapy for NSCLC in our cancer center between January 2005 and April 2010 were reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous NSCLC patients who received second-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " The effects of second-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "Given the lack of research in this area, we here examined whether progression-free survival (PFS) or post-progression survival (PPS) could serve as valid surrogate endpoints for OS after second-line chemotherapy in advanced NSCLC, using individual-level data. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "Between April 2009 and June 2011, 39 patients with advanced non-squamous NSCLC who had received second-line chemotherapy following first-line chemotherapy treatment with cisplatin and pemetrexed were analysed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "Analysis of individual-level data of patients treated with second-line chemotherapy suggested that PPS may be used as a surrogate for OS in patients with advanced non-squamous NSCLC with unknown oncogenic driver mutations and therefore limited options for subsequent chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " BACKGROUND: Efficacy of second-line chemotherapy in platinum-pretreated NSCLC is poor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "This study investigated efficacy of computed tomography-guided percutaneous fine-needle 5% ethanol-cisplatin intratumoral injection (CT-PFNECII) combined with second-line chemotherapy in patients with platinum-pretreated stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "CONCLUSIONS: CT-PFNECII combined with second-line chemotherapy provided a higher response rate and improved survival than second-line chemotherapy for patients with platinum-pretreated stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "Evidence about its efficacy in addition to second-line chemotherapy in non-small cell lung cancer (NSCLC) has been produced by two large randomized phase III clinical trials (LUME-Lung 1 and LUME-Lung 2), conducted in patients with pretreated NSCLC, without major risk factors for bleeding. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Docetaxel is recommended as a second-line chemotherapy agent for the NSCLC; however, drug resistance greatly limits its efficiency. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "CONCLUSION: These findings show the diversity, short treatment duration, and lack of efficacy of second-line chemotherapy regimens for NSCLC in the community oncology setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Case 1: An 86-year-old man was diagnosed with large cell or squamous cell lung cancer of clinical Stage II A.He was administered nanoparticle albumin-bound paclitaxel(nab-PTX)as fourth-line chemotherapy after monochemotherapy with docetaxel, vinorelbine, and S-1.The patient continues to show complete remission at the 15 courses of nab-PTX.Case 2: A 79-year-old man underwent partial resection of the right lower lung, and the pathological diagnosis was large cell lung cancer of pStage I A.However, recurrence in the right lung and multiple lymph node metastases were identified 3 years after the surgery.He was administered nab-PTX as second-line chemotherapy after vinorelbine monotherapy, and he has shown complete remission for a year.Weekly intravenous nab-PTX may be useful in elderly patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " PURPOSE: Second-line chemotherapy of advanced NSCLC with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "CONCLUSION: Only selected NSCLC patients could benefit from second-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " BACKGROUND AND OBJECTIVE: This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "RESULTS: Icotinib was comparable with standard second-line chemotherapy for advanced NSCLC in terms of overall response rate (ORR) (28.1% vs 18.2%, P=0.341), disease control rate (DFS)(43.8% vs 45.5%, P=0.890), and PFS (4.3 months vs 3.8 months, P=0.506). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "CONCLUSIONS: Compared with the standard second-line chemotherapy, icotinib is active in the treatment of advanced NSCLC patients, especially with EGFR unknown in the second line, with an acceptable adverse event profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Supportive Care Costs Associated with Second-Line Chemotherapy in Chinese Patients with Advanced Non-Squamous NSCLC: A Retrospective Cohort Study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " PURPOSE: To compare supportive care costs associated with second-line chemotherapy for advanced non-squamous NSCLC (advNS-NSCLC) in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "METHODS: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for advNS-NSCLC in four Chinese hospitals from 2007 to 2012. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Tumor response and clinical toxicity associated with second-line chemotherapy regimens for advanced non-squamous NSCLC: A retrospective cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "CONCLUSIONS: We recommend that docetaxel or pemetrexed monotherapies should continue to be considered the standard second-line chemotherapy treatment against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "Our meta-analysis suggested that pemetrexed combination chemotherapy was not superior to single-agent arm and was not recommended as the second-line chemotherapy for patients with NSCLC (Tab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "In ALK-translocated NSCLC, a Phase III trial demonstrated the superiority of a multi-target TKI, including ALK, in terms of progression-free survival, response rate and toxicity profile when compared to standard second-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " OBJECTIVES: To compare the effects of adding targeted agents to standard second-line chemotherapy with a single agent (pemetrexed or docetaxel) in patients with advanced NSCLC, a meta-analysis of all relevant randomized controlled trials was performed and overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were assessed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Prognostic score for second-line chemotherapy of advanced NSCLC: external validation in a phase III trial comparing vinflunine with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " A prognostic index for second-line chemotherapy of NSCLC was previously developed, based on individual patient data (IPD) of nine randomized trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " PURPOSE: The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in NSCLC Patients with EGFR Mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " BACKGROUND: Second-line chemotherapy for advanced NSCLC improves survival modestly but new strategies are needed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "The overall survival (OS) for patients (n = 141) receiving first-line TKI followed by second-line chemotherapy were longer than those for patients (n = 187) receiving first-line chemotherapy followed by second-line TKI (HR: 0.69, P = 0.02).Compared with second-line TKI, first-line therapy achieved a significant and longer PFS, and higher ORR in the sensitive EGFR mutated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Immune checkpoint inhibitor is a verified standard of care as a second-line chemotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " A prognostic model for platinum-doublet as second-line chemotherapy in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Poor prognosis of advanced NSCLC patients and the promising therapeutic effect of platinum urge the oncologists to evaluate the role of platinum doublet as second-line chemotherapy and establish the definition of platinum sensitivity in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "We retrospectively analyzed 364 advanced NSCLC patients who received platinum-doublet regimens as second-line chemotherapy after platinum-based first-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "Female, younger than 60\u00a0years, and TTP greater than 12\u00a0months may indicate prolonged survival after platinum-doublet second-line chemotherapy in advanced NSCLCpatients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " BACKGROUND: Patients with locally advanced or metastatic NSCLC should be treated with first-line and second-line chemotherapy or target therapy according to the lung cancer guidelines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Second-line chemotherapy has been established for NSCLCand sensitive relapsed small cell lung cancer(SCLC).Molecular targeted drugs, such as EGFR- and ALK-inhibitors, have improved survival outcome remarkably in patients with NSCLC harboring EGFR mutations or EML4-ALK fusion proteins.In addition, targeted drugs that may overcome T790M-mediated EGFR-TKI resistance have been developed, and the development of future therapeutic strategies is anticipated.On the other hand, molecular targeted drugs against SCLC have not yet been developed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "CONCLUSION: Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "MATERIALS AND METHODS: One thousand and eight patients with advanced NSCLC who received second-line chemotherapy after progression were reviewed in Shanghai Pulmonary Hospital, China, from September 2005 to July 2010. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Outcomes of second-line chemotherapy for advanced NSCLC in one institution. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " BACKGROUND: This study analyzed the negative prognostic factors in patients who received second-line chemotherapy for advanced inoperable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "METHODS: We retrospectively reviewed the records of 137 patients with inoperable stage III-IV NSCLC who received second-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "CONCLUSION: The age factor, T stage and responsiveness to first-line chemotherapy were important factors in predicting the outcome of patients with advanced NSCLC who received second-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "METHODS: From January 2005 to July 2010, we recruited 69 patients with locally advanced NSCLC who had each had first-line chemotherapy four to six times but had progressive disease; 34 received (125)I seed implantation with second-line chemotherapy (Group A) and 35 received second-line chemotherapy only (Group B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "The phase III PROFILE 1007 randomized study of crizotinib versus chemotherapy has demonstrated that crizotinib is superior to standard second-line chemotherapy in ALK-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": "AREAS COVERED: In this article, updated data derived from the development and the use of crizotinib (the most advanced in development among tyrosine kinase ALK inhibitors) in comparison with standard second-line chemotherapy for patients affected by ALK-altered NSCLC are reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Second-Line Chemotherapy", "orig_sen": " Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for NSCLC without EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced NSCLC was evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Tumor-associated stromal caveolin-1 (Cav-1) expression was correlated with improved response rate and survival in NSCLC patients who received nab-paclitaxel in this phase II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Carboplatin and nab-paclitaxel every 21 days demonstrated promising efficacy with tolerable toxicity in NSCLC patients ineligible for bevacizumab therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Further analysis and validation of Cav-1 and SPARC expression in tumor and stromal compartments as prognostic and/or predictive biomarkers of NSCLC or nab-paclitaxel treatment is warranted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The aim of this clinical study was to evaluate the efficacy and safety of nab-paclitaxel to treat patients with advanced NSCLC who failed first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Given the tolerability on grade 3 or 4 adverse events, nab-paclitaxel may be considered an alternative second-line treatment option for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Overexpression of stathmin is resistant to paclitaxel treatment in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The findings demonstrated that paclitaxel effect may be interfered with stathmin; overexpression of stathmin is a predictive marker for a worse prognosis in patients with NSCLC who were treated by both platinum and paclitaxel chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced NSCLC-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "RESULTS: The combination of carboplatin with paclitaxel was most frequently used as the first-line treatment for NSCLC patients with ILD (61\u00a0%). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for NSCLC: North Central Cancer Treatment Group (NCCTG)-N0321. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The combination of bortezomib and carboplatin/paclitaxel and concurrent radiation in unresectable stage III NSCLC was evaluated in this phase I/II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Our cohort consisted of prospective patients with NSCLCs who received chemotherapy (platinum derivates plus paclitaxel) at the [UNICAMP], Brazil. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Patients with NSCLCs harboring EGFR exon 19 deletions or the exon 21 L858R mutation were found to have a higher chance of response to platinum-paclitaxel (OR 9.67 [95\u00a0% CI 1.03-90.41], p\u2009=\u20090.047). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Survival analysis in advanced NSCLC treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "AIM: To evaluate the safety and efficacy of a metronomic schedule of paclitaxel administered weekly in relapsed refractory NSCLC or upfront in patients not eligible for platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: Patients with recurrent and treatment-na\u00efve platinum-ineligible advanced NSCLC were treated with weekly paclitaxel at 80 mg/m 2 with palliative intent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Weekly low-dose continuous metronomic-type scheduling of paclitaxel is safe and effective for relapsed refractory NSCLC and in the first line in platinum-ineligible patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for NSCLC after failure of platinum-doublet chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The primary objective of this study was to determine whether repeated doses of bexarotene capsules affect pharmacokinetic parameters of paclitaxel or carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Bavituximab plus paclitaxel and carboplatin for the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Bavituximab in combination with paclitaxel-carboplatin as first-line therapy demonstrated a tolerable safety profile and potential efficacy in this single-arm phase II trial in patients with advanced local or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This study evaluated the safety of CA4P when combined with carboplatin, paclitaxel, and bevacizumab in chemotherapy-na\u00efve subjects with advanced nonsquamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Adult subjects with confirmed American Joint Committee on Cancer six stage IIIB/IV NSCLC and an Eastern Cooperative Oncology Group performance score of 0 or 1 were randomized to receive six cycles (treatment phase) of paclitaxel (200 mg/m(2)), carboplatin (area under the concentration versus time curve 6), and bevacizumab (15 mg/kg) on day 1 and repeated every 21 days, or this regimen plus CA4P (60 mg/m(2)) on days 7, 14, and 21 of each cycle. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: CA4P plus carboplatin, paclitaxel, and bevacizumab appears to be a tolerable regimen with an acceptable toxicity profile in subjects with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous NSCLC (NS-NSCLC), particularly in those excluded from clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, NSCLC (NS-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " [18F]FDG PET/CT-based response assessment of stage IV NSCLC treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This phase Ia/Ib study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of pictilisib in monotherapy or in combination with carboplatin-paclitaxel and bevacizumab (CP\u00a0+\u00a0BEV) in Japanese patients with advanced solid tumors or non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We previously reported that carboplatin-paclitaxel plus bevacizumab was effective for patients with advanced non-squamous NSCLC and MPE, although we did not evaluate the relationship between treatment outcomes and plasma or pleural effusion levels of VEGF. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous NSCLC with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous NSCLC with pre-existing interstitial lung disease (ILD). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced NSCLC who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4\u2009\u00b1\u20090.9\u00a0MBq (mean\u2009\u00b1\u2009SD) (89)Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous NSCLC were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "OBJECTIVE: To evaluate biomarkers to predict the benefit of paclitaxel and carboplatin plus bevacizumab (PCB) therapy in patients with advanced or recurrent non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced NSCLC patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Chemonaive patients (n = 939) with stage IIIB/IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomized (1:1) to pemetrexed-carboplatin-bevacizumab (pemetrexed arm) or paclitaxel-carboplatin-bevacizumab (paclitaxel arm). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We evaluated dynamic CT-based vascular parameters and plasma cytokines after bevacizumab alone and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore potential biomarkers of treatment response and resistance to this regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous NSCLC harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVES: We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous NSCLC who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by\u00a0Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This study aimed to compare overall survival for Medicare patients diagnosed with NSCLC and treated with either first-line bevacizumab-carboplatin-paclitaxel (BCP) or carboplatin-paclitaxel (CP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Cost-Effectiveness Analysis of Bevacizumab- Paclitaxel-Carboplatin (PC) Versus PC in First-Line Therapy of Advanced NSCLC from Patients' Perspective in Vietnam. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous NSCLC with interstitial lung disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: Optimal chemotherapy for patients with advanced NSCLC with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: We analyzed the outcomes of 21 patients with advanced nonsquamous NSCLC with ILD who received paclitaxel and carboplatin without (paclitaxel-carboplatin group; n\u00a0=\u00a011) or with bevacizumab (paclitaxel-carboplatin-bevacizumab group; n\u00a0=\u00a010) between April 2008 and October 2013. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: The addition of bevacizumab to paclitaxel and carboplatin may provide an effective and safe treatment option for patients with advanced nonsquamous NSCLC with ILD. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Since there is no guideline for third line treatment of NSCLC, some oncology units use paclitaxel-bevacizumab in some NSCLC patient after relapse of the second line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Combined paclitaxel-bevacizumab chemotherapy seems feasible in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel-carboplatin chemotherapy in patients with advanced NSCLC resulted in a 6-month progression-free survival (PFS) rate that compares favorably with the historic rate for bevacizumab combined with paclitaxel-carboplatin in this patient population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: In this phase II, single-arm, open-label, multicenter study, 40 patients with advanced NSCLC received ramucirumab (10 mg/kg intravenous [IV]) followed by paclitaxel (200 mg/m IV) and carboplatin area under the curve = 6 on day 1 every 21 days as first-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " MO06.12 Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous NSCLC (NSCLC): analyses based on age in the phase 3 PointBreak and E4599 trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: Bevacizumab plus carboplatin-paclitaxel (BCP) chemotherapy has Food and Drug Administration approval for advanced nonsquamous, NSCLC based upon improved survival in a clinical trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Using data from four health maintenance organizations (HMOs) belonging to the Cancer Research Network, 1605 HMO nonsquamous, NSCLC patients aged younger than 21 years, diagnosed 2002-2010, who received carboplatin-paclitaxel (CP), with and without bevacizumab for first-line treatment of stage IIIB/IV disease were identified. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " AIM: The aim of this retrospective study was to evaluate bevacizumab combined with weekly paclitaxel with and without carboplatin in pre-treated patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Between November 2009 and October 2011, 43 pre-treated patients with non-squamous NSCLC received bevacizumab (15 mg/kg, day 1) plus weekly paclitaxel (60-80 mg/m(2), days 1, 8, 15) with carboplatin (area under the curve=4-5, day 1) (n=36), or bevacizumab plus weekly paclitaxel (n=7) alone every four weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Even for heavily pre-treated patients, bevacizumab plus weekly paclitaxel with or without carboplatin was effective and tolerable in non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous NSCLC was evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Combination of paclitaxel and bevacizumab in heavily pre-treated NSCLC patients: a case series study on 15 patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "An increase of CEC and CEP was observed in patients with NSCLC treated with paclitaxel and bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous NSCLC: SWOG S0536. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous NSCLC) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Chemo-naive Chinese patients with locally advanced, metastatic or recurrent NSCLC were randomized to receive Bev 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous NSCLC with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase2 study of bevacizumab with carboplatin-paclitaxel for NSCLC with malignant pleural effusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "moto19781205@yahoo.co.jp  Vascular endothelial growth factor (VEGF) is involved in NSCLC with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: One standard of care for advanced NSCLC is paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Bevacizumab and weekly paclitaxel for non-squamous NSCLC patients: a retrospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: Combination of bevacizumab and weekly paclitaxel showed synergitic effects, anti-tumor efficacy and a good toxicity profile for patients with breast cancer but has never been evaluated in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: In our experience, combination of bevacizumab and weekly paclitaxel exhibited acceptable toxicity and had encouraging anti-tumor efficacy as fourth-line treatment or beyond for non-squamous NSCLC patients, supporting further evaluation in larger prospective studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: A patient with advanced NSCLC received four cycles of carboplatin AUC 6, paclitaxel 200\u2009mg/m(2), and bevacizumab 15\u2009mg/kg, and was continued on every-3-week maintenance bevacizumab 15\u2009mg/kg. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "philip_bonomi@rush.edu  INTRODUCTION: We conducted a phase II study of dual-agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with paclitaxel and carboplatin chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with stage IIIB/IV nonsquamous NSCLC randomly received cetuximab (400 mg/m initially, 250 mg/m weekly thereafter) plus bevacizumab (15 mg/kg) for six cycles combined with paclitaxel (200 mg/m) and carboplatin (area under the curve 6) for either six cycles (six-cycle arm) or the first three cycles (three-cycle arm) (one cycle = 3 weeks). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "jardimde@gmail.com  OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic NSCLC, in combination with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " [A case of complete resection of non-squamous NSCLC after induction chemotherapy using carboplatin, paclitaxel, and bevacizumab]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin and paclitaxel (CP) in comparison with CP chemotherapy alone in patients with previously untreated advanced, metastatic or recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Prognostic models to predict survival in NSCLC patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "txh@medicine.wisc.edu  BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced NSCLC patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLC patients can be estimated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " CONTEXT: A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "OBJECTIVE: To examine whether adding bevacizumab to carboplatin and paclitaxel chemotherapy is associated with improved survival in older patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Adding bevacizumab to carboplatin and paclitaxel chemotherapy was not associated with better survival among Medicare patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "siniho@east.ncc.go.jp  PURPOSE: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "As an application example, we describe the analysis for the comparison of four regimens, cisplatin plus irinotecan, carboplatin plus paclitaxel, cisplatin plus gemcitabine (GP), and cisplatin plus vinorelbine, for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The results showed the concentrations of paclitaxel and carboplatin in sputum of patients treated with ambroxol hydrochloride were significantly higher than those of the control group, suggesting that ambroxol hydrochloride significantly increased the local concentrations of chemotherapeutic agents in lung tissues of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin in combination with thoracic radiotherapy for patients with locally advanced stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "[Epub ahead of print]  Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III NSCLC: A Systematic Review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB NSCLC are carboplatin-paclitaxel and cisplatin-etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Objective: To conduct a systematic review of published trials to compare outcomes and toxic effects between cisplatin-etoposide and carboplatin-paclitaxel in patients with NSCLC receiving thoracic radiation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "[Epub ahead of print]  Randomized, Placebo-Controlled, Phase 2 Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The primary endpoint of this phase 2 trial determined whether addition of veliparib to carboplatin and paclitaxel improved PFS in previously untreated advanced/metastatic NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " CONTEXT: Paclitaxel (PTX) and carboplatin (CBP) are widely used for the combined chemotherapy of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " P1.48: nab-Paclitaxel + Carboplatin in Advanced Non-Small Cell Lung Cancer:\u00a0Outcomes in Elderly Patients\u00a0With Squamous Histology: Track: Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVE: This phase I study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase (HDAC) inhibitor, in combination with paclitaxel and carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The patient was diagnosed with NSCLC 9 months ago and received 6 cycles of chemotherapy with motesanib, paclitaxel, and carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing in patients with advanced NSCLC to avoid supra- or subtherapeutic exposure. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: PK-guided dosing of paclitaxel does not improve severe neutropenia, but reduces paclitaxel-associated neuropathy and thereby improves the benefit-risk profile in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: The objective of this clinical trial was to explore the efficacy and tolerability of first-line chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a novel agent that uses a drug delivery system, plus carboplatin, in elderly Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Nab-paclitaxel plus carboplatin, without dose reduction, is indicated to be toxic and intolerable as first-line chemotherapy in elderly Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Health-related quality of life in elderly patients with advanced NSCLC comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced NSCLC were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) NSCLCs (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced NSCLC: Analysis of Safety and Efficacy in Patients With Diabetes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: To examine outcomes in a phase 3 trial of nab-paclitaxel plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C) in a subset of patients with advanced NSCLC and diabetes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " 216PD: nab-Paclitaxel + carboplatin (nab-P/C) in advanced NSCLC: outcomes in elderly patients (pts) with squamous (SCC) histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Nineteen patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-l, and adequate organ function were treated with 60-66 Gy thoracic radiation therapy over 30-33 fractions concurrent with weekly 7.5 mg/m(2) endostatin for 14 days, 50 mg/m(2) paclitaxel, and 2 mg/mL/min carboplatin over 30 min. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Is there a role of nab-paclitaxel in the treatment of advanced NSCLC? The data suggest yes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced NSCLC regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This review will focus on the early development and clinical data to date supporting the use of nab-paclitaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The clinical question central to this review is whether nab-paclitaxel has a place in the current therapeutic landscape of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced NSCLC and Impaired Performance Status as Selected by a Serum Proteomics Assay. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: This study evaluated Reolysin combined with paclitaxel and carboplatin in patients with metastatic/recurrent KRAS-mutated or epidermal growth factor receptor (EGFR)-mutated/amplified NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS AND MATERIALS: We included 52 patients with NSCLC treated with definitive concurrent carboplatin-paclitaxel and RT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Pharmacogenetic analysis of advanced NSCLC patients treated with first-line paclitaxel and carboplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We investigated the effects of genetic polymorphisms on the clinical outcome of advanced NSCLC patients with first-line paclitaxel and carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: This study showed that the SLCO1B3 c.699 G>A polymorphism may predict anemia and ABCB1, HIF1A polymorphism are highly predictive for worse survival in advanced NSCLC with first-line paclitaxel and carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic NSCLC: a single center 10-year experience. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: The primary objective of this retrospective analysis is to assess efficacy and toxicity of a chemotherapeutic regimen using weekly carboplatin in combination with weekly paclitaxel as first-line therapy for advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: All patients with stage IIIB/IV NSCLC treated with weekly carboplatin AUC (area under the curve) 3 days 1, 8, 15, q4w in combination with weekly paclitaxel 75 mg/m(2) days 1, 8, 15, q4w as first-line therapy at the Kantonsspital Graubuenden between August 2004 and May 2014 were retrospectively analyzed by medical record review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Weekly carboplatin in combination with weekly paclitaxel results in good response rates and acceptable toxicity in patients with advanced and metastatic NSCLC including patients with poor risk features (brain metastases, older age, and impaired PS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Albumin-Bound Paclitaxel: A Review in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of NSCLC in patients who are not candidates for curative surgery and/or radiation therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-na\u00efve NSCLC in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " We investigated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) with concurrent radiotherapy for unresectable locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Preliminary efficacy suggests veliparib may enhance carboplatin and paclitaxel activity, providing benefit to patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVES: Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced NSCLC both as monotherapy in the relapsed setting or with carboplatin and paclitaxel in the first-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This signature was validated on baseline plasma samples from patients enrolled in a randomized trial of daily linifanib 7.5 mg, linifanib 12.5 mg, or placebo added to first-line carboplatin and paclitaxel chemotherapy for advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Cost-effectiveness analysis of EGFR mutation testing in patients with NSCLC with gefitinib or carboplatin-paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiation for Stage III NSCLC: Is There an Impact on Radiation Pneumonitis Rates?  Palma DA(1), Senan S(2), Rodrigues G(3). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Survival, quality-adjusted survival, and other clinical end points in older advanced NSCLC patients treated with albumin-bound paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced NSCLC in older patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS AND MATERIALS: Forty-eight patients with previously untreated NSCLC received intensity modulated radiation therapy (63 Gy/35 fractions) on Monday through Friday, with chemotherapy (paclitaxel 45 mg/m\u00b2, carboplatin area under the curve [AUC] = 2) on Mondays, for 7 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Our results suggest that, Paclitaxel or combination of Paclitaxel+Gemcitabine could serve as a suitable therapy against MDR1 in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin (CBDCA) in a phased schedule improved progression-free survival in a phase II NSCLC study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Investigation of prognostic factors affecting efficacy in carboplatin- and paclitaxel-based first-line chemotherapies for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The present meta-analysis aims to investigate prognostic factors affecting overall survival (OS), progression-free survival (PFS) or time to progression (TTP), and overall response rate (ORR) in carboplatin and paclitaxel-based first-line chemotherapies for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: We performed a literature search in PubMed for randomized phase II and III clinical trials in patients with NSCLC treated with carboplatin and paclitaxel as first-line chemotherapy published from January 2000 to December 2013 to investigate prognostic factors affecting OS, PFS or TTP, and ORR by linear regression analysis and logistic regression analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " LESSONS LEARNED: The concomitant use of weekly nab-paclitaxel and carboplatin with concurrent radiotherapy was demonstrated to be a safe therapeutic approach in this phase I trial of 10 evaluable patients with stage III NSCLC.Despite the lack of systemic glucocorticoids, there were no reported infusion reactions or cases of peripheral neuropathy in this trial, both of which are known to occur with the use of paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This study was undertaken to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly nab-paclitaxel given in combination with carboplatin and concurrent radiotherapy in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Concurrent chemoradiotherapy with nab-paclitaxel 40 mg/m(2) and carboplatin AUC 2 is a safe and well-tolerated therapeutic regimen in patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The most common regimen at all stages was carboplatin and paclitaxel.BACKGROUND: Platin-based adjuvant chemotherapy has extended survival in clinical trials in patients with completely resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB NSCLC (RTOG 0617): a randomised, two-by-two factorial phase 3 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the NSCLC cell line H460. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The present study investigated the ability of carboplatin and paclitaxel to sensitize human NSCLC cells to carbon-ion beam irradiation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "NSCLC H460 cells treated with carboplatin or paclitaxel were irradiated with X-rays or carbon-ion beams, and radiosensitivity was evaluated by clonogenic survival assay. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced NSCLC: analysis of safety and efficacy in patients with renal impairment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This analysis evaluated the safety and efficacy of nab-paclitaxel (nab-P) versus solvent-based paclitaxel (sb-P), both in combination with carboplatin (C), in patients with advanced NSCLC and renal impairment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "To evaluate the efficacy and tolerability of combination chemotherapy with biweekly paclitaxel and carboplatin for elderly patients with advanced NSCLC, we conducted a multicenter, non-randomized, open label, phase II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: The combination of biweekly paclitaxel and carboplatin was effective and well tolerated in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m(2)) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "For each tumor type, Medicare patients who were 75 years or older had median survivals that were six to eight weeks shorter than those of trial patients (4.3 vs 5.8 months following treatment with single agent gemcitabine for advanced pancreatic cancer, P = .03; 7.3 vs 8.9 months following treatment with carboplatin and paclitaxel for stage IV NSCLC, P = .91; 8.2 vs 10.2 months following treatment with CDDP/ VP16 for extensive stage small cell lung cancer, P \u2264 .01), whereas younger Medicare patients had survival times that were similar to those of trial patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The aim of the study was to evaluate the efficacy and safety of intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy as induction therapy in clinical stage III unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III NSCLC: an analysis of Veterans Health Administration data. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with poor-risk unresectable stage III NSCLC received two cycles of carboplatin at an AUC of 5 and nab-paclitaxel at 100 mg/m on days 1 and 8 every 21 days, followed by erlotinib administered concurrently with thoracic radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Patients with poor-risk stage III NSCLC had better than expected outcomes with a regimen of induction carboplatin/nab-paclitaxel followed by thoracic radiotherapy and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Cost-Utility Analysis of First-Line Regimen Between Cisplatin Plus Pemetrexed and Carboplatin Plus Paclitaxel In Advanced Non-Squamous NSCLC in Thailand. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced NSCLC treated primarily with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS & METHODS: Genomic DNA samples from 90 adult male patients diagnosed with stage IIIB/IV NSCLC were genotyped for SNPs in candidate genes of relevance to platinating agents and paclitaxel and analyzed for association with survival and toxicities in univariate and multivariate models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or meta-static nsclc. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIAL AND METHODS: In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m(2) or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m(2) (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " nab-Paclitaxel for the treatment of advanced squamous NSCLC: a comprehensive update. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Recently, a subset analysis of a completed phase III trial demonstrated that use of nab-paclitaxel with carboplatin led to improved responses in patients with squamous NSCLC compared with solvent-based paclitaxel with carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In this review, the current experience and evolving role of nab-paclitaxel with carboplatin in the treatment of squamous NSCLC is discussed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Comparing docetaxel plus Cisplatin with Paclitaxel plus Carboplatin in chemotherapy-na\u00efve patients with advanced NSCLC: a single institute study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Motesanib plus carboplatin/paclitaxel in patients with advanced squamous NSCLC: results from the randomized controlled MONET1 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with stage IIIB/IV or recurrent squamous NSCLC (without prior systemic therapy for advanced disease) received up to six 3-week cycles of chemotherapy (carboplatin, area under the curve 6 mg/mL\u2022min/paclitaxel, 200 mg/m) and were randomized 1:1 to receive motesanib 125 mg (Arm A) or placebo (Arm B) once daily. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Motesanib plus carboplatin/paclitaxel had unacceptable toxicity compared with carboplatin/paclitaxel alone in patients with advanced squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "EXPERT OPINION: Encouraging results have been described with the administration of motesanib as first-line treatment in combination with carboplatin and paclitaxel in Asian patients with non-squamous advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVE: To compare the efficacy and safety between liposome-paclitaxel plus carboplatin (LPC) and paclitaxel plus carboplatin (PC) as first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology received open-label figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (area under the concentration-time curve, 6 mg \u00b7 min/mL) or paclitaxel and carboplatin alone once every 3 weeks for up to six cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This study investigates the potential of (18)F-FLT to monitor acute effects of chemotherapy on cellular proliferation and its recovery in bone marrow, spleen, and liver during treatment with 2 different chemotherapy regimens.METHODS: Sixty patients with NSCLC underwent concurrent radical chemoradiotherapy to 60 Gy in 6 wk with either cisplatin/etoposide (C/E, n = 28) weeks 1 and 5 or weekly carboplatin/paclitaxel (C/P, n = 32) regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), NSCLC, and small cell lung cancer (SCLC) tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This phase 1 dose-escalation study evaluated the pharmacokinetics, safety, and efficacy of linifanib in combination with carboplatin/paclitaxel in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Linifanib added to carboplatin/paclitaxel is well tolerated in Japanese patients with advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced NSCLC: A case series of 20 patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We retrospectively assessed the efficacy and toxicity of weekly paclitaxel in combination with carboplatin and concurrent TRT in patients aged \u226575 years with previously untreated locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Synergistic antitumor effect of a combination of paclitaxel and carboplatin with nobiletin from Citrus depressa on NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced NSCLC: north japan lung cancer group trial 0801. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase II trial of paclitaxel-carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: This study was conducted to evaluate the efficacy and safety of paclitaxel-carboplatin combined with intercalated gefitinib in patients with advanced, untreated, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: TS immunohistochem\u00edstry was performed on biopsies and available resection specimens from 65 NSCLC patients stage T1-3N0-2 treated with preoperative carboplatin and paclitaxel [neoadjuvant chemotherapy (NAC)-group] and from 53 NSCLC patients stage T1-4N0-1 treated with surgery without preceding chemotherapy [operation (OP)-group] that served as controls. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB or stage IV advanced primary NSCLC were randomly assigned (1:1:1) to receive up to 6 courses of standard-dose paclitaxel and carboplatin or a combination of paclitaxel, carboplatin, and mapatumumab (10 mg/kg or 30 mg/kg). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: This study showed no clinical benefit from adding mapatumumab to carboplatin and paclitaxel in unselected patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A retrospective comparison of adjuvant chemotherapeutic regimens for NSCLC: paclitaxel plus carboplatin versus vinorelbine plus cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Although paclitaxel plus carboplatin (PC) failed to demonstrate efficacy in patients with stage IB NSCLC, an exploratory analysis suggested that patients with large tumors can benefit from adjuvant PC therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " nab-paclitaxel for the management of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The 130 nm albumin-bound form of paclitaxel, nab-paclitaxel (Abraxane(\u00ae)), was recently approved by the US FDA for the first-line treatment of locally advanced or metastatic NSCLC in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In a Phase III registrational trial, nab-paclitaxel plus carboplatin demonstrated a significantly improved overall response rate, the primary endpoint, and a trend toward improved survival compared with solvent-based paclitaxel plus carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The clinical experience with nab-paclitaxel to date and the role of this newly approved therapy in the management of NSCLC will be summarized in this article. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Phase II clinical trials in advanced NSCLC found efficacy and safety of DCP-plus-paclitaxel comparable to carboplatin-plus-paclitaxel but better tolerability. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " First line treatment of advanced NSCLC - specific focus on albumin bound paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Paclitaxel has a broad spectrum of activity against various malignancies, including NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "A recent Phase III trial compared the effects of weekly nab-paclitaxel in combination with carboplatin versus sb-paclitaxel in combination with carboplatin given every 3 weeks for first line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This trial highlights the weekly nab-paclitaxel combination as an alternate treatment option for NSCLC, with higher response rate in squamous cell NSCLC and longer survival in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This review will focus on the properties of nab-paclitaxel and its use in the first line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: This two-part phase 2 study evaluated the efficacy and safety of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, combined with carboplatin/paclitaxel in patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Although toxicity was predictable and manageable, the addition of panitumumab to paclitaxel/carboplatin did not improve TTP in patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced NSCLC: NCIC Clinical Trials Group study BR29. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: This randomised double-blind placebo-controlled study evaluated the addition of cediranib, an inhibitor of vascular endothelial growth factor receptors 1-3, to standard carboplatin/paclitaxel chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " INTRODUCTION: nab-Paclitaxel (nab-P) is approved, in the United States, in combination with carboplatin for the first-line treatment of advanced NSCLC, based on a randomized phase 3 trial of nab-P plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Patients with unresectable stage III NSCLC were treated with paclitaxel 15 mg/m(2) IV, followed by TTR 6 h later on Monday/Wednesday/Friday, and TTR only on Tuesday/Thursday mornings (total 55 Gy). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Low-dose paclitaxel with concurrent TTR is an effective chemoradiotherapy regimen in unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: TUBB3 expression was investigated by immunohistochemistry performed on diagnostic biopsies and on available subsequent resection specimens in 65 NSCLC patients stage T1-3N0-2 who received neoadjuvant carboplatin and paclitaxel (NAC-group). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced NSCLC: LOGIK0401. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Concurrent chemoradiation with weekly carboplatin and paclitaxel followed by vinorelbine consolidation is effective for stage III NSCLC and shows a generally mild toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-na\u00efve metastatic/unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-na\u00efve patients with metastatic/unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Tigatuzumab was well tolerated but did not improve efficacy of carboplatin/paclitaxel in systemic therapy-na\u00efve, unselected advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "paclitaxel plus carboplatin in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "mnishio@jfcr.or.jp  BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-na\u00efve NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "socinskima@upmc.edu  BACKGROUND: This analysis compared the efficacy and safety outcomes by histology of nab-paclitaxel (nab-P) plus carboplatin (C) versus solvent-based paclitaxel (sb-P) plus C in patients with advanced NSCLC based on preplanned stratification factors specified in the phase III trial protocol. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Carboplatin-paclitaxel chemotherapy combination is the standard first-line treatment of advanced ovarian cancer and is the most commonly used treatment combination shown to be effective in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The study was prospectively performed from February 2009 to July 2011 and involved 103 patients with stages Ic-IV ovarian (n = 51) and advanced NSCLC (n = 52) who were administered a maximum of 6 cycles of carboplatin-paclitaxel as a first-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "txh@medicine.wisc.edu  INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with NSCLC prospectively stratified by beta-3 tubulin status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This randomized phase II study evaluated ixabepilone-based chemotherapy in stage IIIb/IV NSCLC, compared with paclitaxel-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "\u03b23T-positive patients had worse PFS relative to \u03b23T-negative patients, regardless of treatment; hence, \u03b23T expression seems to be a negative prognostic factor, but not a predictive factor, in advanced NSCLC treated with either ixabepilone or paclitaxel platinum-based doublets. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "gbanna@yahoo.com  The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced NSCLC: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with stages II and IIIA/B NSCLC received induction paclitaxel 225 mg/m2 intravenously (IV) and carboplatin area under the curve (AUC) 6 both days 1 and 22, followed by concurrent weekly paclitaxel (50 mg/m2) and carboplatin (AUC 2), with hyperfractionated radiation therapy (69.6 Gy at 1.2 Gy BID). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Carboplatin-paclitaxel is a reference regimen in the treatment of locally advanced or disseminated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In order to understand and overcome the drug resistance pattern of NSCLC after carboplatin plus paclitaxel exposure, levels of mRNA expression of multidrug resistance 1 (MDR1) and multidrug resistance-associated protein 3 (MRP3) were investigated in primary NSCLC cell lines (A-549 and A-427) and a metastasis-derived NSCLC cell line (NODO). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Our results showed that exposure of the three NSCLC lines to plasma concentrations of paclitaxel (5 \u03bcM) produced an increase in MDR1 expression, while MRP3 showed no alteration in expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The combination of carboplatin and paclitaxel is one of the most commonly used regimens for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We retrospectively analyzed the weekly [paclitaxel, 70 mg/m(2)/week on days 1, 8 and 15, and carboplatin, area under the curve (AUC)=6, every 4 weeks] and standard tri-weekly (paclitaxel, 200 mg/m(2), and carboplatin, AUC=6, on day 1 every 3 weeks] schedules in patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "lpazares@hotmail.com  INTRODUCTION: This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "\u201cPhase II study of the anti\u2013insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic NSCLC\u201d. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: A phase III study (Lung Cancer Evaluation of TS-1) previously demonstrated noninferiority in terms of overall survival (OS) at interim analysis for carboplatin-S-1 compared with carboplatin-paclitaxel for first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Images were acquired in 22 consecutive patients with advanced NSCLC randomized to receive carboplatin/paclitaxel/sorafenib or placebo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase I clinical and pharmacokinetic study of bi-weekly carboplatin/paclitaxel chemotherapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " AIM: We evaluated the pharmacokinetics and quality of life of elderly patients with advanced NSCLC treated with bi-weekly carboplatin and paclitaxel chemotherapy, and determined the maximum tolerated dose (MTD) of this treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We evaluated the effectiveness of PCRT for inducing downstaging using mainly three chemoradiotherapy regimens; cisplatin plus Tegafur-Gimeracil-Oteracil Potassium (S-1), cisplatin plus Tegafur-Uracil (UFT), or 1,1'cyclobutanedicarboxylate (Carboplatin, CBDCA) plus paclitaxel, with concurrent radiation therapy in 19 patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced NSCLC receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with advanced, previously untreated NSCLC were randomly assigned to an endostatin treatment group (paclitaxel + carboplatin + endostatin) and a control group (paclitaxel + carboplatin + placebo). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: CECs and CKs could be biomarkers for selecting patients with NSCLC who will benefit from treatment with endostatin in combination with paclitaxel plus carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Safety and efficacy of weekly nab\u00ae-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " RE: A phase I trial of radiation dose escalation using accelerated concomitant boost radiotherapy concurrently with weekly carboplatin/paclitaxel in patients with good performance status and Stage IIB-IIIA/B NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na\u00efve NSCLC with sensitive EGFR gene mutations (NEJ002). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "akinoue@idac.tohoku.ac.jp  BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced NSCLC harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Between January 2007 and January 2012, 141 patients with advanced NSCLC were treated with curative intent according to the CRT protocol (50-70 Gy at 2 Gy/day with paclitaxel 135-175 mg/m(2) and carboplatin 100 mg/m(2) on days 1, 22, and 43). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "For example, in patients with NSCLC treated with paclitaxel and carboplatin, the phased administration of ipilimumab (an antibody against CTLA-4) resulted in substantial improvements in immune-related progression-free survival compared with chemotherapy alone (5.7 versus 4.6 months; P\u00a0=\u00a00.05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase Ib safety and pharmacokinetic study of volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin and paclitaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: This phase Ib study evaluated volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin (Eli Lilly and Co., Indianapolis, IN) and paclitaxel (Taxol) in advanced, untreated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Volociximab combined with carboplatin and paclitaxel was generally well-tolerated and showed preliminary evidence of efficacy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced NSCLC: evaluation of patients recruited from mainland China. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Because of safety findings from the Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy in NSCLC (ESCAPE) trial, patients with squamous cell histology were withdrawn from the trial in February 2008 and excluded from analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous NSCLC: MONET1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous NSCLC and in the subset of patients with adenocarcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under the curve, 6 mg/ml \u00b7 min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with stage III locally advanced NSCLC received paclitaxel, 50\u2009mg/m(2)/week, with carboplatin area under the curve (AUC)\u2009=\u20092, weekly for 7\u2009weeks, and concurrent radiotherapy, 64.8\u2009Gy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: For NSCLC patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV NSCLC: results from a randomized, double-blind, multicenter phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients (N = 204) with chemotherapy-naive NSCLC were randomly assigned 1:1:1 to receive paclitaxel (175 mg/m(2)) and carboplatin (area under the curve, 6) with either placebo (control) or ipilimumab in one of the following two regimens: concurrent ipilimumab (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or phased ipilimumab (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimumab plus paclitaxel and carboplatin).Treatment was administered intravenously every 3 weeks for \u2264 18 weeks (induction). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipilimumab in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced NSCLC: final results of a phase III trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus carboplatin in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: In all, 1,052 untreated patients with stage IIIB to IV NSCLC were randomly assigned 1:1 to receive 100 mg/m(2) nab-paclitaxel weekly and carboplatin at area under the concentration-time curve (AUC) 6 once every 3 weeks (nab-PC) or 200 mg/m(2) sb-paclitaxel plus carboplatin AUC 6 once every 3 weeks (sb-PC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS AND MATERIALS: Nine of 44 patients with stage III NSCLC in a prospective phase II trial of concurrent paclitaxel/carboplatin with proton radiation [74 Gy(RBE) in 37 fractions] had modifications to their original treatment plans after re-evaluation revealed changes that would compromise coverage of the target volume or violate dose constraints; plans for the other 35 patients were not changed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In particular, ipilimumab showed promising results in a first-line NSCLC phase II study combining carboplatin/paclitaxel chemotherapy with concurrent or phased ipilimumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "wlhwq@yahoo.com  OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This phase I, open-label dose-escalation study investigated BIBF 1120 combined with paclitaxel (Taxol) and carboplatin in first-line patients with advanced (IIIB/IV) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III NSCLC: the ECOG 3598 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: Nineteen patients with regionally advanced NSCLC were treated with concurrent chemotherapy (carboplatin and paclitaxel [n = 18]) and proton therapy from August 2008 to April 2010 either with (n = 7) or without (n = 12) induction chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS AND MATERIALS: Patients with unresectable Stage III NSCLC were treated intravenously with carboplatin (area under the concentration curve 2) and paclitaxel (40 mg/m(2)) on Days 1, 8, 15, and 22 with concurrent twice-daily thoracic radiotherapy (1.5 Gy per fraction) beginning on Day 1 followed by two cycles of consolidation chemotherapy using carboplatin (area under the concentration curve 5) and paclitaxel (200 mg/m(2)). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients (n\u00a0=\u00a048) with advanced NSCLC were treated with repetitive cycles of either paclitaxel/carboplatin or cisplatin/vinorelbine chemotherapy, bexarotene (400\u00a0mg/m(2)/day) administered continuously starting on day 4 of chemotherapy, and a lipid-lowering drug, either atorvastatin or fenofibrate, starting at least 5\u00a0days before chemotherapy due to hypertriglyceridemia induced by bexarotene. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Figitumumab combined with carboplatin and paclitaxel in treatment-na\u00efve Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: This phase I, open-label, dose-escalation study (ClinicalTrials.gov: NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg\u00b7min/mL) and paclitaxel (200 mg/m(2)) in Japanese patients (N = 19) with chemotherapy-na\u00efve, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel was well tolerated in chemotherapy-na\u00efve Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-na\u00efve patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We have evaluated the safety, tolerability, pharmacokinetics, and tumor response profile of weekly nab-paclitaxel (100 mg/m(2)) infusion together with administration of carboplatin at an area under the curve (AUC) of 6 every 3 weeks in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: The combination of nab-paclitaxel (100 mg/m(2)) administered weekly and carboplatin at an AUC of 6 every 3 weeks was well tolerated in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in NSCLC Through Altering STAT3 Expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (stage IIIB or IV) were randomized to Cisplatin-Paclitaxel (Chemotherapy group, N=112) or Cisplatin-Paclitaxel plus CADI-05 (Chemoimmunotherapy group, N=109). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: There was no survival benefit with the addition of CADI-05 to the combination of Cisplatin-Paclitaxel in patients with advanced NSCLC; however, the squamous cell subset did demonstrate a survival advantage. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "RESULTS: GSKJ4, alone and in combination with an anti-diabetic drug metformin, induced cell death and inhibited the growth of NSCLC cell lines efficiently at concentrations non-toxic to normal cells, irrespective of their genetic backgrounds (mutations in the KRAS, TP53 and EGFR genes) and also of their resistance to cisplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The expression of various angiogenic factors was assessed in tumour samples of patients with stage III NSCLC and further evaluated in terms of response to induction paclitaxel-ifosfamide-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Patients with potentially operable stage IIIA(N2) or selected stage IIIB NSCLC received three cycles of cisplatin/paclitaxel (induction chemotherapy) followed by neoadjuvant radiochemotherapy (RCT) to 45 Gy (1.5 Gy twice per day concurrent cisplatin/vinorelbine) within the ESPATUE (Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA[N2] and Selected IIIB NSCLC After Induction Chemotherapy and Concurrent Chemoradiotherapy) trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " 155P: PD-L1 polymorphism can predict clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PD-L1 polymorphism can predict clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " This study was conducted to investigate whether polymorphisms of genes involved in immune checkpoints can predict the clinical outcomes of patients with advanced stage NSCLC after 1st line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PD-L1 rs2297136T\u2009>\u2009C and rs4143815C\u2009>\u2009G polymorphisms may be useful for the prediction of clinical outcome of 1(st) line paclitaxel-cisplatin chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " We evaluated the effects of cisplatin and paclitaxel on taste acuity and their associations with nutritional and health-related quality of life (HRQL) in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Sensitivity to taste increased with paclitaxel and cisplatin CT, making foods more unpleasant, and it was associated with neuropathy, worse HRQL, and reduced nutrient intake in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The present study was performed to investigate the association of single nucleotide polymorphisms (SNPs) located in the miRNA target sites with the clinical outcomes of first line paclitaxel-cisplatin chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "These findings suggest that the four SNPs, especially ETS2 rs461155A>G, could be used as biomarkers predicting the clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Serial dilutions of gemcitabine, cisplatin, 5-fluorouracil, vinorelbine, and paclitaxel were administered to the A549 NSCLC cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: We firstly investigated the expression of Pokemon in patients with NSCLC, then characterized the role of Pokemon in evaluating the response to combined cisplatin and paclitaxel chemotherapy and prognosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: In this study, 61 patients with previously untreated locally advanced or metastatic NSCLC were treated with a combination chemotherapy comprising cisplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: The serum level of Pokemon correlated with efficacy of cisplatin and paclitaxel combination chemotherapy and survival time, which indicated that Pokemon may be a potentially useful biomarker for predicting treatment effectiveness of first-line chemotherapy and prognosis in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Knockdown of NIPBL in NSCLC cell lines significantly reduced cellular proliferation, migration, and invasion, and enhanced cellular apoptosis and sensitivity to cisplatin, paclitaxel, and gemcitabine hydrochloride. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In the present study, two human NSCLC cell lines, H1299 and H460, were used to investigate whether Merm1/Wbscr22 affects chemosensitivity to antitumor agents, including cisplatin (CDDP), doxorubicin (ADM), paclitaxel (PTX), mitomycin (MMC), 7-Ethyl-10-hydroxycamptothecin (SN-38; the active metabolite of camptothecin) and 5-fluorouracil (5-FU). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In this study, we observed that NSCLC cells with high Id1 protein expression were vulnerable to the treatment of paclitaxel and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Furthermore, immunohistochemical staining for Id1 followed by Kaplan-Meier survival analysis showed that surgically treated NSCLC patients with high Id1 expression in primary tumor tissues had better disease-free and overall survivals after adjuvant paclitaxel and cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The distinct role of Id1 reported in this study may arise from the phenomenon of Id1 dependence of NSCLC cells for survival, which renders the cancer cells additionally susceptive to the adjuvant chemotherapy with paclitaxel and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "For exploring the mechanism of the failed combination therapy in lung cancer, in the present study, four therapy assessment groups, including a control group, a chemotherapy group [paclitaxel+cisplatin (TP)], a gefitinib monotherapy group (G) and a combination group[paclitaxel+cisplatin+gefitinib (TP+G)], were established in an A549 cell line and mouse xenotransplanted tumor models.By HPLC, we found that the gefitinib concentration was significantly higher in the combination group when compared to that in the G group in the NSCLC cell line, A549 (p<0.05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Azithromycin enhances the favorable results of paclitaxel and cisplatin in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Azithromycin is commonly used for the treatment of Cpn infections; however, there are only few reports regarding the application of azithromycin (A) combined with paclitaxel and cisplatin (TP) for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable NSCLC: KASLC 0401. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Modulation of peripheral immune responses by paclitaxel-ifosfamide-cisplatin chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: The aim of this study was to assess systemic immunological responses in NSCLC patients with stage III/IV disease during treatment with paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with NSCLC treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " This study was conducted to analyze a comprehensive panel of single nucleotide polymorphisms (SNPs) in genes in DNA repair and apoptosis pathways and determine the relationship between polymorphisms and treatment outcomes of patients with NSCLC treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In conclusion, these findings suggest that the six SNPs identified, particularly their combined genotypes, could be used as biomarkers predicting chemotherapy response and survival of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced NSCLC-a multicenter phase-II trial (CISTAXOL). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: Mediastinoscopically proven IIIA(N2)/selected IIIB NSCLC received three cycles cisplatin (50 mg/m(2) day 1+8) and paclitaxel (175 mg/m(2)d1) qd 22. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In particular, it produces dramatically higher drug concentrations in the lymph nodes than occurs with the current formulations of paclitaxel, thus we believe that patients with NSCLC with regional lymphatic metastasis may benefit from this new drug. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced NSCLC: a multicenter randomized phase IIB trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Finally, we examined, in vitro, the potential antiproliferative effect of BKT140 combined with cisplatin or paclitaxel and after irradiation of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " [A randomized trial of liposomal paclitaxel plus cisplatin as first-line therapy for advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND AND OBJECTIVE: Paclitaxel plus cisplatin (TP) is used as the standard regimen for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In this study, we compared the response rate (RR), overall survival (OS), and toxicity of the combined chemotherapy regimen of liposomal paclitaxel plus cisplatin (LP) with those of TP as first-line treatments for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase II trial of weekly nab-paclitaxel for previously treated advanced NSCLC: Kumamoto thoracic oncology study group (KTOSG) trial 1301. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVES: We performed an open-label, multicenter, single-arm phase II study (UMIN ID 000010532) to prospectively evaluate the efficacy and safety of nab-paclitaxel for previously treated patients with advanced non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with advanced NSCLC who experienced failure of prior platinum-doublet chemotherapy received weekly nab-paclitaxel (100mg/m(2)) on days 1, 8, and 15 of a 21-day cycle until disease progression or the development of unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Weekly nab-paclitaxel was associated with acceptable toxicity and a favorable ORR in previously treated patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Taxanes (paclitaxel, docetaxel and cabazitaxel) are frequently prescribed to treat breast cancer, hormone refractory prostate cancer, NSCLC and ovarian cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Involved agents included paclitaxel, docetaxel and vinorelbine; Malignancies included NSCLC, gastric cancer, esophageal carcinoma, ovarian carcinoma, malignant pleural mesothelioma, breast cancer, and small cell lung cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Currently, nab-paclitaxel is approved for the treatment of metastatic breast cancer, locally advanced/metastatic NSCLC, and metastatic pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Clinical studies suggest that nab-paclitaxel may be particularly effective in cancers with squamous histology, including NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Taxane-type anticancer drugs, including paclitaxel and its semi-synthetic derivatives docetaxel and cabazitaxel, are widely applied to chemotherapy of malignancy like breast cancer, ovarian cancer, NSCLC and prostate cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Several pivotal phase III trials have now been concluded and have led regulatory agencies to grant marketing authorization to ramucirumab for use as second line therapy in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (as single agent or in combination with paclitaxel), in patients with advanced colorectal carcinoma (CRC) (in combination with infusional fluorouracil and irinotecan (FOLFIRI regimen)) and in patients with advanced NSCLC (in combination with docetaxel). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " [Complete Remission after Weekly Intravenous Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Case 1: An 86-year-old man was diagnosed with large cell or squamous cell lung cancer of clinical Stage II A.He was administered nanoparticle albumin-bound paclitaxel(nab-PTX)as fourth-line chemotherapy after monochemotherapy with docetaxel, vinorelbine, and S-1.The patient continues to show complete remission at the 15 courses of nab-PTX.Case 2: A 79-year-old man underwent partial resection of the right lower lung, and the pathological diagnosis was large cell lung cancer of pStage I A.However, recurrence in the right lung and multiple lymph node metastases were identified 3 years after the surgery.He was administered nab-PTX as second-line chemotherapy after vinorelbine monotherapy, and he has shown complete remission for a year.Weekly intravenous nab-PTX may be useful in elderly patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Nab-paclitaxel-associated photosensitivity: report in a woman with NSCLC and review of taxane-related photodermatoses. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PURPOSE: We describe a woman with NSCLC who developed a photodistributed dermatitis associated with her nab-paclitaxel therapy and review photodermatoses in patients receiving taxanes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced NSCLC patients, but there is no study comparing the difference between these 2 chemotherapy regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: Paclitaxel and docetaxel are two taxanes approved for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "However, there is limited evidence regarding the efficacy of docetaxel in NSCLC previously treated with a paclitaxel-platinum doublet (PP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: The established method should be helpful for the pharmacokinetic monitoring of paclitaxel, docetaxel, vinblastine, and vinorelbine in the human plasma of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " DNA microarray reveals different pathways responding to paclitaxel and docetaxel in NSCLC cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The wide use of paclitaxel and docetaxel in NSCLC clinical treatment makes it necessary to find biomarkers for identifying patients who can benefit from paclitaxel or docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In present study, NCI-H460, a NSCLC cell line with different sensitivity to paclitaxel and docetaxel, was applied to DNA microarray expression profiling analysis at different time points of lower dose treatment with paclitaxel or docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " NSCLC often exhibits resistance to paclitaxel treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Identifying the elements regulating paclitaxel response will advance efforts to overcome such resistance in NSCLC therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Here we show that ganetespib potentiates the cytotoxic activity of the taxanes paclitaxel and docetaxel in NSCLC models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Paclitaxel (PTX) is a chemotherapeutic agent that is used to treat a variety of cancers, including NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The aim of the current study was to identify whether the 2(nd) TKI treatment or chemotherapy (paclitaxel-containing or non-paclitaxel regimen) is the appropriate treatment for patients with NSCLC based on the efficacy of the initial TKIs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: CrEL-free paclitaxel in combination with gemcitabine demonstrated favorable antitumor activity with little emetogenicities in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "AREAS COVERED: This review reports the clinical findings and the safety data of nab-paclitaxel for MBC, NSCLC and PC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In a Phase III study with NSCLC patients, nab-paclitaxel showed better results in a subgroup of patients with squamous histology, for whom results with conventional therapies are still poor and improved therapeutic options are needed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Albumin-bound paclitaxel (Abraxane; nab\u00ae-Paclitaxel), a novel solvent-free taxane, has demonstrated higher response rates and improved tolerability when compared with solvent-based formulations in patients with advanced MBC and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced NSCLC: results from 6 randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " AIM: The aim was to compare the efficacy and toxicity of paclitaxel plus platinum (TP) with gemcitabine plus platinum (GP) in untreated advanced NSCLC by a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Our meta-analysis showed that paclitaxel plus platinum had similar efficacy and less toxicity compared with gemcitabine plus platinum in first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " We assessed the prognostic and predictive value of \u03b2-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 NSCLC specimens from early-stage patients who received neoadjuvant chemotherapy (paclitaxel- or gemcitabine-based) in a phase III trial (IFCT-0002). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Here, we report results of a randomized phase 3 study comparing two CCRT regimens in improving chest tumor control by low-dose paclitaxel chemoradiation for LA-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Pulsed low-dose paclitaxel CCRT resulted in significantly better RFS and tumor response rate, and less hematologic toxicities than weekly CCRT for LA-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs).Twenty-four patients with NSCLC were randomly assigned for 2 treatment approaches. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " SPARC is a possible predictive marker for albumin-bound paclitaxel in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "There is as yet no predictive marker for cytotoxic agents against NSCLC, and hence we believed that SPARC expression might be associated with tumor response to nab-paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Stromal SPARC was detected by immunohistochemical staining in \u223c70% of NSCLC cases, and good tumor response to nab-paclitaxel was correlated with high stromal SPARC reactivity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Here, we explored the molecular basis resulting in Survivin overexpression in NSCLC and investigated the antitumor activity of the class I HDAC inhibitor entinostat in combination with paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Our data showed that entinostat significantly enhanced paclitaxel-mediated anti-proliferative/anti-survival effects on NSCLC cells in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Our findings also support that the combinatorial treatments of entinostat and paclitaxel will likely exhibit survival benefit in the NSCLC patients with overexpression of DNMT1 and/or Survivin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "However, the function and mechanisms of the combination of LCL161 and paclitaxel in NSCLC remain unknown. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Mouse xenograft NSCLC models were used in vivo to determine the therapeutic efficacy of LCL161 alone or in combination with paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "LCL161, an IAP inhibitor, cooperated with paclitaxel to reduce cell viability and induce apoptosis in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Thus, LCL161 could be a useful agent for the treatment of NSCLC in combination with paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " P1.46: Phase I Study of Nivolumab + Nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small\u00a0Cell Lung Cancer Cohort: Track: Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " [Retrospective analysis of albumin-bound paclitaxel in the treatment of elderly patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVE: To observe the safety and short-term efficacy of sigle drug albumin-bound paclitaxel (ABP) in the treatment of elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Vinorelbine and paclitaxel are effective as single agents in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: Patients with treatment na\u00efve metastatic NSCLC received two cycles comprising 6 weekly doses of vinorelbine and paclitaxel, with restaging scans at week 8. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "[Epub ahead of print]  M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: Paclitaxel is an effective treatment for some of the NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Here, we aimed to examine M30 and M65 values for predicting the therapeutic outcome of paclitaxel treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: The serum levels of M30 and M65 before and after paclitaxel treatment in advance-stage NSCLC patients were analyzed, and compared to those in healthy controls. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Two days after paclitaxel treatment, the serum levels of both M30 and M65 significantly increased in NSCLC patients (p\u00a0<\u00a00.001). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Our results suggest that the serum M30/M65 ratio may be a prognostic factor for the outcome of paclitaxel treatment in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Since nanoparticle albumin-bound (nab)-paclitaxel exerts clinically meaningful antitumor effects on various malignancies, including breast, gastric and NSCLC, we hypothesized that treatment with nab-paclitaxel may also be beneficial for patients with small-cell lung cancer (SCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We compared survival of mice bearing established MDA-MB-231 breast cancer or PC-14 NSCLC brain metastases that were treated with vehicle, macitentan, paclitaxel, or macitentan plus paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Taxol (paclitaxel) is one of the taxane class of anticancer drugs as a first-line chemotherapeutic agent against many cancers including colorectal cancer, breast cancer, NSCLC, ovarian cancer and so on. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "A randomized phase II trial was carried out to compare the efficacy/safety of three doses of linifanib with that of CBDCD + paclitaxel (PTX), as the largest and first placebo-controlled trial of linifanib for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monotherapy as a second-line treatment from January 2010 to March 2014. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Nab-paclitaxel monotherapy administered weekly at a dose of 100 mg/m(2) is shown to be an effective and safe regimen for elderly patients with relapsed squamous NSCLC, especially for patients with stage III disease or good performance status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Paclitaxel and the dietary flavonoid fisetin: a synergistic combination that induces mitotic catastrophe and autophagic cell death in A549 NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The aim of this study was to investigate whether a naturally occurring diet-based flavonoid, fisetin, at physiologically attainable concentrations, could act synergistically with clinically achievable doses of paclitaxel to produce growth inhibitory and/or pro-death effects on A549 NSCLC cells, and if it does, what mechanisms might be involved. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Autophagy regulates resistance of NSCLC cells to paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Paclitaxel is a chemotherapeutic drug that is effective for treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "However, some NSCLCs are not sensitive to paclitaxel treatment with undetermined underlying molecular mechanisms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In this study, we found that paclitaxel dose-dependently activated Beclin-1 in 2 NSCLC cell lines, A549 and Calu-3. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Inhibition of autophagy significantly increased the paclitaxel-induced NSCLC cell death in a cell counting kit-8 (CCK-8) assay. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Moreover, microRNA (miR)-216b levels were significantly downregulated in paclitaxel-treated NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Together, these data suggest that paclitaxel may decrease miR-216b levels in NSCLC cells, which subsequently upregulates Beclin-1 to increase NSCLC cell autophagy to antagonize paclitaxel-induced cell death. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Strategies that increase miR-216b levels or inhibit cell autophagy may improve the outcome of paclitaxel treatment in NSCLC therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in NSCLC via multiple mechanisms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Chemotherapy paclitaxel yields significant reductions in tumor burden in the majority of advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Here we demonstrated that the histone deacetylase (HDAC) was activated in paclitaxel-resistant NSCLC cells, and its activation promoted proliferation and tumorigenesis of paclitaxel-resistant NSCLC cells in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Furthermore, we observed that overexpression of HDAC1 was associated with the downregulation of p21, a known HDAC target, in advanced NSCLC patients with paclitaxel treatment, and predicted chemotherapy resistance and bad outcome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In summary, our data demonstrate a role of HDAC in paclitaxel-resistant NSCLC and provide a promising therapeutic strategy to overcome paclitaxel-acquired resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " PURPOSE: Weekly paclitaxel combined with a platinum-based agent has been advocated as an alternative regimen for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Limited studies exist on the tolerability of weekly paclitaxel in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "To address this issue, we assessed the maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics of weekly paclitaxel in Japanese patients with advanced NSCLC in a dose-escalation Phase I trial and examined the feasibility of dexamethasone taper in these patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "IMPLICATIONS: Weekly paclitaxel at 100 mg/m(2) given as a 1-hour infusion for 6 weeks followed by a 2-week treatment interval was well tolerated by Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Treatment of recurrent and platinum-refractory stage IV NSCLC with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The role of single-agent nab-paclitaxel in relapsed or platinum-refractory advanced NSCLC has not been well reported in Western populations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We analyzed the records of stage IV NSCLC patients with relapsed or platinum-refractory disease treated with single-agent nab-paclitaxel at Weill Cornell Medical College between October 2008 and December 2013. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Thirty-one stage IV NSCLC patients received a median of 4 cycles (range 1-40) of nab-paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Single-agent nab-paclitaxel was well tolerated and demonstrated efficacy in advanced NSCLC patients with relapsed or platinum-refractory disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In NSCLC A549 cells that harbor mutant KRAS, paclitaxel and let-7b mimic-loaded nanoassemblies (N-PTX/let-7b) markedly potentiated the cytotoxicity of paclitaxel, induced apoptosis, and diminished the invasiveness of tumor cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Notably, silencing SET enhanced the pro-apoptotic effects of paclitaxel, while ectopic expression of SET diminished the sensitivity of NSCLC cells to paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Since the SET protein was shown to affect chemosensitivity, we next examined whether combining a novel SET antagonist, EMQA, sensitized NSCLC cells to paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Paclitaxel (or Taxol\u00ae) is a first-line chemotherapeutic drug for the treatment of NSCLC; however, resistance to the drug is an important factor, which influences the outcome of chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In addition, RYBP expression was induced by paclitaxel, the first-line chemotherapeutic agent for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "[Epub ahead of print]  Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The aim of our study was to evaluate the efficacy and safety of nab-paclitaxel in the treatment of advanced NSCLC [NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "PATIENTS AND METHODS: We assessed 101 Chinese patients who were diagnosed with Stage IIIB or IV NSCLC from August 2009 to November 2014.The patients were injected with nab-paclitaxel [260 mg/m(2) , day1] with or without platinum. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: The nab-paclitaxel chemotherapy could achieve significant tumour responses and encourage survival in advanced NSCLC patients with tolerable toxicities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: We conducted a phase I dose escalation study to determine the maximum tolerated dose (MTD), the recommended dose (RD) and the safety profile of amrubicin (AMR) plus paclitaxel (PTX) combination regimen for patients with previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Systemic delivery of micelles loading with paclitaxel using N-succinyl-palmitoyl-chitosan decorated with cRGDyK peptide to inhibit NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Maackia amurensis agglutinin enhances paclitaxel induced cytotoxicity in cultured NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Paclitaxel is one of the widely used traditional chemotherapeutic drugs for treatment of NSCLC but it exerts side-effects on normal healthy cells too. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We have observed that the non-cytotoxic concentration of this lectin was able to enhance the cytotoxic activity of Paclitaxel even at low dose by inducing apoptosis through intrinsic/mitochondrial pathway in all the three types of NSCLC cell lines, although the involvement of extrinsic pathway of apoptosis in case of NCI-H460 cell line could not be ruled out. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "L80 displayed significant inhibitory effects on the viability, colony formation, angiogenesis-stimulating activity, migration, and invasion of a panel of NSCLC cell lines and their sublines with acquired resistance to paclitaxel with minimal toxicity to normal lung epithelial cells, hippocampal cells, vascular endothelial cells, and ocular cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Class III Beta-tubulin Expression in NSCLC: A Predictive Factor for Paclitaxel Response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In this work, sequential exposure of two anticancer agents, paclitaxel (Tx) followed by topotecan (TPT), was shown to have a synergistic effect on NSCLC cell line, NCI-H460. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Nab-paclitaxel (abraxane)-based chemotherapy to treat elderly patients with advanced NSCLC: a single center, randomized and open-label clinical trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Here, we generated isogenic LKB1-wild type and mutant NSCLC cell lines to evaluate the role of LKB1 in paclitaxel resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MATERIALS AND METHODS: SRB, flow cytometry and immunoblotting were used to assess cell proliferation and apoptosis in NSCLC cell lines after paclitaxel treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "These data suggest that LKB1 does not promote paclitaxel-induced apoptosis in most NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In contrast, in some NSCLC, the presence of LKB1 may facilitate increases in either MDR1 or class III beta-tubulin expression which can lead to paclitaxel resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Here, we report the outcomes of concurrent paclitaxel-based chemo-radiotherapy (CRT) for NSCLC patients with microscopically positive bronchial margins or peribronchial infiltration. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: For NSCLC patients with post-surgical microscopic residual tumor at the bronchial stump, concurrent paclitaxel-based chemo-radiotherapy achieved promising outcomes with accepted treatment-related toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Pazopanib 800 mg daily plus paclitaxel 150 mg/m(2) every 3 weeks was the recommended phase II dose, with a manageable safety profile, and with clinical activity in both melanoma and NSCLC that suggest further evaluation of this combination is warranted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Antitumor activity of paclitaxel is significantly enhanced by a novel proapoptotic agent in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Taxols, such as paclitaxel, independently potentiate tumor destruction via apoptosis and are used as first line therapy in patients with advanced non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Human NSCLC cell lines (A-549 and H-322m) were incubated in the presence of PAC-1 and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: PAC-1 significantly enhances the antitumor activity of paclitaxel against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " MicroRNA-7 sensitizes NSCLC cells to paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Paclitaxel (PTX) is the front-line chemotherapeutic agent against human NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The anticancer agent paclitaxel is usually used to treat ovarian, breast, and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Synergistic antitumor effect of \u03b1-pinene and \u03b2-pinene with paclitaxel against non-small-cell lung carcinoma (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The objective of the present research work was to evaluate the synergistic interactions between Paclitaxel (PAC) with \u03b1-pinene and \u03b2-pinene using isobolographic method against NSCLC cells (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Further, mitochondrial membrane potential was monitored in NSCLC cells (NSCLC) when treated with paclitaxel, \u03b1-pinene and \u03b2-pinene alone and in combination. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: \u03b2III-tubulin down-regulated significantly sensitized NSCLC A549/Taxol cells to Paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " 2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of NSCLC in an orthotopic xenograft mouse model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A nanoparticle (NP) formulation with 2'-(2-bromohexadecanoyl)-paclitaxel (Br-16-PX) conjugate was developed in these studies for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced NSCLC receiving first-line platinum-paclitaxel chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The aim of this study was to evaluate the predictive value of APE1, BRCA1, ERCC1 and TUBB3 in advanced NSCLC patients who received platinum-paclitaxel treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: One hundred and thirty-six advanced NSCLC patients, who were treated with first-line platinum-paclitaxel chemotherapy, were enrolled in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: The data indicate that APE1, ERCC1 and TUBB3 could be a useful biomarker to predict clinical outcome in patients with advanced NSCLC receiving first-line platinum-paclitaxel chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Successful chemotherapy with nab-Paclitaxel in a heavily treated NSCLC patient: a case report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "A 69-year-old female with postoperatively recurrent NSCLC was treated weekly with nanoparticle-albumin-bound paclitaxel (nab-paclitaxel) monotherapy every 4 weeks as a tenth line chemotherapy, and stable disease was achieved by seven cycles of this regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "To our knowledge this is the first report of the efficacy of nab-paclitaxel monotherapy in a heavily treated NSCLC patient. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This procedure significantly improves the treatment of metastatic breast cancer compared to conventional paclitaxel-based therapies, including other type of cancers such as metastatic pancreatic cancer, stage IIIB-IV NSCLC and metastatic melanoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Constitutive androstane receptor ligands modulate the anti-tumor efficacy of paclitaxel in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Most of NSCLC cases present CAR gene expression turning it possible to speculate the use of CAR modulation by ligands along with Paclitaxel in NSCLC therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Here we report that intrinsic resistance to paclitaxel in NSCLC occurs at a cell-autonomous level because of the uncoupling of mitotic defects from apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This strategy revealed that prolonging mitotic arrest with a small molecule inhibitor of the APC/cyclosome could sensitize otherwise paclitaxel-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Paclitaxel based combination therapies have long been used as a standard treatment in aggressive NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "But paclitaxel resistance has emerged as a major clinical problem in combating NSCLC and autophagy is one of the important mechanisms involved in this phenomenon. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We investigated the schedule-dependent effect of EGCG and paclitaxel on growth of NCI-H460 NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Its in vitro antiproliferative activity was then evaluated in human NSCLC A549 (NSCLC), stomach adenocarcinoma BGC-823, hepatocellular carcinoma HepG2 and gastric carcinoma HGC-27 cell lines using conventional cancer drugs (paclitaxel, doxorubicin and mitomycin C) as positive controls. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVE: To evaluate clinical efficacy of a dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Patients with locally advanced NSCLC were treated with conventional fractionated radiotherapy or three dimensional conformal radiotherapy (3 DCRT), concurrently with a dose escalating schedule of paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: In treating patients with NSCLC, concurrent chemoradiotherapy with paclitaxel improves early response compared with conventional fractionated radiotherapy or 3 DCRT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "For cancer treatment, the paclitaxel albumin nanoparticle Abraxane has been approved for treating metastatic breast cancer, NSCLC, and advanced pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Metronomic paclitaxel synergized with adoptive CIK cell immunotherapy to inhibit the growth of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Prospective study of paclitaxel and irinotecan for elderly patients with unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " We conducted a phase II study of combination chemotherapy with paclitaxel (Pac) and irinotecan (CPT) to determine the effects and toxicities in patients 70 years or older with unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " BACKGROUND: Paclitaxel (PTX; Taxol, Abraxane) is used in many regimens for breast cancer, NSCLC, and ovarian cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "To ascertain whether ICAM-3 also promotes anticancer drug resistance, mock control (H1299/pcDNA3) or ICAM-3-expressing stable transfectants (H1299/ICAM-3) of the NSCLC cell line, NCI-H1299, were generated and treated with the microtubule-damaging agents, paclitaxel (TXL) and vincristine (VCS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In combination with paclitaxel, weekly dosing of BAY 80-6946 is sufficient to reach sustained response in all animals bearing patient-derived NSCLC xenografts, despite a short plasma elimination half-life (1 hour) in mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "To date, paclitaxel albumin-bound nanoparticles (Abraxane\u00ae) have been approved by the FDA for the treatment of metastatic breast cancer and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " [Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Selective cytotoxicity and combined effects of camptothecin or paclitaxel with sodium-R-alpha lipoate on A549 human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The effect of sodium-R-alpha lipoate on camptothecin- and paclitaxel-induced cytotoxicity was evaluated on A549 NSCLC and BEAS-2B \"normal\" lung epithelial cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " [Comparison of platinum-containing doublet chemotherapy and liposome paclitaxel monotherapy for the treatment of elderly patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVE: Given controversy remains on monotherapy and combinatory chemotherapy in elderly patients (> or = 70 years) with advanced NSCLC, we conducted this study to compare the safety and efficacy of liposome paclitaxel and platinum-containing doublets. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Platinum-containing doublet chemotherapy achieved a higher response rate, longer time-to-progression and overall survival compared with liposome paclitaxel monotherapy in the treatment of elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Based on preclinical demonstration of additive cytotoxicity, we evaluated the safety and efficacy of combining pemetrexed and nanoparticle albumin bound (nab) paclitaxel with a focus on NSCLC for phase II expansion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In this study, we evaluated the dynamics and feasibility of imaging NSCLC apoptosis induced by paclitaxel treatment using a (99)Tc(m)-labeled Annexin V recombinant with ten consecutive histidines (His10-Annexin V) in a mouse model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The human H460 NSCLC tumor cell line (H460) tumor-bearing mice were treated with intravenous paclitaxel 24, 48 and 72 hours later. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Lipusu is the first paclitaxel liposome preparation approved in the world and has been widely used in China for the treatment of ovary, breast and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " OBJECTIVE: To observe the efficacy and safety of albumin-bound paclitaxel (ABP) monotherapy in treating recurrent advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV NSCLC: a series of 20 cases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " The purpose of this study was to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel as a rescue regimen in the treatment of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In summary, weekly-administered albumin-bound paclitaxel seems to be an effective and safe regimen for elderly patients with stage IV NSCLC who were refractory to conventional therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In combination with paclitaxel, anti-PLK-1 siRNA chemosensitized NSCLC and prostate carcinoma cell lines, leading up to a 2-fold increase in the drug cytotoxic effect. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Nanoparticle albumin-bound (nab)-paclitaxel has been recently approved for the use in breast and NSCLC with very promising results in pancreatic adenocarcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "MRP7 is highly expressed in NSCLC cells, and Mrp7-KO mice are highly sensitive to paclitaxel, making MRP7 an attractive chemotherapeutic target of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A retrospective study of the novel combination of paclitaxel and S1 for pretreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: The usefulness of paclitaxel plus S1 (PTX+S1) was evaluated in 46 pretreated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Class III \u03b2-tubulin overexpression has been linked to resistance to paclitaxel and correlated with poor survival in ovarian, breast, gastric, NSCLC and unknown primary tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "On the other hand, paclitaxel (Taxol) is a new antineoplastic drug that has shown promise in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Overall, our results suggest that inhibition of the p38 MAPK signaling by metformin coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "To demonstrate this, we examined the effect of the combinational treatment of ascorbic acid and paclitaxel using H1299 (a NSCLC cell line) and BALB/c mice implanted with or without sarcoma 180 cancer cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "draaranade@yahoo.com  AIMS: Paclitaxel is extensively used in the treatment of advanced carcinomas of the breast, ovary and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: This single-stage, open-label phase II study evaluated pulse dose imatinib and weekly paclitaxel in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "To begin to address their functional relevance to tumorigenesis, we identified a cohort of proteins which display synthetic lethality with paclitaxel in NSCLC and whose expression is biased toward testes and tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSION: Expression of \u03b2V-tubulin was associated with treatment response and PFS following paclitaxel-based chemotherapy of locally advanced and oligometastatic NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This phase I study investigated the tolerability, safety and pharmacokinetics (PK) of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "Matuzumab combined with paclitaxel was generally well tolerated in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "A randomized clinical trial comparing this dosing algorithm with conventional BSA-based dosing of paclitaxel in patients with advanced NSCLC is currently ongoing. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This study aims to investigate the effects of COP and BER combined with chemotherapeutic agents, including fluorouracil (5-FU), camptothecin (CPT), and paclitaxel (TAX), on cell proliferation, ROS production, and MDR in A549 human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Radiation/paclitaxel treatment of p53-abnormal NSCLC xenograft tumor and associated mechanism. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "RESULTS: We demonstrated that radiation and paclitaxel alone inhibited tumor growth, but a combined therapy of radiation and paclitaxel was more effective in inhibiting NSCLC tumor growth. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: Our study suggested that a PTEN-PI3K-Akt-Bax signaling cascade is involved in the therapeutic effect of combined radiation/paclitaxel treatment in NSCLC without p53 expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We evaluated the cytotoxicities of paclitaxel and sorafenib alone and in combination in NSCLC cell lines with KRAS or BRAF mutations and investigated the mechanism of the interaction between the drugs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We found synergistic antitumor efficacy with paclitaxel followed by sorafenib in in vitro and in vivo models of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In the present study, paclitaxel and parthenolide were loaded into mixed micelles and tested against taxol sensitive (A549) and resistant (A549-T24) NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " [A randomized clinical trial on the clinical efficacy and toxicities of single-agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as first-line chemotherapy for advanced NSCLC in elderly patients]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "CONCLUSIONS: The clinical efficacy of paclitaxel liposome plus oxaliplatin as a first-line chemotherapy for elderly patients with advanced NSCLC is more better than that of the single-agent paclitaxel liposome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": " Association between class III \u03b2-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for NSCLC: a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "zhanghl@amoydx.com  BACKGROUND: It has been proposed that the level of class III \u03b2-tubulin gene expression can be used to predict clinical sensitivity to paclitaxel/vinorebine-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "We conducted a meta-analysis of all relevant published data to provide a combined statistical assessment of the proposed association of expression variations of class III \u03b2-tubulin with objective response and median survival in patients with NSCLC treated with paclitaxel/vinorebine-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: We conducted the meta-analysis using data from ten studies, each of which evaluated the correlation between class III \u03b2-tubulin expression levels and objective response in patients treated with paclitaxel/vinorebine-based chemotherapy for NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In our analysis, NSCLC patients treated with paclitaxel had more favorable clinical outcomes than those treated with vinorelbine (Chi(2)=3.69, P=0.05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "This result supports the usefulness of class III \u03b2-tubulin mRNA level as a biomarker for sensitivity to paclitaxel/vinorebine-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "ghgao103@hotmail.com  OBJECTIVE: The published data on the curative effects of comparing the once weekly paclitaxel-based chemotherapies (W-paclitaxel) with the standard every 3 weeks paclitaxel-based chemotherapies (S-paclitaxel) in the first-line treatment of advanced NSCLC were still controversial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "METHODS: Medical databases and conference proceedings were searched for randomized controlled trials which compared W-paclitaxel with S-paclitaxel in patients with first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "The following keywords were used: \"paclitaxel\", \"weekly schedule\" and \"NSCLC\". ", "polarity": 1, "disease": "NSCLC"}, {"drug": "paclitaxel", "orig_sen": "In the five NSCLC (non small cell lung cancer) trials, the summary effect revealed a better response rate with weekly paclitaxel (odds ratio: 1.24, p=0.042). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care for the initial management of advanced and metastatic NSCLC without a targetable molecular abnormality. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVES: This phase II trial investigated the efficacy and safety of S-1 plus bevacizumab (SB) after failure of platinum-based chemotherapy in patients with non-squamous NSCLC (non-sq NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients with non-sq NSCLC who had undergone prior platinum-based chemotherapy, regardless of the use of bevacizumab, were eligible. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced NSCLC patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: The addition of bevacizumab to the first-line chemotherapy of advanced NSCLC of non-squamous histology has been shown to improve survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients with previously untreated recurrent or metastatic non-squamous, NSCLC, with no contraindications for bevacizumab, were enrolled. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: The combination of bevacizumab with chemotherapy in the first-line setting of NSCLC is safe and active when used in appropriately selected patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Here, we evaluated the effects of chemotherapy in general, and the anti-angiogenic agent bevacizumab, more specifically, on the pulmonary vasculature in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous NSCLC (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Bevacizumab combined with platinum-based chemotherapy has been established as a standard treatment option in the first-line setting for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: West Japan Oncology Group 5910L was designed as a multicenter, open-label, randomized, phase 2 trial of docetaxel versus docetaxel plus bevacizumab every 3 weeks for patients with recurrent or metastatic nonsquamous NSCLC whose disease had progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Further evaluation of bevacizumab beyond disease progression is warranted for patients with advanced NSCLC whose disease has progressed after treatment with bevacizumab plus a platinum-based doublet. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Being approved for the first-line treatment of non-squamous advanced NSCLC, the addition of bevacizumab should be considered for patients presenting with MPE. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Original data concerns different induction regimens plus bevacizumab with bevacizumab maintenance to progression in advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "These results suggest Cav-1 might serve as a potential biomarker in this patient population.BACKGROUND: The combination of bevacizumab with platinum-based chemotherapy results in greater response rate (RR) and overall survival (OS) in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Carboplatin and nab-paclitaxel every 21 days demonstrated promising efficacy with tolerable toxicity in NSCLC patients ineligible for bevacizumab therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous NSCLC previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVES: This randomized phase II trial investigated the efficacy and safety of docetaxel plus bevacizumab and S-1 plus bevacizumab in the second-line treatment of non-squamous (non-Sq) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: Patients with non-Sq NSCLC who experienced disease progression after prior platinum-based chemotherapy with or without bevacizumab were randomly assigned to receive docetaxel plus bevacizumab (DB) once every 3 weeks or S-1 orally twice daily on days 1-14 plus bevacizumab (SB) on day 1 every 3 weeks until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Because of the toxicity of DB and the low response rate of SB, neither regimen warrants further investigation, excluding DB in bevacizumab-na\u00efve patients with advanced non-Sq NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab in combination with anticancer drugs for previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "For patients with advanced NSCLC who failed in previously platinum-based chemotherapy, bevacizumab also showed enhancing efficacy to antitumor drugs recommended by the latest NCCN guideline. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This review intends to present the recent progress and prospects of bevacizumab in second- or third-line treatment for patients with refractory NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: Patients with metastatic NSCLC received pemetrexed (with or without bevacizumab) for 12 months or longer, either as maintenance treatment after first-line platinum-based chemotherapy or as subsequent treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous NSCLC: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVES: To compare the activity and tolerance of the consecutive administration of four active chemotherapeutic agents in combination with bevacizumab to a bevacizumab- and platinum-based chemotherapy doublet as front-line treatment in patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This is the same approach that is generally recommended for other forms of advanced NSCLC, with the presence or absence of a driver mutation used to guide the selection of an epidermal growth factor receptor inhibitor, an anaplastic lymphoma kinase inhibitor, or conventional platinum-based chemotherapy (with the potential addition of bevacizumab). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A single-arm phase II trial of pazopanib in patients with advanced NSCLC with non-squamous histology with disease progression on bevacizumab containing therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVES: Platinum-based chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV NSCLC with non-squamous (NS) histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Pazopanib has limited activity in NSCLC-NS in patients who have experienced disease progression on bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This study assessed the prognostic and predictive value of circulating micro-RNA (miRNA) in patients with non-squamous NSCLC enrolled in the phase II SAKK (Swiss Group for Clinical Cancer Research) trial 19/05, receiving uniform treatment with first-line bevacizumab and erlotinib followed by platinum-based chemotherapy at progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous NSCLC: AVAPERL (MO22089). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacizumab alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Efficacy of bevacizumab-containing chemotherapy for non-squamous NSCLC with bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab is now allowed for NSCLC patients with brain metastases and non-squamous histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Soria JC(1), Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP; meta-analysis of bevacizumab in advanced NSCLC collaborative group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Previous studies have demonstrated the efficacy and safety of bevacizumab in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Summary data from randomised trials comparing first-line bevacizumab plus platinum-based chemotherapy with chemotherapy alone for inoperable locally advanced, recurrent or metastatic NSCLC were meta-analysed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous NSCLC (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "francesco.zappa@clinicaluganese.ch  PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-based CT at disease progression (PD). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Evaluating the impact of bevacizumab maintenance therapy on overall survival in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "george.dranitsaris@gmail.com  BACKGROUND: In patients with advanced-stage NSCLC with nonsquamous histology, bevacizumab maintenance therapy after initial combination with platinum-based chemotherapy has been approved in the United States and Europe. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Bevacizumab maintenance therapy contributed to an OS benefit in this retrospective sample of patients with NSCLC, even after multiple statistical adjustments for selection bias. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous NSCLC (WJOG 5910L). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We have now designed a randomized phase II trial to examine the clinical benefit and safety of continued bevacizumab treatment in patients with advanced nonsquamous NSCLC whose disease has progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS/DESIGN: WJOG 5910L was designed as a multicenter, open-label, randomized, phase II trial by the West Japan Oncology Group of docetaxel (arm A) versus docetaxel plus bevacizumab (arm B) in patients with recurrent or metatstatic nonsquamous NSCLC whose disease has progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for NSCLC after failure of platinum-doublet chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Successful treatment of solitary bone metastasis of NSCLC with bevacizumab and hyperthermia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab (BEV) has been approved as first line treatment in combination with platinum based chemotherapy and maintenance therapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Because histology information is not available in this database, we also conducted a subgroup analysis of EGFR testing among patients who were treated with bevacizumab or pemetrexed, who are likely to have non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "[Epub ahead of print]  Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous NSCLC: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Inclusion criteria were NSCLC patients with bone metastases confirmed by pathology or cytology; available imaging data of pelvic metastatic lesions; aged 18 to 75 years old; expected survival at least 3 months; not receiving taxane, bevacizumab, thalidomide, rh-endostatin, or bisphosphonate; not having radiation therapy within 3 months of enrollment into study; normal results of routine blood tests, liver and kidney function, and electrocardiogram; absence of cardiovascular disease, autoimmune disease, vasculitis, severe infection, diabetes, and other concomitant disease; and signed informed consent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This study evaluated the safety of CA4P when combined with carboplatin, paclitaxel, and bevacizumab in chemotherapy-na\u00efve subjects with advanced nonsquamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Adult subjects with confirmed American Joint Committee on Cancer six stage IIIB/IV NSCLC and an Eastern Cooperative Oncology Group performance score of 0 or 1 were randomized to receive six cycles (treatment phase) of paclitaxel (200 mg/m(2)), carboplatin (area under the concentration versus time curve 6), and bevacizumab (15 mg/kg) on day 1 and repeated every 21 days, or this regimen plus CA4P (60 mg/m(2)) on days 7, 14, and 21 of each cycle. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: CA4P plus carboplatin, paclitaxel, and bevacizumab appears to be a tolerable regimen with an acceptable toxicity profile in subjects with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Following the approval of bevacizumab, an antibody targeting vascular endothelial growth factor-A (VEGF-A), for advanced non-squamous NSCLC in 2006, intensive efforts were put into the clinical development of antiangiogenic agents for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous NSCLC who are eligible for bevacizumab and maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In particular, in case of WT NSCLC with non-squamous histology, the use of platinum-based combinations including pemetrexed or bevacizumab became the standard treatment and the maintenance therapy with pemetrexed a further opportunity for selected patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The present report provides an overview of antiangiogenic therapy for NSCLC, including both currently approved antiangiogenic therapies (bevacizumab [anti-VEGF] and ramucirumab [anti-VEGF receptor 2] monoclonal antibodies), and a variety of promising novel agents in development. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Immune-modulating effects of bevacizumab in metastatic NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "For this reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II trial, who received fractioned cisplatin (30\u2009mg/sqm days 1-3q21) and oral etoposide (50\u2009mg, days 1-15q21) (mPE doublet) \u00b1bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous NSCLC: A Retrospective Cohort Study in US Oncology Community Practices. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous NSCLC (NS-NSCLC), particularly in those excluded from clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "To the best of our knowledge, this is the first report on cardiogenic syncope due to left ventricular dysfunction that is most consistent with bevacizumab-associated cardiotoxicity in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Our results indicate that bevacizumab could lead to cardiotoxicity in patients with NSCLC and suggest the importance of the follow-up cardiac ultrasonography. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab for NSCLC: A nested case control study of risk factors for hemoptysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Potentially life-threatening, serious hemoptysis is an adverse event associated with bevacizumab in non-squamous NSCLC trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "After bevacizumab was approved for NSCLC, physicians registered all NSCLC patients scheduled for bevacizumab therapy, from November 2009 to August 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Although technically classed as a clinical trial, a nested case-control study was a non-interventional surveillance study analyzing all NSCLC patients receiving bevacizumab in Japan, therefore it was not registered as a phase II/III clinical trial would be. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "To improve inhibitory effect and decrease side-effects on NSCLC, we used Re-188, which is a \u03b2 emitting radionuclide, directly labeled with bevacizumab for radioimmunotherapy in a human A549 tumor model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Thus, (188)Re-bevacizumab enhanced the therapeutic effect of bevacizumab, suggesting a potential therapeutic strategy for NSCLC treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "[Epub ahead of print]  First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: We aimed to explore the use of platinum plus bevacizumab in a real world NSCLC population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: We retrospectively collected data from patients affected by NS-NSCLC treated with platinum plus bevacizumab across Tuscany. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Platinum-based doublet chemotherapy\u00a0\u00b1\u00a0bevacizumab was moderately effective, indicating the need for targeted therapies for patients with T790M mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, NSCLC (NS-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " [18F]FDG PET/CT-based response assessment of stage IV NSCLC treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In this study, plasma levels of VEGF, bFGF, E-selectin, and S-ICAM and gene expression profiles of peripheral blood mononuclear cells from NSCLC patients treated with chemotherapy plus bevacizumab were analyzed before and after treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Herein, we report on a case treated with erlotinib plus bevacizumab for leptomeningeal metastases from EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This phase Ia/Ib study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of pictilisib in monotherapy or in combination with carboplatin-paclitaxel and bevacizumab (CP\u00a0+\u00a0BEV) in Japanese patients with advanced solid tumors or non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " [Advances in Bevacizumab Therapy for NSCLC \u2029with Brain Metastases]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Recently, more and more studies and trials laid emphasis on the bevacizumab for NSCLC with brain metastases treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In this review, bevacizumab therapy of NSCLC with brain metastases were summarized. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Bevacizumab combined with chemotherapy has become the first-line therapy in advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "However, few studies have focused on cisplatin/pemetrexed with bevacizumab as the first-line therapy to treat advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: We speculate that bevacizumab in combination with cisplatin/pemetrexed as the first-line therapy is well tolerated and results in a clinically meaningful treatment benefit, irrespective of the gene drive type in advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab plus chemotherapy was approved by the US Food and Drug Administration (FDA) as a first-line treatment for advanced nonsquamous, NSCLC in 2006. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This study retrospectively compared the efficacy of bevacizumab plus chemotherapy with chemotherapy alone as the first-line and second-line treatment as well as the maintenance treatment for advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In conclusion, chemotherapy plus bevacizumab as the first-line and maintenance treatment, led to better curative rates and tolerable adverse reactions compared with chemotherapy alone in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "By analogy with the indication of bevacizumab in advanced NSCLC, use of antiangiogenic agents in the perioperative setting is currently restricted to nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: TGI metrics were estimated using longitudinal tumor size data from two Phase III first-line NSCLC studies evaluating bevacizumab and erlotinib as MTx in 1632 patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "[Epub ahead of print]  Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND/AIM: First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of NSCLC: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVES: Bevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Therefore, we conducted a meta-analysis to compare combination treatment with bevacizumab and erlotinib to bevacizumab or erlotinib monotherapy in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The combination of bevacizumab and erlotinib significantly improved PFS (HR=0.63, 95% CI 0.53 to 0.75; p=0.000) and the ORR (RR=1.91, 95% CI 1.19 to 3.06; p=0.007) in the second-line treatment of NSCLC compared with bevacizumab or erlotinib alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The addition of bevacizumab to erlotinib can significantly improve PFS and the ORR in the second-line treatment of NSCLC with an acceptable and manageable risk of rash and diarrhoea. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab to combat EGFR-TKI resistance in a patient with advanced NSCLC harboring an EGFR mutation: A case report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Treatment with bevacizumab can induce a marked improvement in the overall and progression-free survival of patients with NSCLC; however, the effect of bevacizumab on TKI resistance in patients with NSCLC with an activating EGFR mutation is largely unknown. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab in the treatment of nonsquamous NSCLC: clinical trial evidence and experience. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage IV nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Finally, this review explores the future directions for bevacizumab development in nonsquamous NSCLC and for a biological selection of patients with research on predictive biomarkers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We previously reported that carboplatin-paclitaxel plus bevacizumab was effective for patients with advanced non-squamous NSCLC and MPE, although we did not evaluate the relationship between treatment outcomes and plasma or pleural effusion levels of VEGF. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: VEGF levels in the plasma and pleural effusion may predict the outcome of bevacizumab treatment in patients with NSCLC and MPE. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "[Epub ahead of print]  [Bevacizumab in combination with first-line treatment for metastatic NSCLC in clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: The EOLE cohort aimed to describe, in routine clinical practice, the characteristics and management of patients receiving bevacizumab in combination with first-line metastatic chemotherapy for advanced metastatic or recurrent non squamous NSCLC (nsNSCLC), as well as its efficacy and safety. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: EOLE confirms the efficacy and safety of bevacizumab in aNSCLC patients, in current medical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: A retrospective analysis analyzed data from three international phase III studies comprising 2301 advanced, non-squamous NSCLC patients who received a platinum-based, first-line doublet, with or without bevacizumab and maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: The bevacizumab plus erlotinib study (BEVERLY) is a randomized, open-label, phase III trial investigating first-line erlotinib plus bevacizumab versus erlotinib in patients with advanced NSCLC harboring activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: If the primary endpoint of PFS is met, the erlotinib plus bevacizumab combination will be confirmed as the best first-line treatment for patients with advanced NSCLC harboring activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " 77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced NSCLC (A-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " 186P: Antiangiogenic therapy using bevacizumab in patients older than 75 years old with stage IV non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous NSCLC: Outcomes according to Thymidylate Synthase Expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous NSCLC through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: In the peripheral blood of patients with NSCLC, bevacizumab-based chemotherapy significantly reduced the levels of granulocytic MDSCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous NSCLC in elderly patients: TORG1015. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: The addition of bevacizumab to cytotoxic agents prolongs survival in patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "To date, there is no evidence to suggest that treatment with a cytotoxic agent plus bevacizumab is more effective than a cytotoxic agent alone for nonsquamous NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We conducted a feasibility study of pemetrexed plus bevacizumab as a first-line treatment for advanced or recurrent nonsquamous NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Pemetrexed plus bevacizumab in the treatment of elderly patients with nonsquamous NSCLC was well tolerated and shows promise as first-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Risk of adverse events with bevacizumab addition to therapy in advanced NSCLC: a meta-analysis of randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor ligand, has shown survival benefits in the treatment of many types of malignant tumors, including NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We conducted this systematic review and meta-analysis to investigate the risk of the most clinically relevant adverse events related to bevacizumab in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We included prospective randomized controlled Phase II/III clinical trials that compared therapy with or without bevacizumab for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: The addition of bevacizumab to therapy in advanced NSCLC did significantly increase the risk of proteinuria, hypertension, and hemorrhagic events but not arterial/venous thromboembolic events, gastrointestinal perforation, or fatal adverse events. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We aimed to evaluate the effect of bevacizumab-induced hypertension in terms of prognosis in patients with colorectal cancer and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In the patient group with NSCLC, treated with bevacizumab, Grade 2-3 hypertension was present in 20.5%. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Patients who developed hypertension during treatment with bevacizumab for colorectal cancer and NSCLC had significantly prolonged overall survival when compared with normotensive patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab-induced chronic interstitial pneumonia during maintenance therapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor receptor and a key drug for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This case report is the first description of bevacizumab-induced chronic interstitial pneumonia during maintenance therapy in a patient with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Pemetrexed and bevacizumab are currently evaluated as two of the most reliable chemotherapeutic drugs for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "To compare the clinical efficacy and safety of bevacizumab concomitant with chemotherapy regimens in patients with advanced NSCLC as first- or second-line therapy, we retrospectively reviewed the effects of adding bevacizumab to chemotherapy regimens in naive-chemotherapy and pre-chemotherapy patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "A total of 79 patients with advanced non-squamous NSCLC received at least two cycles of bevacizumab with chemotherapy between October 2010 and December 2013 were selected. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "EXPERT OPINION: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab Combined with Chemotherapy as First-line Therapy for Advanced NSCLC: A Retrospective Study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with NSCLC treated with bevacizumab and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Therefore we have evaluated the inter-reader reproducibility of response classification by DCE-MRI in patients with NSCLC treated with bevacizumab and erlotinib enrolled in a multicenter trial.MATERIALS AND METHODS: Twenty-one patients were scanned before and 3 weeks after start of treatment with DCE-MRI in a multicenter trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The present study assessed the predictive value of (99m)Tc-3(poly-(ethylene glycol), PEG) 4-arginine-glycine-aspartic ((99m)Tc-3P-RGD2) single photon emission computed tomography (SPECT) for the early identification of response to antiangiogenic treatment with bevacizumab in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Patients with advanced NSCLC treated with bevacizumab were prospectively studied with (99m)Tc-3P-RGD2 SPECT before and after 2 weeks from start of treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "(99m)Tc-3P-RGD2 SPECT scan is a promising test to predict tumor response in patients with advanced NSCLC early in the course of bevacizumab therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "It is concluded that bevacizumab should be reserved only for highly select elderly patients with advanced NSCLC when the clinician deems it useful in the face of acceptable toxicities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab beyond disease progression for advanced NSCLC: Does persistence have its rewards?  Guijarro-Mu\u00f1oz I(1), Roarty EB(1), Heymach JV(1,)(2). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected NSCLC Patient-Derived Xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Data of one nsNSCLC (stage IIIB/IV, AVAiL) and two breast cancer bevacizumab trials (HER2 negative, AVADO; HER2 positive, AVEREL) were retrospectively analyzed regarding the frequency of the brain versus other organs being the site of first relapse. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In a brain-seeking nsNSCLC metastasis model, treatment with bevacizumab inhibited brain metastases formation, which resulted in improved overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In summary, bevacizumab has the potential to prevent brain metastases in nsNSCLC, but no preventive activity could be detected outside the brain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with NSCLC and nonsquamous histologic features. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: The included patients had stage IIIB (malignant pleural effusion) or IV NSCLC with nonsquamous histologic features, adequate organ function, no contraindications to bevacizumab, and no previous cytotoxic therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Effectiveness of bevacizumab exposure beyond disease progression in patients with NSCLC: analyses of the ARIES observational cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: Bevacizumab used in combination with first-line chemotherapy confers an overall survival (OS) benefit for patients with non-squamous non-small-cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This analysis from the ARIES observational cohort study (OCS) was initiated to evaluate the effect of bevacizumab use beyond disease progression (BBP) on clinical outcomes in patients with NSCLC receiving first-line treatment with bevacizumab and chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: The ARIES OCS prospectively enrolled patients from 2006 to 2009 in the United States who had advanced non-squamous NSCLC, received bevacizumab with chemotherapy in the first-line setting, and survived progressive disease (PD). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: BBP was associated with a lower risk of death in patients with NSCLC treated with first-line bevacizumab and chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab and ramucirumab, monoclonal antibodies targeting VEGF and the VEGFR, respectively, have each led to improvements in overall survival (OS) for NSCLC when added to standard first and second line chemotherapy, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on NSCLC patients with brain metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This study retrospectively evaluated the efficacy of different adjuvant therapies for 776 cases of advanced NSCLCs with brain metastasis who treated with chemotherapy, chemotherapy plus bevacizumab, tyrosine kinase inhibitor (TKI) alone, or supportive care. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "For patients with EGFR-mutated NSCLC, the efficacy of TKI treatment was not statistically better than that of chemotherapy plus bevacizumab but was significantly better than that of other therapies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Moreover, for patients with EGFR wild-type NSCLC, the mPFS and mOS after chemotherapy plus bevacizumab were greater than those with other two therapies (P < 0.01). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Chemotherapy plus bevacizumab was more effective for NSCLC patients with brain metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: Data on the role of angiogenesis inhibitors (AIs) rechallenge in the treatment of advanced NSCLC patients who previously received bevacizumab remain limited. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Eligible studies included prospective randomized controlled trials evaluating AIs in advanced NSCLC, with survival data on patients who previously received bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "RESULTS: A total of 452 patients with advanced NSCLC who previously received bevacizumab were identified for analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: The findings of this study suggest that NSCLC patients who relapsed after a first-line bevacizumab-containing chemotherapy obtain improved clinical benefits from AI rechallenge. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Using this methodology, we investigated the genome-wide alteration of alternative splicing in patients with NSCLC treated by bevacizumab/erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced NSCLC: Thoracic Oncology Research Group (TORG) 1014. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " An exceptional overall survival using bevacizumab beyond progression in a patient with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In this report, we describe a patient with NSCLC who was treated with continuation of Bevacizumab (Bev) beyond progression to first-line Bev-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Impact of bevacizumab in combination with erlotinib on EGFR-mutated NSCLC xenograft models with T790M mutation or MET amplification. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab (BEV), a humanized monoclonal antibody to vascular endothelial cell growth factor (VEGF), in combination with ERL (BEV+ERL) significantly extended progression-free survival in patients with EGFR-mutated NSCLC compared with ERL alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " EGFR-TKI rechallenge with bevacizumab in EGFR-mutant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Erlotinib, bevacizumab, and pemetrexed improved survival of metastatic non-small cell lung cancer (mNSCLC) in clinical trials, but their benefits are restricted to non-squamous histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Incidence and risk of hypertension with bevacizumab in NSCLC patients: a meta-analysis of randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " AIM: A study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Ulcerative colitis in a patient with NSCLC receiving bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, is anticipated to prolong survival with inhibition of angiogenesis in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Adding Bevacizumab to the Treatment of Patients With NSCLC: Caveat Emptor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In patients with NSCLC treated with bevacizumab and erlotinib, Franzini and colleagues find that angiogenesis- and hypoxia-associated gene expression signatures predict tumor response and/or clinical outcome, and may define distinct angiogenic patterns. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "To date, bevacizumab is currently the only angiogenesis inhibitor that has been approved for the treatment of patients with advanced NSCLC in first-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous NSCLC harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for NSCLC with Brain Metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous NSCLC: A Systematic Review. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We conducted a systematic review of the efficacy of bevacizumab in combination with taxane or non-taxane containing regimens for untreated, nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The outcomes between taxane and non-taxane regimens when given in combination with bevacizumab for patients with nonsquamous NSCLC are comparable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: We aimed to assess computed tomography (CT) intratumoral heterogeneity changes, and compared the prognostic ability of the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, an alternate response method (Crabb), and CT heterogeneity in NSCLC treated with chemotherapy with and without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The aim of the present study was to retrospectively evaluate the feasibility of cisplatin/pemetrexed/bevacizumab (CPB) therapy at a bevacizumab (BEV) dose of 15 mg/kg as a first-line chemotherapeutic strategy for patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous NSCLC with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous NSCLC with pre-existing interstitial lung disease (ILD). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced NSCLC who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: The aim of this pilot study was to evaluate whether the uptake of (89)Zr-bevacizumab in NSCLC tumors could be visualized and quantified. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4\u2009\u00b1\u20090.9\u00a0MBq (mean\u2009\u00b1\u2009SD) (89)Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: This pilot study shows that (89)Zr-bevacizumab PET imaging in NSCLC is feasible. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced NSCLC in real world setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous NSCLC were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "On the basis of the strong antiedemigenous effect and no risk of intracranial bleeding, we administered a bevacizumab-based chemotherapy to patients with NSCLC and symptomatic metastatic brain lesions who were not suitable candidates for a specific local therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab radiosensitizes NSCLC xenografts by inhibiting DNA double-strand break repair in endothelial cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Briefly, bevacizumab was administered intravenously to Balb/c nude mice bearing NSCLC H1975 xenografts; in addition, bevacizumab was added to NSCLC or endothelial cells (ECs) in vitro, followed by irradiation (IR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In vitro, bevacizumab more effectively increased DSBs and apoptosis prior to IR and inhibited the clonogenic survival of ECs but not NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In conclusion, bevacizumab radiosensitizes NSCLC xenografts mainly by inhibiting DSB repair in ECs rather than by inducing vascular normalization. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab, a monoclonal antibody which targets vascular endothelium growth factor (VEGF), has been fully developed in NSCLC, and small-molecule tyrosin kinase inhibitors (TKIs) have been approved as first-line therapy for patients with advanced and metastatic NSCLC harbouring EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous NSCLC Patients (SAKK 19/05 trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: We aimed to identify gene expression signatures associated with angiogenesis and hypoxia pathways with predictive value for treatment response to bevacizumab/erlotinib (BE) of nonsquamous advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous NSCLC receiving chemoradiotherapy plus bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Functional imaging can help clinicians assess the individual response of advanced nonsquamous NSCLC to chemoradiation therapy plus bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients with advanced nonsquamous NSCLC diagnosed by histological or cytological examination were imaged with (99m)Tc-3PRGD2 SPECT/CT at 3 time points: 1-3\u00a0days before the start of treatment (SPECT1), 40\u00a0Gy radiotherapy with 2 cycles of chemotherapy plus bevacizumab (SPECT2) and 4\u00a0weeks after chemoradiotherapy plus bevacizumab (SPECT3). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The results indicated that rmhTNF effectively potentiated chemotherapy in patients with advanced NSCLC and was comparable with bevacizumab, an angiogenesis inhibitor approved by the Food and Drug Administration (FDA) for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "While Bevacizumab (Avastin) has proven successful in increasing the objective tumor response rate and in prolonging progression and overall survival in patients with NSCLC, the survival benefit is however relatively short and the majority of patients eventually relapse. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced NSCLC Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "OBJECTIVE: To evaluate biomarkers to predict the benefit of paclitaxel and carboplatin plus bevacizumab (PCB) therapy in patients with advanced or recurrent non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Along with bevacizumab and nintedanib, ramucirumab is the third anti-angiogenic agent that has yielded positive overall survival results in a phase III trial of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Since vascular endothelial growth factor (VEGF) has been implicated in MPE, we hypothesized that bevacizumab, an anti-VEGF antibody, may be effective against MPE in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We analysed the records of 21 patients treated for NSCLC-associated MPE between February, 2010 and August, 2013 who consequently underwent bevacizumab combination chemotherapy at the Institute of Biomedical Research and Innovation Hospital. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In conclusion, this study demonstrated a high R R to bevacizumab combination therapy for the MPE associated with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Therefore, bevacizumab therapy may be considered a therapeutic option for patients with non-squamous NSCLC who develop MPE. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous NSCLC: a phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced NSCLC patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III NSCLC: SWOG S0533. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: The aim of this trial was to determine feasibility of incorporating bevacizumab (B) into concurrent chemoradiotherapy (CRT) for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Bevacizumab was not safely integrated into CRT for stage III NSCLC in patients considered at high risk for hemoptysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced NSCLC with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant NSCLCs (NSCLCs) remains unknown. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations, especially those with EGFR exon 19 deletion mutations, although the primary end point was not met because the lower limit of the CI was less than 40%. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We have made a summary on the current therapeutic models of EGFR-TKI combined with chemotherapy/bevacizumab in this review and aimed to find the optimal therapeutic strategy for NSCLC patients with EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Overall, this work warrants further evaluation of TP53 as a ready biomarker to predict bevacizumab response in NSCLC and possibly other tumor types. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  \u00a9AlphaMed Press. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous NSCLC: Secondary Analyses of the ECOG 4599 and PointBreak Trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Patient-level data from 2 phase III studies in patients with previously untreated, advanced-stage, nonsquamous NSCLC were pooled to examine outcomes with bevacizumab and chemotherapy based on age. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: This analysis suggests that the survival benefits associated with PC+bevacizumab extend to patient subgroups below 75 years with advanced-stage NSCLC; no benefit, however, was observed for bevacizumab-eligible patients who were 75 years or above. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab in Patients with Nonsquamous NSCLC and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: The phase II prospective, noncomparative BRAIN study (NCT00800202) investigated efficacy and safety of bevacizumab in chemotherapy-na\u00efve or pretreated patients with NSCLC and asymptomatic untreated brain metastases to provide data in this previously unexplored subgroup. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Chemonaive patients (n = 939) with stage IIIB/IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomized (1:1) to pemetrexed-carboplatin-bevacizumab (pemetrexed arm) or paclitaxel-carboplatin-bevacizumab (paclitaxel arm). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We evaluated dynamic CT-based vascular parameters and plasma cytokines after bevacizumab alone and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore potential biomarkers of treatment response and resistance to this regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This hypothesis-generating study supports the notion that excessively decreasing vascular permeability and pruning/rarefaction after bevacizumab therapy may negatively impact the outcome of combination therapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of NSCLC: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The meta-analysis evaluated the efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Chemotherapy or TKIs in combination with bevacizumab significantly prolonged PFS (HRpfs 0.72, 95\u00a0% CIpfs 0.66-0.79, P pfs\u00a0<\u00a00.001) and OS (HRos 0.90, 95\u00a0% CIos 0.82-0.99, P os\u00a0=\u00a00.029) as first-line treatment for NSCLC compared with chemotherapy or TKIs alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Additional data on the efficacy of first-line therapy with afatinib and the combination of erlotinib and bevacizumab for patients with EGFR mutant NSCLC were presented. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Clinical outcomes in elderly patients with advanced NSCLC: results from ARIES, a bevacizumab observational cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " AIMS: Retrospective analyses from first-line clinical studies in advanced NSCLC have reported conflicting results on progression-free survival (PFS) and overall survival benefits with the addition of bevacizumab to chemotherapy in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: ARIES enrolled patients with advanced non-squamous NSCLC who received first-line bevacizumab-containing treatment per physician's choice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Data from the ARIES study suggest that treatment with bevacizumab in combination with chemotherapy is a viable first-line treatment option for elderly bevacizumab-eligible patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Effectiveness and safety of post-induction phase bevacizumab treatment for patients with NSCLC: results from the ARIES observational cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Data from randomized, controlled trials suggest that post-induction phase (IP) treatment with bevacizumab may benefit patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "ARIES was a large, prospective OCS of patients who received chemotherapy in combination with bevacizumab for the first-line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In conclusion, post-IP bevacizumab exposure was associated with improved post-IP OS in patients with advanced NSCLC who were enrolled in the ARIES OCS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous NSCLC harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVES: We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous NSCLC who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by\u00a0Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Clinicopathological factors affecting progression-free survival of patients with previously treated advanced NSCLC after S-1 therapy with or without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: Between October 2009 and June 2013, 56 patients with advanced NSCLC were analyzed for EGFR somatic mutations and treated with S-1 with or without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Patients with non-progressive, advanced NSCLC after platinum-based doublet (first-line) chemotherapy (with or without bevacizumab), any histology, with Eastern Cooperative Oncology Group performance status 0-1 were eligible. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVE: The use of bevacizumab in advanced non-squamous NSCLC is controversial among elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This study aimed to compare overall survival for Medicare patients diagnosed with NSCLC and treated with either first-line bevacizumab-carboplatin-paclitaxel (BCP) or carboplatin-paclitaxel (CP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous NSCLC (ns-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab (Bev), a monoclonal antibody against vascular endothelial growth factor, when combined with standard first-line chemotherapy, shows impressive clinical benefit in advanced non-squamous NSCLC (ns-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In nonsquamous NSCLC, novel agents, such as pemetrexed and bevacizumab, have improved survival in the first-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-na\u00efve patients with stage IIIB/IV non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Cost-Utility of Bevacizumab with PC Regimen in NSCLC Treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Cost-Effectiveness Analysis of Bevacizumab- Paclitaxel-Carboplatin (PC) Versus PC in First-Line Therapy of Advanced NSCLC from Patients' Perspective in Vietnam. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Addition of bevacizumab enhances antitumor activity of erlotinib against NSCLC xenografts depending on VEGF expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, are promising therapies for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Our study was aimed to determine whether there were conditions under which the addition of bevacizumab would enhance the antitumor activity of erlotinib against NSCLC tumors in vitro and in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "RESULTS: Bevacizumab alone did not inhibit NSCLC cell growth in vitro. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " We report a case of an elderly patient with non-squamous NSCLC who was successfully treated with chemotherapy using carboplatin(CBDCA), pemetrexed(PEM), and bevacizumab(Bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Results of phase III trials demonstrate that adding intravenous bevacizumab to antineoplastic agents improves progression-free survival and/or overall survival in patients with advanced cancer, including when used as first- or second-line therapy in metastatic colorectal cancer, as first-line therapy in advanced nonsquamous NSCLC, as first-line therapy in metastatic renal cell carcinoma, as first-line therapy in metastatic breast cancer, and as first-line therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer or in recurrent, platinum-sensitive or platinum-resistant disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-na\u00efve patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous NSCLC with interstitial lung disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: We analyzed the outcomes of 21 patients with advanced nonsquamous NSCLC with ILD who received paclitaxel and carboplatin without (paclitaxel-carboplatin group; n\u00a0=\u00a011) or with bevacizumab (paclitaxel-carboplatin-bevacizumab group; n\u00a0=\u00a010) between April 2008 and October 2013. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The addition of bevacizumab to paclitaxel and carboplatin may provide an effective and safe treatment option for patients with advanced nonsquamous NSCLC with ILD. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The availability of antineoplastic monoclonal antibodies, small molecules and newer cytotoxics such as pemetrexed, the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as the anti-angiogenic bevacizumab and the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: Bevacizumab is recommended in first line chemotherapy for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Since there is no guideline for third line treatment of NSCLC, some oncology units use paclitaxel-bevacizumab in some NSCLC patient after relapse of the second line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Combined paclitaxel-bevacizumab chemotherapy seems feasible in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " AIM: This phase II study was conducted to evaluate the efficacy and safety of docetaxel and bevacizumab combination therapy in patients with previously-treated non-squamous NSCLC (Nsq NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: The combination regimen of docetaxel-plus-bevacizumab is very active in patients with previously-treated Nsq NSCLC and warrants further research. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous NSCLC harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We aimed to compare the efficacy and safety of the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non-squamous NSCLC with activating EGFR mutation-positive disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: In this open-label, randomised, multicentre, phase 2 study, patients from 30 centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating EGFR mutations, Eastern Cooperative Oncology Group performance status 0 or 1, and no previous chemotherapy for advanced disease received erlotinib 150 mg/day plus bevacizumab 15 mg/kg every 3 weeks or erlotinib 150 mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "INTERPRETATION: Erlotinib plus bevacizumab combination could be a new first-line regimen in EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel-carboplatin chemotherapy in patients with advanced NSCLC resulted in a 6-month progression-free survival (PFS) rate that compares favorably with the historic rate for bevacizumab combined with paclitaxel-carboplatin in this patient population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Intramedullary spinal cord hemorrhage after treatment with bevacizumab in a long-term survivor with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous NSCLC with good performance status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: We hypothesized that the combination of bevacizumab, carboplatin, and pemetrexed will be an effective first-line regimen in fit, elderly patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVES: ABIGAIL, a phase II, randomized, open-label, multicenter study evaluated the correlation between biomarkers and best overall response (BOR) to bevacizumab with chemotherapy in patients with advanced or recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: A total of 303 patients with NSCLC were randomized to receive bevacizumab 7.5mg/kg or 15mg/kg until progression or unacceptable toxicity (plus six cycles of chemotherapy). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced NSCLC (ATLAS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: ATLAS compared bevacizumab plus erlotinib (B+E) with bevacizumab plus placebo (B+P) as maintenance therapy after first-line bevacizumab plus chemotherapy (B+C) for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Safety and effectiveness of bevacizumab-containing treatment for NSCLC: final results of the ARIES observational cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: From 2006 to 2009, ARIES enrolled patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Incidences of bevacizumab-associated adverse events (19.7% overall) were consistent with those in randomized controlled trials of bevacizumab in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Results from ARIES demonstrate similar outcomes to randomized controlled trials of bevacizumab when added to standard chemotherapy in a real-world patient population with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab concomitant with chemotherapy is effective in treating Chinese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVES: To retrospectively review the safety and clinical efficacy of bevacizumab concomitant with chemotherapy in Chinese patients with advanced non-squamous NSCLC (NSNSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Clinical data for 79 patients with NSNSCLC who received bevacizumab concomitant with chemotherapy in Chinese PLA General Hospital from April 28th 2009 to May 5th 2013 were retrospectively reviewed to analyze the clinical efficacy including disease control rate (DCR), overall response rate (ORR), progression-free survival (PFS), overall survival (OS), the Eastern Cooperative Oncology Group (ECOG) score and the safety. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with chemotherapy is effective and the related toxicity can be well tolerated in Chinese patients with NSNSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The average prescription compliance scores were as follows: bevacizumab, 83% for metastatic colorectal cancer, 100% for metastatic breast cancer, and 82.3% for NSCLC; cetuximab, 62.0% for colorectal cancer and 50% for head and neck cancer; trastuzumab, 95.1% for early breast cancer and 82.4% for metastatic breast cancer; and bortezomib, 63.7% for multiple myeloma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab was the first US FDA-approved inhibitor of angiogenesis after demonstrating improved progression-free survival and overall survival in combination with chemotherapy in treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF) that provides a survival benefit to patients with non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "However, the treatment is sometimes accompanied by life-threatening bleeding events, and studies have not yet identified factors that can predict outcomes for NSCLC patients receiving bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: To identify prognostic factors for patients with NSCLC who are undergoing bevacizumab therapy, this study retrospectively investigated 34 consecutive patients with NSCLC treated with bevacizumab-containing chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The onset of adverse cardiovascular events during bevacizumab therapy may be a favorable prognostic factor for patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This article discusses the first-line treatment of NSCLC with no identifiable mutations with FDA-approved targeted therapies for patients treated outside a clinical trial, particularly focusing on difficult clinical decisions, such as when the use of bevacizumab is appropriate, choosing a platinum partner, and treatment of patients with an ECOG performance status of 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab in NSCLC: an overview of practice in the era of molecular testing. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The place of bevacizumab in the management of advanced NSCLC was reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The result of this recent research means that bevacizumab has little, if any, place in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OBJECTIVE: To observe the clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic NSCLC: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " MO06.12 Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous NSCLC (NSCLC): analyses based on age in the phase 3 PointBreak and E4599 trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous NSCLC: results of the phase II randomized ABIGAIL study (BO21015). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: Avastin Biomarkers In lunG And 3D Innovative anaLysis (ABIGAIL), which is a phase II, open-label, randomized study, investigated correlations between biomarkers and best overall response to bevacizumab plus platinum-doublet chemotherapy for patients with advanced/recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic NSCLC patients who have progressed following chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The objective of this phase Ib dose-escalation trial (3 + 3 design) was to determine the recommended phase II dose (RP2D) of IMO-2055 when combined with erlotinib and bevacizumab in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients with stage 3/4 NSCLC and progressive disease (PD) following chemotherapy received IMO-2055 0.08, 0.16, 0.32, or 0.48 mg/kg once weekly plus erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: IMO-2055 demonstrated good tolerability and possible antitumor activity in combination with erlotinib and bevacizumab in heavily pretreated patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Two large phase III trials, ECOG4599 and the AVAiL study, showed that bevacizumab combined with chemotherapy improves the outcome of patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Based on these results, bevacizumab is currently the only anti-angiogenic agent approved as the first-line of treatment for advanced nonsquamous NSCLC in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The use of bevacizumab in NSCLC: an update. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Currently bevacizumab is the only anti-angiogenic agent approved for the first-line treatment of NSCLC in selected patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In this review, we aimed to summarize the currently available treatment options and present a therapeutic strategy for NSCLC patients with brain metastases, with a special emphasis on bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: Bevacizumab plus carboplatin-paclitaxel (BCP) chemotherapy has Food and Drug Administration approval for advanced nonsquamous, NSCLC based upon improved survival in a clinical trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Using data from four health maintenance organizations (HMOs) belonging to the Cancer Research Network, 1605 HMO nonsquamous, NSCLC patients aged younger than 21 years, diagnosed 2002-2010, who received carboplatin-paclitaxel (CP), with and without bevacizumab for first-line treatment of stage IIIB/IV disease were identified. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The objective of this study was to analyze the predictive roles of VEGF/KDR/Ras/MAPK gene expression in patients with advanced NSCLC treated with bevacizumab plus chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In first-line the combination of platinum plus pemetrexed with or without bevacizumab is a reasonable choice in patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " AIM: The aim of this retrospective study was to evaluate bevacizumab combined with weekly paclitaxel with and without carboplatin in pre-treated patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: Between November 2009 and October 2011, 43 pre-treated patients with non-squamous NSCLC received bevacizumab (15 mg/kg, day 1) plus weekly paclitaxel (60-80 mg/m(2), days 1, 8, 15) with carboplatin (area under the curve=4-5, day 1) (n=36), or bevacizumab plus weekly paclitaxel (n=7) alone every four weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Even for heavily pre-treated patients, bevacizumab plus weekly paclitaxel with or without carboplatin was effective and tolerable in non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous NSCLC was evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Combination of paclitaxel and bevacizumab in heavily pre-treated NSCLC patients: a case series study on 15 patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "An increase of CEC and CEP was observed in patients with NSCLC treated with paclitaxel and bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in NSCLC models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab improves antitumor efficacy of CIK cells transfer therapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab treatment for advanced NSCLC: A case report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Patients with untreated, locally advanced, metastatic or recurrent non-squamous NSCLC were administered up to six cycles of chemotherapy combined with bevacizumab-humanized monoclonal antibodies, followed by maintenance therapy with bevacizumab until further progression of the disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The present study concluded that the long-term application of bevacizumab monoclonal antibodies (mABs) was safe in a late-stage NSCLC patient. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced NSCLC, and are currently approved for use in clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous NSCLC: SWOG S0536. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: Cetuximab and bevacizumab have each been demonstrated to prolong survival when added to chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous NSCLC) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab, a monoclonal antibody targeted against the vascular endothelial growth factor, is the only antiangiogenic agent currently recommended by NCCN for the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab has been widely used for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line NSCLC treated with chemotherapy with or without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Categorizations of best response observed at week 8 (between week 3 and 14) of first-line treatment in two studies of bevacizumab plus chemotherapy in Western (878 patients) and Chinese (198 patients) patients with NSCLC were assessed together with baseline prognostic factors in multivariate parametric models to predict overall survival (OS) and progression free survival (PFS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "DCR predicted OS benefit with bevacizumab in first-line NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: This phase III trial was performed to assess the potential benefit of adding maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: One thousand one hundred forty-five patients with histologically or cytologically confirmed NSCLC (stage IIIB with malignant pleural effusion, stage IV, or recurrent) received four cycles of chemotherapy plus bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Health-related quality of life in patients with advanced nonsquamous NSCLC receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: In the phase III AVAPERL trial, patients with advanced nonsquamous NSCLC receiving bevacizumab-plus-pemetrexed maintenance after first-line induction had a significant progression-free survival benefit relative to those treated with single-agent bevacizumab maintenance but with an increase in grade \u22653 adverse events. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The use of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), in combination with standard therapeutic approaches, has offered clinical benefit for patients with advanced colorectal, breast, ovarian, renal, NSCLC and glioblastoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab (Avastin), a monoclonal antibody that reacts directly against VEGF, has been demonstrated to be an effective treatment for various cancers such as rectal cancer, colon carcinoma, and NSCLC, etc. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: We used the monoclonal antibody against VEGFA, bevacizumab, in various in vitro experiments using cell lines derived from different tumor entities (non small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer (BC) and renal cell carcinoma (RCC)) in order to determine if potential VEGFA signaling could be blocked in tumor cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This phase II study aimed to determine the safety and efficacy of this doublet with bevacizumab as first-line treatment for stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Newly diagnosed patients \u226518 years with histologically proven non-squamous NSCLC and Eastern Cooperative Oncology Group performance status (ECOG PS) \u22642 received six 21-day cycles of docetaxel, oxaliplatin, and bevacizumab followed by single-agent bevacizumab for a total of 1 year. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The addition of bevacizumab to docetaxel/oxaliplatin is effective with an acceptable safety profile in patients with chemotherapy-na\u00efve advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We identified the expression of EGFR exon 18 as a new predictive marker for patients with untreated metastatic NSCLC treated with bevacizumab and erlotinib in the first line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: The antitumor activity of elacytarabine, was tested at the maximal tolerable dose (MTD; 50 mg/kg) and half MTD (25 mg/kg), alone and in combination with the antibodies bevacizumab (5 mg/kg), cetuximab (20 mg/kg) and trastuzumab (4 mg/kg) in two human NSCLC xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Previous studies have demonstrated the efficacy of first-line bevacizumab combination therapy in advanced, non-squamous NSCLC (NS-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Chemo-naive Chinese patients with locally advanced, metastatic or recurrent NSCLC were randomized to receive Bev 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The safety and efficacy of first-line bevacizumab-based treatment in Chinese population with advanced NS-NSCLC are consistent with those in previous studies as well as in Asian subgroup population from SAiL study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The TASK study evaluated the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab as first-line therapy in unselected, advanced non-squamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The TASK study did not show a benefit in terms of PFS for the combination of erlotinib with bevacizumab in unselected first-line advanced non-squamous NSCLC compared with chemotherapy plus bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " OPINION STATEMENT: Bevacizumab is an effective targeted therapy with demonstrated survival benefits for many patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous NSCLC with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: S-1 plus cisplatin with bevacizumab is an active and well-tolerated regimen in patients with chemotherapy-na\u00efve non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase2 study of bevacizumab with carboplatin-paclitaxel for NSCLC with malignant pleural effusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "moto19781205@yahoo.co.jp  Vascular endothelial growth factor (VEGF) is involved in NSCLC with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: Bevacizumab improves survival in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This phase II clinical trial assessed the effects of the addition of bevacizumab to neoadjuvant chemotherapy in resectable nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients with resectable stage IB-IIIA nonsquamous NSCLC were treated with bevacizumab followed by imaging 2 weeks later to assess single-agent effect. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD \u22656 months/PR (PR=3; SD \u22656 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " [Long-term survival of a patient with advanced NSCLC on bevacizumab therapy: case report and review of the literature]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Our findings suggest that maintenance bevacizumab for the treatment of non-small cell lung cancer (NSCLC) is safe and its benefit for long-term survival overwhelms its side effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab is a humanized anti-VEGF monoclonal antibody able to produce clinical benefit in advanced non-squamous NSCLC patients when combined to chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We conducted a retrospective analysis to investigate the role of peripheral blood cells count and of an inflammatory index, the neutrophil-to-lymphocyte ratio (NLR), as predictors of clinical outcome in NSCLC patients treated with bevacizumab plus chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "One hundred and twelve NSCLC patients treated with chemotherapy \u00b1 bevacizumab were retrospectively evaluated for the predictive value of clinical or laboratory parameters correlated with inflammatory status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "12.0 mo, HR: 0.29, p < 0.001 respectively) only in NSCLC patients treated with bevacizumab plus chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Our results suggest that a baseline systemic inflammatory status is marker of resistance to bevacizumab treatment in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A 61-year-old woman with recurrent NSCLC presented with thrombocytopenia, microangiopathic hemolytic anemia, neurological abnormalities, renal failure and a fever that appeared during chemotherapy with gemcitabine and bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Effectiveness of specific agents was assessed at time periods immediately following the approval of the agent for NSCLC: baseline, 1988-1994; platinum, 1995-1999; docetaxel, 1999-2003; pemetrexed and bevacizumab, 2004-2005. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: The extent of the benefit of bevacizumab combined with chemotherapy in the treatment of advanced NSCLC is still unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We performed this meta-analysis to compare the efficacy of bevacizumab with other commonly used targeted drugs for different patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Bevacizumab accompanied by chemotherapy was found to significantly improve patients' response rate, progression free survival (PFS), and overall survival (OS) among chemotherapy-na\u00efve patients compared to other targeted drugs in the treatment of non-small cell lung carcinoma (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "e-dansin@o-lambret.fr  Bevacizumab (Avastin(\u00ae)) is the first antiangiogenic therapy approved in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: One standard of care for advanced NSCLC is paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Bevacizumab leads to improved survival for patients with metastatic colorectal cancer (CRC) or NSCLC when added to chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We examined differences in characteristics and outcomes of patients with CRC and NSCLC cancers who received bevacizumab with chemotherapy versus chemotherapy alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In the current study, the authors evaluated the efficacy and safety of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab in chemotherapy-naive patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The regimen of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab was active and feasible as first-line treatment for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous NSCLC: a retrospective cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients with stage IIIB/IV, non-squamous NSCLC who started chemotherapy before the approval of bevacizumab were reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "RESULTS: Among 283 patients with stage IIIB/IV non-squamous NSCLC, eligibility for bevacizumab was evaluated in 154 patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Eligibility for bevacizumab itself represents a powerful prognostic factor for patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients with NSCLC, treated by conventional chemotherapy with (Group 1; n\u2009=\u200917) or without (Group 2; n\u2009=\u200923) anti-vascular endothelial growth factor (anti-VEGF) drug (bevacizumab) underwent CT perfusion before (TIME\u20090) and after 1 (TIME\u20091), 3 (TIME\u20092) and 6 (TIME\u20093) cycles of chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab (Bev) is a humanized antibody against VEGF-A (11) that binds to all VEGF-A isoforms, and it is approved for clinical use in metastatic colon carcinoma and NSCLC (12). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " We report contemporaneous bronchoscopic findings for a case of bevacizumab-related pulmonary hemorrhage in a patient with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Our case report highlights the potential mechanistic insights into bevacizumab-related bleeding and importance of performing bronchoscopy at diagnosis in NSCLC patients, given that abnormal bronchoscopic findings may be a risk factor for bleeding. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Intrapleural combination therapy with bevacizumab and cisplatin for NSCLC\u2011mediated malignant pleural effusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Administration of bevacizumab and erlotinib in combination with first-line chemotherapy, followed by bevacizumab and erlotinib monotherapy as maintenance, showed promising results in patients with NSCLC, with reduced toxicity as compared with chemotherapy alone, but did not translate into longer overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " [Bevacizumab combined with chemotherapy for advanced NSCLC: a meta-analysis]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND AND OBJECTIVE: Bevacizumab is a recombinant, humanised, monoclonal antibody against the vascular endothelial growth factor receptor (VEGFR), the aim of this meta-analysis is to evaluate the clinical efficacy and safety of bevacizumab combined with chemotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: The CBM, CNKI, VIP, WanFang, The Cochrane Library, PubMed, Ovid, EMBASE and SCI etc were retrieved by computer, the randomized controlled trials (randomized control trial, RCT) of bevacizumab combined with chemotherapy in the treatment of NSCLC were collected by us. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Whether first-line or second-line treatment, the addition of bevacizumab to chemotherapy in patients with advanced NSCLC prolongs RR, OS and PFS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab and weekly paclitaxel for non-squamous NSCLC patients: a retrospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: Combination of bevacizumab and weekly paclitaxel showed synergitic effects, anti-tumor efficacy and a good toxicity profile for patients with breast cancer but has never been evaluated in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: In our experience, combination of bevacizumab and weekly paclitaxel exhibited acceptable toxicity and had encouraging anti-tumor efficacy as fourth-line treatment or beyond for non-squamous NSCLC patients, supporting further evaluation in larger prospective studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Esophageal fistula after EUS-FNA in a patient treated with bevacizumab for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "sklempne@bidmc.harvard.edu  OBJECTIVES: This study reports on the safety of the complementary and alternative medicine (CAM) practice of cupping in a patient undergoing concomitant therapy with bevacizumab for advanced NSCLC, and raises awareness of the need for improved communication between CAM practitioners and oncologists during the care of patients with cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: A patient with advanced NSCLC received four cycles of carboplatin AUC 6, paclitaxel 200\u2009mg/m(2), and bevacizumab 15\u2009mg/kg, and was continued on every-3-week maintenance bevacizumab 15\u2009mg/kg. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "gerald.schmid-bindert@medma.uni-heidelberg.de  Bevacizumab is a monoclonal antibody that specifically inhibits vascular endothelial growth factor, and is the first antiangiogenic agent to be approved for first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Evidence from two large phase III trials demonstrates that bevacizumab combined with chemotherapy improves outcomes for patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Clinical research is still ongoing to define the role of bevacizumab in different settings, such as single-agent bevacizumab for continuation maintenance therapy in advanced disease, treatment beyond disease progression, adjuvant therapy in early-stage NSCLC, or bevacizumab in combination with other targeted agents. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This article reviews the extensive information from randomized trials and large observational studies for bevacizumab in advanced NSCLC, and shortly describes the current clinical development of antiangiogenic monoclonal antibodies, TKIs and related compounds. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "philip_bonomi@rush.edu  INTRODUCTION: We conducted a phase II study of dual-agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with paclitaxel and carboplatin chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: Patients with stage IIIB/IV nonsquamous NSCLC randomly received cetuximab (400 mg/m initially, 250 mg/m weekly thereafter) plus bevacizumab (15 mg/kg) for six cycles combined with paclitaxel (200 mg/m) and carboplatin (area under the curve 6) for either six cycles (six-cycle arm) or the first three cycles (three-cycle arm) (one cycle = 3 weeks). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous NSCLC: a multicenter phase II study of the Hellenic Oncology Research Group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "kentenik@hotmail.com  BACKGROUND: The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic NSCLC, and bevacizumab (B) improves the efficacy of frontline chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, NSCLC with serum proteomic evaluation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "wallace.akerley@hci.utah.edu  BACKGROUND: Erlotinib alone or bevacizumab in combination with chemotherapy improve survival in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Survival in an unselected population of patients with NSNSCLC treated with bevacizumab and erlotinib approximated that expected with conventional chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "First line treatment with bevacizumab plus platinum-doublet and maintenance monotherapy with bevacizumab until disease progression has been shown to be effective in patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Evidence-based role of bevacizumab in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "EXPERT OPINION: The addition of bevacizumab or cetuximab to chemotherapy has shown promising benefits to the patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Clinical trials of cetuximab against NSCLC and of bevacizumab against stomach cancer have shown that these agents are only active in Caucasians. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab as first-line therapy in advanced NSCLC: a brazilian center experience. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "jardimde@gmail.com  OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic NSCLC, in combination with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: We retrospectively identified patients with non-squamous NSCLC treated with bevacizumab plus chemotherapy combinations as first-line chemotherapy between July 1, 2006, and January 30, 2011, at Sirio Libanes Hospital in Sao Paulo, Brazil. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Our results confirm the efficacy and safety data of bevacizumab first-line combinations for NSCLC in a Brazilian population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "An antibody to VEGF-A, bevacizumab, has demonstrated a survival benefit in conjunction with platinum-based doublet chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Despite the fact that these improvements have been largely data-driven, the following questions arise: what is the role of adjuvant chemotherapy in elderly patients with NSCLC? What is the role of targeted agents, such as erlotinib and bevacizumab, in older NSCLC patients? These questions are relevant because the current median age of lung cancer patients at diagnosis in the USA is 69 years, and the number of older patients developing this malignancy is increasing. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In NSCLC, OS scores of bevacizumab improved from 0% to 50%, as a result of histology, lower prices, and extended therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In NSCLC, 10 cycles of bevacizumab scored 0%. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab plus chemotherapy for advanced non-squamous NSCLC with malignant pleural effusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Because vascular endothelial growth factor (VEGF) is the key mediator MPE production, we evaluated the efficacy and safety of chemotherapy plus bevacizumab, an anti-VEGF antibody, in non-squamous NSCLC patients with MPE, especially regarding the control of pleural effusions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: This is the first study to report that bevacizumab plus chemotherapy is highly effective for the management of MPE in non-squamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Among these agents that have been tested bevacizumab, a monoclonal antibody against VEGF, has been approved for the treatment of metastatic NSCLC in combination with chemotherapy, while several other agents are under phase III investigation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Antiangiogenic agents, including the approved vascular endothelial growth factor (VEGF)-targeted monoclonal antibody, bevacizumab, as well as a number of investigational tyrosine kinase inhibitors (TKIs) that simultaneously target multiple angiogenic pathways, have demonstrated activity in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with metastatic colorectal cancer (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: Ten NSCLC patients treated with bevacizumab underwent DECT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab-containing chemotherapy for NSCLC patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " To evaluate the efficacy and safety of bevacizumab-containing chemotherapy for NSCLC, we performed a population-based observational study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The efficacy and safety of bevacizumab-containing chemotherapy for NSCLC patients were evaluated at 14 sites (17 hospital departments) in a prefecture of Japan between December 2009 and August 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We deduced that bevacizumab-containing chemotherapy is effective against NSCLC and also tolerable in clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous NSCLC, a phase II study of the Hoosier Oncology Group: LUN04-77. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "A phase II study combining erlotinib and bevacizumab for treatment of recurrent NSCLC showed encouraging efficacy and acceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: This single-arm phase II study evaluated erlotinib and bevacizumab as first-line therapy for newly diagnosed nonsquamous advanced NSCLC patients with Eastern Cooperative Oncology Group PS \u2265 2 or age 70 or older. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: The combination of erlotinib and bevacizumab had insufficient activity in the absence of known activating epidermal growth factor receptor gene mutations to warrant study in newly diagnosed elderly or poor PS patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Societal savings in patients with advanced non-squamous NSCLC receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: The purpose of this study was to investigate the savings accrued using bevacizumab-based treatment for NSCLC from the societal perspective, taking only public costs into account, in France, Germany, Italy, and Spain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: This analysis shows that bevacizumab-based treatment in NSCLC is associated with more savings to society compared to standard chemotherapy in terms of increased productivity and decreased social benefits paid to patients who are able to work in France, Germany, Italy, and Spain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " [A case of complete resection of non-squamous NSCLC after induction chemotherapy using carboplatin, paclitaxel, and bevacizumab]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab maintenance in patients with advanced NSCLC, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " INTRODUCTION: The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin and paclitaxel (CP) in comparison with CP chemotherapy alone in patients with previously untreated advanced, metastatic or recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III NSCLC: results of a phase I/II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " PURPOSE: Bevacizumab and erlotinib have been shown to improve survival in stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "However, little is known about variation in first-line NSCLC chemotherapy use in younger patients, health maintenance organization (HMO)-based settings, and for high-cost, novel agents, such as bevacizumab and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " First-line bevacizumab-based therapy in advanced non-squamous NSCLC : analysis of the Italian patients enrolled in the SAiL study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "abearz@cro.it  BACKGROUND AND OBJECTIVE: First-line bevacizumab-based therapy has been shown to improve outcomes in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: In the SAiL study, patients with untreated locally advanced, metastatic or recurrent non-squamous NSCLC received bevacizumab (7.5 or 15 mg/kg) every 3 weeks plus chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Nevertheless, the first-line use of bevacizumab in combination with chemotherapy offers clinical benefits to Italian patients with advanced or recurrent non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "hashemn@ccf.org  OPINION STATEMENT: The standard of care for the treatment of patients with advanced NSCLC includes 4-6 cycles of platinum-doublet chemotherapy with or without bevacizumab, with modest improvements in survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This phase II study examined ixabepilone/carboplatin (cohort A) and ixabepilone/carboplatin/bevacizumab (cohort B) as first-line therapy for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Eligible patients had newly diagnosed stage III/IV NSCLC, ECOG PS 0-1, adequate organ function, no active CNS metastases, and, in cohort B, bevacizumab treatment criteria. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Economic evaluation of bevacizumab in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Prognostic models to predict survival in NSCLC patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "txh@medicine.wisc.edu  BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced NSCLC patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLC patients can be estimated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab (an anti-VEGF agent) is undergoing investigation in clinical trials on brain metastases from NSCLC, breast cancer and melanoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab is approved for clinical use in metastatic colon carcinoma and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "c_dasanu@yahoo.com  A recent retrospective analysis of a large cohort of patients aged 65 and older with advanced NSCLC failed to demonstrate any improvement in survival with the addition of bevacizumab to the platinum doublet in the first-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Before bevacizumab treatment, three NSCLC patients (75%) had normal renal function and only one pancreatic cancer patient (25%) had mild renal impairment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Tumoral cavitation in patients with NSCLC treated with antiangiogenic therapy using bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "mizuki_nishino@dfci.harvard.edu  RATIONALE AND OBJECTIVES: To investigate the frequency and radiographic patterns of tumoral cavitation in patients with NSCLC treated with bevacizumab, and correlate the imaging findings with the pathology, clinical characteristics and outcome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: Seventy-two patients with NSCLC treated with bevacizumab therapy were identified retrospectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Tumoral cavitation occurred in 19% in patients with NSCLC treated with bevacizumab and demonstrated 3 radiographic patterns. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Anti-VEGF antibody bevacizumab was approved for advanced NSCLC, but the clinical benefits are modest and all patients eventually develop resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " In NSCLC, anti-angiogenic strategies like bevacizumab have developed into standard treatment options. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous NSCLC chemo-na\u00efve patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "luis.leon.mateos@sergas.es  OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: Patients previously treated with one to two chemotherapy regimens (including one platinum-based regimen) for recurrent NSCLC, and for whom erlotinib was indicated, were randomly assigned (1:1) to sunitinib 37.5 mg/d plus erlotinib 150 mg/d or to placebo plus erlotinib 150 mg/d, stratified by prior bevacizumab use, smoking history, and epidermal growth factor receptor expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "bpiperdi@montefiore.org  BACKGROUND: This study aimed to establish the maximum tolerated dose (MTD) of weekly bortezomib in combination with fixed standard doses of carboplatin and bevacizumab, and to estimate the efficacy (response rate and progression free survival [PFS]) and safety of combination therapy with carboplatin, bortezomib, and bevacizumab as first-line therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " CONTEXT: A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "OBJECTIVE: To examine whether adding bevacizumab to carboplatin and paclitaxel chemotherapy is associated with improved survival in older patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Adding bevacizumab to carboplatin and paclitaxel chemotherapy was not associated with better survival among Medicare patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Bevacizumab for the treatment of nonsquamous NSCLC in Portugal: a retrospective, multicenter study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In patients with nonsquamous NSCLC stage IIIB/IV treatment with chemotherapy plus bevacizumab led to significant improvements in progression-free and median overall survival (OS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "AIM: To report the experience of five Portuguese centers in treating patients with nonsquamous NSCLC in stage IIIB or IV with bevacizumab and chemotherapy regarding survival and toxicity outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "MATERIALS AND METHODS: This was a retrospective, multicenter study on patients with nonsquamous stage IIIB/IV NSCLC treated with bevacizumab and chemotherapy from November 2007 to August 2010 through special use permits. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: The results of chemotherapy plus bevacizumab treatment for nonsquamous NSCLC obtained from the daily clinical practice of the centers involved in this study were similar to those of published clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Osteonecrosis of the jaw in a patient with advanced NSCLC receiving bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab, a monoclonal antibody against circulating vascular endothelial growth factor (VEGF), is already approved for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous NSCLC received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "riessjo@stanford.edu  We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " The combination of bevacizumab and standard chemotherapy prolongs progression-free survival and improves response rates in advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We evaluated the efficacy and safety of bevacizumab based chemotherapy in 31 cases of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab-based chemotherapy is an efficacious and safe treatment for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "kreckamp@coh.org  With the approval of the antiangiogenic antibody bevacizumab in NSCLC and other malignancies, the tumor vasculature has emerged as a worthwhile therapeutic target. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "ohuchikor@chugai-pharm.co.jp  BACKGROUND: Bevacizumab is a humanized monoclonal antibody to human vascular endothelial cell growth factor (VEGF) and has been used for many types of cancers such as colorectal cancer, NSCLC, breast cancer, and glioblastoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Complete regression of a NSCLC choroidal metastasis with intravitreal bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "siniho@east.ncc.go.jp  PURPOSE: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: Study JO19907 met its primary endpoint, demonstrating that the addition of bevacizumab to first-line CP significantly improves PFS in Japanese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "e-dansin@o-lambret.fr  INTRODUCTION: The clinical benefit and safety profile associated with first-line bevacizumab with doublet chemotherapy in patients with advanced non-squamous NSCLC was established in two large phase III studies, E4599 and AVAiL. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: This analysis from the SAiL trial reaffirms a comparable incidence of clinically significant bleeding associated with first-line bevacizumab and chemotherapy as previous phase III studies in NSCLC patients despite less stringent first-line selection criteria. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab, an anti-VEGF recombinant humanized monoclonal antibody, is the first targeted agent which, when combined with chemotherapy, has shown superior efficacy versus chemotherapy alone as first-line treatment of advanced non-squamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This review will focus on the potential role of bevacizumab and other anti-angiogenetic agents in the treatment of brain metastases from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The most well studied signaling pathway associated with angiogenesis is the vascular endothelial growth factor (VEGF) pathway, and the only antiangiogenic agent currently approved for the treatment of NSCLC is bevacizumab, an antibody targeted against VEGF. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for NSCLC, a phase II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Risk profile of bevacizumab in patients with NSCLC: a meta-analysis of randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Currently, safety of bevacizumab in patients with NSCLC is not clear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We conducted a meta-analysis to evaluate the risk profile of bevacizumab in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "In addition, treatment with bevacizumab was associated with several grade 3 or 4 AEs in patients with NSCLC, especially in high-dosage bevacizumab group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSION: The use of the bevacizumab increases the risk of treatment-related deaths and several grade 3 or 4 AEs in patient with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The anti-vascular endothelial growth factor (VEGF) monoclonal antibody, bevacizumab, is the only US Food and Drug Administration-approved antiangiogenic agent for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Accumulated safety data with bevacizumab in NSCLC shows that patients are at risk for hemorrhage, venous thromboembolism, hypertension, and proteinuria. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "This review describes the molecular rationale for targeting angiogenic pathways in anticancer therapy and summarizes safety and tolerability data from clinical trials of bevacizumab or aflibercept in combination with chemotherapy and the investigational TKIs and VDAs in patients who have advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: A panel of expert oncologists, pulmonologists and radiologists reviewed the available data to identify predictive factors for PH in order to help guide physicians using bevacizumab in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: An individualised risk-benefit assessment should be undertaken in all patients with NSCLC in whom bevacizumab is being considered. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "Bevacizumab is currently approved when given in combination with first-line platinum-based therapy in selected patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " BACKGROUND: In October 2006, bevacizumab was approved for treatment for patients with metastatic NSCLC other than squamous carcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "The only antiangiogenic agent currently approved for treatment of NSCLC is bevacizumab, although numerous other antiangiogenic inhibitors (e.g., sorafenib, sunitinib, cediranib, motesanib, BIBF 1120) are in clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We present an overview of the molecular pathways involved in angiogenesis, discuss clinical trials of bevacizumab and developmental antiangiogenic agents, and address the challenges of developing individualized treatment paradigms for NSCLC, particularly the use of biomarkers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced NSCLC treated with bevacizumab plus chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": " We sought to find blood-based biomarkers that can be used to predict efficacy in advanced NSCLC patients treated with bevacizumab plus chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "[Epub ahead of print]  Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "We investigated the activity and tolerability of the novel combination of dose-dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "METHODS: This multicenter phase II trial evaluated the safety and efficacy of the combination of pemetrexed (400 mg/m(2)), gemcitabine (1200 mg/m(2)), and bevacizumab (10\u00a0mg/kg), given every 14 days in patients with untreated, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Bevacizumab", "orig_sen": "CONCLUSIONS: Treatment with dose-dense pemetrexed, gemcitabine, and bevacizumab met the primary endpoint with promising efficacy and a manageable safety profile in patients with untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "thalidomide", "orig_sen": "Inclusion criteria were NSCLC patients with bone metastases confirmed by pathology or cytology; available imaging data of pelvic metastatic lesions; aged 18 to 75 years old; expected survival at least 3 months; not receiving taxane, bevacizumab, thalidomide, rh-endostatin, or bisphosphonate; not having radiation therapy within 3 months of enrollment into study; normal results of routine blood tests, liver and kidney function, and electrocardiogram; absence of cardiovascular disease, autoimmune disease, vasculitis, severe infection, diabetes, and other concomitant disease; and signed informed consent. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "thalidomide", "orig_sen": " A potential new enriching trial design for selecting NSCLC patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "thalidomide", "orig_sen": "We performed a retrospective analysis of 722 stage IIIB/IV NSCLC patients from a double-blind placebo-controlled trial of thalidomide or placebo 100-200 mg/day, combined with gemcitabine/carboplatin (for up to four cycles), then given as single agent maintenance therapy. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "thalidomide", "orig_sen": " Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III NSCLC: the ECOG 3598 study. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "thalidomide", "orig_sen": " PURPOSE: The primary objective of this study was to compare the survival of patients with unresectable stage III NSCLC treated with combined chemoradiotherapy with or without thalidomide. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "thalidomide", "orig_sen": "CONCLUSION: The addition of thalidomide to chemoradiotherapy increased toxicities but did not improve survival in patients with locally advanced NSCLC. ", "polarity": 0, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: Pemetrexed maintenance therapy (MT) after induction with platinum-based chemotherapy has recently become a common treatment strategy for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In patients with NSCLC with anaplastic lymphoma kinase (ALK) rearrangements, phase III trials of crizotinib have demonstrated superior efficacy compared to platinum-pemetrexed in the first-line setting and standard chemotherapy in the second-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with NSCLC pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Chemotherapy (platinum and pemetrexed) in combination with erlotinib in NSCLC induces major gastrointestinal toxicity: two case reports from the FLARE/GFPC 03-2013 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The overall survival benefit was strongest for maintenance therapy with pemetrexed for patients with nonsquamous NSCLC (hazard ratio\u00a0= 0.74, 95% confidence interval: 0.64-0.86) but not significant for patients with squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: For patients with advanced, stable stage IIIB/IV NSCLC whose disease has not progressed after four to six cycles of platinum-based chemotherapy, the\u00a0overall survival benefits were strongest for pemetrexed maintenance therapy followed by epidermal growth factor receptor tyrosine kinase inhibitor maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: In the present single-arm phase II trial, patients with previously untreated, unresectable stage IIIA-IIIB NSCLC (all histologic types) were treated with pemetrexed-cisplatin (500 mg/m(2) intravenously on days 1 and 22, 20 mg/m(2) intravenously on days 1-5 and days 22-26) concurrent with radiotherapy (61-66 Gy in 31-35 fractions), followed by 2 cycles of consolidation pemetrexed-cisplatin (75 mg(2)) therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "A report by Edelman recently published in the Journal of Clinical Oncology demonstrated the results of a prospective randomized trial using a combination of chemotherapy (docetaxel or pemetrexed) and either COX-2 inhibitor or a placebo for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Currently, pemetrexed is indicated for use in the first-line, maintenance, and second-line settings for the treatment of nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This review aims to summarize the current knowledge and future prospects of the use of pemetrexed-platinum as a backbone for combination with targeted therapies for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This randomized, phase II trial (n [ 143) investigated volasertib monotherapy or in combination with pemetrexed compared with pemetrexed monotherapy in patients with NSCLC whose disease had progressed after previous platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study we compared volasertib, volasertib with pemetrexed, and pemetrexed alone in patients with advanced NSCLC whose disease progressed after first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: For treatment in the second-line for advanced or metastatic NSCLC, the combination of volasertib with standard pemetrexed did not increase toxicity significantly but also did not improve efficacy compared with single-agent pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed is approved in the treatment of advanced stage nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with metastatic NSCLC received pemetrexed (with or without bevacizumab) for 12 months or longer, either as maintenance treatment after first-line platinum-based chemotherapy or as subsequent treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Among patients with NSCLC who received pemetrexed for an extended time, those with ALK and ROS1 gene rearrangements were proportionally overrepresented compared with that anticipated in a general nonsquamous NSCLC population, and patients with oncogenic driver mutations had improved outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Furthermore, a phase III randomized study demonstrated the superiority of crizotinib to standard chemotherapy (pemetrexed or docetaxel) in the treatment of NSCLC patients harboring the ALK rearrangement who had received one prior platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring wild-type epidermal growth factor receptor (EGFR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Maintenance therapy is a new treatment strategy for advanced non-small-cell lung cancer(NSCLC), and it consists of switch maintenance and continuation maintenance.Switch maintenance is the introduction of a different drug, not included as part of the induction therapy, immediately after completion of 4 cycles of first-line platinum-based chemotherapy.Continuation maintenance is a continuation of at least one of the drugs used in the induction therapy in the absence of disease progression.Several phase III trials have reported survival benefits with continuation maintenance of pemetrexed and switch maintenance of pemetrexed or erlotinib.Therefore, maintenance therapy has become a part of the standard first-line treatment for advanced NSCLC.However, further research is needed to elucidate the selection criteria of patients who may benefit the most from maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed+erlotinib in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed+erlotinib treatment significantly improved PFS, OS and TTTF in 2nd line non-squamous NSCLC and was associated with an increase in grade 3/4 toxicities compared with pemetrexed alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: To evaluate the impact of histology on efficacy of pemetrexed in Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This report summarized the results of two clinical trials of pemetrexed in Chinese patients with advanced NSCLC in 2nd line setting and maintenance setting after 1st line (JMID study and Chinese subgroup from JMEN study) treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "For the global JMEN study (maintenance), patients initially diagnosed with IIIB or IV NSCLC, those who had not progressed after completing at least four cycles of platinum-based chemotherapy were enrolled to test for the superiority of pemetrexed (500 mg/m(2), day 1 of each 21-day cycle) over placebo with progression free survival (PFS) as primary endpoint. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Consistent with global results, in Chinese NSCLC patients, histology has an impact on the efficacy of pemetrexed, in which non-squamous histology predicts a positive outcome for patients treated with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Based on consistent Chinese data from the two studies, pemetrexed is recommended as a standard chemotherapy regime in both second-line and maintenance setting after first-line treatment for Chinese non-squamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: MILES-3 and MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the first-line therapy of elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "faupe@libero.it  INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for NSCLC after failure with cisplatin-based doublets. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous NSCLC: AVAPERL (MO22089). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacizumab alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced NSCLC: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "From January 2007 to December 2010, 25 patients with stage IIIB or IV NSCLC (17 with adenocarcinoma and 8 with squamous cell carcinoma), who had previously failed on platinum-based chemotherapy, received pemetrexed 500 mg/mq every 3 weeks until disease progression or unacceptable toxicities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "leedaeho@amc.seoul.kr  This study was designed to evaluate the efficacy of combination treatment of pemetrexed plus oxaliplatin as second-line treatment in advanced/metastatic NSCLC patients who have failed first-line platinum-based chemotherapy, assuming that oxaliplatin can overcome the resistance to a platinum agent and translate into better outcome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous NSCLC in Spain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Estimating a 30% reduction in acquisition costs for pemetrexed (Alimta\u00aeEli Lilly Nederland B.V.), due to the forthcoming launch of generic medications, the cis/pem treatment would become the predominant alternative for 1st line treatment of NSCLC patients, by offering the best health results at a lower cost. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Because histology information is not available in this database, we also conducted a subgroup analysis of EGFR testing among patients who were treated with bevacizumab or pemetrexed, who are likely to have non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous NSCLC: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced NSCLC (LUME-Lung 2): A randomized, double-blind, phase III trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVES: LUME-Lung 2 investigated the efficacy/safety of nintedanib plus pemetrexed in patients with pretreated non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Although recruitment stopped prematurely, combining nintedanib with pemetrexed significantly prolonged PFS in patients with advanced non-squamous NSCLC after first-line chemotherapy, with a manageable safety profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous NSCLC who are eligible for bevacizumab and maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We investigated whether red blood cell (RBC) total folate, a phenotypic rather than genotypic, marker of cellular folate status was associated with the response to pemetrexed-based chemotherapy in advanced nonsquamous NSCLC (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: We conducted a prospective cohort study of patients with stage IV nonsquamous NSCLC receiving first-line chemotherapy containing pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: A low pretreatment RBC total folate was associated with an inferior response to pemetrexed-based chemotherapy in stage IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In particular, in case of WT NSCLC with non-squamous histology, the use of platinum-based combinations including pemetrexed or bevacizumab became the standard treatment and the maintenance therapy with pemetrexed a further opportunity for selected patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " AIM: To assess the cost-effectiveness of first-line pemetrexed/platinum and other commonly administered regimens in a representative US elderly population with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed/platinum yielded either improved survival at increased cost or similar survival at reduced cost relative to comparator regimens in the treatment of advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "However, few studies have focused on cisplatin/pemetrexed with bevacizumab as the first-line therapy to treat advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: We speculate that bevacizumab in combination with cisplatin/pemetrexed as the first-line therapy is well tolerated and results in a clinically meaningful treatment benefit, irrespective of the gene drive type in advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous NSCLC: Outcomes according to Thymidylate Synthase Expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous NSCLC through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous NSCLC in elderly patients: TORG1015. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We conducted a feasibility study of pemetrexed plus bevacizumab as a first-line treatment for advanced or recurrent nonsquamous NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed plus bevacizumab in the treatment of elderly patients with nonsquamous NSCLC was well tolerated and shows promise as first-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed and bevacizumab are currently evaluated as two of the most reliable chemotherapeutic drugs for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with NSCLC and nonsquamous histologic features. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Erlotinib, bevacizumab, and pemetrexed improved survival of metastatic non-small cell lung cancer (mNSCLC) in clinical trials, but their benefits are restricted to non-squamous histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The aim of the present study was to retrospectively evaluate the feasibility of cisplatin/pemetrexed/bevacizumab (CPB) therapy at a bevacizumab (BEV) dose of 15 mg/kg as a first-line chemotherapeutic strategy for patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced NSCLC in real world setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced NSCLC Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  \u00a9AlphaMed Press. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Chemonaive patients (n = 939) with stage IIIB/IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomized (1:1) to pemetrexed-carboplatin-bevacizumab (pemetrexed arm) or paclitaxel-carboplatin-bevacizumab (paclitaxel arm). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The results of a phase III trial of crizotinib compared to platinum-pemetrexed in the first-line setting, and a phase I trial and expansion cohort of ceritinib, provided additional efficacy and toxicity data for patients with anaplastic lymphoma kinase rearranged NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by\u00a0Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous NSCLC (ns-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Our study aims to investigate whether the addition of Bev to pemetrexed improves progression-free survival (PFS) in advanced ns-NSCLC patients after the failure of at least one prior chemotherapy regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The combination of Bev and pemetrexed every 21 days is effective in ns-NSCLC patients who failed of prior therapies with improved PFS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Our results may provide more a regimen containing Bev and pemetrexed for Chinese clinical practice in previously treated ns-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In nonsquamous NSCLC, novel agents, such as pemetrexed and bevacizumab, have improved survival in the first-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-na\u00efve patients with stage IIIB/IV non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " We report a case of an elderly patient with non-squamous NSCLC who was successfully treated with chemotherapy using carboplatin(CBDCA), pemetrexed(PEM), and bevacizumab(Bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The availability of antineoplastic monoclonal antibodies, small molecules and newer cytotoxics such as pemetrexed, the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as the anti-angiogenic bevacizumab and the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous NSCLC with good performance status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: We hypothesized that the combination of bevacizumab, carboplatin, and pemetrexed will be an effective first-line regimen in fit, elderly patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: To observe the clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic NSCLC: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In first-line the combination of platinum plus pemetrexed with or without bevacizumab is a reasonable choice in patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous NSCLC) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Health-related quality of life in patients with advanced nonsquamous NSCLC receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: In the phase III AVAPERL trial, patients with advanced nonsquamous NSCLC receiving bevacizumab-plus-pemetrexed maintenance after first-line induction had a significant progression-free survival benefit relative to those treated with single-agent bevacizumab maintenance but with an increase in grade \u22653 adverse events. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous NSCLC in the US outpatient setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous NSCLC with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Effectiveness of specific agents was assessed at time periods immediately following the approval of the agent for NSCLC: baseline, 1988-1994; platinum, 1995-1999; docetaxel, 1999-2003; pemetrexed and bevacizumab, 2004-2005. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed is used for maintenance therapy for non-squamous NSCLC, whereas patients with squamous NSCLC lack easy options for maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "For patients with non-squamous NSCLC who respond or remain stable after four cycles of platinum-doublet chemotherapy, either continuation of pemetrexed (if included in the induction regimen) or switch to pemetrexed as maintenance has been shown to improve OS compared with observation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The standard treatment for squamous NSCLC remains a platinum doublet with a drug other than pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous NSCLC received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Methods In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced NSCLC, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Conclusions Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced NSCLC (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous NSCLC: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, we examined the drug interaction between pemetrexed and PPIs in hOAT3-expressing cultured cells, and retrospectively analyzed the impact of PPIs on the development of hematologic toxicity in 108 patients who received pemetrexed and carboplatin treatment of nonsquamous NSCLC for the first time between January 2011 and June 2015. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of platinum doublets, TKIs, pemetrexed and nivolumab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous NSCLC: The Central Japan Lung Study Group Trial 0906. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim of this phase II study was to evaluate the efficacy and safety of pemetrexed-carboplatin combination as first-line chemotherapy in advanced non-squamous NSCLC limited to EGFR-wild-type cases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The pemetrexed-carboplatin combination was effective and well-tolerated in patients with EGFR-wild-type non-squamous NSCLC (UMIN-CTR number: UMIN000003393). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous NSCLC: treating the right patients based on individualized treatment effect prediction. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, we developed and validated a prediction model for estimating absolute treatment effect of pemetrexed plus carboplatin versus single-agent pemetrexed in the second-line treatment of non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Using data of relapsed patients with advanced non-squamous NSCLC from the NVALT-7 trial, a Weibull model for prediction of gain in median progression-free survival (PFS) by pemetrexed-carboplatin was derived based on patient and tumor characteristics. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "There is important heterogeneity in the effects on PFS of pemetrexed-carboplatin versus pemetrexed in pretreated patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase I study recommended carboplatin (CBDCA, area under the curve\u00a0=\u00a05) plus pemetrexed (PEM, 500\u00a0mg/m(2)) for elderly patients (\u226575-years old) with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We identified English-language literature (through March\u00a02015) involving completed and ongoing studies through searches of PubMed, meeting abstracts, ClinicalTrials.gov and the European Clinical Trials Register; search terms included 'pemetrexed,' 'NSCLC' and 'PS2'. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In a phase\u00a03 study, chemonaive advanced NSCLC patients with PS2 receiving pemetrexed\u2011carboplatin versus pemetrexed experienced improved overall survival [hazard ratio\u00a0(HR)=0.62; P=0.001], progression-free survival (HR=0.46; P<0.001) and response (P=0.032). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed plus carboplatin therapy is widely administered to patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced NSCLC and performance status 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: A cost-effectiveness analysis was conducted based on a randomized phase III trial in patients with advanced NSCLC and ECOG performance status of 2 (PS2), comparing doublet regimen pemetrexed plus carboplatin with pemetrexed alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Our study suggests superiority of the combined pemetrexed plus carboplatin regimen in terms of efficacy as well as cost-effectiveness in advanced NSCLC patients with a poor performance status of 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Plasma samples from 40 patients with stage IV adeno-NSCLC, treated with first-line chemotherapy with carboplatin (AUC5) plus pemetrexed (500 mg/m(2)), were collected prior to chemotherapy and 48 h after treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Activity of pemetrexed-based regimen as first-line chemotherapy for advanced NSCLC with asymptomatic inoperable brain metastasis: a retrospective study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed and gemcitabine versus carboplatin and gemcitabine in NSCLC: a randomized noninferiority phase II study in one center. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed can replace platinum compounds in the first-line treatment of stage IIIb and IV NSCLC without increasing the side effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III NSCLC: a systematic review of completed and ongoing studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This literature search of concurrent pemetrexed and RT treatment of patients with stage III NSCLC included MEDLINE database, meeting abstracts, and the clinical trial registry database. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Of the ongoing trials, there is one phase III and four phase II trials with pemetrexed in locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "While results from the ongoing phase III PROCLAIM trial are needed to address definitively the efficacy of pemetrexed-cisplatin plus RT in stage III NSCLC, available results from phase II trials suggest that this regimen has promising activity with an acceptable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous NSCLC: Kumamoto thoracic oncology study group trial 1002. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVES: This study was designed to determine the recommended dose of carboplatin and pemetrexed for elderly (\u226570-year-old) chemotherapy-na\u00efve patients with advanced nonsquamous NSCLC and to investigate the pharmacokinetics of pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: For elderly chemotherapy-na\u00efve patients with advanced nonsquamous NSCLC, the combination of carboplatin AUC 5 plus pemetrexed 500 mg/m(2) is recommended as a promising regimen; however, a reduction of the pemetrexed dose may be required for patients with renal dysfunction because of the high risk of hematotoxicities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This phase 2 study investigated ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: The primary endpoint of significant prolongation of PFS was not met; however, ramucirumab showed evidence of clinical activity in combination with pemetrexed and platinum in nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Cost-Utility Analysis of First-Line Regimen Between Cisplatin Plus Pemetrexed and Carboplatin Plus Paclitaxel In Advanced Non-Squamous NSCLC in Thailand. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous NSCLC, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: This phase II study evaluated the response rate (RR) and safety of combination therapy with carboplatin (CBDCA) and pemetrexed (PEM) in Japanese patients with non-squamous NSCLC (non-sq NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-line chemotherapy efficacy in advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous NSCLC: a randomised, phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Clinical experience of the use of pemetrexed (PEM) combined with cisplatin (CDDP)/Carboplatin (CBDCA) followed by long-term maintenance PEM in patients with non-squamous NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous NSCLC that were treated in our hospital. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction is recommended as a first-line treatment for patients who have advanced non-squamous NSCLC and as a maintenance strategy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: The primary objective of this study was to evaluate the safety and tolerability of carboplatin plus pemetrexed for elderly patients (\u226575 years) with chemotherapy-na\u00efve advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: The combination of carboplatin at an area under the concentration-time curve of 5 plus pemetrexed at 500 mg/m(2) was determined as the recommended dose in chemotherapy-na\u00efve elderly patients (\u226575 years) with advanced non-squamous NSCLC, in view of overall safety and tolerability. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Acute cerebral arterial embolism following pemetrexed and carboplatin treatment in NSCLC: A case report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The combination of pemetrexed and carboplatin has exhibited significant antitumor activity, with mild manageable toxicity in patients with advanced non-small-cell lung cancer (NSCLC), whereas cerebral arterial embolism has not been recognized as a side effect associated with this regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed plus carboplatin is routinely used for the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 NSCLC harbouring EGFR mutations: a randomized, phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The current study aimed at investigating whether TS expression changes during non-pemetrexed chemotherapy of NSCLC, thus making rebiopsy necessary for deciding on pemetrexed second-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Associations between TS, TTF-1, FR-\u03b1, FPGS, and overall survival in patients with advanced NSCLC receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: Pemetrexed is effective in the treatment of NSCLC, mainly in nonsquamous cell carcinomas. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim was to investigate associations between these biomarkers and survival in patients who participated in a phase III trial comparing pemetrexed plus carboplatin with gemcitabine plus carboplatin as first-line chemotherapy in advanced NSCLC (n = 436). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed plus carboplatin (PC) had better chemotherapy compliance and efficiency in advanced non-squamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II trial of pemetrexed continuation--maintenance after carboplatin-based induction in untreated non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " AIM: We conducted a phase II study to evaluate the efficacy and safety of pemetrexed continuation-maintenance after carboplatin-based induction for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Thirty-four patients with advanced or recurrent non-squamous NSCLC received carboplatin (area under the concentration-time curve 6 mg/ml\u00d7min) plus pemetrexed (500 mg/m(2)) on day 1 tri-weekly. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The favorable risk-benefit profile of pemetrexed + carboplatin makes it an appropriate first-line treatment option for elderly patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed use in the adjuvant setting for completely resectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed, an antifolate, is currently indicated for first-line, maintenance, and second-line therapy for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "To date, more than 1000 patients with early stage NSCLC have been enrolled in adjuvant therapy studies evaluating various pemetrexed-containing treatment regimens, and additional patients are being enrolled in ongoing studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "hzsx888@163.com  OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC: a randomized, phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We evaluated the efficacy and safety of continuation maintenance with pemetrexed and switch maintenance with docetaxel in advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Continuation maintenance with pemetrexed may be a feasible treatment option for patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin and pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced NSCLC and Eastern Cooperative Oncology Group performance status of 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced NSCLC with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-na\u00efve patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: This study prospectively evaluated the efficacy and safety of pemetrexed and carboplatin followed by maintenance pemetrexed in chemo-na\u00efve patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed/carboplatin followed by pemetrexed was well tolerated and active for front-line treatment of advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced NSCLC: a phase II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The synergistic activity of pemetrexed with platinum agents in NSCLC and the renal safety of carboplatin suggest a balanced benefit/risk profile for this combination in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This multicenter, single-arm, phase II study included 62 patients (\u226570 years) with chemona\u00efve advanced NSCLC, Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and assigned to receive 6 cycles of 3-weekly pemetrexed 500 mg/m(2) and carboplatin AUC 5. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In advanced NSCLC, pemetrexed use is restricted to non-squamous histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The ORR is within the range of data reported for pemetrexed-carboplatin in the general NSCLC population (24-31%). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "wolfgang.schuette@martha-maria.de  BACKGROUND: Pemetrexed plus cisplatin was approved for first-line treatment of NSCLC in patients with nonsquamous histology after initiation of this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed, a multi-targeted antifolate enzyme inhibitor, was approved by the United States Food and Drug Administration as a first-line chemotherapy for advanced non-squamous NSCLC in 2007. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pharmacogenetic study of patients with advanced NSCLC treated with second-line pemetrexed or pemetrexed-carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "mtiseo@ao.pr.it  PURPOSE: To correlate candidate polymorphisms affecting pemetrexed and carboplatin activity with clinical outcome of patients with advanced NSCLC treated in second-line with pemetrexed or pemetrexed plus carboplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: MTHFR-C667T polymorphisms appear to predict survival differences in pemetrexed-treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II study of carboplatin and pemetrexed in advanced non-squamous, NSCLC: Kyoto Thoracic Oncology Research Group Trial 0902. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "ekim@kuhp.kyoto-u.ac.jp  BACKGROUND: Subgroup analyses of randomized studies have consistently shown that pemetrexed is exclusively effective in NSCLC other than squamous cell carcinoma and the combination of pemetrexed and platinum agents is recommended for first-line chemotherapy in advanced non-squamous NSCLC; however, there have been few prospective studies of a selected population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: This was a single-arm phase II study of carboplatin and pemetrexed in Japanese patients with chemo-naive advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: The combination of carboplatin and pemetrexed was safe and effective in advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Although the sample size was small, our results indicate that pemetrexed is a key drug for advanced non-squamous NSCLC, irrespective of the EGFR mutation status (UMIN-CTR number 000002451). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We report our experience with an upfront association of carboplatin and pemetrexed (areas under the curve, 5 and 500 mg/m(2), respectively), every 3 weeks, in 30 patients presenting with newly diagnosed brain metastases and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The upfront association of carboplatin plus pemetrexed allows simultaneous treatment of cerebral and systemic disease in patients with NSCLC with newly diagnosed brain metastases and appears to be particularly interesting in terms of radiologic response and overall survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced NSCLC in China. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed/cisplatin is the preferred chemotherapy in nonsquamous NSCLC, but the efficacy of this treatment for nonsquamous NSCLC with BM is uncertain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The findings of clinical trials and theoretical studies about the current pemetrexed/cisplatin in the treatment of nonsquamous NSCLC with BM are also summarized to provide a reference for the application of pemetrexed/cisplatin in nonsquamous NSCLC with BM. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Whether or not pemetrexed/cisplatin is definitely effective in nonsquamous NSCLC with BM must be proven by subsequent phase III clinical trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: In this open-label, phase II study, patients with stage IV nonsquamous NSCLC and a performance status of 0 to 1 were randomized (1:1) to receive 20 mg/kg cixutumumab, 500 mg/m(2) pemetrexed, and 75 mg/m(2) cisplatin (cixutumumab [n\u00a0= 87]) or pemetrexed and cisplatin (control [n\u00a0= 85]). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Efficacy was not improved in patients with nonsquamous NSCLC when cixutumumab was added to pemetrexed/cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The phase III PROCLAIM trial, recently published in the Journal of Clinical Oncology entitled \"PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous NSCLC\", compared two different chemotherapy regimens given concurrently with radiotherapy in patients with stage III non-squamous lung cancer: pemetrexed plus cisplatin versus cisplatin plus etoposide. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " AIM: PROCLAIM, a phase III trial of patients with nonsquamous NSCLC comparing concurrent pemetrexed-cisplatin and thoracic radiation therapy followed by consolidation pemetrexed, did not meet its primary endpoint of superior overall survival versus etoposide-cisplatin and thoracic radiation therapy followed by a consolidation platinum doublet of choice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: For East Asian patients, pemetrexed-cisplatin combined with thoracic radiation therapy, followed by consolidation pemetrexed, did not improve overall survival but did have a good safety profile with a trend for improved progression-free survival and objective response rate compared to standard chemoradiotherapy for stage III unresectable nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous NSCLC: cost minimization analysis in 12 European countries. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed and cisplatin are recommended in front-line chemotherapy of non-squamous NSCLC (NS-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Given the reported efficacy with both regimens, this pan-European economic analysis provides compelling evidence supporting oral vinorelbine use over pemetrexed for the treatment of NS-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed-based chemotherapy presented about 40% response rate on brain lesions of NSCLC with brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: This trial assessed the efficacy and safety of high-dose pemetrexed plus cisplatin in NSCLC with brain metastases after WBRT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "RESULTS: The NSCLC CDX expressed lung lineage markers TTF1 and CK7 and was unresponsive to cisplatin and pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "NSCLC accounts for approximately 85% of all lung cancers, with the current standard regimen of care for NSCLC including chemotherapy with pemetrexed as a single agent or in combination with platinum-based agents, e.g. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: NSCLC A549 and H460 cells were treated with pemetrexed for 72 h. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The present study describes the case of a 65-year-old female patient with stage IIA NSCLC who received cisplatin/pemetrexed treatment at the Leo W. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIA/B unresectable nonsquamous NSCLC randomly received (1:1) pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) intravenously every 3 weeks for three cycles plus concurrent TRT (60 to 66 Gy) followed by pemetrexed consolidation every 3 weeks for four cycles (arm A), or standard therapy with etoposide 50 mg/m(2) and cisplatin 50 mg/m(2) intravenously, every 4 weeks for two cycles plus concurrent TRT (60 to 66 Gy) followed by two cycles of consolidation platinum-based doublet chemotherapy (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed-cisplatin combined with TRT followed by consolidation pemetrexed was not superior to standard chemoradiotherapy for stage III unresectable nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous NSCLC: Quality of Life Results From a Randomized Phase III Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous NSCLC (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (TREAT study) was designed to test the hypothesis that a protocol with reduced toxicity might improve feasibility of postoperative delivery of adjuvant chemotherapy drugs to patients with NSCLC, thereby improving compliance and, potentially, survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous NSCLC: Final Overall Survival Results from a Randomized Phase 3 Study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous NSCLC and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Cost Distribution Analysis Related to the Use of Tyrisine-Kinase Inhibitors (Tki) and the Combination of Pemetrexed/Cisplatin in the Treatment of Non-Small Cell Lung Cancer (Nsclc) Locally Advanced or Metastatic in Presence of Epidermal Growth Factor Receptor (Egfr) Mutations in a Mexican Institutional Context. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous NSCLC: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Take-home message in times of crisis: Is it really better to treat with cisplatin & pemetrexed than cisplatin & gemcitabine in first line NSCLC? The power of statistical considerations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Since the data of pemetrexed in combination with cisplatin were published, several oncologists chose this schedule as first choice in non squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC in the United States. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVES: To determine the cost-effectiveness of tyrosine kinase inhibitors erlotinib or afatinib, or chemotherapy cisplatin-pemetrexed, for first-line treatment of advanced epithelial growth factor receptor mutation-positive NSCLC in the United States. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "For patients with non-squamous NSCLC, Pemetrexed plus Cisplatin is recommended in first-line systemic therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous NSCLC: A Biomarker-Stratified Randomized Phase II Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: We investigated whether thymidylate synthase (TS) expression is a predictive marker for the clinical outcome of pemetrexed/cisplatin in patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced NSCLC harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous NSCLC With Particular Regard to the KRAS Status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous NSCLC and wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Histology could represent a positive predictive factor for patients with Non squamous NSCLC (Nsq-NSCLC) respect to pemetrexed treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed in combination with cisplatin is approved in the first line setting and as monotherapy in the switch or continuous maintenance of Non Squamous A-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "These findings suggest that a single dose of dexamethasone 20\u2009mg may be an alternative premedication regimen in patients with metastatic NSCLC receiving pemetrexed or pemetrexed-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVES: This single-arm multicenter Phase II study investigated the efficacy and safety of pemetrexed (Pem) and cisplatin (Cis) induction chemotherapy (CT) followed by full-dose Pem-Cis plus concurrent radiotherapy (RT) in patients with locally advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for Japanese patients with advanced non-squamous NSCLC -- a retrospective analysis]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m/(2)) and pemetrexed (500 mg/m(2)) as a first-line treatment for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous NSCLC (INSPIRE): an open-label, randomised, controlled phase 3 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previously untreated, stage IV, non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "INTERPRETATION: Our findings show no evidence to suggest that the addition of necitumumab to pemetrexed and cisplatin increases survival of previously untreated patients with stage IV non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Compared with other platinum-based doublet chemotherapy, pemetrexed plus platinum is more effective and tolerable as the first-line treatment for nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Thus, we examined the feasibility of using thoracic radiotherapy combined with concurrent full-dose pemetrexed as the first-line treatment for advanced nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "From January 2009 to July 2012, 41 patients with stage IIIB or IV nonsquamous NSCLC were treated with full-dose pemetrexed plus cisplatin as the first-line chemotherapy combined with concurrent thoracic radiotherapy, with or without radiotherapy for metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "As the first-line treatment for selected patients with advanced nonsquamous NSCLC, thoracic radiotherapy combined with concurrent full-dose pemetrexed plus cisplatin was safe and highly tolerable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed (Alimta(\u00ae)) is a new-generation antifolate used to treat malignant pleural mesothelioma and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Adjuvant chemotherapy of NSCLC: Tolerance of combined cisplatin-pemetrexed therapy]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The study analyzed a cohort of non-squamous NSCLC patients treated in an adjuvant setting by combined cisplatin (75 mg/m(2)) and pemetrexed (500 mg/m(2)), under vitamin B12 and folic acid cover, 4 cycles at 21-day intervals. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: We report exploratory gene-expression profiling data from a single-arm Phase-II-study in patients with non-squamous (ns)NSCLC treated with pemetrexed and cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Treatment-na\u00efve nsNSCLC patients (IIIB/IV) received 4 cycles of pemetrexed/cisplatin; non-progressing patients continued on pemetrexed-maintenance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Best Supportive Care Immediately Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-Squamous NSCLC\") trial, patients with advanced nonsquamous NSCLC (NS-NSCLC) benefited from pemetrexed maintenance therapy after induction therapy with pemetrexed and cisplatin by extending survival, delaying disease progression, and maintaining quality of life (QoL). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: PARAMOUNT demonstrated a low incidence of low-grade toxicities with long-term pemetrexed exposure without compromising QoL in patients with NS-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND:: Pemetrexed is the preferred treatment of nonsquamous non-small cell lung cancer (ns-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS:: Retrospective analysis of all ns-NSCLC patients undergoing first-line treatment with pemetrexed-containing platinum doublet over 3\u00bd years was carried out. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Among ns-NSCLC patients treated with pemetrexed and with FAS of 400 to 1000 \u03bcg daily, HTox was not associated with either baseline tpHcy levels or with graded baseline FAS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous NSCLC following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The PARAMOUNT phase III trial compared maintenance pemetrexed versus placebo after patients with nonsquamous NSCLC completed 4 cycles of first-line pemetrexed-cisplatin without disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed, a folate antimetabolite, combined with cisplatin is used as a first-line therapy for malignant pleural mesothelioma (MPM) and locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non-squamous cell NSCLC in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: A previous study showed a survival benefit with maintenance therapy with pemetrexed in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Here, we present our phase II study that assessed the efficacy and safety of cisplatin plus pemetrexed as induction chemotherapy, followed by maintenance therapy with pemetrexed in advanced NSCLC patients in Japan. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Continuation maintenance chemotherapy with pemetrexed is associated with a survival benefit in patients who have completed induction chemotherapy for non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Between April 2009 and June 2011, 39 patients with advanced non-squamous NSCLC who had received second-line chemotherapy following first-line chemotherapy treatment with cisplatin and pemetrexed were analysed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Preclinical experiments analyzed NCI-H2122 and NCI-H441 NSCLC cell lines and in vitro/in vivo models treated with pemetrexed and LY2603618 to provide rationale for evaluating this combination in a clinical setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: The PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus cisplatin induction was well tolerated and effective for patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Erlotinib and pemetrexed have been approved for the second-line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVES: We performed a post hoc analysis of progression-free survival (PFS), overall survival (OS), and recurrent sites in patients with locally advanced nonsquamous NSCLC who were enrolled in a phase I trial of combination chemotherapy consisting of pemetrexed plus cisplatin with concurrent thoracic radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We report the observation of two patients suffering from NSCLC who developed acute kidney injury (AKI) after administration of pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We evaluated pCR rate of cisplatin with pemetrexed in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance significantly reduced the risk of disease progression (hazard ratio = 0.62) and death (hazard ratio = 0.78) versus placebo in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The combination of pazopanib/pemetrexed in first-line treatment of NSCLC showed some antitumor activity but had unacceptable levels of toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed (PEM), a multi-targeted antifolate, has promising clinical activity in non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Between April 2009 and June 2011, 50 patients with advanced non-squamous NSCLC treated with cisplatin and pemetrexed as first-line chemotherapy were analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed and cisplatin for advanced non-squamous NSCLC in Japanese patients: phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Although pemetrexed/cisplatin (P-C) is a standard treatment for advanced non-squamous NSCLC (Nsq-NSCLC), neither its efficacy nor the effects of potential differences between driver mutations, such as the anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) mutations, have been thoroughly examined. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The combination of pemetrexed and cisplatin was effective and safe in Japanese patients with Nsq-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous NSCLC received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexed-cisplatin induction therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "gerald.schmid-bindert@medma.uni-heidelberg.de  OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed, cisplatin, and cetuximab appeared efficacious and tolerable in advanced nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous NSCLC in a prospective blinded assessment phase II clinical trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "mnicolson@nhs.net  INTRODUCTION: In retrospective analyses of patients with nonsquamous NSCLC treated with pemetrexed, low thymidylate synthase (TS) expression is associated with better clinical outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Treatment-naive patients with nonsquamous NSCLC (stage IIIB/IV) had four cycles of first-line chemotherapy with pemetrexed/cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed is approved as a first-line treatment for advanced non-squamous NSCLC with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced NSCLC patients treated with pemetrexed-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The aim of this study was to evaluate the association between thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR) and reduced folate carrier (SLC19A1) gene polymorphisms and the treatment efficacy of pemetrexed-based chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Advanced NSCLC patients received pemetrexed and cisplatin every three weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The polymorphisms of the 5'-UTR of the TS gene and exon 6 (2522) C/T of the SLC19A1 gene predict the survival of advanced NSCLC patients treated with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Treatment of stage IIIb/IV NSCLC with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: In this cohort of patients treated for stage IV NSCLC, renal function falls below commonly used thresholds for cisplatin and for pemetrexed in fewer than a quarter of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed-based chemotherapy presented about 40 % response rate (RR) on brain lesions of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The combined treatment with pemetrexed-cisplatin and concurrent WBRT are effective in patients with NSCLC with newly diagnosed BM. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "francoise.mornex@chu-lyon.fr  PURPOSE: This is a phase I, escalating-dose trial targeting exclusively patients with NSCLC, investigating pemetrexed and fixed-dose cisplatin concurrently administered with high-dose radiotherapy (RT) after induction chemotherapy (CT). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND MATERIALS: Patients with unresected stage III NSCLC, planned V20 \u2264 35%, and FEV \u2265 1.3 L, were treated every 21 days for 2 cycles (pemetrexed 500 mg/m2; cisplatin 75 mg/m2), followed by 2 cycles of concurrent CT-RT: pemetrexed starting dose was 400 mg/m2, escalated up to 800 mg/m2 per 100mg/m2 dose level (DL), cisplatin at 75 mg/m2 and RT at fixed dose of 66 Gy/33 fractions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: This phase I report of pemetrexed is dedicated to NSCLC with induction therapy and fixed high-dose RT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous NSCLC: estimates from the perspective of the Chinese health care system. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Continuation maintenance treatment with pemetrexed is approved by current clinical guidelines as a category 2A recommendation after induction therapy with cisplatin and pemetrexed chemotherapy (CP strategy) for patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "OBJECTIVE: We completed a trial-based assessment, from the perspective of the Chinese health care system, of the cost-effectiveness of maintenance pemetrexed treatment after a CP strategy for patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "It was based on a clinical trial that compared continuation maintenance pemetrexed therapy plus best supportive care (BSC) versus placebo plus BSC after a CP strategy for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Continuation maintenance of pemetrexed after a CP strategy for patients with advanced nonsquamous NSCLC is not cost-effective based on a recent clinical trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The switch maintenance strategy with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor erlotinib (in all the histologies) or with pemetrexed (in non-squamous histologies) have been demonstrated to be two possible effective options versus the classic break from cytotoxic chemotherapy after a fixed course in the treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Toxic epidermal necrolysis after pemetrexed and cisplatin for NSCLC in a patient with sharp syndrome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "cornelia.then@med.uni-muenchen.de  BACKGROUND: Pemetrexed is an antifolate drug approved for maintenance and second-line therapy, and, in combination with cisplatin, for first-line treatment of advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: The aim of this study was to examine the effect of hydration with magnesium and mannitol without furosemide on the nephrotoxocity accompanying combination chemotherapy using cisplatin and pemetrexed in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Fifty patients with NSCLC who received cisplatin plus pemetrexed, using either old hydration protocol including normal saline with mannitol and furosemide, or a new one including normal saline with magnesium and mannitol without furosemide were retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Univariate and multivariate analyses were performed to identify the independent factors associated with protection against nephrotoxicity in patients with NSCLC who received cisplatin plus pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The new hydration protocol with supplemented magnesium with mannitol without furosemide was an independent factor for the protection against nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced NSCLC [HR 0.232 (95% CI: 0.055-0.986), P=0.039]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in NSCLC and mesothelioma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Previous studies have demonstrated that pemetrexed combined with platinum had promising efficacy and safety profile in NSCLC, especially in patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: The both regimens have similar efficacy as the treatment for advanced nonsquamous NSCLC, but pemetrexed plus cisplatin regimen has better safety profile and seems to have longer PFS, which makes it a new option as the first line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "cgridelli@libero.it  INTRODUCTION: In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: After four 21-day cycles of pemetrexed-cisplatin (N = 939), patients with advanced nonsquamous NSCLC, whose disease had not progressed and who had a performance status of 0/1, were randomized 2:1 (N = 539) to maintenance pemetrexed 500 mg/m plus best supportive care or placebo plus best supportive care every 21 days until disease progression or unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: To the best of our knowledge, this is the third case of TEN due to pemetrexed in a patient with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: This multicenter, randomized, phase 2 study compared continuation maintenance therapy with pemetrexed (500\u2009mg/m2 every 21\u2009days) and best supportive care (BSC) versus BSC alone in patients with advanced, non-squamous NSCLC who had not progressed after 4\u2009cycles of induction chemotherapy with pemetrexed (500\u2009mg/m2) and cisplatin (75\u2009mg/m2). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Continuation pemetrexed maintenance therapy resulted in promising PFS with an acceptable safety profile in a Middle Eastern population with advanced non-squamous NSCLC and is worthy of further investigation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed plus platinum or gemcitabine plus platinum for advanced NSCLC: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND AND OBJECTIVE: Pemetrexed plus platinum has shown efficacy as a first-line treatment for advanced NSCLC, but little is known about its efficacy and safety in East Asian patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "An additional meta-analysis was performed to systematically evaluate pemetrexed/platinum as first-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Meta-analysis supports the use of pemetrexed-platinum as first-line treatment for female patients and those with the non-squamous cell subtype of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We determined the recommended dose (RD) of thoracic radiotherapy (TRT) with a concurrent chemotherapy combination of pemetrexed and cisplatin in Japanese patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Expected toxicities from concurrent chemoradiation were not worsened with concurrent TRT at a total dose of 66 Gy combined with pemetrexed in Japanese patients with locally advanced (LA) nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including NSCLC, colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed-induced cellulitis: a rare toxicity in NSCLC treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "skatsenos@yahoo.gr  Pemetrexed is indicated for locally advanced or metastatic non-squamous NSCLC as an initial treatment in combination with cisplatin or after prior chemotherapy as a single agent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Herein, we report a patient with advanced NSCLC who experienced bilateral peripheral edema after pemetrexed administration. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous NSCLC (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Patients with advanced non-squamous NSCLC benefit from pemetrexed maintenance therapy after induction therapy with a platinum-containing, non-pemetrexed doublet. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "INTERPRETATION: Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This trial was designed to evaluate the safety and efficacy of first-line enzastaurin plus cisplatin-pemetrexed in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Enzastaurin and cisplatin-pemetrexed is tolerable with preliminary activity in patients with advanced NSCLC, but because of a lack of efficacy improvement in other phase II NSCLC studies, the study was terminated early. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The objective of these analyses was to evaluate the survival and safety of treatment with pemetrexed in elderly patients with nonsquamous NSCLC and PS 0-1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: For elderly patients with nonsquamous advanced NSCLC and PS 0-1, pemetrexed therapy, with its favorable toxicity profile, is a viable option, either in combination with cisplatin in the first-line setting or as maintenance therapy after initial chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced NSCLC: a combined analysis of three phase 3 trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "treatjo@lilly.com  INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Our objectives were to determine the maximum tolerated dose and recommended dose of pemetrexed in combination with cisplatin, with concurrent late course accelerated hyperfractionated (LCAF) intensity modulated radiotherapy (IMRT) in patients with LANSCLC and to investigate the safety and efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: The combination of pemetrexed and cisplatin with concurrent LCAF IMRT optimized based on single photon emission photography lung perfusion imaging is well tolerated in patients with LANSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Of the 42 patients with NSCLC treated with trametinib plus pemetrexed, six (14%) had a PR; the ORR was 17% (four of 23) in patients with KRAS-mutated NSCLC versus 11% (two of 19) in KRAS wild-type NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Clinical activity exceeding the ORRs previously reported with docetaxel or pemetrexed alone in KRAS-mutated NSCLC and meeting prespecified criteria was observed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Docetaxel or pemetrexed is the standard treatment for recurrent advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Among Chinese patients receiving platinum-based doublets in the first-line setting for AdvNS-NSCLC, the higher acquisition costs for nonplatinum cytotoxic drugs associated with pemetrexed-platinum could be partially offset by its significantly lower hospital costs for nonchemotherapy drugs and nondrug care. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at second- or third-line therapy was retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Clinical and biological significance of erlotinib therapy after pemetrexed in NSCLC with wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed is a\u00a0multi-targeted anti-folate agent that confers favorable benefits to patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "However, the optimal use including treatment schedule of pemetrexed and other drugs in clinical practice remains to be determined, particularly for NSCLC with wild-type epidermal growth factor receptor (EGFR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The present study investigated a\u00a0potential therapeutic strategy for NSCLC patients with wild-type EGFR who were treated with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The cell growth assay confirmed that treatment with pemetrexed followed by erlotinib significantly inhibited proliferation of NSCLC cells regardless of EGFR mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In conclusion, use of erlotinib at the time of progression after pemetrexed therapy confers a\u00a0survival benefit in NSCLC patients with wild-type EGFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim was to conduct a meta-analysis to compare the efficacy and safety of docetaxel and pemetrexed or docetaxel and vinca alkaloid for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The objective of this study was to evaluate the association between polymorphisms of TS and MHFR genes and clinical outcomes in NSCLC patients treated with pemetrexed monotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "DNA was isolated from peripheral blood of 72 non-squamous NSCLC patients treated with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Prognostic factors in NSCLC patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: Docetaxel or pemetrexed monotherapy is recommended either as a second-line treatment for NSCLC patients without EGFR mutation or ALK fusion genes or as a third-line treatment for patients with EGFR mutation or ALK fusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: When planning clinical studies of NSCLC patients recommended to receive docetaxel or pemetrexed as single-agent chemotherapy, the EGFR status and stage before first-line treatment should be considered as stratification factors of randomized clinical studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: Second-line chemotherapy of advanced NSCLC with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND AND OBJECTIVE: This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for advNS-NSCLC in four Chinese hospitals from 2007 to 2012. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed singlet cost significantly less for supportive care than pemetrexed or docetaxel-based doublets when treating Chinese patients with AdvNS-NSCLC in the second-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: The main objective of the current post hoc analysis was to compare patient-reported outcomes between crizotinib (N = 172) and chemotherapy subgroups (pemetrexed [N = 99] and docetaxel [N = 72]) in previously treated patients with advanced ALK-positive NSCLC, in PROFILE 1007 study (Pfizer; NCT0093283). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Previously reported superior tumor response of pemetrexed in the second-line setting for advanced non-squamous NSCLC (advNS-NSCLC) has never been confirmed in real-world studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: A retrospective cohort study was conducted including patients receiving pemetrexed or docetaxel-based chemotherapy in the second-line setting for advNS-NSCLC in four Chinese tertiary care hospitals. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed was associated with significantly postponed tumor progression and significantly less hematological toxicity than docetaxel in the real-world second-line setting for advNS-NSCLC in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Over the past decade, well tolerated second-line therapies for advanced NSCLC have been approved including erlotinib and pemetrexed in addition to docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: The efficacy of docetaxel, vinorelbine, or gemcitabine monotherapy in previously untreated elderly patients with NSCLC has been reported.Pemetrexed monotherapy has shown clinically equivalent efficacy to docetaxel, a standard therapeutic option, in patients with previously treated NSCLC and in those with a lower incidence of toxicity such as febrile neutropenia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: Two standard single-agent chemotherapy treatments (docetaxel and pemetrexed) were combined in this trial and administered as second-line treatment in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: We recommend that docetaxel or pemetrexed monotherapies should continue to be considered the standard second-line chemotherapy treatment against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced NSCLC: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Our aim was to conduct a meta-analysis to compare the efficacy and safety of pemetrexed and docetaxel for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: We systematically searched the Cochrane Library, PubMed, Embase, China Biology Medicine Database for randomized controlled trials (RCTs) comparing the efficacy and toxicities of pemetrexed versus docetaxel as a treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed was almost as effective as docetaxel in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A meta-analysis of pemetrexed-based doublet compared with pemetrexed alone for the second-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: This meta-analysis investigated pemetrexed-based doublet compared with pemetrexed alone as second-line therapy for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Randomized controlled trials which compared pemetrexed-based doublet with single-agent pemetrexed in patients as second-line treatment of advanced NSCLC were searched. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: This is the first meta-analysis to compare pemetrexed-based doublet with single-agent pemetrexed in second-line therapy of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Our meta-analysis suggested that pemetrexed combination chemotherapy was not superior to single-agent arm and was not recommended as the second-line chemotherapy for patients with NSCLC (Tab. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced NSCLC: a meta-analysis of 14 randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVES: To compare the effects of adding targeted agents to standard second-line chemotherapy with a single agent (pemetrexed or docetaxel) in patients with advanced NSCLC, a meta-analysis of all relevant randomized controlled trials was performed and overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were assessed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous NSCLC in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: The efficacy of pemetrexed in the second-line treatment of Chinese patients with advanced NSCLC has been shown to be similar to that of docetaxel in a recent study; additionally, pemetrexed was associated with much better safety and toxicity profiles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: A total of 154 patients with nonsquamous NSCLC received either pemetrexed (500 mg/m(2) intravenously (IV)) or docetaxel (75 mg/m(2) IV) on day 1 of 21-day cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Chinese patients with nonsquamous NSCLC disease treated with pemetrexed had improved SWT beyond 6 months than those receiving docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This analysis supports a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of Chinese nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive NSCLC after platinum-based therapy: a phase 3, open-label, randomised trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II study of pemetrexed as first-line treatment in elderly (\u226575) non-squamous NSCLC: Kyoto Thoracic Oncology Research Group Trial 0901. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: This was a single-arm phase II study of pemetrexed in elderly (\u226575) Japanese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Although this study did not meet our primary endpoint, pemetrexed showed favorable antitumor activity with mild toxicity in elderly patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "mmajem@santpau.cat  Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced NSCLC patients with disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic NSCLC: a randomized, open-label study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "suny@cae.cn  INTRODUCTION: This randomized, open-label study compared pemetrexed versus docetaxel as second-line therapy for Chinese patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The comparable efficacy and superior tolerability of pemetrexed compared with docetaxel in this study supports the use of single-agent, second-line pemetrexed for advanced non-squamous NSCLC in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "faupe@libero.it  The only approved agents for second-line therapy in unselected NSCLC are docetaxel and pemetrexed (chemotherapies) and erlotinib (targeted therapies). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Currently only three second-line NSCLC pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed versus docetaxel in second line NSCLC: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "viserlee@gmail.com  BACKGROUND: Pemetrexed and docetaxel are established therapies in second line NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS AND PATIENTS: We designed and performed a multi-center, randomized, exploratory clinical trial of pemetrexed compared with docetaxel in second line chemotherapy in Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Eligible patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks, were randomized to receive either pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone, or docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The efficacy of pemetrexed was equivalent to that of docetaxel in the second-line treatment for Chinese NSCLC (ORR: pemetrexed vs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Treatment with pemetrexed resulted in equivalent efficacy outcomes and better safety profiles compared with docetaxel in second-line therapy for advanced NSCLC in Chinese lung cancer population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of NSCLC, but no head-to-head data from large clinical trials are available. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pharmacodynamic separation of pemetrexed and erlotinib avoids negative cellular interactions and results in antitumor synergy in erlotinib-resistant NSCLC cells, independent of EGFR (epidermal growth factor receptor) genotype. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with platinum-treated metastatic nonsquamous NSCLC were randomly assigned 1:2 to pemetrexed alone (500 mg/m(2) provided intravenously on day 1) or pemetrexed followed by erlotinib (150 mg provided orally once daily on days 2-17) every 21 days. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: In patients with unselected or EGFR wild-type advanced nonsquamous NSCLC, pharmacodynamic separation of pemetrexed and intercalated erlotinib had promising antitumor activity without new safety concerns. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed and erlotinib represent different agents commonly used for the second-line treatment of patients with advanced-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: We analyzed data of 137 patients with advanced-stage non-squamous NSCLC treated with pemetrexed or erlotinib in the second line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced NSCLC: an updated meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed is currently recommended as the second-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In addition, subgroup analyses indicated that improved OS was only observed in nonsquamous NSCLC patients who received the combination of pemetrexed and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Among patients with advanced NSCLC, pemetrexed-based doublet treatment tended to be associated with improved PFS, ORR, and increased toxicity, but not OS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous NSCLC: Exploratory Subgroup Analysis of a Phase II Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: Never-smoker patients (n=240) with locally advanced or metastatic nonsquamous NSCLC included 133 EA patients randomized to pemetrexed supplemented with dexamethasone, folic acid, and vitamin B12 plus erlotinib (pemetrexed-erlotinib) (n=41), erlotinib (n=49), or pemetrexed (n=43), and 107 non-EA patients randomized to pemetrexed-erlotinib (n=37), erlotinib (n=33), or pemetrexed (n=37). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, NSCLC patients without an EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: This was a phase II study of pemetrexed and erlotinib in patients with pretreated advanced non-squamous NSCLC with wild-type epidermal growth factor receptor (EGFR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV NSCLC who had treatment with TKI. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The outstanding results of the JMEN study proved that maintenance of pemetrexed significantly improved the overall survival (OS) in advanced NSCLC patients was a proof of principle. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous NSCLC with documentation of epidermal growth factor receptor mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: We could not demonstrate the add-on effect of intermittent erlotinib on pemetrexed in a second-line setting for patients with non-squamous NSCLC without EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "fiala.o@centrum.cz  BACKGROUND: Pemetrexed and erlotinib represent novel agents for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: This randomised controlled phase 2 study compared pemetrexed and erlotinib in combination with either agent alone in terms of efficacy and safety as second-line treatment in a clinically selected population of never-smokers with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed versus erlotinib in pretreated patients with advanced NSCLC: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line treatment were randomized to receive either pemetrexed or erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Both pemetrexed and erlotinib had comparable efficacy in pre-treated patients with metastatic NSCLC, and the current results indicated that genotyping of tumor cells may have an important effect on treatment efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Erlotinib versus pemetrexed for pretreated non-squamous NSCLC patients in clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We present a retrospective single-center series of advanced non-squamous NSCLC patients treated with erlotinib or pemetrexed as second-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Patients with EGFR-mutant stage IIIB or IV NSCLC that progressed during gefitinib or erlotinib therapy were administered pemetrexed with the continuation of EGFR-TKI treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced NSCLC: a phase I dose-finding study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Erlotinib and pemetrexed have been approved for the second-line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Combination chemotherapy of intermittent erlotinib with pemetrexed was well-tolerated, with promising efficacy against pretreated advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This paper aims to systematically review the evidence from all available clinical trials of erlotinib and pemetrexed as maintenance therapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: There is evidence to suggest that maintenance treatment with erlotinib or pemetrexed has clinically relevant and statistically significant advantages over treatment with placebo or observation in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Currently, erlotinib and pemetrexed are registered as maintenance treatment in patients with NSCLC not progressing after four cycles of standard platinum-based doublet chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "marknuijten@planet.nl  Erlotinib and pemetrexed were approved by the European Medicines Agency for first-line maintenance treatment of patients with locally advanced or metastatic NSCLC to prolong overall survival after first-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We conducted a cost-comparison analysis of erlotinib versus pemetrexed in first-line maintenance treatment of locally advanced or metastatic, non-squamous NSCLC in France, Germany, Italy and Spain, performed from the perspective of national health-care decision-makers or purchasers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We investigated the activity and tolerability of the novel combination of dose-dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: This multicenter phase II trial evaluated the safety and efficacy of the combination of pemetrexed (400 mg/m(2)), gemcitabine (1200 mg/m(2)), and bevacizumab (10\u00a0mg/kg), given every 14 days in patients with untreated, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Treatment with dose-dense pemetrexed, gemcitabine, and bevacizumab met the primary endpoint with promising efficacy and a manageable safety profile in patients with untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In the present study, the in vitro antitumor effects and correlated molecular mechanisms of sorafenib combined with gemcitabine or pemetrexed were explored in the K-ras mutation-positive NSCLC A549 cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this regard, we have synthesized Pem-PEG-Gem, wherein pemetrexed (Pem) and gemcitabine (Gem) are conjugated to a heterobifunctional polyethylene glycol (PEG) polymer for the effective treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with NSCLC and prior interstitial lung disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This study was conducted to elucidate the safety and efficacy of palliative chemotherapy with gemcitabine or pemetrexed, both in combination with a platinum agent in NSCLC patients with ILD. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with advanced or recurrent NSCLC and ILD who received gemcitabine or pemetrexed in combination with a platinum agent as first-line chemotherapy were retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Our results suggest that gemcitabine or pemetrexed in combination with platinum agents could be a feasible option for advanced NSCLC with ILD with some risk of AE-ILD or early death. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Even if most meta-analyses in NSCLC yielded contradictory results, a number of candidate biomarkers for response/resistance to conventional chemotherapeutic agents such as gemcitabine, platinum-compounds, pemetrexed and taxanes have been proposed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Even if most studies in NSCLC yielded contradictory results, several potential biomarkers for sensitivity/resistance to platinum compounds, gemcitabine, taxanes and pemetrexed have been proposed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Based on preclinical demonstration of additive cytotoxicity, we evaluated the safety and efficacy of combining pemetrexed and nanoparticle albumin bound (nab) paclitaxel with a focus on NSCLC for phase II expansion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The phase II portion accrued 37 pts before early closure due to increasing first-line pemetrexed/platinum doublet use in non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B12 and Folate Supplementation in Nonsquamous, NSCLC Patients Undergoing First-line Pemetrexed-based Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed is the preferred chemotherapeutic drug for nonsquamous, NSCLC patients whenever the predictive molecular biomarkers for targeted therapy have either not been assessed or are absent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Hence, an open-label, randomized trial (PEMVITASTART [Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy]; ClinicalTrials.gov identifier, NCT02679443) is being undertaken to evaluate whether any differences exist in pemetrexed-related hematologic toxicity among patients who receive delayed initiation of chemotherapy (after 5-7 days of vitamin B12 and FA supplementation [delayed arm]) compared with those for whom vitamin B12 and FA supplementation is started simultaneously (within 24 hours) of chemotherapy initiation (immediate arm). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The dermatitis began 3 weeks after receiving an initial infusion of pemetrexed (500 mg/m(2)) as induction chemotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A folylpoly-\u03b3-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVES: In this study, we investigated whether single nucleotide polymorphisms (SNPs) in folylpoly-\u03b3-glutamate synthase (FPGS), which catalyzes the polyglutamation of pemetrexed (PEM), is related to FPGS expression and the response to PEM in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: This study was designed to investigate potential molecules that predict chemosensitivity to pemetrexed (Alimta\u00ae) in surgically resected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Unconvincing Benefit of Combination Therapy With Gefitinib and Pemetrexed in Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous NSCLC With Activating Epidermal Growth Factor Receptor Mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Effectiveness and safety of pemetrexed for NSCLC in the Andalusian Public Health System. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic NSCLC when it\u00b4s used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Adult patients with locally advanced/metastatic NSCLC who received pemetrexed in any hospital in the Andalusian Public Health System during the last term of 2011 were included. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed resulted quite effective in NSCLC when it was used on real clinical practice, with higher survival in non-squamous histology and patients with the best score of Eastern Cooperative Oncology Group scale. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  The role of thymidylate synthase in NSCLC treated with pemetrexed continuation maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed continuation maintenance therapy has been proven to be beneficial for patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This study sought to evaluate thymidylate synthase (TS) as a predicting biomarker for pemetrexed continuation maintenance treatment in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Our results indicate that in NSCLC patients treated with pemetrexed continuation maintenance therapy, low TS expression is associated with improved PFS and OS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Radiosensitization of NSCLC cells and xenografts by the interactive effects of pemetrexed and methoxyamine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Addition of methoxyamine to pemetrexed and fractionated radiotherapy may improve outcome for patients with locally advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed, a multitargeted antifolate agent, has demonstrated clinical activity in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Combination of pemetrexed and astaxanthin resulted in synergistic enhancing cytotoxicity and cell growth inhibition in NSCLC cells, accompanied with reduced activation of phospho-MKK1/2, phopho-ERK1/2, and TS expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Our findings suggested that the down-regulation of MKK1/2-ERK1/2-mediated TS expression by astaxanthin is an important regulator of enhancing the pemetrexed-induced cytotoxicity in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Patients with ROS1 rearrangement-positive NSCLC benefit from pemetrexed-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We investigated pemetrexed-based treatment efficacy in ROS1 translocation NSCLC patients and determined the expression of thymidylate synthetase (TS) to provide a rationale for the efficacy results. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "For comparison, we evaluated the TS mRNA status and pemetrexed-based treatment efficacy from 170 NSCLC patients with anaplastic lymphoma kinase (ALK) translocation (n\u00a0=\u00a046), EGFR mutation (n\u00a0=\u00a050), KRAS mutation (n\u00a0=\u00a032), and wild-type of EGFR/ALK/ROS1/KRAS (n\u00a0=\u00a042). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This study aimed to investigate the efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative radiotherapy (SABR) for oligoprogressive disease during maintenance pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "[Epub ahead of print]  Early detection of pemetrexed-induced inhibition of thymidylate synthase in NSCLC with FLT-PET imaging. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Next, using a mouse model of NSCLC, we validated the kinetics of the pemetrexed-mediated \"flare\" in thymidine salvage pathway activity in vivo using FLT-PET imaging. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In NSCLC cells in vitro, we identified a burst in pemetrexed-mediated thymidine salvage pathway activity, assessed by 3H-thymidine assays, thymidine kinase 1 (TK1) expression, and equilibrative nucleoside transporter 1 (ENT1) mobilization to the cell membrane, that peaked at 2hrs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This 2hr time-point was also optimal for FLT-PET imaging of pemetrexed-mediated TS inhibition in murine xenograft tumors and was demonstrated to be feasible in a NSCLC patient. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "It has been reported that ROS1-tranlslocated NSCLCs may also respond well to Pemetrexed-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Noninvasive monitoring of the genetic evolution of EGFR-mutant NSCLC by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: NSCLC A549 cells were treated with 1\u00a0\u00b5M pemetrexed for 72\u00a0h. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Increased risk of severe infections in NSCLC patients treated with pemetrexed: a meta-analysis of randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This meta-analysis assessed the overall incidence and risk of severe infections (\u2265 grade 3) associated with the use of pemetrexed in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Eligible studies included randomized controlled trials (RCTs) of pemetrexed for NSCLC patients that reported grade 3-5 infection and febrile neutropenia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The use of pemetrexed was associated with an increased risk of developing severe infections and febrile neutropenia in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous NSCLC With Activating Epidermal Growth Factor Receptor Mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: To determine whether the addition of pemetrexed to gefitinib (P+G) provides clinical benefit, compared with gefitinib monotherapy, in patients with advanced nonsquamous (NS) NSCLC and activating epidermal growth factor receptor (EGFR) mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve for advanced NSCLC patients from China, Japan, Korea, and Taiwan (35 sites) with advanced, EGFR-mutant, NS NSCLC were randomly assigned (2:1; computer-generated, interactive voice response) to open-label pemetrexed (500 mg/m(2) on day 1 of every 21-day cycle) plus gefitinib (250 mg/d [n = 129]) or gefitinib alone (n = 66). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed is widely used for the treatment of advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: We compared the clinical and molecule pathological characteristics of good and poor responders among a cohort of 1,848 non-squamous NSCLC patients who had received at least two cycles of pemetrexed therapy between November 2006 and February 2015. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Predictive factors, such as smoking status, the status of genetic alteration and tumor burden, should be considered when administering pemetrexed therapy for non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: The efficacy of pemetrexed-based first-line chemotherapy in anaplastic lymphoma kinase (ALK)-positive NSCLC has been demonstrated in several studies; however, there is a lack of data from Chinese populations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: The clinicopathological characteristics and treatment outcomes of 52 patients with ALK-positive advanced NSCLC who received pemetrexed as first-line chemotherapy at the Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences were retrospectively reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed is efficient and tolerated as first-line treatment for ALK-positive NSCLC in a cohort of Chinese patients and may prove to be an alternative option for the treatment of ALK-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This phase II trial assessed the overall response rate, safety, and pharmacokinetics (PK) of LY2603618 and pemetrexed in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Methods In this open-label, single-arm trial, patients with advanced or metastatic NSCLC progressing after a prior first-line treatment regimen (not containing pemetrexed) and Eastern Cooperative Oncology Group performance status \u22642 received pemetrexed (500\u00a0mg/m(2), day 1) and LY2603618 (150\u00a0mg/m(2), day 2) every 21\u00a0days until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Conclusions There was no significant clinical activity of LY2603618 and pemetrexed combination therapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: Pemetrexed (PEM) is an anticancer agent used for the treatment of NSCLC, malignant pleural mesothelioma and thymoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed is an approved antimetabolite agent, now widely used for treating locally advanced or metastatic nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed for advanced stage nonsquamous NSCLC: latest evidence about its extended use and outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "During the last decade, pemetrexed, an antifolate agent, gradually became a key component of the treatment for patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Currently, more than 400 trials of pemetrexed for the treatment of nonsquamous NSCLC are ongoing. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed plus platinum has become a standard of care in first-line treatment for patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed/platinum had good efficacy and also resulted in better overall response and tolerability than other platinum-based doublets as first-line treatment in nonsquamous NSCLC in elderly East Asians, which was consistent with data observed in all-age East Asians. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed monotherapy has come to be recognized as the standard of care for second-line therapy of non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Thymidylate synthase (TS) expression is recognized as a potential predictor of the response to pemetrexed-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: The records of non-squamous NSCLC patients without driver mutations who received pemetrexed monotherapy as a second or later line of chemotherapy at Kitasato University Hospital between March 2009 and October 2015 were retrospectively reviewed, and the treatment outcomes were evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The clinical data obtained in this study may provide a valuable basis for the use of smoking status as a predictor of pemetrexed monotherapy in wild-type NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed is an antifolate chemotherapeutic indicated for NSCLC, yet its hepatobiliary elimination pathway has yet to be determined. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced NSCLC Harboring EGFR Mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " To evaluate the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in advanced EGFR-mutated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed-containing chemotherapy has shown promise in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "However, although adenosquamous cell lung cancer (ASCLC) is a type of NSCLC, the availability of studies investigating its response to pemetrexed-containing chemotherapy is limited. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: To assess the efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous NSCLC through a trial-level meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "RESULTS: A total of 2,551 patients with advanced nonsquamous NSCLC from ten trials were included for analysis: 1,565 patients were treated with pemetrexed plus platinum doublet chemotherapy and 986 with platinum plus other first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "When compared to other platinum-based doublet chemotherapies, the use of pemetrexed plus platinum chemotherapy significantly improved OS (hazard ratio [HR] =0.86, 95% CI: 0.77-0.97, P=0.01) but not PFS (HR =0.90, 95% CI: 0.80-1.01, P=0.084) in advanced nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed plus platinum doublet regimen is an efficacious treatment for advanced nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Our findings support the use of pemetrexed plus platinum doublet regimen as first-line treatment in advanced nonsquamous NSCLC patients because of its potential survival benefits. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: The effect of different combinatorial schedules of gefitinib and pemetrexed on cell proliferation, cell cycle, apoptosis, and acquisition of gefitinib resistance in PC9 and HCC827 NSCLC cell lines and in PC9 xenograft models was investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed (PMX) is an antifolate drug utilized in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "For the 50% of patients with EGFR-mutated NSCLC who progress on EGFR-tyrosine kinase inhibitors (without evidence of a T790M mutations) as well as platinum doublets and pemetrexed/taxane, no other clinically established treatment options exist. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed and cyclophosphamide combination therapy for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This study was undertaken to investigate the efficacy and safety of adding regulatory T cell inhibitor cyclophosphamide to pemetrexed therapy for the second-line treatment of NSCLC with wild-type epidermal growth factor receptor (EGFR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The present study showed that pemetrexed in combination with low-dose cyclophosphamide may be a better treatment approach than pemetrexed monotherapy when considering second-line treatment for wild-type EGFR NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with NSCLC undergoing pemetrexed therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We conducted a Phase II study to evaluate the safety of oral administration of vitamin B12 in patients with advanced NSCLC who received pemetrexed single agent therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed is an antifolate chemotherapeutic agent approved for use in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: We performed a phase I study evaluating the combination of pemetrexed and temsirolimus in advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The present review summarizes the main findings on NSCLC pharmacogenetics, critically reappraising the most important studies on polymorphisms correlated with outcome of pemetrexed and EGFR-inhibitors, and provides perspective on clinical application of genomic tests for treatment decision-making. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We focused on evaluating the predictive and prognostic role of the seven following tumor biomarkers: carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), fragments of cytokeratin 8, 18 and 19 (MonoTotal), neuron-specific enolase (NSE), chromogranin A, thymidine kinase (TK) and squamous cell carcinoma antigen (SCCA) in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: In total, 114 patients with advanced-stage (IIIB or IV) non-squamous NSCLC treated with pemetrexed-based chemotherapy (monotherapy or combination with a platinum derivative) were included. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PROFILE 1014 compared crizotinib to up to six cycles of standard platinum-pemetrexed chemotherapy as the first line treatment of advanced anaplastic lymphoma kinase positive (ALK+) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Specifically, the benefit of the control arm (platinum-pemetrexed), although inferior to that of crizotinib, was remarkable and expands the dataset on the increased sensitivity of ALK+ NSCLC to pemetrexed; (III) identifying the central nervous system (CNS) as a key battleground for metastatic NSCLC, especially for ALK+ disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: This open-label, phase I, dose-escalation part of a phase I/II study evaluated the safety, pharmacokinetics, and preliminary efficacy of nintedanib, a triple angiokinase inhibitor, combined with pemetrexed in Japanese patients with advanced NSCLC after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Nintedanib plus pemetrexed had a manageable safety profile and showed promising signs of efficacy in previously treated Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed, a chemotherapeutic drug, is highly active in NSCLC and malignant pleural mesothelioma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous NSCLC: A Retrospective Analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The purpose of this study was to quantitatively assess the impact of TYMS gene expression in tumor cells as a predictor of the efficacy of pemetrexed therapy in patients with advanced NSCLC treated at our institution. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Sixty-two NSCLC patients were included in this study: 16 patients received platins-pemetrexed as first-line NSCLC, and 46 pemetrexed in monotherapy as second- or subsequent-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: TYMS overexpression in tumor cells correlated with a reduced response to pemetrexed-containing chemotherapy and might be used as a predictive biomarker in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed plus platinum versus pemetrexed alone in NSCLC patients who have progressed after first-line EGFR TKIs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Based on this retrospective analysis, platinum combination with pemetrexed resulted in a better disease control rate and a tendency toward prolongation of progression-free survival in NSCLC patients who progressed after first-line EGFR TKIs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed, a multitarget antifolate used to treat malignant mesothelioma and NSCLC, has been shown to stimulate autophagy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, we determined whether autophagy could be induced by pemetrexed and simvastatin cotreatment in malignant mesothelioma and NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Malignant mesothelioma MSTO-211H and A549 NSCLC cells were treated with pemetrexed and simvastatin alone and in combination to evaluate their effect on autophagy and apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Cotreatment with pemetrexed and simvastatin induced greater caspase-dependent apoptosis and autophagy than either drug alone in malignant mesothelioma and NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Our data indicate that pemetrexed and simvastatin cotreatment augmented apoptosis and autophagy in malignant mesothelioma and NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Inhibition of pemetrexed and simvastatin-induced autophagy was shown to enhance apoptosis, suggesting that this could be a novel therapeutic strategy against malignant mesothelioma and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced NSCLC harboring a sensitive EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We evaluated the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in EGFR-mutated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Analysis of Pemetrexed Monotherapy in Advanced NSCLC Patients with Impaired Renal Function]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Toxicity and efficacy of pemetrexed monotherapy in advanced NSCLC patients with impaired renal function treated between May 2009 and May 2012 at Gifu University Hospital were retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Thus, in this analysis, treatment with pemetrexed resulted in clinically equivalent efficacy in advanced NSCLC patients regardless of the state of renal function. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, we showed that chemoresistance to pemetrexed, a multi-target anti-folate (MTA) chemotherapeutic agent for NSCLC, is associated with a stem cell-like phenotype characterized by an enriched stem cell gene signature, augmented aldehyde dehydrogenase activity and greater clonogenic potential. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In conclusion, patients positive for the EML4-ALK fusion gene in NSCLC tissues are likely to have a low expression level of TYMS, and may benefit from the first-line chemotherapy drug pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Randomized study of gefitinib versus pemetrexed as maintenance treatment in patients with advanced glandular NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Gefitinib was compared with pemetrexed as maintenance therapy in Patients with Advanced Glandular NSCLC, mainly regarding clinical effect and side effect. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Considering the disease control rate and the tolerance of patients with advanced NSCLC, pemetrexed is strongly recommended to be used in clinical. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Feasibility of home delivery of pemetrexed in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVES: To evaluate the feasibility and adherence to home delivery (HD) of pemetrexed maintenance treatment in patients with advanced non-squamous NSCLC (nsqNSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: HD of pemetrexed maintenance treatment in patients with advanced nsqNSCLC was feasible, safe, and preferred by patients, while maintaining HRQoL. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Total Plasma Homocysteine Level Assessment and Timing of Folate/B12 Supplementation Prior to Initiation of Pemetrexed-Based Chemotherapy for Nonsquamous NSCLC Patients: An Irrelevant Investigation, an Unnecessary Delay, or Both?  Singh N(1), Maturu VN(1), Behera D(1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Use of pemetrexed for NSCLC in the Andalusian public health system. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The aim of this study is to determine the profile of the use of pemetrexed in metastatic or locally advanced NSCLC in Andalusia and its variation over 2 years (2010-2011). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Adult patients with locally advanced/metastatic NSCLC who received pemetrexed in any hospital in the Andalusian Public Health System during the first term of 2010 or the last term of 2011 were included. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In conclusion, pemetrexed combined with platinum is mainly used as first-line treatment in NSCLC patients with stage IV, adenocarcinoma histologic subtype and good performance status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "An adequate therapeutic positioning for pemetrexed based on effectiveness and safety analysis should be defined, so that NSCLC patients could be beneficiated with the most cost-effective chemotherapy treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase II study of pemetrexed monotherapy in chemo-na\u00efve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous NSCLC (HANSHIN Oncology Group 002). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: The aim of our study was to investigate the efficacy and safety of pemetrexed monotherapy in chemo-na\u00efve Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 patients with epidermal growth factor receptor (EGFR) wild-type or unknown advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Pemetrexed was administered at 500\u00a0mg/m(2) triweekly until progression with supplementations in chemo-na\u00efve ECOG PS 2 patients with EGFR wild-type or unknown advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed monotherapy demonstrated moderate efficacy and good safety in chemo-na\u00efve PS 2 patients with EGFR wild-type or unknown non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVES: Pemetrexed has been approved for the treatment of advanced non-small cell lung cancer (NSCLC) non-squamous histology, both as first- and second-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim of this study was the evaluation of the impact of pemetrexed on erythrocyte mean corpuscular volume (MCV) change and its possible correlation with disease control rate (DCR), progression free (PFS) and overall survival (OS) in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: A retrospective collection of clinical and laboratory data (including basal MCV and maximum MCV occurred during therapy) in advanced NSCLC patients treated with pemetrexed at seven Italian centers was performed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Effect of liver toxicity on clinical outcome of patients with NSCLC treated with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Liver toxicity (LT) is a common side effect of pemetrexed (PEM); however, the effect of LT on clinical outcome has not been investigated in patients with NSCLC treated with PEM. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced NSCLC previously treated with chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m\u00b2 of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed is a multitargeted antifolate used for the treatment of malignant mesothelioma and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In the present study, we investigated the involvement of reactive oxygen species (ROS) and sirtuin 1 (SIRT1) in pemetrexed-induced apoptosis in MSTO-211 malignant mesothelioma cells and A549 NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "These results show that pemetrexed induces apoptosis in MSTO-211 mesothelioma cells and A549 NSCLC cells through mitochondrial dysfunction mediated by ROS accumulation and SIRT1 downregulation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The pretreatment plasma homocysteine levels were measured in NSCLC patients treated with pemetrexed alone under folate supplementation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic NSCLC With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We report on a dose-escalation study of lapatinib combined with pemetrexed in second-line treatment to evaluate the safety and efficacy in advanced or metastatic NSCLC and an exploratory study in which circulating cell-free thymidylate synthase ribonucleic acid (cfTSmRNA) was measured in all patients and compared with clinical benefit. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in NSCLC Patients with EGFR Mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The purpose of this study was to compare the clinical efficacy of pemetrexed versus a platinum-based doublet as second-line therapy after failure of EGFR TKI used as first-line therapy for NSCLC patients with EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Our retrospective analysis found that second-line pemetrexed singlet therapy provided significantly prolonged PFS compared to second-line platinum-based doublet chemotherapy for NSCLC patients with EGFR mutations who failed first-line EGFR TKI. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The purpose of this study was to explore the predictive factors of the effectiveness and treatment toxicity for pemetrexed as continuation maintenance therapy in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "However, a decrease in estimated Ccr was associated with a increased risk of Grade 3/4 neutropenia and anemia.BACKGROUND: The purpose of this study was to explore the predictive factors of the effectiveness and treatment toxicity for pemetrexed as continuation maintenance therapy in patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC treated with pemetrexed as continuation maintenance therapy were enrolled. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, we investigated whether H9, and/or co-treatment with an anticancer drug, pemetrexed (PEM), inhibited tumor growth in BALB/c nude mice models bearing A549 NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The advent of both pemetrexed and molecular-targeted drugs has improved the survival of nonsquamous NSCLC and changed the chemotherapeutic algorithm for NSCLC; (2) Among patients with distant metastatic recurrence without locoregional recurrence at the primary tumor site, the metastasis is often limited in both organ and number. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: A recent phase III study (PARAMOUNT) demonstrated that pemetrexed continuation maintenance therapy is a new treatment paradigm for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We reviewed efficacy and safety data from two clinical trials, which enrolled East Asian (EA) patients, to supplement data from PARAMOUNT on pemetrexed continuation maintenance therapy in patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "RESULTS: In EA patients with nonsquamous NSCLC, the median progression-free survival (PFS) for pemetrexed continuation maintenance therapy was 4.04 months (95% confidence interval [CI], 3.22 to 5.29 months) in study S110 and 3.9 months (95% CI, 3.2 to 5.2 months) in study JMII. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "These data represent consistent evidence for pemetrexed continuation maintenance therapy in EA patients with advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "A 70 years old patient affected by a poorly differentiated NSCLC, subjected to his first pemetrexed administration, developed an acute thrombocytopenic thrombotic purpura, fatal in a few hours. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Additionally, we found that the BIM deletion polymorphism was an effective predictor of short progression-free survival in individuals with EGFR-mutant NSCLC and treated with chemotherapy containing pemetrexed (3.32 vs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed, a multi-target folate antagonist, has demonstrated efficacy in NSCLC histological subtypes characterized by low thymidylate synthase (TS) expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Since high levels of TS have been linked to clinical resistance to pemetrexed in NSCLC, herein we investigated the molecular and functional effects of combined pemetrexed and ITF2357, a pan-HDACi currently in clinical trials as an anti-cancer agent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In vivo experiments in NSCLC xenografts confirmed that sequential pemetrexed/ITF2357 is feasible and results in increased inhibition of tumor growth and increased mice survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Overall, these data provide a strong rationale for the clinical development of sequential schedules employing pemetrexed followed by HDACi in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Rechallenge chemotherapy with pemetrexed was shown to be efficient in malignant pleural mesothelioma; however, its role in NSCLC has not been investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, we retrospectively enrolled 31 patients with non-squamous NSCLC who had achieved disease control with initial pemetrexed treatment, followed by rechallenge with pemetrexed-based chemotherapy (PBC) upon disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in NSCLC cells is mediated by PARP activation and enhanced NAD consumption. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed is an inhibitor of dihydrofolate reductase currently used to treat patients with nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We found that combining pemetrexed with GMX1777 produced a synergistic therapeutic benefit in A549 and H1299 NSCLC cells in vitro and in a mouse A549 xenograft model of lung cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "These findings provide a mechanistic rationale for combining GMX1777 with pemetrexed as an effective new therapeutic strategy to treat nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Analysis of factors associated with the quality of life in patients with NSCLC who received outpatient pemetrexed maintenance therapy]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed is a multitarget antifolate currently used for the treatment of malignant mesothelioma and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, we investigated whether combination treatment with pemetrexed and simvastatin potentiates the apoptotic activity above that is seen with either drug alone in malignant mesothelioma and NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We found that the combination of pemetrexed and simvastatin induced more extensive caspase-dependent apoptosis than either drug alone in malignant mesothelioma cells (MSTO-211) or NSCLC cells (A549). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed for advanced NSCLC patients with interstitial lung disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed (PEM) is the key drug for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Assessment of folate receptor-\u03b1 and epidermal growth factor receptor expression in pemetrexed-treated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Specimens from 160 advanced NSCLC patients receiving pemetrexed-based chemotherapy were assessed for membranous FRA and EGFR protein expression using immunohistochemistry and the Hybrid (H)-score. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed induced acute kidney injury in patients with NSCLC: reversible and chronic renal damage. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed (Alimta(\u00ae)) (PEM) is an antifolate antineoplastic agent effective in several tumor types, such as NSCLC and mesothelioma, among others. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Our findings suggested different possible strategies of overcoming the resistance of topotecan and pemetrexed in the NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Retreatment with pemetrexed chemotherapy in advanced NSCLC patient. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: The aim of this study was to evaluate the feasibility and safety of retreatment the pemetrexed after the failure prior pemetrexed-based chemotherapy in NSCLC from our institute. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Retreatment of pemetrexed seems to be a potential therapeutic option for treatment of selected advanced NSCLC patients after failure of initial pemetrexed therapy, especially for the patients with a PFS more than 6 months in the initial pemetrexed treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed, a new multitarget antifolate antineoplastic agent, has significantly improved the overall survival in nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This is the case report of a patient with NSCLC harboring EML4-ALK rearrangement, who experienced slowly progressive disease within 4 years of maintenance treatment with pemetrexed and later exhibited a marked response to crizotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced NSCLC receiving pemetrexed-platinum doublet chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed-platinum doublet therapy is a standard treatment for stage IIIb/IV nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Forty-six patients with advanced NSCLC were enrolled for a bioequivalence study of two pemetrexed formulations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Third-space fluid distribution of pemetrexed in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed (PEM) is a multi-targeted antifolate similar to MTX approved for the treatment for malignant pleural mesothelioma and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed is approved to treat NSCLC and has an overall favorable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed is an antimetabolite agent that inhibits multiple folate-requiring enzymes and is used in the treatment of mesothelioma and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed is approved for first-line and maintenance treatment of patients with advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This study showed that stimulation with pemetrexed induced S-phase arrest and cell apoptosis and a parallel increase in sustained Akt phosphorylation and nuclear accumulation in the NSCLC A549 cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The purpose of the present study was to investigate the combined effects of gefitinib and pemetrexed on EGFR-TKI-sensitive and EGFR\u2011TKI\u2011resistant human non-small cell lung cancer (NSCLC) cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The antiproliferative effects of gefitinib and pemetrexed, alone and in combination, on the growth of NSCLC cell lines, were assessed using an MTT assay. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The combination of pemetrexed and gefitinib generated synergistic effects in gefitinib-acquired resistant cells and antagonistic effects in gefitinib-sensitive cells, suggesting that EGFR-TKIs combined with pemetrexed may be a beneficial treatment strategy for NSCLC patients with acquired resistance to EGFR-TKIs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Safety and effectiveness of pemetrexed in patients with NSCLC in Japan - analysis of post-marketing surveillance]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The safety and effectiveness of pemetrexed(PEM)in patients with NSCLCwere reviewed using data from post-marketing surveillance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of NSCLC cells to pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: Pemetrexed is an S-phase targeted drug in front-line or maintenance therapy of advanced nonsquamous NSCLC but methods are needed for predicting the drug response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: The results predict that in nonsquamous NSCLC tumors, reversible S-phase suppression by dexamethasone, possibly combined with a reduction in the drug transporters, attenuates responsiveness to pemetrexed and that GR status is a principal determinant of tumor variability of this response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Twenty-eight polymorphisms within eleven candidate genes were genotyped using the Illumina Human Exome v1.1 BeadChip and tested for their association with the clinical outcomes of NSCLC and mesothelioma patients receiving pemetrexed/platinum doublet chemotherapy (n=136). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced NSCLC patients receiving pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: We studied whether thymidylate synthase (TS) genotype has an independent prognostic/predictive impact on a European population of advanced NSCLC patients receiving pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Proliferation studies demonstrated higher responsiveness to methotrexate, pemetrexed, and other antifolates in KRAS-mutant NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed is a widely used drug for NSCLC and inhibits several folate-dependent enzymes including thymidylate synthase (TS). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Here, we show that the combination of rapamycin and pemetrexed synergistically inhibits proliferation of NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In vivo, the combination of rapamycin and pemetrexed inhibited growth of NSCLC xenografts, which correlated with decreased mTOR activity and suppression of pemetrexed-induced TS expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The ability of rapamycin to enhance the efficacy of pemetrexed and prevent TS expression has implications for the design of Phase I and/or Phase II NSCLC clinical trials with mTOR inhibitors in combination with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed versus vinorelbine treatment of advanced non-squamous NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed, a multitargeted antifolate agent, has been shown to have clear activity in non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "As a result, pemetrexed monotherapy might be considered as a good option in the treatment of elderly patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The pemetrexed-containing treatments in the NSCLC is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: The predictive value of thymidylate synthase (TS) for clinical sensitivity to pemetrexed-containing chemotherapy in patients with NSCLC remains controversial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This meta-analysis is performed to provide an assessment of whether expression variations of TS are associated with objective response in patients with NSCLC treated with pemetrexed-containing chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "A systemic review of the studies on the association between TS expression in NSCLC and objective response of pemetrexed-containing regimen was performed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: -/low expression of TS was associated with higher objective response in NSCLC patients treated with pemetrexed-containing chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "TS may be a suitable marker of sensitivity to pemetrexed-based chemotherapy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed is a recently marketed drug added to NSCLC therapeutic arsenal. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "AIM OF THE REVIEW: To evaluate the efficacy and safety of pemetrexed in NSCLC, in the different therapy lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Association between different EGFR mutation status and survival in pemetrexed-based chemotherapy for advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: To explore the association between different epidermal growth factor receptor (EGFR) mutation status and survival in pemetrexed-based chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Median progression-free survival (PFS) was determined.For comparison, median PFS was evaluated for EGFR-positive,EGFR-negative versus EGFR mutation unknown NSCLC patients in first-line pemetrexed therapy and pemetrexed maintenance therapy groups. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The multitargeted antifolate pemetrexed has demonstrated certain clinical activities against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, we evaluated the effects of pemetrexed on NSCLC cell lines (H520 and H1703) and found that treatment with this drug at 20-50 \u00b5M increased the MSH2 mRNA and protein levels in a MKK3/6-p38 MAPK signal activation-dependent manner. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The expression of constitutively active MKK6 (MKK6E) or HA-p38 MAPK vectors significantly rescued the decreased p38 MAPK activity, and restored the MSH2 protein levels and cell survival in NSCLC cells co-treated with pemetrexed and Hsp90 inhibitor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Patients with stage IIIB/IV NSCLC with performance status 0 to 1 progressive after first-line chemotherapy were eligible for randomization to pemetrexed, sunitinib, or the combination. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Reality check for pemetrexed and maintenance therapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: 55 patients with progressive NSCLC after platinum therapy were randomized to receive (Arm A) cetuximab, followed by pemetrexed at progression, or (Arm B) concurrent cetuximab and pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: To determine clinical efficacy, safety and prognostic factors of pemetrexed plus platinum as first- line treatment in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: Clinical characteristics, short-term efficacy, survival and adverse reactions of 47 advanced non-squamous NSCLC patients who had received pemetrexed plus platinum as first-line treatment in Shanghai Pulmonary Hospital from January 2009 to June 2011 were retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum as first-line treatment has excellent efficacy and slight adverse reactions with favorable drug-tolerance in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: NSCLC patients with brain metastasis benefited from pemetrexed and/or tyrosine kinase inhibitors along with localized treatments, and the graded prognostic assessment index is a robust model for prognostic evaluation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase II study of pemetrexed in chemotherapy-naive elderly patients aged \u2265 75 years with advanced non-squamous NSCLC (HANSHIN Oncology Group 003). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: Pemetrexed has relatively mild toxicity and possibly can be administered long term to patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We conducted a Phase II trial to evaluate the efficacy and safety of pemetrexed in chemotherapy-na\u00efve elderly patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed monotherapy is not recommended in chemotherapy-na\u00efve elderly patients aged \u226575 years with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase II study of pemetrexed in patients with previously heavily treated non-squamous NSCLC (HANSHIN Oncology Group 001). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: Pemetrexed has shown substantial activity in non-squamous NSCLC and is one of the current standard agents in second-line settings due to its efficacy and favorable tolerability profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We conducted phase II study to evaluate the safety and efficacy of pemetrexed in Japanese patients with previously heavily treated, advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Patients with stage IIIB or IV non-squamous NSCLC, performance status (PS) 0-2, previous two to five regimens of chemotherapy were enrolled and received pemetrexed (500 mg/m(2)) on day 1 every 21 days until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Treatment with pemetrexed in previously heavily treated Japanese non-squamous NSCLC patients is feasible and shows encouraging activity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Synergistic effects of pemetrexed and amrubicin in NSCLC cell lines: Potential for combination therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this study, we evaluated the effects of a novel CHK1 inhibitor, MK-8776, in combination with pemetrexed (PMX) on cell proliferation and survival in a panel of p53 mutant NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Home administration of maintenance pemetrexed for patients with advanced non-squamous NSCLC: rationale, practicalities and phase II feasibility study design. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In advanced non-squamous NSCLC, pemetrexed is approved as maintenance therapy after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "At least 50 patients with advanced non-squamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1 and no progressive disease after four cycles of platinum-based first-line therapy are required to allow investigation of the feasibility of home-based administration of pemetrexed maintenance therapy (500 mg/m(2) every 3 weeks until progressive disease or unacceptable toxicity). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Vitamin supplementation in patients receiving pemetrexed for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The PARAMOUNT study recently updated for survival analysis, showed that continuous maintenance with pemetrexed (P) lead to a 3 months overall survival (OS) benefit in NSCLC patients not progressing after P-based induction chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for NSCLC: a systemic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: Observational and preclinical studies suggested an association between the expression of thymidylate synthase (TS) and clinical effects of pemetrexed-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim of the study was to further appraise the association between the expression of TS and clinical efficacy pemetrexed-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "There was a significant association between TS expression and outcomes of pemetrexed-based chemotherapy for NSCLC (PFS: HR = 0.63 95 % CI 0.52, 0.76; OS: HR = 0.74, 95 % CI: 0.63, 0.88). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: This meta-analysis evaluated the predictive value of TS and provided evidence that NSCLC patients with lower TS expression could significantly benefit from pemetrexed-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced NSCLC: a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: The predictive value of thymidylate synthase (TYMS) to sensitivity to pemetrexed-based chemotherapy in advanced NSCLC patients is controversial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We conducted a meta-analysis of all relevant published data to assess the association of TYMS expression with the clinical outcomes of pemetrexed-based regimen in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [A randomized clinical study of Gefitinib and pemetrexed as second line therapy for advanced non-squamous NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND AND OBJECTIVE: Gefitinib and Pemetrexed are drugs used as second-line therapy for advanced NSCLC, although studies comparing the two drugs are limited. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim of this study is to explore the effects, safety, and quality of life (QoL) of Gefitinib and Pemetrexed on patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Forty-six advanced non-squamous NSCLC patients who failed to first-line therapy were randomly divided into two groups with 23 patients each, one using oral Gefitinib (Gefitinib group) and the other using intravenous injection Pemetrexed (Pemetrexed group). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Retrospective analyses suggest enhanced sensitivity to pemetrexed in crizotinib naive ALK+ NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Crizotinib and pemetrexed are active drugs in ALK+ NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim of this study was to assess the predictive value of RFC expression in patients receiving pemetrexed for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: The study was carried out in a population of 48 patients with advanced NSCLC which have received pemetrexed monotherapy in second and third line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: This prospective observational study evaluated the effect of race on disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) in patients with NSCLC treated with second-line pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Eligibility criteria included stage IIIB or IV NSCLC patients receiving single-agent pemetrexed for second-line therapy in routine clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Forty-two inoperable stage IIIB (with pleural effusion) and IV NSCLC patients who had had tumor progression received pemetrexed 500 mg/m(2) iv q3w together with daily TTFields therapy until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: The combination of TTFields and pemetrexed as a second line therapy for NSCLC is safe and potentially more effective than pemetrexed alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "pmartins-filho@hotmail.com  Pemetrexed is a novel, multitargeted antifolate approved for the treatment of malignant pleural mesothelioma and NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed has been widely used in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim of this study was to evaluate the expression levels of circulating miR-22, miR-24, and miR-34a, possibly involved in folate pathway, in NSCLC patients treated with pemetrexed compared with healthy controls and to investigate their impact on patient clinical outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "A total of 22 consecutive patients with advanced NSCLC, treated with pemetrexed-based chemotherapy and 27 age and sex matched healthy controls were included in this preliminary analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The correlation between high expression of miR-22 in whole blood and the lack of response in pemetrexed treated NSCLC patients indicates that miR-22 could represent a novel predictive biomarker for pemetrexed-based treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed is a multi-targeted anti-metabolite and has shown comparable activity for Caucasian patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this single-center retrospective study, we analyzed the outcome in 75 Chinese non-squamous NSCLC patients treated with pemetrexed as first-line therapy and assessed its efficacy and tolerability. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Taken together, pemetrexed was safe and effective in Chinese patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed induced thymidylate synthase inhibition in NSCLC patients: a pilot study with 3'-deoxy-3'-[\u00b9\u2078F]fluorothymidine positron emission tomography. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "v.frings@vumc.nl  OBJECTIVES: Pemetrexed is a thymidylate synthase (TS) inhibitor and is effective in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The aim of this study was to investigate the effect of pemetrexed-induced TS-inhibition on \u00b9\u2078F-FLT uptake 4 hours after pemetrexed administration in metastatic NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Fourteen NSCLC patients underwent dynamic \u00b9\u2078F-FLT positron emission tomography (PET) scans at baseline and 4 hours after the first dose of pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: The main objective of this study was to evaluate the association between polymorphisms of the target genes of pemetrexed and clinical outcomes in NSCLC patients treated with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The TS genotype was associated with survival and one DHFR polymorphism was associated with fatigue in NSCLC patients treated with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "We analyzed adverse events during the first cycle of pemetrexed therapy in 350 patients with advanced NSCLC who had received pemetrexed monotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed , a multi-target folate antagonist, has improved the survival of non-squamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Clinical trials and meta-analyses involving pemetrexed in NSCLC were evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed improved survival of non-squamous NSCLC in first-line, maintenance, and second-line treatments; this benefit is limited to non-squamous histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed (PEM) is effective in first-line treatment for patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed is a key drug for therapy of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "MATERIALS AND METHODS: In a search for biomarkers for study of the efficacy of pemetrexed treatment, we examined the thymidylate synthase (TYMS) copy number in NSCLC cell lines and in clinical NSCLC samples treated with pemetrexed, combined with platinum drugs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Moreover, TYMS copy number was significantly lower in clinical NSCLC samples responsive to treatment with pemetrexed combined with platinum drugs (p=0.0067). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "obasaju_coleman_k@lilly.com  BACKGROUND: This was a post hoc analysis of patients with non-squamous histology from a phase III maintenance pemetrexed study in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: ASBI and PS are associated with survival for non-squamous NSCLC patients, suggesting that maintenance pemetrexed is useful for LSB or PS 0 patients following induction. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "These data will help inform the evaluation of correlative data from a recently completed phase II NSCLC trial and a planned phase IB trial of NVP-AUY922 in combination with pemetrexed in NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The place of pemetrexed in the management of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In this setting, pemetrexed has become one of the most important partners of current chemotherapy regimens for nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Indeed, pemetrexed demonstrated a comparable efficacy to other previously available drugs in NSCLC, with however a better safety profile and an easier schedule of administration. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In addition, pemetrexed demonstrated a greater efficacy in nonsquamous NSCLC that lead to an exploration of the underlying potential biological background. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "derick.lau@ucdmc.ucdavis.edu  BACKGROUND: Pemetrexed, a multitargeted antifolate drug, is an active agent in NSCLC, especially adenocarcinomas. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed is a multi-targeted anti-folate agent approved for treatment of nonsquamous NSCLC but has anti-tumor activity in other solid tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of NSCLC to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This study investigated the expressions of TS and its gene SNPs in NSCLC, and then its association with sensitivity to pemetrexed treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: This study showed that TS protein is highly expressed in NSCLC and that polymorphisms of TS 3'-UTR 1494del 6 bp are associated with sensitivity of lung adenocarcinoma patients to pemetrexed treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Continuous pemetrexed treatment for brain metastasis in NSCLC--a report of two cases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " The standard palliative treatment for advanced stage NSCLC remains a platinum doublet but by tailoring chemotherapy according to tumour histology the results can be improved through using pemetrexed-containing schemas in non-squamous-cell disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Significance of folate receptor alpha and thymidylate synthase protein expression in patients with NSCLC treated with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed (PMX) is an antineoplastic antifolate used in the treatment of NSCLC, mesothelioma and several types of neoplasms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed for previously treated patients with NSCLC and differences in efficacy according to thymidylate synthase expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "igawa@kitasato-u.ac.jp  The purpose of this study was to evaluate the efficacy of pemetrexed monotherapy in previously treated patients with advanced NSCLC including salvage treatment, and to evaluate whether thymidylate synthase (TS) expression is a predictor for pemetrexed efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Hundred and four previously treated patients with advanced NSCLC who received pemetrexed monotherapy were retrospectively evaluated for clinical efficacy and toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed monotherapy could be considered as an option in the fourth or later lines of treatment of previously treated patients with advanced NSCLC as well as a second- or third-line treatment, and TS expression may be a potentially predictive factor for pemetrexed efficacy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed, given as a second- or further-line therapy, showed favorable clinical outcomes in ALK-positive NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent NSCLC: a prospective phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Aim of this study was to evaluate the safety and efficacy of a palliative regimen combining pemetrexed and LDR (as a chemopotentiator) on patients affected by recurrent NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Safety of pemetrexed mono-therapy in elderly patients with NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Safety of pemetrexed mono-therapy in elderly patients with NSCLC was examined between May 2009 and April 2010 at Kobe City Medical Center General Hospital . ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "PATIENTS AND METHODS: Participants (n=50) were patients with advanced NSCLC treated with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "TYMS mRNA expression affected the therapeutic efficacy of pemetrexed and could therefore constitute a useful predictive biomarker for NSCLC patients receiving pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The finding that pemetrexed is an excellent PCFT substrate explains its demonstrated clinical efficacy for mesothelioma and NSCLC, and prompted development of more PCFT-selective tumor-targeted 6-substituted pyrrolo[2,3-d]pyrimidine antifolates that derive their cytotoxic effects by targeting de novo purine nucleotide biosynthesis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed-based chemotherapy in patients with advanced, ALK-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "To determine whether ALK-positive NSCLC is also sensitive to pemetrexed, we retrospectively evaluated progression-free survival (PFS) of ALK-positive versus ALK-negative patients who had been treated with pemetrexed-based chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " New drugs such as pemetrexed, the epidermal growth factor receptor (egfr) tyrosine kinase inhibitors, and the Alk inhibitor crizotinib have recently enabled progress in the management of advanced NSCLC (nsclc). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed, a folate metabolic antagonist, is considered to be effective against plural mesotheliomas, NSCLC, and especially for non-squamous cell cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This open-label, phase I study investigated the maximum tolerated dose (MTD), safety, efficacy, and pharmacokinetics (PK) of BI 2536 IV in combination with standard-dose pemetrexed in previously treated advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: BI 2536 200 mg combined with standard-dose pemetrexed has an acceptable safety profile in relapsed NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed plus platinum as the first-line treatment option for advanced NSCLC: a meta-analysis of randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " To compare the efficacy and toxicities of pemetrexed plus platinum with other platinum regimens in patients with previously untreated advanced NSCLC.METHODS: A meta-analysis was performed using trials identified through PubMed, EMBASE, and Cochrane databases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Pemetrexed plus platinum chemotherapy (PPC) improved survival compared with other platinum-based regimens (PBR) in patients with advanced NSCLC (HR\u200a=\u200a0.91, 95% CI: 0.83-1.00, p\u200a=\u200a0.04), especially in those with non-squamous histology (HR\u200a=\u200a0.87, 95% CI: 0.77-0.98, p\u200a=\u200a0.02). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed (PEM) is a novel, multitargeted, antifolate, antineoplastic agent for the treatment of NSCLC and malignant pleural mesothelioma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Management and maintenance of pemetrexed monotherapy regimen - initial experience of pretreated NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " AIMS: Pemetrexed (Pem) is a potent inhibitor of thymidylate synthase (TS), and has shown efficacy in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Effect of pemetrexed plus platinum for chemotherapy-naive advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " OBJECTIVE: To evaluate the effect of pemetrexed plus platinum for chemotherapy-naive advanced NSCLC, and to explore thymidylate synthetase (TS) expression as the predictive and prognostic factor for this treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The therapeutic effect and tolerance of pemetrexed plus platinum regiment were definite as first-line treatment for chemotherapy-naive advanced NSCLC, and TS expression was an independent prognostic factor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND AND OBJECTIVE: Pemetrexed is a standard second-line therapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This study evaluated the efficacy and safety of pemetrexed as a salvage regimen in heavily pretreated patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: Clinical data on 37 patients with advanced NSCLC who received pemetrexed as second-line therapy or beyond in Cancer Hospital of Peking Union Medical College from Feb 2005 to Sep 2009 were reviewed and analyzed retrospectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Pemetrexed is efficacious and tolerable as second-line therapy or beyond for advanced NSCLC and should thus be recommended for patients with this disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Safety and efficacy of pemetrexed in maintenance therapy of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Maintenance therapy has been added to the algorithm of NSCLC management and Pemetrexed has been studied as single agent or in combination in this setting with recent studies showing safety and improved progression free survival (PFS) and/or overall survival (OS), still the disease for the most part has a dismal outcome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "RESULTS: Two patients with stage IIIB NSCLC developed interstitial lung disease after chemotherapy with pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " [Clinical investigation of efficacy of third-line and beyond pemetrexed treatment in advanced non-squamous NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND AND OBJECTIVE: Pemetrexed in combination with platinum or a single-agent has been approved for the first- and second-line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "However, the role of pemetrexed therapy in the third-line and beyond treatment of NSCLC has yet to be generally accepted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "The present retrospective study reports the efficacy and safety of pemetrexed in the third-line and beyond treatment of advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: A total of 46 patients with advanced non-squamous NSCLC received a combination of pemetrexed plus platinum or a single-agent after multi-line treatment failed to yield positive results. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Administration of pemetrexed after failure of multi-line treatment is clinically beneficial to patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Quality of life in patients with advanced NSCLC given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: Pemetrexed maintenance therapy significantly improved overall survival and progression-free survival compared with placebo, and had a good safety profile in a phase 3 placebo-controlled study in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: After four cycles of platinum-based induction therapy, 663 patients with stage IIIB or stage IV NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (in a 2:1 ratio) from March 15, 2005, to July 20, 2007, using the Pocock and Simon minimisation method to receive pemetrexed (500 mg/m(2) every 21 days; n=441) or placebo (n=222) plus best supportive care until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "In view of the improvements in overall and progression-free survival noted with pemetrexed maintenance therapy, such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Role of pemetrexed in advanced NSCLC: meta-analysis of randomized controlled trials, with histology subgroup analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS: We undertook a systematic review of the literature for randomized controlled trials that compared the efficacy of pemetrexed with that of other treatments in advanced nsclc. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSIONS: Compared with other chemotherapy agents, pemetrexed is more effective for the treatment of nsclc in patients with non-squamous histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced NSCLC: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " BACKGROUND: To compared pemetrexed-based doublet with single-agent pemetrexed as second-line treatment for advanced NSCLC METHODS: We systematically searched for randomized clinical trials that compared pemetrexed-based doublet with single-agent pemetrexed in patients with histologically proven NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: Pemetrexed-based doublet therapy didn't gain any benefit in survival but significantly improved PFS and better ORR compared with single-agent pemetrexed as second-line therapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " PURPOSE: Pemetrexed, an inhibitor of thymidylate synthase (TS) and additional folate-dependent enzymes, is clinically active in patients suffering from \"non-squamous\" NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Against this background, we studied whether inhibition of mTOR could lower expression of TS and thus sensitize NSCLC cells to pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "METHODS AND RESULTS: Using squamous cell carcinoma and adenocarcinoma NSCLC cell lines, we observed that constitutive TS expression levels failed to correlate with sensitivity to growth inhibition or apoptosis imposed by pemetrexed in vitro. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Surprisingly, cotreatment with everolimus protected NSCLC cells against pemetrexed-induced apoptosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This resulted in increased long-term clonogenic survival of NSCLC cells treated with pemetrexed plus everolimus as compared to pemetrexed alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "This should be considered when combining pemetrexed and mTOR inhibitors in NSCLC treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "Using a validated RNA interference approach, dUTPase was effectively silenced in a panel of NSCLC cell lines and response to the fluoropyrimidine fluorodeoxyuridine (FUdR) and the antifolate pemetrexed was analyzed using growth inhibition and clonogenic assays. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "RNA interference-mediated silencing of dUTPase significantly sensitized NSCLC cells to growth inhibition induced by FUdR and pemetrexed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed, approved for the treatment of NSCLC and malignant mesothelioma, has adverse effects including neutropenia, leucopenia, thrombocytopenia, anemia, fatigue and nausea. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous NSCLC: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " INTRODUCTION: In a recent global phase 3 trial, patients with advanced non-small cell lung cancer (NSCLC), who had not progressed after four cycles of platinum-based induction chemotherapy, were randomized to maintenance therapy with pemetrexed or placebo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "CONCLUSION: The results of this subgroup analysis support pemetrexed as maintenance therapy for East Asian patients with advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " Pemetrexed, a new-generation antifolate, has demonstrated promising single-agent activity in front- and second-line treatments of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": " A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "pemetrexed", "orig_sen": "For illustration, an application of the proposed non-parametric method to a trial involving pemetrexed, a recently approved drug for first-line treatment of NSCLC, is included. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Given the recently documented potential of SMARCA4 loss as a predictor of chemosensitivity to platinum-based chemotherapy in NSCLC, recognition of the clinicopathological features of SMARCA4-deficient NSCLC in routine surgical pathology practice is recommended. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced NSCLC Patients Undergoing Platinum-Based Chemotherapy  Kaewbubpa W(1), Areepium N, Sriuranpong V. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study aimed to investigate the effects of the ERCC1 (C118T) polymorphism on treatment response in 26 Thai advanced NSCLC patients receiving first line platinum-based chemotherapy during January to July 2015 at King Chulalongkorn Memorial Hospital (KCMH). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Maintenance erlotinib versus erlotinib at disease progression in patients with advanced NSCLC who have not progressed following platinum-based chemotherapy (IUNO study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVE: The phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at progression in advanced/metastatic NSCLC that had not progressed following four cycles of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " INTRODUCTION: Pemetrexed maintenance therapy (MT) after induction with platinum-based chemotherapy has recently become a common treatment strategy for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Purpose The phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic NSCLC selected by MET immunohistochemistry whose disease had progressed after treatment with a platinum-based chemotherapy regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Gefitinib, erlotinib and afatinib provide remarkable response rates and progression-free survival compared to platinum-based chemotherapy in patients with NSCLC harboring epidermal growth factor receptor-activating mutations, and are therefore standard first-line treatment in these patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "It is the first PD-L1 inhibitor approved for use in patients with metastatic NSCLC that has advanced in spite of treatment with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Future studies will explore nivolumab in combination strategies with either platinum-based chemotherapy or other ICBs in treatment-na\u00efve advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " INTRODUCTION: Based on the results of several randomised controlled trials, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now replaced platinum-based chemotherapy as first-line therapy for advanced NSCLC harboring an activating EGFR mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In conclusion, afatinib is an important option for the first-line treatment of patients with advanced NSCLC and activating EGFR mutations, and provides an additional option for the treatment of patients with squamous NSCLC that has progressed following first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Can Aidi injection restore cellular immunity and improve clinical efficacy in NSCLC patients treated with platinum-based chemotherapy? A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Can Aidi injection restore the cellular immunity and improve the clinical efficacy in NSCLC patients treated with platinum-based chemotherapy? There is a lack of strong evidence to prove it. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We collected all studies about the clinical efficacy and cellular immunity of Aidi injection plus platinum-based chemotherapy for NSCLC in Medline, Embase, Web of Science, China national knowledge infrastructure database (CNKI), Chinese Scientific Journals Full-Text Database (VIP), Wanfang, China biological medicine database (CBM) (established to June 2015), Cochrane Central Register of Controlled Trials (CCRCT) (June 2015), Chinese clinical trial registry, and US-clinical trials (June 2015). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Aidi injection plus platinum-based chemotherapy can improve the clinical efficacy of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In the REVEL trial advanced NSCLC patients whose disease had progressed after first line platinum-based chemotherapy, were administered ramucirumab plus docetaxel or placebo plus docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The P38\u03b1 rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with NSCLC Treated with Platinum-Based Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We hypothesize that functional single nucleotide polymorphisms (SNPs) of genes of these pathways modulate outcomes of patients with advanced NSCLC treated with first-line platinum-based chemotherapy (PBC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "[Epub ahead of print]  A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced NSCLC (KCSG LU12-01). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced NSCLC after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Genetic variants of BCL2 gene predict clinical outcomes of NSCLC patients treated with platinum-based chemotherapy in a Chinese population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In this study, we evaluated whether single nucleotide polymorphism (SNPs) of BCL2 can affect the overall survival (OS) and progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We genotyped 48 SNPs of BCL2 gene by Illumina Custom Designed Chip in 972 advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "As a result, five SNPs, rs949037, rs3810027, rs4987739, rs4987726 and rs7226979, were significantly associated with overall survival time in 972 NSCLC patients after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "As representative, the G allele of rs949037 was associated with longer OS in NSCLC patients with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "To conclude, polymorphisms of BCL2 gene may have an impact on the OS of platinum-based chemotherapy in NSCLC patients, which may be prognostic biomarkers of chemotherapy if validated in larger studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "[Epub ahead of print]  Serum APE1 as a predictive marker for platinum-based chemotherapy of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "EXPERIMENTAL DESIGN: We measured APE1 protein levels in biopsy tissue from 172 NSCLC patients and sera of 412 NSCLC patients receiving platinum-based chemotherapy by immunohistochemistry and a newly established sensitive and specific enzyme-linked immunosorbent assay, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Patients with Stage I-III NSCLC, prescribed 60\u00a0Gy in 30 fractions RT with concurrent platinum-based chemotherapy, routine CBCT and enrolled in a prospective study of serial PET/CT (baseline, weeks two and four) were eligible. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In July 2011, icotinib was approved by the China Food and Drug Administration at a dose of 125 mg three times daily for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one platinum-based chemotherapy regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Association of CHEK2 polymorphisms with the efficacy of platinum-based chemotherapy for advanced NSCLC in Chinese never-smoking women. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Using DNA from blood samples of 272 Chinese advanced NSCLC non-smoking female patients treated with first-line platinum-based chemotherapy, we have analyzed the relationships between four SNPs in the CHEK2 gene and clinical outcomes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Expert opinion: The addition of ramucirumab to docetaxel in the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy confers a 1.4-month improvement in overall survival, with an acceptable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Purpose: We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Conclusions: Immunohistochemical analysis of the ERCC1 expression level did not differentiate the efficacy of platinum-based chemotherapy in advanced NSCLC (NCT01003964). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Methods In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Conclusions In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " RICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " AIM: We investigated the association between RICTOR polymorphisms and clinical outcomes of platinum-based chemotherapy for Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In patients with NSCLC harboring specific genetic alterations the anti EGFR TKIs and the ALK TKIs have improved the response rate and the quality of life compared to standard platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the first-line treatment of non-small cell lung cancer (NSCLC); it is therefore important to discover biomarkers that can be used to predict the efficacy and toxicity of this treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study aimed to evaluate the association of genetic polymorphisms of these transporters with platinum-based chemotherapy response and toxicity in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "All patients were newly diagnosed with NSCLC and received at least two cycles of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "To date, two programmed death-1 inhibitors, namely nivolumab and pembrolizumab, have received the US Food and Drug Administration approval for the treatment of advanced NSCLC that failed platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV NSCLC (current smokers who failed first-line platinum-based chemotherapy) were randomized to receive E150 or E300 until progression/death/unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Erlotinib has been approved as second-line treatment in patients with NSCLC experiencing relapse after first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "However, the majority of patients with NSCLC will ultimately develop resistance to initial platinum-based chemotherapy, and many remain candidates for subsequent lines of therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " INTRODUCTION: Adjuvant platinum-based chemotherapy is standard treatment for surgically resected stage II to IIIA NSCLC, but the relapse rate is high. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In patients with NSCLC with an activating epidermal growth factor receptor (EGFR) mutation (defined as exon 19 deletion and exon 21 L858R point mutation), phase III trials of EGFR tyrosine kinase inhibitors (TKI) compared to platinum-based chemotherapy have demonstrated superior efficacy in the first-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy is the standard treatment for NSCLC patients with EGFR wild-type, and as alternative to failure to EGFR inhibitors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The aim of this study was to evaluate the effect of these polymorphisms on platinum-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In conclusion, ERCC1 C118T, ERCC2 rs50872, ERCC2 Asp312Asn, ABCB1 C1236T, IL1B rs12621220 and IL16 rs7170924 polymorphisms may substantially act as prognostic factors in NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the standard front-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Nivolumab (Opdivo(\u00ae)), a human immunoglobulin (Ig)G4 anti-programmed death (PD)-1 monoclonal antibody, was the first PD-1 inhibitor approved in the treatment of patients with advanced stage squamous cell NSCLC following platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Platinum-based chemotherapy is the first-line treatment for NSCLC, however, the therapeutic efficiency varies remarkably among individuals. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "[Epub ahead of print]  Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced NSCLC patients following platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Data are presented from a phase II trial (ASCEND-2) in which ceritinib efficacy and safety were evaluated in patients who had ALK-rearranged NSCLC previously treated with at least one platinum-based chemotherapy and who had experienced progression during crizotinib treatment as their last prior therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVES: This phase II trial investigated the efficacy and safety of S-1 plus bevacizumab (SB) after failure of platinum-based chemotherapy in patients with non-squamous NSCLC (non-sq NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Patients with non-sq NSCLC who had undergone prior platinum-based chemotherapy, regardless of the use of bevacizumab, were eligible. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: Although SB was well tolerated, this combination did not provide any additional benefit in terms of PFS for patients with non-sq NSCLC after failure of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We investigated the impact of 2 SNPs of excision repair cross-complementation group 1 and 2 of xeroderma pigmentosum complementation group G on the outcome in patients with NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The aim of the present study was to perform a systematic review and meta-analysis comparing platinum-based chemotherapy alone with platinum-based chemotherapy plus Astragalus-based Chinese botanicals, with and without prescription based on syndrome differentiation, as first-line treatment for advanced nsclc. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Astragalus-based Chinese botanical therapy, especially when based on syndrome differentiation, is associated with increased efficacy of platinum-based chemotherapy and decreased platinum-derived toxicities for patients with advanced nsclc. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Nivolumab is the first PD-1 inhibitor approved for the treatment of advanced-stage squamous cell NSCLC following platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: A randomized phase III study was designed to assess the efficacy and safety of second-line platinum-based chemotherapy with or without erlotinib in NSCLC with EGFR-activating mutation after secondary resistance to EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: In this phase 2, multicentre, non-randomised, open-label study, we enrolled adult patients (aged \u226518 years) with pretreated metastatic stage IV BRAF(V600E)-mutant NSCLC who had documented tumour progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Eligible patients are those with locally advanced or metastatic NSCLC (Stage IIIB/IV), without epidermal growth factor receptor tyrosine kinase activating mutations or anaplastic lymphoma kinase rearrangements, who have received at least 2 prior systemic regimens, including 1 platinum-based chemotherapy regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The programmed death (PD)-1 immune checkpoint inhibitor nivolumab (Opdivo(\u00ae)) is approved in the USA for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have progression on or after platinum-based chemotherapy and in the EU for the treatment of adults with locally advanced or metastatic NSCLC after prior chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "[Epub ahead of print]  Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced NSCLC Patients Treated with Platinum-Based Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We evaluated the association of Romo1 expression with clinical outcomes in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Conclusion: Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly NSCLC patients receiving platinum-based chemotherapy?  Kato T(1), Morise M(2), Ando M(3), Kojima E(4), Ogasawara T(5), Suzuki R(6), Shindoh J(7), Matsumoto M(8), Sugino Y(9), Ogawa M(10), Nozaki Y(11), Hase T(1), Kondo M(1), Saito H(12), Hasegawa Y(1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70\u00a0years) patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: One hundred and ninety-eight consecutive elderly NSCLC patients receiving platinum-based chemotherapy were retrospectively reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: Baseline serum albumin might be useful for predicting the feasibility of platinum-based chemotherapy, and the risk estimation of early treatment termination without PD might be beneficial for the treatment selection in elderly NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " In this study, we aimed to establish a platinum-based chemotherapy response and toxicity prediction model in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In conclusion, we provided platinum-based chemotherapy response and toxicity prediction models for advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In a Phase III clinical trial, ramucirumab was shown to improve the overall survival in patients with disease progression, despite platinum-based chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Platinum-based doublet chemotherapy and endostar plus standard second-line regimen can improve the efficacy in some characterized advanced NSCLC as compared with the patients by standard mono-drug therapy, wherein the platinum-based chemotherapy revealed the best efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: There is no definitive conclusion so far on the predictive values of ERCC1 polymorphisms for clinical outcomes of platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "ERCC1 C118T and C8092A could predict both ORR and OS for platinum-based chemotherapy in Asian NSCLC patients (CT + TT versus CC, ORR: OR = 0.80, 95% CI = 0.67-0.94; OS: HR = 1.24, 95% CI = 1.01-1.53) (CA + AA versus CC, ORR: OR = 0.76, 95% CI = 0.60-0.96; OS: HR = 1.37, 95% CI = 1.06-1.75). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Current evidence strongly indicated the prospect of ERCC1 C118T and C8092A as predictive biomarkers for platinum-based chemotherapy in Asian NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: We retrospectively reviewed CT scans of the lungs of 75 chemo-na\u00efve patients with advanced non-squamous NSCLC, for measurement of CSA, before and after first-line platinum-based chemotherapy, using a semi-automatic image-processing program. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " [Effect of polymorphisms of NF-\u03baB and PXR on platinum-based chemotherapy for NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVE: To investigate the effect of polymorphisms of NF-\u03baB rs230521, NF-\u03baB rs4648068 and pregnane X receptor (PXR) rs3814058 on platinum-based chemotherapy for NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Polymorphism of NF-\u03baB rs4648068 did not show significant effect on chemotherapy efficacy and occurrence of gastrointestinal toxicity and hematological toxicity.\u2029 CONCLUSION: Patients with NF-\u03baB rs230521 CC, PXR rs3814058 CC and CT had higher risk to suffer hematological toxicity during platinum-based chemotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: MEDLINE, EMBASE, and the Cochrane Library were searched for phase III randomized controlled trials\u00a0comparing maintenance systemic treatment against another systemic treatment or placebo in patients with stage IIIB or IV NSCLC who had received a minimum of\u00a0four prior cycles of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: For patients with advanced, stable stage IIIB/IV NSCLC whose disease has not progressed after four to six cycles of platinum-based chemotherapy, the\u00a0overall survival benefits were strongest for pemetrexed maintenance therapy followed by epidermal growth factor receptor tyrosine kinase inhibitor maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy in advanced NSCLC: optimal number of treatment cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy remains the standard-of-care for most patients affected by advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The JNK and P38\u03b1 pathways play a crucial role in tissue homeostasis, apoptosis and autophagy under genotoxic stresses, but it is unclear whether single nucleotide polymorphisms (SNPs) of genes in these pathways play a role in platinum-based chemotherapy-induced toxicities in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The present study provides evidence that genetic variants in genes involved in the JNK and P38\u03b1 pathways may predict platinum-based chemotherapy toxicity outcomes in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " NSCLCs (NSCLC) are commonly treated with a platinum-based chemotherapy such as cisplatin (CDDP) in combination with ionizing radiation (IR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Approval was based on demonstration of an improvement in overall survival (OS) in an international, multicenter, open-label, randomized trial comparing nivolumab to docetaxel in patients with metastatic nonsquamous NSCLC with progression on or after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "My practice pattern for patients with EGFR wild-type NSCLC is platinum-based chemotherapy as first-line therapy, immunotherapy as second-line therapy, and single-agent chemotherapy as third-line therapy for patients with preserved performance status who want to pursue further therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: REVEL demonstrated improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV NSCLC patients with disease progression following platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic NSCLC patients with progression after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVES: REVEL demonstrated that ramucirumab+docetaxel (RAM+DTX) improved overall survival, progression-free survival, and objective response rate in patients with advanced/metastatic NSCLC with progression after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Role of BCL2-associated athanogene in resistance to platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The present study aimed to address the pharmacogenetic role of BAG1 in platinum-based chemotherapy in advanced NSCLC and in cultured human lung adenocarcinoma A549 cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Efficacy of tamoxifen in combination with docetaxel in patients with advanced NSCLC pretreated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "A total of 120 advanced NSCLC patients pretreated with platinum-based chemotherapy were randomized into two treatment groups (the TXT and TXT+TAM groups) in a 1 : 1 ratio. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " INTRODUCTION: Concurrent thoracic radiation and platinum-based chemotherapy is the standard of care for treatment of unresectable stage IIIA-IIIB NSCLC, but the optimal drug regimen has not been established. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Prognostic implications of survivin and lung resistance protein in advanced NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy is the first-line treatment for NSCLC, but the chemotherapy often results in the development of chemoresistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The present study aimed to explore the prognostic implications of survivin and lung resistance protein (LRP) in advanced NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Tumor samples were collected from 61 hospitalized patients with stage IIIB-IV NSCLC that underwent platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Either the expression of survivin or the combined expression of LRP and survivin is associated with a poor prognosis in advanced NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Although adjuvant platinum-based chemotherapy has been demonstrated to improve survival in patients with completely resected NSCLC, individualized approaches to therapy are urgently required to improve the treatment efficacy and reduce unnecessary toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVE: The purpose of the study was to assess the efficacy and safety of using Chinese herbal medicine (CHM) as maintenance therapy considering the survival of advanced NSCLC patients after first-line conventional platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Bevacizumab combined with platinum-based chemotherapy has been established as a standard treatment option in the first-line setting for advanced nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " A phase I multicenter study of antroquinonol in patients with metastatic NSCLC who have received at least two prior systemic treatment regimens, including one platinum-based chemotherapy regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVES: To explore patient and disease factors, and reasons behind the physician's choice of platinum backbone for the first-line treatment of NSCLC, as observed in a European prospective observational study of patients receiving platinum-based chemotherapy as first-line treatment for advanced or metastatic NSCLC (the FRAME study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "As a case study we evaluated how a particular predictive biomarker, ERCC1, was assessed in research on platinum-based chemotherapy in NSCLC and what motivated the choice of procedure. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "RESULTS: Thirty-three studies of platinum-based chemotherapy in NSCLC using ERCC1 were identified. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: From a cohort of 178 patients with advanced NSCLC treated with platinum-based chemotherapy as first-line treatment, we selected all surgical tumor samples at diagnosis (n\u00a0= 36). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: The Shh pathway is associated with resistance to platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The prognosis of metastatic NSCLC is poor, and platinum-based chemotherapy improves the median survival for only a few months. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Low expression of SMARCA4/BRG1 is significantly associated with worse prognosis; however, it is a novel significant predictive biomarker for increased sensitivity to platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study investigated the association of BCL2-938C>A(rs2279115) and BAX-248G>A(rs4645878) promoter region SNPs and the clinical responses and outcomes of 235 NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The data from the current study provide evidence that BCL2-938C>A and BAX-248G>A polymorphisms may be useful in predicting clinical outcomes of patients with advanced inoperable NSCLC to platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "However, two phase III clinical trials using COX-2 inhibitor in combination with platinum-based chemotherapy showed no survival benefit for \"unselected\" patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This cohort of patients with NSCLC received platinum-based chemotherapy subsequent to the surgical removal of tumor lesions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "High hCtr1 expression combined with low ATP7A expression was associated with an improved prognosis in patients with resected NSCLC that received platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Subsequent to surgery, all 72 patients with NSCLC were treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The mRNA expression of these genes may have prognostic value for patients with NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Association of polymorphisms in translesion synthesis genes with prognosis of advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study aimed to investigate the relationship between single nucleotide polymorphisms (SNPs) in the TLS genes and clinical outcome of advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Genetic polymorphisms in the TLS genes might serve as potential predictive biomarkers of prognosis of advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The present study was designed to further evaluate the efficacy and safety of icotinib in patients with advanced NSCLC previously treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "RESULTS: Absolute count of CD19+ and the CD4/CD8 ratio were significantly lower in NSCLC patients than in age-paired controls, while highly differentiated T cells increased in NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study assessed the prognostic performance of LMR in early-stage NSCLC patients and investigated the influence of LMR on the treatment response in patients receiving first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Decreased LMR may be a potential biomarker of disease status, worse response to first-line platinum-based chemotherapy, and worse survival for NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Patients with NSCLC are mostly treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The aim of this study is to investigate the regulatory functions of miR-17 and miR-92 families on the formation of cisplatin resistance and the predictive functions of them as biomarkers of platinum-based chemotherapy resistance in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Moreover, we demonstrate that the expressions of miR-17 and miR-92 families in NSCLC tissues are significantly associated with platinum-based chemotherapy response. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: KRAS MT are not associated with inferior progression-free and overall survival in advanced NSCLC patients treated with standard first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS AND RELEVANCE: The FDA granted nivolumab traditional approval on March 4, 2015, for treatment of metastatic SQ NSCLC with progression during or after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic NSCLC Following Disease Progression On or After Platinum-Based Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Food and Drug Administration approval of ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2, given in combination with docetaxel for the treatment of patients with metastatic NSCLC whose disease has progressed on or after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "JUNIPER is a randomized study of abemaciclib (200 mg orally every 12 hours) with best supportive care (BSC) versus erlotinib (150 mg orally every 24 hours) with BSC in patients with stage IV NSCLC whose tumors have detectable Kirsten rat sarcoma (KRAS) mutations and whose disease has progressed after platinum-based chemotherapy and 1 other previous therapy, or who are not eligible for further chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Patients with advanced NSCLC and known KRAS mutation, treated with first-line platinum-based chemotherapy, were retrieved from hospital databases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Use of platinum-based chemotherapy doublets is the standard of care for patients with advanced-stage NSCLC, being associated with improved survival compared with best supportive care in fit patients with good performance status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Adjuvant platinum-based chemotherapy has developed its stability as the first-line treatment in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Patients having NSCLC with MAC30 overexpression showed a poorer response to platinum-based chemotherapy, while there was no prognostic value of MAC30 expression on molecularly targeted therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "A multivariate analysis exhibited that increased MAC30 expression was an independent prognostic factor for overall survival in patients having NSCLC with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In conclusion, patients having NSCLC with higher MAC30 expression resisted to platinum-based chemotherapy and exhibited worse survival. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Standard platinum-based chemotherapy combinations for advanced NSCLC have reached a plateau in terms of the survival benefit they offer for patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, developed by Bristol-Myers Squibb Inc., has activity across NSCLC histologies and is Food and Drug Administration approved for treatment of metastatic squamous NSCLC with progression on or after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Pembrolizumab has also received breakthrough status for the treatment of EGFR mutation-negative, ALK rearrangement-negative NSCLC that has progressed on or following platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Stage III/IV NSCLC patients who did not progress after platinum-based chemotherapy were randomised 1:1 to receive maintenance belagenpumatucel-L or placebo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Surgery, platinum-based chemotherapy, molecular targeted agents and radiotherapy are the main treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " We carried out a meta-analysis to evaluate the benefit of epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKI) over the standard first-line platinum-based chemotherapy for metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Eight studies were identified that compared EGFR-TKI versus standard first-line platinum-based chemotherapy to treat NSCLC in 2962 patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Standard treatment for advanced NSCLC with no known driver mutation is platinum-based chemotherapy, which has a response rate of only 30-33%. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " INTRODUCTION: Platinum-based chemotherapy and 3rd generation drugs is still the main treatment option for advanced NSCLC patients without activating EGFR mutations or ALK rearrangements. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Patients with stage IIIB/IV NSCLC and unsuccessful first-line platinum-based chemotherapy were randomly divided into two arms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Data of 904 patients who have progressed after receiving first-line platinum-based chemotherapy in 11 centers with the diagnosis of stage IIIB and IV NSCLC and who were evaluated for second-line treatment were retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Patients (n=392) with NSCLC were treated with at least two cycles of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In conclusion, our research demonstrated the combined effects of BAG-1 and XPD polymorphisms on chemotherapy sensitivity and survival in patients with advanced NSCLC, which might be the important predictive markers for platinum-based chemotherapy efficacy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "These results suggest Cav-1 might serve as a potential biomarker in this patient population.BACKGROUND: The combination of bevacizumab with platinum-based chemotherapy results in greater response rate (RR) and overall survival (OS) in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy has been shown to improve the survival of advanced NSCLC patients; the platinum-induced toxicity severely impedes the success of chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "To identify SNPs that modify the risk of hepatotoxicity in NSCLC patients receiving platinum-based chemotherapy, we performed a genome-wide association scan in 334 subjects followed by a replication study among 375 subjects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This randomized, phase II trial (n [ 143) investigated volasertib monotherapy or in combination with pemetrexed compared with pemetrexed monotherapy in patients with NSCLC whose disease had progressed after previous platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In this study we compared volasertib, volasertib with pemetrexed, and pemetrexed alone in patients with advanced NSCLC whose disease progressed after first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Platinum-based chemotherapy has long been the standard of care for the initial treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "MATERIALS AND METHODS: Patients with non-Sq NSCLC who experienced disease progression after prior platinum-based chemotherapy with or without bevacizumab were randomly assigned to receive docetaxel plus bevacizumab (DB) once every 3 weeks or S-1 orally twice daily on days 1-14 plus bevacizumab (SB) on day 1 every 3 weeks until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Switch maintenance with pazopanib following platinum-based chemotherapy in advanced NSCLC patients had limited side-effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "WEE1 rs3910384 genotype correlated to overall survival (OS) and progress-free survival (PFS) of NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study aimed to investigate the association of TERT polymorphisms with clinical outcome of advanced NSCLC patients receiving first-line platinum-based chemotherapy, including response rate, clinical benefit, progression-free survival (PFS), overall survival (OS), and grade 3 or 4 toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Seven polymorphisms of TERT were assessed, and a total of 1004 inoperable advanced NSCLC patients treated with platinum-based chemotherapy were enrolled. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: Crizotinib is superior to platinum-based chemotherapy in NSCLC patients with ALK rearrangement. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: To investigate the correlation between protein expression of breast cancer susceptibility gene 1 (BRCA1) and topoisomerase II\u03b2-binding protein 1 (TopBP1) and clinical outcome of NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: The role of second-line chemotherapy in patients with NSCLC and preexisting interstitial pneumonia (IP) previously treated with platinum-based chemotherapy remains uncertain. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Correlation of MSH3 polymorphisms with response and survival in advanced NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We examined MutS homolog 3 (MSH3), a mismatch repair gene, and whether polymorphisms of MSH3 were associated with response and survival in advanced NSCLC (NCSLC) patients who were treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Eligible patients had advanced NSCLC and had been treated with first-line platinum-based chemotherapy but still had disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced NSCLC patients: results of an open-label, randomized, controlled phase II study (CERTO). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Cyclooxygenase-2 expression is a prognostic biomarker for NSCLC patients treated with adjuvant platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We evaluated the efficacy of second-line platinum-based chemotherapy after gefitinib for advanced NSCLCs harboring epidermal growth factor receptor mutations (the NEJ002 study). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Seventy-one NSCLCs, treated with gefitinib as first-line therapy and then receiving platinum-based chemotherapy as second-line therapy were evaluated in NEJ002. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "MATERIALS AND METHODS: Manual axial longest diameter, semiautomatic axial longest diameter, and volume of NSCLC lesions were independently analyzed by 4 readers at baseline and after at least 1 cycle of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Genome-wide association study of myelosuppression in NSCLC patients with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "MATERIALS AND METHODS: We recruited 663 patients with advanced NSCLC who had been treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: The results of our study suggest that SNPs in MDM2 might be used to predict the toxicities of platinum-based chemotherapy and overall survival in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Platinum-based chemotherapy remains as the standard of treatment for most of advanced NSCLC patients, and although therapeutic improvements have been achieved in the last years, the benefits are quite modest. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Platinum-based chemotherapy is a standard strategy for NSCLC, while chemoresistance remains a major therapeutic challenge in current clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVE: To evaluate the correlation between genetic polymorphisms in x-ray repair cross complementing group 1 (XRCC1) and sensitivity to platinum-based chemotherapy drugs in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: Genetic polymorphisms in the XRCC1 gene are correlated with sensitivity to platinum-based chemotherapy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Outcomes and resource use of NSCLC patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Consenting adult patients initiating FLT for advanced or metastatic NSCLC with platinum-based chemotherapy, with or without a targeted agent, entered the study between April 2009 and February 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In this study, we investigated the association of the positively selected SNPs of eIF3a with the response to and toxicity of platinum-based chemotherapy in Chinese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: The positively selected SNPs of eIF3a are significantly correlated with platinum-based chemotherapy toxicities in Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "For patients with advanced NSCLC who failed in previously platinum-based chemotherapy, bevacizumab also showed enhancing efficacy to antitumor drugs recommended by the latest NCCN guideline. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Treatments for advanced NSCLC are largely palliative and a benefit plateau appears to have reached with the platinum-based chemotherapy regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In conclusion, patients with NSCLC with EGFR mutations tend to have a low expression of ERCC1 mRNA and may potentially benefit from platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: Patients with metastatic NSCLC received pemetrexed (with or without bevacizumab) for 12 months or longer, either as maintenance treatment after first-line platinum-based chemotherapy or as subsequent treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVES: To compare the activity and tolerance of the consecutive administration of four active chemotherapeutic agents in combination with bevacizumab to a bevacizumab- and platinum-based chemotherapy doublet as front-line treatment in patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "RESULTS: We found that WISP1 rs16893344, rs2977530, rs2977537, and rs62514004 (P = .009, .033, .049, and .036, respectively) polymorphisms were related to susceptibility of lung cancer; and WISP1 rs11778573 (P = .023, nonsmokers), rs16893344 (P = .013, \u2265 50 years old), rs2977536 (P = .039, \u2265 50 years old; P = .044, nonsmokers; P = .047, NSCLC, respectively), rs2977549 (P = .013, smokers), and rs62514004 (P = .033, \u2265 50 years old) polymorphisms were significantly associated with platinum-based chemotherapy response in lung cancer patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This is the same approach that is generally recommended for other forms of advanced NSCLC, with the presence or absence of a driver mutation used to guide the selection of an epidermal growth factor receptor inhibitor, an anaplastic lymphoma kinase inhibitor, or conventional platinum-based chemotherapy (with the potential addition of bevacizumab). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " ERCC1 SNPs as Potential Predictive Biomarkers in NSCLC Patients Treated With Platinum-Based Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Polymorphisms in ERCC1, XPD, and XRCC1 were examined for (a) association with the clinical outcome of 107 NSCLC patients receiving front-line platinum-based chemotherapy, and (b) correlation with the ERCC1 mRNA levels of 176 chemo-naive primary tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Prognostic role of apoptosis-related gene functional variants in advanced NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Our study aimed to evaluate the correlations of four functional single-nucleotide polymorphisms - FAS -670 A>G, FAS ligand -844 T>C, survivin -31 G>C, and survivin 9386 C>T - with drug response and clinical outcomes in advanced NSCLC patients who received platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: The functional FAS -670 A>G and survivin 9386 C>T polymorphisms are potential independent prognostic factors in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced NSCLC, who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The aim of this study was to determine the response of advanced-stage NSCLC patients with or without EGFR mutations to platinum-based chemotherapy with or without gefitinib maintenance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " We performed a systematic review and meta-analysis to assess the potential of erlotinib plus platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Search of PubMed, EMBASE, Web of Science, CBM, CNKI, China Wan Fang databases and the Cochrane library was performed for studies regarding erlotinib plus platinum-based chemotherapy for advanced NSCLC published between 1 January 2000 and 28 August 2014. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Effect of platinum-based chemotherapy for NSCLC patients with interstitial lung disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "To assess the prognosis of NSCLC patients with ILD treated with platinum-based chemotherapy, we retrospectively analyzed the clinical course of those with ILD. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: One hundred and four NSCLC patients with ILD treated with platinum-based chemotherapy at Shizuoka Cancer Center between August 2002 and June 2013 were retrospectively reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The overall response rate was 38\u00a0% in 104 NSCLC patients with ILD treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: This single-arm phase 2 study was designed to assess the safety and efficacy of combination treatment with aromatase inhibitor\u2014letrozole\u2014and mTOR inhibitor\u2014everolimus\u2014in the treatment of patients with advanced (unresectable stage III or stage IV) NSCLC who had failed at least one line of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " ERCC1 mRNA expression is associated with the clinical outcome of NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In summary, low ERCC1 mRNA expression was associated with better response to chemotherapy and correlated with longer survival in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Adverse events in platinum-based chemotherapy for patients with advanced NSCLC are major challenges. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In this study, we investigated the role of the p53 and MDM2 genes in predicting adverse events in NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We determine that MDM2 c.14 + 309T > G was significantly associated with severe hematologic and overall toxicities for advanced NSCLC patients treated with platinum-based chemotherapy, especially for patients aged 57 and younger. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In addition, no significant associations were observed between the 3 SNPs and the response to first-line platinum-based chemotherapy in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Pro72Arg, MDM2 c.14 + 309T > G and MDM2 c.-461C > G polymorphisms are associated with toxicity risks following platinum-based chemotherapy treatment in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We suggest that MDM2 c.14 + 309T > G may be used as a candidate biomarker to predict adverse events in advanced NSCLC patients who had platinum-based chemotherapy treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: This was a phase Ib/II study in patients with nonsquamous NSCLC in whom 1 previous platinum-based chemotherapy regimen had failed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Furthermore, a phase III randomized study demonstrated the superiority of crizotinib to standard chemotherapy (pemetrexed or docetaxel) in the treatment of NSCLC patients harboring the ALK rearrangement who had received one prior platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "How much platinum-based chemotherapy is enough in NSCLC?  Peters S(1), Adjei AA(2). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " With no large randomized phase III trials to provide definitive answers, the ideal number of platinum-based chemotherapy cycles in patients with advanced NSCLC has long been unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Further study is needed to confirm survival benefit of platinum-based chemotherapy for elderly NSCLC [UMIN-CTR (www.umin.ac.jp/ctr/) ID: C000000146]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Serum ferritin is elevated in advanced NSCLC patients and is associated with efficacy of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " AIM: The aim of this study was to determine the expression levels of serum ferritin (SF) and investigate the correlation between SF expression levels and clinical characteristics as well as the efficacy to platinum-based chemotherapy for advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced NSCLC receiving first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The objective of this study was to investigate the correlation between EZH2 expression and platinum-based chemotherapy response as well as survival of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "MATERIALS AND METHODS: We identified 360 consecutive stage IIIB and IV NSCLC patients who underwent first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: To examine the expression of osteopontin (OPN) in patients with advanced NSCLC, and to analyze the correlation of the expression level of OPN with response to platinum-based chemotherapy and the prognosis of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVES: Although adjuvant platinum-based chemotherapy improves survival in completely resected NSCLC, its effect is limited. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We evaluated whether the expression of heat shock protein 70 (Hsp70) is associated with clinical outcomes in patients with completely resected NSCLC who were treated with or without adjuvant platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The potential predictive role of PKM2 in patients with metastatic/advanced non-small-cell lung cancer (NSCLC) receiving platinum-based chemotherapy as first-line was investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: PKM2 expression may be a predictive biomarker of platinum sensitivity in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Six versus fewer planned cycles of first-line platinum-based chemotherapy for NSCLC: a systematic review and meta-analysis of individual patient data. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the standard first-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "INTERPRETATION: Six cycles of first-line platinum-based chemotherapy did not improve overall survival compared with three or four courses in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The aim of this study was to examine the prognostic value of breast cancer susceptibility gene 1 (BRCA1), excision repair cross-complementation 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), and ribonucleotide reductase subunit M2 (RRM2) in patients with advanced NSCLC who received platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " This retrospective study was conducted to determine whether endostatin improves the efficacy and safety of platinum-based chemotherapy administered via both intravenous and arterial infusions for stage III/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVES: Platinum-based chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV NSCLC with non-squamous (NS) histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for NSCLC: randomized non-comparative phase IIIb NEXT trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Maintenance therapy is a new treatment strategy for advanced non-small-cell lung cancer(NSCLC), and it consists of switch maintenance and continuation maintenance.Switch maintenance is the introduction of a different drug, not included as part of the induction therapy, immediately after completion of 4 cycles of first-line platinum-based chemotherapy.Continuation maintenance is a continuation of at least one of the drugs used in the induction therapy in the absence of disease progression.Several phase III trials have reported survival benefits with continuation maintenance of pemetrexed and switch maintenance of pemetrexed or erlotinib.Therefore, maintenance therapy has become a part of the standard first-line treatment for advanced NSCLC.However, further research is needed to elucidate the selection criteria of patients who may benefit the most from maintenance therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The aim of this study is to investigate the association between COX-2 polymorphisms and clinical outcomes in advanced NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: A total of 190 patients with IIIB or IV NSCLC who received platinum-based chemotherapy were recruited in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: Our study suggested that rs689465 polymorphism could be a prognostic biomarker for advanced NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Retrospective evaluation of thromboembolic events in patients with NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The aim of this study was to describe the incidence of TE in patients with NSCLC, occurring during treatment with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: We retrospectively selected patients with NSCLC treated with platinum-based chemotherapy at the VU University Medical Center Amsterdam between 2000 and 2012. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In our study, a total of 1,004 advanced NSCLC patients receiving first-line, platinum-based chemotherapy regimens were used for genotyping 10 tag single nucleotide polymorphisms (SNPs) of MTHFR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The results indicate that a heterozygous advantage may exist in certain MTHFR variants, and the polymorphisms (especially rs1537514) may play a predictive role of treatment efficacy and adverse effects in NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: The study comprised 161 patients with inoperable NSCLC who received CRT with a target radiation dose greater than \u200960 Gy and platinum-based chemotherapy from 1998 to 2007. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Platinum-based chemotherapy improves survival among patients with NSCLC, but the efficiency is limited due to resistance. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " This study aimed to evaluate the association between RRM1 and BRCA1 expressions and the therapeutic efficacy of platinum-based chemotherapy in NSCLC patients in terms of their response and prognosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Pharmacogenetics of the DNA repair pathways in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Genetic variants in DNA repair genes may play a role in the effectiveness of platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We therefore investigated the clinical significance of changes in CECs count after three cycles of platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "A significant effect of SNPs on platinum-based chemotherapy response was observed among 296 advanced NSCLC patients without surgical operation: rs2790, rs4246215 and rs1882. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Furthermore, a phase III randomized study indicated that crizotinib is superior to standard chemotherapy in the treatment of patients with NSCLC harboring the ALK rearrangement who had received 1 previous platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In 598 stage III-IV NSCLC patients receiving platinum-based chemotherapy at the MD Anderson Cancer Center (MDACC), we correlated survival with 441 host single-nucleotide polymorphisms (SNPs) in 50 Wnt pathway genes. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We then assessed the most significant SNPs in 240 Mayo Clinic patients receiving platinum-based chemotherapy for advanced NSCLC, 127 MDACC patients receiving platinum-based adjuvant chemotherapy and 340 early stage MDACC patients undergoing surgery alone (cohorts 2-4). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The study aims to investigate whether the glutathione S transferase P1 (GSTP1) and excision repair cross-complementing group 1 (ERCC1) polymorphism influence the response to treatment with platinum-based chemotherapy in Chinese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of NSCLC receiving platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: ERCC1 and BRCA1 mRNA expression could be important predictive markers for individualized platinum-based chemotherapy for NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Association of CDC25 phosphatase family polymorphisms with the efficacy/toxicity of platinum-based chemotherapy in Chinese advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS & MATERIALS: We genotyped 14 SNPs of the CDC25 family in 663 Chinese patients with advanced NSCLC who were treated with first-line platinum-based chemotherapy and, in evaluable patients, analyzed relationships between the CDC25 family and the efficacy of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: These findings reveal a relationship between genetic variations of the CDC25 family and the efficacy and toxicity of platinum-based chemotherapy in patients with advanced NSCLC, especially in those with non-squamous-cell carcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "For locally advanced NSCLC patients, the recommended treatment is platinum-based chemotherapy or chemoradiotherapy if possible. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Nucleotide excision repair gene polymorphisms and prognosis of NSCLC patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The purpose of the present meta-analysis was to determine the roles of the genetic variants of the nucleotide excision repair genes on the prognosis of platinum-based chemotherapy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study assessed the prognostic and predictive value of circulating micro-RNA (miRNA) in patients with non-squamous NSCLC enrolled in the phase II SAKK (Swiss Group for Clinical Cancer Research) trial 19/05, receiving uniform treatment with first-line bevacizumab and erlotinib followed by platinum-based chemotherapy at progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Treatment of unselected patients with advanced NSCLC receiving third-generation platinum-based chemotherapy has reached a plateau of effectiveness. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Clinical trials have demonstrated that the response to icotinib among advanced NSCLC patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " We analyzed the role of three common single-nucleotide polymorphisms (SNPs) of ERCC1 in predicting the tumor responses and the survival of NSCLC patients who received platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Expression of ERCC1 and BRCA1 predict the clinical outcome of NSCLC in patients receiving platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Thus, the aim of this study is to evaluate the potential prognostic value of HORMAD2 polymorphisms in Han Chinese patients with advanced NSCLC and undergoing first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The aim of the study was to analyze the frequency of epidermal growth factor receptor (EGFR) mutations in Brazilian NSCLC patients and to correlate these mutations with response to benefit of platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: We identified paraffin-embedded NSCLC tissue blocks of known tissue platinum concentrations from 30 patients who underwent neoadjuvant platinum-based chemotherapy at MD Anderson Cancer Center. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " We aimed to assess the role of polymorphisms of the XRCC1 Arg194Trp, XRCC1 Arg399Gln, ERCC5 His1104Asp, and ERCC5 His46His genes on clinical outcomes of advanced NSCLC patients receiving platinum-based chemotherapy regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Expression of ERCC1, MSH2 and PARP1 in NSCLC and prognostic value in patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " This study aimed to investigate the effects of single-nucleotide polymorphisms (SNPs) XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XRCC3 Thr241Met, XPG His104Asp, and XPG His46His in genes involved in the DNA-repair pathway on the outcomes of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Moreover, the XPG 46T/T genotype increased the likelihood of longer disease-free survival and overall survival of NSCLC patients treated with platinum-based chemotherapy (HR=0.47; 95%CI=0.22-0.82 and HR=0.52; 95%CI=0.31- 0.96, respectively). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "These results indicate that XRCC1 Arg399Gln and XPG His46His might significantly affect the clinical outcomes of platinum-based chemotherapy, highlighting the need for larger studies to confirm the role of these two SNPs in outcomes of NSCLC treatments. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Patients with stage IIIB/IV NSCLC previously treated with platinum-based chemotherapy were randomized (2:1) to 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E) or placebo plus erlotinib (P/E) in 21-day cycles until disease progression or unacceptable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The relationship between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response (TR) of platinum-based chemotherapy in NSCLC patients have been extensively investigated by many studies, but the results were inconsistent and inconclusive. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Our study suggested that the GSTP1 A313G and GSTM1 null/present polymorphisms could predict the treatment response of the platinum-based chemotherapy in NSCLC patients, especially in East-Asian patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The aim of this study was to investigate whether single-nucleotide polymorphisms (SNPs) in DNA repair genes NBS1, LIG4, and RAD51 were correlated with tumor response in advanced NSCLC patients in a Chinese population who received platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The treatment outcomes of 146 advanced NSCLC patients who were treated with platinum-based chemotherapy were evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: NSCLC stage III-IV patients who failed one prior platinum-based chemotherapy regimen, \u2265 1 measurable lesion by Response Evaluation Criteria in Solid Tumors, and Eastern Cooperative Oncology Group performance status \u2264 2 were eligible. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "For the global JMEN study (maintenance), patients initially diagnosed with IIIB or IV NSCLC, those who had not progressed after completing at least four cycles of platinum-based chemotherapy were enrolled to test for the superiority of pemetrexed (500 mg/m(2), day 1 of each 21-day cycle) over placebo with progression free survival (PFS) as primary endpoint. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Concomitant platinum-based chemotherapy and radiotherapy (CT-RT) is the recommended treatment for unresectable locally advanced stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Outcome of platinum-based chemotherapy for NSCLC patients with pleural dissemination detected during surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "To assess the outcomes of platinum-based chemotherapy in NSCLC patients in whom pleural dissemination was detected during exploratory thoracotomy with or without a videoscope, the clinical records of NSCLC patients who were admitted to Shizuoka Cancer Center between September, 2002 and April, 2009 were reviewed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This retrospective study was performed to evaluate the predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) on the therapeutic efficacy of platinum-based chemotherapy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: Surgical resection plus adjuvant platinum-based chemotherapy is considered standard care for stage II to III NSCLC, but its efficacy is limited, and it involves toxic risks, justifying patient-tailored treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Prognostic impact of 18F-FDG uptake on PET in NSCLC patients with postoperative recurrence following platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "(18)F-FDG uptake in the primary tumors was an independent prognostic factor for predicting outcome in NSCLC patients receiving platinum-based chemotherapy for the treatment of postoperative recurrence. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The clinical effect of platinum-based chemotherapy for NSCLC is constrained by the resistance to drug. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The objective of the current study was to evaluate the cost-effectiveness of maintenance gefitinib therapy after four chemotherapeutic cycle's stand first-line platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC with unknown EGFR mutations, from a Chinese health care system perspective. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Maintenance gefitinib following first-line platinum-based chemotherapy for patients with locally advanced/metastatic NSCLC with unknown EGFR mutations is not cost-effective. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "On November 20, 2013, crizotinib received full approval based on an improvement in progression-free survival in patients with metastatic ALK-positive NSCLC previously treated with one platinum-based chemotherapy regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Multiple randomized studies have confirmed the superiority of EGFR TKIs over platinum-based chemotherapy and established EGFR TKIs as standard first-line therapy for patients with EGFR mutation-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study was conducted to evaluate the influence of TYMS polymorphisms on the survival of Portuguese patients with advanced NSCLC undergoing platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "According to our results, the TYMS polymorphisms may be useful tools to predict which advanced NSCLC patients could benefit more from platinum-based chemotherapy regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Differentially expressed miRNAs were further analyzed in sera from 94 healthy subjects and 94 advanced NSCLC patients receiving platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " To investigate whether theNAD(P)H: quinone oxidoreductase 1 (NQO1) gene polymorphisms determine the Platinum-based chemotherapy in advanced NSCLC in a Chinese cohort. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The NQO1 C609T polymorphism is an important molecular marker for advanced NSCLC, since it is associated with the NSCLC risk as well as the response status of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Analysis of NSCLC patients included in 2 prospective trials (NCT00573040 and NCT00572325) stage T4N0-1 or IIIA-N2 with 1 pathologic nodal station, treated with chemo-radiotherapy (CRT) using INDAR with concurrent or sequential platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Our results suggest that ERCC1 and BRCA1 mRNA expressions are associated with PFS and OS in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the cornerstone of treatment of advanced NSCLC patients, but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " OBJECTIVES: Platinum-based chemotherapy regimens are the standard treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We conducted a cohort study to assess the associations of ERCC1 and XPF polymorphisms with response to platinum-based chemotherapy and clinical outcome of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "One hundred eighty-seven NSCLC cases treated with platinum-based chemotherapy were prospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study reported that variants in ERCC1 can be used as a prognostic maker to platinum-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We investigated the impact of several potential SNPs of XPG on the efficacy of platinum-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Four to six cycles of platinum-based chemotherapy are currently recommended for the first-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy is a primary treatment of choice for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: Although platinum-based chemotherapy is a standard first-line treatment in advanced NSCLC, further research for the safety and efficacy of combination chemotherapy in elderly patients has been required. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in NSCLC: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The relationship between the ERCC1/2 single nucleotide polymorphisms (SNPs) and the clinical outcomes of the platinum-based chemotherapy in the NSCLC is still inconsistent and inconclusive despite extensive investigations have been conducted to address this question. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The inclusion criteria were platinum-based chemotherapy in NSCLC patients and evaluation of clinical outcomes in relation to the ERCC1 C118T, ERCC1 C8092A, ERCC2 Asp312Asn, and ERCC2 Lys751Gln. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This meta-analysis suggested that the ERCC1 C118T, ERCC2 Asp312Asn, and Lys751Gln may be useful biomarkers to predict the clinical outcomes of the platinum-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for NSCLC patients: a meta-analysis of 24 studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Here we performed a meta-analysis to better evaluate the association between the two XPD SNPs and clinical outcome of platinum-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Cox analyses confirmed that the SIRT 1 expression was a strong predictor for a poor OS and PFS in NSCLC patients underwent Platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: We used a pathway-based approach to investigate the association between genetic polymorphisms in MIF-pathway genes and the outcomes of platinum-based chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We used iSelect 24\u00d71 HD BeadChip (Illumina, Inc, San Diego, CA) to genotype 32 tag and potentially functional single nucleotide polymorphisms (SNPs) of 8 selected genes and evaluated their associations with different outcomes for 1004 patients with advanced NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: Our study is the first to suggest, to our knowledge, that polymorphisms in CD74 might be a marker of lower hematologic toxicity for patients with advanced NSCLC receiving platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The predictive value of 53BP1 and BRCA1 mRNA expression in advanced NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted NSCLCs (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: Eligible patients with advanced NSCLC of any histologic subtype and who had obtained a best response to prior platinum-based chemotherapy of at least stable disease received saracatanib 175 mg orally daily in a 28 day cycle. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In conclusion, low expression of RRM1 and RRM2 could be used to predict the treatment response to platinum-based chemotherapy and survival in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced NSCLC: an updated meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: Methylenetetrahydrofolate reductase (MTHFR) has been implicated in lung cancer risk and response to platinum-based chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We performed meta-analysis to investigate the effect of MTHFR C677T polymorphism on lung cancer risk and response to platinum-based chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Nineteen studies on MTHFR C677T polymorphism and lung cancer risk and three articles on C677T polymorphism and response to platinum-based chemotherapy in advanced NSCLC, were identified. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In addition, MTHFR 677TT homozygote carriers had a better response to platinum-based chemotherapy in advanced NSCLC in the recessive model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type NSCLC segregated according to KRAS mutation status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: We hypothesized that KRAS mutations function as a marker of poor sensitivity to first-line platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type (WT) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: KRAS mutation appears to negatively affect sensitivity to first-line platinum-based chemotherapy in patients with advanced nonsquamous EGFR WT NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "To date, eight randomized clinical trials have demonstrated that first-line treatment with TKIs in advanced NSCLC patients harboring activating EGFR mutations is associated with significant improvement in response rate, progression-free survival, quality of life and tolerability, compared with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: These findings suggest a predictive role of XRCC3 Thr241Met polymorphism on response to platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " In completely resected NSCLC patients with pathologically involved mediastinal lymph nodes (N2), administration of adjuvant platinum-based chemotherapy is now considered the standard of care, based on level 1 evidence. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In the current study the impact of the tumoral ERCC1 protein expression on the outcome of patients with advanced stage NSCLC treated with platinum-based chemotherapy, was investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy with third generation drugs (such as gemcitabine) is an efficacious regimen of first-line treatment of patients with advanced, unresectable NSCLC, without activating EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "AIM: To evaluate the safety and efficacy of a metronomic schedule of paclitaxel administered weekly in relapsed refractory NSCLC or upfront in patients not eligible for platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Predictive value of XPD polymorphisms on platinum-based chemotherapy in NSCLC: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: The correlation between xeroderma pigmentosum group D (XPD) polymorphisms (Lys751Gln and Asp312Asn) and clinical outcomes of NSCLC patients, who received platinum-based chemotherapy (Pt-chemotherapy), is still inconclusive. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: These results suggest that XPD Asp312Asn polymorphism may function as a predictive biomarker on platinum-based chemotherapy in NSCLC and further studies are warranted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND/OBJECTIVE: Non-platinum-based chemotherapy is a potential alternative to platinum doublet therapy for advanced NSCLC in selected patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: Pt-(GpG) adducts can be detected in CTC from NSCLC patients and assessing their kinetics may constitute a clinically feasible biomarker for response prediction and dose individualisation of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The aim of this study was to assess the role of EGFR mutations and ERCC1 in predicting the efficacy of platinum-based chemotherapy and the outcome of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: We conducted a retrospective study to analyze the relationships between EGFR mutations or ERCC1 expression and progression-free survival (PFS) in patients with NSCLC who received platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "RESULTS: Among the NSCLC patients who received platinum-based chemotherapy, the median PFS was significantly better in those who had never smoked and those with exon 19 deletion, and the median overall survival (OS) was significantly better in those who had never smoked, those with exon 19 deletion, and women. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Our results indicate that among NSCLC patients receiving platinum-based chemotherapy, those with exon 19 deletion have a longer PFS and OS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Our findings suggest that platinum-based chemotherapy is more effective against ERCC1-negative and exon 19-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Published evidence has shown controversial results about the relationship between XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: A systematic review and meta-analysis was performed to evaluate the predictive value of XRCC3 Thr241Met polymorphism on clinical outcomes of advanced NSCLC receiving platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: This systematic review and meta-analysis shows that carriers of the XRCC3 241Met allele are associated with good response to platinum-based chemotherapy in advanced NSCLC, while the XRCC3 Thr241Met polymorphism is not associated with OS or PFS. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: With the limitations of small and not randomised trials included, this pooled analysis shows that NSCLC patients who relapsed after a first-line platinum-based chemotherapy obtain a tumour response of 27% from a platinum rechallenge containing PEM or TAXs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We enrolled patients who had metastatic NSCLC, had had platinum-based chemotherapy, and had wild-type EGFR as assessed by direct sequencing. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The treatment of advanced disease (stage IIIb and IV) of NSCLC is based on systemic treatment with platinum-based chemotherapy or biological compounds depending on the disease molecular profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacizumab alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " KRAS mutations in advanced nonsquamous NSCLC patients treated with first-line platinum-based chemotherapy have no predictive value. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: On the basis of our multicenter data presented here, we conclude that KRAS mutation is not predictive for worse response to chemotherapy, PFS, and OS in advanced NSCLC patients treated with platinum-based chemotherapy in first-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: A prospective multi-institutional trial was designed to judge the feasibility of videothoracoscopy to restage the ipsilateral nodes in mediastinoscopy-proven stage IIIA (N2) NSCLC after 2 cycles of platinum-based chemotherapy and/or 40 Gy or more of radiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage NSCLC patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The published data on the predictive role of ERCC1 polymorphisms in lung cancer risk and survival of patients with advanced NSCLC receiving platinum-based chemotherapy remains inconsistent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Overall survival (OS) of patients with NSCLC receiving platinum-based chemotherapy was significantly related to ERCC1 C118T (HR: 1.29, 95% CI: 1.07-1.56, p=0.007, CT/TT vs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The backbone of first-line treatment for Epidermal Growth Factor (EGFR) wild-type (wt) advanced NSCLC patients is the use of a platinum-based chemotherapy combination. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable NSCLC Treated With First-line Platinum-based Chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Therefore, we investigated whether ABCG2 haplotype-tagging SNPs (htSNPs) were associated with clinical outcomes in patients with unresectable NSCLC treated with front-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: We genotyped 4 ABCG2 htSNPs for 129 unresectable NSCLC cases treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Thus, the ABCG2 htSNP rs2725264 may be independently associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Patients with stage IV or recurrent stage I to III NSCLC whose disease does not progress after 4 cycles of first-line platinum-based chemotherapy will be randomized in a 1:1 ratio to 1 of 2 study arms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy is the standard treatment for patients with advanced NSCLC, but the evidence of its efficacy among ECOG performance status (PS)2 patients is weak because these patients are usually excluded from clinical trials; concern exists about tolerability and feasibility of standard chemotherapy in these patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We aimed to investigate the role of five potential SNPs of XPG gene on the response to platinum-based chemotherapy in advanced Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In conclusion, our study found that polymorphisms in rs1047768 C/T and rs2296147 C/T are associated with response to platinum-based chemotherapy in advanced NSCLC, and XPG polymorphisms could be predictive of prognosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study aimed at investigating the association between COX-2 polymorphisms and the occurrence of grade 3 or 4 toxicity in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: This investigation for the first time suggested that polymorphism in COX-2 rs689466 may be a potent bio-marker in predicting severe hematologic toxicity in NSCLC patients after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy is a primary treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Chemotherapy with platinum agents is the standard of care for NSCLC; however, novel molecular-targeted agents like gefitinib have been approved for advanced NSCLCs, including recurrent cases previously treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Results of platinum-based chemotherapy in unselected performance status (PS) 2 patients with advanced NSCLC: a cohort study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "sjouveshomme@hpsj.fr  Recent phase-III trials show that platinum-based chemotherapy (PBCT) for patients with advanced NSCLC and poor performance status (PS) improves survival without increasing toxicity, compared to single-agent chemotherapy (CT). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We investigated the impact of XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp and XPD Lys751Gln gene polymorphisms on the efficacy of platinum-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: We found polymorphisms in XPD to be associated with response to platinum-based chemotherapy in NSCLC, and our findings provide information for therapeutic decisions for individualized therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: We retrospectively reviewed consecutive patients with non-squamous NSCLC who received first-line platinum-based chemotherapy with zoledronic acid at Shizuoka Cancer Center between 2007 and 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: The aim of this study was to explore the association between vitamin D receptor (VDR) genetic polymorphisms and platinum-based chemotherapy response as well as the prognosis of NSCLC in a Chinese cohort. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Platinum-based chemotherapy was given to each patient with NSCLC, and the therapeutic effect was evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Here, we investigated whether the regulatory variant rs2269577 of the XBP1 gene influences clinical outcome in advanced NSCLC patients undergoing platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: Platinum-based chemotherapy is the most common treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In this study, we investigated whether nonsynonymous single nucleotide polymorphisms (SNPs) in the BER pathway were associated with the response, progression-free survival (PFS) and overall survival (OS) of NSCLC patients following platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: We used TaqMan to genotype four SNPs (APE1 Asp148Glu, PARP1 Va1762Ala, XRCC1 Arg194Trp and XRCC1 Arg399Gln) in 147 patients with advanced NSCLC who had undergone routine platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: We found that XRCC1 Arg399Gln, PARP1 Va1762Ala and APE1 Asp148Glu SNPs in the BER pathway may influence the prognosis of advanced NSCLC patients following platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Erlotinib was first approved for the treatment of unselected NSCLC patients with advanced disease after failure of at least one prior chemotherapy regimen, and it was subsequently demonstrated to also confer a significant clinical benefit as maintenance therapy after first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The predictive value of BRCA1 and RAP80 mRNA expression in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " VCP gene variation predicts outcome of advanced NSCLC platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We investigated the association between VCP polymorphisms and clinical outcome in advanced NSCLC patients undergoing platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: Patients with advanced NSCLC have poor survival, and platinum-based chemotherapy agents are the standard first-line chemotherapy agents for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study aimed to identify predictive factors associated with the response to chemotherapy and survival in 258 patients with advanced NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Included in the study were 32 patients with stage III NSCLC who were treated with induction platinum-based chemotherapy followed in 21 by surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Fourteen advanced NSCLC patients showing disease progression after platinum-based chemotherapy regimens were recruited. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Cetuximab improved survival when added to first-line platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Summary data from randomised trials comparing first-line bevacizumab plus platinum-based chemotherapy with chemotherapy alone for inoperable locally advanced, recurrent or metastatic NSCLC were meta-analysed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Platinum-based chemotherapy is the first-line treatment for NSCLC, but recurrence occurs in most patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " AIM: To investigate the influence on platinum-based chemotherapy sensitivity by silencing xeroderma pigmentosum group A (XPA) gene expression in NSCLC drug resistance cell lines (A549/DDP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In this study, we assessed whether polymorphisms in genes of nucleotide excision repair (NER) pathway, including ERCC5, ERCC6, MMS19L, CCNH, XPC, RRM1, can affect the tolerability of platinum-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We used AllGloTM probe to assess genotyping and polymorphisms in 388 stage IIIB and IV NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Outcomes after adjuvant platinum-based chemotherapy in elderly NSCLC patients with T4 disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Even after development of molecular targeting therapies, platinum-based chemotherapy is still a standard care for treatment of locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Platinum-based chemotherapy was given to 432 subjects with advanced inoperable NSCLC and their responses to chemotherapy were evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Our findings indicate that SNPs in XRCC3, XPD or Aurora kinase A cannot predict outcomes in advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous NSCLC (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We aimed to investigate the association between NLR and therapy response, progression free survival (PFS) and overall survival (OS) in advanced NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: Elevated pretreatment NLR might be a potential biomarker of worse response to first-line platinum-based chemotherapy and shorter PFS and OS for advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Inclusion criteria were patients with advanced NSCLC who received platinum-based chemotherapy, an evaluated polymorphism of ERCC/MDR1 and overall response rate. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Longitudinal changes in peripheral T-cell subsets in 40 patients with malignant mesothelioma (MM) or advanced NSCLC receiving platinum-based chemotherapy were assessed by flow cytometry and evaluated for associations with clinical outcome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Recently, several studies have demonstrated that maintenance therapy in NSCLC can prolong overall survival in patients who have benefited from initial platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: We measured total platinum concentrations by flameless atomic absorption spectrophotometry in 44 archived fresh-frozen NSCLC specimens from patients who underwent surgical resection after neoadjuvant platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Genome-wide association study of prognosis in advanced NSCLC patients receiving platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: In this three-stage genome-wide association studies, we identified five SNPs as markers for survival of advanced-stage NSCLC patients treated with first-line platinum-based chemotherapy in Chinese Han populations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "george.dranitsaris@gmail.com  BACKGROUND: In patients with advanced-stage NSCLC with nonsquamous histology, bevacizumab maintenance therapy after initial combination with platinum-based chemotherapy has been approved in the United States and Europe. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This international, randomized, placebo-controlled, double-blinded phase III trial examines the efficacy and safety of ramucirumab treatment administered in combination with docetaxel, as compared with docetaxel administered with placebo, in patients with stage IV NSCLC whose disease progressed during or after first-line platinum-based chemotherapy with or without maintenance treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The purposes of this study were to: 1) analyze the association between chemotherapy-induced changes in plasma fibrinogen level and the chemotherapeutic response after the first two courses of standard first-line platinum-based chemotherapy; and 2) evaluate the prognostic significance of the basal plasma fibrinogen level in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous NSCLC (WJOG 5910L). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: CP with BEV was effective and feasible as a salvage chemotherapy after failure of platinum-based chemotherapy for patients with non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In this study, we aimed to comprehensively assess single nucleotide polymorphisms (SNPs) of the caspase-8 (CASP8) and caspase-10 (CASP10) genes in relation to toxicity outcomes with first-line platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We genotyped 13 tag SNPs of CASP8 and CASP10 in 663 patients with advanced NSCLC treated with platinum-based chemotherapy regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Our results provide novel evidence that polymorphisms in CASP8 and CASP10 may modulate toxicity outcomes in patients with advanced NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Multi-loci analysis reveals the importance of genetic variations involved in DNA repair and apoptotic pathways in sensitivity of platinum-based chemotherapy in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Association between eIF3\u03b1 polymorphism and severe toxicity caused by platinum-based chemotherapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Low ERCC1 expression has already been correlated with better treatment efficacy in NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Clinical outcome for EML4-ALK-positive patients with advanced NSCLC treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Limited data have been available, however, on the outcome of first-line platinum-based chemotherapy in patients with EML4-ALK-positive advanced NSCLC who have not been treated with an ALK kinase inhibitor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: The efficacy of platinum-based chemotherapy was compared between patients with advanced nonsquamous NSCLC who harbor EML4-ALK and those who harbor EGFR mutations and those with neither molecular abnormality. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " AIM: To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC) patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "MDR1 C3435T (OR = 1.97, 95% CI: 1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI: 1.44-4.74, P = 0.002) and GSTP1 A313G (OR = 0.32, 95% CI: 0.17-0.58, P = 0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The management of patients with SD after first-line chemotherapy is an important issue because only a minority of patients with advanced NSCLC experience tumour shrinkage after standard platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced NSCLC patients: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: Published data have shown conflicting results about the relationship between X-ray repair cross-complementing group 1 (XRCC1) gene polymorphisms (Arg399Gln and Arg194Trp) and clinical outcome of platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " The treatment for advanced stage NSCLC often includes platinum-based chemotherapy and IR. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable NSCLC treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " BACKGROUND: First-line platinum-based chemotherapy is currently considered the standard treatment for unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Therefore, we evaluated the impact of ERCC2 haplotype-tagging SNPs (htSNPs) on the clinical parameters of first-line platinum-based chemotherapy in unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: We genotyped 8 ERCC2 htSNPs for 129 unresectable NSCLC (stage IIIA, 12; stage III, 36; stage IV, 82) cases treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We pursued a pathway-based approach to investigate the association of potentially functional genetic polymorphisms of the corresponding genes with the outcomes of platinum-based chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The associations between these single nucleotide polymorphisms and the outcomes of 445 advanced NSCLC patients treated with platinum-based chemotherapy were evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " PURPOSE: To utilize a novel circulating tumor cell (CTC) technology to quantify ERCC1 expression on CTCs and determine whether ERCC1 expression levels predict efficacy of platinum-based chemotherapy in patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced NSCLC--a pilot study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "krapa@poczta.onet.pl  Platinum-based chemotherapy is the main type of I-line treatment of advanced and non-operative NSCLC patients without EGFR gene mutation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We investigated whether ERCC1 gene polymorphism has an effect on the response to chemotherapy and survival in 43 patients with NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Influence of DNA repair gene polymorphisms on prognosis in inoperable NSCLC patients treated with radiotherapy and platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "In this study, we analyzed the association between the XPA -4G>A, XPD Asp312Asn, hOGG1 Ser326Cys, XRCC1 Arg399Gln, XRCC2 -4234G>C, XRCC3 -4541A>G and Thr241Met polymorphisms and prognosis in 250 inoperable NSCLC patients treated with radiotherapy and platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "This study aims to identify whether XPD polymorphisms affect clinical efficacy among advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "EXPERIMENTAL DESIGN: 353 stage III-IV NSCLC patients receiving platinum-based chemotherapy as the first-line treatment were enrolled in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Our study provides evidence for the predictive role of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln polymorphisms/haplotype on NSCLC prognosis in inoperable advanced NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " AIM: To explore the association between the galectin-3 genetic polymorphisms and Platinum-based chemotherapy response as well as the prognosis of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The aim of this study was to investigate the prognostic and predictive value of TIL subtypes in patients with advanced NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Association of CASP7 polymorphisms and survival of patients with NSCLC with platinum-based chemotherapy treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We, therefore, explored whether single nucleotide polymorphisms (SNPs) of the CASP7 gene can modulate outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: We systematically genotyped 17 SNPs of CASP7 first in a discovery set of 279 patients with advanced NSCLC treated with platinum-based chemotherapy and then replicated the results in an independent set of 384 patients, in whom we evaluated associations with overall survival (OS) and progress-free survival (PFS) by Kaplan-Meier analysis and Cox hazards regression analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: This study provides evidence that genetic variations of CASP7 may modulate OS and PFS of patients with advanced NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "From January 2007 to December 2010, 25 patients with stage IIIB or IV NSCLC (17 with adenocarcinoma and 8 with squamous cell carcinoma), who had previously failed on platinum-based chemotherapy, received pemetrexed 500 mg/mq every 3 weeks until disease progression or unacceptable toxicities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " INTRODUCTION: The potential predictive role of BRCA1 and ERCC1 expression levels in patients with metastatic NSCLC receiving second-line platinum-based chemotherapy was investigated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: Real-time quantitative polymerase chain reaction after reverse transcription was used to assess the expression levels of BRCA1 and ERCC1 in 100 microdissected primary tumors from platinum-naive NSCLC patients treated with platinum-based chemotherapy in the second-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "MATERIAL AND METHODS: From September 2005 to June 2009, 355 advanced-stage NSCLC patients were accrued to compare the SNP variants with the outcome of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "XPD 751 Lys/ Lys might be a better prognostic marker of elderly or noncarcinoma NSCLC subgroup treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Thus platinum-based chemotherapy combined with cetuximab represents a new treatment option for patients with advanced NSCLC and high EGFR expression in their tumors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Phase III randomized studies have clearly demonstrated that a reversible EGFR-TKI is significantly superior in terms of response rate, progression-free survival and quality of life to platinum-based chemotherapy in advanced NSCLC patients who carry an activating EGFR mutation, thus resulting into a new standard of care for this biologically selected group of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " [Relationship of insulin-like growth factor receptor single nucleotide polymorphism (SNP) with platinum-based chemotherapy outcomes in advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The aim of this study is to investigate the relationship of IGF-1R+1013(G/A) and IGF-2R+1619(G/A) single nucleotide polymorphism (SNP) with platinum-based chemotherapy outcomes in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "METHODS: A total of 132 patients with NSCLC were routinely treated with platinum-based chemotherapy, and their clinical responses were evaluated after four cycles of chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Treatment for NSCLC consists mainly of platinum-based chemotherapy regimens and improvements are urgently needed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: ATP7A overexpression played an important role in platinum-resistance of NSCLC, and was a negative prognostic factor of NSCLC patients treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The aim of this work was to investigate the correlation between DNA repair gene expression levels in tumour tissue, normal tissue and peripheral blood samples from patients with two common human cancers, NSCLC and squamous cell carcinoma of the head and neck (HNSCC), to test if blood gene expression could be a proxy for tumour tissue gene expression to predict response to platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Our meta-analysis indicates that the ERCC1 Asn118Asn and C8092A polymorphisms may not be good prognostic biomarkers for platinum-based chemotherapy in patients with stage III-IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: Results of the TRUST study in the Polish population confirmed the efficacy of erlotinib in advanced NSCLC after failure of prior platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The most common mutations (L858R and exon 19 deletions) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum-based chemotherapy in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We hypothesized that an intronic polymorphism (rs430397G>A) in GRP78 affects survival among patients with NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSIONS: The rs430397 AA genotype of GRP78 is associated with reduced survival and higher prevalence of early relapses in patients with advanced NSCLC treated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "lidairong@sohu.com  This study aimed to investigate association between single-nucleotide polymorphisms (SNPs) of excision repair cross-complementing gene 1 (ERCC1), excision repair cross-complementing gene 2 (ERCC2), and X-ray repair cross-complementing group 1 (XRCC1) with sensitivity of advanced NSCLC patients to platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "A total of 89 NSCLC patients were recruited and treated with two cycles of platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "The combined polymorphisms of ERCC1, ERCC2, and XRCC1 may be associated with sensitivity of NSCLC to platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Further studies will verify these SNPs as biomarkers for prediction of platinum-based chemotherapy responses of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "We investigated the predictive and prognostic values of hCtr1, and copper efflux transporters ATP7A and ATP7B, in patients with locally advanced NSCLC receiving first-line platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "CONCLUSION: This is the first report to state that hCtr1 is not only an independent predictor of platinum-based chemotherapy response but also a prognostic factor in stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV NSCLC-proven tumor progression during or after one platinum-based chemotherapy regimen received a fixed dose of 1250 mg vatalanib either once-daily dosing (QD) or two divided daily dosing (TDD: 500 mg a.m. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "leedaeho@amc.seoul.kr  This study was designed to evaluate the efficacy of combination treatment of pemetrexed plus oxaliplatin as second-line treatment in advanced/metastatic NSCLC patients who have failed first-line platinum-based chemotherapy, assuming that oxaliplatin can overcome the resistance to a platinum agent and translate into better outcome. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": "selda.samakoglu@imclone.com  BACKGROUND: Although the addition of epidermal growth factor receptor (EGFR) antibodies to various platinum-based chemotherapy regimens for NSCLC is being actively pursued in the clinic, rationale for the prioritization of specific regimens is lacking. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "Platinum-based chemotherapy", "orig_sen": " INTRODUCTION: Platinum-based chemotherapy is standard for untreated, advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "[Epub ahead of print]  Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The purpose of the study was to investigate potential factors, including MDR genes polymorphisms, that could be used in qualification for second-line docetaxel therapy in NSCLC patients after failure of platinum based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Expert opinion: Nivolumab is the preferred treatment option for platinum-pretreated advanced NSCLC, having convincingly shown higher efficacy compared with standard docetaxel chemotherapy in phase III trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "A recent phase III randomized trial named REVEL, demonstrated the efficacy of ramucirumab in combination with docetaxel as second line treatment of advanced NSCLC, leading to its FDA and EMA approval in this clinical setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In the REVEL trial advanced NSCLC patients whose disease had progressed after first line platinum-based chemotherapy, were administered ramucirumab plus docetaxel or placebo plus docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Expert opinion: The addition of ramucirumab to docetaxel in the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy confers a 1.4-month improvement in overall survival, with an acceptable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The potential impact of the approval of the programmed death receptor-1 (PD-1)-blocking antibody nivolumab or pembrolizumab on the use of ramucirumab plus docetaxel in advanced NSCLC patient population is uncertain in clinical practice. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In order to improve overall outcomes for patients with advanced NSCLC, both ramucirumab plus docetaxel and the PD-1-blocking antibody should be used in any treatment line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In previously-treated patients with advanced nonsquamous NSCLC, overall survival was significantly prolonged and the overall response rate was significantly higher in patients who received intravenous nivolumab 3\u00a0mg/kg every 2\u00a0weeks versus intravenous docetaxel in the pivotal CheckMate 057 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Currently, ramucirumab is approved for the second-line treatment of metastatic NSCLC in combination with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Approval was based on demonstration of an improvement in overall survival (OS) in an international, multicenter, open-label, randomized trial comparing nivolumab to docetaxel in patients with metastatic nonsquamous NSCLC with progression on or after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV NSCLC Following Disease Progression after One Prior Platinum-Based Therapy (REVEL). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: REVEL demonstrated improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV NSCLC patients with disease progression following platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic NSCLC patients with progression after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVES: REVEL demonstrated that ramucirumab+docetaxel (RAM+DTX) improved overall survival, progression-free survival, and objective response rate in patients with advanced/metastatic NSCLC with progression after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Efficacy of tamoxifen in combination with docetaxel in patients with advanced NSCLC pretreated with platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The aim of this study was to evaluate the efficacy and safety of the combination of docetaxel (TXT) plus tamoxifen (TAM) in advanced NSCLC patients who had received platinum-based first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: West Japan Oncology Group 5910L was designed as a multicenter, open-label, randomized, phase 2 trial of docetaxel versus docetaxel plus bevacizumab every 3 weeks for patients with recurrent or metastatic nonsquamous NSCLC whose disease had progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "A report by Edelman recently published in the Journal of Clinical Oncology demonstrated the results of a prospective randomized trial using a combination of chemotherapy (docetaxel or pemetrexed) and either COX-2 inhibitor or a placebo for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In late December 2014, the US Food and Drug Administration (FDA) obtained the data monitoring committee report of a planned interim analysis of a trial in second-line SQ NSCLC (CM017) that demonstrated an overall survival benefit for patients treated with nivolumab compared with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "OBSERVATIONS: In that trial, 272 patients with metastatic SQ NSCLC patients had been randomized to receive nivolumab (n = 135) or docetaxel (n = 137). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Food and Drug Administration approval of ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2, given in combination with docetaxel for the treatment of patients with metastatic NSCLC whose disease has progressed on or after platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Nivolumab versus Docetaxel in Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous NSCLC that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks or docetaxel at a dose of 75 mg per square meter of body-surface area every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous NSCLC previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVES: This randomized phase II trial investigated the efficacy and safety of docetaxel plus bevacizumab and S-1 plus bevacizumab in the second-line treatment of non-squamous (non-Sq) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: Patients with non-Sq NSCLC who experienced disease progression after prior platinum-based chemotherapy with or without bevacizumab were randomly assigned to receive docetaxel plus bevacizumab (DB) once every 3 weeks or S-1 orally twice daily on days 1-14 plus bevacizumab (SB) on day 1 every 3 weeks until disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Second-line docetaxel for patients with platinum-refractory advanced NSCLC and interstitial pneumonia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This study was conducted to elucidate the efficacy and tolerability of second-line docetaxel monotherapy for patients with platinum-refractory advanced (stage IIIB, IV, or relapse) NSCLC and preexisting IP. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Docetaxel monotherapy has a poor activity and substantial risks when used for the treatment of platinum-resistant NSCLC with IP. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced NSCLC\u2020. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "RESULTS: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous NSCLC: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Furthermore, a phase III randomized study demonstrated the superiority of crizotinib to standard chemotherapy (pemetrexed or docetaxel) in the treatment of NSCLC patients harboring the ALK rearrangement who had received one prior platinum-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced NSCLC: Japan Clinical Oncology Group (JCOG) 0207\u2020. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Elderly patients (age \u226570 years, ECOG performance Status 0-1) with advanced NSCLC were randomized to receive docetaxel 20 mg/m(2) plus cisplatin 25 mg/m(2) on Day 1, 8 and 15 (docetaxel plus cisplatin) or docetaxel 25 mg/m(2) on the same schedule (docetaxel). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Patients with untreated advanced NSCLC received oral meloxicam (150 mg daily), carboplatin (area under the curve = 5 mg/ml \u00d7 min on day 1) and docetaxel (60 mg/m(2) on day 1) every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV NSCLC after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "INTERPRETATION: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Growth inhibition by DCA was also evaluated in a panel of 54 NSCLC cell lines with and without cytotoxic chemotherapeutics (cisplatin and docetaxel) in normoxic and hypoxic conditions. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "faupe@libero.it  INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for NSCLC after failure with cisplatin-based doublets. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Erlotinib versus docetaxel as second-line treatment of patients with advanced NSCLC and wild-type EGFR tumours (TAILOR): a randomised controlled trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV NSCLC after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "EGaron@mednet.ucla.edu  This article describes the treatment rationale and study-related procedures for the A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV NSCLC Following Disease Progression after One Prior Platinum-Based Therapy (REVEL) study (I4T-MC-JVBA; ClinicalTrials.govNCT01168973). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This international, randomized, placebo-controlled, double-blinded phase III trial examines the efficacy and safety of ramucirumab treatment administered in combination with docetaxel, as compared with docetaxel administered with placebo, in patients with stage IV NSCLC whose disease progressed during or after first-line platinum-based chemotherapy with or without maintenance treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The goal of the REVEL study is to demonstrate that ramucirumab in combination with docetaxel improves overall survival of patients with NSCLC with progressive disease after first-line therapy, and to advance our knowledge of the role of angiogenesis blockade in patients with NSCLC by identifying patients who are likely to experience maximum benefit based on extensive clinical biomarker correlative analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous NSCLC (WJOG 5910L). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS/DESIGN: WJOG 5910L was designed as a multicenter, open-label, randomized, phase II trial by the West Japan Oncology Group of docetaxel (arm A) versus docetaxel plus bevacizumab (arm B) in patients with recurrent or metatstatic nonsquamous NSCLC whose disease has progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In this phase II trial the efficacy and safety of bavituximab combined with docetaxel for previously treated, advanced nonsquamous NSCLC were evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "However, these advances, did not allow an improvement of the same endpoints in the management of NSCLC with squamous cell histology (SCC), where until very recently, docetaxel in monotherapy remained as a corner stone treatment for the second line, although associated with an unfavorable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Nintedanib has also shown promising clinical efficacy in combination with docetaxel and has been approved for treating patients with locally advanced and metastatic NSCLC in Europe. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced NSCLC: Thoracic Oncology Research Group (TORG) 1014. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Docetaxel monotherapy is one of the standard treatments for NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In particular, we will focus on nintedanib, from the preclinical studies to the latest phase III clinical trial that allowed this new agent to be approved by the European Medicines Agency as a second-line treatment option in association with docetaxel for NSCLC patients with adenocarcinoma histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " In the REVEL trial, ramucirumab, a monoclonal antibody to VEGFR-2, improved overall survival in combination with docetaxel compared to docetaxel alone in the second-line setting of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III NSCLC: SWOG S0533. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-na\u00efve patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " AIM: This phase II study was conducted to evaluate the efficacy and safety of docetaxel and bevacizumab combination therapy in patients with previously-treated non-squamous NSCLC (Nsq NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: The combination regimen of docetaxel-plus-bevacizumab is very active in patients with previously-treated Nsq NSCLC and warrants further research. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated NSCLC (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "INTERPRETATION: Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Newly diagnosed patients \u226518 years with histologically proven non-squamous NSCLC and Eastern Cooperative Oncology Group performance status (ECOG PS) \u22642 received six 21-day cycles of docetaxel, oxaliplatin, and bevacizumab followed by single-agent bevacizumab for a total of 1 year. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: The addition of bevacizumab to docetaxel/oxaliplatin is effective with an acceptable safety profile in patients with chemotherapy-na\u00efve advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Effectiveness of specific agents was assessed at time periods immediately following the approval of the agent for NSCLC: baseline, 1988-1994; platinum, 1995-1999; docetaxel, 1999-2003; pemetrexed and bevacizumab, 2004-2005. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous NSCLC: a multicenter phase II study of the Hellenic Oncology Research Group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "kentenik@hotmail.com  BACKGROUND: The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic NSCLC, and bevacizumab (B) improves the efficacy of frontline chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic NSCLC: a randomized, controlled phase III trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "rramlau@onet.eu  PURPOSE: To compare the efficacy of aflibercept (ziv-aflibercept), a recombinant human fusion protein targeting the vascular endothelial growth factor (VEGF) pathway, with or without docetaxel in platinum-pretreated patients with advanced or metastatic nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "To investigate this concept, a study was performed in NSCLC patients using positron emission tomography (PET) and radiolabeled docetaxel ([(11)C]docetaxel). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) NSCLCs (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: In a multicenter, open-label, phase III trial, elderly patients \u2265 70 years old with a PS of 0 to 2 and stage IV NSCLC were randomly assigned between chemotherapy allocation on the basis of PS and age (standard arm: carboplatin-based doublet if PS \u2264 1 and age \u2264 75 years; docetaxel if PS = 2 or age > 75 years) and treatment allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel for vulnerable patients, and best supportive care for frail patients). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Comparing docetaxel plus Cisplatin with Paclitaxel plus Carboplatin in chemotherapy-na\u00efve patients with advanced NSCLC: a single institute study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of nimotuzumab in combination with chemotherapy (docetaxel and carboplatin) versus chemotherapy alone in patients with stage IIIB/IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Analysis of continuous first-line treatment with docetaxel and carboplatin for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The present study aimed to analyze the efficacy and safety of multiple cycles of docetaxel and carboplatin (CBDCA) as a first-line treatment in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced NSCLC: north japan lung cancer group trial 0801. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This study aimed to evaluate the efficacy and safety of weekly docetaxel with carboplatin as first-line chemotherapy for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Author information: (1)Beijing Lung Cancer Center, Capital Medical University, Beijing, China;  BACKGROUND: To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: In this rapidly accrued study, docetaxel and carboplatin were well-tolerated in the adjuvant treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC: a randomized, phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We evaluated the efficacy and safety of continuation maintenance with pemetrexed and switch maintenance with docetaxel in advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Author information: (1)Department of Medical Oncology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA  INTRODUCTION: After early reports of vandetanib's efficacy in the induction setting, we evaluated the effect of combination docetaxel, carboplatin, and vandetanib, followed by maintenance therapy with either vandetanib, or placebo on progression-free survival (PFS) in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Patients with advanced NSCLC were randomized to induction docetaxel (75 mg/m) + carboplatin (area under the curve of 6) on day 1 of a 21-day cycle, and daily vandetanib (100 mg/day orally) for four cycles, followed by daily vandetanib (300 35 mg/day orally) or placebo until progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "txh@medicine.wisc.edu  INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel for NSCLC harboring the activated EGFR mutation with T790M at initial presentation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic NSCLC--results of the nonrandomised phase II study TaxErb. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "jr.fischer@klinik-loewenstein.de  This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, NSCLC: clinical application of a protocol used in a previous phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "junsaito@sannet.ne.jp  PURPOSE: To assess the clinical applicability of a protocol evaluated in a previously reported phase II study of concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin in patients with stage III, unresectable, NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B NSCLC treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The methodology is applied on the retrospective data of thirteen patients with NSCLC who received cisplatin in combination with gemcitabine, vinorelbine or docetaxel in the neoadjuvant context. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "[Epub ahead of print]  Clinical Observation of Docetaxel or Gemcitabine Combined with Cisplatin in the Chemotherapy after Surgery for Stage II-III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced NSCLC treated with chemoradiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB NSCLC: 10-year follow-up of the SAKK 16/01 trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The aim of this study was to confirm adjuvant chemotherapy of HSS with docetaxel plus cisplatin (DP) against NSCLC by evaluating antitumor activity and attenuated effect. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the treatment of locally recurrent stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "A total of 82 NSCLC patients undergoing Docetaxel combined with Cisplatin were randomly divided into group A and group B. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III NSCLC: KCSG-LU05-04. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally advanced NSCLC (LA-NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Effects of docetaxel plus three-dimensional conformal radiation therapy on microvessel density and apoptosis expression in local advanced squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " AT-101 is a BH3 mimetic and pan-Bcl-2 inhibitor that has shown potent anticancer activity in NSCLC in murine models, but failed to show clinical efficacy when used in combination with docetaxel in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced NSCLC: TCOG0701 CATS trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV NSCLC, an Eastern Cooperative Oncology Group performance status of 0-1 and adequate organ function were randomized to receive either oral S-1 80 mg/m(2)/day on days 1-21 plus cisplatin 60 mg/m(2) on day 8 every 4-5 weeks, or docetaxel 60 mg/m(2) on day 1 plus cisplatin 80 mg/m(2) on day 1 every 3-4 weeks, both up to six cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Oral S-1 plus cisplatin is not inferior to docetaxel plus cisplatin and is better tolerated in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected NSCLC with quality of life as the primary objective. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "GHRH antagonists potentiate docetaxel effects on growth of H460 NSCLC and MX-1 breast cancer plus suppressive action of doxorubicin on MX-1 and HCC1806 breast cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced NSCLC: the intergroup trial JCOG0803/WJOG4307L. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with stage III, stage IV, or recurrent NSCLC age \u2265 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel 60 mg/m(2) on day 1, every 3 weeks, or docetaxel 20 mg/m(2) plus cisplatin 25 mg/m(2) on days 1, 8, and 15, every 4 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: This study failed to demonstrate any survival advantage of weekly docetaxel plus cisplatin over docetaxel monotherapy as first-line chemotherapy for advanced NSCLC in elderly patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Patients with unresectable stage III NSCLC were treated with Endostar (7.5mg/m(2)/d) for 7days at weeks 1, 3, 5, and 7, while two cycles of docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) were administered on days 8 and 36, with concurrent thoracic radiation to a dose of 60-66Gy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The objective of this study was to evaluate the efficacy and safety of oxaliplatin combined with docetaxel as a first-line treatment for stage IV NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Patients with chemotherapy-naive NSCLC received 60\u2009mg/m(2) docetaxel (day 1) and 70\u2009mg/m(2) oxaliplatin (day 2) every three weeks for up to six cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: The results suggest that the combination of oxaliplatin and docetaxel is effective in patients with NSCLC with reasonable toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with NSCLC after failure of first-line chemotherapy: GFPC 10.02 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "OBJECTIVE: To assess the efficacy and tolerability of second-line sequential administration of erlotinib and docetaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Sequential erlotinib and docetaxel was not more effective than docetaxel alone as second-line treatment for advanced NSCLC with wild-type or unknown EGFR status. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: In this phase II trial, 78 patients with locally advanced NSCLC, of whom 56 were considered not resectable at initial diagnosis, were treated with three neoadjuvant cycles of docetaxel and cisplatin and subjected to radical surgery if resectable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Frequency and functional activity of Treg was analyzed in 31 NSCLC stage IB-IIIA patients treated by neoadjuvant Cetuximab/Docetaxel/Cisplatin prior to surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We sought to assess the preclinical efficacy of MK-5108 in a panel of NSCLC cell lines as a single agent and in combination with cisplatin and docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced NSCLC: A meta-analysis of randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "China ;  Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced NSCLC remains controversial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel and Cisplatin regimen for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "However, the administration of docetaxel to patients with metastatic prostate or breast cancer, as well as that of cisplatin plus vinorelbine to NSCLC patients, appears to significantly increase the ratio between effector T cells and Tregs and to reduce the immunosuppressive activity of the latter in the majority of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Tomotherapy (HT) is a novel radiotherapeutic technique, which allows the delivery of Image Guided-IMRT (IG-IMRT), with a highly conformal radiation dose distribution.The goal of the study was to estimate tolerability of Docetaxel concurrent with IMRT and to find the maximum tolerated dose of weekly Docetaxel concurrent with IMRT delivered with HT Tomotherapy after induction chemotherapy with Cisplatin and Docetaxel in patients affected with stage III NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: We designed a phase I, dose-finding study to determine the dose of weekly Docetaxel concurrent with Tomotherapy after induction chemotherapy, in patients affected by NSCLC with Stage III disease, not suitable for surgery. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "A 72-yr-old male patient with stage IV NSCLC developed diarrhea repeatedly after docetaxel-cisplatin chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: We investigated the efficacy and toxicity of a biweekly schedule of docetaxel and cisplatin in high-risk patients with unresectable (stages IIIB-IV) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: In this study, 48 high-risk patients with previously untreated locally advanced or metastatic NSCLC were treated with combination chemotherapy consisting of docetaxel 40 mg/m(2) and cisplatin 40 mg/m(2); both drugs were given biweekly, on days 1 and 15, every 4 weeks in an outpatient setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: As a front-line chemotherapy for high-risk patients with unresectable NSCLC in an outpatient setting, the biweekly schedule of docetaxel and cisplatin showed feasible efficacy with acceptable hematologic toxicities, comparable to the results of previous studies of triweekly or weekly schedules. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Additional large randomized studies are needed to optimize the schedule and dosage of combination therapy with docetaxel and cisplatin in high-risk patients with unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Patients with newly diagnosed metastatic NSCLC received docetaxel 75 mg/m\u00b2 and cisplatin 75 mg/m\u00b2 on day 1 and pegfilgrastim on day 2 every 14 days for four cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable NSCLC: KASLC 0401. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Moreover, immunohistochemical expression of Prx1 was evaluated in paraffin-embedded tissues from 24 NSCLC patients who had received docetaxel-cisplatin regimens as a first-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected NSCLC: Thoracic Oncology Research Group Study 0809. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "siniho@east.ncc.go.jp  BACKGROUND: We conducted a multicentre feasibility study for single agent long-term S-1 chemotherapy following docetaxel plus cisplatin in patients with curatively resected stage II-IIIA NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " [Series: Clinical study from Japan and its reflections; randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin for advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVES: To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy (CRT) followed by consolidation with docetaxel and cisplatin in locally advanced unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We are currently performing a prospective, randomized phase III trial comparing non-customized cisplatin/docetaxel with customized therapy in metastatic NSCLC patients (NCT00617656/GECP-BREC) and a parallel phase II study (ChiCTR-TRC-12001860) is being carried out in China (BREC-China) under the auspices of the SLCG. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIAL AND METHODS: Sixty patients with NSCLC receiving a chemotherapy regimen consisting of Cisplatin and Docetaxel were evaluated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The goals of this phase I/II study were to determine the recommended phase II dose (RP2D) of 1,25-D3 with cisplatin and docetaxel and its efficacy in metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " INTRODUCTION: To assess the efficacy and potential prognostic factors of patients with stage III N2 NSCLC treated with neoadjuvant docetaxel-cisplatin (DP) chemotherapy followed by surgical resection. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A combination of docetaxel (D) and cisplatin (P) is one of the standard regimens for the initial treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced NSCLC with bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "kyoh@east.ncc.go.jp  BACKGROUND: This study evaluated the safety and efficacy of combined zoledronic acid, cisplatin and docetaxel in patients with NSCLC with bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: The combination of zoledronic acid, cisplatin and docetaxel is well-tolerated with acceptable renal toxicity, and has modest activity as a first-line treatment of NSCLC patients with bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human NSCLC xenograft models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: These data demonstrate that motesanib had antitumor activity against five different human NSCLC xenograft models containing diverse genetic mutations, and that it had enhanced activity when combined with cisplatin or docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced NSCLC patients: a phase II trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A phase II study of docetaxel plus nedaplatin in patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The aim of this study was to evaluate the efficacy and safety of combination chemotherapy with docetaxel plus nedaplatin in patients with metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: The combination of docetaxel plus nedaplatin was well tolerated and demonstrated potent activity in patients with metastatic NSCLC, particularly squamous cell carcinoma of the lung. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced NSCLC: a multicenter phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III NSCLC (JCOG9901DI). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Prospective study of transarterial infusion of docetaxel and cisplatin to treat NSCLC in patients contraindicated for standard chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Fifty patients with clinically diagnosed N2 or N3 NSCLC who underwent induction CRT with docetaxel and cisplatin concurrently with thoracic radiation followed by surgery were examined in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including NSCLC, colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for NSCLC with mediastinal lymph node metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "toyooka@md.okayama-u.ac.jp  The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for NSCLC with mediastinal nodal metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Updated survival and outcomes for older adults with inoperable stage III NSCLC treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Consolidation docetaxel after EP/XRT does not improve survival in LA-NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "On these bases, the combination of docetaxel and nintedanib can be considered a new option for the second-line treatment for patients with advanced NSCLC with adenocarcinoma histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "[Epub ahead of print]  Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell NSCLC failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " INTRODUCTION: Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: EMPHASIS-lung is a randomized phase III multicenter trial exploring the differential activity of second-line erlotinib versus docetaxel on progression-free survival (PFS) in Veristrat good versus poor patients with squamous cell NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We assessed its efficacy and safety versus docetaxel in previously treated patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "INTERPRETATION: To our knowledge, OAK is the first randomised phase 3 study to report results of a PD-L1-targeted therapy, with atezolizumab treatment resulting in a clinically relevant improvement of overall survival versus docetaxel in previously treated NSCLC, regardless of PD-L1 expression or histology, with a favourable safety profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND/AIM: The TArceva and docetaxeL In former-Smokers MAle patients with recurrent NSCLC (TALISMAN) phase II, open-label randomized trial evaluates the combination of erlotinib with docetaxel in the second-line therapy of ex-smoker males with advanced squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The aim of this report is to assess the added benefit of nintedanib in combination with docetaxel in comparison with the appropriate comparator therapy (ACT) in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "[Epub ahead of print]  Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "[Epub ahead of print]  A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "A confirmed partial response (PR) was observed in 10 of the 47 patients with NSCLC who received trametinib plus docetaxel (21%). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Clinical activity exceeding the ORRs previously reported with docetaxel or pemetrexed alone in KRAS-mutated NSCLC and meeting prespecified criteria was observed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "[Epub ahead of print]  Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR NSCLC cell nude mouse xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This study explored antitumor activity of high-dose icotinib (an EGFR tyrosine kinase inhibitor) plus sequential docetaxel against wild-type EGFR NSCLC cells-generated nude mouse xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The study indicate that the high dose of icotinib plus sequential docetaxel (IcoH-DTX) have an additive effect on suppressing the growth of wild-type EGFR NSCLC cell nude mouse xenografts, possibly through microvessel density reduction. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The present study investigated the role of miR-141 regulation of eukaryotic initiation factor-4E (EIF4E) expression in docetaxel chemoresistance of human NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The expression of miR-141 in docetaxel chemoresistant patients with NSCLCs was markedly higher than those of non-docetaxel chemoresistant patients with NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The expression of EIF4E in docetaxel chemoresistant patients with NSCLCs was markedly lower than those of non-docetaxel chemoresistant patients with NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Thus, the present study is the first to show the induction of miR-141/EIF4E expression in an acquired model of docetaxel chemoresistant patients with NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This serves as a mechanism of acquired docetaxel chemoresistant patients with NSCLCs, possibly through direct interactions with VEGF, c-Myc, and Bax, therefore presenting a potential therapeutic target for the treatment of docetaxel chemoresistant patients with NSCLCs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In the period when a therapy has gained marketing authorisation and is no longer available to patients through clinical trials, but has not yet been granted approval or reimbursement, compassionate use programmes (CUPs) and named patient programmes (NPPs) can bridge this gap, enabling much-needed therapies to reach patients prior to approval or launch.In this Industry Corner article, we describe the experience with nintedanib in combination with docetaxel, which was first approved in the European Union in 2014 for the treatment of patients with NSCLC of adenocarcinoma histology after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "It results non-inferior to docetaxel in a randomized phase III trial including previously treated NSCLC patients; additionally, its safety profile is generally considered manageable. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "A population pharmacokinetic-pharmacodynamic (PK-PD) model was introduced to predict the development of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The REVEL study demonstrated a significant improvement of response rate, progression-free survival and overall survival by adding ramucirumab to docetaxel compared to docetaxel plus a placebo in second-line treatment of advanced NSCLC, irrespective of histology, with an acceptable safety profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This article has for objective to summarize efficacy and safety data of the use of ramucirumab in combination with docetaxel in second line in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "[Epub ahead of print]  The role of docetaxel in the treatment of NSCLC lung cancer: an update. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Areas covered: We searched Medline, Embase, Scopus and Cochrane Library for randomized phase III trials that evaluated docetaxel in various clinical settings of NSCLC and for meta-analyses of such trials and we present all relevant data regarding the pharmacology and clinical use of docetaxel in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Expert commentary: Despite its diminishing role, docetaxel in combination with novel targeted agents remains an important option of the therapeutic armamentarium in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A multicentre phase II trial of cabazitaxel in patients with advanced NSCLC progressing after docetaxel-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We investigated its activity in patients with advanced NSCLC progressing under or after docetaxel-based regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Patients with locally advanced unresectable or metastatic NSCLC, with an Eastern Cooperative Oncology Group performance status of 0-2, were enrolled; patients had to have received up to two prior chemotherapy regimens for the treatment of advanced disease, including one docetaxel-containing regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Cabazitaxel exhibits activity in NSCLC patients pre-treated with docetaxel-based chemotherapy with a substantial but manageable toxicity profile. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: The aim of our study was to explore the relationships between the M2 isoform of pyruvate kinase (PKM2) and the sensitivity of human NSCLC cells to docetaxel in vitro. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Silencing of PKM2 increased docetaxel sensitivity of human NSCLC A549 and H460 cells in a collaborative manner, resulting in strong suppression of cell viability. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Nintedanib in combination with docetaxel for second-line treatment of advanced NSCLC; GENESIS-SEFH drug evaluation report. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Nintedanib is a triple angiokinase inhibitor that has been approved by the European Agency Medicines (EMA) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non small cell lung cancer (NSCLC) of adenocarcinoma tumour histology, after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "placebo plus docetaxel improved progression free survival (PFS) in NSCLC patients, and improved overall survival in the population of adenocarcinoma patients, particularly in those with progression within 9 months after first line treatment initiation, median 10.9 months ( [95% CI 8.5-12.6] vs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV NSCLC after disease progression on platinum-based therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVES: Ramucirumab plus docetaxel prolongs survival in patients with NSCLC with disease progression after platinum-based therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This phase II, double-blind, randomized, placebo-controlled study assessed efficacy and safety of second-line ramucirumab-docetaxel in Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: Patients with NSCLC with progression after platinum-based therapy (28 Japanese sites; 19 December, 2012 to 22 May, 2015) were randomized (computer-generated sequence) to ramucirumab 10mg/kg or placebo, followed by docetaxel 60mg/m(2) (Day 1, 21-day cycle). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Second-line ramucirumab-docetaxel improved PFS similar to that seen in the REVEL trial with a manageable safety profile in Japanese patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In two Phase III trials, nivolumab was compared to docetaxel in patients with, respectively, squamous (CheckMate 017) and non-squamous NSCLC (CheckMate 057). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In both trials, nivolumab significantly reduced the risk of death compared to docetaxel (41% and 27% lower risk of death for squamous and non-squamous NSCLC, respectively). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In several large, randomized studies, PD-1/PD-L1 inhibitors have produced significant improvements in overall survival compared with single-agent docetaxel delivered in the second-line setting, effectively establishing a new standard of care in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel is recommended as a second-line chemotherapy agent for the NSCLC; however, drug resistance greatly limits its efficiency. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Forkhead box M1 (FoxM1), an oncogenic transcription factor, is believed to be involved in the chemoresistance of various human cancers; whereas the association of FoxM1 with acquired docetaxel-resistance in NSCLC remains unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Our results suggest a critical role of FoxM1 in docetaxel-resistance of the A549 cells and form the basis for the development of combined therapy of docetaxel and FoxM1 depletion in treating NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Selumetinib (AZD6244, ARRY-142886) is a potent and selective inhibitor of MEK1/2 which has demonstrated significant efficacy in combination with docetaxel in patients with KRAS mutant pretreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In this study, we found that fibronectin expression was inversely correlated with clinical responses to docetaxel treatment in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(\u00ae) nanoparticle formulation against NSCLC brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " AIM: Particle Replication in Nonwetting Templates (PRINT(\u00ae)) PLGA nanoparticles of docetaxel and acid-labile C2-dimethyl-Si-Docetaxel were evaluated with small molecule docetaxel as treatments for NSCLC brain metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: The decreased toxicity of the PRINT-C2-docetaxel improved treatment efficacy against NSCLC brain metastasis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Docetaxel or pemetrexed is the standard treatment for recurrent advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel-loaded PEG-albumin nanoparticles with improved antitumor efficiency against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The aim of the present study was mainly to assess the advantage of docetaxel-loaded PEG-albumin nanoparticles (PEG-DANPs) against NSCLC compared with the commercial product of docetaxel (Aisu\u00ae) and docetaxel-albumin nanoparticles (DANPs). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Previously treated PS0-1 patients with IIIB/IV EGFR (epidermal growth factor receptor) wild genotype NSCLC were randomly assigned to docetaxel (60\u2009mg/m(2) on Day 1) plus PPV based on preexisting host immunity or docetaxel plus placebo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PPV did not improve the survival in combination with docetaxel for previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "[Epub ahead of print]  Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced NSCLC and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVES: To compare first-line treatment with docetaxel plus gemcitabine (DG) versus gemcitabine (G) in elderly patients with advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Taxanes (paclitaxel, docetaxel and cabazitaxel) are frequently prescribed to treat breast cancer, hormone refractory prostate cancer, NSCLC and ovarian cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel (DTX) is an effective commercial anticancer agent for chemotherapy in NSCLC, breast cancer, gastric cancer, and prostate cancer, but its adverse effects including edema, neurotoxicity, and hair loss limit its application. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Involved agents included paclitaxel, docetaxel and vinorelbine; Malignancies included NSCLC, gastric cancer, esophageal carcinoma, ovarian carcinoma, malignant pleural mesothelioma, breast cancer, and small cell lung cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Nintedanib (Vargatef(\u00ae) ) plus docetaxel is approved in the EU for the treatment of patients with adenocarcinoma NSCLC after first-line chemotherapy, and as monotherapy (Ofev(\u00ae) ) in the United States and EU for the treatment of patients with idiopathic pulmonary fibrosis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: To investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced NSCLC patients in Korea. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: This prospective observational study included Korean advanced NSCLC patients with Eastern Cooperative Oncology Group performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: In Korean patients, the weekly regimen of docetaxel monotherapy was safe and efficacious against advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: To determine the safety and therapeutic efficacy of nimotuzumab (h-R3) combined with docetaxel in advanced NSCLC patients who have failed to respond to prior first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: In this single-center, open-label, dose-escalating phase I trial, patients with epidermal growth factor receptor (EGFR)-expressing stage IV NSCLC were treated with nimotuzumab plus docetaxel according to a dose escalation schedule. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at second- or third-line therapy was retrospectively analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Atezolizumab versus docetaxel for patients with previously treated NSCLC (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We assessed efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analysed by PD-L1 expression levels on tumour cells and tumour-infiltrating immune cells and in the intention-to-treat population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "INTERPRETATION: Atezolizumab significantly improved survival compared with docetaxel in patients with previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: The current analysis of data indicates that the benefit from PD-1 inhibitors versus docetaxel in second line treatment of NSCLC is limited to the PD-L1>1% subpopulation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " 3FDT, an analog of docetaxel with a blocked metabolism at its 3'-N-tert-butyloxyl group with three fluorine atoms, exhibits more potent cytotoxicity than docetaxel both with human cancer cell line SK-OV-3 in vitro and with human NSCLC A549 xenografts in vivo. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Taxane-type anticancer drugs, including paclitaxel and its semi-synthetic derivatives docetaxel and cabazitaxel, are widely applied to chemotherapy of malignancy like breast cancer, ovarian cancer, NSCLC and prostate cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Several pivotal phase III trials have now been concluded and have led regulatory agencies to grant marketing authorization to ramucirumab for use as second line therapy in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (as single agent or in combination with paclitaxel), in patients with advanced colorectal carcinoma (CRC) (in combination with infusional fluorouracil and irinotecan (FOLFIRI regimen)) and in patients with advanced NSCLC (in combination with docetaxel). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced NSCLC (SELECT-1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In a recent phase II study, selumetinib (AZD6244, ARRY-142886), an oral, potent and selective, allosteric MEK1/2 inhibitor with a short half-life, combined with docetaxel, improved clinical outcome as second-line treatment for patients with KRASm NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: SELECT-1 (NCT01933932) is a randomized, double-blind, placebo-controlled phase III study assessing the efficacy and safety of selumetinib plus docetaxel in patients with KRASm locally advanced or metastatic NSCLC, eligible for second-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: If the primary endpoint of PFS is met, selumetinib plus docetaxel would be the first targeted treatment for patients with KRASm advanced NSCLC who are eligible for second-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The phase II/III randomized KEYNOTE-010 trial demonstrated that pembrolizumab improved OS versus docetaxel in patients with previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: To gain a better understanding of the impact of dose and other prognostic factors on safety and efficacy of docetaxel in second-line NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: A model-based meta-analysis (MBMA) of a published docetaxel monotherapy data in 6085 second-line NSCLC patients from 46 trials was conducted. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced NSCLC (KEYNOTE-010): a randomised controlled trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel (Taxotere(\u00ae)) is an agent that is indicated for the treatment of patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage NSCLC in a University Hospital in Turkey. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: To compare the efficacy and toxicity of gemcitabine versus docetaxel in a second-line setting of nonsmall cell lung cancer (NSCLC) patients previously treated with platin-based combination chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: We retrospectively evaluated the medical records of 57 patients treated with single agent gemcitabine or docetaxel in second-line setting of advanced NSCLC who received one prior platinum-based therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Treatment with gemcitabine demonstrated clinically equivalent efficacy with a significantly improved safety profile compared with those receiving docetaxel in the second-line setting for advanced NSCLC in this study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "A recent Phase III trial demonstrated that treatment with the combination of nintedanib and docetaxel resulted in a significant and clinically meaningful improvement in both progression-free survival and overall survival compared with docetaxel alone in predefined NSCLC patients with adenocarcinoma tumor histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Nintedanib, combined with docetaxel, has been approved in the European Union for the treatment of patients with NSCLC with adenocarcinoma tumor histologic type after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Archival tumor samples collected from patients with platinum-refractory NSCLC in the phase III ZODIAC study of vandetanib plus docetaxel or placebo plus docetaxel (N= 294) were screened forKDRamplification by FISH. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Patients with NSCLC whose tumor hadKDRamplification were not associated with clinical benefit for vandetanib in combination with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We have reported the analysis performed on the role of the polymorphism located in the KRAS-LCS (rs61764370) which is involved in the disruption of the let-7 complementary site in NSCLC patients enrolled within the TAILOR trial, a randomised trial comparing erlotinib versus docetaxel in second line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In the pivotal CheckMate 017 trial, intravenous nivolumab 3\u00a0mg/kg every 2\u00a0weeks was associated with significantly better overall survival and progression-free survival and a significantly higher overall response rate than intravenous docetaxel in the second-line treatment of advanced, squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "A head-to-head comparison of docetaxel and nivolumab for second-line treatment of squamous cell NSCLC demonstrated superior overall survival and reduced grade 3 or 4 adverse effects in nivolumab-treated patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " In NSCLC, the first immune checkpoint inhibitor to be approved by the US Food and Drug Administration was nivolumab, based on a survival advantage over docetaxel in recurrent squamous NSCLC, a difficult-to-treat histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Case 1: An 86-year-old man was diagnosed with large cell or squamous cell lung cancer of clinical Stage II A.He was administered nanoparticle albumin-bound paclitaxel(nab-PTX)as fourth-line chemotherapy after monochemotherapy with docetaxel, vinorelbine, and S-1.The patient continues to show complete remission at the 15 courses of nab-PTX.Case 2: A 79-year-old man underwent partial resection of the right lower lung, and the pathological diagnosis was large cell lung cancer of pStage I A.However, recurrence in the right lung and multiple lymph node metastases were identified 3 years after the surgery.He was administered nab-PTX as second-line chemotherapy after vinorelbine monotherapy, and he has shown complete remission for a year.Weekly intravenous nab-PTX may be useful in elderly patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel inhibits the proliferation of NSCLC cells via upregulation of microRNA-7 expression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Several new chemotherapeutic agents have recently shown encouraging activity in NSCLC, especially docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We studied miRNAs in NSCLC cell lines to identify those that can regulate and predict the effectiveness of docetaxel on NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CCK8, Annexin and V-FITC assays were carried out to evaluate the inhibitory effect of docetaxel on NSCLC cell lines A549 and H460, and qRT-PCR was used to detect and compare six miRNAs expression levels in the two cells with docetaxel or not. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Docetaxel induced NSCLC cell apoptosis and suppressed cell proliferation in vitro. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MiR-7 overexpression improved anti-proliferative and pro-apoptotic effects of docetaxel on the NSCLC cells and that miR-7 down-regulation decreased those effects. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Anti-angiogenic-specific adverse events in patients with NSCLC treated with nintedanib and docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVES: LUME-Lung 1 was a randomized, placebo-controlled, Phase III trial investigating nintedanib+docetaxel versus placebo+docetaxel in patients with advanced NSCLC progressing after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Among these, nivolumab demonstrated a survival benefit versus docetaxel in refractory squamous NSCLC, reporting 41% reduction in risk of death (median overall survival: 9.2 versus 6.0 months; objective response rate: 20% versus 9%), and better safety profile than standard-of-care chemotherapy (grade 3-4 adverse events: 7% versus 55%). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A comparative study on the effect of docetaxel-albumin nanoparticles and docetaxel-loaded PEG-albumin nanoparticles against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The present study mainly compared the effect of docetaxel-albumin nanoparticles (DANPs) and docetaxel-loaded PEG-albumin nanoparticles (PEG-DANPs) against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Efficacy and safety of docetaxel for advanced NSCLC: a meta-analysis of Phase III randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The aim was to conduct a meta-analysis to compare the efficacy and safety of docetaxel and pemetrexed or docetaxel and vinca alkaloid for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Docetaxel leads to a better result than vinca alkaloid in effectiveness and safety on patients with advanced NSCLC as first-line therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Prognostic factors in NSCLC patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: Docetaxel or pemetrexed monotherapy is recommended either as a second-line treatment for NSCLC patients without EGFR mutation or ALK fusion genes or as a third-line treatment for patients with EGFR mutation or ALK fusion. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: When planning clinical studies of NSCLC patients recommended to receive docetaxel or pemetrexed as single-agent chemotherapy, the EGFR status and stage before first-line treatment should be considered as stratification factors of randomized clinical studies. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Zinc supplementation induces apoptosis and enhances antitumor efficacy of docetaxel in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Therefore, zinc supplementation may show anticancer efficacy solely and may increase docetaxel-induced cytotoxicity in NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Zinc has anticancer efficacy against NSCLC cells in the presence of functionally active p53 and enhances docetaxel efficacy in both p53-wild-type and p53-deficient cancer cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic NSCLC: evaluation of drug-drug interaction. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: Docetaxel and gefitinib play key roles in the treatment of NSCLC, and their combination could be of interest. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Nintedanib in combination with docetaxel for second-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Nintedanib is a potent, oral, triple angiokinase inhibitor of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor, and was recently approved in Europe for use in combination with docetaxel for the treatment of adults with locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma tumor histology, following first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Nintedanib has been investigated extensively in preclinical research and in a number of clinical studies, the most important of which was the Phase III LUME-Lung 1 study, which investigated nintedanib in combination with docetaxel in patients with advanced NSCLC after failure of first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: Second-line chemotherapy of advanced NSCLC with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV NSCLC (NSCLC; NCT00890825). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Different KRAS mutations in NSCLC may influence selumetinib/docetaxel sensitivity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND AND OBJECTIVE: This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type NSCLC: a retrospective real-world practice review at a single tertiary care centre. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The present practice review of tki use for second- and third-line treatment in EGFR wild-type nsclc also compares clinical outcomes for tki and single-agent docetaxel as second-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: In our study cohort, second-line therapy for EGFR wild-type nsclc with tki (compared with docetaxel) was associated with statistically better pfs and efs and noninferior os. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Subgroup analysis showed that OS benefit was presented only in patients treated with docetaxel plus antiangiogenic agents (HR 0.92, 95%CI: 0.86-0.99, p=0.02) and patients with non-squamous NSCLC (HR for OS 0.92, 95%CI: 0.86-0.99, p=0.02). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Nivolumab versus Docetaxel in Advanced Squamous-Cell NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced NSCLC (GALAXY-1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced NSCLC and to identify patient populations most likely to benefit from the combination. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Docetaxel, a taxane chemotherapy drug widely used in the treatment of many types of solid tumors including NSCLC, rarely causes infiltrative pneumonitis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in NSCLC patients previously treated with platinum-based chemoradiotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This study aimed to evaluate the efficacy and toxicity of platinum combination chemotherapy versus docetaxel monotherapy in NSCLC patients previously treated with platinum-based CRT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "From September 2002 to December 2009, at three participating institutions, 24 patients with locally advanced NSCLC, who had previously received platinum-based CRT, were treated with platinum combination re-challenge therapy, whereas 61 received docetaxel monotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In the EU, nintedanib in combination with docetaxel is indicated for adults with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Nintedanib in combination with docetaxel relative to placebo plus docetaxel significantly prolonged progression-free survival (PFS), but did not increase overall survival (OS), in the overall population of patients with advanced NSCLC in the phase III LUME-Lung 1 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "To conclude, nintedanib in combination with docetaxel is an effective treatment option for patients with advanced NSCLC of adenocarcinoma histology after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for advNS-NSCLC in four Chinese hospitals from 2007 to 2012. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Pemetrexed singlet cost significantly less for supportive care than pemetrexed or docetaxel-based doublets when treating Chinese patients with AdvNS-NSCLC in the second-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Epithelial-mesenchymal transition contributes to docetaxel resistance in human NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In the current study, we established a new docetaxel-resistant human non-small lung cancer (NSCLC) cell line A549/Docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In summary, we have established a typical docetaxel-resistant human NSCLC cell line A549/Docetaxel, and it was suggested that the multidrug resistance of A549/Docetaxel was related to EMT. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced NSCLC and a poor performance status (IFCT-0301). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Erlotinib versus docetaxel as second- or third-line therapy in patients with advanced NSCLC in the era of personalized medicine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced NSCLC patients, but there is no study comparing the difference between these 2 chemotherapy regimens. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " INTRODUCTION: The purpose of this study was to assess whether an intercalated dosing schedule of erlotinib and docetaxel could avoid possible negative interactions and optimize the benefit obtained as second-line therapy in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Therefore, we investigated the molecular mechanism of action of IPI-504 (retaspimycin HCl), a potent and selective inhibitor of HSP90, in combination with the microtubule targeting agent (MTA) docetaxel, in preclinical models of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Our data provide a preclinical rationale for testing the combination of IPI-504 and docetaxel in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " INTRODUCTION: The LUME-Lung 1 trial (NCT00805194; Study 1199.13) demonstrated a significant overall survival (OS) advantage for nintedanib plus docetaxel compared with placebo plus docetaxel as second-line therapy for patients with advanced NSCLC and adenocarcinoma histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: Cytochrome P450 1B1 (CYP1B1) is involved in the metabolism of anticancer agents; its overexpression was associated with resistance to docetaxel, a commonly used drug for second-line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The objective of this study was to retrospectively evaluate the correlation of CYP1B1 SNPs with the outcome of NSCLC patients treated with docetaxel in second or third line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: CYP1B1 4326C>G polymorphism emerged as possible prognostic/predictive marker of activity and efficacy of docetaxel in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Nintedanib plus docetaxel has proven an overall survival benefit over docetaxel monotherapy in second-line treatment of NSCLC of adenocarcinoma histology in the LUME-Lung 1 pivotal trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "No published trials have previously compared nintedanib plus docetaxel with agents \u2013 other than docetaxel \u2013 that are approved second-line treatments for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: In patients with advanced NSCLC of adenocarcinoma histology, results suggest that nintedanib plus docetaxel offers clinical benefit compared with docetaxel alone, when used as second-line treatment, and suggests that this combination may also add clinical benefit compared with erlotinib in this patient group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Sequence-dependent antiproliferative effects of gefitinib and docetaxel on NSCLC cells and the possible mechanism. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with NSCLC: a randomized open-label phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "To investigate whether blocking survivin expression enhances docetaxel-induced apoptosis in patients with NSCLC, we compared the antitumor activity of the survivin inhibitor LY2181308 plus docetaxel with docetaxel alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Patients (N = 162) eligible for second-line NSCLC treatment (stage IIIB/IV) with an Eastern Cooperative Oncology Group performance status of 0 to 1 were randomized 2:1 to receive LY2181308 (750 mg intravenously, weekly) and docetaxel (75 mg/m intravenously, day 1) or docetaxel alone every 21 days. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " INTRODUCTION: The main objective of the current post hoc analysis was to compare patient-reported outcomes between crizotinib (N = 172) and chemotherapy subgroups (pemetrexed [N = 99] and docetaxel [N = 72]) in previously treated patients with advanced ALK-positive NSCLC, in PROFILE 1007 study (Pfizer; NCT0093283). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Nintedanib has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of IPF, and for the second-line treatment in combination with docetaxel of locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: This phase I, open-label study evaluated the safety/tolerability and maximum tolerated dose of second-line nintedanib combined with docetaxel in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Continuous treatment with second-line nintedanib combined with docetaxel was manageable and showed promising signs of efficacy in Japanese patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " AIM: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: The benefit of docetaxel-based therapy in the second-line treatment of advanced NSCLC is still unclear. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The goal of this meta-analysis was to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed to improve with first-line treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "IMPLICATIONS: Based on the available evidence, docetaxel-based doublet therapy seems superior to docetaxel monotherapy as a second-line treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: A retrospective cohort study was conducted including patients receiving pemetrexed or docetaxel-based chemotherapy in the second-line setting for advNS-NSCLC in four Chinese tertiary care hospitals. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Pemetrexed was associated with significantly postponed tumor progression and significantly less hematological toxicity than docetaxel in the real-world second-line setting for advNS-NSCLC in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Over the past decade, well tolerated second-line therapies for advanced NSCLC have been approved including erlotinib and pemetrexed in addition to docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: The efficacy of docetaxel, vinorelbine, or gemcitabine monotherapy in previously untreated elderly patients with NSCLC has been reported.Pemetrexed monotherapy has shown clinically equivalent efficacy to docetaxel, a standard therapeutic option, in patients with previously treated NSCLC and in those with a lower incidence of toxicity such as febrile neutropenia. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " INTRODUCTION: Two standard single-agent chemotherapy treatments (docetaxel and pemetrexed) were combined in this trial and administered as second-line treatment in patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: We recommend that docetaxel or pemetrexed monotherapies should continue to be considered the standard second-line chemotherapy treatment against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: Paclitaxel and docetaxel are two taxanes approved for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "However, there is limited evidence regarding the efficacy of docetaxel in NSCLC previously treated with a paclitaxel-platinum doublet (PP). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The aim of our study was to evaluate the response to docetaxel in NSCLC patients with prior PP treatment. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Patients with stage IV NSCLC treated with PP that presented disease progression and received docetaxel as second-line treatment were included. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Previous use of PP does not preclude a favorable response to docetaxel in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Long PFS with PP may help select NSCLC patients who benefit from second-line docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: ZODIAC was a randomized phase III study of second-line treatment in patients with advanced NSCLC that evaluated the addition of vandetanib to docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: After progression following first-line chemotherapy, 1391 patients with locally advanced or metastatic (stage IIIB/IV) NSCLC were randomized 1 : 1 to receive vandetanib (100 mg/day) plus docetaxel (75 mg/m(2) every 21 days) or placebo plus docetaxel in the ZODIAC study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: High EGFR gene copy number or activating EGFR mutations may identify patient subgroups who receive increased clinical benefit from vandetanib in combination with docetaxel in second-line NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Docetaxel resistance remains a major obstacle in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Response to first-line chemotherapy of docetaxel combined with platinum predicting the prognosis and subsequent treatment of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: The aim of this study was to confirm the association between the response to docetaxel combined with platinum as first-line chemotherapy and prognosis and subsequent treatment for patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Our study demonstrated that the response to docetaxel in combination with platinum as a first-line chemotherapy was an independent prognostic factor for patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The present work evaluated the in vitro effects of chitosan cross-linked \u03b3-poly(glutamic acid) (\u03b3-PGA) nanoparticles (Nps) loaded with docetaxel (DTXL) and decorated with Cetuximab (CET), targeted to EGFR over-expressing non-small-cell-lung-cancer (NSCLC) cells (A549). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This randomized phase 2 study evaluated PX-866 combined with docetaxel in patients with advanced, refractory NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Patients with locally advanced, recurrent, or metastatic NSCLC who had received at least one and no more than two prior systemic treatment regimens were randomized (1:1) to a combination of docetaxel (75 mg/m intravenous every 21 days) with or without PX-866 (8 mg orally daily; arms A and B, respectively). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: The addition of PX-866 to docetaxel did not improve PFS, response rate, or OS in patients with advanced, refractory NSCLC without molecular preselection. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Docetaxel is a key antineoplastic drug for treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CASE PRESENTATION: We encountered three Japanese NSCLC patients who developed epiphora after the administration of docetaxel-based chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced NSCLC: a systematic review and meta-analysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Our aim was to conduct a meta-analysis to compare the efficacy and safety of pemetrexed and docetaxel for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIALS AND METHODS: We systematically searched the Cochrane Library, PubMed, Embase, China Biology Medicine Database for randomized controlled trials (RCTs) comparing the efficacy and toxicities of pemetrexed versus docetaxel as a treatment for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Pemetrexed was almost as effective as docetaxel in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced NSCLC: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: To investigate the efficacy of erlotinib versus docetaxel in previously treated patients with advanced NSCLC in an epidermal growth factor receptor (EGFR) -unselected patient population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "EGFR wild-type NSCLC was present in 109 and 90 patients in the erlotinib and docetaxel groups, respectively. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Phase II study of zoledronic acid combined with docetaxel for NSCLC: West Japan Oncology Group. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The aim of this open-label, multicenter, randomized phase II trial was to evaluate the efficacy and safety of zoledronic acid in combination with docetaxel in previously treated patients with NSCLC and bone metastases. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Zoledronic acid combined with docetaxel was well tolerated but did not meet the primary endpoint of demonstrating a longer progression-free survival in advanced NSCLC patients with bone metastases compared with docetaxel alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " [A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced NSCLC]. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The aim of this study is to evaluate the efficacy and safety of docetaxel plus platinum (DP) compared with vinorelbine plus platinum (VP) regimens in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u4ee5\u94c2\u7c7b\u4e3a\u57fa\u7840\u8054\u5408\u7b2c\u4e09\u4ee3\u836f\u7269\u7684\u53cc\u836f\u5316\u7597\u65b9\u6848\u662f\u6cbb\u7597\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC, NSCLC\uff09\u7684\u6807\u51c6\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u3002\u672c\u7814\u7a76\u91c7\u7528meta\u5206\u6790\u7684\u65b9\u6cd5\u8bc4\u4ef7\u591a\u897f\u4ed6\u8d5b\u8054\u5408\u94c2\u7c7b\uff08docetaxel plus platinum, DP\uff09\u65b9\u6848\u5bf9\u6bd4\u957f\u6625\u745e\u6ee8\u8054\u5408\u94c2\u7c7b\uff08vinorelbine plus platinum, VP\uff09\u65b9\u6848\u6cbb\u7597\u665a\u671fNSCLC\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u65b9\u6cd5 \u8ba1\u7b97\u673a\u68c0\u7d22Pubmed\u3001EMBASE\u3001Cochrane Library\u3001\u4e2d\u56fd\u671f\u520a\u5168\u6587\u6570\u636e\u5e93\uff08CNKI\uff09\u3001\u4e2d\u56fd\u751f\u7269\u533b\u5b66\u6587\u732e\u6570\u636e\u5e93\uff08CBM\uff09\u3001\u4e2d\u6587\u79d1\u6280\u671f\u520a\u5168\u6587\u6570\u636e\uff08VIP\uff09\u5e93\u53ca\u4e07\u65b9\u6570\u636e\u5e93\u5173\u4e8eDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u6cbb\u7597\u665a\u671fNSC LC\u7684\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\uff08randomized controlled trial, RCT\uff09\u3002\u6839\u636eCochrane Handbook 5.1.0\u7684\u8d28\u91cf\u8bc4\u4ef7\u6807\u51c6\uff0c\u7528Stata 12.0\u8f6f\u4ef6\u8fdb\u884c\u7edf\u8ba1\u5b66\u5206\u6790\u3002\u7ed3\u679c \u7814\u7a76\u5171\u7eb3\u51657\u9879RCTs\uff0c\u5305\u62ec\u665a\u671fNSCLC\u60a3\u80052,381\u4f8b\u3002DP\u65b9\u6848\u76842\u5e74\u751f\u5b58\u7387\uff08HR=0.887, 95%CI: 0.810-0.972, P=0.010\uff09\u3001\u6709\u6548\u7387\uff08RR=1.276, 95%CI: 1.107-1.450, P=0.001\uff09\u548c\u8179\u6cfb\u53d1\u751f\u7387\uff08RR=3.134, 95%CI: 1.918-5.121, P<0.001\uff09\u8f83VP\u65b9\u6848\u9ad8\uff1bDP\u65b9\u6848\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff08RR=0.386, 95%CI: 0.311-0.478, P<0.001\uff09\uff1bDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u57281\u5e74\u751f\u5b58\u7387\u3001\u767d\u7ec6\u80de\u51cf\u5c11\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u3001\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u538c\u98df\u3001\u6076\u5fc3\u3001\u5455\u5410\u65b9\u9762\u7684\u5dee\u5f02\u65e0\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u7ed3\u8bba DP\u65b9\u6848\u867d\u7136\u589e\u52a0\u4e86\u8179\u6cfb\u53d1\u751f\u7387\uff0c\u4f46\u5374\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff0c\u540c\u65f6\u63d0\u9ad8\u4e862\u5e74\u751f\u5b58\u7387\u548c\u6709\u6548\u7387\u3002\u76f8\u6bd4VP\u65b9\u6848\uff0cDP\u65b9\u6848\u53ef\u80fd\u66f4\u9002\u5408\u4e00\u7ebf\u6cbb\u7597\u665a\u671fNSCLC\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.07 PMID: 24758908 [PubMed - indexed for MEDLINE]   299. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Our research aimed at exploring the cytotoxic interactions between gefitinib and docetaxel with different concentrations for NSCLC cell lines, and furthermore, the mechanisms underlying the cytotoxic synergism. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Development of a novel orthotopic NSCLC model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The aims of these studies were to establish an orthotopic NSCLC mouse model and to investigate the therapeutic efficacy of lipid-based nanoparticles (NPs) containing 2'-(2-bromohexadecanoyl)-docetaxel (Br-C16-DX) in this new model. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced NSCLC: a meta-analysis of 14 randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVES: To compare the effects of adding targeted agents to standard second-line chemotherapy with a single agent (pemetrexed or docetaxel) in patients with advanced NSCLC, a meta-analysis of all relevant randomized controlled trials was performed and overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were assessed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human NSCLC cells. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR-TKI-sensitive cells and antagonistic effects in EGFR-TKI-primary and acquired resistant cells, suggesting that EGFR-TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In the H1299 human NSCLC bone metastasis model, OPG-Fc plus docetaxel in combination resulted in significantly greater inhibition of skeletal tumor growth compared with either single agent alone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Feasibility re-evaluation of 75 mg/m\u00b2 docetaxel in Japanese patients with previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVE: The primary objective of this study was to re-evaluate the feasibility of docetaxel at doses of up to 75 mg/m\u00b2 in Japanese patients with previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Although docetaxel administration at an initial dose of 75 mg/m\u00b2 requires careful attention because of the high incidence of febrile neutropenia, this dose is considered feasible according to the protocol definition in Japanese patients with previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "IPI-504 and ganetespib have activity in NSCLC both as monotherapy and in combination with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Selumetinib added to docetaxel has improved outcome compared with docetaxel in a randomized phase II trial in patients with advanced KRAS-mutant NSCLC and this combination is currently studied in a phase III trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Nintedanib added to docetaxel improved progression-free survival in the second-line therapy of patients with advanced NSCLC but many other angiogenesis inhibitors failed to improve clinical outcome in phase III trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: The established method should be helpful for the pharmacokinetic monitoring of paclitaxel, docetaxel, vinblastine, and vinorelbine in the human plasma of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Obatoclax was administered with docetaxel in patients with relapsed or refractory NSCLC- docetaxel as a 1-hour infusion on day 1 and obatoclax as a 24-hour infusion on days 1 and 2-every 3 weeks for up to eight cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Combined obatoclax mesylate plus docetaxel is tolerable in patients with NSCLC, but response was minimal and neutropenia was a common adverse event. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: The efficacy of pemetrexed in the second-line treatment of Chinese patients with advanced NSCLC has been shown to be similar to that of docetaxel in a recent study; additionally, pemetrexed was associated with much better safety and toxicity profiles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: A total of 154 patients with nonsquamous NSCLC received either pemetrexed (500 mg/m(2) intravenously (IV)) or docetaxel (75 mg/m(2) IV) on day 1 of 21-day cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Chinese patients with nonsquamous NSCLC disease treated with pemetrexed had improved SWT beyond 6 months than those receiving docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This analysis supports a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of Chinese nonsquamous NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " OBJECTIVE: To analyze the efficacy and safety of combination of rh-endostatin (Endostar) with docetaxel treatment on patients of NSCLC who presented PD or intolerable toxicity in/after first-line chemotherapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Endostar may prolong TTP in patients with advanced NSCLC benefited from docetaxel treatment without increased toxicities. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Docetaxel (Taxotere) (DTX) is a widely used chemotherapy agent used in many regimens for the treatment of solid tumors, for example breast cancer, NSCLC, gastric, prostate, and head and neck cancers. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive NSCLC after platinum-based therapy: a phase 3, open-label, randomised trial. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Prognostic significance of circulating tumor cells in advanced NSCLC patients treated with docetaxel and gemcitabine. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: To evaluate the association in the change of circulating tumor cell (CTC) levels and clinical outcomes (PFS and OS) in patients with advanced NSCLC treated homogenously with docetaxel and gemcitabine administered every 2 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel is one of the most important anti-tumor drugs and has shown powerful therapeutic activity against breast cancer, NSCLC, prostate cancer and so on. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Recently, in a randomised, phase II trial selumetinib plus docetaxel has proven to improve progression free survival compared to docetaxel alone in previously treated patients with advanced KRAS-mutant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel in the treatment of NSCLC -- an observational study focusing on symptom improvement. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Results of an observational study on docetaxel-based therapy in NSCLC with focus on symptom control and therapy response, are reported. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: A total of 233 patients with NSCLC treated with docetaxel-containing therapy were analyzed. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human NSCLC cell lines. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " To examine the antiproliferative effect of the combination of docetaxel and sorafenib, applied to the representative NSCLC cell line A549 cells either wild type or with acquired resistance to docetaxel (A549/D). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " DNA microarray reveals different pathways responding to paclitaxel and docetaxel in NSCLC cell line. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The wide use of paclitaxel and docetaxel in NSCLC clinical treatment makes it necessary to find biomarkers for identifying patients who can benefit from paclitaxel or docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In present study, NCI-H460, a NSCLC cell line with different sensitivity to paclitaxel and docetaxel, was applied to DNA microarray expression profiling analysis at different time points of lower dose treatment with paclitaxel or docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced NSCLC as second- or third-line treatment: phase IIa study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "With recent development of expanding autologous ex vivo NK cell-enriched lymphocytes (NKL), we designed a trial to augment the anticancer effect by co-administering NKL and docetaxel, one of the second-line agents used for treatment of patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: To our knowledge, this is the first report on the combination of NKL with docetaxel in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The aim of this study was to reveal the impact of nail alterations associated with low-dose metronomic (LDM) docetaxel chemotherapy on the survival of NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "ekim@kuhp.kyoto-u.ac.jp  BACKGROUND: Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "SETTING: Five randomised controlled trials comparing docetaxel-based chemotherapy with vinorelbine-based chemotherapy for the first-line treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Accordingly, a recent randomized Phase II study evaluating docetaxel plus selumetinib or placebo in KRAS-mutant pretreated advanced NSCLC patients has demonstrated a significant improvement in terms of response rate, progression-free survival and patient-reported outcomes in favor of the combination arm. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We explored an approach combining a recently described antiangiogenic drug, rapamycin, with standard docetaxel cytotoxic therapy on the growth of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "ssramal@emory.edu  We conducted a phase II study of docetaxel in combination with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced NSCLC based on promising preclinical and early-phase clinical data. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Patients with advanced-stage NSCLC treated with one or two previous systemic therapy regimens were given docetaxel (60 mg/m) and everolimus (5 mg orally once daily on days 1-19) every 3 weeks. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The combination of everolimus and docetaxel was tolerated well, but the efficacy was relatively modest in an unselected population of patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in NSCLC in combination with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: Evaluation of in-vivo anticancer activity of aerosolized Celecoxib encapsulated Nanolipidcarriers (Cxb-NLC) as a single therapeutic agent and combined with intravenously administered Docetaxel (Doc) against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "mmajem@santpau.cat  Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced NSCLC patients with disease progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant NSCLC: optimization and in vitro, in vivo evaluation. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The aim of this work was to establish a novel polymeric mixed micelle composed of Pluronic P105 and F127 copolymers loaded with the poorly soluble antitumor drug docetaxel (DTX) against Taxol-resistant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel has been used as one of the first-line chemotherapies in solid tumors including advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Selumetinib plus docetaxel for KRAS-mutant advanced NSCLC: a randomised, multicentre, placebo-controlled, phase 2 study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Eligible patients were older than 18 years of age; had histologically or cytologically confirmed stage IIIB-IV KRAS-mutant NSCLC; had failed first-line therapy for advanced NSCLC; had WHO performance status of 0-1; had not received previous therapy with either a MEK inhibitor or docetaxel; and had adequate bone marrow, renal, and liver function. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "INTERPRETATION: Selumetinib plus docetaxel has promising efficacy, albeit with a higher number of adverse events than with docetaxel alone, in previously treated advanced KRAS-mutant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "These findings warrant further clinical investigation of selumetinib plus docetaxel in KRAS-mutant NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic NSCLC: a randomized, open-label study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "suny@cae.cn  INTRODUCTION: This randomized, open-label study compared pemetrexed versus docetaxel as second-line therapy for Chinese patients with locally advanced or metastatic NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: The comparable efficacy and superior tolerability of pemetrexed compared with docetaxel in this study supports the use of single-agent, second-line pemetrexed for advanced non-squamous NSCLC in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "faupe@libero.it  The only approved agents for second-line therapy in unselected NSCLC are docetaxel and pemetrexed (chemotherapies) and erlotinib (targeted therapies). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " INTRODUCTION: This phase II single-arm trial of docetaxel and capecitabine in previously untreated NSCLC patients was designed to evaluate response rate of this regimen based on promising efficacy data from phase II testing in pre-treated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated NSCLC (KRSG-0601). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Combination of S-1, an oral fluorouracil derivative, plus docetaxel against NSCLC showed promising efficacy but clinically problematic emesis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: A biweekly regimen of docetaxel on day 1 with oral S-1 on days 1-7 was administered to previously treated NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Combination of 1-week administration of S-1 with biweekly docetaxel is safe and active for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We describe a case of docetaxel-induced photo-recall skin rash in a woman treated for a NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Currently only three second-line NSCLC pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "MATERIAL AND METHODS: Italy was selected for base case analysis to compare the total therapy costs, estimated by combining country-specific drug costs, administration costs, and adverse event costs of erlotinib and generic docetaxel in second-line NSCLC therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "kouichi@sahs.med.osaka-u.ac.jp  Docetaxel, a taxane derivative, is frequently used for the treatment of advanced breast cancer, NSCLC, and metastatic prostate cancer. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Pemetrexed versus docetaxel in second line NSCLC: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "viserlee@gmail.com  BACKGROUND: Pemetrexed and docetaxel are established therapies in second line NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS AND PATIENTS: We designed and performed a multi-center, randomized, exploratory clinical trial of pemetrexed compared with docetaxel in second line chemotherapy in Chinese NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Eligible patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks, were randomized to receive either pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone, or docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "The efficacy of pemetrexed was equivalent to that of docetaxel in the second-line treatment for Chinese NSCLC (ORR: pemetrexed vs. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Treatment with pemetrexed resulted in equivalent efficacy outcomes and better safety profiles compared with docetaxel in second-line therapy for advanced NSCLC in Chinese lung cancer population. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Prof.Manegold@t-online.de  INTRODUCTION: This multicenter, open-label, phase II study was carried out to compare the efficacy and safety of cilengitide (EMD 121974), a selective inhibitor of the cell-surface integrins \u03b1V\u03b23 and \u03b1V\u03b25, with that of docetaxel in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Patients (n\u2009=\u2009140) with advanced NSCLC who had failed first-line chemotherapy were randomized to cilengitide 240, 400, or 600 mg/m(2) twice weekly, or docetaxel 75 mg/m(2) once every 3 weeks for eight cycles. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Phase II trial of capecitabine combined with docetaxel in previously treated patients with NSCLC: A randomized controlled study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Docetaxel alone has been confirmed to be beneficial to patients with advanced previously treated NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We conducted this randomized controlled phase II trial to comparatively evaluate the efficacy and side effects of capecitabine combined with docetaxel in previously treated patients with NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Patients with previously treated NSCLC who failed first-line chemotherapy were randomized into two groups; one received capecitabine combined with docetaxel (XT group) and the other received docetaxel alone (T group). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "In conclusion, compared with docetaxel alone, capecitabine combined with docetaxel for patients with previously treated NSCLC achieved a significantly longer TTP and this regimen was well tolerated. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "All had: (a) stage III or IV NSCLC, (b) Karnofsky performance status (KPS)\u2009 \u2265\u2009 60, (c) no prior chemotherapy, and (d) received initial courses of docetaxel + platinum. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Interstitial lung disease associated with docetaxel in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Docetaxel is a well tolerated chemotherapy for NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "PATIENTS AND METHODS: Between September 2002 and March 2008, 392 patients with advanced NSCLC were treated with docetaxel and we retrospectively reviewed the radiography. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: Pre-existing interstitial change on CT was associated with a higher incidence of ILD (25.9%) among NSCLC patients treated with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSION: \u2003 Gefitinib is a dominant cost saving strategy compared with docetaxel for the second-line treatment of advanced NSCLC from the Thai payer perspective. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Compared with the known NSCLC drug docetaxel, BRP800 displayed potent and similar antitumor activity but with less toxicity. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Prognostic score for second-line chemotherapy of advanced NSCLC: external validation in a phase III trial comparing vinflunine with docetaxel. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "docetaxel in second-line treatment of advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "krapa@poczta.onet.pl  BACKGROUND: We evaluated the effectiveness of docetaxel or erlotinib in second-line treatment of NSCLC and focused on the impact of predictive factors on the outcome of therapy. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "CONCLUSIONS: Erlotinib and docetaxel show similar efficacy in the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Pharmacokinetics of docetaxel in a patient with NSCLC undergoing continuous ambulatory peritoneal dialysis. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced NSCLC: a meta-analysis on 9 randomized controlled trials. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " PURPOSE: The aim was to compare the efficacy and toxicity of gemcitabine plus docetaxel (GD) with platinum-based regimens in patients with untreated advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " BACKGROUND: Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of NSCLC, but no head-to-head data from large clinical trials are available. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Here we show that ganetespib potentiates the cytotoxic activity of the taxanes paclitaxel and docetaxel in NSCLC models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Notably, concurrent exposure to ganetespib and docetaxel improved antitumor activity in 5 of 6 NSCLC xenograft models examined. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " The objective of present investigation was to develop and assess comparative enhancement in cytotoxicity of liposomal Etoposide and Docetaxel in NSCLC cell lines after pre-treatment and co-administration of p53 tumor suppressor gene and to assess direct lung targeting of optimized formulations by dry powder inhaler technology. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Docetaxel (Doc) is considered as first-line chemotherapy for the treatment of NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Tubular nephrotoxicity induced by docetaxel in NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Docetaxel has a proven significant activity against NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Concurrent and sequential administration of sunitinib malate and docetaxel in human NSCLC cells and xenografts. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "We compared the effects of concurrent and sequential administration of docetaxel and multi-target inhibitor sunitinib malate on tumor cells and xenografts and studied several mechanisms involved in drug interaction to provide experimental data in support of their clinical use in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": "METHODS: Eligible patients had castration-resistant prostate cancer (CRPC) or relapsed urothelial or NSCLC after \u22651 prior chemotherapy regimen not containing docetaxel, performance status of 0-2, and adequate organ function. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "docetaxel", "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u4ee5\u94c2\u7c7b\u4e3a\u57fa\u7840\u8054\u5408\u7b2c\u4e09\u4ee3\u836f\u7269\u7684\u53cc\u836f\u5316\u7597\u65b9\u6848\u662f\u6cbb\u7597\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC, NSCLC\uff09\u7684\u6807\u51c6\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u3002\u672c\u7814\u7a76\u91c7\u7528meta\u5206\u6790\u7684\u65b9\u6cd5\u8bc4\u4ef7\u591a\u897f\u4ed6\u8d5b\u8054\u5408\u94c2\u7c7b\uff08docetaxel plus platinum, DP\uff09\u65b9\u6848\u5bf9\u6bd4\u957f\u6625\u745e\u6ee8\u8054\u5408\u94c2\u7c7b\uff08vinorelbine plus platinum, VP\uff09\u65b9\u6848\u6cbb\u7597\u665a\u671fNSCLC\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u65b9\u6cd5 \u8ba1\u7b97\u673a\u68c0\u7d22Pubmed\u3001EMBASE\u3001Cochrane Library\u3001\u4e2d\u56fd\u671f\u520a\u5168\u6587\u6570\u636e\u5e93\uff08CNKI\uff09\u3001\u4e2d\u56fd\u751f\u7269\u533b\u5b66\u6587\u732e\u6570\u636e\u5e93\uff08CBM\uff09\u3001\u4e2d\u6587\u79d1\u6280\u671f\u520a\u5168\u6587\u6570\u636e\uff08VIP\uff09\u5e93\u53ca\u4e07\u65b9\u6570\u636e\u5e93\u5173\u4e8eDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u6cbb\u7597\u665a\u671fNSC LC\u7684\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\uff08randomized controlled trial, RCT\uff09\u3002\u6839\u636eCochrane Handbook 5.1.0\u7684\u8d28\u91cf\u8bc4\u4ef7\u6807\u51c6\uff0c\u7528Stata 12.0\u8f6f\u4ef6\u8fdb\u884c\u7edf\u8ba1\u5b66\u5206\u6790\u3002\u7ed3\u679c \u7814\u7a76\u5171\u7eb3\u51657\u9879RCTs\uff0c\u5305\u62ec\u665a\u671fNSCLC\u60a3\u80052,381\u4f8b\u3002DP\u65b9\u6848\u76842\u5e74\u751f\u5b58\u7387\uff08HR=0.887, 95%CI: 0.810-0.972, P=0.010\uff09\u3001\u6709\u6548\u7387\uff08RR=1.276, 95%CI: 1.107-1.450, P=0.001\uff09\u548c\u8179\u6cfb\u53d1\u751f\u7387\uff08RR=3.134, 95%CI: 1.918-5.121, P<0.001\uff09\u8f83VP\u65b9\u6848\u9ad8\uff1bDP\u65b9\u6848\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff08RR=0.386, 95%CI: 0.311-0.478, P<0.001\uff09\uff1bDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u57281\u5e74\u751f\u5b58\u7387\u3001\u767d\u7ec6\u80de\u51cf\u5c11\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u3001\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u538c\u98df\u3001\u6076\u5fc3\u3001\u5455\u5410\u65b9\u9762\u7684\u5dee\u5f02\u65e0\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u7ed3\u8bba DP\u65b9\u6848\u867d\u7136\u589e\u52a0\u4e86\u8179\u6cfb\u53d1\u751f\u7387\uff0c\u4f46\u5374\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff0c\u540c\u65f6\u63d0\u9ad8\u4e862\u5e74\u751f\u5b58\u7387\u548c\u6709\u6548\u7387\u3002\u76f8\u6bd4VP\u65b9\u6848\uff0cDP\u65b9\u6848\u53ef\u80fd\u66f4\u9002\u5408\u4e00\u7ebf\u6cbb\u7597\u665a\u671fNSCLC\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.07 PMID: 24758908 [PubMed - indexed for MEDLINE]   116. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "[Epub ahead of print]  Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV NSCLC: METLung. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": " Purpose The phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic NSCLC selected by MET immunohistochemistry whose disease had progressed after treatment with a platinum-based chemotherapy regimen. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "Conclusion Onartuzumab plus erlotinib did not improve clinical outcomes, with shorter OS in the onartuzumab arm, compared with erlotinib in patients with MET-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "Given the role of MET in NSCLC, we investigated whether onartuzumab added to first-line chemotherapy efficacy in non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "CONCLUSION: Onartuzumab does not appear to provide any additional clinical benefit when given in combination with current first-line standard-of-care chemotherapy for non-squamous NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "[Epub ahead of print]  Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "We assessed the efficacy and safety of onartuzumab plus platinum-doublet chemotherapy in previously untreated advanced squamous cell NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "However, with the lack of clinical activity seen in the present study, the development of onartuzumab for squamous cell NSCLC will not be pursued further. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "A recent example of a failed trial is the Phase III MetLung trial that compared the effects of the c-MET monovalent antibody onartuzumab with erlotinib versus erlotinib alone in late-stage NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": " Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced NSCLC?  Charakidis M(1), Boyer M(1). ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": " Onartuzumab is a monovalent, humanized, monoclonal antibody that showed significant survival benefits in combination with erlotinib in MET-positive NSCLC in pre-specified subgroup analyses of a randomized phase II study. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "Stage 1 investigated the safety, tolerability, pharmacokinetics (PK), and recommended dose of onartuzumab in patients with solid tumors, and Stage 2 determined the safety, tolerability, and PK of onartuzumab plus erlotinib in patients with MET-positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": " Combining onartuzumab with erlotinib inhibits growth of NSCLC with activating EGFR mutations and HGF overexpression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EGFR) to overexpress hHGF and evaluated the effects of an onartuzumab and erlotinib combination in vitro and in vivo in xenograft models. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "Our findings raised the possibility that patients with NSCLC with EGFR mutations who express high levels of HGF may benefit from onartuzumab and erlotinib combination therapy, and that HGF can be a novel biomarker for selecting such patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": " Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib\u00b1onartuzumab in advanced NSCLC: MET expression levels are predictive of patient benefit. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": " PURPOSE: In a recent phase II study of onartuzumab (MetMAb), patients whose NSCLC tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": " Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "PATIENTS AND METHODS: Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib; crossover was allowed at progression. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "The intravenous (IV) pharmacokinetics (PK) of onartuzumab were investigated in a phase I study and a phase II study in recurrent NSCLC patients. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "epenuel@gene.com  The objective of this study was to evaluate circulating hepatocyte growth factor (cHGF) as a pharmacodynamic biomarker of Met inhibition for onartuzumab (MetMAb, OA5D5v2) in a phase I trial in patients with advanced cancers and a phase II trial in NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "The phase II study was a randomized two-arm trial in which onartuzumab or placebo was administered in combination with erlotinib in 137 patients with second and third line (2/3L) NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": " Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive NSCLC. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced NSCLC who are Met-positive by immunohistochemistry. ", "polarity": 1, "disease": "NSCLC"}, {"drug": "onartuzumab", "orig_sen": "[Epub ahead of print]  Onartuzumab ineffective in NSCLC. ", "polarity": 1, "disease": "NSCLC"}]